<SEC-DOCUMENT>0000939767-21-000045.txt : 20210506
<SEC-HEADER>0000939767-21-000045.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506163032
ACCESSION NUMBER:		0000939767-21-000045
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20210402
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		21898318

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20210402.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:84867dad-da96-4e08-a2f6-a31b9b3022af,g:df225ca8-d190-43b7-90ff-2fc6e5818592,d:f4ea03d0b1584cb19695d6d2c569a8c8--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:exel="http://www.exelixis.com/20210402" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20210402</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl8yLTEtMS0xLTA_ed5f2441-310b-4cfd-92ce-4f1d62bf81e0">false</ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl80LTEtMS0xLTA_05548c55-4828-4baf-910b-75dad4531f91">2021</ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl81LTEtMS0xLTA_b7a5dfc0-cded-4ea1-b5bb-5ebd46851c75">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl82LTEtMS0xLTA_fd984d31-3fbe-4aea-bee2-9a7e522ca59f">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl83LTEtMS0xLTA_d9b2bd72-338c-46e4-8bbb-341d5bd1e39c">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20210402.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="icbcb1d3131ca4167a7ff2b8ca6254b1b_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i048e6e9f5b9b4e0ba2126e2a863f1d6a_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i592bc5a3806f402f856d8fbd3249538c_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f00123ecb754d409c9d6be859b4fdee_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d09b08c1f784f428f462bef31987f4a_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9858fc09c7b54fd1845c5fda3918a98a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9a0be4715d45f2b1b8c059009f2389_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75411ce18e84324abc3dc776c48c674_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bf9d2f48e04ceb99b9304f3f84faf4_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic410500a0c8b410381c4e4bbee8f365a_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cacc83750d84b399462ea235ec6323b_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713d2897e6a74b35aa381b133355de13_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c195dc608249e3bf58c4e4e2307058_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e566d0502942fca3c3b78c08b2698f_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia914428f35354de39626e9a26f516c1a_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1462009eba74249b8e6d01c54abade3_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a6170ae38049f98a1b0f885593db8a_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic669bf72aa434685b03e7f33f063bc4c_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if985cb26685e42e1a5a365f3817d1a89_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c78236539674a37ac21c6d6337ead9c_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366dca17411041bebbcc3bc9f6af0ebb_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9391bb26733440a8f33658cba5d97ee_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b86543d8f8f4ff3ab021af4701ad04f_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22aa948226244f6fb9cc2d1dfb676393_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if452b79a99af416fa1fe1c2fc78ecba7_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced95de5963448ac971de4994c5ac45a_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91abab7d19a343a4b06202fe09657540_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie272ec5d42f9472290f2325ef65b788b_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99cda1e69634b08b343ceeb851e2c7f_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:context id="i58866e6deacc4148bb07d20840bf1d70_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408f9d80116040c38606e6e6c337a915_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982d3bb2ce4643ee9cc102ef593e25a7_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i91deeede7b214054b29b855842eef51d_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8898a28def344c1f9498ba826c92cd6c_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3baa2e8821bd4cfabd0848feb53fa5c3_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d240db1d02c4ee0bf2a46143b9f379e_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e133af899104a37bb4e10ef4a36a743_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ca58c530c04c0a90377ee5dad43da3_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id6dc7e8bd8ec407b89698d13a23ff3a6_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3353acb8df5349fcacfe665fc7964fff_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29eb60ff6b6e4824ac262e719a07f775_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd90892a68449c1be0d524436467c64_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc9d41e68f324a95b996b386418e5c09_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i924eb348cf9042fd9031133e05c98fe2_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b621907fd54e6ab9fb72223fc3cce0_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4979a471ca488b9d64b5802fd2808f_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96161bc61bb64082ad9bfe6554af5de8_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275fbd17545d4f8b807507bd55e10fb3_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if932bb37d2414b9980b74b899a1de12f_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0267ecf78e1743a6a1a623e79ad10130_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbead320fb374843a5973991f2729b28_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aecec8e5f714843bc680fc320329bea_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41350dbef7e647b68e40059774e4ab18_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a15f998b54b45e38f5eb360f2fd42ea_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccc2e4b26604b8ea916b910ab9dd639_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc54d6c3da5453e9ed0a4216e6a54e7_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i033f4863b9914aba94c5752bddff7dbf_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee8f86874504109a2f7f134f40a822f_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2d347c3248461bbac83c443362c76d_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4440cbe5c8ee44e8b1840c7f93915a2f_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7513f3df79784ca184d5576f5feaa6d9_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9833f33d37c343598d92bce315de9ef6_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117710a18dd3442b82fba13f802c6502_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d143f3e9b8641a0a4577a8bac49ef18_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cacac77f313426ca97a1e07efbf2a65_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174d54dbbfea4b6bad9fae3f525eccc8_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056bc3d8fccb421993c4071a717225d5_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97002ec6f9544a39132f917c4592192_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5a426a6b1946c89b6817f64c12e299_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice3ee77a9cff45ac9945571ab644d883_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i935fa856289043ebb8784c517f1d2af2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd7e209de56458d92e416e590288a81_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda8e5037b204db3976ae10c6e028ac7_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb298ecd26c450db75de5a5f0fb2155_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f81bce7d9042b5bcbe2a95f60b3a9a_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9d86fd3b5944978f4a854f4a7afa13_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d78f7d5227d4a02aff49883e41f93ab_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ea16dceb12421a8f3ad991f4018890_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5be727a8bd4c47ed98837d53bd0c5424_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36eac876d5c64caa8af0b1d90f8647d5_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd260ef2e89045b09b489e3188306512_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2257faa0011b4db494f9ed2b1349487b_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0598c8e5e7946afbf373a833d52f32c_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c953dc7f8e45ca83f3d4357a8d0e6a_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc59cc9f93348c6a6d15ebba27b76f9_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1338ac5d655940fb81117935b0c226e0_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a72e61479e84a879347cd4381d1ede0_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaff5cec481d74bcea3ef68f582e81de0_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b66b3d22614d23aa88f2b13229ca74_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42981c9c0704111836c5dcbda3df875_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea0b7048aa4459185b0dda8013edb1c_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9805e61daf3145378cc62ee23939e9ff_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40279315ce444f11a37ef540f6d742b5_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c01c5a5d8f54262b32390c82a09e601_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithAdageneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4664d16060941379ab6fa2d61b74a13_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithWuXiBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c52c8abd6f4b608764f83a27cbc14a_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithAdageneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6f1409c99d4cb69907fadf7fd41180_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithWuXiBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32119146b8b54758a862a6fc16e21509_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88ed0d294474275a7e78a0ec710c85d_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9769920780449fbdaf815855b16f9c_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0b6bb63ed24207bf551f83d299b039_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd209a5a49a4d98986e05725389c2fe_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079f6e55e7604e41981bb55d026449bb_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4bdd567b1f84314b22e6f47db7ed986_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcc7386ed5c43fd9b000593557060ec_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if66c4113d53e4bb3957023006b998620_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab172e9d9f744789028b9b209c7b067_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dea8d433b994133ad734c5e0261047a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3bfc70915c45dc8a4ed22128e381e3_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:unit id="forwardcontract"><xbrli:measure>exel:forwardContract</xbrli:measure></xbrli:unit><xbrli:context id="iaf9c81849c224cf1a0586e1bcd1d2538_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i9c90e1d818864936ad88a7d0eecd505d_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9921b8f98f46428c8230f8cc4d5b8de5_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fef9dd01c3463884a549e712c67975_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b066d94ab5d48e4a3165fe4d64c48cd_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79ae71b4d194663b3217ba40d89497a_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie91a81478309419e9d65e9da67aa5b90_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a6af5ad3d6491eb55e7a02e03ca7f0_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba1677dbd26445dc9bd4d84baffd67f6_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e586cbac7b74f1d80c273b7797e092d_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6350986f2c204a2488862f0ace5acbcd_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i554b0eab7ff4477ca7fd008d3dd2c260_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i415a1c2ee7384eba9691f7dbb9a64ac0_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibccddea8bdc34321a373d4b211f85366_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a320379c33746e8a62505863f507b0b_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02f8f448a7e44f71893357d3ac2b9a60_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e178b46a658489fb7b95d67e5ac005c_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5966995df7754c27a0b4f6cf9ddfcf30_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifacaab7c5ee54a3d9ae628433835e5b2_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e3fe01255048d58bc6c48c899a44f9_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14575a1b1fbe41f2ad3f7b52e297ed34_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe4c382d26c42ca9aab7aae9c0d74cb_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cc15096d7544af483700aaf508a964a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec009171117540bdbb58c1be5851a2d7_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe21729df9640cdbe357f4ec3f1d02a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320b4929fd414ebf96f80e9078a55169_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82d730819e3d4d3c9dde3eeeb9a8b9c9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61fc1e1e560a449a9311f3bf3efd3e52_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c476589a9744e4a0a2d5a9ec2bb854_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i317939be92c5441a8c74c4d69f167550_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c07b0da2b0d43f8bd7ff0a0f78a9545_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68847f2d1e1d4718a5bda4b12d840afe_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f1822a756341a984f6f5e493514983_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie576c7303b774e12a574df1fb982d1f0_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a800e8408eb4e51a4f63612b53ab204_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2191e1eb15cf4c0385b5db4eb3d8d740_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba91e88df5042f390aa570d7bc9525f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa26564d1144ad68101916a752c72c5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c81d2dc86224957b76780b9b01b05fc_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12afb5247d4341d8b3086641b3b17606_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81956f5ad624fb3a34af890cb926767_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9234350c43af4d5fa786ab8abc166d55_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504de91fc7df4dbd9eba09e75fabc924_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ff09f3344f4de1a78249a095f43788_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02becf95ad41458a9f42b2d89fbc17fd_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb144073f9ec4ff78af65d49175c7cbe_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ddda20eb4846618e6298bc462af14b_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1369691551dc4fafb80d4de87f27c595_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed02b22b90b48f3b8a0903941c79c91_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcfe7378fa74f1399955c024d098430_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18980bf9a07498daf97936c223cd8bd_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408345112b514492b8672264d5e9495e_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3af9d6876ad41e9a9459ff5b52f0864_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666a5e9b8134485fa80a9e4de6771543_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i949dcc93029c4d24bde4a783adbeeacb_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa0e1f1fe17409098662f0eaa3cf7f2_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8c9c247bbf4f2fa55811d4b33ba5b9_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i677b05d55bac4440b27c7ed808660a68_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8622ebd208ee40748f3badc2d3baff8b_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21631f07cfc643bd9432ab5a17b6267d_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf3d4993c944a21a332310247496165_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9911c9d99e354292b6c84ef2ea046b40_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6017a4101e7f412f89057676d1636d3e_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc070254d7a9427b9acaf2c3ca6a6317_D20210102-20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i103b70fa1d1e4257bec9058596619e69_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6NTVkZjJhOTE4ZGQyNDUwZTlkZGIxM2ExNzJjNGU4M2UvdGFibGVyYW5nZTo1NWRmMmE5MThkZDI0NTBlOWRkYjEzYTE3MmM0ZTgzZV8wLTEtMS0xLTA_ec4f9e49-22f5-493a-8a7b-3e3bc86637e2">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGI5MDA4M2IzM2FlNDY2NDhhN2I2NTIxZjE2NDA5MjQvdGFibGVyYW5nZTpkYjkwMDgzYjMzYWU0NjY0OGE3YjY1MjFmMTY0MDkyNF8wLTAtMS0xLTA_a2b5cb2a-9f79-4177-bd1e-06a9925f41f2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl81NDk3NTU4MTQwNzg4_b36008d2-f858-458c-9f22-04df5a796361">April 2, 2021</ix:nonNumeric></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6OWIyNTY0ZmUyZDIxNDNjZWE0Mjg1MjNjMTE4NmMzOGIvdGFibGVyYW5nZTo5YjI1NjRmZTJkMjE0M2NlYTQyODUyM2MxMTg2YzM4Yl8wLTAtMS0xLTA_65272f7b-975f-4c59-925e-f3e4ecfd217a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg5_4b1a1a8c-b85d-47d5-a2da-0bd70e328e19">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20210402_g1.jpg" alt="exel-20210402_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:188px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6YmQzZWVjZmE2ZTJiNDRlNDlmNzUwNTIwYWI5OGQ5NTgvdGFibGVyYW5nZTpiZDNlZWNmYTZlMmI0NGU0OWY3NTA1MjBhYjk4ZDk1OF8xLTAtMS0xLTA_353b1a24-d74d-4863-9944-764cf5256094">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6NmU5ZjdhNmQ1NDEzNGU4NTkyZWRhNTcwZDgwZTI4YzMvdGFibGVyYW5nZTo2ZTlmN2E2ZDU0MTM0ZTg1OTJlZGE1NzBkODBlMjhjM18wLTAtMS0xLTA_ce43d3bc-d448-4a03-8c7b-9c1adfab5c94">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6NmU5ZjdhNmQ1NDEzNGU4NTkyZWRhNTcwZDgwZTI4YzMvdGFibGVyYW5nZTo2ZTlmN2E2ZDU0MTM0ZTg1OTJlZGE1NzBkODBlMjhjM18wLTEtMS0xLTA_b065a031-a9c5-4f6a-bf14-2d399ea140f4">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODkw_af7b6426-9909-4fa5-8a44-16c395d68328">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg2_6401d7e7-7c9b-4255-9e55-3bda5a481f6c">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg0_747e367b-a660-4709-9e94-9d27369db50f">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg3_5ed3ab37-bbed-49d0-8083-3abbe16b5340">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg1_6b9c2dd2-61c0-4de1-8d0f-5a0b59cec956">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg4_2c993a3b-291b-4817-9d1a-5586a77ce69e">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGJjY2FjZTU4NDEzNGY3MTgyOTVhZWZhMDAzYzk3M2EvdGFibGVyYW5nZTpkYmNjYWNlNTg0MTM0ZjcxODI5NWFlZmEwMDNjOTczYV8xLTAtMS0xLTA_c0096cab-0e17-45bd-b865-cdef170e8c8c">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGJjY2FjZTU4NDEzNGY3MTgyOTVhZWZhMDAzYzk3M2EvdGFibGVyYW5nZTpkYmNjYWNlNTg0MTM0ZjcxODI5NWFlZmEwMDNjOTczYV8xLTEtMS0xLTA_12cbdff2-1df6-4ba6-a1ea-41e781d1d2f7">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGJjY2FjZTU4NDEzNGY3MTgyOTVhZWZhMDAzYzk3M2EvdGFibGVyYW5nZTpkYmNjYWNlNTg0MTM0ZjcxODI5NWFlZmEwMDNjOTczYV8xLTItMS0xLTA_e1f76463-9362-4f25-9b00-939d6786f6d9">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODgx_f21d7a36-6061-43f9-b572-0e02d622991d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODgy_611a5b0b-772f-4d17-9d2e-1a69bed9a390">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZTEzNTQwNmE5MjU5NGE4MmExMTM5MDIxMDU1YWFmNWIvdGFibGVyYW5nZTplMTM1NDA2YTkyNTk0YTgyYTExMzkwMjEwNTVhYWY1Yl8wLTAtMS0xLTA_beb9fcba-e2e7-46d6-9092-ac5281be238f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZTEzNTQwNmE5MjU5NGE4MmExMTM5MDIxMDU1YWFmNWIvdGFibGVyYW5nZTplMTM1NDA2YTkyNTk0YTgyYTExMzkwMjEwNTVhYWY1Yl8xLTQtMS0xLTA_ca9a9d65-d20b-4da2-b1d9-dbdaacc5a038">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZTEzNTQwNmE5MjU5NGE4MmExMTM5MDIxMDU1YWFmNWIvdGFibGVyYW5nZTplMTM1NDA2YTkyNTk0YTgyYTExMzkwMjEwNTVhYWY1Yl8yLTEtMS0xLTA_8c894180-4478-4efe-833e-064c7315c217">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODgz_111724f2-6f0c-48a3-b9eb-b8365c9baf3f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of April&#160;26, 2021, there were <ix:nonFraction unitRef="shares" contextRef="icbcb1d3131ca4167a7ff2b8ca6254b1b_I20210426" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODI2_f6f2149f-0d46-4078-ab06-76e14286e259">313,387,205</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_19">Condensed Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_22">Condensed Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_64">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_79">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_82">32</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_85">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_88">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_91">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_94">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_97">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_100">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_103">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_103">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_106">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_106">52</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_109">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNy0xLTEtMS0w_99532cb1-38c8-4646-b6ac-f5656df49233">370,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNy0zLTEtMS0w_ed7320c4-eea6-4d35-bebd-855b549655d7">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOC0xLTEtMS0w_042ef8d7-dcf5-410a-a9bf-04f2cabb8141">815,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOC0zLTEtMS0w_0968542e-a935-4a8d-be74-680b765e1c47">887,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOS0xLTEtMS0w_b607b521-880d-4f03-894c-48c7a84afb23">177,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOS0zLTEtMS0w_eb431aec-2d8b-49cd-86d5-350e117dc91e">160,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTAtMS0xLTEtMA_ebbe1a7d-fdd5-4cfd-862a-7e9f9c7656ad">24,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTAtMy0xLTEtMA_566e3229-3b40-4921-aa74-23e958aa5a5b">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTItMS0xLTEtMA_e69e0a31-693d-4c45-993a-b0eabea5cf4c">46,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTItMy0xLTEtMA_ccd68666-b51d-4ad8-9ca4-2536a8de0c89">57,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTMtMS0xLTEtMA_1fbb92d1-d862-48d5-8543-ed6ae1d34a16">1,434,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTMtMy0xLTEtMA_d7028ea5-ae87-47da-af85-e4706f4c1b7f">1,445,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTQtMS0xLTEtMA_3d254d2e-f56d-4bdc-b7e6-ab84b4ed955c">328,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTQtMy0xLTEtMA_3c2d41be-9dc2-4d3a-899a-9bd159b72eac">330,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTUtMS0xLTEtMA_272fa8b3-d37a-4a15-b9b0-004d8d7b839a">78,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTUtMy0xLTEtMA_cba9e055-bf71-4e1e-a7a5-269f40ac0910">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTYtMS0xLTEtMA_4ab4522f-0f11-432a-9e3a-2a5600ac3037">160,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTYtMy0xLTEtMA_76bf92c1-5c6f-4636-8f2c-22d8daeb87eb">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTctMS0xLTEtMA_7ba06e73-7790-4855-a6eb-6eeba5eaf1a3">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTctMy0xLTEtMA_6cae87a8-c126-4985-ba41-927427e73409">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTgtMS0xLTEtMA_81495862-a801-459a-8c7a-a4b263fe7363">124,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTgtMy0xLTEtMA_f6a767f8-67e3-4757-a7f7-60fb7167fd17">73,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTktMS0xLTEtMA_f5ee10e4-bfb2-4ad1-9c98-b7d5b0d0e747">2,190,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTktMy0xLTEtMA_d1261ee1-6b10-4874-b5eb-8db06a2a2bf9">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjItMS0xLTEtMA_5c12d6aa-13ae-4ffa-af9a-01f6a19d761c">13,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjItMy0xLTEtMA_c9889a19-c09c-497a-a959-1029a7e24411">23,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjMtMS0xLTEtMA_effae359-52b7-4432-a0b3-b39d00d3f4cc">37,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjMtMy0xLTEtMA_5cc3ab74-b272-4d5f-8858-5211a66657fc">51,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjQtMS0xLTEtMA_68170948-5a3a-43b6-971b-633bcf697ec0">59,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjQtMy0xLTEtMA_3e616397-8453-45b0-b122-765c7968108f">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjUtMS0xLTEtMA_9e890a30-7aed-42bf-a398-60da4e0848ae">31,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjUtMy0xLTEtMA_087356eb-3cec-4d4a-9f74-73894c99929d">20,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjYtMS0xLTEtMA_a67be957-d6f7-4d96-829f-d43f842a6947">13,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjYtMy0xLTEtMA_e2d563d9-f945-4d99-90e1-f5102c53c67a">12,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjgtMS0xLTEtMA_0f1efba4-52c8-40ca-b34d-f3a9a6d1f36c">56,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjgtMy0xLTEtMA_0632f5b1-938f-4c6e-bc13-0076ca57a88e">44,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjktMS0xLTEtMA_ebb98a2a-e0bd-462d-8e61-3b8c8a4e2e32">213,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjktMy0xLTEtMA_f1501017-f61b-4886-bc2a-067a5043c426">204,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzAtMS0xLTEtMA_db614917-7007-4144-90fb-e66813cf45d4">9,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzAtMy0xLTEtMA_20e803bd-3745-4d1d-b5a3-942c270b40a5">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzEtMS0xLTEtMA_6cd94a8d-86b4-4e84-8da4-8b52d1c74f75">52,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzEtMy0xLTEtMA_4db5f8fa-6033-43ca-aa4c-5c54e135c332">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzItMS0xLTEtMA_3639eec4-98b7-4e86-b9dc-9b75c2bb6d9e">3,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzItMy0xLTEtMA_93fca196-b6f9-4dd9-9ef6-98163983019e">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzMtMS0xLTEtMA_6d0b0ea8-b45d-4597-852b-6b112f0a4d36">279,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzMtMy0xLTEtMA_e774782d-eaf7-4235-82ad-20a8e09ebb72">258,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzQtMS0xLTEtMA_7c43127e-fbea-418b-b5ec-c35ddb00ef38"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzQtMy0xLTEtMA_4ea24791-f7a4-4e68-98e9-6cc0f35ecdc4"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzIx_52b59cd4-6952-4735-9568-c74ff6e453b9"><ix:nonFraction unitRef="usdPerShare" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzIx_fb3d2a04-24f3-471e-a446-66191f8540ef">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzM1_b3cc8fe4-b0b9-48e2-8025-2853a60e3982"><ix:nonFraction unitRef="shares" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzM1_e01cc99d-83e7-4856-8dfa-3bc5fd44aa74">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzYw_b07d48e5-cc1a-469f-a64f-2ac793d2d93c"><ix:nonFraction unitRef="shares" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzYw_e46db632-e0d5-423c-9610-ff35865e0df2">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMS0xLTEtMA_fed92670-a004-419a-8b0e-f5913bb62291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMy0xLTEtMA_1f351ffd-233c-47ff-a4c6-7743d788dc79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzE4_859fa434-ba6d-41ad-80d3-6ab017042098"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzE4_b10351e3-fa50-4a99-829d-0be069d42b61">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzMy_643ac0c0-4107-4d7c-8b9f-a50c95de7247"><ix:nonFraction unitRef="shares" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzMy_bc4aecf8-c5d1-4b80-91ae-761aa57af019">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzc4_526e4ad0-02d5-4165-bb7c-7c49902bd681"><ix:nonFraction unitRef="shares" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzc4_da30f299-1ff7-4df8-9029-1fd8388827cc">313,262</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzg1_16ab2b83-69de-400b-84e9-f18755c30e4a"><ix:nonFraction unitRef="shares" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzg1_86fec39b-96b4-4ebf-b94b-8bdaf070bb0a">311,627</ix:nonFraction></ix:nonFraction> at March&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMS0xLTEtMA_100a4098-1b35-44d6-aa3e-b8b49e6f856f">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMy0xLTEtMA_4c6f62f1-f292-4936-8453-84ee3343ab84">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzgtMS0xLTEtMA_ffd6a70f-3d57-4a1d-b079-1f58f55d50bf">2,354,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzgtMy0xLTEtMA_d80e21ba-e555-4c17-b88b-258fb5e92a82">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzktMS0xLTEtMA_83ac758f-e9e0-4b6a-9404-b7c9d673e952">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzktMy0xLTEtMA_93e15a1a-54a2-430f-85ee-7d701c79868c">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDAtMS0xLTEtMA_6993c995-98e0-4486-9fc8-c3cdce8c73f4">445,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDAtMy0xLTEtMA_e340e0a9-55ff-4168-9d73-1ad3882470ec">447,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDEtMS0xLTEtMA_71452c8e-583f-4abc-9b22-3b3cc3d83bd3">1,911,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDEtMy0xLTEtMA_82498784-112a-452e-89bc-b1675167cbbe">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDItMS0xLTEtMA_6e70e6f8-de50-4cb7-b252-1f7cf34ce46c">2,190,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDItMy0xLTEtMA_c67fce0c-9898-4f62-b1bb-01fa3abc9a88">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMy01LTEtMS0w_644a7c62-b311-4238-a192-2a8ea241162d">227,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMy03LTEtMS0w_38fe9dc1-20f4-445b-9f44-07153e0b30c0">193,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e6e9f5b9b4e0ba2126e2a863f1d6a_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNC01LTEtMS0w_572bf001-769a-4272-985e-76a2260838e5">27,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592bc5a3806f402f856d8fbd3249538c_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNC03LTEtMS0w_759186dc-6ed0-40f1-bbdb-16e47bc3c5e1">20,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f00123ecb754d409c9d6be859b4fdee_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNS01LTEtMS0w_96079154-1930-450b-8dcc-60005844b8a3">15,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d09b08c1f784f428f462bef31987f4a_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNS03LTEtMS0w_e605fa22-94c2-4252-809d-8396d0bcad01">12,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNi01LTEtMS0w_f2c0b6aa-ce66-4fd2-91c7-dac3cb92ec95">270,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNi03LTEtMS0w_90f7b23b-5b2b-4de2-8b61-0c5379ba1560">226,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOC01LTEtMS0w_b26da604-ec60-4478-88b2-2aca1cdaf3b6">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOC03LTEtMS0w_505a4bf5-e1cc-43b6-85ff-dcc29609cbcd">9,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOS01LTEtMS0w_a7cd087d-9131-4d2c-85c0-ad11340cef68">159,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOS03LTEtMS0w_daeeba09-0092-4c90-b962-0f23d244c35a">101,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTAtNS0xLTEtMA_b3697842-8947-4657-9841-6978517cdfee">102,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTAtNy0xLTEtMA_516be175-2778-4ec9-a1cd-6b8178a31aaa">62,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTEtNS0xLTEtMA_16915667-8880-41c6-afa2-3771e883733e">274,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTEtNy0xLTEtMA_9a48c3ec-f1b1-4e9f-b465-3184888554d7">174,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTItNS0xLTEtMA_cfe08af9-93a5-43f4-9330-66c8e5855aac">4,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTItNy0xLTEtMA_00ff71c7-114e-4561-8ee0-7fbabb91b8d1">52,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTMtNS0xLTEtMA_fadeefce-ba6a-469e-b2db-1080dbbf924c">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTMtNy0xLTEtMA_7bbf7c14-ae24-4292-9ae5-7ad5b743becf">7,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTQtNS0xLTEtMA_f2ece92a-2812-4d20-987a-645b683947a7">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTQtNy0xLTEtMA_4561af3c-2f4f-406e-a6ee-b3d05d4290a9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTUtNS0xLTEtMA_c4f94103-f0e2-4091-be7b-d0f6ba7eb4f4">2,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTUtNy0xLTEtMA_554fcefc-faca-4801-ad9a-05025c825160">60,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTYtNS0xLTEtMA_608fb8ca-0060-42c4-b560-863c77d74a81">3,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTYtNy0xLTEtMA_698825c0-531d-434a-8b59-b1214eab3842">11,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTctNS0xLTEtMA_ecd714ce-eb21-40a9-a879-48e71daa1ad0">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTctNy0xLTEtMA_0ea809f2-6783-488f-8721-7b546a97a932">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTktNS0xLTEtMA_8837b32e-dc83-4ee5-806b-ba1cee33e6a1">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTktNy0xLTEtMA_740a180a-c9c6-4f24-b5e1-b2c8efee53c7">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjAtNS0xLTEtMA_74a03a98-91a0-44fe-82d7-22b29dbaa525">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjAtNy0xLTEtMA_abb427d7-1f97-46a5-b120-899ea61f714a">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjItNS0xLTEtMA_a936ce71-94fc-45ba-a4a5-bbce48f3a549">312,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjItNy0xLTEtMA_3c79c02c-5009-4846-a1b4-331cdf843814">305,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjMtNS0xLTEtMA_62a1aecf-4b5c-4d87-88a0-dcc49bcc3e2a">321,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjMtNy0xLTEtMA_7f75f5a3-d781-41a7-a322-6e4ea27bdd24">315,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_22"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfMi01LTEtMS0w_ecd714ce-eb21-40a9-a879-48e71daa1ad0">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfMi03LTEtMS0w_0ea809f2-6783-488f-8721-7b546a97a932">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC0wLTEtMS0wL3RleHRyZWdpb246MWM0OTkzMjBmZmNkNDRmODg3NTIyYTBlY2ZkNzFlNDhfMTAy_e1a8e360-978d-48c6-af63-06a9191aff46">499</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC0wLTEtMS0wL3RleHRyZWdpb246MWM0OTkzMjBmZmNkNDRmODg3NTIyYTBlY2ZkNzFlNDhfMTA5_e3654b6f-d849-4835-adb2-a61144805f60">941</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC01LTEtMS0w_e428168e-5d3d-49c6-968b-e6962fdbcedf">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC03LTEtMS0w_6a713bd4-8923-4e21-9c9e-e702c258bceb">3,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNi01LTEtMS0w_89788ef8-640e-4020-9819-43401993ab1c">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNi03LTEtMS0w_78210514-fd56-4ae9-8333-2317731649f6">45,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:42.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9858fc09c7b54fd1845c5fda3918a98a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtMS0xLTEtMA_0a2f1f33-93bf-4ecc-92e4-3783404acf0d">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9858fc09c7b54fd1845c5fda3918a98a_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtMy0xLTEtMA_34815454-8fda-4e4b-8156-21ef43120df8">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9a0be4715d45f2b1b8c059009f2389_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtNS0xLTEtMA_a056316a-fc24-4dd6-9e82-9ec0106ce7fc">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75411ce18e84324abc3dc776c48c674_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtNy0xLTEtMA_d8364554-9913-4d70-a265-a0d0d211c721">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6bf9d2f48e04ceb99b9304f3f84faf4_I20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtOS0xLTEtMA_bf141971-bfae-445c-895b-de704e4df683">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtMTEtMS0xLTA_e26dd80d-fdce-4e19-b08e-46a409098d48">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410500a0c8b410381c4e4bbee8f365a_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjQtOS0xLTEtMA_70b25710-e9e2-4619-80b5-1299b7930a3a">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjQtMTEtMS0xLTA_d77ab880-7a05-4c2b-b65a-45c9c594f729">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cacc83750d84b399462ea235ec6323b_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjUtNy0xLTEtMA_874156d7-69b4-446b-bf2a-745d13f70e80">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjUtMTEtMS0xLTA_3dd2b08a-e4d7-426a-961f-bdb483b4d953">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i713d2897e6a74b35aa381b133355de13_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtMS0xLTEtMA_b81578bf-a064-4c82-93bb-53624c3f89aa">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713d2897e6a74b35aa381b133355de13_D20210102-20210402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtMy0xLTEtMA_16e9e401-eb30-49e3-9fce-c46659b2f9d8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtNS0xLTEtMA_057c0280-93fa-476e-badc-c20c5f3dc5b1">4,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtMTEtMS0xLTA_7723e242-e74c-4389-b154-ccbab2552b0b">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjctNS0xLTEtMA_baec149f-6904-4774-9960-827a98d8130f">6,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjctMTEtMS0xLTA_e6330b0f-9121-4052-b5a0-27a2580078d7">6,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjgtNS0xLTEtMA_cabfe078-687a-45a3-ba71-51fc856745df">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjgtMTEtMS0xLTA_efb7beed-ca4b-46e7-a949-14a29b2fb0b3">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06c195dc608249e3bf58c4e4e2307058_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktMS0xLTEtMA_ece2acf2-2266-4ad3-a3df-3928e55ca1cb">313,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c195dc608249e3bf58c4e4e2307058_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktMy0xLTEtMA_a6bd9508-5175-4415-9995-db285b22cca3">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e566d0502942fca3c3b78c08b2698f_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktNS0xLTEtMA_c789c3a4-d8b9-41ac-8130-378a80bbafff">2,354,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia914428f35354de39626e9a26f516c1a_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktNy0xLTEtMA_21d97a67-af00-4220-b03f-f11dfb029f5b">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1462009eba74249b8e6d01c54abade3_I20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktOS0xLTEtMA_48d2c8bd-af98-420b-bd4f-2f66d34578ca">445,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktMTEtMS0xLTA_362522f4-b982-4e07-b808-a6748724fcae">1,911,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2020</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89a6170ae38049f98a1b0f885593db8a_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtMS0xLTEtMA_1f45860c-8dcd-4a1b-bc89-4bd145f40033">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a6170ae38049f98a1b0f885593db8a_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtMy0xLTEtMA_957b19ef-705a-49e2-8be3-fd7b37b5f68e">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic669bf72aa434685b03e7f33f063bc4c_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtNS0xLTEtMA_a5ae91a1-5d3f-4e7e-80fc-37dd2d3f5403">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if985cb26685e42e1a5a365f3817d1a89_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtNy0xLTEtMA_74e3d9cd-c40c-461c-882a-17146d1dcc8a">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c78236539674a37ac21c6d6337ead9c_I20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtOS0xLTEtMA_685e52f2-9eac-4f9e-ab66-438532aec8ef">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366dca17411041bebbcc3bc9f6af0ebb_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtMTEtMS0xLTA_bb5cd0a0-b288-44d1-a3ce-024b64576887">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9391bb26733440a8f33658cba5d97ee_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjQtOS0xLTEtMA_94cad7e6-adb8-4125-a07a-bbd1aeb8817e">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjQtMTEtMS0xLTA_69b0e731-efe2-42b1-9eab-309377cc8547">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b86543d8f8f4ff3ab021af4701ad04f_D20200104-20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjUtNy0xLTEtMA_e1da9733-6950-417c-8de0-3fb71d2ba428">3,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjUtMTEtMS0xLTA_ebedf0e2-9600-4ccf-aec5-4122cbc63468">3,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22aa948226244f6fb9cc2d1dfb676393_D20200104-20200403" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtMS0xLTEtMA_d923ae3d-a4ae-493c-9ea9-e4d705f513d6">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22aa948226244f6fb9cc2d1dfb676393_D20200104-20200403" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtMy0xLTEtMA_0a5934bc-5344-45f1-87ee-953463bd2eee">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtNS0xLTEtMA_0c589369-7b80-4c9e-9dc3-f1f6578fd98f">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtMTEtMS0xLTA_e5d37143-f410-4ff8-b9fe-b8f54079de11">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtNS0xLTEtODM4_feceb6b6-b53e-47a8-93e4-96f96dadfbe9">1,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtMTEtMS0xLTkyMA_c561ea6b-0eb2-44b3-8f0d-cb3548774d77">1,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtNS0xLTEtMA_faa74b57-07d2-459a-8a71-ab0b083c27b6">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtMTEtMS0xLTA_51f883e2-159f-4c7b-8cb0-10fe94432db9">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if452b79a99af416fa1fe1c2fc78ecba7_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktMS0xLTEtMA_59261b44-5e58-47e6-903b-289a4363136e">305,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if452b79a99af416fa1fe1c2fc78ecba7_I20200403" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktMy0xLTEtMA_b77d3ce0-d17d-4b30-b2aa-dab3541b8c48">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced95de5963448ac971de4994c5ac45a_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktNS0xLTEtMA_98fc26e4-929e-484b-931e-ac4adec0f297">2,258,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91abab7d19a343a4b06202fe09657540_I20200403" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktNy0xLTEtMA_31139447-3469-4430-8afb-deedff7b344d">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie272ec5d42f9472290f2325ef65b788b_I20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktOS0xLTEtMA_bb6e1080-e317-49af-b4df-af42096fff56">510,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99cda1e69634b08b343ceeb851e2c7f_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktMTEtMS0xLTA_44fd4f14-3cbc-4dec-b61c-36ff9dc5e2c2">1,747,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMi0xLTEtMS0w_ecd714ce-eb21-40a9-a879-48e71daa1ad0">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMi0zLTEtMS0w_0ea809f2-6783-488f-8721-7b546a97a932">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNC0xLTEtMS0w_bf6cd119-a3dc-46f0-b728-66fb3aaff426">3,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNC0zLTEtMS0w_00eee545-2843-4434-a2e4-eb6736172387">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNS0xLTEtMS0w_704a062a-c98a-44a8-9efa-7716e520e0c5">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNS0zLTEtMS0w_a8bc7b04-c35c-44ad-9b0a-1fc667081240">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNi0xLTEtMS0w_140a58be-99ea-4554-b07e-63b4c35ee55f">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNi0zLTEtMS0w_47413064-3a0f-44dc-91a4-800ca97dee04">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNy0xLTEtMS0w_87eecec3-4911-4631-9eaa-a4c502b78692">3,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNy0zLTEtMS0w_aaaff98d-5901-4a8f-b890-12ede3fb1231">10,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfOC0xLTEtMS0w_ed3cb637-2c52-4dd1-8a92-bb123ca8b894">6,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfOC0zLTEtMS0w_233c125e-f9d8-4354-ad77-1e9a4873e1c6">888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTAtMS0xLTEtMA_dba27a53-d3d3-4e6e-a5dc-384401f0ae8c">17,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTAtMy0xLTEtMA_802ed9d3-c894-4bc2-a2fe-854840aceeb7">18,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTEtMS0xLTEtMA_71785a28-50b9-4d15-8f8f-ecd518dc6485">2,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTEtMy0xLTEtMA_4258f58f-1ab6-4c1b-aad3-993c63815d5d">4,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTMtMS0xLTEtMA_04b3ab29-1ee8-44a9-8398-e06692bdb853">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTMtMy0xLTEtMA_952be2c8-082f-48c8-a7b6-70bb7591ae67">2,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTUtMS0xLTEtMA_77e77e2e-a940-408b-842f-daad943ae142">13,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTUtMy0xLTEtMA_f0705669-b0b7-4656-9ed6-9dc1152d7a86">8,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTYtMS0xLTEtMA_f3309004-d7ce-4ba9-aeb7-00599d958bb4">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTYtMy0xLTEtMA_f03e4685-659d-4807-b4f3-81cee7831791">2,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTctMS0xLTEtMA_a0be747d-7b09-4f6a-a923-1520ff14f488">39,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTctMy0xLTEtMA_f3658d52-baec-4a19-9884-378d68f0e704">56,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTktMS0xLTEtMA_58cc7ed0-340c-47e2-a320-a982caab32eb">13,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTktMy0xLTEtMA_a7a56cc1-d0a6-4db4-a7ea-41adf2fd2e1a">2,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjEtMS0xLTEtMA_5538bae0-978e-4a4f-9458-d299749496ba">331,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjEtMy0xLTEtMA_dc1fb49f-5eee-4b7c-9fc8-4c3f46d046af">251,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjItMS0xLTEtMA_464b38dd-669a-4839-8c41-f39b5ac36e96">407,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjItMy0xLTEtMA_b2294f40-dc8a-4ae5-9e85-152c0fb8909c">287,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjMtMS0xLTEtMA_10d6e668-2765-4c5b-a973-6a41b404ff19">62,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjMtMy0xLTEtMA_1063115d-3f24-449f-bcec-ad80d0acd714">32,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjUtMS0xLTEtMA_636a1f00-68b6-494b-9ecc-41754de0e3f5">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjUtMy0xLTEtMA_a7242f68-a7da-498c-b38d-cffd1ab11a74">3,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjYtMS0xLTEtMA_dbe8372f-36cb-406b-aa61-447d0bafc19f">5,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjYtMy0xLTEtMA_e292c693-373e-46a2-ba5a-f5196110442c">1,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjktMS0xLTEtMA_38f55cbc-a467-4571-b13a-2791b92866d7">2,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjktMy0xLTEtMA_2cc569cc-6715-4c24-80e6-e2330e4b52bb">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzAtMS0xLTEtMA_45499fe2-6c6c-42d5-a8a8-0ad3cd23f9d7">99,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzAtMy0xLTEtMA_653e94e9-014e-43f3-8096-9e367efef60a">90,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzEtMS0xLTEtMA_7ebb6327-858b-4b4b-91f5-9ef989ccfa1b">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366dca17411041bebbcc3bc9f6af0ebb_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzEtMy0xLTEtMA_4194218f-1838-4462-a3cd-599e077830bb">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzItMS0xLTEtMA_a7670021-75dd-4b6c-94b0-f55e7fcbf491">419,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99cda1e69634b08b343ceeb851e2c7f_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzItMy0xLTEtMA_aad2d564-b965-44a2-a139-7831f102ca83">358,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzctMS0xLTEtMA_737903a5-d7c3-4025-b885-7d7cfaa3144a">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzctMy0xLTEtMA_7c0d73a6-3995-4eca-9b76-bf35cb71cad5">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE3NDM_7492e6db-c118-4138-811b-a7c753595077" continuedAt="ifdcb6a1d9db748169cc05cdcd4d4fe41" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ifdcb6a1d9db748169cc05cdcd4d4fe41" continuedAt="i01fe86d813ec49e29477b7227f4338ac"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, <ix:nonFraction unitRef="product" contextRef="i58866e6deacc4148bb07d20840bf1d70_D20210102-20210402" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNTcw_4f267372-0e22-40ea-be70-9c2fc460ebb0">four</ix:nonFraction> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. <ix:nonFraction unitRef="product" contextRef="i408f9d80116040c38606e6e6c337a915_D20210102-20210402" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNzcz_7e07f5fa-3694-4935-b945-b02fa79bf310">Two</ix:nonFraction> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="i982d3bb2ce4643ee9cc102ef593e25a7_D20210102-20210402" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMTQ5NA_777b9cb3-cae7-47fe-9841-abc0ca5c1dc2">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple regimens to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE2OTg_813acd03-9fc5-475f-8aa6-8497ea7951d4" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE3MDc_16db90be-a60b-443e-ae68-717d4603e98e" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE2OTE_b6f71811-567f-4d32-9ade-abef54c643c5" continuedAt="i90362b8db6f442f48c2a2000298dc356" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90362b8db6f442f48c2a2000298dc356">. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the three months ended April&#160;2, 2021 and April&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended March&#160;31, 2021 and March&#160;31, 2020 and the year ended December&#160;31, 2020, respectively.</ix:continuation> </span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNjA0NzMxNDAyMDc3MQ_d9ec6f86-c8ec-4e73-baec-515a22b15e7e" continuedAt="ie251c65cb23340b293ead0b720d80c23" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNjA0NzMxNDAyMDc3Nw_773d80b1-4ce0-43d4-adc7-672b847969eb">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i01fe86d813ec49e29477b7227f4338ac"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie251c65cb23340b293ead0b720d80c23">Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNzE0NjgyNTYzOTI0NA_5b01ae5d-553d-4cf4-8306-ddae5bab2efc" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNzE0NjgyNTYzOTI0NQ_7f833ce4-c158-4387-ab11-ec0685569c41" continuedAt="i144af772fce04c61ad81a3aad9c57a59" escape="true">Reclassifications</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i144af772fce04c61ad81a3aad9c57a59">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the significant accounting policies disclosed in Note 1 &#8211; Significant Accounting Policies included in the our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNjA0NzMxNDAxNDk5Nw_f9d3464a-1be5-4005-890b-9fdc320dca2e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into foreign currency forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE3MTg_52719e8b-57e6-422f-adbd-62ee0b043427" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg3Mg_d7d13a56-2ef1-4ea3-aa50-5f7a07b5e8e6" continuedAt="id9200555492946f7b0ada58b1a7fb57a" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="id9200555492946f7b0ada58b1a7fb57a" continuedAt="i558dc17c576f4723a49f13fb37acf7a3"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg4NQ_9b0143a9-3570-4700-a835-3157e5f95f70" continuedAt="i806217ef722844a3aff73fbe4c483e27" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91deeede7b214054b29b855842eef51d_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMy01LTEtMS0w_fcfa880f-97b1-435f-ae78-f2338ebfbac3">314,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8898a28def344c1f9498ba826c92cd6c_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMy03LTEtMS0w_aaffad51-61a8-4802-b658-b71b59bd44ee">252,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3baa2e8821bd4cfabd0848feb53fa5c3_D20210102-20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNC01LTEtMS0w_b5d1fdc4-e0c2-44c8-95c6-1371c864fd1d">86,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d240db1d02c4ee0bf2a46143b9f379e_D20200104-20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNC03LTEtMS0w_036ac31e-e28e-4438-9b63-c8b50ff398c5">58,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNS01LTEtMS0w_644a7c62-b311-4238-a192-2a8ea241162d">227,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNS03LTEtMS0w_38fe9dc1-20f4-445b-9f44-07153e0b30c0">193,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e6e9f5b9b4e0ba2126e2a863f1d6a_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNy01LTEtMS0w_572bf001-769a-4272-985e-76a2260838e5">27,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592bc5a3806f402f856d8fbd3249538c_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNy03LTEtMS0w_759186dc-6ed0-40f1-bbdb-16e47bc3c5e1">20,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f00123ecb754d409c9d6be859b4fdee_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOC01LTEtMS0w_96079154-1930-450b-8dcc-60005844b8a3">15,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d09b08c1f784f428f462bef31987f4a_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOC03LTEtMS0w_e605fa22-94c2-4252-809d-8396d0bcad01">12,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e133af899104a37bb4e10ef4a36a743_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOS01LTEtMS0w_1422036a-2626-4d8a-8c40-05e1c88f54c9">43,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ca58c530c04c0a90377ee5dad43da3_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOS03LTEtMS0w_60d000c4-af3a-4ed1-b28a-e94d6f51fdd7">33,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMTAtNS0xLTEtMA_f2c0b6aa-ce66-4fd2-91c7-dac3cb92ec95">270,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMTAtNy0xLTEtMA_90f7b23b-5b2b-4de2-8b61-0c5379ba1560">226,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNjA0NzMxMzk2NDY1NA_115666a1-7d26-43ca-a0b3-f298102d4b17" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6dc7e8bd8ec407b89698d13a23ff3a6_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMi01LTEtMS02MTg3_48af7235-fbcb-47a9-af1f-36e6ff53b07a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3353acb8df5349fcacfe665fc7964fff_D20200104-20200403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMi03LTEtMS02MTg3_05ef8cae-2a83-4177-820b-e25ef41a7c47">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29eb60ff6b6e4824ac262e719a07f775_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMy01LTEtMS02MTg3_9193e646-5078-4e31-9f6c-801a8587a244">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd90892a68449c1be0d524436467c64_D20200104-20200403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMy03LTEtMS02MTg3_b6735d49-c5c9-4b5a-b0e4-457bae0f69bc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc9d41e68f324a95b996b386418e5c09_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC01LTEtMS02MjA2_48296832-2533-4e72-bfae-7906da8bd506">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i924eb348cf9042fd9031133e05c98fe2_D20200104-20200403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC03LTEtMS02MjA2_4e1d14b6-4dc4-455f-b180-b3ebf2ec1f0a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2b621907fd54e6ab9fb72223fc3cce0_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC01LTEtMS02MTg3_ffc72d6e-002f-4d9b-bf55-f0d3beb90b95">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b4979a471ca488b9d64b5802fd2808f_D20200104-20200403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC03LTEtMS02MTg3_7a25973c-058f-45cd-be28-aa7bde236d19">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96161bc61bb64082ad9bfe6554af5de8_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNi01LTEtMS02MTg3_4849d6f0-1b48-4128-a801-9bc7d58a1c42">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i275fbd17545d4f8b807507bd55e10fb3_D20200104-20200403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNi03LTEtMS02MTg3_2c639bd5-2f74-4000-bdb4-470aff1a9852">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if932bb37d2414b9980b74b899a1de12f_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0xLTEtMS02MTg3_0c2069cb-ccae-4dd5-808f-11dc5f2927a0">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0267ecf78e1743a6a1a623e79ad10130_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0zLTEtMS02MTg3_eef8984d-dec1-4123-9e27-8d3000221203">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibbead320fb374843a5973991f2729b28_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0xLTEtMS02MjE2_f0d92438-b6f7-4380-b032-b8508fff411e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9aecec8e5f714843bc680fc320329bea_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0zLTEtMS02MjE2_1e807d41-29da-4d18-8ba0-cb12e77b81a2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41350dbef7e647b68e40059774e4ab18_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0xLTEtMS02MjIw_4ebac690-19a4-473f-b52d-85c5e7f79fde">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a15f998b54b45e38f5eb360f2fd42ea_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0zLTEtMS02MjIw_500a5e59-a86f-4534-8934-1e662306fb11">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaccc2e4b26604b8ea916b910ab9dd639_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfNC0xLTEtMS02MjIw_95da7868-bb89-41e7-bbdc-7625710e8101">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfc54d6c3da5453e9ed0a4216e6a54e7_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfNC0zLTEtMS02MjIw_86526894-9d8f-4eee-9be0-84fc54c00d4f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i033f4863b9914aba94c5752bddff7dbf_D20210102-20210402" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0xLTEtMS02MTg3_6745193a-b4be-45c6-bd87-9f87013f6350">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idee8f86874504109a2f7f134f40a822f_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0zLTEtMS02MTg3_1cfa4cef-6de9-4025-b4b9-83c548aea7f5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNjA0NzMxMzk2NDY1Nw_49a5516b-1eb0-4f71-8542-de91765a6c79" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide2d347c3248461bbac83c443362c76d_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMi01LTEtMS02MTg3_1266436d-a9be-45f9-b5e3-7eeffe35f7ab">229,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4440cbe5c8ee44e8b1840c7f93915a2f_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMi03LTEtMS02MTg3_86c46b3f-2a29-4035-b8bb-8d7ddf421da1">196,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7513f3df79784ca184d5576f5feaa6d9_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMy01LTEtMS02MTg3_bc01c24b-bf6a-4a46-86db-319b34186fe3">33,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9833f33d37c343598d92bce315de9ef6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMy03LTEtMS02MTg3_59cd9517-d00f-417c-8872-9a10f4ae04b6">29,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117710a18dd3442b82fba13f802c6502_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNC01LTEtMS02MTg3_33797359-c973-4db2-a032-5f67c78b8757">6,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d143f3e9b8641a0a4577a8bac49ef18_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNC03LTEtMS02MTg3_60c22d8d-97ed-4b1b-9636-9aab98de8f7f">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNS01LTEtMS02MTg3_065f5b8b-25fe-4887-bd23-8009e603ec96">270,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNS03LTEtMS02MTg3_a0efa8a9-5b78-4bd1-915a-dad5f96a63ba">226,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg2NQ_39672e54-7dbe-4131-b3bd-bd0b78ba2088" continuedAt="ica61e37c1b58480f9f4891d65a9b9397" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i558dc17c576f4723a49f13fb37acf7a3" continuedAt="ifd1aeaad90f1452b936b8af5a31a8c6d"><div style="margin-top:9pt"><ix:continuation id="ica61e37c1b58480f9f4891d65a9b9397" continuedAt="idcccb80ec872454a8b33ed5bba648d52"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></ix:continuation></div><ix:continuation id="i806217ef722844a3aff73fbe4c483e27"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cacac77f313426ca97a1e07efbf2a65_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMi01LTEtMS0w_5682a390-aa68-492e-8367-5e091936e8d6">223,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i174d54dbbfea4b6bad9fae3f525eccc8_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMi03LTEtMS0w_9fb1a7f5-90eb-4454-933c-f22b388710a7">189,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056bc3d8fccb421993c4071a717225d5_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMy01LTEtMS0w_fd5aa277-365b-4ff2-a322-5f7f114fcb78">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97002ec6f9544a39132f917c4592192_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMy03LTEtMS0w_6f8d23f0-bf27-45c8-a981-c5b54b6fdb0c">4,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfNC01LTEtMS0w_a17265e9-6fc7-43ff-ac7e-5e670e0171c1">227,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfNC03LTEtMS0w_5b220c95-5796-40b7-b4d9-ad8266c13fc0">193,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg4MQ_8dfafcf2-6817-4809-ac8a-cb880de60e53" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5a426a6b1946c89b6817f64c12e299_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS0xLTEtMS0w_d51af9f0-6ec5-49e6-ac22-50ef2bd73668">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice3ee77a9cff45ac9945571ab644d883_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS0zLTEtMS0w_6033bbd7-7fb9-4e93-ad54-0bdd7205a0cf">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i935fa856289043ebb8784c517f1d2af2_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS01LTEtMS0w_03559544-62a2-4a67-b8c9-ea1a10f29c92">17,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS05LTEtMS0w_d906359c-7def-499a-a306-117ba2b67a6f">30,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7e209de56458d92e416e590288a81_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy0xLTEtMS0w_ce87c7b0-a9fb-467d-92bf-2e8a161c2c70">52,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy0zLTEtMS0w_b2a380ae-d5f4-4c09-8666-4957564fbfd4">8,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy01LTEtMS0w_27964001-4bf7-4f41-9416-13a1c42bf9ff">25,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy05LTEtMS0w_7ab114db-bd5c-4b21-8ac1-7050b737ac9b">85,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fd7e209de56458d92e416e590288a81_D20210102-20210402" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC0xLTEtMS0w_e4ba5c57-0edd-4021-b987-2720846c9fbe">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC0zLTEtMS0w_05baf70a-6230-4c80-86ad-dce0f2807a43">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC01LTEtMS0w_5889d589-93be-45fd-8d37-66574f430113">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC05LTEtMS0w_4dfa62da-be56-4b0e-840a-e2e8f0ce19db">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fd7e209de56458d92e416e590288a81_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS0xLTEtMS0w_7f58952a-d263-4338-8270-e3d1ae205d39">49,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS0zLTEtMS0w_b5c603ff-4da0-4a85-b9b6-8e9c920be5d1">5,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS01LTEtMS0w_eef30bcf-7bd1-4342-b216-6a6be4a02ff9">15,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS05LTEtMS0w_db0fcfd8-6123-4310-b6d9-8c101050a03d">71,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda8e5037b204db3976ae10c6e028ac7_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi0xLTEtMS0w_4611de01-f58b-47d6-b730-06771bb972f9">12,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb298ecd26c450db75de5a5f0fb2155_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi0zLTEtMS0w_533f556b-a28f-4944-9400-b4343294d387">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f81bce7d9042b5bcbe2a95f60b3a9a_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi01LTEtMS0w_efef02a4-43bf-4c46-9205-dfbd5a169d0e">27,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi05LTEtMS0w_0f339c0d-2143-450a-93ff-cb94bb4972c5">46,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="idcccb80ec872454a8b33ed5bba648d52" continuedAt="iedf312150d534094b40ef16e18bf0d92"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers or as other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iedf312150d534094b40ef16e18bf0d92">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</ix:continuation> <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNjA0NzMxMzk1OTY4NA_d25ce27a-8f28-4e9e-a199-dafcd20ded3d" continuedAt="i1209b8d01c544fb6bb269b5e0d3f5334" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="ifd1aeaad90f1452b936b8af5a31a8c6d"><ix:continuation id="i1209b8d01c544fb6bb269b5e0d3f5334" continuedAt="i62f2cecd65104b96a74be53d474824c9"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfMS0xLTEtMS0xMjgy_7861c0e2-b16e-4e9d-9cf4-fc2143c86781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfMS0zLTEtMS0xMjY3_74ef7304-a525-4bee-a337-08cf30b71ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNC0xLTEtMS0xMjg4_4a779bfb-2e75-4913-bb08-6cc89a54a058">9,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNC0zLTEtMS0xMjkz_e016cc03-da36-4d6c-b98b-2073982627c0">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNS0xLTEtMS0xMjk5_66070cf3-d09d-47d4-8dc6-ec2d09e7f762">9,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNS0zLTEtMS0xMjkz_5775389d-c4c2-4eee-859c-906d93284748">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNi0xLTEtMS0xMjk5_d414ee41-9698-4af8-9eca-1ad8181443f7">18,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNi0zLTEtMS0xMjkz_8ccedbd0-d5c5-4516-9e5d-7cdd2deca1b1">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.  </span></div></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i62f2cecd65104b96a74be53d474824c9">(2)   Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMzg0Nw_fe77015a-9cde-438c-b78f-0cd43979aecd">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-5" format="ixt:numdotdecimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMTA5OTUxMTYzNDI2Nw_b6722ea4-ba96-49b5-90f9-76c2d0c7efb1">1.6</ix:nonFraction> million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMTA5OTUxMTYzNDM2Mw_4001a7d2-051e-48f3-8ce7-ff267d60c2cd">27.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMTA5OTUxMTYzNDQ5NA_35763dd0-18f4-41ee-ab64-d0e123efbf80">18.8</ix:nonFraction> million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda Pharmaceutical Company Limited (Takeda), Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Genentech Inc. (a member of the Roche Group) (Genentech).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDM1Mg_fd738657-84de-47a4-b2ff-2a8a7f5610ba">87.3</ix:nonFraction> million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMTEyOTY_453f2f59-2677-4c40-8389-b4193bc79333" continuedAt="i35f0592eb50f4e0db0e45819f2795df1" escape="true">COLLABORATION AGREEMENTS AND IN-LICENSING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i35f0592eb50f4e0db0e45819f2795df1" continuedAt="i682b2bdee45c47888b2011602b8697c7"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i682b2bdee45c47888b2011602b8697c7" continuedAt="ib93296c2b3e94627aafcf8df15c88918"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMTEyOTA_a5fd9fdb-69ef-4a63-8edb-b5b3a521c9f4" continuedAt="i943b7fd040c84b9fa0939f5a0c1d6d4e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9d86fd3b5944978f4a854f4a7afa13_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMi01LTEtMS0w_1c48e2f2-0f37-4397-95af-5b9fe142aaa0">22,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d78f7d5227d4a02aff49883e41f93ab_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMi03LTEtMS0w_1090f217-a0ea-4d5a-b635-f66520f9caf7">17,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ea16dceb12421a8f3ad991f4018890_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMy01LTEtMS0w_e0d1ee04-a854-45f1-a6cb-8c35dabfd486">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be727a8bd4c47ed98837d53bd0c5424_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMy03LTEtMS0w_3e0d5263-1591-47ee-9a80-ab9f7a792de4">11,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36eac876d5c64caa8af0b1d90f8647d5_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfNC01LTEtMS0w_c695e3f3-8acb-4b24-9c94-222481a8085f">33,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd260ef2e89045b09b489e3188306512_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfNC03LTEtMS0w_5f045c1d-2b27-40f0-a7e8-0e761cd6d012">29,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i2257faa0011b4db494f9ed2b1349487b_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMzYxMQ_22ab2cd1-414f-463e-919a-e8c4a5d0420c">44.8</ix:nonFraction> million of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020 to, among other things, modify the amount of reimbursements we are eligible to receive for costs associated with our required pharmacovigilance activities, modify the amount of milestones we are eligible to receive, and modify certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02 clinical trials. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><ix:continuation id="i943b7fd040c84b9fa0939f5a0c1d6d4e" continuedAt="iee308d7631974865b80acbc7c68a6827"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.940%"><tr><td style="width:1.0%"></td><td style="width:62.693%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0598c8e5e7946afbf373a833d52f32c_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMi01LTEtMS0w_7cab5ba1-4475-4101-aac9-6b7d1aceec62">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c953dc7f8e45ca83f3d4357a8d0e6a_D20200104-20200403" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMi03LTEtMS0w_1caff836-9c63-4da5-b1fb-95562170d340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc59cc9f93348c6a6d15ebba27b76f9_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMy01LTEtMS0w_c8160674-30b6-447b-9e82-5d964f6f679d">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338ac5d655940fb81117935b0c226e0_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMy03LTEtMS0w_ae43622e-78de-4c43-8771-d425d275c0ee">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a72e61479e84a879347cd4381d1ede0_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfNC01LTEtMS0w_5d2d089d-2c82-4493-a684-51620f33b001">5,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaff5cec481d74bcea3ef68f582e81de0_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfNC03LTEtMS0w_0da1d0a5-d271-4f6d-b65e-351922a0eaa7">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i64b66b3d22614d23aa88f2b13229ca74_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNzM5OQ_62d30e24-e3dc-4e41-9386-7bb8348058b5">42.5</ix:nonFraction> million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK &amp; Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a <ix:nonFraction unitRef="number" contextRef="ic42981c9c0704111836c5dcbda3df875_D20210102-20210402" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNzY4MA_51ea31e1-78a0-439c-97b6-864f308d2193">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="i3ea0b7048aa4459185b0dda8013edb1c_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfODAzMA_cf1df6fe-d3be-43d5-a733-011d91f62509">10.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9805e61daf3145378cc62ee23939e9ff_D20200104-20200403" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMTA5OTUxMTY2MDI1MQ_e029cae5-8ed9-472e-897c-ba6d19d937f6">8.1</ix:nonFraction> million during the three months ended March&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. <ix:continuation id="iee308d7631974865b80acbc7c68a6827" continuedAt="i6dc04ca4d3ef4339bfb0703cc948c52b">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</ix:continuation></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="ib93296c2b3e94627aafcf8df15c88918" continuedAt="i255e9fd03a8c4891940f608a89b6fb12"><div style="margin-top:9pt"><ix:continuation id="i6dc04ca4d3ef4339bfb0703cc948c52b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMi01LTEtMS0w_698d9f27-49d0-4986-81c7-38e7ce6243fa">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40279315ce444f11a37ef540f6d742b5_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMi03LTEtMS0w_b8e43d23-dabe-4ea3-893b-dc4d57c46c48">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMy01LTEtMS0w_ab3d9376-a9d2-4cf7-a8f8-6f22dfad7d94">951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40279315ce444f11a37ef540f6d742b5_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMy03LTEtMS0w_813555e0-6f05-4de4-8068-ad6fb378b6b1">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations and In-Licensing Arrangements </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i255e9fd03a8c4891940f608a89b6fb12">In the first quarter of 2021, we entered into additional licensing and collaboration agreements in support of our preclinical pipeline with Adagene, Inc. (Adagene) and WuXi Biologics Ireland Ltd (WuXi Bio). As part of these agreements we made aggregate upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i1c01c5a5d8f54262b32390c82a09e601_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5Mzc5NA_81f21a08-7982-47c6-8ead-81f7eeb1b047"><ix:nonFraction unitRef="usd" contextRef="ib4664d16060941379ab6fa2d61b74a13_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5Mzc5NA_fc4c68c6-94b3-45ea-8900-cfb8dce72945">14.0</ix:nonFraction></ix:nonFraction>&#160;million in exchange for licenses to develop and commercialize products. We committed to make payments to Adagene for potential future development milestones of $<ix:nonFraction unitRef="usd" contextRef="i60c52c8abd6f4b608764f83a27cbc14a_I20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjE4Mg_fb08d053-6640-46f6-b362-b03434b00187">55.0</ix:nonFraction>&#160;million, regulatory milestones of $<ix:nonFraction unitRef="usd" contextRef="i60c52c8abd6f4b608764f83a27cbc14a_I20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjE5Nw_4592764e-e5e0-4e7d-a607-8ed48cf71f8d">200.0</ix:nonFraction>&#160;million, and commercial milestones of $<ix:nonFraction unitRef="usd" contextRef="i60c52c8abd6f4b608764f83a27cbc14a_I20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjIxMw_b72c3ce2-28ff-4f9d-b160-052ab5112d0e">525.0</ix:nonFraction>&#160;million, each in the aggregate, as well as royalties on future net product sales. We also committed to make payments to WuXi Bio for potential future development milestones of $<ix:nonFraction unitRef="usd" contextRef="iad6f1409c99d4cb69907fadf7fd41180_I20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjIyOQ_88d1f17d-ca58-41a1-89fe-a8a7f45079a4">18.5</ix:nonFraction>&#160;million, regulatory milestones of $<ix:nonFraction unitRef="usd" contextRef="iad6f1409c99d4cb69907fadf7fd41180_I20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjI0NA_3307a5f9-2188-4862-b838-844463ca17bf">30.0</ix:nonFraction>&#160;million, and commercial milestones of $<ix:nonFraction unitRef="usd" contextRef="iad6f1409c99d4cb69907fadf7fd41180_I20210402" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjI1OQ_9a3fecc3-354f-4242-92e4-a1dcae965113">80.0</ix:nonFraction>&#160;million, each per product, as well as royalties on future net product sales.</ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjI0Mw_a13a2a94-2997-4f41-bfbf-236efa3d5b9c" continuedAt="i1d0dfc7e445b427b9546e4c8a346d829" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i1d0dfc7e445b427b9546e4c8a346d829" continuedAt="i39fb81fa33834155b775ed50cf165794"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjIxMg_1efacf07-0412-465f-a518-40beb9eb8c88" continuedAt="i52a28706230843f7841f29db7b2d60f2" escape="true"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjIxMw_2696d6b5-2af2-4948-be64-118e8745e16c" continuedAt="i49c6089c0f994c998b62b69c753e0a7a" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i52a28706230843f7841f29db7b2d60f2"><ix:continuation id="i49c6089c0f994c998b62b69c753e0a7a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMS0xLTEtMS0w_99532cb1-38c8-4646-b6ac-f5656df49233">370,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMS0zLTEtMS0w_ed7320c4-eea6-4d35-bebd-855b549655d7">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMy0xLTEtMS0w_e6e5a5fa-d420-4cab-9a6d-d37bd1dfcfb2">49,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMy0zLTEtMS0w_9755c214-3335-44c5-967c-8cbacbb7fa5a">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfNC0xLTEtMS0w_22dff960-d997-437f-8ce8-e3bdabb6e1ff">419,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfNC0zLTEtMS0w_4bc7bbce-78f0-470c-814b-bbdb6d3f1e4d">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of March 31, 2021, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTA5OTUxMTYzMTQzOA_2b16dd5b-5060-4338-ad2b-bce21a952cd4">48.2</ix:nonFraction>&#160;million of short-term investments as collateral under our standby letter of credit entered into in January 2021 as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjI0NQ_ad0f1bfc-4702-4f22-85b9-aed43ff0cfb1" continuedAt="ibd9767f38d6e478a85abd918bed4e729" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32119146b8b54758a862a6fc16e21509_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy0xLTEtMS0w_0b4a6dfc-7b96-4132-a56e-eec9c2dd67f3">667,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32119146b8b54758a862a6fc16e21509_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy0zLTEtMS0w_7d0e5884-308a-4aad-a1ef-d1a153e435ce">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32119146b8b54758a862a6fc16e21509_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy01LTEtMS0w_3dbb1272-80d0-40c0-b040-e65b904559b2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32119146b8b54758a862a6fc16e21509_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy03LTEtMS0w_5c2b8a1f-b2c5-4f4f-802b-a1cfeb8b77cd">667,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC0xLTEtMS0w_4f2ef425-cd73-4fae-be15-afad71b7f956">495,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC0zLTEtMS0w_75ed31fa-44cf-41ee-92e4-18f4df1917b1">3,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC01LTEtMS0w_e629a624-d42d-4c3e-9c17-cdb5da70a711">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC03LTEtMS0w_113d8af6-ea51-41b9-9c5a-88a52a7e944f">498,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS0xLTEtMS0w_afe93cdf-69e3-4dc2-81c2-06b1faed2318">148,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS0zLTEtMS0w_1c4ffc23-9081-4b8f-b8c0-70f6d2e1e490">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS01LTEtMS0w_fb8b6e50-bf52-48f9-ac90-bad957701b08">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS03LTEtMS0w_538f896c-4af9-4645-8987-812623d91cb5">148,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi0xLTEtMS0w_2460de61-e2b6-4dd9-919b-851a27fac6a4">27,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi0zLTEtMS0w_b01acb66-3245-482a-a957-95aef0d3eb2a">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi01LTEtMS0w_d5480fd7-51b6-4ab9-aca2-de52e431abca">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi03LTEtMS0w_9eb2284c-8564-4ebf-8b98-e144d7e7d5ae">27,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy0xLTEtMS0w_db4e53b8-acd6-4c7d-a79a-ea1264d009c1">1,338,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy0zLTEtMS0w_49440462-10eb-466b-9aec-19430994c96b">3,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy01LTEtMS0w_7d1f7344-0721-44ff-8ace-03993bbb1695">291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy03LTEtMS0w_1facc5a2-81e6-4c72-bcf4-8ab2da7a2bf5">1,342,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC0xLTEtMS0w_f7638261-7674-4ce2-bfb4-fb442d586afd">52,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC0zLTEtMS0w_894c1e43-8fec-48ae-8089-8a19f76ea50a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC01LTEtMS0w_8c71271f-28e4-4e5e-ac58-2b65cf93cce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC03LTEtMS0w_ba73e551-35b5-40fb-a24f-204f3e0b7815">52,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS0xLTEtMS0w_29a76942-b4af-47ab-83ab-0cc1e73ea0d3">105,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS0zLTEtMS0w_4c744441-9096-498f-84cf-6fb8cbd8c76a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS01LTEtMS0w_2c1fd28f-539e-4231-b45d-34146957935d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS03LTEtMS0w_18d6688f-dc24-413e-8844-071fe190bfd5">105,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtMS0xLTEtMA_42997821-0641-4b93-9ecb-749ed6fde9a5"><ix:nonFraction unitRef="usd" contextRef="ie4bdd567b1f84314b22e6f47db7ed986_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtMS0xLTEtMA_ac0af483-b36c-41f1-9e8c-8e825da06254">63,305</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtMy0xLTEtMA_7159dd5e-8b94-41b0-ad20-08385e77e8bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtNS0xLTEtMA_91f8a3ec-5d7b-4aab-941c-7ca5051f2db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtNy0xLTEtMA_d06e3bf9-33d9-4f5c-8cb9-9405586d84cf">63,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtMS0xLTEtMA_04852853-587e-4647-8a29-ddfc81567a74">1,560,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtMy0xLTEtMA_a598b9cf-218e-495e-a1e9-8ac454e3bb7a">3,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtNS0xLTEtMA_eafa71b0-747c-4902-8cd9-35db3564b94b">291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtNy0xLTEtMA_4783b3e9-b7ba-4184-9ce8-424efeb0764a">1,564,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i39fb81fa33834155b775ed50cf165794" continuedAt="i0f0054b77594442db08e1208019b6dbb"><div style="margin-top:9pt;text-align:center"><ix:continuation id="ibd9767f38d6e478a85abd918bed4e729"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy0xLTEtMS0w_c5114268-8f6b-41f7-81c8-3eb8c3bc9a43">569,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy0zLTEtMS0w_686ff8ba-e160-408e-b530-ba7f25ea625b">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy01LTEtMS0w_5c8af7dc-5bb0-4938-9741-e99bed037e14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy03LTEtMS0w_4c4dd548-3ab5-4dba-9c0f-ce4fa1323edb">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66c4113d53e4bb3957023006b998620_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC0xLTEtMS0w_f6989159-6530-4ff3-9fa7-21c676028738">543,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66c4113d53e4bb3957023006b998620_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC0zLTEtMS0w_d4a6fc97-7ec4-4cf7-89b5-432ae5d996c9">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66c4113d53e4bb3957023006b998620_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC01LTEtMS0w_e94538cb-78dc-49f7-abf2-9afab69e0107">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66c4113d53e4bb3957023006b998620_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC03LTEtMS0w_eaa54624-a5d5-4322-bce1-bcc3b6b2be77">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS0xLTEtMS0w_dfcd3748-81d4-476c-9000-7452e65506b6">208,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS0zLTEtMS0w_73ef982e-5155-4782-b1d9-17a696c57f36">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS01LTEtMS0w_00f7ac4f-47e5-4693-b605-9e2685f1d019">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS03LTEtMS0w_584bd6e3-c464-4f77-9fb8-67135c6f4532">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0xLTEtMS00MjY_66c6db85-a8ca-4bd1-ac0d-7267353905f9">28,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0zLTEtMS00MjY_974824dd-cfea-4824-abe0-8ae20c742c7f">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi01LTEtMS00MjY_ad982cd7-e3e3-4ffb-824a-aae35174056a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi03LTEtMS00MjY_4d747ef4-7cf6-4cef-b74c-28d0cdd14189">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0xLTEtMS0w_b6759153-7da0-4ae4-b9d7-335c8d6b44b0">1,349,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0zLTEtMS0w_b92bbf52-236a-4a72-829e-f72a97324f5c">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi01LTEtMS0w_b6582cf3-9619-451c-86fc-786ff57a7fef">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi03LTEtMS0w_e6d4eee1-1a2b-4534-91a4-61c30749a3f1">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy0xLTEtMS0w_b5bcd41d-a072-4a53-a4db-6f2421872e23">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy0zLTEtMS0w_f1666bd5-455d-45cd-b6a1-6e8f22c6d905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy01LTEtMS0w_3bdd837b-df5b-4d09-88d0-1fcf1685798c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy03LTEtMS0w_86b06b9b-9832-4803-931c-c94c1f734a71">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC0xLTEtMS0w_5d349c87-331a-46d3-aeac-53d090bcf65b">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC0zLTEtMS0w_54182645-2898-49fa-95b2-598d5b777222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC01LTEtMS0w_8ec1666a-a2a1-4385-93a2-af5a88fba911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC03LTEtMS0w_dac9d2f4-aa08-415a-b2f1-4d3489c2dacd">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS0xLTEtMS0w_5b814ef2-87b7-4ea2-b767-ff5278ab32d7">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS0zLTEtMS0w_08fa9a33-0e5c-4143-8457-34a79541543f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS01LTEtMS0w_85d24f03-46c4-472c-9ada-6f368534d05a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS03LTEtMS0w_81eb5e7f-54d9-49b9-bd3d-6f9bd2c0c9fb">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtMS0xLTEtMA_1c60b128-e214-418e-a095-134650a82614">1,532,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtMy0xLTEtMA_2d8ea918-743b-4a85-b3d2-0fb2e331aa18">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtNS0xLTEtMA_9e2d53c6-6de0-4266-aae7-b8af7d0948e4">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtNy0xLTEtMA_21e7d68f-e67d-4527-a6ba-477790042d66">1,538,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfNzUy_9269b779-3aa9-4e84-8f18-032167f91433">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfNzU5_3c115c82-8fe7-45a2-bdbb-ac553fb137de">4.5</ix:nonFraction> million as of March&#160;31, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjI1NA_4fe2d56b-12ea-4adf-8ff9-1ef808d5d1eb" continuedAt="ib92e54a0bbf6454d8facbc9bfb8bbdf2" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ib92e54a0bbf6454d8facbc9bfb8bbdf2"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32119146b8b54758a862a6fc16e21509_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi05LTEtMS00Nzc3_cdb8662e-70a2-4484-9e28-db6c91130a14">4,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32119146b8b54758a862a6fc16e21509_I20210402" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi0xMS0xLTEtNDc3Nw_9ff8ab77-ef4f-4528-b4d3-2647d80ebca5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi05LTEtMS0w_ee15c480-e59b-4133-8785-0559a5013e2e">131,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi0xMS0xLTEtMA_ecc82ac6-961d-40cf-a0de-ea1a9a7a7fd0">275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMy05LTEtMS0w_12977306-e283-4921-a4fe-5f522fcf1374">31,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMy0xMS0xLTEtMA_cd97f2e8-b033-4095-8703-1e489df828e5">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNS05LTEtMS0w_73dd2e68-5bed-4584-ad13-24a9d90860be">12,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNS0xMS0xLTEtMA_fa2de607-fca2-44c3-ac20-c7523a29aa56">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNi05LTEtMS0w_808fa3e4-bb04-4703-85c5-5d35aa0fca71">180,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNi0xMS0xLTEtMA_10825a9c-3c59-4d98-90ac-3ebabb43259e">291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66c4113d53e4bb3957023006b998620_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMi05LTEtMS0w_d8c4aa74-1cb4-4932-87b1-62cf456f8bf7">28,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66c4113d53e4bb3957023006b998620_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMi0xMS0xLTEtMA_ce490e8e-3975-4273-afb5-0f738da5c974">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMy05LTEtMS0w_b8d35914-53a7-4020-8a2d-e7f3538afbfd">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMy0xMS0xLTEtMA_849993de-c201-4918-acf4-e25de069081d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNC05LTEtMS0w_b23b5dbf-f144-4a10-8265-45ef802145ab">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNC0xMS0xLTEtMA_7631a1c0-84c9-4098-a2ea-8abb84fdd2c6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNS05LTEtMS0w_1da02aff-df2a-40a8-ba73-85d70454379e">56,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNS0xMS0xLTEtMA_d1a52c4c-a53c-4e33-9935-1dbcc032b835">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were <ix:nonFraction unitRef="investment" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTQ3OQ_5442b978-6cbf-4b48-b5db-ce01b412124c">53</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTQ4Ng_3f2ea138-0a15-4232-964f-c1ca1fa1bbd1">14</ix:nonFraction> investments in an unrealized loss position as of March&#160;31, 2021 and December&#160;31, 2020, respectively. During the three months ended March&#160;31, 2021 and 2020, we did <ix:nonFraction unitRef="usd" contextRef="ic99cda1e69634b08b343ceeb851e2c7f_I20200403" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTU5NQ_230f8040-9e0d-45ef-bcb9-5a2d17299141"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTU5NQ_ce9fb230-30ce-4cd9-a87a-0f1dace9effb">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i0f0054b77594442db08e1208019b6dbb"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjIyNg_dc3def0e-ab43-4953-b081-389078161239" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMS0xLTEtMS0w_8e9e3f9e-4dd5-4da6-9d7a-a0a4264be305">1,021,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMS0zLTEtMS0w_a04f7a37-c398-4487-830e-18c3893091f7">1,034,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMi0xLTEtMS0w_6bf4064a-c570-4c93-b80d-073cd95043eb">320,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMi0zLTEtMS0w_ba6f2c93-33b8-4ca4-b348-674d22a0bb0f">321,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMy0xLTEtMS0w_209fe46e-3a55-4b0f-a609-623e93fcf3d9">1,342,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMy0zLTEtMS0w_6cd528a1-8323-4269-9a74-c71a84c4d385">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_939"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzYwNDczMTM5NTM5NzA_620f164f-6696-4822-83f4-069373a51aa8" continuedAt="i9040a5b1d74848a9934c3e1d7dd55243" escape="true">FORWARD CURRENCY CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="i9040a5b1d74848a9934c3e1d7dd55243"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had <ix:nonFraction unitRef="forwardcontract" contextRef="iaf9c81849c224cf1a0586e1bcd1d2538_I20210402" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzU0OTc1NTgxNDAzOTQ_3e697086-04a4-4174-9d09-99b9817ece67">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="iaf9c81849c224cf1a0586e1bcd1d2538_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzYwNDczMTM5NTQwMTM_5c23c78e-f1b8-408e-bb88-79cca4b8558f">9.3</ix:nonFraction>&#160;million. The forward contract has a maturity of <ix:nonNumeric contextRef="i9c90e1d818864936ad88a7d0eecd505d_D20210102-20210402" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzU0OTc1NTgxNDA0MDI_7c2c74cd-44fb-4beb-8de8-d9f89741f02f">three months</ix:nonNumeric>, is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The fair value of the forward contract at March 31, 2021 was not material. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the three months ended March 31, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i9c90e1d818864936ad88a7d0eecd505d_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainOnDerivativeInstrumentsPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzYwNDczMTM5NTM5ODU_01585ab4-5cb1-43ad-ac83-1644e681a6fe">0.4</ix:nonFraction>&#160;million of gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RleHRyZWdpb246OGExMjkxZmZjZjRiNDI1NThlMjM2ZDEyZmJmNzQ0OWRfMTUzNQ_8b827ee2-b4a9-41aa-83ab-f37b72115506" continuedAt="i2d3936850f284cdcbe9d696e2c3c9134" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i2d3936850f284cdcbe9d696e2c3c9134" continuedAt="i697cdc850307407fac0e78ceece5fd47"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RleHRyZWdpb246OGExMjkxZmZjZjRiNDI1NThlMjM2ZDEyZmJmNzQ0OWRfMTU0Mw_ae652e74-65ef-4b8b-a444-977e04553209" continuedAt="i796adcf4052f466e8b774f7d2f13914b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9921b8f98f46428c8230f8cc4d5b8de5_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMi0xLTEtMS0w_4177d0b6-6e6c-40ca-9f6d-b1843d52710e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9fef9dd01c3463884a549e712c67975_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMi0zLTEtMS0zNjc1_892ffd24-56ea-4dc6-922c-8752ea874a06">667,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b066d94ab5d48e4a3165fe4d64c48cd_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMi01LTEtMS0w_358d127f-106c-4ebc-89cf-c90ac72c900f">667,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79ae71b4d194663b3217ba40d89497a_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMy0xLTEtMS0w_d2e59e0d-37a5-469b-8269-1dcce3b0c432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91a81478309419e9d65e9da67aa5b90_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMy0zLTEtMS0zNjc1_0995fb8f-cea7-448c-bc47-b4a5aceb8381">498,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a6af5ad3d6491eb55e7a02e03ca7f0_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMy01LTEtMS0w_d23539eb-4329-4224-8f58-f46e3027b4cc">498,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba1677dbd26445dc9bd4d84baffd67f6_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNC0xLTEtMS0w_c3d1b9d9-11d2-47fb-a6a4-3fc15ce3ba34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e586cbac7b74f1d80c273b7797e092d_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNC0zLTEtMS0zNjc1_9e1dd71c-9748-4404-8b8d-feb33ad45647">148,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6350986f2c204a2488862f0ace5acbcd_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNC01LTEtMS0w_51e4eb01-9266-4f1a-902a-cb8d322a04d8">148,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554b0eab7ff4477ca7fd008d3dd2c260_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNS0xLTEtMS0w_4cda96ad-e3f0-43da-a2c7-c81e950412e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9769920780449fbdaf815855b16f9c_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNS0zLTEtMS0zNjc1_9eb2284c-8564-4ebf-8b98-e144d7e7d5ae">27,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i415a1c2ee7384eba9691f7dbb9a64ac0_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNS01LTEtMS0w_323ae705-21d5-4cc6-98d2-695a475b6fce">27,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccddea8bdc34321a373d4b211f85366_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNi0xLTEtMS0w_105604e1-5248-44d4-941a-55680ae0577b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a320379c33746e8a62505863f507b0b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNi0zLTEtMS0w_b1c85175-d269-440a-b69f-469949949945">1,342,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f8f448a7e44f71893357d3ac2b9a60_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNi01LTEtMS0w_26620e2e-56a9-4332-b8a5-db3026d23c46">1,342,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e178b46a658489fb7b95d67e5ac005c_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy0xLTEtMS0zNjc3_2bb36dc2-6526-4afe-af68-578b957eeaf1"><ix:nonFraction unitRef="usd" contextRef="i7e178b46a658489fb7b95d67e5ac005c_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy0xLTEtMS0zNjc3_b4be7724-23db-4c99-ba5d-4996f67a16cb">105,775</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5966995df7754c27a0b4f6cf9ddfcf30_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy0zLTEtMS0w_2cc43d76-2234-4ce4-b602-2a9f8ee7eaec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacaab7c5ee54a3d9ae628433835e5b2_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy01LTEtMS0w_0f6afda4-8732-4fcb-94b3-a45759713880">105,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e3fe01255048d58bc6c48c899a44f9_I20210402" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC0xLTEtMS0w_8a321a8a-9320-4fb6-bbee-8493400bb2be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC0zLTEtMS0zNjc5_42997821-0641-4b93-9ecb-749ed6fde9a5"><ix:nonFraction unitRef="usd" contextRef="ie4bdd567b1f84314b22e6f47db7ed986_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC0zLTEtMS0zNjc5_ac0af483-b36c-41f1-9e8c-8e825da06254">63,305</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14575a1b1fbe41f2ad3f7b52e297ed34_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC01LTEtMS0w_89fa8ac3-a013-48bf-9763-32bd97e6f427">63,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccddea8bdc34321a373d4b211f85366_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOS0xLTEtMS0w_8cdc3bba-b700-487a-98ad-cd93cdc10887">105,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a320379c33746e8a62505863f507b0b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOS0zLTEtMS0w_ee8a8e60-5952-45a6-a567-cdd448c813fb">1,405,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f8f448a7e44f71893357d3ac2b9a60_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOS01LTEtMS0w_69474720-c7d8-4c1e-9f69-aa9fd5f06c7e">1,511,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i697cdc850307407fac0e78ceece5fd47"><div style="margin-top:9pt;text-align:center"><ix:continuation id="i796adcf4052f466e8b774f7d2f13914b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe4c382d26c42ca9aab7aae9c0d74cb_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMi0xLTEtMS0w_0187c235-c33b-4140-bc79-0bec77e5df3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cc15096d7544af483700aaf508a964a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMi0zLTEtMS0w_dba637f4-b6f7-4dfa-a182-12b79946e06b">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec009171117540bdbb58c1be5851a2d7_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMi01LTEtMS0w_c65cdcc4-d903-4218-b6e5-ff4e9a8e2b14">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe21729df9640cdbe357f4ec3f1d02a_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMy0xLTEtMS0w_52614c7d-dc35-4f78-acc8-c8d70cb5de67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320b4929fd414ebf96f80e9078a55169_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMy0zLTEtMS0w_41eee934-6c34-4f17-88be-95cee831d370">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82d730819e3d4d3c9dde3eeeb9a8b9c9_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMy01LTEtMS0w_90b44f78-2dbd-411c-93c4-1a2d7db9fc20">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fc1e1e560a449a9311f3bf3efd3e52_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNC0xLTEtMS0w_cd03de6a-e52d-48cf-9740-f5872d8eb1dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c476589a9744e4a0a2d5a9ec2bb854_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNC0zLTEtMS0w_dc5d076c-708c-4203-9463-13d11894d44b">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i317939be92c5441a8c74c4d69f167550_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNC01LTEtMS0w_08367f66-04cc-4800-a436-ce6ef315e3d5">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c07b0da2b0d43f8bd7ff0a0f78a9545_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0xLTEtMS00NDk_6dab7d8e-53bb-4b3d-bd9a-d54363f12909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68847f2d1e1d4718a5bda4b12d840afe_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0zLTEtMS00NDk_3cda3cb8-ea44-420a-ae51-3cf7d65c64d0">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f1822a756341a984f6f5e493514983_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS01LTEtMS0zNjgx_ae84191a-a124-43a6-9067-2b59d0746fad">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie576c7303b774e12a574df1fb982d1f0_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0xLTEtMS0w_afbd4c89-4b42-4ca1-8c3d-385e73e50582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a800e8408eb4e51a4f63612b53ab204_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0zLTEtMS0w_491596d4-8d2a-4f8b-9ce1-d629f6abf60c">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191e1eb15cf4c0385b5db4eb3d8d740_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS01LTEtMS0w_dfc5df8a-cd79-45c5-b919-a0fb1e9117d3">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba91e88df5042f390aa570d7bc9525f_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNi0xLTEtMS0w_92a428fe-8c8a-4bfd-b587-6308f62d89b4">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa26564d1144ad68101916a752c72c5_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNi0zLTEtMS0w_d22bb3f8-9632-4033-8130-2add4d6af006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c81d2dc86224957b76780b9b01b05fc_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNi01LTEtMS0w_69312c38-8f7e-408a-8b68-0ac1c669950e">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12afb5247d4341d8b3086641b3b17606_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNy0xLTEtMS0w_04deb7d7-ae0b-40fb-a694-b677396e88c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81956f5ad624fb3a34af890cb926767_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNy0zLTEtMS0w_5a8b91f6-5daf-4594-b4b0-75fb71301f45">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9234350c43af4d5fa786ab8abc166d55_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNy01LTEtMS0w_1e32cadd-3d25-49bb-839e-383177fab871">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie576c7303b774e12a574df1fb982d1f0_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfOC0xLTEtMS0w_e37bb0f1-1fef-445e-8b78-467683b93c9b">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a800e8408eb4e51a4f63612b53ab204_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfOC0zLTEtMS0w_d352e0fa-8d45-4574-bd54-3d120c93e408">1,415,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191e1eb15cf4c0385b5db4eb3d8d740_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfOC01LTEtMS0w_63fa2e0a-5426-4550-affe-07535135c2bc">1,456,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTky_18da5085-d31d-48b0-a76d-e163f070bd58" continuedAt="ibc67244bc50d406597491d243f48fc15" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="ibc67244bc50d406597491d243f48fc15"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTg1_c3043ad5-b780-41d5-af03-c0c1e9f7298c" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMS0xLTEtMS0w_a8e57614-2214-439e-b063-c13653a5e485">7,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMS0zLTEtMS0w_fe678d94-8b37-4bad-a2d2-381f0fb4e504">7,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMi0xLTEtMS0w_9ff29431-804c-42cd-8ead-5afa46214204">21,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMi0zLTEtMS0w_9888630f-7aaa-4034-b0d7-99cb82a350da">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMy0xLTEtMS0w_fd95965d-d52a-4cd8-97cc-76e923a5fdfd">5,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMy0zLTEtMS0w_83af9f83-382e-4579-b065-6e5051547014">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNC0xLTEtMS0w_7f96b4ee-32a6-44b2-bf34-2af30f22e1db">35,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNC0zLTEtMS0w_82acf29e-9e65-495a-b8e6-248cb88c21a9">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504de91fc7df4dbd9eba09e75fabc924_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNi0xLTEtMS0w_29167b26-2a29-4ee3-8792-e71746fd095a">24,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ff09f3344f4de1a78249a095f43788_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNi0zLTEtMS0w_76ac6aa8-32bd-4f7d-bd39-2feb0643f575">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02becf95ad41458a9f42b2d89fbc17fd_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNy0xLTEtMS0w_3242afee-c1d1-43de-8141-c98df966b2cc">10,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb144073f9ec4ff78af65d49175c7cbe_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNy0zLTEtMS0w_8e9968d2-f94b-4945-b670-403bb33a63f6">14,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfOC0xLTEtMS0w_f526b0e0-d703-4922-a422-fdaa60ff0cf5">35,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfOC0zLTEtMS0w_acdc804b-abc1-4461-82a1-6f722ac8af5e">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $<ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTM2_55ddfba7-af7e-4324-b4a6-1c94778cf2aa">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTQz_fe3cf5da-7367-439a-ac7a-af6eae66ff1c">0.2</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNDI4Ng_a582709e-6d78-49ae-a025-6e990fd0363b" continuedAt="if953f1115e704d62a231a2e1dba82a3f" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="if953f1115e704d62a231a2e1dba82a3f" continuedAt="i88b3877b2b124d049ccc5434cbadbf62"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNDI3OQ_85d18aa5-e328-4812-90fd-47648040d5a2" continuedAt="i01c639218d3b4d82a3c4984f9b444d68" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ddda20eb4846618e6298bc462af14b_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMi01LTEtMS0w_81e4398b-5c89-4a35-98ae-24d1d25851e7">12,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1369691551dc4fafb80d4de87f27c595_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMi03LTEtMS0w_ebb6e8ae-9036-4827-b5ca-600f8fbb02b8">5,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed02b22b90b48f3b8a0903941c79c91_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMy01LTEtMS0w_e3b9b737-32d0-4340-af32-0b78d81b91a4">22,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcfe7378fa74f1399955c024d098430_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMy03LTEtMS0w_ffd1b04c-5bc7-4972-a6b1-62221100315e">8,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfNC01LTEtMS0w_0c78a9f5-951f-49ca-aa8e-4dd1b2072ac6">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfNC03LTEtMS0w_a08409b5-b20a-4689-9066-22b1deda0a3d">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i88b3877b2b124d049ccc5434cbadbf62"><ix:continuation id="i01c639218d3b4d82a3c4984f9b444d68"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMi01LTEtMS0zNjkx_42ab78f2-3810-421a-b8de-7dba36ed3c52">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18980bf9a07498daf97936c223cd8bd_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMi03LTEtMS04Njc_60a8e3db-299d-4c6c-99a8-db5bf0cf1845">4,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408345112b514492b8672264d5e9495e_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMy01LTEtMS0zNjkx_dd4bc807-decd-4cb0-972f-4a6a374faf5a">11,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3af9d6876ad41e9a9459ff5b52f0864_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMy03LTEtMS04Njc_54da0e9b-efe0-4693-9800-65213c176742">7,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNC01LTEtMS0zNjkx_3d6d92bf-9be7-4542-b655-4a191abede39">17,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666a5e9b8134485fa80a9e4de6771543_D20200104-20200403" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNC03LTEtMS04Njc_b700cdf2-19d7-410c-a26f-d22bdf05d691">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i949dcc93029c4d24bde4a783adbeeacb_D20210102-20210402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNS01LTEtMS0zNjkx_3e675927-2800-465e-ad70-fb3b11b6405b">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa0e1f1fe17409098662f0eaa3cf7f2_D20200104-20200403" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNS03LTEtMS04Njc_22317178-1168-4984-9203-9352f4739261">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNi01LTEtMS0zNjkx_df53770b-99be-4ce0-82a8-1324e26e8c7a">34,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNi03LTEtMS0zNjkz_f3b251ac-aaec-4351-afdc-d7611298ae0a">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjA3_932485a6-aeb1-4e05-a5d2-47c727c973f9">9,272,614</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMzY4_d1693d9b-b302-442d-bce9-14dba6bf48e4">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNDU4_c130a5eb-0b5c-44de-afa1-2bb0361c0c65">1.5</ix:nonFraction> shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we granted <ix:nonFraction unitRef="shares" contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfOTI4_804942e6-7f71-4472-ac0d-437f530d082e">881,440</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfOTg3_2eaaa0e3-6aaf-49d8-88fc-4a9a61d6e38b">21.75</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTA0OA_2c43834d-3ce4-45d4-a4ff-c47544bde9ad">9.88</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of March&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ibc8c9c247bbf4f2fa55811d4b33ba5b9_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTA4Mw_c29d5f1d-827c-4d44-9532-ad83c8bbcf27">15,688,044</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="ibc8c9c247bbf4f2fa55811d4b33ba5b9_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTExNg_a6af9723-3f0d-40f5-87fa-ebb98bddaadb">30.7</ix:nonFraction> million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we granted <ix:nonFraction unitRef="shares" contextRef="i408345112b514492b8672264d5e9495e_D20210102-20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTE4NA_6e6c7cf8-c915-4cf0-9b21-b107a7fe1ef8">3,059,698</ix:nonFraction> service-based restricted stock units (RSUs) with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i408345112b514492b8672264d5e9495e_D20210102-20210402" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTI1NQ_ac45e4bf-3aa5-473e-b0a1-873645016e01">21.43</ix:nonFraction> per share. As of March&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i677b05d55bac4440b27c7ed808660a68_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTI5MA_833f81a4-4ea4-43b2-a3ab-c0c349a370b2">8,282,867</ix:nonFraction> RSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="i677b05d55bac4440b27c7ed808660a68_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTMxNA_c6ceb304-fb14-4499-a01d-355eff0f8a45">155.9</ix:nonFraction> million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the three months ended March&#160;31, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we awarded <ix:nonFraction unitRef="shares" contextRef="i8622ebd208ee40748f3badc2d3baff8b_D20210301-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTA5OTUxMTY1MjY5NQ_a52ecb3f-468c-468a-8278-505e6077d491">1,027,650</ix:nonFraction> (the target amount) performance-based restricted stock units (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to <ix:nonFraction unitRef="number" contextRef="i8622ebd208ee40748f3badc2d3baff8b_D20210301-20210331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNjA0NzMxMzk3NzUyNw_0ce3c7a5-c04f-4046-ba44-291eb9b73e4f">200</ix:nonFraction>% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. <ix:nonFraction unitRef="number" contextRef="i21631f07cfc643bd9432ab5a17b6267d_D20210301-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNTQ5NzU1ODE2NTkxNA_1436b797-3828-4982-82ac-a7fcb53b560c">Fifty</ix:nonFraction> percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately <ix:nonNumeric contextRef="ifcf3d4993c944a21a332310247496165_D20210301-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNTQ5NzU1ODE2NTkzNA_0e7716be-e403-47a2-a6f4-b0c10d561e75">one year</ix:nonNumeric> later subject to employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.</span></div><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNjA0NzMxMzk3NzUwMA_e1795d02-33df-4935-a0ad-c89075a70dcd" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNTQ5NzU1ODE2NTkwNg_16f1bb99-c80d-4209-b185-de9fc11bacef">24.54</ix:nonFraction> for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9911c9d99e354292b6c84ef2ea046b40_I20210402" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMC0xLTEtMS0zNzU0_4e8f99b5-ba8b-4252-ac18-c799c6be69f4">21.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMS0xLTEtMS0zNzU0_11ac59bb-316e-437f-b8a6-ff62e04aa878">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMi0xLTEtMS0zNzU0_299106d3-afa7-430a-9654-afcbec9a917a">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMy0xLTEtMS0zNzU0_5ede2eb4-bda3-4888-a53e-652c6819ed3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2021, there were&#160;<ix:nonFraction unitRef="shares" contextRef="i9911c9d99e354292b6c84ef2ea046b40_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjE5OTAyMzI3OTIzMA_78f2ff64-2ac2-440d-91ac-3a20ffc4bf1c">8,767,305</ix:nonFraction> PSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="i9911c9d99e354292b6c84ef2ea046b40_I20210402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjE5OTAyMzI3OTMwMQ_7c9ffd0c-17f8-4c15-bfcd-1fa0810f186c">161.2</ix:nonFraction> million of related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended March&#160;31, 2021, we achieved additional performance targets for <ix:nonFraction unitRef="shares" contextRef="i6017a4101e7f412f89057676d1636d3e_I20210402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjE5OTAyMzI3OTc3MQ_24f83694-a3a0-4f5e-89b5-b672b6bdfbf4">461,532</ix:nonFraction> additional PSUs granted during 2019. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81NS9mcmFnOmVjYzg5OWI3NWFlZjQwNWJhOTkzNmM3MjNkNWM4ODA5L3RleHRyZWdpb246ZWNjODk5Yjc1YWVmNDA1YmE5OTM2YzcyM2Q1Yzg4MDlfNjk0_f90d3a0e-ade0-4b38-8601-906b061a0fb0" continuedAt="i31c73ede5ac64341bdcf919bc8a617ee" escape="true">PROVISION FOR (BENEFIT FROM) INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31c73ede5ac64341bdcf919bc8a617ee">The effective tax rate for the three months ended March&#160;31, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period. The effective tax rate for the three months ended March&#160;31, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits.</ix:continuation> </span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RleHRyZWdpb246YmIyY2I5YmI2OTY3NDBlOTllZmJjMWRjNjhjMTU0N2RfNjg2_7460e692-181d-412b-a6ba-cffb567ad596" continuedAt="iedeccca708d94134b3e69f495f15ded9" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="iedeccca708d94134b3e69f495f15ded9"><ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RleHRyZWdpb246YmIyY2I5YmI2OTY3NDBlOTllZmJjMWRjNjhjMTU0N2RfNjcz_5aa0bc62-fc1e-4dcc-b9b5-bf05415dd0e8" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfMy01LTEtMS0w_ecd714ce-eb21-40a9-a879-48e71daa1ad0">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfMy03LTEtMS0w_0ea809f2-6783-488f-8721-7b546a97a932">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNS01LTEtMS0w_a936ce71-94fc-45ba-a4a5-bbce48f3a549">312,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNS03LTEtMS0w_3c79c02c-5009-4846-a1b4-331cdf843814">305,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNi01LTEtMS0w_edfdc474-86c1-4aa8-86c6-3eac1d790b01">8,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNi03LTEtMS0w_f9287e95-e9ab-4150-b10a-e8b41b4cb7b7">10,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNy01LTEtMS0w_7106682a-f312-46f6-b47e-3b88af616a2f">321,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNy03LTEtMS0w_2926b046-776b-44a2-bbd5-3f1c59a07826">315,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOC01LTEtMS0w_8837b32e-dc83-4ee5-806b-ba1cee33e6a1">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOC03LTEtMS0w_740a180a-c9c6-4f24-b5e1-b2c8efee53c7">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOS01LTEtMS0w_74a03a98-91a0-44fe-82d7-22b29dbaa525">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOS03LTEtMS0w_abb427d7-1f97-46a5-b120-899ea61f714a">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options and PSOs, unvested RSUs and PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RleHRyZWdpb246YmIyY2I5YmI2OTY3NDBlOTllZmJjMWRjNjhjMTU0N2RfNjkw_7658ad91-c5e8-4169-9fbe-52719d2a026c" continuedAt="ib2f2e3d9a66a49a3b78f5ef54c159008" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="ib2f2e3d9a66a49a3b78f5ef54c159008"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc070254d7a9427b9acaf2c3ca6a6317_D20210102-20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOmVjOGZiOTQ3MzA5YTRhZjRiZGM3NzNmNmFiNWIwNzkzL3RhYmxlcmFuZ2U6ZWM4ZmI5NDczMDlhNGFmNGJkYzc3M2Y2YWI1YjA3OTNfMi01LTEtMS0w_91504a61-c4d4-4adc-a76d-60034bfb5da1">10,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i103b70fa1d1e4257bec9058596619e69_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOmVjOGZiOTQ3MzA5YTRhZjRiZGM3NzNmNmFiNWIwNzkzL3RhYmxlcmFuZ2U6ZWM4ZmI5NDczMDlhNGFmNGJkYzc3M2Y2YWI1YjA3OTNfMi03LTEtMS0w_a8a96556-0894-4853-b5b9-47effaa868e9">12,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF82MS9mcmFnOjg0ZmUzNjMzODY1MjQxMDQ5NzY5ZDg5M2Q0NDVmYzhhL3RleHRyZWdpb246ODRmZTM2MzM4NjUyNDEwNDk3NjlkODkzZDQ0NWZjOGFfMzEzMg_6bce8432-85e3-4e77-a16b-14f25081b280" continuedAt="i25fa6787d614490095d954ef4b2796ba" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i25fa6787d614490095d954ef4b2796ba" continuedAt="i253731a652a34695be541f973e325b17">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><ix:continuation id="i253731a652a34695be541f973e325b17"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a notice letter from Teva Pharmaceuticals USA, Inc. (Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. We are reviewing the details of the Paragraph IV certification notice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="if4ea03d0b1584cb19695d6d2c569a8c8_64"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 submitted to the Securities and Exchange Commission (SEC) on February&#160;10, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (FDA) first approved CABOMETYX for previously treated patients with advanced RCC in April 2016, and in December 2017 the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib. Most recently on January 22, 2021, the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda). We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the European Commission (EC) for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC , and both Ipsen and BMS plan to submit applications to approve the combination in other territories beyond the EU. With respect to the Japanese market, Takeda has received Manufacturing and Marketing Approvals from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In October 2020, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine. We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator-sponsored trial program. Informed by the available data from these clinical trials, we continue to advance the development program for the cabozantinib franchise with potentially label-enabling trials. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after up to two VEGF receptor-targeted therapies. In December 2020, we announced that COSMIC-311 had met its co-primary endpoint of demonstrating significant improvement in progression-free survival (PFS), and in February 2021, we announced the FDA had granted Breakthrough Therapy Designation to cabozantinib as a potential treatment for patients with RAI-refractory DTC who have progressed following prior therapy. We intend to discuss the study results, proposed changes to the study conduct, as well as plans for filing an sNDA with the FDA in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are particularly interested in continuing to evaluate cabozantinib&#8217;s potential in combination with immune checkpoint inhibitors (ICIs) to determine if these combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC, for which we and our collaboration partner BMS announced positive top-line results in April 2020, is reflective of this strategy. The trial met its primary endpoint of PFS at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis and objective response rate (ORR), and showed that the combination of cabozantinib with nivolumab significantly improved the three key efficacy outcomes as compared with sunitinib, doubling PFS and ORR and reducing the risk of disease progression or death by 40 percent compared with sunitinib. Data from CheckMate -9ER served as the basis for the FDA&#8217;s and EC&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021 and March 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Enrollment for COSMIC-313 was completed in March 2021, and we expect to report top-line results of the event-driven analyses from the trial in 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to expand our exploration of combinations with ICIs, we have also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche) ICI, atezolizumab. COSMIC-312 is a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, for which we announced in August 2020 that enrollment was completed. Based on current event rates, we anticipate announcing top-line results in the second quarter of 2021, and if the data are supportive, we anticipate filing a supplemental New Drug Application (sNDA) with the FDA in the second half of 2021. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Based on continuing encouraging efficacy and safety data certain cohorts have been or may be further expanded, including the cohorts of patients with non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. We anticipate completing enrollment of up to 1,732 patients in the trial in the first half of 2021, although both the timing and final number of patients are subject to the initiation of additional cohorts or expansion of selected existing cohorts, as well as any further delays resulting from the COVID-19 pandemic. Since the initiation of the trial, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic NSCLC, mCRPC and advanced RCC, respectively. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication in 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. The first compound to advance from our recent drug discovery efforts is XL092, a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining the target profile of cabozantinib while improving key characteristics, including the pharmacokinetic half-life. We are currently evaluating XL092 in STELLAR-001, a phase 1b clinical trial in patients with advanced solid tumors, for which dose-escalation cohorts evaluating the compound, both as a single agent and in combination with atezolizumab, are currently enrolling, and we expect the trial will begin to enroll patients in additional dose-escalation cohorts evaluating XL092 in combination with avelumab, an ICI developed by Merck KGaA, Darmstadt, Germany (Merck KGaA) and Pfizer Inc. (Pfizer), during the second quarter of 2021. We expect that once recommended doses of both single-agent XL092 and XL092 in combination with atezolizumab or avelumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, hormone-receptor positive breast cancer, mCRPC and urothelial carcinoma (UC).  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also augment our internal small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery. The most advanced compound to emerge from these arrangements is XL102 (formerly AUR102), the lead program targeting cyclin-dependent kinase 7 under our collaboration with Aurigene Discovery Technologies Limited (Aurigene). In December 2020, based on encouraging preclinical data, we exercised our exclusive option to license XL102 from Aurigene. Following the FDA&#8217;s acceptance of our Investigational New Drug (IND) application in December 2020, we initiated a phase 1 clinical trial of the compound in January 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have additionally launched rigorous efforts to discover and advance biologic drug candidates, such as bispecific antibodies, antibody drug conjugates (ADCs) and other innovative biologics that have the potential to become anti-cancer therapies. To facilitate the growth of these biologics programs, we have established multiple research collaborations and in-licensing arrangements, expanding our access to antibodies or other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or bispecific antibodies. Most recently, we entered into a collaboration and license agreement with Adagene Inc. (Adagene), focused on using Adagene&#8217;s SAFEbody</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to develop novel masked ADCs or other innovative biologics with potential for improved therapeutic index, as well as an exclusive license agreement with WuXi Biologics Ireland Limited, a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wholly owned subsidiary of WuXi Biologics (Cayman) Inc. (individually and collectively referred to as WuXi Bio), focused on leveraging WuXi Bio&#8217;s panel of monoclonal antibodies (mAbs) for the development of ADC, bispecific and certain other novel tumor-targeting biologics applications. We have already made significant progress under our biologics-focused research collaborations and in-licensing arrangements and believe we will continue to do so during the remainder of 2021. For example, based on promising preclinical data for XB002 (formerly known as ICON-2), the lead Tissue Factor ADC program under our research collaboration with Iconic Therapeutics, Inc. (Iconic), we exercised our exclusive option to license XB002 in December 2020. Following the FDA&#8217;s acceptance of our IND in April 2021, we expect to initiate a phase 1 clinical trial of XB002 during the second quarter of 2021. Also, in May 2021, we executed an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), under which we will, upon the closing of the asset purchase and subject to certain conditions, acquire all rights, title and interest in GamaMabs&#8217; antibody program directed at anti-M&#252;llerian hormone receptor 2 (AMHR2), a novel oncology target with relevance in multiple forms of cancer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. In total, we are advancing drug candidates across approximately 20 ongoing discovery programs toward and through preclinical development, and subject to preclinical data, we have the potential to submit multiple INDs later in 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. Beginning during the second quarter of 2020 and throughout the rest of 2020 and the first quarter of 2021, however, that trend reversed, and screening and enrollment activity began to increase. As a result, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful overall in preventing material delays to our ongoing and planned clinical trials due to the COVID-19 pandemic. We have done this through ongoing assessment of the COVID-19 pandemic&#8217;s impact and, wherever possible, taking proactive steps in compliance with guidance issued by the FDA, EMA and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may be further slowed due to the COVID-19 pandemic, especially if it is further prolonged or grows in severity.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Preclinical Development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have partially resumed internal drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While this temporary suspension did not result in any significant changes to the timelines for our late-stage discovery work, we did experience modest delays in the advancement of certain of our early-stage programs. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. However, those service providers have resumed discovery work and are meeting their contractual obligations in accordance with planned timelines. With respect to the preclinical development work outsourced to third-party contractors, to date that work has continued without substantial delay or interference resulting from the COVID-19 pandemic.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our field employees have partially resumed their in-person promotional activities while supplementing these activities with telephonic and virtual interactions. These efforts enabled them to remain engaged with healthcare professionals and to be available to them as an informational resource. Overall, despite the challenges posed by the COVID-19 pandemic, we believe our commercial business has been only modestly impacted. We believe this is the case largely because of the gravity of the cancer conditions that our products are indicated to treat and because CABOMETYX has been available in the U.S. since 2016, which means its safety and efficacy profile is well known to most healthcare professionals that treat the conditions for which it is indicated. </span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not experienced production delays or seen any significant impairment to our supply chain as a result of the COVID-19 pandemic. In addition, we continue to maintain substantial safety stock inventories for </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our commercial drug substance and drug products, which should be sufficient to maintain robust long-term supply. We continue to work closely with our third-party contract manufacturers, distributors, suppliers, comparator drug sourcing vendors and collaboration partners to safeguard both the timely production and delivery of our products. </span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Business Operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken numerous temporary precautions to help mitigate the risk of transmission of the virus, including reducing the number of our employees working on-site at our Alameda headquarters under enhanced safety and social distancing protocols and initiating an on-site testing program. Although having most of our employees continue to work remotely has required that we devise new ways of working and collaborating, to date, the COVID-19 pandemic has only had a modest impact on our productivity and has not caused significant interruptions in our general business operations. For a discussion of workplace safety measures we have taken as a result of the COVID-19 pandemic, see &#8220;Business&#8212;Environmental, Health and Safety&#8212;Workplace Safety Measures in Response to COVID-19&#8221; in Part I, Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, submitted to the SEC on February&#160;10, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The circumstances surrounding the COVID-19 pandemic are volatile and subject to rapid change. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout 2021, and potentially into 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2021 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2021, the FDA approved the combination of CABOMETYX and OPDIVO as a first-line treatment of patients with advanced RCC, and we commenced the commercial launch of the combination upon such approval. The approval was based on positive results from the phase 3 pivotal trial, CheckMate -9ER, in which the combination met its primary endpoint of significantly improving PFS at final analysis, as well as the secondary endpoints of OS at a pre-specified interim analysis and ORR, versus sunitinib.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2021, we announced the initiation of a phase 1 clinical trial evaluating XL102, both as a single agent and in combination with other anti-cancer therapies for the treatment of inoperable, locally advanced or metastatic solid tumors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2021, we announced a collaboration and license agreement with Adagene to utilize Adagene&#8217;s SAFEbody technology platform to generate masked versions of mAbs from our growing preclinical pipeline for the development of ADCs or other innovative biologics.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2021, cabozantinib was the subject of multiple data presentations at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2021), including updated trial results with extended follow-up and patient-reported outcomes from the CheckMate -9ER trial demonstrating continued superior PFS, OS and ORR vs. sunitinib across both the subgroup of 75 patients with sarcomatoid histology and the full study population, as well as significantly improved health-related quality of life. Additional cabozantinib presentations at ASCO GU 2021 included: positive results from PAPMET (also known as SWOG S1500), a randomized phase 2 trial conducted by the Southwest Oncology Group evaluating cabozantinib versus sunitinib in patients with metastatic papillary RCC; positive findings from an international retrospective study of cabozantinib in RCC patients with brain metastases; and positive final results from the phase 1 clinical trial sponsored and conducted by NCI-CTEP, including seven expansion cohorts, evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with refractory metastatic genitourinary tumors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2021, we announced the FDA had granted Breakthrough Therapy Designation to cabozantinib as a potential treatment for patients with RAI-refractory DTC who have progressed following prior therapy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021, we announced an exclusive license agreement with WuXi Bio for a panel of mAbs, discovered based on WuXi Bio&#8217;s integrated technology platforms for the development of ADC, bispecific and certain other novel tumor-targeting biologics applications.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021, we announced a clinical trial collaboration and supply agreement with Merck KGaA and Pfizer to evaluate the safety and tolerability of XL092 in combination with avelumab in patients with locally advanced or metastatic UC as part of the ongoing STELLAR-001 phase 1b dose escalation study.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021, we announced the completion of patient enrollment in COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. COSMIC-313 is a multicenter, randomized, double-blind, controlled phase 3 pivotal trial that enrolled approximately 840 patients globally. The primary endpoint of the trial is PFS, and additional endpoints include OS and ORR.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021 and April 2021, Ipsen and BMS, respectively, received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In April 2021, we announced the FDA&#8217;s acceptance of the IND for XB002 and our plans to initiate a phase 1 trial during the second quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2021, we announced an asset purchase agreement with GamaMabs to acquire GamaMabs&#8217; antibody program directed at AMHR2.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2021, we received a notice letter from Teva Pharmaceuticals USA, Inc. (Teva) regarding an Abbreviated New Drug Application (ANDA) Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. We are reviewing the details of the Paragraph IV certification notice. We intend to continue to vigorously defend our cabozantinib intellectual property estate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the first quarter of 2021 were $227.2 million, compared to $193.9 million for the first quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the first quarter of 2021 were $270.2 million, compared to $226.9 million for the first quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the first quarter of 2021 were $159.3 million, compared to $101.9 million for the first quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the first quarter of 2021 were $102.4 million, compared to $62.9 million for the first quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for (benefit from) income taxes for the first quarter of 2021 was $(3.6) million, compared to $11.4 million for the first quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the first quarter of 2021 was $1.6 million, or $0.01 per share, basic and $0.00 per share, diluted, compared to net income of $48.6 million, or $0.16 per share, basic and $0.15 per share diluted, for the first quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Cash, cash equivalents, restricted cash equivalents and investments were $1.6 billion as of March&#160;31, 2021, compared to $1.5 billion as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the challenges and risks imposed by the COVID-19 pandemic and described under &#8220;&#8212;COVID-19 Update&#8221; above, we will also continue to face challenges and risks that may impact our ability to execute on our 2021 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone or in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our 2021 business objectives will also depend on our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy for the treatment of cancer, which we may not be able to do. While we have had success in adapting our development strategy for the cabozantinib franchise and other product candidates to address the expanding role of therapies that combine targeted agents with ICIs and/or with other mechanisms of action, it is uncertain whether current and future clinical trials will lead to regulatory approvals, or whether physicians will prescribe regimens containing our products instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN) and Teva, and the approval of either MSN&#8217;s or Teva&#8217;s ANDA could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. As described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2021, which is a 52-week fiscal year, will end on December 31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021. For convenience, references in this report as of and for the three months ended April 2, 2021 and April 3, 2020, and as of and for the fiscal year ended January 1, 2021 are indicated as being as of and for the three months ended March 31, 2021 and March 31, 2020, and the year ended December 31, 2020, respectively.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net product revenues for CABOMETYX for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily related to an increase in the number of units sold that was partially driven by the strong uptake for the combination therapy of CABOMETYX and OPDIVO following approval by the FDA in January 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in net product revenues for COMETRIQ for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was due to a decrease in the number of units sold.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our net product revenues for the remainder of 2021 may increase relative to the corresponding prior year period, primarily as a result of the growth in the number of units sold following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first line treatment of patients with advanced RCC, as well as an increase in selling price.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. The increase in discounts and allowances for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was primarily the result of an increase in Public Health Service hospital utilization and the dollar amount of the related chargebacks, an increase in returns and allowances and an increase in Medicare utilization. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our discounts and allowances as a percentage of gross revenues may increase during the remainder of 2021 relative to the corresponding prior year period as the number of patients participating in government programs continues to increase and as the discounts given and rebates paid to government payers also increase.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and the profit on the U.S. commercialization of COTELLIC from Genentech. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties increased primarily as a result of increases in royalties earned on Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $22.5 million for the three months ended March&#160;31, 2021, compared to $17.9 million for the comparable period in 2020. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to increased demand of CABOMETYX, which, as of March&#160;31, 2021, is approved in 60 countries outside of the U.S. Royalties also increased due to the commercial launch of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan by Takeda during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $1.8 million for the three months ended March&#160;31, 2021, compared to $1.4 million for the corresponding prior year </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $1.0 million for the three months ended March&#160;31, 2021, compared to $1.3 million for the corresponding prior year period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. We project our license revenues for the remainder of 2021 to decrease, relative to fiscal 2020, as a result of the anticipated achievement of fewer milestones in 2021, partially offset by an increase in royalty revenues related to an increase in product sales by Ipsen and Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales by Ipsen and Takeda of products containing cabozantinib. We received notification that, effective January 1, 2021, Royalty Pharma plc acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $18.3 million for the three months ended March&#160;31, 2021, compared to $14.4 million for the corresponding prior year period. The increase in development cost reimbursements was primarily a result of the reimbursements from Ipsen and Takeda associated with their decision to opt in and co-fund CONTACT-02 and additional cohorts of COSMIC-021 studies in 2020 and their respective share of the increase in spending on the CONTACT-02 study, partially offset by a decrease in spending on COSMIC-021 and COSMIC-312 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $3.3 million for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the three months ended March&#160;31, 2021, compared to $2.4 million for the corresponding prior year period. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease for the remainder of 2021, relative to fiscal 2020, primarily as a result of lower development cost reimbursements projected to be earned under our collaboration agreements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increase in cost of goods sold for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was primarily the result of an increase in write-downs for excess and expiring inventory, certain other period costs, as well as an increase in royalties as a result of increased U.S. cabozantinib sales, partially offset by favorable purchase price variances. We do not project our gross margin to change significantly during the remainder of 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes stock-based compensation, the allocation of general corporate costs to research and development, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was primarily related to increases in license and other collaboration costs, clinical trial costs, personnel expenses and stock-based compensation expense. License and other collaboration costs increased primarily due to increases in upfront license fees, program initiation fees and research funding commitments related to business development activities. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, increased primarily due to costs associated with the expanding clinical trial program for cabozantinib. Personnel expenses increased primarily due to increases in headcount to support our expanding discovery and development organization. Stock-based compensation expense increased primarily due to the performance-based restricted stock units (PSUs) granted in 2019 that became probable of achievement during the first quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a significant portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable company-sponsored studies resulting from this program include: COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; CONTACT-02 for which Roche is sharing the development costs and providing atezolizumab free of charge; and COSMIC-311.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. In this regard, we conduct drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may continue to increase for the remainder of 2021 compared to 2020, primarily driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including XL092, XL102, and XB002, and anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required for clinical development of a particular product candidate and our development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.660%"><tr><td style="width:1.0%"></td><td style="width:62.097%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.896%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs, and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was primarily related to the increases in personnel expenses, marketing costs, corporate giving and stock-based compensation expense, partially offset by a decrease in the Branded Prescription Drug Fee due to a change in estimate for such fees in 2020 following our receipt of the preliminary fee notice from the Internal Revenue Service. Personnel expenses increased primarily due to increases in administrative headcount to support our commercial and research and development organizations. Marketing costs increased primarily due to increased marketing activities in support of the launch of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination therapy of CABOMETYX and OPDIVO following approval by the FDA in January 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in stock-based compensation expense was primarily due to PSUs granted in 2019 that became probable of achievement during the first quarter of 2021. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may continue to increase for the remainder of 2021 relative to 2020 in support of our continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in non-operating income for the three months ended March&#160;31, 2021, relative to the corresponding prior year period, was primarily the result of the decreases in interest income due to lower interest rates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes and effective income tax rates were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a benefit from income taxes for the three months ended March&#160;31, 2021 as a result of a current period pre-tax loss, relative to the corresponding prior year period in which we reported pre-tax income. The effective tax rate for the three months ended March&#160;31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period. The effective tax rate for the three months ended March 31, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had $1.6 billion in cash, cash equivalents, restricted cash equivalents and investments, compared to $1.5 billion as of December&#160;31, 2020. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other business development activities that align with our oncology drug development, regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $49.7 million and $1.6 million as of March 31, 2021 and December 31, 2020, respectively. As of March 31, 2021, none of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by short-term investments. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and are presented in other long-term assets in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Condensed Consolidated Balance Sheets and will be reduced as we fund our portion of the tenant improvements. As of March 31, 2021, restricted cash equivalents included $48.2&#160;million of short-term investments as collateral under our standby letter of credit.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for the three months ended March&#160;31, 2021, decreased relative to the corresponding prior year period, primarily due to an increase in cash paid for operating expenses, which was partially offset by favorable changes in operating assets and liabilities.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the three months ended March&#160;31, 2021 consisted of maturities and sales of investments of $407.4 million, partially offset by cash used in investment purchases of $331.6 million and purchases of property, equipment and other of $13.6 million.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the three months ended March&#160;31, 2020 consisted of cash provided by the maturities and sales of investments of $287.1 million, partially offset by cash used in investment purchases of $251.5 million and purchases of property and equipment and other of $3.0 million.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the three months ended March&#160;31, 2021 consisted of $5.4 million of withholding taxes paid related to net share settlements of equity awards, partially offset by $2.8 million in proceeds from the issuance of common stock under our equity incentive plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the three months ended March&#160;31, 2020 consisted of $3.9 million in proceeds from the issuance of common stock under our equity incentive plans, partially offset by $1.8 million of withholding taxes paid related to net share settlements of equity awards.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of March&#160;31, 2021 from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2021, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 submitted to the SEC on February&#160;10, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_79"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of March&#160;31, 2021 have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_82"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_88"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_91"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Legislation and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for additional cabozantinib indications or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely  on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for the cabozantinib franchise to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, whether as a result of the COVID-19 pandemic or otherwise, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could depend on numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. For example, with respect to the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, we cannot predict whether our commercialization efforts will lead to increased adoption of this combination by healthcare professionals, who may continue to treat first-line RCC patients with competing product combinations and reserve CABOMETYX for later in their treatment plan. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products, combination therapies and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by constant technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Given the shifting landscape of therapeutic strategy following the advent of ICIs, we believe our future success will depend upon our ability to achieve positive clinical trial results for therapies combining cabozantinib with ICIs across multiple indications, and if approved, successfully commercialize such combination therapies. While we have had success in adapting our development strategy for the cabozantinib franchise to address the expanding role of therapies that combine ICIs with other targeted agents, including the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical and biotechnology organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">function appropriately, or should we have to revert back to primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended (PPACA), some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, there is no assurance that the repeal, modification or invalidation of some or all of the provisions of the PPACA in the future, will not have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Drug Discount Program through the PPACA has increased the number of purchasers who are eligible for significant discounts on branded drugs, including our marketed products. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid, which affect the amount of rebates that we pay on prescription drugs under Medicaid and to covered entities under the 340B Drug Discount Program; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and facilitate the importation of certain lower-cost drugs from other countries. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted legislative proposals or executive rulemaking, such as those incorporating International Pricing Index or Most-Favored-Nation models, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and Ipsen might establish for CABOMETYX, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug, and Cosmetic Act (FDCA), the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail in &#8220;Item 1. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 submitted to the SEC on February 10, 2021. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets. For a more detailed discussion of the litigation matter involving MSN, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. The FDA Reauthorization Act of 2017 includes, inter alia, measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. In addition, the FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken and continues to take steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, was signed into law as part of the 2019 year-end federal spending package. The legislation purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biological product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The U.S. Department of Health and Human Services Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities.  Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve globally and in the U.S. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by California Privacy Rights Act of 2020 (CPRA), which will be operational in most key respects on January 1, 2023. Similar legislative proposals are being advanced in other states and Congress is also considering federal privacy legislation. In addition, most healthcare providers are subject to privacy and security requirements under HIPAA. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of that product for a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib (or of other product candidates) in new indications, and in some cases, as described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such developments to occur. These may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additional complexities posed by clinical trials evaluating cabozantinib or our other product candidates in combination with other therapies, including the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: characteristics of the product candidate under investigation; the number of patients who </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for additional cabozantinib indications or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-approval studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. For example, based on the regulatory feedback from the FDA, and if supported by the clinical data from COSMIC-021, we intend to submit an sNDA to the FDA seeking accelerated approval of cabozantinib in an mCRPC indication in 2021. We expect that as a condition of any potential accelerated approval, the FDA will require us to perform confirmatory post-marketing clinical trials to confirm the clinical benefit, if any, of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, such as mCRPC. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in that indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders enacted or executed in response to the COVID-19 pandemic could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $1.6 million for the three months ended March&#160;31, 2021 and $111.8 million for the year ended December&#160;31, 2020, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates. For example, we reported a net loss for the quarter ended September 30, 2020, primarily due to substantial increases in clinical trial costs, license and other collaboration costs, and personnel expenses relative to the prior fiscal quarters, and it is possible that we may experience net losses in future fiscal quarters or fiscal years, whether due to increases in costs and expenses or otherwise. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. Disruptions in the U.S. and global financial markets, including disruptions that have resulted and may continue to result from the COVID-19 pandemic and the related downturn in the U.S. and global economy, as well as future potential U.S. federal government shutdowns, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise additional funds in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to fund and grow our business. In particular, our inability to access additional funds, whether due to the COVID-19 pandemic or otherwise, could in the future inhibit our ability to engage in larger-scale strategic transactions or investments. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their sales of CABOMETYX in their respective territories outside of the U.S., could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or other factors. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies, including, Ipsen, Takeda, Roche and Genentech, BMS, Merck KGgA, Pfizer and Daiichi Sankyo, for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial (including as a result of the COVID-19 pandemic), or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our research and in-licensing partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic, which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or disadvantage healthcare products made by foreign competitors, or general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, whether as a result of the COVID-19 pandemic or otherwise, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities, distribution facilities or resources for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although we have not yet experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by external factors, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cyber-attack. The level of vulnerabilities that exist under normal conditions may have been exacerbated by the fact that, during the COVID-19 pandemic, the portion of our workforce operating remotely has increased, at least temporarily, and some phishing attacks are specifically designed to target remote workers. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on access to treatment sites that is necessary to monitor clinical study progress and initiation. However, as the COVID-19 pandemic continues to surge or continues to have a significant presence in various parts of the world, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites and the implementation </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of crisis management initiatives have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could delay our clinical trial plans or require certain trials to be temporarily suspended. Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also interfere with and potentially negatively impact clinical trial execution, and ultimately results. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Specifically, with respect to our clinical trials evaluating cabozantinib in combination with therapies that must be administered via professional intravenous infusion, such as COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02, CONTACT-03, or our early-stage trials evaluating XL092, XL102 and other product candidates to the extent they may incorporate additional therapies that must be administered via professional intravenous infusion, limited patient movement or interrupted healthcare services at medical institutions have delayed in some instances, and may continue to delay or prevent, on-site infusion of the therapies being evaluated in combination with cabozantinib. If a sizable portion of patients in our combination studies are unable or unwilling to receive all components of the combination therapy being tested in accordance with the applicable clinical trial protocol, it could cause those studies to be delayed, suspended or prevented from producing statistically significant results.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in the commencement of new clinical trials of cabozantinib, or our earlier-stage investigative product candidates. The COVID-19 pandemic could also impede clinical operations and delay our planning and preparation timelines for new clinical trials, as well as adversely affect our ability to obtain regulatory approval for clinical protocols and increase the operating expenses associated with these new clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic caused us to suspend drug discovery work in our laboratories temporarily while we observed the shelter in place orders issued by the State of California and Alameda County. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. While both drug discovery work in our laboratories and outsourced drug discovery activities have since partially resumed, we may be unable to maximize the potential of these programs due to reduced staffing and the imposition of increased safety protocols, and should the COVID-19 pandemic continue to grow in severity, we may have to further scale back or suspend activities in the future. For example, as a result of spikes or surges in infection, positivity or hospitalization rates, or emergence of new SARS-CoV-2 variants, we may choose or be required to suspend work in our laboratories, which will once again impede our drug discovery efforts. With respect to the preclinical development work and drug discovery activities outsourced to third-party contractors, the COVID-19 pandemic could again impede these third parties from providing timely deliverables to us in the future. In addition, should we experience delays in the construction of new laboratory facilities due to the COVID-19 pandemic, our ability to expand our drug discovery activities may be impaired. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our commercial business has, to date, only experienced a modest impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including any shifts from in-person back to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although as of the date of this Quarterly Report on Form 10-Q, we continue to maintain substantial safety stock inventories for our drug substance and drug products and have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. These delays or disruptions could be further exacerbated if the COVID-19 pandemic begins to impact essential distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have taken numerous temporary precautions to help mitigate the risk of transmission of the virus, including: reducing the number of our employees working on-site at our Alameda headquarters under enhanced safety and social distancing protocols; suspending all non-essential business travel for our employees; and partially limiting the circumstances under which our field employees may engage in in-person promotional activities with healthcare professionals. Over a longer period, these measures could delay our research and development programs, reduce engagements with potential prescribers for our products, and impede our ability to execute on our long-term </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business plans. Further, extended periods of remote work could impede the focused attention of management or reduce the productivity of teams that would otherwise be working closely together. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of broad economic shifts during and as a consequence of efforts to address unemployment and other negative economic effects of the COVID-19 pandemic, we may experience further reductions in the net price of our products. For example, there may be a substantial shift from private health insurance coverage to government insurance coverage, or additional downward pressure on the prices government purchasers will pay for our products due to significant increases in government debt incurred in connection with relief efforts, as well as significant increases in demand for our patient assistance and/or free drug program or other impacts that may not be foreseeable, all or any of which would adversely affect our product revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic and resulting disruptions to normal business and personal activities in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the rate at which vaccinations are made available and the percentage of the population that becomes vaccinated.  These continuing or future effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We plan to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Similarly, the COVID-19 pandemic could negatively impact the health of key personnel or make it difficult to recruit qualified personnel for critical positions. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties of these materials, and such liability may exceed our insurance coverage and our total assets. In addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other business development activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, such as the impact of the COVID-19 pandemic on financial markets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, including the effects of the COVID-19 pandemic, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_106"></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/10/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/10/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/25/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/23/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt">Specimen Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1,<br/>as amended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-96335</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/7/2000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101ipsencollaborati.htm">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102firstamendmentto.htm">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103secondamendmentt.htm">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104thirdamendmentto.htm">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105ipsensupplyagree.htm">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106firstamendmentto.htm">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210331exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210331exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210331exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formatted as Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="if4ea03d0b1584cb19695d6d2c569a8c8_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if4ea03d0b1584cb19695d6d2c569a8c8_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101ipsencollaborati.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i88c4de4c1ff646d2bb728e929f16265e_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS COLLABORATION AND LICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of February 29, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Ipsen Pharma SAS, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis, a biopharmaceutical company, is developing its proprietary compound known as cabozantinib for the treatment of cancer, and owns or controls certain patents, know-how and other intellectual property relating to such compound&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee, a fully-integrated pharmaceutical company, possesses substantial resources and expertise in the development and commercialization of pharmaceutical products&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Licensee and Exelixis desire to form a collaboration for the continued development and commercialization of cabozantinib, under which Exelixis will continue to have primary responsibility for the conduct of the global development program for cabozantinib, with Licensee providing input and support in order for Exelixis and Licensee to collaborate and pursue such development as the Parties agree&#59; Licensee will obtain the exclusive rights to commercialize cabozantinib outside the U.S., Canada, and Japan and will have primary responsibility for the commercialization of cabozantinib outside the U.S., Canada, and Japan as well as development responsibility outside the U.S., Canada and Japan&#59; and, Exelixis will manufacture and supply cabozantinib for all development and commercialization activities by the Parties&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Parties wish to establish such collaboration, all on the terms and conditions set forth below. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Exelixis and Licensee hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Markets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such party, but for only so long as such control exists.  As used in this Section&#160;1.1, &#8220;control&#8221; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance&#59; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each respective period of three (3) consecutive months ending on March&#160;31, June&#160;30, September&#160;30, and December&#160;31.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each respective period of twelve (12) consecutive months ending on December 31. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial or Phase 4 Clinical Trial as the context dictates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">cGCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the current clinical practice as set out in (i) ICH Harmonized Guidance on current Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95), (ii) US Code of Federal Regulations, Title 21, Chapters 50, 54, 56, 58, 210, 211 and 312, as may be amended from time to time, (iii) EU Directive 2001&#47;20&#47;EC and related guidelines, and (iv) the equivalent law or regulation in any other applicable jurisdiction in the Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">cGLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S.), as they may be updated from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the current minimum standards for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug as specified by applicable laws of the relevant countries at the time of manufacturing conducted in accordance with this Agreement, defined under (i) 21 C.F.R. Part 210 and 211, (ii) Directive 2003&#47;94&#47;EC, (iii) Volume 4, Rules Governing Medicinal Products in the EU, Part I and II, in each case, as amended from time to time, and (iv) equivalent law or regulations in any other applicable jurisdiction in the Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cometriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain pharmaceutical product containing the Compound in capsule formulation and known as Cometriq&#174;, which has been developed and commercialized by Exelixis as of the Effective Date for the treatment of progressive, metastatic medullary thyroid cancer (MTC). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical support, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering Products to customers) of Products in the Field in or outside of the Licensee Territory, including sales force efforts, detailing, advertising, market research, market access (including price and reimbursement activities), medical education and information services, publication, scientific and medical affairs&#59; advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales (including receiving, accepting and filling Product orders) and distribution.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; have correlative meanings. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party and its obligations under this Agreement, those commercially reasonable efforts and resources consistent with the usual practices of a similarly situated company for the development and commercialization of a pharmaceutical product originating from its own research and development department without a royalty obligation to others, which is at a similar stage of research, development or commercialization, taking into account that product&#8217;s profile of efficacy and safety&#59; proprietary position, including patent and regulatory exclusivity&#59; regulatory status, including anticipated or approved labeling and anticipated or approved post-approval requirements&#59; present and future market and commercial potential, including competitive market conditions (but not taking into account any payment owed to the other Party under this Agreement), and all other relevant factors, including technical, legal, scientific and&#47;or medical factors.  Commercially Reasonable Efforts requires that a Party&#58; (i) at a minimum establish a plan to achieve objectives and assign specific responsibilities for the achievement of that plan and (ii) make and implement decisions and allocate resources designed to advance progress with respect to such objectives.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the JSC, JDC, JCC or any subcommittee established by the JSC, as applicable. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any product or compound, other than the Compound and Products&#58; (a) for which the mechanism of action includes modulation of the kinase activities of cMET, VEGFR2, Ret or any combination of these targets&#59; and (b) which directly binds and modulates the activity of&#58; (i) VEGFR2&#59; (ii) cMET&#59; and&#47;or (iii) Ret, &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means cabozantinib, having the chemical structure set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including &#91; * &#93;. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain Confidential Disclosure Agreement between Exelixis and Licensee dated as of February 10, 2015.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How and other proprietary scientific, marketing, financial or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">discoveries, inventions, data, designs or formulae in relation to this Agreement&#59; provided that all Exelixis Technology will be deemed Exelixis&#8217; Confidential Information, all Licensee Technology will be deemed Licensee&#8217;s Confidential Information, and all Joint Inventions and Joint Patents will be deemed both Parties&#8217; Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Know-How, Patents or other intellectual property rights, the legal authority or right (whether by ownership, license or otherwise but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license or a sublicense of or under such Know-How, Patents or other intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost of Goods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Compound or Product, the fully burdened cost to manufacture such Compound or Product, which means&#58; (a)&#160;in the case of &#91; * &#93;&#59; and (b)&#160;in the case of &#91; * &#93;.  Actual unit costs shall consist of &#91; * &#93;.  Direct material costs shall include the &#91; * &#93;.  Direct labor costs shall include the cost of&#58; &#91; * &#93;.  Manufacturing &#91; * &#93; shall include &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all scientific, technical, test, marketing or sales data pertaining to any Product that is generated by or on behalf of Exelixis, Licensee, their respective Affiliates and Sublicensees, including research data, clinical pharmacology data, pre-clinical data, clinical data, clinical study reports or submissions made in association with an IND or MAA with respect to any Product.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all development activities for the Compound and Product (whether alone or for use together, or in combination, with another active agent or pharmaceutical product as a combination product or combination therapy) that are directed to obtaining Regulatory Approval(s) of the Product and lifecycle management of the Product in any country in the world, including all non-clinical, preclinical and clinical testing and studies of the Product&#59; toxicology, pharmacokinetic and pharmacological studies&#59; statistical analyses&#59; assay development&#59; protocol design and development&#59; the preparation, filing and prosecution of any MAA for the Product&#59; development activities directed to label expansion and&#47;or obtaining Regulatory Approval for one or more additional indications following initial Regulatory Approval&#59; development activities conducted after receipt of Regulatory Approval, including Phase 4 Clinical Trials&#59; and all regulatory affairs related to any of the foregoing.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; have correlative meanings. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the costs incurred by a Party or for its account, during the Term and pursuant to this Agreement, that are specifically directed (or reasonably allocable) to the Development of a Product.  The Development Costs shall include amounts that a Party pays to Third Parties involved in the Development of a Product (at cost, and excluding any Third Party Royalties), and all internal costs (calculated on an FTE basis at the then-current FTE Rate) and out-of-pocket costs incurred by or on account of a Party in performing Development in accordance with the GDP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Drug Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any (a) drug master files filed with the FDA with respect to the Product, (b) active substance master file (ASMF) filed with the EMA, and (c) equivalent filing in other countries in the Licensee Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency or its successor. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Economic Area and Switzerland.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; the Chief Executive Officer of Exelixis and the Chief Executive Officer of Licensee. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How that Exelixis Controls as of the Effective Date or during the Term, including any Joint Inventions, that is&#160;necessary or reasonably useful for the Development, use, importation, offer for sale or sale of any Compound or Product in the Field in the Licensee Territory.  The Exelixis KnowHow includes the Exelixis Data. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patents in the Licensee Territory that Exelixis Controls as of the Effective Date or during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the Development, use, importation, offer for sale or sale of any Compound or Product in the Field in the Licensee Territory (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Exelixis).  The Exelixis Patents existing as of the Effective Date are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Exelixis KnowHow and the Exelixis Patents, including Exelixis&#8217; interest in the Joint Inventions and Joint Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S., Canada, and Japan. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.31&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expanded Access Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the administration of the Product to named individuals who do not meet the clinical trial enrollment criteria either outside of a clinical trial or after the completion of a clinical trial.  Expanded Access Programs are also known as named patient programs, named patient supply, and temporary authorization for use. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.32&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C. &#167;&#167; 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701-1706, the Trading with the Enemy Act, 50 U.S.C. &#167;&#167; 1 et. seq., the Arms Export Control Act, 22 U.S.C. &#167;&#167; 2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.33&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.34&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration or its successor. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.35&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all indications and uses in humans and animals.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.36&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, on a Product-by-Product and country-by-country basis, the earlier of (i) the First Commercial RCC Sale or (ii) first sale by Licensee or any of its Affiliates or Sublicensees to a Third Party for end use of Cometriq for the MTC indication in a given country in the Licensee Territory after Regulatory Approval has been granted with respect to such Product in such country.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.37&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial RCC Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, on a Product-by-Product and country-by-country basis, the first sale by Licensee or any of its Affiliates or Sublicensees to a Third Party for end use of a Product in a given country in the Licensee Territory after Regulatory Approval has been granted with respect to such Product in such country for the first indication approved by the relevant Regulatory Authority in the treatment of RCC (e.g., 2nd line therapy for RCC).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.38&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the equivalent of a full-time individual&#8217;s work for a twelve (12) month period (consisting of a total of &#91; * &#93; hours per year of dedicated effort).  Any person who devotes more or less than &#91; * &#93; hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such person on such activities, divided by &#91; * &#93;.  For avoidance of doubt, the hours spent by Exelixis temporary workers and contractors on applicable activities may be treated as FTE on a pro-rata basis, but the hours allocated to the work of general corporate or administrative personnel shall not be incorporated into FTE.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.39&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an initial rate of (a) with respect to Exelixis&#8217; personnel, &#91; * &#93; Dollars ($&#91; * &#93;) per FTE per year and (b) with respect to Licensee&#8217;s personnel, &#91; * &#93; Euros (&#8364;&#91; * &#93;), which rate shall apply through December 31, 2016.  Thereafter, the FTE Rate shall be changed annually on a Calendar Year basis to reflect any year-to-year percentage increase or decrease (as the case may be) (i) with respect to Exelixis, in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) with respect to Licensee, in the French consumer price index as published by the French National Institute of Statistics and Economic Studies (&#8220;INSEE&#8221;) available at insee.fr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(both changes based on the change in the CPI from the most recent applicable index available as of the Effective Date to the most recent applicable index available as of the date of the calculation of such revised FTE Rate). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.40&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Future Exelixis Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any licensee or Sublicensee of Exelixis (other than Licensee) to which a license or a sublicense with respect to Products is granted by Exelixis for all or any portion of the Exelixis Territory (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the U.S., Canada and&#47;or Japan) or will be granted after the Effective Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.41&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Generic Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Product in a particular regulatory jurisdiction, any pharmaceutical product that (a) contains the same active pharmaceutical ingredient(s) as such Product&#59; (b) is approved by the Regulatory Authority in such country as a substitutable generic for such Product (for an indication for which such Product obtained Regulatory Approval from the applicable Regulatory Authority in such jurisdiction) on an expedited or abbreviated basis based on bioequivalence or interchangeability with the Product&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (c) is sold in such jurisdiction by a Third Party that is not a Sublicensee and did not purchase such product in a chain of distribution that included any of Exelixis, Licensee, or their respective Affiliates, licensees, or sublicensees. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.42&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any national, international, federal, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.43&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means hepatocellular carcinoma.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.44&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the International Conference on Harmonization (of Technical Requirements for Registration of Pharmaceuticals for Human Use).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.45&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an investigational new drug application or equivalent application filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.46&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Clinical Trial, the first dosing of the first human subject in such Clinical Trial.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.47&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice, in the course of activities contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.48&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all technical information, know-how and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models and other physical, biological, or chemical materials, expertise and other technology applicable to, development, registration, use or marketing or to methods of assaying or testing them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, nonclinical and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise and information, relevant to the research, development, use, importation, offering for sale or sale of, or which may be useful in studying, testing, developing, Products.  Know-How excludes Patents and manufacturing know-how of Compound or Product.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.49&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How that Licensee or its Affiliate Controls as of the Effective Date or during the Term, including any Joint Inventions, that is &#91; * &#93; for the research, Development, manufacture, use, importation, offer for sale or sale of any Compound or Product in the Field.  The Licensee KnowHow includes the Licensee Data.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.50&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patents that Licensee or its Affiliate Controls as of the Effective Date or during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale or sale of any Compound or Product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Licensee or its Affiliate).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.51&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Licensee Know-How and the Licensee Patents, including Licensee&#8217;s interest in the Joint Inventions and Joint Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.52&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the world outside the Exelixis Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.53&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in any country or jurisdiction.  For clarity, MAA does not include any application for Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.54&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a Product in the applicable country or jurisdiction, but excluding any pricing and&#47;or reimbursement approval. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.55&#160;&#160;&#160;&#160;&#8220;Major Market Countries&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.56&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Affairs&#8221; or &#8220;Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, the Product, including by way of example&#58;  (a) activities of medical scientific liaisons who, among their other functions, may&#58; (i) conduct service based medical activities including providing input and assistance with consultancy meetings, proposing investigators for clinical trials sponsored or co-sponsored by a Party or Affiliate, and providing input in the design of such trials and other research related activities&#59; and&#47;or (ii) deliver non-promotional communications and conduct non-promotional activities&#59; (b) grants to support continuing medical education, symposia, or Third Party research related to the Product&#59; (c) development, publication and dissemination of publications relating to the Products&#59; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call or email&#59; (e) conducting advisory board meetings, international advisory board activities or other consultant programs, including the engagement of key opinion leaders and health care professional in individual or group advisory and consulting arrangements&#59; and (f) the evaluation of applications submitted to Licensee for support of investigator-initiated trials.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.57&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means medullary thyroid cancer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.58&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Product, the gross amounts invoiced for sales or other dispositions of such Product by or on behalf of Licensee and its Affiliates and Sublicensees to Third Parties, less the following deductions to the extent included in the gross invoiced sales price for such Product or otherwise directly paid or incurred by Licensee or its Affiliates or Sublicensees, as applicable, with respect to the sale or other disposition of such Product&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">normal and customary trade and quantity discounts actually allowed and properly taken directly with respect to sales of such Product (provided that such discounts are not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">applied disproportionately to such Product when compared to the other products of Licensee or its Affiliate or Sublicensee, as applicable)&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">credits or allowances given or made for rejection or return of previously sold Products or for retroactive price reductions and billing errors&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rebates and chargeback payments granted to managed health care organizations, pharmacy benefit managers (or equivalents thereof), national, state&#47;provincial, local, and other governments, their agencies and purchasers and reimbursers, or to trade customers&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">costs of freight, carrier insurance, and other transportation charges directly related to the distribution of such Product&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">taxes, duties or other governmental charges (including any tax such as a value added or similar tax, other than any taxes based on income) directly levied on or measured by the billing amount for such Product, as adjusted for rebates and refunds.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon any sale or other disposition of any Product that should be included within Net Sales for any consideration other than exclusively monetary consideration on bona fide arms&#8217;-length terms, then for purposes of calculating Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for money at the average sales price of the relevant Product in arm's length transactions during the applicable reporting period generally achieved for such Product in the country in which such sale or other disposition occurred when such Product is sold alone and not with other products (average sales price to be measured as the aggregate Product Net Sales divided by the aggregate number of units sold in such country). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event will any particular amount identified above be deducted more than once in calculating Net Sales.  Sales of a Product between Licensee and its Affiliates or Sublicensees for resale shall be excluded from the computation of Net Sales, but the subsequent resale of such Product to a Third Party shall be included within the computation of Net Sales. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The supply of Product as samples, for use in non-clinical or clinical trials, or for use in any test or studies reasonably necessary to comply with any applicable laws, rules, or regulations or as is otherwise normal and customary in the industry shall not be included in the computation of Net Sales, so long as Licensee, its Affiliates, and Sublicensees do not receive payment for such Product in excess of the Cost of Goods of such Product.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.59&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NSCLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means non-small cell lung cancer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.60&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;all patents, certificates of invention, applications for certificates of invention, priority patent filings and patent applications, and (b)&#160;any renewals, divisions, continuations (in whole or in part), or requests for continued examination of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.61&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#160;1 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a clinical trial in any country conducted in a small number of human volunteers designed or intended to establish an initial safety profile, pharmacodynamics, or pharmacokinetics of a Product.  For clarity, a Phase 1 Clinical Trial may include studies conducted in oncology patients.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.62&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#160;2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a clinical trial of a Product in human patients in any country to determine initial efficacy and safety and dose range finding.  A Phase 2 Clinical Trial is typically conducted before embarking on a Phase&#160;3 Clinical Trial, but may be registrational.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.63&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#160;3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a pivotal clinical trial of a Product in human patients in any country with a defined dose or a set of defined doses of a Product designed to ascertain efficacy and safety of such Product for the purpose of submitting applications for Regulatory Approval to the competent Regulatory Authorities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.64&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 4 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a product support clinical trial of a Product that is commenced after receipt of MAA Approval in the country where such trial is conducted.  Phase 4 Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, post-marketing surveillance trials, and any such trials conducted as part of an Expanded Access Program. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.65&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Product, the approval, agreement, determination or decision of any Governmental Authority establishing the price or level of reimbursement for such Product, as required in a given country or jurisdiction prior to sale of such Product in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.66&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product containing the Compound as an active ingredient, in any form, presentations, dosage or formulation, including but not limited to Cometriq.  For purposes of this Agreement, all formulations of single-agent Product containing the Compound shall be considered the same Product, and all formulations of combination product, if any, containing the same set of active agents shall be considered the same Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.67&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Public Official or Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b)&#160;any candidate for political office, any political party or any official of a political party. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.68&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means renal cell carcinoma.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.69&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, individually and collectively, the following regions&#58; &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.70&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all approvals (including MAA Approval, and Pricing and Reimbursement Approval, if applicable), licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of a Product in any country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.71&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA and EMA.  For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority shall also include any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.72&#160;&#160;&#160;&#160;&#8220;Regulatory Exclusivity&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Product other than patents, including, without limitation, rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity), or rights similar thereto outside the U.S., such as Directive 2001&#47;83&#47;EC (as amended) in the EU.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.73&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications and authorizations (or waivers) with respect to the testing, Development, manufacture or Commercialization of any Product made to or received from any Regulatory Authority in a given country, including any INDs and MAAs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.74&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Safety Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Data related solely to any adverse drug experiences and serious adverse drug experience as such information is reportable to Regulatory Authorities.  Safety Data also includes &#8220;adverse events&#8221;, &#8220;adverse drug reactions&#8221; and &#8220;unexpected adverse drug reactions&#8221; as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management&#58; Definitions and Standards for Expedited Reporting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.75&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent such as the French </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233;s des March&#233;s Financiers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or otherwise, as applicable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.76&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Party that takes the ultimate responsibility for the initiation, performance and management of, including financing or arranging the financing for, the appropriate Clinical Trial.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.77&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stockout Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a period during which Licensee, as a result of failure of Exelixis to supply Product, has no commercial inventory available to supply the market in the Licensee Territory.  Inventory stockouts arising from Licensee&#8217;s failure to maintain the &#91; * &#93; safety stock in accordance with the Supply Agreement shall not give rise to a Stockout Period.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.78&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Third Party to whom Licensee grants a sublicense to Develop, use, import, promote, offer for sale or sell any Product in the Field in the Licensee Territory, beyond the mere right to purchase Products from Licensee and its Affiliates, and excluding wholesalers, full-service distributors that do not promote the sale of the Product, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other similar physical distributors.  In no event shall Exelixis or any of its Affiliates be deemed a Sublicensee. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.79&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any entity other than Exelixis or Licensee or an Affiliate of Exelixis or Licensee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.80&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tier 1 Additional Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line), HCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line), &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.81&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tier 2 Additional Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any line of therapy for &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.82&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Top 5 EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United Kingdom, Germany, France, Spain, and Italy.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.83&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America, including its territories and possessions (including Puerto Rico).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.84&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) a claim of an issued and unexpired patent that has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a claim of a pending patent application that has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken and that has not been pending for more than &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.85&#160;&#160;&#160;&#160;Additional Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table identifies the location of definitions set forth in various Sections of the Agreement&#58; </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Defined Terms</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acquisition Transaction</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.8(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alliance Manager</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Allowable Increases</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Auditor</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Beneficial Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2(e)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change of Control</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.9(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Claim</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Competing Program</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.9(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compound Invention</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1(b)(i)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Budget</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disputed Matter</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Divest</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.8(c)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Excess Funds</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis Data</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1(a)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis Entity</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.8(a)(i)(1)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis Indemnitee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis Only Development Work</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5(e)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Global Development Plan or GDP</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnitee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnitor</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Independent Work</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Independent Work Cost</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2(c)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Initial Committed Studies</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Injunctive Relief</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.3(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee Data</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee Indemnitee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee Only Development Work</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5(e)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Commercialization Committee or JDC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Development Committee or JDC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Steering Committee or JSC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Inventions</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1(b)(ii)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Patents</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1(b)(ii)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Losses</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Materials</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.14</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PV Costs</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacovigilance Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Infringement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Marks</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.7(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Promotional Materials</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recall</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.10</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Meeting</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty Term</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5(c)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sales Forecast</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sobi</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sobi Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sole Inventions</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1(b)(ii)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Standstill Period</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.8(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sunshine Reporting Laws</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.11</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Supply Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Supply Contacts</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TMC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Withholding Tax Action</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3(c)</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;GRANT OF LICENSES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Licenses Granted to Licensee.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Agreement (including Section 8.1), Exelixis hereby grants to Licensee, during the Term&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an exclusive (even as to Exelixis, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses solely as provided in Section 2.2, under the Exelixis Technology to use, sell, offer for sale, import and otherwise Commercialize (but not to make or have made) the Products in the Field and in the Licensee Territory&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a non-exclusive license, with the right to grant sublicenses solely as provided in Section 2.2, under the Exelixis Technology to Develop (but not to make or have made) the Products on a worldwide basis under the GDP, and to use the Products for that purpose.  Exelixis agrees not to grant any further license to Develop the Products except to Future Exelixis Licensees.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Sublicenses.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee shall have the right to grant sublicenses under the licenses granted in Section 2.1&#58; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to an Affiliate of Licensee without Exelixis&#8217; express prior written consent and without providing any written notice to Exelixis, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such sublicense will terminate if such sublicensee no longer qualifies as an Affiliate of Licensee.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to any Third Party distributor identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto (which list of approved distributors shall be agreed upon by the Parties within thirty (30) days following the Effective Date) without Exelixis&#8217; express prior written consent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Licensee does not have an Affiliate that is then engaged in selling pharmaceutical products in such sublicensed territory.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to any Third Party distributor not listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> without Exelixis&#8217; express prior written consent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) Licensee does not have an Affiliate that is then engaged in selling pharmaceutical products in such sublicensed territory&#59; (ii) Licensee has conducted a reasonable investigation of such Third Party and believes that such Third Party is qualified and competent, and such Third Party annually certifies its compliance with, and actually complies with, Applicable Laws and other applicable requirements, (iii) such Third Party is then engaged in the promotion and commercialization of oncology products, and (iv) Licensee is then using such Third Party for distribution of pharmaceutical products other than Products&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Licensee notifies Exelixis in writing &#91; * &#93; days&#8217; in advance of granting such sublicense specifying (x) the name of such Third Party and the country(ies) such sublicense will cover, and (y) that Licensee has met the conditions set forth in (ii) &#8211; (iv).  If Exelixis believes Licensee should not grant such sublicense to such Third Party, it may direct such concern and any documentation supporting such concern to the JSC for discussion.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to a Third Party other than as set forth in (b) and (c) with Exelixis&#8217; express prior written consent.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All sublicenses granted under the licenses granted in Section 2.1 shall be in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement and shall provide that any such Sublicensee (for clarity, including any distributor) shall not further sublicense except with the consent of Licensee and Exelixis.  Licensee shall ensure that each agreement with a Sublicensee grants Exelixis all rights with respect to Data, Inventions and Regulatory Filings made or generated by such Sublicensee as if such Data, Inventions and Regulatory Filings were made or generated by Licensee.  Licensee shall be responsible for the compliance of its Affiliates, Sublicensees (for clarity, including any distributors), and subcontractors with the terms and conditions of this Agreement.  Licensee shall provide written notice to Exelixis of each sublicense granted to a Third Party hereunder, specifying the name of the Sublicensee, the territory, and the duration of the sublicense.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee agrees that in countries where it is not Commercializing Products through its Affiliates, it will only contract with Third Party distributors who satisfy the conditions of paragraphs (b), (c), or (d) above, whether or not a sublicense of rights hereunder is actually required.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Reserved Rights.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis hereby expressly reserves&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the right under Exelixis Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more licensees or subcontractors, including the right to Develop the Compound and Products in the Licensee Territory under the GDP&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to Section 2.8, all rights to practice, and to grant licenses under, the Exelixis Technology outside of the scope of the licenses granted in Section 2.1, including the exclusive right to make and have made the Compound and Products anywhere in the world, and the exclusive rights to practice the Exelixis Patents and Exelixis Know-How with respect to compounds and products other than Compound and Products. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;Licenses Granted to Exelixis.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Agreement, Licensee hereby grants to Exelixis&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an exclusive (even as to Licensee, except as expressly set forth herein), royalty-free, fully paid-up license, with the right to sublicense (provided that any such sublicensee may only grant a further sublicense at two tiers), under the Licensee Technology to use, sell, offer for sale, import and otherwise Commercialize the Products in the Field in the Exelixis Territory&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a co-exclusive, royalty-free, fully paid-up license, with the right to sublicense (provided that any such sublicensee may only grant a further sublicense at two tiers), under the Licensee Technology to Develop the Compound and Products on a worldwide basis under the GDP&#59; and </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an exclusive (even as to Licensee), royalty-free, fully paid-up license, with the right to sublicense  (provided that any such sublicensee may only grant a further sublicense at </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">two tiers), under the Licensee Technology to make and have made the Compound and Products anywhere in the world. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicenses&#58;  Exelixis shall have the right to grant sublicenses under the licenses granted in Section 2.4</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">without Licensee&#8217;s consent and without providing any written notice to Licensee if such sublicense is granted to an Affiliate&#59; and</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">without Licensee&#8217;s prior written consent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> however that a written notice is sent to Licensee for Licensee&#8217;s information if such sublicense is granted to Third Parties to manufacture the Product and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such Third Party is qualified and certified to manufacture the Product in such country in accordance with Applicable Laws and other applicable requirements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.5&#160;&#160;&#160;&#160;No Implied Licenses&#59; Negative Covenant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How or other intellectual property owned or controlled by the other Party.  Neither Party shall, nor shall it permit any of its Affiliates or sublicensees to, practice any Patents or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.6&#160;&#160;&#160;&#160;Disclosure of Know-How.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For as long as the Parties are conducting Development activities under the GDP, Exelixis shall, without additional compensation, disclose and make available to Licensee, in electronic form where, all Exelixis Know-How that comes into existence after the Effective Date and that was not previously provided to Licensee, promptly after the development, making, conception or reduction to practice of such Exelixis Know-How.  For as long as the Parties are conducting Development activities under the GDP, Licensee shall and shall cause its Affiliates to, without additional compensation, disclose and make available to Exelixis, in electronic form where possible, any Licensee Know-How not previously provided to Exelixis, and promptly after the earlier of the development, making, conception or reduction to practice of such Licensee Know-How.  The JDC and JCC shall each establish a mechanism for the reciprocal disclosure of Know-How within its respective area of responsibility. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.7&#160;&#160;&#160;&#160;Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Exelixis enters into any agreement with a Third Party after the Effective Date that includes a license from such Third Party to Exelixis under any Know-How or Patents that are necessary or reasonably useful to Develop, use, sell, offer for sale or import the Products in the Field and in the Licensee Territory, then Exelixis shall notify Licensee, identifying the relevant Know-How or Patents, by providing Licensee with the substantive terms of the applicable Third Party license agreement to Licensee, to the extent applicable to the rights that would be sublicensed to Licensee, which Exelixis hereby agrees to do.  Such Know-How and Patents, to the extent falling within the definition of Exelixis Technology, will be sublicensed to Licensee if Licensee provides Exelixis with written notice in which (i) Licensee consents to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">adding such Patents and Know-How to the definition of Exelixis Technology, (ii) Exelixis and Licensee, acting reasonably in good faith, agree on the terms and conditions of the payments that would be owed under such license agreement as a result of Exelixis&#8217; granting a sublicense to Licensee or Licensee&#8217;s practice thereunder, including Licensee&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; Development, use, sale, offer for sale and importation of the Compound and Products in the Field and in the Licensee Territory, and a reasonable allocation of all other payments under such license agreement, and to make all payments when due and provide all reports required under such license agreement&#59; and (iii) Licensee acknowledges in writing that its sublicense under such license agreement is subject to the terms and conditions of such license agreement.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee shall promptly notify Exelixis if it becomes aware of any Third Party Know-How or Patents that are necessary or reasonably useful to Develop, make, have made, use, sell, offer for sale or import the Compound and Products in the Field, and shall give Exelixis the first right to negotiate and obtain a license from such Third Party under such Know-How or Patents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except with the prior written consent of the other Party, neither Party shall obtain a license to Third Party Patents or Know-How that is necessary or reasonably useful to Develop, make, have made, use, sell, offer for sale or import the Products, for use with the Products in the other Party&#8217;s territory, unless it obtains the right to sublicense such rights to the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.8&#160;&#160;&#160;&#160;Exclusivity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Section 2.8(c) below, for the period starting from the Effective Date and for ten (10) years following the first Regulatory Approval of the Product in the first indication other than MTC, neither Party (nor any of its Affiliates) shall, directly or indirectly (including through a Third Party), commercialize any Competing Product for therapeutic or prophylactic use (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Section 2.8(c) below, for the period starting from the Effective Date and for five (5) years following the first Regulatory Approval of the Product in the first indication other than MTC, neither Party (nor any of its Affiliates) shall, directly or indirectly (including through a Third Party) develop any Competing Program &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that a Third Party becomes an assignee of this Agreement, or an Affiliate of a Party after the Effective Date through merger, acquisition, consolidation or other similar transaction, and such Third Party, as of the closing date of such transaction, is engaged in the conduct of a Competing Program&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if such transaction constitutes a Change of Control of &#91; * &#93;, &#91; * &#93; shall have the right to terminate the Agreement as provided herein.  &#91; * &#93; shall have &#91; * &#93; following the announcement of such transaction to give written notice to &#91; * &#93; of its intent to terminate the Agreement, such termination to be effective &#91; * &#93; after receipt of notice of termination (but only after completion of the transaction with such entity having a Competing Product) unless &#91; * &#93; notifies &#91; * &#93; within &#91; * &#93; of receipt of the notice of termination of its decision to (a) Divest any such Competing Product to a Third Party, (b) discontinue the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Competing Program, or (c) acting reasonably and in good faith agree with &#91; * &#93; and such assignee or new Affiliate to find a mutually acceptable agreement whereby they can, on compliance with Applicable Laws, jointly exploit such Competing Product together with the Product.  Such disposition shall be completed within &#91; * &#93; of completion of any such sale or Change of Control transaction.  During the &#91; * &#93;, such assignee or new Affiliate (as the case may be) shall have the right to continue the Competing Program and such continuation shall not constitute a breach of such Party&#8217;s exclusivity obligations set forth above&#59; provided that such assignee or new Affiliate (as the case may be) conducts the Competing Program independently of the activities of this Agreement and does not use any &#91; * &#93; in the conduct of the Competing Program.  In the event this Agreement is terminated in accordance with the foregoing, neither Party shall &#91; * &#93;&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if such transaction constitutes a Change of Control of &#91; * &#93;, then such assignee or new Affiliate shall continue to Develop and Commercialize the Product using a level of Commercially Reasonable Efforts that assumes the Competing Program was not acquired and shall, within &#91; * &#93; after the closing of such Change of Control transaction&#58; (a) Divest the Competing Program to a Third Party, or (b) discontinue the Competing Program.  During the &#91; * &#93; period, such assignee or new Affiliate (as the case may be) shall continue to fulfill its obligations under this Agreement in all respects, shall conduct Competing Program activities independently of the activities pursuant to this Agreement and shall not use any &#91; * &#93; in the conduct of the Competing Program&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if such transaction does not constitute a Change of Control of such Party, then such Party and its new Affiliate shall have &#91; * &#93; from the closing date of such transaction to wind down or complete the Divesture of the Competing Program&#59; during this period, the Party&#8217;s conduct of the Competing Program shall not deemed a breach of the exclusivity obligations set forth above, provided that the Party continues to fulfill its obligations under this Agreement in all respects, conducts its Competing Program activities independently of the activities pursuant to this Agreement and does not use&#58; (A) any &#91; * &#93; or (B) &#91; * &#93;, in each case in the conduct of such Competing Program.  For clarity, if such Party completely winds down the Competing Program within the &#91; * &#93; time period, it shall be allowed to divest the Competing Program later, provided that it does not restart the Competing Program. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As used in this Section 2.8(c), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party&#58; (1) a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation&#59; or (2) a person or entity, or group of persons or entities acting in concert, acquire more than fifty percent (50%) of the voting equity securities or management control of such Party&#59; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Divest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the sale or transfer of rights to the Competing Program to a Third Party without receiving a continuing share of profit, royalty payment or other economic interest in the success of such Competing Program. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the Term of this Agreement, neither Party (nor any of its Affiliates) shall, directly or indirectly (including through a Third Party), commercialize the Product or any Generic Product of any Product in the other party&#8217;s territory. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Governance</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Joint Steering Committee. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> As of the Effective Date, the Parties have established a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), composed of an equal number of up to &#91; * &#93; senior officers of each Party, to oversee and guide the strategic direction of the collaboration of the Parties under this Agreement.  The JSC shall act as a joint consultative body and to the extent expressly provided herein, a joint decision-making body.  The JSC shall in particular&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide a forum for discussion of the Development and Commercialization of the Compound and Products in the Licensee Territory and the Exelixis Territory&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and approve the global strategy for the Development of the Product worldwide and review and approve any proposed amendments to the GDP, including corresponding budgets, following recommendation by the JDC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and approve the Commercialization Plans for the Licensee Territory, including proposed amendments, following recommendation by the JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and approve Sales Forecasts (and corrective plans, if any) submitted by Licensee pursuant to Section 6.3(c), following recommendation by the JCC&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review the manufacturing and supply strategy, supply performance and Cost of Goods, including periodic review of worldwide order forecasts for the Product to avoid supply shortage and unfavorable treatment of Licensee&#8217;s supply requirements disproportionate to those of Exelixis and Future Exelixis Licensees on the basis of their respective volumes&#59;     </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and approve any recommendations of the JCC not to launch (or to significantly delay the launch of) a Product in a particular country of the Licensee Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and approve coordinated activities under global brand strategies for the Products in each of the Parties&#8217; territories, following recommendation by the JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">approve decisions of the JDC, JCC and any other joint subcommittee established by JSC, including appointment of memberships, membership changes, and resolving any disputed matter submitted to it by such Committees&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">establish additional joint subcommittees as it deems necessary or advisable to further the purpose of this Agreement, including approving establishment and membership of subcommittees if proposed by the JDC or JCC&#59; and </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or allocated to it by the Parties&#8217; written agreement, including providing financial oversight of the activities conducted pursuant to this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, any information sharing of Commercialization matters regarding the Exelixis Territory shall be for solely for purposes of the coordination of the Parties&#8217; activities, and Exelixis shall retain all decision making authority with respect to such matters without requiring any approvals except as expressly provided in Sections 14.4 and 14.5.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Joint Development Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  As of the Effective Date, the Parties have established a joint Development, Medical Affairs, and regulatory committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), composed of up to &#91; * &#93; representatives of each Party, to monitor and coordinate the Development of, and Medical Affairs Activities connected with, the Compound and Products at the operational level.  Each JDC representative shall have knowledge and expertise in the clinical development of products similar to the Products.  The JDC shall in particular&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">report to the JSC on all significant Development activities, including implementation of the GDP, and on the activities of the JDC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">coordinate and monitor the Development activities of the Parties under the GDP and oversee implementation of the GDP&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide a forum for and facilitate communications between the Parties with respect to the Development of Products in the Licensee Territory and the Exelixis Territory, including sharing of Development information and Data in accordance with Section 4.7(a)&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">elaborate, review and approve clinical trial protocols, including investigator-initiated and cooperative group clinical trial plans and protocols, and statistical analysis plans for Clinical Trials (and any amendments thereto) in the Exelixis and Licensee Territories and monitor the progress of the clinical studies&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">define areas of permissible scientific and medical inquiry and parameters for Phase 4 Clinical Trials in the Exelixis and Licensee Territories&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review Data resulting from Phase 1&#47;1b&#47;2 Clinical Trials against go&#47;no-go criteria in the GDP to determine progression to a Phase 3 Clinical Trial&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review Data resulting from Phase 3 Clinical Trials against go&#47;no-go criteria in the GDP to determine progression to submission of Regulatory Filing&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prepare amendments to the GDP (including the Development Budget) and submit such amendments to the JSC for approval&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">monitor and coordinate all regulatory actions worldwide, communications and submissions for the Compound and Products under the GDP and pharmacovigilance and safety matters worldwide&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">establish joint working groups (such clinical, regulatory and safety) as it deems necessary or appropriate to oversee the day-to-day management of different aspects of the Development work under the GDP&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">oversee and coordinate the Medical Affairs Activities for the Product in all indications, which shall be subject to a Medical Affairs portion of the GDP and may be coordinated through a Medical Affairs working group established and overseen by the JDC&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">oversee and coordinate decisions related to research or Development of new indications, characterization and Development of bio-markers (if any), which may be coordinated through a Medical Affairs working group established and overseen by the JDC&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review activities related to pharmaceutical development, Phase 3 Clinical Trial active ingredient and drug product new campaigns (i.e., chemical process scale-up&#47;optimization (if needed) and micronization process study, manufacturing, QC testing and release of GMP batches of active ingredient and drug product as needed for Phase 3 Clinical Trial, in particular, review and approval of the protocols on manufacturing, micronization, scale-up plan and process optimization&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">maintain and review the &#8220;Company Core Data Sheet&#8221;, which shall cover material relating to safety, indications, dosing, pharmacology and other information concerning the Product including Company Core Safety Information&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">coordinate the supply of the Compound and Products to Licensee for Development use&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">oversee and facilitate the Parties&#8217; communications and activities with respect to publications under Section 14.4&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">establish and supervise the global publication strategy with respect to the Compound and Products&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(r)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Development of Products, including endeavoring to resolve any disputes between the Parties arising from the deliberations of the JDC, or as otherwise directed by the JSC. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Joint Commercialization Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  As of the Effective Date, the Parties have established a joint commercialization committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Commercialization Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), composed of up to &#91; * &#93; representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level.  Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products.  The JCC shall in particular&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">report to the JSC on all significant Commercialization activities in the Licensee Territory, including implementation of the Commercialization Plan, and on the activities of the JCC&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review, discuss and approve the Commercialization Plans and related activities with respect to the Commercialization of Products in the Licensee Territory&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide a forum for and facilitate communications and coordination between the Parties with respect to the Commercialization of Products in the Licensee Territory and the Exelixis Territory&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">on an annual basis, review and approve Licensee&#8217;s Sales Forecast prepared pursuant to Section 6.3(b) as well as any corrective plans submitted thereunder&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and approve any recommendation by Licensee not to launch (or to significantly delay the launch of) any Product in any country of the Licensee Territory&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and discuss the major findings of Licensee&#8217;s market research with respect to any Product in the Licensee Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide input to the JDC on the global publication strategy with respect to the Products and implement such strategy under supervision of the JDC once it has been established&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and oversee the branding and product positioning strategy for Products in the Licensee Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">establish pricing corridors for Products in the Licensee Territory for the purpose of reimbursement and potential international pricing reference by relevant Regulatory Authorities&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">define and coordinate medical messaging worldwide with respect to the Products&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">oversee and facilitate the Parties&#8217; communications and activities with respect to publications under Section 14.4&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">design a global brand strategy for the Licensee Territory (e.g., a four-year brand plan, resource plan, , etc.) and submit such strategy to the JSC for review and approval&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">discuss and coordinate the manufacture and supply of the Products to Licensee for Commercial use&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Commercialization of Products, including endeavoring to resolve any disputes between the Parties arising from the deliberations of the JCC, or as otherwise directed by the JSC.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Executive Committee.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall designate an appropriate senior executive officer of Exelixis and&#47;or Licensee (e.g., CEO or members of each Party&#8217;s executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">committee) to meet once a year to discuss strategic issues and other issues that either Party deems important to maintain a successful partnership and collaboration.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Committee Membership and Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Committee Members.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Committee representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the applicable Committee&#8217;s responsibilities.  Each Party may replace its representatives on any Committee on written notice to the other Party, but each Party shall strive to maintain continuity in the representation of its Committee members.  The &#91; * &#93;.  &#91; * &#93;.  The chairperson shall prepare and circulate agendas to Committee members at least seven (7) days before each Committee meeting and shall direct the preparation of reasonably detailed minutes for each Committee meeting, which shall be approved by the chairperson and circulated to Committee members within thirty (30) days of such meeting.  The initial members of each of the JSC, JCC and JDC shall be determined by the Parties promptly following the Effective Date. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Committee shall hold meetings at such times as it elects to do so, but in no event shall meetings of the JDC and JCC be held less frequently than once every &#91; * &#93;, and meetings of the JSC once every &#91; * &#93;, during the &#91; * &#93; following the Effective Date and then the Parties may decide to reduce the frequency of the Committee meetings.  The first JSC meeting, first JDC meeting, and first JCC meeting shall be held within &#91; * &#93; after the Effective Date, at which meetings the dates for the first calendar year shall be set.  Meetings of any Committee may be held in person, or by audio or video teleconference&#59; provided that unless otherwise agreed by both Parties at least &#91; * &#93; meetings per year shall be held in person during the first &#91; * &#93; following the Effective Date, and, for the subsequent years of the Term, at least one (1) meeting per year of each Committee shall be held in person.  In-person Committees shall be held at locations alternately selected by the Parties.  Each Party shall be responsible for all of its own expenses of participating in any Committee meetings.  No action taken at any meeting of a Committee shall be effective unless at least one (1) representative of each Party is participating.  In addition, upon written notice to the other Party, either Party may request that a special </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> meeting of the JSC be convened for the purpose of resolving any disputes in connection with, or for the purpose of reviewing or making a decision pertaining to any material subject-matter within the scope of the JSC, the review or resolution of which cannot be reasonably postponed until the following scheduled JSC meeting.  Such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than &#91; * &#93; following the notification date of request that such meeting be held.    </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Non-Member Attendance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the Committee meetings in a nonvoting capacity&#59; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#8217;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.  Such Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;Decision-Making. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All decisions of each Committee shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote.  If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before a Committee, the representatives of the Parties cannot reach an agreement as to such matter within &#91; * &#93; after such matter was brought to such Committee for resolution, then, except as provided in Section 3.6(c), if such disagreement arose within the JDC or JCC, it shall be referred to the JSC for resolution.  If the JSC cannot resolve such matter within &#91; * &#93;, or if the disagreement first arose within the JSC, then either Party at any time may refer such issue to the Executive Officers for resolution.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Executive Officers cannot resolve such matter within &#91; * &#93; after such matter has been referred to them, then&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to Development matters, except for&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the addition of &#91; * &#93;, the cost of which would be &#91; * &#93;&#59; and,</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any material modification to a &#91; * &#93;&#59; for the purpose of this clause, &#8220;material modification&#8221; means any material changes to the agreed upon &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to (1) Commercialization in the Licensee Territory, except with respect to the decision &#91; * &#93; a particular Product in a country, (2) Medical Affairs in the Licensee Territory, and (3) regulatory matters in the Licensee Territory that do not affect the Exelixis Territory&#59; provided that Licensee&#8217;s decision shall be consistent with the terms and conditions of this Agreement, including without limitation Section 6.4(b) regarding pricing, and Section 6.3(c) regarding sales forecasts.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither Party shall have the final decision making authority with respect to the matters in Sections 3.6(b)(i)(1) and (2) or with respect to the decision not to &#91; * &#93; a particular Product in a particular country &#91; * &#93;, and the status quo shall persist with respect to such matter if the Parties are unable to agree. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding Section 3.6(a), &#91; * &#93; representative shall have the deciding vote on all tactical &#91; * &#93; matters for the Products &#91; * &#93;, and such matter shall not be subject to escalation to &#91; * &#93;&#59; provided that such decision does not directly affect &#91; * &#93; and such decision shall be consistent with the terms and conditions of this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;Limitations on Authority.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Committee shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, no Committee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will have the power to amend this Agreement, and no decision of a Committee may be in contravention of any terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.8&#160;&#160;&#160;&#160;Discontinuation of Committees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The activities to be performed by each Committee shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services.  Each Committee shall continue to exist until the first to occur of&#58;  (a) the Parties mutually agree to disband such Committee&#59; or (b) Exelixis provides written notice to Licensee of its intention to disband and no longer participate in such Committee.  Once the Parties mutually agree or Exelixis has provided written notice to disband such Committee, such Committee shall have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under this Agreement or such exchange of information shall be made through Alliance Managers, and decisions of such Committee shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.9&#160;&#160;&#160;&#160;Alliance Managers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Term.  The Alliance Manager will ensure communication to the JSC of all relevant matters raised at the JDC, the JCC and at any joint subcommittees and project teams.  Each Alliance Manager shall be permitted to attend meetings of the JSC and other Committees as appropriate as non-voting participants.  The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder.  Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.  Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.  Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment within the JSC and its subcommittees.  Each Party shall bear its own costs of its Alliance Manager, which costs shall be excluded from the Parties&#8217; respective Development and manufacturing costs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.10&#160;&#160;&#160;&#160;Supply Contacts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall designate one (1) qualified and experienced supply chain professional to serve as that Party's primary supply contact regarding the supply of Compound and Products within this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supply Contacts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and under the direction of the JCC.  Each Party may replace its Supply Contact with an alternative representative at any time with prior written notice to the other Party.  Supply Contacts shall be responsible for facilitating information exchange and discussion between the Parties regarding the supply of Compound and Products under this Agreement.  &#91; * &#93;.  Each Party shall bear its own costs of its Supply Contact, which costs shall be excluded from the Parties&#8217; respective Development and Cost of Goods.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Overview. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to the terms and conditions of this Agreement, the Parties will collaborate with respect to the Development of the Compound and Products and share the Data </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">resulting from such collaboration to facilitate the Development of the Compound and Products throughout the Licensee Territory and the Exelixis Territory. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Development of the Compound and Products under this Agreement (including the development of the Compound and any Product as a combination product or combination therapy with another product and&#47;or therapy), including Independent Work and Licensee Only Development Work, shall be conducted only pursuant to a comprehensive written global Development plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which shall be incorporated by reference as part of this Agreement.  The GDP shall set forth the timeline and details (including line of therapy, tumor type, primary endpoints, approximate patient size, combination agents and comparator agents) of all preclinical and clinical Development activities to be conducted by the Parties as necessary to generate Data sufficient to meet the common requirements of both the EMA and FDA for MAA Approval of the Compound and Products for RCC, HCC, and other indications agreed upon by the Parties.  The GDP may also include any other Development activities approved by the JSC, including parameters for permissible scientific inquiry in Phase 4 Clinical Trials.  The GDP will include Clinical Trials that the Parties are committed to conducting (unless modification is required by a Regulatory Authority or any local or regional IRB&#47;ethics committee, or is reasonably necessary to protect patient safety) as well as Clinical Trials that will be decided by the JDC and JSC based on Data and results obtained after the Effective Date and the Parties&#8217; review of the future competitive landscape.  The GDP shall include a coordinated Development and regulatory strategy, including the Parties&#8217; respective roles in the Development of the registration dossier and Regulatory Filings for the Products and the countries in which Development of the Products will occur.  The GDP shall also set forth the detailed budget of the anticipated costs for such Development activities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on a study-by-study or Clinical Trial-by-Clinical Trial basis.  As of the Effective Date, the Parties have agreed upon an initial GDP and Development Budget, attached to this Agreement as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the terms of the GDP contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern.  From time to time during the Term (at least on &#91; * &#93; basis), the JDC shall prepare updates and amendments, as appropriate, to the then-current GDP, including budgets, and shall submit such updates and amendments to the JSC for review and approval before such updates and amendments are adopted.  If upon the determination by the JDC as reviewed and approved by the JSC, any pre-clinical, or Clinical Trials not included in the GDP (i) are required in order to obtain and&#47;or maintain MAA Approval for a Product in the EU and in one or all the countries of the Exelixis Territory, or (ii) are otherwise recommended by the EMA or the FDA in the EU and in one or all of the countries of the Exelixis Territory, then the JDC shall review and recommend and the JSC shall review and approve an amendment to the GDP reflecting such additional studies, including associated budget.  The costs of such additional studies shall be borne by the Parties as provided in Section 4.5(a).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Independent Work.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If either Party is interested in pursuing additional Development work on a Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Developing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the benefit of the Exelixis Territory (in the case of Exelixis) or the Licensee Territory (in the case of Licensee) beyond what is set forth in the then current GDP, then such Party shall provide the other Party with a written detailed plan and budget for such additional work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Within &#91; * &#93; of receipt of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proposal, the JDC or delegated team shall meet to review the Proposal and to permit the other Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Developing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) an opportunity to ask questions and request additional information from the Developing Party related to the Proposal, including whether such Proposal is reasonably likely to have a material and adverse effect on the Product in the Non-Developing Party&#8217;s territory.  The Parties acknowledge that it is their intent to collaborate in good faith to establish a similar review and approval process with any Future Exelixis Licensee.  No additional Development work shall proceed without the approval of the JSC, and following each such approval such additional Development work and corresponding budget shall be incorporated into the GDP by the JDC. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Newly-Proposed Development)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For any Newly-Proposed Development work, the Non-Developing Party that did not propose such work originally may elect, at its discretion, to share the Development Costs with respect to such Development work under Section 9.2(b).  If the Non-Developing Party does not decide to pursue the Newly-Proposed Development work jointly with the Developing Party or does not share the Development Costs with respect to such Development work, in which event such Development work shall be deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Independent Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the Developing Party may pursue such work in the Field in its respective territory and the Development Costs with respect thereto shall be deemed Independent Work Costs and subject to Sections 4.5(d) and 9.2(b).  Notwithstanding the foregoing, following the approval of the Independent Work by the JSC, the Party proposing the Independent Work may conduct such Independent Work, provided that&#58; (A) it shall do so in accordance with the amended GDP&#59; (B) such Independent Work shall be conducted under the oversight of the JDC and the JSC&#59; and (C) neither Party shall conduct Independent Work in a manner that would have a material adverse effect on the Products in either Party&#8217;s territory.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Annual Update to Development Budget.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The JDC shall discuss and agree upon the subsequent year&#8217;s Development Budget on an annual basis no later than November 1 of each year.  The JDC shall report any significant changes in the annual budgets to the JSC for approval at the next scheduled JSC meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Development Cost.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Committed Studies As Of The Effective Date (Current Budget).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as set forth in Section 4.5(b) below, Exelixis shall bear one hundred percent (100%) of all Development Costs for the first &#91; * &#93; dollars ($&#91; * &#93;) of Development Costs for all Clinical Trials that are committed studies in the GDP &#91; * &#93; as of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Committed Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Thereafter, except as set forth in Section 4.5(b) below, (i) Exelixis shall bear sixty-five percent (65%) and Licensee shall bear thirty-five percent (35%) of all Development Costs for such Clinical Trials &#91; * &#93; until the aggregate Development Costs of such Clinical Trials equals &#91; * &#93; dollars ($&#91; * &#93;), and (ii) if aggregate Development Costs for such Clinical Trials &#91; * &#93; exceed &#91; * &#93; dollars ($&#91; * &#93;), Exelixis shall bear &#91; * &#93; percent (&#91; * &#93;%) and Licensee shall bear &#91; * &#93; percent (&#91; * &#93;%) of all remaining Development Costs for such Clinical Trials.  For Clinical Trials that become committed studies in the GDP after the Effective Date, Exelixis shall bear sixty-five percent (65%) and Licensee shall bear thirty-five percent (35%) of all Development Costs of such Clinical Trials.  If Exelixis completes the Initial Committed Studies for an amount less than &#91; * &#93; dollars ($&#91; * &#93;), any amount not spent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excess Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be credited against the Parties&#8217; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respective share of Clinical Trials that become committed studies in the GDP after the Effective Date.  Without limiting the foregoing, if any &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Allowable Increases.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Separate from the cost allocation provided for in Section 4.5(a), Exelixis shall bear sixty-five percent (65%) and Licensee shall bear thirty-five percent (35%) of all Allowable Increases in Development Costs for all Clinical Trials that are committed studies in the GDP as of the Effective Date.  &#8220;Allowable Increases&#8221; are defined as increased Development Costs resulting from (i) changes in study design after the Effective Date that are approved by the JDC and JSC &#91; * &#93; (up to the amount of a mutually-agreed budget increase), (ii) changes in regulatory requirements arising after the Effective Date (including changes required or recommended by Regulatory Authorities, but excluding changes required or recommended specifically by a Regulatory Authority of the Exelixis Territory solely for the benefit of the Exelixis Territory), and (iii) extensions in the duration of Clinical Trials resulting from a lower than anticipated rate of clinical events or higher rates of survival.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Expanded Access Program 214.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis shall bear the first &#91; * &#93; dollars ($&#91; * &#93;) of Development Costs (excluding the costs of Licensee FTEs and other internal costs of Licensee) associated with Expanded Access Program 214.  Licensee shall bear one hundred percent (100%) of its internal costs of such program, inclusive of its FTEs, as well as one hundred percent (100%) of all Development Costs of such program in excess of the &#91; * &#93; dollars ($&#91; * &#93;) borne by Exelixis.  If such program is completed for an amount of Development Costs less than &#91; * &#93; dollars ($&#91; * &#93;), no financial adjustment shall be made.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Independent Work Cost.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding Section 4.5(a), the Party conducting the Independent Work approved by the JSC under Section 4.3 shall be solely responsible for the Development Costs with respect to such Independent Work, subject to Section 9.2(c). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Country-Specific Development Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding Section 4.5(a), each Party shall be solely responsible for all Development Costs with respect to Development activities that are exclusively for the benefit of the countries within such Party&#8217;s Territory, including&#58; (i) any and all country-specific activities (e.g., a Canada or Japan only trial for Exelixis or China only trial for Licensee, Expanded Access Programs)&#59; (ii) all Phase 4 Clinical Trials solely benefiting such Party&#8217;s territory&#59; (iii) any and all Development activities required for any pricing and&#47;or reimbursement approvals in such Party&#8217;s territory (but are not required for the MAA Approval in such territory).  The Development work set forth in this Section 4.5(e) pertaining to Licensee shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Only Development Work&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Development work set forth in this Section 4.5(e) pertaining to Exelixis shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Only Development Work.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  All planned and in-process Licensee Only Development Work and Exelixis Only Development Work shall be included in and conducted in accordance with the GDP, to be performed reasonably and subject to the oversight of the JDC and the JSC. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;Development Responsibilities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The JDC shall reasonably allocate Development responsibilities of the Compound and Products under the GDP between the Parties and such allocation shall be set forth in the GDP, provided that&#58; (a) Exelixis shall be the Sponsor and have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the operational responsibility for all Development work under the GDP that is ongoing as of the Effective Date&#59; (b) each Party shall have the operational responsibility for its own Independent Work&#59; and (c) Licensee shall be the Sponsor and have the operational responsibility for the Licensee Only Development Work and Exelixis shall be the Sponsor and have the operational responsibility for the Exelixis Only Development Work. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Data Exchange and Use.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In addition to its adverse event and Safety Data reporting obligations pursuant to Section 5.5, each Party shall promptly provide the other Party with (i) &#91; * &#93; status reports on trial recruitment and other metrics consistent with the performing Party&#8217;s internal reporting for clinical studies and Development activities, provided however that in case of unexpected events that may have any impact on safety and recruitment, each Party shall inform the other Party within forty-eight (48) hours from knowledge of the occurrence of such event&#59; (ii) supporting documentation (e.g. protocols, CRFs, analysis plans, etc.)&#59; (iii) preliminary and final Data, and interim, preliminary and final results and reports&#59; and (iv) output from advisory committees and investigator meetings, any and all such documentation generated by each Party (including by any Sublicensee or any Future Exelixis Licensee) from its Development activities under this Agreement as such documentation could reasonably be deemed to affect the Development or Commercialization activities of the Product in each Party&#8217;s territory.  As time may be of the essence, each Party shall collaborate in good faith in the exchange of any such Data set forth in this Section within &#91; * &#93; of receipt.  The Parties shall cooperate on a secure website to facilitate the sharing of reports, Data and other information on a routine basis.  Except as set forth in Section 4.7(b) below, each Party shall have the right to use and reference, without additional consideration, any and all Data generated by or on behalf of the other Party (including by any Sublicensee or any Future Exelixis Licensee) under this Agreement for obtaining and maintaining Regulatory Approval for the Products and otherwise Commercializing the Products in its territory in accordance with the terms of this Agreement.  For clarity, this Section 4.7(a) shall apply to all Development under the GDP, including Independent Work (but subject to Section 4.7(b) below), Exelixis Only Development Work and Licensee Only Development Work.  Notwithstanding the foregoing, should either Party fail to obtain such use and reference rights from any Sublicensee or Future Exelixis Licensee, such Party shall not have the right to grant use and access or rights to such Sublicensee or Future Exelixis Licensee to any documentation listed in this Section 4.7(a) generated by or on behalf of the other Party.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Independent Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding the foregoing, the Party receiving Data resulting from the other Party&#8217;s Independent Work shall have the right to use such Data only to the extent reasonably necessary for the receiving Party to comply with its regulatory reporting and compliance obligations, including safety reporting obligations, but shall not have the right to use such Data to support its own Development, Regulatory Approval or Commercialization except pursuant to Section 9.2(c).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall use Commercially Reasonable Efforts to perform the Development activities assigned to such Party under and in accordance with the GDP.  Unless otherwise agreed by the Parties, Exelixis shall be the Sponsor and be responsible for conducting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">all Clinical Trials that are required to obtain MAA Approvals by both the EMA and FDA for RCC, HCC, NSCLC, and other indications in the GDP.  In addition, Licensee shall also use Commercially Reasonable Efforts to Develop Licensee Only Development Work and any Licensee Independent Work, file MAAs and seek and maintain Regulatory Approval (including Pricing and Reimbursement Approval, as applicable) for the Products throughout the Licensee Territory.   </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.9&#160;&#160;&#160;&#160;Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall Develop the Compound and Products in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.10&#160;&#160;&#160;&#160;Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities.  Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.  Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, cGCP, cGLP, and cGMP).    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.11&#160;&#160;&#160;&#160;Development Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  At &#91; * &#93; JDC meeting, each Party shall provide the JDC with regular reports detailing its Development activities for the Products under this Agreement, and the results of such activities.  In addition, after the completion of any Clinical Trial or other study of the Products, the Party responsible for the conduct of such Clinical Trial or study shall promptly provide the other Party (but in no event more than &#91; * &#93; following receipt) with a data package consisting of, at a minimum, tables, lists and figures, as well as any other Data specified in the GDP or otherwise agreed by the Parties.  The Parties shall discuss the status, progress and results of each Party&#8217;s Development activities under this Agreement at such JDC meetings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.12&#160;&#160;&#160;&#160;Use of Subcontractors.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party may perform its Development activities under this Agreement through one or more subcontractors, provided that (a) such Party will remain responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself&#59; (b) each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article 14, and (c) each subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work to such Party (or, in the event such assignment is not feasible, a license to such intellectual property with the right to sublicense to such other Party).  The Parties may also subcontract work on terms other than those set forth in this Section 4.12 with the prior approval of the JDC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.13&#160;&#160;&#160;&#160;Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After the Effective Date and during the Term, neither Party nor any of its Affiliates or Sublicensees shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Product for use in connection with, or otherwise fund&#58; (a) any Development of any Product outside the scope of the GDP, including Phase 4 Clinical Trials conducted pursuant to parameters of scientific inquiry defined in the GDP or otherwise approved by the JDC&#59; or (b) comparative studies of its product versus the Product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">outside the scope of the GDP.  For clarity and without limiting the foregoing, except as expressly approved by the JDC and included in the GDP, Licensee shall not perform or sponsor any study or test on the Compound or Products, including any pre-clinical or non-clinical study, toxicology study or CMC-related study.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.14&#160;&#160;&#160;&#160;Materials Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In order to facilitate the Development activities contemplated by this Agreement, either Party may provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for use by the other Party in furtherance of such Development activities.  Except as otherwise provided for under this Agreement, all such Materials delivered to the other Party will remain the sole property of the supplying Party, will be used only in furtherance of the Development activities conducted in accordance with this Agreement, will not be used or delivered to or for the benefit of any Third Party, except to subcontractors, without the prior written consent of the supplying Party, and will be used in compliance with all Applicable Laws.  The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known.  Except as expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED &#8220;AS IS&#8221; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;REGULATORY ACTIVITIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Regulatory Responsibilities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;General.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The GDP shall set forth the regulatory strategy for seeking Regulatory Approval for the Compound and Products by the appropriate Regulatory Authorities in the Licensee Territory and Exelixis Territory.  The GDP shall also specify which Party shall apply for and hold Regulatory Filings in each country with respect to the conduct of Development activities.  Subject to the direction and oversight of the JDC, each Party shall be responsible for implementing such regulatory strategy in its territory.  Except as otherwise provided herein or required by Applicable Law, each Party shall be responsible for the preparation and submission of any and all Product registrations and marketing approvals in its territory and shall own and hold all such Regulatory Filings (including Regulatory Approvals), and neither Party shall submit any application for Product registration or marketing approval in the other Party&#8217;s territory.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall be responsible for the cost and expense of all regulatory activities in its territory.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee acknowledges that Exelixis may be required to communicate with Regulatory Authorities in the Licensee Territory as a result of Development </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and manufacturing activities in such territory.  Exelixis shall notify Licensee as soon as reasonably possible of such communication with Regulatory Authorities and seek to incorporate input from Licensee in preparation for such communication.  Exelixis shall then keep Licensee informed of any such communications.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Transfer of Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Section 5.2, Exelixis shall, in each case as may be required to enable Licensee to submit and file Regulatory Filings and obtain MAA Approvals for Products in the Licensee Territory&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">transfer to Licensee all Regulatory Approvals and Regulatory Filings submitted to any Regulatory Authority in the Licensee Territory for the Compound and Products that are in Exelixis&#8217; name and Controlled by Exelixis, other than INDs relating to Clinical Trials conducted and sponsored by Exelixis pursuant to the GDP&#59;  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the extent that such transfer is not permitted under Applicable Laws, Exelixis shall provide to Licensee a right of reference or use to such Regulatory Approvals and Regulatory Filings.  Exelixis shall provide appropriate notification of Licensee&#8217;s access and reference rights to the applicable Regulatory Authorities (including, to the extent applicable, an informed consent letter under Article 10c of Directive 2001&#47;83&#47;EC as amended), at the expense of Licensee seeking such right of reference.  For the purposes of this Agreement, &#8220;right of reference&#8221; shall mean the &#8220;right of reference or use&#8221; as defined in 21 C.F.R. &#167;314.3(b) and any equivalent regulation outside the US, including Article 10c of Directive 2001&#47;83&#47;EC, as each may be amended from time to time&#59;  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide to Licensee copies in electronic form of all Regulatory Approvals and Regulatory Filings submitted to any Regulatory Authority in the Licensee Territory including those related to CMC, manufacturing and product development, validation and manufacturing for the Compound and Products that are in Exelixis&#8217; name and Controlled by Exelixis, regulatory dossiers in Exelixis&#8217; possession or Control, and the Drug Master File&#59; and</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the extent any variations to the chemistry, manufacturing, and controls (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) section of the Regulatory Filing are required to conform with a variation that is initiated by Exelixis at its sole discretion, Exelixis shall reimburse Licensee for all associated fees that are paid by Licensee in filing such variations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for variations required to comply with Applicable Laws or any requirement of a Regulatory Authority, (a) Exelixis shall remain responsible for submissions and associated fees for all CMC variations originally attributable to a Regulatory Authority in the Exelixis Territory, and (b) Licensee shall be responsible for submissions and associated fees for all CMC variations originally attributable to a Regulatory Authority in the Licensee Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Existing Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge that as of the Effective Date, Exelixis&#59; its regulatory agent, TMC Pharma Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and its authorized distributor, Swedish Orphan Biovitrum AB (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sobi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), hold certain Regulatory Filings, licenses, and MAA Approvals related to Cometriq for MTC in the EU.  Exelixis, and Exelixis on behalf of TMC and Sobi, will ensure that Exelixis, TMC and Sobi will transfer Regulatory Filings, licenses, and MAA Approvals for Cometriq for MTC to Licensee in accordance with Article 8.  In addition, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis holds certain EMA Regulatory Filings, including the EMA MAA filing, for the Product in RCC.  As set forth in Section 5.1(b), the Parties shall cooperate to be ready to transfer and assign these EMA Regulatory Filings to Licensee and Exelixis shall notify the EMA promptly after the Effective Date that Licensee shall be the Marketing Authorization Holder as from the date of the transfer of the MAA.  The Parties agree to work toward the transfer of MAA holder status to Licensee by &#91; * &#93;.  Until the MAA transfer is accepted by the EMA, Exelixis shall be responsible for preparing and filing the MAA for the Product in RCC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Regulatory Information Sharing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall, upon the other Party&#8217;s reasonable request, promptly provide the other Party (but in no event more than &#91; * &#93;) with copies of any Regulatory Filings prepared (including any drafts), submitted or received by such Party in the U.S. and the Licensee Territory pertaining to the Compound and Products, and such other Party shall have the right to review and comment on drafts of such Regulatory Filings, provided that such review and comment shall not delay the submission of any Regulatory Filings.  The sharing of Regulatory Filings shall, as applicable, be the following communications&#47;correspondence with the Regulatory Authority&#58; (i) summary of contact reports either Party receives concerning substantive conversations or substantive meetings in its respective territory with the FDA, EMA, CFDA and PMDA with respect to the Product or if contacts with those Regulatory Authorities are made orally, to be reduced in writing, (ii) documents related to regulatory milestones and dates (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, submission, validations, agency review questions, CHMP opinion and FDA complete response letter and their equivalent), (iii) IND annual reports and cover letters of all agency submissions relating to the Compound or any Product.  If any Regulatory Filing to be provided under this Section 5.3 was originally created in a language other than the English language, then at the receiving Party&#8217;s request and to the extent already existing and readily available, the providing Party shall provide an English translation along with the original document to the receiving Party.  The Parties acknowledge that it is their intent to collaborate in good faith in the exchange of such Regulatory communications including with any Sublicensee or Future Exelixis Licensee.  Each of Licensee and Exelixis shall use Commercially Reasonable Efforts to grant the other Party access and rights to use any such communications with any Regulatory Authority generated by or on behalf of any Sublicensee or Future Exelixis Licensee, respectively.  Should either Party fail to obtain such access and rights from any Sublicensee or Future Exelixis Licensee, such Party shall not have the right to grant access or rights to such Sublicensee or Future Exelixis Licensee to any such communications with any Regulatory Authority generated by or on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.4&#160;&#160;&#160;&#160;Meetings with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On a current and ongoing basis, each Party shall provide the other Party with a list and schedule of any in-person meeting or material teleconference with the Regulatory Authorities (or related advisory committees) in the Licensee Territory planned for the next Calendar Quarter that relates to the Development of the Compound and Products under the GDP in the Licensee Territory (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In addition, each Party shall notify the other Party as soon as reasonably possible if such Party becomes aware of any additional Regulatory Meetings that become scheduled for such Calendar Quarter and will keep the other Party informed of any significant interface or communication with any Regulatory Authority which might affect efforts to obtain Regulatory Approval for the Product.  Licensee shall be solely responsible for any communications with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Authorities occurring or required in connection with performing its regulatory responsibilities set forth in this Article 5 with respect to the Product in the Licensee Territory, and Exelixis shall have the right to provide input in preparation for all Regulatory Meetings and, with the consent of Licensee, not to be unreasonably withheld, the right, but not the obligation, to have its representatives attend (but, unless otherwise requested by the other Party, not participate in) the Regulatory Meetings.  Licensee shall have these same rights with respect to any such Regulatory Meetings before such Regulatory Filings are transferred to Licensee under Sections 5.1(b) and 5.2. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall permit the Regulatory Authority(ies) in the Exelixis Territory to conduct inspections of Licensee, its Affiliates, and acting reasonably and in good faith of Sublicensees or subcontractors (including Clinical Trial sites) relating to the Development of the Product under the GDP, and shall ensure that such Affiliates, and acting reasonably and on good faith, such Sublicensees and subcontractors permit such inspections.  In addition, Licensee shall promptly notify Exelixis of any such inspection and shall supply Exelixis with all information pertinent thereto.  Licensee shall use Commercially Reasonable Efforts to allow an Exelixis representative to attend any such inspection with the presence of Licensee.  Exelixis shall permit the Regulatory Authority(ies) in the Licensee Territory to conduct inspections of Exelixis, its Affiliates, and acting reasonably and in good faith of Sublicensees or subcontractors (including Clinical Trial sites) relating to the Development of the Product under the GDP for the Licensee Territory, and shall ensure that such Affiliates, and acting reasonably and on good faith, such Sublicensees and subcontractors permit such inspections.  In addition, Exelixis shall promptly notify Licensee of any such inspection and shall supply Licensee with all information pertinent thereto.  Exelixis shall use Commercially Reasonable Efforts to allow a Licensee representative to attend any such inspection with the presence of Exelixis.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.5&#160;&#160;&#160;&#160;Adverse Event Reporting&#59; Pharmacovigilance Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within sixty (60) days after the Effective Date, but in any case prior to transfer of the marketing authorization,  the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Products, such as Safety Data sharing, adverse events reporting and safety signal and risk management (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which agreement shall be amended by the Parties &#91; * &#93; to comply with any changes in Applicable Laws or any guidance received from Regulatory Authorities.  Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws (including to the extent applicable, those obligations contained in ICH guidelines, E2A, E2B, E2C, E2D and E2F) to monitor the patients&#8217; safety.  Exelixis has established and shall continue to hold at its costs and expenses the global safety database for the Products, and shall maintain such global safety database for so long as such Product is under Development and&#47;or Commercialization by the Parties.  The Parties will collaboratively agree on data cut points for periodic aggregate safety reports and Exelixis will author such reports&#59; the Parties will jointly review and approve such reports before submission to worldwide Regulatory Authorities as required.  Exelixis shall bear one hundred percent (100%) of the cost and expense for establishing and maintaining such global database and the preparation of periodic aggregate safety reports (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date through &#91; * &#93;.  After such date, and subject to Section 4.5(a), Exelixis shall bear &#91; * &#93; percent (&#91; * &#93;%) and Licensee shall bear &#91; * &#93; percent (&#91; * &#93;%) of PV Costs.  Exelixis will ensure that each Party and any Future Exelixis Licensee are able to access the data, if necessary indirectly, from the global safety database in order to meet legal and regulatory obligations.  The Parties agree that Exelixis shall not transfer the responsibility or holding of the global safety database to any CRO, sublicensee, Future Exelixis Licensee or any Third Party without Licensee&#8217;s prior written consent and approval, which shall not be unreasonably withheld, conditioned or delayed if such transferee (and its Affiliates) is a pharmaceutical company of comparable size as Licensee and agrees to grant Licensee access and other rights to the global safety database substantially equivalent to those granted by Exelixis under the Pharmacovigilance Agreement.  The use by Exelixis of a CRO, sublicensee, Future Exelixis Licensee shall be at Exelixis&#8217; sole cost and expenses.  The JDC shall establish a safety subcommittee and all Safety Data, including adverse event reports, shall be submitted to such safety subcommittee and Exelixis concurrently so that Exelixis may update the global safety database accordingly.  Such safety subcommittee shall coordinate with respect to any Safety Data reporting for the Products to the Regulatory Authorities in the Licensee Territory, but each Party shall be primarily responsible for reporting quality complaints, adverse events and Safety Data related to the Products to any Regulatory Authorities and responding to safety issues and to all requests of Regulatory Authorities related to the Products under any MAA or Regulatory Approval for the Product held by such Party and filed with such Regulatory Authorities, in each case at its own cost.  Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and sublicensees to comply with such obligations. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.6&#160;&#160;&#160;&#160;No Harmful Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Party believes that the other Party is taking or intends to take any action with respect to a Product that could reasonably be expected to have a material adverse impact upon the regulatory status of such Product in the first Party&#8217;s territory, then such Party may bring the matter to the attention of the JDC and the Parties shall discuss in good faith to resolve such concern.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.7&#160;&#160;&#160;&#160;Notification of Threatened Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall notify the other Party within &#91; * &#93; of any information it receives regarding any threatened or pending action, inspection or communication by any Regulatory Authority, which may affect the safety or efficacy claims of any Product or the continued Development or Commercialization of any Product.  Upon receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.8&#160;&#160;&#160;&#160;Right of Reference to Regulatory Materials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party hereby grants to the other Party the right of reference to all Regulatory Filings pertaining to the Compound and Products submitted by or on behalf of such Party.  The receiving Party may use such right of reference solely for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Products for use in its territory in accordance with this Agreement.  Notwithstanding the foregoing, the receiving Party may use such right of reference to any Regulatory Filings based on Data resulting from the other Party&#8217;s Independent Work only to comply with its safety reporting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">obligations, unless the receiving Party pays the other Party for such work pursuant to Section 9.2(c). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.9&#160;&#160;&#160;&#160;Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that a recall, withdrawal or correction (including the dissemination of relevant information) of any Product in a Party&#8217;s territory is required by a Regulatory Authority of competent jurisdiction, or if any Regulatory Authority requires or advises either Party or such Party&#8217;s Affiliates or Sublicensees to distribute a &#8220;Dear Doctor&#8221; letter or its equivalent regarding use of such Product in a Party&#8217;s territory or if a recall, withdraw or correction of a Product in its territory is deemed advisable by such Party in its sole discretion, such Party shall so notify the other Party no later than &#91; * &#93; in advance of the earlier of (i) initiation of a recall, withdrawal or correction&#59; or (ii) the submission of plans for such an action to a Regulatory Authority.&#160; Any such recall, withdrawal, correction, or dissemination of information (e.g., &#8220;Dear Doctor&#8221; letter) shall be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.&#160; Promptly after being notified of a Recall, each Party shall provide the other Party with such assistance in connection with such Recall as may be reasonably requested by such other Party.&#160; All costs and expenses in connection with a Recall in a Party&#8217;s territory shall be paid by such Party, including without limitation the costs and expenses related to the dissemination of relevant information.&#160; Each Party shall handle exclusively the organization and implementation of all Recalls of Products in its territory.  Notwithstanding the foregoing, any Recall related to the manufacture and supply of the Product by Exelixis to Licensee shall be governed by the terms and conditions of the Supply Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.10&#160;&#160;&#160;&#160;Sunshine Reporting Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party acknowledges that the other Party may be subject to federal, state, local and international laws, regulations and rules related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sunshine Reporting Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and agrees to provide the other Party with all information regarding such payments or transfers of value by such Party as necessary for such other Party to comply in a timely manner with its reporting obligations under the Sunshine Reporting Law.     </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;COMMERCIALIZATIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subject to the terms and conditions of this Article 6 (including Section 6.7), Licensee shall have the sole and exclusive responsibility, at its own expense, for all aspects of the Commercialization of the Products in the Licensee Territory, including&#58; (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Products&#59; (c) marketing and promotion&#59; (d) booking sales and distribution and performance of related services&#59; (e) handling all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">aspects of order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">processing, invoicing and collection, inventory and receivables&#59; (f) providing customer support, including handling medical queries, and performing other related functions&#59; and (g) conforming its practices and procedures to Applicable Laws relating to the promotion, sales and marketing, access, and distribution of the Products.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;Commercialization Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  As soon as practical after the Effective Date, Licensee shall prepare and present to the JCC a Commercialization plan for Products in the Licensee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Territory, including a reasonably detailed description and an anticipated timeline for Licensee&#8217;s significant Commercialization activities for the Products for the next &#91; * &#93; commencing with the &#91; * &#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Taking into consideration the requirements of Section 6.3(c), the Commercialization Plan shall include such information on a country-by-country basis for each of the Major Market Countries.  Licensee shall update and amend the Commercialization Plan annually starting in November 2017 and each subsequent November, shall present such updates and amendments to the JCC for review and discussion.  Without limiting the provisions of this Section&#160;6.2, through the JCC, Licensee shall consult with and provide updates to Exelixis (&#91; * &#93;) regarding the commercial strategy and Commercialization of Products in the Licensee Territory.  Subject to the provisions of this Agreement and compliance with the Commercialization Plan, Licensee shall have full Control and authority with respect to the day-to-day Commercialization of the Products and implementation of the Commercialization Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160; Diligence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;General.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the Term, Licensee shall use Commercially Reasonable Efforts to Commercialize the Products for all indications that have received or will receive Regulatory Approval throughout the Licensee Territory.  In addition, and without limitation of the foregoing, Licensee shall, as soon as possible following each MAA Approval(s), subject to Section 6.4(b), launch the Product for such indication and obtain all necessary Price and Reimbursement Approvals at least in &#91; * &#93; (subject to the business judgment to delay or not to launch a particular Product in a particular country of the EU because of adverse pricing or other business considerations).  In the event that Licensee recommends not to launch a particular Product in a particular country of the Licensee Territory, or to deliberately defer such launch, it shall advise the JCC at the next meeting of such Committee and provide a reasonably detailed rationale for such determination.  Thereafter, Licensee shall utilize Commercially Reasonable Efforts in the ongoing support for the Product in each such country.  Licensee shall report to the JCC its efforts in each of these countries at least &#91; * &#93; at meetings of the JCC &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Additional Markets.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Promptly after the Effective Date, Licensee shall commence preparation of a reasonably detailed Commercialization plan, sales forecast, and launch timing for Commercialization of the Product, using Commercially Reasonable Efforts, in the Additional Markets.  On or before December 31, 2016, Licensee shall present to the JCC such reasonably detailed Commercialization plan, sales forecast, and launch timing for Commercialization of the Product, using Commercially Reasonable Efforts, in the Additional Markets.  Such report shall specifically assess the opportunity and plans for &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Minimum Commercial Performance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the foregoing general commitments, and subject to Section 6.3(e), for each Calendar Year for &#91; * &#93; full Calendar Years commencing &#91; * &#93;, Licensee shall prepare a commercially reasonable forecast of commercial sales of Product in the Licensee Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and submit the Sales Forecast to the JCC with sufficient time for the JCC to review and finalize such Sales Forecast by &#91; * &#93; of the year immediately preceding the year covered in such Sales Forecast.  The Sales Forecast shall be based upon the same market share trajectory as the Product achieved in the U.S. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the same time period following Regulatory Approval (including Pricing and Reimbursement Approval, if required) for each indication, as may be modified on the basis of other relevant commercial considerations, including other comparable product experience in Europe compared to the U.S.  For the first &#91; * &#93; Calendar Years following &#91; * &#93;, Sales Forecasts will be used solely for management purposes and have no effect under this Agreement.  If in any Calendar Year during the remaining &#91; * &#93; Calendar Years (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Minimum Commercial Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) Net Sales realized in the Licensee Territory are less than &#91; * &#93; percent (&#91; * &#93;%) of forecasted sales for such year, then Licensee shall submit a corrective plan to the JCC for review and approval for the next Calendar Year in order to achieve forecasted sales and such corrective plan shall be incorporated into the Commercialization Plan. If, for a second Calendar Year during the Minimum Commercial Performance Period, Net Sales realized are again less than &#91; * &#93; percent (&#91; * &#93;%) of forecasted sales then&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if Licensee failed to execute the corrective plan submitted to the JCC, it shall be considered a material breach giving rise to Exelixis&#8217; right to terminate this Agreement pursuant to Section 15.2&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if Licensee did execute the corrective plan submitted to the JCC, but still failed to achieve at least &#91; * &#93; percent (&#91; * &#93;%) of forecasted sales, then Licensee must submit a new corrective plan to the JCC&#59; and</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if during the Minimum Commercial Performance Period, Licensee fails to achieve at least &#91; * &#93; percent (&#91; * &#93;%) of forecasted sales in &#91; * &#93; of the &#91; * &#93; Calendar Years during the Minimum Commercial Performance Period, it shall be considered a material breach after the &#91; * &#93; of such Calendar Years giving rise to Exelixis&#8217; right to terminate this Agreement pursuant to Section 15.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Minimum Commercial Performance Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If in any Calendar Year during the Minimum Commercial Performance Period Net Sales realized in the Licensee Territory are less than &#91; * &#93; percent (&#91; * &#93;%) of forecasted sales for such year, then Licensee shall owe to Exelixis the Minimum Commercial Performance Compensation in respect of such year, to be paid within &#91; * &#93; of the end of the relevant Calendar Year. For the purposes of this Agreement, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Minimum Commercial Performance Compensation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be equal to the royalty payments due on the difference between &#91; * &#93; percent (&#91; * &#93;%) of the forecasted sales for the applicable Calendar Year and the Net Sales realized during the applicable Calendar Year.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Minimum Commercial Performance Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of conditions that give rise to a Stockout Period, Licensee shall be relieved of the obligation to meet minimum commercial performance obligations pursuant to Section 6.3(c) for the Calendar Year in which such Stockout Period occurs.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Commercial Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall update the JCC on a &#91; * &#93; basis regarding its Commercialization activities with respect to the Products in the Licensee Territory.  Each such update shall be in a form to be agreed by the JCC and shall summarize Licensee&#8217;s, its Affiliates&#8217; and Sublicensees&#8217; significant Commercialization activities with respect to the Products in the Licensee Territory, and shall contain at least such information at such level of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">detail reasonably required by Exelixis to determine Licensee&#8217;s compliance with its diligence obligations set forth herein.  Such updates shall include, on a &#91; * &#93; basis, Licensee&#8217;s sales activities, marketing activities and Medical Affairs Activities.  In addition, if Licensee is then working under a corrective plan under Section 6.3(c), such updates shall also include the budget and actual cost and expense (including FTE levels) for such activities in &#91; * &#93; for the current year and previous year.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;Coordination of Commercialization Activities.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Generally.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties recognize that their collaboration may benefit from the coordination of certain activities in support of the Commercialization of the Products in both the Licensee Territory and the Exelixis Territory.  As such, the Parties, through the JCC, shall develop and coordinate Commercialization strategies for the Product (e.g., for branding and messaging, international congresses, advisory boards), and the Parties shall conduct Commercialization activities for the Product in their respective territories consistent with such global strategy.  The foregoing shall not be construed as requiring Exelixis to seek Licensee&#8217;s consent in connection with the establishment and&#47;or implementation of any sales, marketing, or medical affairs practices in the Exelixis Territory.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Pricing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall keep Exelixis timely informed on the status of any application for Pricing and Reimbursement Approval or material updates to an existing Pricing and Reimbursement Approval in the Licensee Territory, including any discussion with a Regulatory Authority with respect thereto.  Licensee shall have the right to determine the price of the Product sold in the Licensee Territory &#91; * &#93;.  &#91; * &#93;.  In the event the Pricing and Reimbursement Approvals in a given country of the Licensee Territory is &#91; * &#93;, Licensee shall have no obligation to launch the Product in such country.  Licensee and its Affiliates and Sublicensees shall not sell any Product in combination with, as part of a bundle with, or as a combination therapy with other products, or offer packaged arrangements to customers that include a Product, in such a manner as to disproportionately discount the selling price of the Product &#91; * &#93;.  For clarification, should Licensee derive direct economic benefit from the sale of another pharmaceutical product that is approved to be used in combination with Product, &#91; * &#93;. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Sharing of Promotional Materials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall, at its own expense, prepare, develop, produce or otherwise obtain, and utilize sales, promotional, advertising, marketing, website, educational and training materials (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to support its Commercialization activities in the Licensee Territory.  The Parties shall share samples of Promotional Materials (including English translation, if available) with respect to the Commercialization of the Products with one another.  Additional materials, including medical education and medical information, sales force and sales force training materials, will be made available to the other Party upon request. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Commercialization in Exelixis Territory.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subject to the terms and conditions of this Agreement (including Section 6.7), Exelixis shall have the exclusive right to Commercialize the Product in the Exelixis Territory at its own cost and expense, with or without Third Party(ies).     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.5&#160;&#160;&#160;&#160;Detailing and Promotion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall not engage any contract sales organization to conduct sales activities for the Product in the Licensee Territory without written JCC approval, nor shall Licensee use the same sales force to promote the Product and a separate product that is indicated for the same indication without written JCC approval. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.6&#160;&#160;&#160;&#160;Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Coordination of Global Medical Affairs Activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Commencing with transfer of the RCC MAA to Licensee, but subject to the final sentence of this Section 6.6(a), Licensee shall lead and conduct all Medical Affairs Activities for the Product in the Licensee Territory in accordance with the medical affairs portion of the GDP.  From such date, Licensee shall be responsible for Medical Affairs Activities in the Licensee Territory, provided however, that Exelixis shall have the right, but not the obligation, to also conduct Medical Affairs Activities in the Licensee Territory in global support of the Product consistent with the medical affairs portion of the GDP and in coordination with Licensee.  Exelixis will not undertake Medical Affairs Activities in the Licensee Territory without prior coordination with Licensee. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Advisory Panels.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent practicable, each Party shall give the other Party written notice at least &#91; * &#93; in advance of any major market or international level advisory panel meetings with key opinion leaders with respect to the Commercialization of the Products in the Licensee Territory and the Exelixis Territory that are held, sponsored or attended by either Party or its Affiliate or sublicensee, and each Party shall have the right to attend and participate in such meetings.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.7&#160;&#160;&#160;&#160;Diversion.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party hereby covenants and agrees that it and its Affiliates shall not, and it shall contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligation) its sublicensees not to, directly or indirectly, promote, market, distribute, import, sell or have sold any Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like in the other Party&#8217;s territory.  Neither Party shall engage, nor permit its Affiliates and sublicensees to engage, in any advertising or promotional activities relating to any Product for use directed primarily to customers or other buyers or users of such Product located in any country or jurisdiction in the other Party&#8217;s territory, or solicit orders from any prospective purchaser located in any country or jurisdiction in the other Party&#8217;s territory.  If a Party or its Affiliates or sublicensees receives any order for a Product for use from a prospective purchaser located in a country or jurisdiction in the other Party&#8217;s territory, such Party shall immediately refer that order to such other Party and shall not accept any such orders.  Neither Party shall, nor permit its Affiliates and sublicensees to, deliver or tender (or cause to be delivered or tendered) any Product for use in the other Party&#8217;s territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;MANUFACTURE AND SUPPLY.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Manufacture and Supply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis will manufacture and supply, itself and&#47;or through a Third Party contract manufacturer, all Compound and Products for use in the Development and Commercialization of the Products under this Agreement.  All Products supplied by Exelixis to Licensee shall be at a price equal to &#91; * &#93;.  It is anticipated that Exelixis will supply commercial Product to Licensee in either bulk final dosage form or primary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">packaged bulk form as Licensee may specify from time to time.    Exelixis shall be responsible for packaging and labeling for all countries in the Licensee Territory until Licensee assumes such responsibilities pursuant to a transition plan, as further described in Section 2.4(e) of the Supply Agreement.  The Cost of Goods of the Compound and Products used in the Development work under the GDP shall be included in the Development Cost and shared by the Parties in accordance with Sections 4.5 and 9.2.  Exelixis shall source such Product supply for both Parties either from a facility owned by Exelixis or from a reputable, qualified and certified Third Party and, in the event Licensee is responsible for conducting any Clinical Studies pursuant to Section 4.3, 4.5(d) or 4.5(e), Exelixis shall provide such supply to Licensee for such Clinical Studies in accordance with the GDP.  Within two (2) months of the Effective Date, the Parties shall enter into a Supply Agreement for the manufacture and supply of the Compound and Products to Licensee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;TRANSITION OF EU REGULATORY AND COMMERCIALIZATION OPERATION.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.1&#160;&#160;&#160;&#160;Termination of Sobi Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee acknowledges that as of the Effective Date, Exelixis has entered into an Amended and Restated Commercialization Agreement with Swedish Orphan Biovitrum AB (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sobi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the distribution of the Product in the EU in MTC, effective January 1, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sobi Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  No later than March 4, 2016, Exelixis shall exercise its right to terminate the Sobi Agreement and Exelixis shall bear the cost of any resulting termination payment to Sobi under Section 8.3(g) of the Sobi Agreement.  Prior to the effective date of the termination of the Sobi Agreement, Licensee acknowledges and agrees that the licenses granted by Exelixis to Licensee hereunder are subject to the rights granted by Exelixis to Sobi under the Sobi agreement.  Exelixis shall ensure that a meeting be held with Sobi and Licensee within sixty (60) days of the Effective Date to achieve a smooth transition from Sobi to Licensee for the distribution of the Product in MTC in the EU.  Exelixis agrees, if necessary, to enforce the obligations of the Sobi Agreement as against Sobi to provide for a smooth transition of commercial responsibility for the distribution of the Product in the EU in MTC as contemplated by the Sobi Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.2&#160;&#160;&#160;&#160;Transfer of Regulatory Filings.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As soon as practicable, but no later than &#91; * &#93;, the Parties shall cooperate to transfer the EMA MAA filing from TMC for Cometriq in MTC to Licensee, including Marketing Authorization Holder status (including commitments and obligations listed in the MAA, and Exelixis shall ensure with TMC that such transfer shall occur, except that Exelixis shall complete the EMA post-marketing commitment of Study XL184-401, with the costs of such study to be shared in accordance with Section4.5), and the Pediatric Investigation Plan, provided that Licensee shall be responsible for all Regulatory Filings and interactions with the EMA with respect to such studies and Regulatory Filings, maintaining Orphan Drug Status, and all further EMA requirements with respect to such studies and Regulatory Filings.  Without limiting the foregoing, such transfer efforts shall include (a) providing supporting documentation, responding to requests by applicable Regulatory Authorities and other reasonable efforts in connection with the MAA Approvals, (b) preparing and filing Regulatory Filings in countries of the Licensee Territory where Sobi and&#47;or TMC has not as of the Effective Date filed Regulatory Filings and it is or it becomes commercially </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reasonable to do so.  Licensee&#8217;s rights and obligations as a regulatory sponsor with respect to each particular Regulatory Filing under Article 5 shall commence upon the completion of such transfer.   </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.3&#160;&#160;&#160;&#160;Transition of Commercial Responsibilities for Cometriq.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee and Exelixis acknowledge and agree that Licensee shall assume the rights and responsibilities for the Commercialization of Cometriq in the EU concurrent with the effective date of the termination of the Sobi Agreement.  Consistent with Section 8.2, the Parties shall cooperate to effectuate the transfer of such rights and responsibilities to Licensee in a manner that minimizes any delay or interruption of the Commercialization of Cometriq in the EU.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;FINANCIAL PROVISIONS </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;Upfront Payment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee shall make a one-time, non-refundable, non-creditable upfront payment to Exelixis of two hundred million dollars ($200,000,000) within five (5) business days after the Effective Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;Sharing&#47;Reimbursements of Development Costs and PV Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Future Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than &#91; * &#93; after the beginning of each Calendar Quarter during which a Party will perform any Development activity (other than the Independent Work and Licensee Only Development Work) in such Calendar Quarter pursuant to the GDP, such Party shall submit to the other Party a statement setting forth the Development Costs incurred, including the other Party&#8217;s share (calculated in accordance with Section 4.5) of (i) estimated Development Costs for the then current quarter&#59; (ii) variances from prior invoiced estimates and actual Development Costs&#59; and (iii) Development Costs incurred by or on account of such Party in the past quarter not previously invoiced.  Such invoice shall include a reasonably detailed report for such Development Costs, including supporting documents.  To the extent provided in Section 4.5, the other Party shall pay the amount invoiced within &#91; * &#93; after the receipt of the invoice, subject to the other Party&#8217;s right to audit the invoicing Party&#8217;s records and books related to such costs as provided in Section 10.4.  For clarity, making such a payment does not preempt the paying Party&#8217;s audit rights under Section 10.4, which remain in full force and effect.  If both Parties will perform Development activities under the GDP in such Calendar Quarter, the Parties shall consolidate the payments for such Calendar Quarter into a single payment from one Party to the other Party. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Independent Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as set forth below in this Section 9.2(c), each Party shall bear all the internal (calculated on an FTE basis using the then current FTE Rate) and out-of-pocket costs and expenses incurred by or on account of such Party in performing its own Independent Work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Independent Work Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  After the completion of such Independent Work, such Party shall provide the other Party with a report of such Independent Work Costs.  If a Party desires to submit any portion of the Data resulting from any Independent Work conducted by the other Party and related Regulatory Filings generated by the other Party to support Regulatory Approval in its territory, then such Party shall notify the other Party in writing at any time upon the completion of such Independent Work.  Within &#91; * &#93; after its receipt of such notice, the Party conducting or having conducted such Independent Work shall submit to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the other Party a reasonably detailed invoice setting forth &#91; * &#93; percent (&#91; * &#93;%) of the Independent Work Costs that would have been incurred by or on account of such other Party in connection with the generation of such Data under Section 9.2(b) as if such Independent Work Costs were Development Costs.  If the Party seeking to use such Data decides to use such Data to support Regulatory Approval in its territory, then such Party shall notify the other Party in writing and pay the amount invoiced within &#91; * &#93; after the receipt of such invoice, subject to such Party&#8217;s right to audit the invoicing Party&#8217;s records and books related to such costs as provided in Section 10.4.  For clarity, making such a payment does not preempt the paying Party&#8217;s audit rights under Section 10.4, which remain in full force and effect. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Internal Development Cost.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall record and calculate its internal Development Costs on an FTE basis at the FTE Rate.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Development Cost for Products in Combination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If any Product is Developed under this Agreement in combination with a Party&#8217;s proprietary product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Beneficial Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), either as a combination product or combination therapy, then such Development work shall be conducted in accordance with the GDP and the Development Costs with respect to such Development shall be included in the Development Budget, provided that only &#91; * &#93; percent (&#91; * &#93;%) of the Development Cost with respect to such Development shall be subject to the Parties&#8217; cost sharing under Section 9.2(b) and the Beneficial Party shall be solely responsible for the other &#91; * &#93; percent (&#91; * &#93;%) of the Development Costs. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;PV Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Commencing &#91; * &#93;, no later than &#91; * &#93; after the beginning of each Calendar Quarter, Exelixis shall submit to Licensee a statement setting forth the PV Costs incurred, including Licensee&#8217;s share (calculated in accordance with Section 5.5) of (i) estimated PV Costs for the then current quarter&#59; (ii) variances from prior invoiced estimates and actual PV Costs&#59; and (iii) PV Costs incurred by or on account of Exelixis in the past quarter not previously invoiced.  Such invoice shall include a reasonably detailed report for such PV Costs, including supporting documents.  To the extent provided in Section 5.5, Licensee shall pay the amount invoiced within &#91; * &#93; after the receipt of the invoice, subject to Licensee&#8217;s right to audit Exelixis records and books related to such costs as provided in Section 10.4.  For clarity, making such a payment does not preempt Licensee&#8217;s audit rights under Section 10.4, which remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Development Milestones.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the remainder of this Section 9.3, Licensee shall pay to Exelixis the non-refundable, non-creditable payment set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Licensee, Exelixis, or their Affiliates, licensee(s) of Exelixis or Sublicensees)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.102%"><tr><td style="width:1.0%"></td><td style="width:17.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.348%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Event</font></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payments</font></td></tr><tr style="height:44pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For HCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tier 1 Additional Indication</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tier 2 Additional Indication</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone #1&#58; Initiation of first Phase 3 Clinical Trial</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">n.a.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">n.a.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$20 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone #2&#58; First MAA filing with the EMA</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">n.a</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$25 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone #3&#58; First MAA Approval by EMA</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$60 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$40 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$50 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$60 million</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$50 million</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$95 million</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line) and for HCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line), each milestone payment shall be paid once for the applicable events described above for each different applicable Product.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Tier 1 Additional Indications and Tier 2 Additional Indications, each milestone payment shall be paid once for the applicable milestone events described above for a total payment of &#91; * &#93; for up to &#91; * &#93;.  For clarity, such milestone payments may be earned if &#91; * &#93;.  In the event that any indication &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Milestone #1 shall be deemed achieved and payable, if not already achieved, upon achievement of any of Milestone #2 and&#47;or Milestone #3 for the same indication.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone #2 shall be deemed achieved and payable, if not already achieved, upon achievement of Milestone #3 for the same indication.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Notice and Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall notify the other Party in writing within &#91; * &#93; after the achievement of any milestone set forth in this Section 9.3 by such Party, its Affiliates or its Sublicensees.  Licensee shall pay to Exelixis the applicable development milestone payments within &#91; * &#93; after the delivery or receipt of such notice.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4&#160;&#160;&#160;&#160;Commercial Milestones Payments.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;EU Launch Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall pay to Exelixis the non-refundable, non-creditable payment set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Licensee, its Affiliates, or Sublicensees)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EU Launch Milestones</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payments</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First commercial sale of a Product in any country in the Top 5 EU</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10 million</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First commercial sale of a Product in any second country in the Top 5 EU</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10 million</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Net Sales Milestones.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall pay to Exelixis the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in the Licensee Territory in any period of four (4) consecutive Calendar Quarters first reach the values indicated in the table below.  Once one of the values indicated in the table below is first reached and the corresponding Milestone Payment is paid by Licensee under this Section 9.4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Previously Achieved Commercial Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the period of four (4) consecutive Calendar Quarters to be applied to determine the reaching of a subsequent Net Sales amount in the table below shall only start at the Calendar Quarter immediately following the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Calendar Quarter which served as the period to determine the reaching of the Net Sales amount triggering the Previously Achieved Commercial Milestone.  For the avoidance of doubt, each payment in this Section 9.4 shall be payable once only, regardles</font><font style="color:#3d4240;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the number of times such mile</font><font style="color:#3d4240;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">tone is sub</font><font style="color:#3d4240;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">equently achieved.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Aggregate Net Sales of all Products in the Licensee Territory in any 4 consecutive Calendar Quarters</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payments</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed&#160;&#160;&#160;&#160;$100 million</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$25 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed&#160;&#160;&#160;&#160;$250 million</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$50 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed                               $&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Notice and Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee shall notify Exelixis in writing within &#91; * &#93; after the achievement of any EU launch milestone set forth in Section 9.4(a) above by Licensee, its Affiliates or its Sublicensees.  Licensee shall pay to Exelixis the applicable EU launch milestone payments within &#91; * &#93; after the delivery or receipt of such notice.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As part of the report in Section 10.1, Licensee shall provide written notice to Exelixis if the aggregated Net Sales of all Products in the Licensee Territory in any four (4) consecutive Calendar Quarters first reach the values set forth in Section 9.4(b) above, and Licensee shall pay to Exelixis the corresponding Net Sales milestone payment within &#91; * &#93; after the end of the Calendar Quarter.   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.5&#160;&#160;&#160;&#160;Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Royalty Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subject to the other terms of this Section 9.5, during the Royalty Term, Licensee shall make quarterly non-refundable, non-creditable royalty payments to Exelixis on the annual Net Sales of all Products sold in the Licensee Territory at the applicable rate set forth below&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Net Sales of all Products in the Licensee Territory</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Rate</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:17.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:17.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91; * &#93;%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:17.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26%</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Royalty Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Royalties shall be paid on a Product-by-Product and country-by-country basis in the Licensee Territory from the First Commercial Sale of such Product in such country by or on behalf of Licensee, its Affiliates or Sublicensees, until the latest of (i)&#160;expiration of the lasttoexpire Valid Claim of the Exelixis Patents and Licensee Patents covering such Product in such country, including its composition, method of manufacture or method of use, each covering the Product as Commercialized&#59; (ii) the expiration of any Regulatory Exclusivity covering such Product in such country&#59; or (iii)&#160;ten (10) years after the First Commercial Sale of such Product in such country for the first indication to obtain Regulatory Approval in the Licensee Territory other than MTC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Royalty Reductions </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If one or more Generic Products to a Product is sold in any country in the Licensee Territory during the Royalty Term for such Product in such country, and &#91; * &#93;, the royalty rates provided in Section 9.5(a) for such Product shall be reduced in such country by &#91; * &#93; percent (&#91; * &#93;%) &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If it is &#91; * &#93; for Licensee to obtain a license from a Third Party under any Patent in a particular country in the Licensee Territory in order to sell a Product in such country and Licensee obtains such a license, Licensee may deduct, from the royalty payment that would otherwise have been due pursuant to Section 9.5(a) with respect to Net Sales of such Product in such country in a particular Calendar Quarter, an amount equal to &#91; * &#93; percent (&#91; * &#93;%) of the royalties paid by Licensee to such Third Party pursuant to such license on account of the sale of such Product in such country during such Calendar Quarter. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Applicable Laws (including legal doctrine) in a particular country or jurisdiction requires a royalty reduction after the expiration of the relevant patents, and the Royalty Term for a particular Product in such country or jurisdiction extends beyond the time period set forth in Section 9.5(b)(i), then the royalty rates provided in Section 9.5(a) shall be reduced by &#91; * &#93; percent (&#91; * &#93;%) for such Product in such country (e.g., a reduction from &#91; * &#93;% to &#91; * &#93;%) during the remainder of the Royalty Term that extends beyond the time period set forth </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in Section 9.5(b)(i) unless and until the royalty reduction set forth in Section 9.5(c)(i) becomes applicable.   For the same period of time, if neither Exelixis nor Licensee has &#91; * &#93; in such country, such royalty reduction shall be &#91; * &#93; percent (&#91; * &#93;%) instead of &#91; * &#93; percent (&#91; * &#93;%).</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, during any Calendar Quarter in the Royalty Term for a Product in a country, the operation of clause (i), (ii) and (iii) above, individually or in combination, shall not reduce by more than &#91; * &#93; percent (&#91; * &#93;%) the royalties that would otherwise have been due under Section 9.5(a) with respect to Net Sales of such Product in such country during such Calendar Quarter.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Basis of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Section 9.5 is intended to provide for royalty payments to Exelixis equal to the percentages of Net Sales set forth in this Section 9.5 for the entire duration of the Royalty Term.  In establishing this payment structure, Licensee recognizes and acknowledges the substantial value of the various actions and investments that Exelixis has taken and will undertake under this Agreement, as well as the fact that the value of the license granted hereunder resides substantially in the Know-How.  Therefore, Licensee agrees that the royalty payments set forth above are appropriate for the entire duration of such payment obligation.  The Parties have agreed to the payment structure set forth herein as a convenient and fair mechanism for both Parties to be compensated for the value of their actions and investments under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Launch Period Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the first fifty million dollars ($50,000,000) of cumulative Net Sales, Licensee shall make quarterly non-refundable, non-creditable royalty payments to Exelixis on the Net Sales of all Products sold in the Licensee Territory at the rate of two percent (2%) rather than at the rate set forth in Section 9.5(a).  For the first one hundred million dollars ($100,000,000) of cumulative Net Sales immediately following the initial fifty million dollars ($50,000,000) of cumulative Net Sales, Licensee shall make quarterly non-refundable, non-creditable royalty payments to Exelixis on the Net Sales of all Products sold in the Licensee Territory at the rate of twelve percent (12%) rather than at the rate set forth in Section 9.5(a).  Thereafter, the royalty rate for all Net Sales shall be at the applicable rate set forth in Section 9.5(a).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Stockout Holiday</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of conditions that give rise to a Stockout Period, Licensee shall be relieved of the obligation to pay royalties pursuant to Section 9.5(a) on Net Sales occurring for a period of time, commencing with the first commercial sale following the end of the Stockout Period, equal in duration to the Stockout Period. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.6&#160;&#160;&#160;&#160;Exelixis Payments to Third Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis shall be solely responsible for all payments, including royalties and milestone payments, due with respect to Compound and Products pursuant to any Third Party agreement that Exelixis entered into prior to or as of the Effective Date, including any obligations surviving the termination of the Product Development and Commercialization Agreement between &#91; * &#93;, as set forth in such Collaboration Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.7&#160;&#160;&#160;&#160;Supply Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall pay Exelixis for Compound and Product  Exelixis supplies to Licensee an amount equal to &#91; * &#93;, all as provided in the Supply Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;PAYMENT&#59; RECORDS&#59; AUDITS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;Payment&#59; Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Royalty payments due by Licensee to Exelixis under Section 9.5 shall be calculated and reported for each Calendar Quarter.  All royalty payments due under Section 9.5 shall be paid within &#91; * &#93; after the end of each Calendar Quarter and shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Products by Licensee and its Affiliates and Sublicensees in the Licensee Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, for each country, the number of Products sold, the gross sales and Net Sales of Products, including the deductions from gross sales to arrive at Net Sales, the royalties payable, the method used to calculate the royalties, the exchange rates used, any adjustments to royalties in accordance with Section 9.5, and whether any commercial milestone under Section 9.4 has been achieved.  Promptly after the Effective Date, the Parties will agree on the form of royalty report.  Licensee shall submit a single report for all Net Sales during the Calendar Quarter, including all Licensee&#8217;s, Affiliates&#8217; and Sublicensees&#8217; Net Sales but shall separately identify the Net Sales and other information applicable to each entity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;Exchange Rate&#59; Manner and Place of Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  All references to dollars and &#8220;$&#8221; herein shall refer to U.S. dollars.  All payments hereunder shall be payable in U.S. dollars.  When conversion of Net Sales from any currency other than U.S. dollars is required, such conversion shall be at the exchange rate &#91; * &#93;.  All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Exelixis, unless otherwise specified in writing by Exelixis.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.3&#160;&#160;&#160;&#160;Taxes.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Taxes on Income.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Tax Cooperation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of the milestone payments, milestone payments and other payments made by Licensee to Exelixis under this Agreement.  To the extent Licensee is required by Applicable Laws to deduct and withhold taxes on any payment to Exelixis, Licensee shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Exelixis an official tax certificate or other evidence of such payment sufficient to enable Exelixis to claim such payment of taxes.  Exelixis shall provide Licensee any tax forms that may be reasonably necessary in order for Licensee to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so.  Exelixis shall use reasonable efforts to provide any such tax forms to Licensee in advance of the due date.  Licensee shall provide Exelixis with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Exelixis.  Licensee shall have the right to deduct any such tax, levy or charge actually paid from payment due to Exelixis.  Each Party agrees to assist the other Party in claiming exemption from such deductions or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Taxes Resulting From Licensee&#8217;s Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee represents and warrants that, as of the Effective Date, Licensee is not required by Applicable Law to deduct or withhold taxes on the upfront payment, milestone payments, royalty payments, and other payments payable to Exelixis under this Agreement.  If a Party takes any action of its own discretion (not required by a Regulatory Authority), including any assignment, sublicense, change of place of incorporation, or failure to comply with Applicable Laws or filing or record retention requirements, which results in a withholding or deduction obligation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Withholding Tax Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then such Party shall pay the sum associated with such Withholding Tax Action.  For clarity, if Licensee undertakes a Withholding Tax Action, then the sum payable by Licensee (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Exelixis receives a sum equal to the sum which it would have received had no such Withholding Tax Action occurred.  Otherwise, the sum payable by Licensee (in respect of which such deduction or withholding is required to be made) shall be made to Exelixis after deduction of the amount required to be so withheld or deducted.  If a change in Applicable Laws results in a withholding or deduction obligation absent either Party taking a Withholding Tax Action, then the amount of such withholding or deduction obligation shall be paid by Licensee to the applicable Governmental Authority on behalf of Exelixis, provided that Licensee shall assist Exelixis in minimizing or recovering such withholding or deduction obligation.  The Parties shall use commercially reasonable efforts to invoke the application of any applicable bilateral income tax treaty that would reduce or eliminate otherwise applicable taxes with respect to payments payable pursuant to this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.4&#160;&#160;&#160;&#160;Records&#59; Audit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit the other Party to confirm the accuracy of the amount of Development Costs and the Cost of Goods to be reimbursed or shared, achievement of commercial milestones, the amount of royalty and other payments under this Agreement.  Each Party will keep such books and records for at least &#91; * &#93; following the Calendar Year to which they pertain.&#160; Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement.  Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.  Such audits may occur no more often than once each Calendar Year and not more frequently than once with respect to records covering any specific period of time.  Each Party shall only be entitled to audit the books and records from the &#91; * &#93; Calendar Years prior to the Calendar Year in which the audit request is made.  Such auditor shall not disclose the audited Party&#8217;s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement.  In the event that the final </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within &#91; * &#93; after the Auditor&#8217;s report.  The auditing Party shall bear the full cost of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which underpayment or overpayment was more than &#91; * &#93; percent (&#91; * &#93;%) of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit.  With respect more specifically to the Development Costs to be paid or shared pursuant to Section 9.2, in addition to the right of inspection and audit by an Auditor, the Party making the payment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall have the right at its expense to review any records of out-of-pocket costs and expenses incurred by the Party requesting the payment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and time-keeping logs of Payee sufficient to justify the work-time spent by each FTE of the Payee as well as the books of the Payee upon reasonable notice sent by Payor to Payee and during regular business hours.  For clarity, making such a payment does not preempt the paying Party&#8217;s audit rights under this Section 10.4, which remain in full force and effect.  Payee&#8217;s FTE&#8217;s work-time shall be appropriately allocated between the other product and the Product for purpose of calculating the internal costs specifically dedicated to the Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.5&#160;&#160;&#160;&#160;Late Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at the &#91; * &#93; interest rate of &#91; * &#93; percent (&#91; * &#93;%) &#91; * &#93;&#59; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.  The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;INTELLECTUAL PROPERTY </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.1&#160;&#160;&#160;&#160;Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Data.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  All Data generated in connection with any Development or Commercial activities with respect to any Product conducted by or on behalf of Exelixis and its Affiliates and licensees (other than Licensee) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be the sole and exclusive property of Exelixis or its Affiliates or licensees, as applicable.  All Data generated in connection with any Development or Commercial activities with respect to any Product conducted by or on behalf of Licensee or its Affiliates or Sublicensees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be the sole and exclusive property of Licensee or of its Affiliates or Sublicensees, as applicable.  For clarity, each Party shall have access and right to use and reference the other Party&#8217;s Data as and to the extent set forth in this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Inventions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Inventorship of any Inventions will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.  The Parties will work together to resolve any issues regarding inventorship or ownership of Inventions.  Ownership of Inventions will be allocated as follows&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis will solely own all data, Inventions, and Patents claiming such Inventions that relate to the composition, manufacture or use of any Compound, or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">improvement of any such composition, manufacture or use (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compound Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  All Compound Inventions will be included in the Exelixis Know-How, and Patents in the Licensee Territory claiming such Inventions will be included in the Exelixis Patents.  To the extent any Compound Invention is made by Licensee, whether solely or jointly with Exelixis, Licensee shall, and hereby does, transfer and assign to Exelixis, without additional consideration, all of its interest in such Compound Invention. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except for Compound Inventions, each Party shall solely own any Inventions made solely by its and its Affiliates&#8217; employees, agents, or independent contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sole Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Parties shall jointly own any Inventions that are made jointly by employees, agents, or independent contractors of one Party and its Affiliates together with employees, agents, or independent contractors of the other Party and its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  All Patents claiming patentable Joint Inventions shall be referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign and otherwise exploit its interest under the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.2&#160;&#160;&#160;&#160;Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Exelixis Patents. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to this Section 11.2(a), Exelixis shall have the sole right, but not the obligation, to control the preparation, filing, prosecution and maintenance (including any interferences, reissue proceedings, reexaminations, inter partes review, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of the Exelixis Patents (other than Joint Patents) worldwide, using counsel of its own choice in the Exelixis Territory and counsel mutually agreed to by the Parties in the Licensee Territory.  Licensee shall reimburse Exelixis for all costs and expenses incurred with respect to the preparation, filing, prosecution and maintenance of Exelixis Patents in the Licensee Territory after the Effective Date, within &#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis.  In the event that Licensee does not reimburse Exelixis for such costs and expenses for any Exelixis Patent or notifies Exelixis in writing that it elects to cease reimbursing Exelixis for such costs and expenses for any Exelixis Patent, such Patent shall cease to be an Exelixis Patent and shall no longer be subject to the licenses and other rights granted by Exelixis to Licensee under this Agreement.  Exelixis shall keep Licensee informed of material progress with regard to the preparation, filing, prosecution and maintenance of Exelixis Patents in the Licensee Territory, sufficiently in advance for Licensee to be able to review any material documents, including content, timing and jurisdiction of the filing of such Exelixis Patents in the Licensee Territory, and Exelixis shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to strategies for filing, prosecuting and defending, if any, Exelixis Patents in the Licensee Territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Exelixis desires to abandon or cease prosecution or maintenance of any Exelixis Patent in any country in the Licensee Territory, Exelixis shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide reasonable prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91; * &#93; prior to the next deadline for any action that must be taken with respect to any such Exelixis Patent in the relevant patent office).  In such case, upon Licensee&#8217;s written election provided no later than &#91; * &#93; after such notice from Exelixis, Exelixis shall continue prosecution and maintenance of such Exelixis Patent at Licensee&#8217;s direction and expense.  If Licensee does not provide such election within &#91; * &#93; after such notice from Exelixis, Exelixis may, in its sole discretion, continue prosecution and maintenance of such Exelixis Patent or discontinue prosecution and maintenance of such Exelixis Patent.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Licensee Patents.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to this Section 11.2(b), Licensee shall have the first right, but not the obligation, to control the preparation, filing, prosecution and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of all Licensee Patents (other than Joint Patents) worldwide, at its sole cost and expense and by counsel of its own choice in the Licensee Territory and by counsel mutually agreed to by the Parties in the Exelixis Territory.  Licensee shall keep Exelixis informed of the status of filing, prosecution, maintenance and defense, if any, of the Licensee Patents, and Licensee shall consult with, and consider in good faith the requests and suggestions of, Exelixis with respect to strategies for filing, prosecuting and defending, if any, Licensee Patents.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Licensee desires to abandon or cease prosecution or maintenance of any Licensee Patent, Licensee shall provide reasonable prior written notice to Exelixis of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91; * &#93; prior to the next deadline for any action that must be taken with respect to any such Licensee Patent in the relevant patent office).  In such case, upon Exelixis&#8217; written election provided no later than &#91; * &#93; after such notice from Licensee, Exelixis shall have the right to assume prosecution and maintenance of such Licensee Patent at Exelixis&#8217; expense and Licensee shall assign to Exelixis all of its rights, title and interest in and to such Licensee Patent.  If Exelixis does not provide such election within &#91; * &#93; after such notice from Licensee, Licensee may, in its sole discretion, continue prosecution and maintenance of such Licensee Patent or discontinue prosecution and maintenance of such Licensee Patent.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Joint Patents.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to this Section 11.2(c), Exelixis shall have the first right, but not the obligation, to prepare, file, prosecute and maintain (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) Joint Patents using a patent counsel selected by Exelixis in the Exelixis Territory and counsel mutually agreed to by the Parties in the Licensee Territory.  Licensee shall reimburse Exelixis for all costs and expenses incurred with respect to the preparation, filing, prosecution and maintenance of Joint Patents in the Licensee Territory, within </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis.  In the event that Licensee does not reimburse Exelixis for such costs and expense for any Joint Patent or notifies Exelixis in writing that it elects to cease reimbursing Exelixis for such costs and expense for any Joint Patent, Licensee shall execute such documents and perform such acts, at Licensee&#8217;s expense, as may be reasonably necessary to effect an assignment of Licensee&#8217;s entire right, title, and interest in and to such Joint Patent to Exelixis, and such Patent shall cease to be either a Joint Patent or a Exelixis Patent and shall no longer be subject to the licenses and other rights granted by Exelixis to Licensee under this Agreement.  Exelixis shall keep Licensee informed of material progress with regard to the preparation, filing, prosecution, maintenance and defense, if any of Joint Patents, including content, timing and jurisdiction of the filing of such Joint Patents, and Exelixis shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to filing, prosecuting and defending, if any, Joint Patents in the Licensee Territory.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Exelixis desires to abandon or cease prosecution or maintenance of any Joint Patent in any country in the Licensee Territory, Exelixis shall provide reasonable prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91; * &#93; prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).  In such case, at Licensee&#8217;s sole discretion, upon written notice from Licensee to Exelixis, Licensee may elect to continue prosecution or maintenance of any such Joint Patent at its own expense, and Exelixis shall execute such documents and perform such acts, at Licensee&#8217;s expense, as may be reasonably necessary to allow Licensee to continue the prosecution and maintenance of such Joint Patent in such country in the Licensee Territory.  Any such assignment shall be completed in a timely manner to allow Licensee to continue prosecution and maintenance of any such Joint Patent and any such Patent so assigned shall cease to be either a Joint Patent or a Licensee Patent and shall no longer be subject to the licenses and other rights granted by Licensee to Exelixis under this Agreement </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Cooperation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance and defense, if any, of Patents under Section 11.2 and in the obtaining and maintenance of any patent term extensions, supplementary protection certificates and their equivalent with respect thereto respectively, at its own cost (except as expressly set forth otherwise in this Article 11).  Such cooperation includes&#58; (i)&#160;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 11.2&#59; and (ii)&#160;promptly informing the other Party of any matters coming to such Party&#8217;s attention that may affect the preparation, filing, prosecution or maintenance of any such patent application and the obtaining of any patent term extensions, supplementary protection certificates and their equivalent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.3&#160;&#160;&#160;&#160;Patent Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall notify the other within &#91; * &#93; of becoming aware of any alleged or threatened infringement by a Third Party of any of the Exelixis Patents (including Joint Patents) in the Licensee Territory, which infringement adversely affects or is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">expected to adversely affect any Product, including any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Exelixis Patents (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Enforcement Right.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall have the first right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate.  If Exelixis (i) decides not to bring such legal action against a Product Infringement (the decision of which Exelixis shall inform Licensee promptly) or (ii) Exelixis otherwise fails to bring such legal action against a Product Infringement within &#91; * &#93; of first becoming aware of such Product Infringement, Licensee shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with Exelixis.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Collaboration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party&#8217;s request and expense, including to be named in such action if required by Applicable Laws to pursue such action.  The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party&#8217;s comments on any such efforts, including, without limitation, determination of litigation strategy, filing of material papers to the competent court.  The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Expense and Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as set forth in clause (ii) below, the enforcing Party shall be solely responsible for any cost and expenses incurred by such Party as a result of such enforcement action.  If such Party recovers monetary damages in such enforcement action, such recovery shall be allocated first to the reimbursement of any expenses incurred by the enforcing Party in such enforcement action, second to the reimbursement of any expenses incurred by the other Party in such enforcement action, and any remaining amounts shall be retained by the enforcing Party. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if Exelixis is the enforcing Party against a Product Infringement in the Licensee Territory, Licensee shall have the option to share &#91; * &#93; percent (&#91; * &#93;%) of the cost and expense incurred by Exelixis in such enforcement action, which option may be exercised by Licensee by providing written notice to Exelixis within &#91; * &#93; after receiving a notice from Exelixis that Exelixis decides to bring such action.  If Licensee exercises such option, then (1) Licensee shall reimburse Exelixis for &#91; * &#93; percent (&#91; * &#93;%) of all costs and expenses incurred by Exelixis in such enforcement action, within &#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis&#59; (2) If Exelixis recovers any monetary damages in such enforcement action, such recovery shall be allocated &#91; * &#93; percent (&#91; * &#93;%) to Exelixis and &#91; * &#93; percent (&#91; * &#93;%) to Licensee. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Other Infringement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except for Product Infringement as set forth above, each Party shall have the exclusive right to enforce its own Patent against any infringement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">anywhere in the world.  For clarity, Exelixis shall have the exclusive right to enforce (i) the Exelixis Patents against any infringement in the Licensee Territory that is not a Product Infringement, and (ii) the Exelixis Patents and Joint Patents against any infringement in the Exelixis Territory, in each case at its own expense as it reasonably determines appropriate.  The Parties shall discuss global enforcement strategy for the Exelixis Patents and Licensee Patents, including the defense of validity and enforceability challenges arising from any enforcement action.    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.4&#160;&#160;&#160;&#160;Infringement of Third Party Rights.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any Product used or sold by Licensee, its Affiliates or Sublicensees becomes the subject of a Third Party&#8217;s claim or assertion of infringement of any intellectual property rights in a jurisdiction within the Licensee Territory, Licensee shall promptly notify Exelixis and the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a &#8220;common interest agreement&#8221; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.  Absent any agreement to the contrary, and subject to claims for indemnification under Article 13, each Party defend itself from any such Third Party claim at its own cost and expense, provided, however, that the provisions of Section 11.3 shall govern the right of Licensee to assert a counterclaim of infringement of any Exelixis Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.5&#160;&#160;&#160;&#160;Patents Licensed From Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party&#8217;s rights under this Article 11 with respect to the prosecution and enforcement of any Exelixis Patent and Licensee Patent shall be subject to the rights&#58; (a) retained by any upstream licensor to prosecute and enforce such Patent Right, if such Patent Right is subject to an upstream license agreement&#59; and (b) granted to any Third Party prior to such Patent Right becoming subject to the license grant under this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.6&#160;&#160;&#160;&#160;Trademarks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Product Trademarks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis shall develop and adopt trademarks, including trade names, trade dresses, branding, and logos, to be used for the Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis shall own the Product Marks throughout the world and all goodwill in the Product Marks shall accrue to Exelixis.  The Parties (including any Future Exelixis Licensee to the extent feasible) shall collaborate to have a global, worldwide trademark to be used on the Product.  The Parties acknowledge that Exelixis has been using the trademark Cometriq&#174; for the Product in MTC, and unless otherwise mutually agreed, the Parties shall continue to use Cometriq&#174; in MTC.  Exelixis shall select another Product Mark for the Product to be used for all other indications.  In the event Exelixis is unable to obtain or maintain the Product Marks for the Product in the Licensee Territory or in some countries in the Licensee Territory, the Parties shall collaborate to select such other Product Marks (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, back-up names) as may be available for registration and marketing of the Product in those countries.  Exelixis shall be responsible for the registration, maintenance, defense and enforcement of the Product Marks using counsel of its own choice in the Exelixis Territory and counsel mutually agreed to by the Parties in the Licensee Territory.  Licensee shall reimburse Exelixis for all costs and expenses incurred with respect to the registration and maintenance of the Product Marks in the Licensee Territory, within &#91; * &#93; from the date of invoice for such costs and expenses provided by Exelixis.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall keep Licensee informed of material progress with regard to the registration, prosecution, maintenance and defense, if any, of Exelixis Trademarks in the Licensee Territory, including content, timing and jurisdiction of the filing of such Exelixis Trademarks in the Licensee Territory, sufficiently in advance for Licensee to be able to review any material documents, and Exelixis shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to strategies for filing, prosecuting and defending, if any, Exelixis Trademarks in the Licensee Territory.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Trademark License.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall use the Product Marks selected by Exelixis to Commercialize the Product in the Licensee Territory.  Where Licensee reasonably believes the Product Mark is not appropriate for commercial use in a specific country, the Parties shall agree on an alternative product trademark for such country and such alternative product trademark shall be included in Product Mark.  In addition, unless prohibited by Applicable Laws, Licensee shall use Commercially Reasonable Effort to include Exelixis&#8217; corporate trademark on the packaging and product information (i.e. SmPC) of the Products sold in the Licensee Territory to indicate that the Product is licensed from Exelixis.  Exelixis hereby grants to Licensee a limited royalty-free license to use such Product Marks and Exelixis&#8217; corporate trademark solely in connection with the Commercialization of the Product in the Licensee Territory under this Agreement.  All use of the Product Marks and Exelixis&#8217; corporate trademark shall comply with Applicable Laws and regulations and shall be subject to Exelixis&#8217; review and approval.  For clarity, Licensee shall also include its (or its Affiliate&#8217;s or Sublicensee&#8217;s) corporate logo in the Product sold in the Licensee Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party represents and warrants to the other that, as of the Effective Date&#58; (a)&#160;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof, (b)&#160;it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action, (c)&#160;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it, and (d)&#160;it has the right to grant the licenses granted by it under this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.2&#160;&#160;&#160;&#160;Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Employees, Consultants and Contractors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions in a manner consistent with the provisions of this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Debarment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party represents, warrants and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Product.  In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee covenants as follows&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the performance of its obligations under this Agreement, Licensee shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee and its Affiliates&#8217; employees and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including, Licensee (and Licensee represents and warrants that as of the Effective Date, Licensee, and to its knowledge, its and its Affiliates&#8217; employees and contractors, have not directly or indirectly promised, offered or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection with the performance of Licensee&#8217;s obligations under this Agreement, and Licensee covenants that it and its Affiliates&#8217; employees and contractors shall not, directly or indirectly, engage in any of the foregoing).   </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee and its Affiliates, and their respective employees and contractors, in connection with the performance of their respective obligations under this Agreement, shall not cause its Indemnitees to be in violation of the FCPA, Export Control Laws, or any other Applicable Laws, rules or regulations or otherwise cause any reputational harm to Exelixis. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee shall immediately notify Exelixis if Licensee has any information or suspicion that there may be a violation of the FCPA, Export Control Laws, or any other Applicable Laws, rules or regulations in connection with the performance of this Agreement or the Development, manufacture or Commercialization of any Product. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In connection with the performance of its obligations under this Agreement, Licensee shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with Licensee&#8217;s own anti-corruption and anti-bribery policy, a copy of which has been provided to Exelixis prior to the Effective Date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis will have the right, upon reasonable prior written notice and during Licensee&#8217;s regular business hours, to conduct at its own cost and expenses inspections of and to audit Licensee&#8217;s books and records in the event of a suspected violation or to ensure compliance with the representations, warranties or covenants of this Section 12.2(c)&#59; provided, however, that in the absence of good cause for such inspections and audits, Exelixis exercise this right no more than annually. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Licensee has violated or been suspected of violating any of the representations, warranties, or covenants in this Section 12.2(c), Licensee will cause its or its Affiliates&#8217; personnel or others working under its direction or control to submit to periodic training that Licensee will provide on anti-corruption law compliance.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(viii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee will, at Exelixis&#8217; request, annually certify to Exelixis in writing Licensee&#8217;s compliance, in connection with the performance of Licensee&#8217;s obligations under this Agreement, with the representations, warranties, or covenants in Section 12.2(c), which certification shall be issued by Licensee&#8217;s global commercial head for the Product.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ix)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall have the right to suspend or terminate this Agreement in its entirety where there is a credible finding, after a reasonable investigation, that Licensee, its Affiliates, or its Sublicensees, in connection with performance of Licensee&#8217;s obligations under this Agreement, has engaged in chronic or material violations of the FCPA. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.3&#160;&#160;&#160;&#160;Additional Exelixis Representations, Warranties and Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis represents, warrants and covenants, as applicable, to Licensee that, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> lists all Patents Controlled by Exelixis in the Licensee Territory as of the Effective Date that claim the composition of matter or use of the Compound and have been filed, prosecuted and maintained in a manner consistent with Exelixis&#8217; standard practice, in each applicable jurisdiction in which such Patent have been filed, that no official final deadlines with respect to prosecution thereof have been missed and all applicable fees have been paid on or before the due date for payment&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All inventors of Inventions claimed in the Patent listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have assigned their entire right, title and interest in and to such inventions to Exelixis and the inventors listed are correct and there are no claims or assertions in writing received by Exelixis regarding the inventorship of such Patent alleging that additional or alternative Inventors ought to be listed&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis has the right to grant all rights and licenses it purports to grant to Licensee with respect to the Exelixis Technology under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis has not granted any liens or security interests on the Exelixis Technology&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis has not received any written notice from a Third Party that the Development of any Product conducted by Exelixis prior to the Effective Date has infringed any Patents of any Third Party&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis has not as of the Effective Date, and will not during the Term, grant any right to any Third Party under the Exelixis Technology that would conflict with the rights granted to Licensee hereunder&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">no claim or action has been brought or, to Exelixis&#8217; knowledge, threatened in writing, by any Third Party alleging that the Exelixis Patents are invalid or unenforceable, and no Exelixis Patent is the subject of any interference, opposition, cancellation or other protest proceeding &#91; * &#93;&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to Exelixis&#8217; knowledge, no Third Party is infringing or misappropriating or has infringed or misappropriated the Exelixis Technology in the Licensee Territory&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis has disclosed to Licensee all clinical and non-clinical data in the Control of Exelixis that is material to the evaluation of the safety, efficacy and manufacturing process of the Product&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to Exelixis&#8217; knowledge, there are no issues or information, which to Exelixis&#8217; knowledge and reasonable opinion, are reasonably likely to have a material impact on the Development of the Product that have not been fully disclosed to Licensee in the course of Licensee&#8217;s due diligence.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.4&#160;&#160;&#160;&#160;Additional Licensee Representations, Warranties and Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee represents, warrants and covenants to Exelixis that, as of the Effective Date, Licensee has not granted, and will not grant during the Term, any right to any Third Party under the Licensee Technology that would conflict with the rights granted to Exelixis hereunder.  Licensee further represents, warrants and covenants to Exelixis that, as of the Effective Date, Licensee does not own or control any Licensee Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.5&#160;&#160;&#160;&#160;Disclaimer.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as expressly set forth in this Agreement, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#8220;AS IS&#8221; AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.  Without limiting the foregoing, (a)&#160;neither Party represents or warrants that any data obtained from conducting Clinical Trials in one country or jurisdiction will comply with the laws and regulations of any other country or jurisdiction, and (b)&#160;neither Party represents or warrants the success of any study or test conducted by pursuant to this Agreement or the safety or usefulness for any purpose of the technology it provides hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.1&#160;&#160;&#160;&#160;Indemnification by Exelixis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis hereby agrees to defend, indemnify and hold harmless Licensee and its Affiliates and their respective directors, officers, employees and agents (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all liabilities, expenses and losses including any product liability, personal injury, property damage, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to which any Licensee Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise out of&#58; (a) the Development, use, handling, storage, Commercialization or other disposition of any Compound or Product by Exelixis or its Affiliates or licensees or the contractors of any of them (excluding any activities by or on behalf of Licensee or its Affiliates or Sublicensees), (b) the gross negligence or willful misconduct of any Exelixis Indemnitee, or (c)&#160;the breach by Exelixis of any warranty, representation, covenant or agreement made by Exelixis in this Agreement&#59; except, in each case (a)-(c), to the extent such Losses arise out of any activities set forth in Section 13.2(a), (b) or (c) for which Licensee is obligated to indemnify the Exelixis Indemnitee under Section 13.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.2&#160;&#160;&#160;&#160;Indemnification by Licensee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee hereby agrees to defend, indemnify and hold harmless Exelixis, its Affiliates and licensees and their respective directors, officers, employees and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Losses to which any Exelixis Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise out of&#58; (a)&#160;the Development, use, handling, storage, Commercialization or other disposition of any Compound or Product by Licensee or its Affiliates or Sublicensees or the contractor of any of them, (b) the gross negligence or willful misconduct of any Licensee Indemnitee, or (c)&#160;the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement&#59; except, in each case (a)-(c), to the extent such Losses arise out of any activities set forth in Section 13.1(a), (b) or (c) for which Exelixis is obligated to indemnify the Licensee Indemnitee under Section 13.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.3&#160;&#160;&#160;&#160;Procedure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  A party that intends to claim indemnification under this Article&#160;13 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall promptly notify the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in writing of any Third Party claim, demand, action or other proceeding (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof.  The Indemnitee may participate at its expense in the Indemnitor&#8217;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#8217;s own selection.  The indemnity arrangement in this Article&#160;13 shall not apply to amounts paid in settlement of any action with respect to a Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably.  The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article&#160;13 if and to the extent the Indemnitor is actually prejudiced thereby.  The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.4&#160;&#160;&#160;&#160;Insurance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party, at its own expense, for a period until &#91; * &#93; after expiration or termination of this Agreement, shall maintain commercial general liability insurance, including public and product liability and other appropriate insurance (e.g., contractual liability, bodily injury, property damage and personal injury coverage) (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term, at a minimum equivalent to &#91; * &#93; dollars ($&#91; * &#93;) for any one claim or in the aggregate.  Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request.  It is understood that such insurance shall not be construed to create any limit of either Party&#8217;s obligations or liabilities with respect to its indemnification obligations hereunder.  In the event of use by either Party of subcontractors, Sublicensees or any Third Party in the performance of such Party&#8217;s obligations under the Agreement, such Party shall ensure that its subcontractor, Sublicensee or Third Party shall have a proper and adequate general liability insurance to cover its risks with respect to the other Party for damages mentioned above.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.5&#160;&#160;&#160;&#160;Limitation of Liability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 14, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER&#59; provided, however, that this Section 13.5 shall not be construed to limit either Party&#8217;s indemnification obligations under this Article 13.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.1&#160;&#160;&#160;&#160;Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for &#91; * &#93; thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to Sections 14.2 and 14.3 and 14.5, shall not publish or otherwise disclose the terms of this Agreement.  Each Party may use the other Party&#8217;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.  Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors and other representatives do not disclose or make any unauthorized use of the Confidential Information of the other Party.  Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.2&#160;&#160;&#160;&#160;Exceptions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The obligations of confidentiality and restriction on use under Section 14.1 will not apply to any information that the receiving Party can prove by competent written evidence&#58; (a)&#160;is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public&#59; (b)&#160;is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disclosing Party, or its Affiliates, employees, agents, consultants, or contractors&#59; (c)&#160;is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right&#59; or (d)&#160;is independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the disclosing Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.3&#160;&#160;&#160;&#160;Authorized Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">filing, prosecuting, or maintaining Patents as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">regulatory filings for Products that such Party has a license or right to Develop and Commercialize hereunder in a given country or jurisdiction&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prosecuting or defending litigation as permitted by this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">complying with applicable court orders or governmental regulations&#59; and </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disclosure to its and its Affiliates&#8217; employees, consultants, contractors and agents, to its licensees and sublicensees, in each case on a need-to-know basis in connection with the Development, manufacture and Commercialization of the Compound and Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disclosure to potential and actual investors, acquirors, licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the disclosing Party redacts the financial terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment, acquisition or collaboration, which redaction shall be prepared in consultation with the other Party.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;14.3(c) or (d), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as such Party would use to protect its own confidential information, but in no event less than reasonable efforts.  In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.  Any information disclosed pursuant to Section 14.3(c) or (d) shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 14.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.4&#160;&#160;&#160;&#160;Publications.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall have the right to review and comment on any material proposed for disclosure or publication by the other Party regarding results of and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information regarding the other Party&#8217;s Development activities with respect to &#91; * &#93;, whether by oral presentation, manuscript or abstract.  Before any such material is submitted for publication, or presentation of any such material is made, each Party shall deliver a complete copy of the material proposed for disclosure to the other Party at least three (3) weeks (for oral presentations or abstracts) or five (5) weeks (for manuscripts) prior to submitting the material to a publisher or initiating any other disclosure.  Each Party shall review any such material and give its comments to the other Party within two (2) weeks (for oral presentations or abstracts) or twenty (20) days (for manuscripts) of the receipt of such material.  With respect to oral presentation materials and abstracts, each Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the other Party with appropriate comments, if any.  Each Party shall comply with the other Party&#8217;s request to delete references to its Confidential Information in any such material and agrees to not make any submission for publication or other public disclosure in order not to jeopardize the patentability of any results or data for the purpose of preparing and filing appropriate patent applications as provided in Section 14.4(b).    </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the non-Publishing Party notifies the Publishing Party that such publication or presentation, in the non-Publishing Party&#8217;s reasonable judgment, (i) contains an invention for which such Party desires to obtain patent protection, (ii) contains any Confidential Information of such Party, or (iii) could be expected to have an adverse effect on the commercial value of any Confidential Information disclosed by such Party to the Publishing Party, the Publishing Party shall delete such Confidential Information from the proposed publication or presentation.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For as long as the JDC or JCC remains in place, the JDC or JCC shall be responsible for overseeing and facilitating the Parties&#8217; communications and activities with respect to publications and presentations under this Section, and for serving as the initial forum for resolving any disputes between the Parties arising under this Section.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.5&#160;&#160;&#160;&#160;Publicity&#59; Public Disclosures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Parties agree to issue a joint press release substantially in a form agreed by the Parties and attached to this Agreement as Exhibit E announcing the signature of this Agreement at or shortly after the Effective Date within the time-period as required by relevant securities laws.  It is understood that each Party may desire or be required to issue subsequent press releases relating to this Agreement or activities hereunder.  The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, to the extent practicable, provided that a Party may not unreasonably withhold, condition or delay consent to such releases by more than &#91; * &#93;, and that either Party may issue such press releases or make such disclosures to the SEC or other applicable agency as it determines, based on advice of counsel, as reasonably necessary to comply with laws or regulations or for appropriate market disclosure.  Each Party shall provide the other Party with advance notice of legally required disclosures to the extent practicable.  The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or as otherwise required by Applicable Laws&#59; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws.  In addition, following the initial joint press </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">release announcing this Agreement, either Party shall be free to disclose, without the other Party&#8217;s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.6&#160;&#160;&#160;&#160;Prior Confidentiality Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  As of the Effective Date, the terms of this Article 14 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including the Confidentiality Agreement.  Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.7&#160;&#160;&#160;&#160;Equitable Relief. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 14.  In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.1&#160;&#160;&#160;&#160;Term.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this Article 15 or by mutual written agreement of the Parties, shall continue until the expiration of the last Royalty Term in the Licensee Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein, on a Product-by-Product and country-by-country basis, upon the expiration of the Royalty Term (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> all royalty payment obligations for a Product in a country), the licenses granted to Licensee in Section 2.1 shall be deemed to be perpetual and fully paid-up with respect to such Product in such country, but thereafter shall be on a non-exclusive basis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.2&#160;&#160;&#160;&#160;Termination for Cause.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Material Breach.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within &#91; * &#93; (&#91; * &#93; with respect to any payment breach) after notice of such breach from the non-breaching Party.  If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party, and such alleged breaching Party provides the other Party notice of such dispute within &#91; * &#93;, then the other Party shall not have the right to terminate this Agreement under this Section 15.2 unless and until an arbitral panel, in accordance with Article 16, has determined that the alleged breaching Party has materially breached the Agreement and that such Party fails to cure such breach within the applicable cure period set forth above following such decision.  In the event Exelixis commences </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an arbitration alleging material breach by Licensee and Licensee later delivers notice of voluntary termination under Section 15.3(b), then, at the election of Exelixis, the period of time set forth in Section 15.3(b) shall be reduced by an amount of time equal to the duration of time from the commencement of the arbitration to the delivery of such notice, &#91; * &#93;. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within &#91; * &#93; after the commencement thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Exelixis shall have the right to terminate this Agreement immediately in its entirety upon written notice to Licensee if Licensee or any of its Affiliates or Sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Exelixis Patent.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Safety Reasons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the terminating Party reasonably determines, based upon additional information that becomes available or an analysis of the existing information at any time, that the medical risk&#47;benefit of such Product is so unfavorable that it would be incompatible with the welfare of patients to Develop or Commercialize or to continue to Develop or Commercialize such Product.  Prior to any such termination, the terminating Party shall comply with such internal review and management approval processes as it would normally follow in connection with the termination of the development and commercialization of its own products for safety reasons.  The terminating Party shall document the decisions of such committees or members of management and the basis therefor and shall make such minutes and documentation available to the other Party promptly upon written request.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Discontinuation of Clinical Trials. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Licensee may terminate this Agreement upon &#91; * &#93; advance written notice to Exelixis, if substantially all ongoing Clinical Trials of the Product are ordered or required to be terminated by the FDA or the EMA.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.3&#160;&#160;&#160;&#160;Termination without Cause.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Termination in Its Entirety by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall have the right to terminate this Agreement in its entirety, or for only the countries that are under the EMA jurisdiction, without cause upon &#91; * &#93; prior written notice to Exelixis if the EMA refuses to approve the MAA for the Product in Renal Cell Carcinoma (2nd line therapy).  For the purpose of this Section 15.3(a), if EMA conditions such MAA Approval on the performance of additional </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase 3b or other studies, then EMA shall not be deemed to have refused the approval of such MAA. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Termination by Region by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall have the right to terminate this Agreement on a Region-by-Region basis without cause upon &#91; * &#93; prior written notice to Exelixis following the First Commercial RCC Sale of any Product in a given Region&#59; provided however that Licensee may not provide such notice of termination of this Agreement in a Region prior to the &#91; * &#93; anniversary of the First Commercial RCC Sale of any Product (other than Cometriq) in such Region.  In the event that termination occurs for the EU, then termination shall automatically be considered to have occurred for the entire Licensee Territory.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.4&#160;&#160;&#160;&#160;Effects of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Upon any termination of this Agreement by either Party, the following will apply&#58;  If this Agreement is terminated only with respect to a particular Region, then the following shall apply to the terminated Region and the terminated Region shall be included in Exelixis Territory.  For clarity, during the pendency of any dispute regarding material breach and&#47;or any termination notice period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All licenses granted by Exelixis to Licensee will automatically terminate, including all sublicenses granted by Licensee to any Sublicensee.  Except in the event of termination by Licensee under Section 15.2(a) for material breach by Exelixis, the licenses granted by Licensee to Exelixis shall survive such termination and shall automatically become worldwide or for the terminated Region if the Agreement is terminated only for a particular Region. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Regulatory Materials&#59; Data.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except in the event of termination by Licensee under Section 15.2(a) for material breach by Exelixis, within &#91; * &#93; of the effective date of such termination, Licensee shall transfer and assign to Exelixis, at no cost to Exelixis, all Regulatory Filings and Regulatory Approvals for the Products, Data from all preclinical, non-clinical and clinical studies conducted by or on behalf of Licensee, its Affiliates or Sublicensees on the Product and all pharmacovigilance data (including all adverse event database) on the Products.  In addition, at Exelixis&#8217; request, Licensee shall provide Exelixis with reasonable assistance with any inquiries and correspondence with Regulatory Authorities regarding the Product in the Licensee Territory, such assistance shall be limited to a period of &#91; * &#93; after such termination and not to exceed a total of &#91; * &#93; of working time without charge (with any additional time to be charged at the FTE Rate).  The transfer and assignment under this Section 15.4(b) shall apply with respect to the terminated Region if the Agreement is terminated only for a particular Region.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Development Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall either, as directed by Exelixis, (i) wind-down any ongoing Development activities (including any Clinical Trials) of Licensee and its Affiliates and Sublicensees with respect to any Product in the Licensee Territory in an orderly fashion or (ii) promptly transfer such Development activities to Exelixis or its designee, in compliance with all Applicable Laws.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Cost of Ongoing Trials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If there is any ongoing Clinical Trial of the Product under the GDP for which the Parties are sharing cost, then Licensee shall continue to share the cost of such Clinical Trial until the effective date of termination.  The remaining costs from the effective date of termination until completion of such Clinical Trial (or early termination of such Clinical Trial by Exelixis) shall be either (i) borne entirely by Exelixis following the effective date of termination if termination occurs as a result of Exelixis&#8217; breach, or (ii) shared by Licensee for the duration of such Clinical Trial if termination occurs as a result of Licensee&#8217;s breach, or pursuant to Section 15.3 or Section 2.8(c)(i).   </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Commercial Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall, as directed by Exelixis, (i) continue certain ongoing Commercial activities of Licensee and its Affiliates and Sublicensees with respect to any Product in the Licensee Territory for a period of up to &#91; * &#93; as determined by Exelixis, and (ii) handoff such Commercial activities to Exelixis or its designee, on a timetable to be set by Exelixis, not to exceed &#91; * &#93;, and in compliance with all Applicable Laws.  During such commercial wind-down period, the Licensee shall continue to book sales and pay royalties to Exelixis.  Except as necessary to conduct the foregoing activities as directed by Exelixis, Licensee shall immediately discontinue its (and shall ensure that its Affiliates and Sublicensees immediately discontinue their) promotion, marketing, offering for sale, and servicing of the Product and its use of all Product Marks.  In addition, Licensee shall immediately deliver to Exelixis (at Licensee&#8217;s expense) all samples, demonstration equipment, sales materials, catalogs, and literature of Exelixis in Licensee&#8217;s possession or control.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Transition Assistance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall use Commercially Reasonable Efforts to seek an orderly transition of the Development and Commercialization of the Compound and Products to Exelixis or its designee.  Except for termination by Licensee under Section 15.2, Exelixis may, in its sole discretion, postpone the effective date of any termination for a period of up to &#91; * &#93;.  Except in the event of termination by Licensee under Section 15.2(a) for material breach by Exelixis, Licensee shall, at no cost to Exelixis, provide reasonable consultation and assistance for a period of no more than &#91; * &#93; after termination (and in any case not to exceed a total of &#91; * &#93; of working time including the assistance provided under Section 15.4(b)) for the purpose of transferring or transitioning to Exelixis all Licensee Know-How not already in Exelixis&#8217; possession and, at Exelixis&#8217; request, all then-existing commercial arrangements relating to the Products that Licensee is able, using Commercially Reasonable Efforts, to transfer or transition to Exelixis or its designee, in each case, to the extent reasonably necessary or for Exelixis to continue the Development and&#47;or Commercialization of the Compound and Products in the Licensee Territory.  If any such contract between Licensee and a Third Party is not assignable to Exelixis or its designee (whether by such contract&#8217;s terms or because such contract does not relate specifically to the Products) but is otherwise reasonably necessary for Exelixis to continue the Development and&#47;or Commercialization of the Compound and Products in the Licensee Territory, or if Licensee is performing such work for the Compound and Product itself (and thus there is no contract to assign), then Licensee shall reasonably cooperate with Exelixis to negotiate for the continuation of such services for Exelixis from such entity, or Licensee shall continue to perform such work for Exelixis, as applicable, for a reasonable period (not to exceed &#91; * &#93;) after termination at Exelixis&#8217; cost until Exelixis establishes an alternate, validated source of such services.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;Remaining Inventories. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exelixis shall have the right, at its discretion, to purchase from Licensee any or all of the inventory of the Products held by Licensee as of the date of termination at a price equal to the transfer price paid by Licensee to acquire such inventory from Exelixis.  Exelixis shall notify Licensee within &#91; * &#93; after the date of termination whether Exelixis elects to exercise such right.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following any termination of this Agreement by Licensee pursuant to Section 2.8(c)(i) or Section 15.3, or by Exelixis pursuant to Section 15.2, neither Licensee nor any of its Affiliates shall (directly or indirectly, either with or without a bona fide collaborator or any other Third Party) commercialize any Competing Product for either (i) a period of &#91; * &#93; (in case of termination pursuant to Section 2.8(c)(i)) or &#91; * &#93; (in case of termination by Licensee pursuant to Section 15.3 or Exelixis pursuant to Section 15.2) following the effective date of such termination, or (ii) &#91; * &#93;, whichever is shorter. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.5&#160;&#160;&#160;&#160;Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Upon expiration or termination of this Agreement in its entirety, except to the extent that a Party obtains or retains the right to use the other Party&#8217;s Confidential Information, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#8217;s possession or control containing Confidential Information of the other Party&#59; provided that such Party may keep one copy of such materials for archival purposes only subject to continuing confidentiality obligations.  All Licensee Data and Regulatory Filings assigned to Exelixis upon termination of this Agreement will be deemed Exelixis&#8217; Confidential Information and no longer Licensee&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.6&#160;&#160;&#160;&#160;Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.  Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement&#58; Article 1 (Definitions)&#59;  Article 10 (Payments, Records, Audits)&#59; Article 13 (Indemnification)&#59; Article 15 (Dispute Resolution)&#59; Article 17 (General Provisions)&#59; Section 5.10 (Sunshine Reporting Laws)&#59; Section 11.1 (IP Ownership)&#59; Sections 14.1, 14.2, 14.3, 14.6, 14.7 (Confidentiality)&#59; and Section 15.4 (Effects of Termination).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.7&#160;&#160;&#160;&#160;Exercise of Right to Terminate.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All rights and obligations of a Party accrued prior to the effective date of a termination (including the rights to receive reimbursement for costs incurred prior to the effective date of such termination and payments accrued or due prior to the effective date of such termination) shall survive such termination.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.8&#160;&#160;&#160;&#160;Rights in Bankruptcy.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All rights and licenses granted under or pursuant to this Agreement by one Party to the other Party are, and will otherwise be deemed to be, for purposes of Section&#160;365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of right to &#8220;intellectual property&#8221; as defined under Section&#160;101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.  The Parties agree that a Party that is a licensee of such rights under this Agreement will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party to this Agreement under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, will be promptly delivered to it (a)&#160;upon any such commencement of a bankruptcy or insolvency proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b)&#160;if not delivered under (a) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;DISPUTE RESOLUTION </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.1&#160;&#160;&#160;&#160;Objective.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Parties recognize that disputes as to matters arising under or relating to this Agreement or either Party&#8217;s rights and obligations hereunder may arise from time to time.  It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation.  To accomplish this objective, the Parties agree to follow the procedures set forth in this Article&#160;16 to resolve any such dispute if and when it arises.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.2&#160;&#160;&#160;&#160;Executive Mediation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will try to settle any dispute, controversy or claim that arises out of, or relates to, any provision of the Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disputed Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by first referring the Disputed Matter to the CEO of Exelixis (or his designee) and the CEO of Licensee (or his designee).  Either Party may initiate such informal dispute resolution by sending written notice of the Disputed Matter to the other Party, and, within &#91; * &#93; after such notice, such CEOs (or their respective designees having the authority to settle such Disputed Matter) of the Parties will meet for attempted resolution by good faith negotiations.  If such CEOs (or their respective designees) are unable to resolve such dispute within &#91; * &#93; of their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with Section 16.3 below. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.3&#160;&#160;&#160;&#160;Dispute Resolution.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Parties are unable to resolve a Disputed Matter using the process described in Section 16.2, then a Party seeking further resolution of the Disputed Matter will submit the Disputed Matter to resolution by final and binding arbitration.  Whenever a Party will decide to institute arbitration proceedings, it will give written notice to that effect to the other Party.  Arbitration will be held in London, the United Kingdom, and administered by the International Chamber of Commerce pursuant to its ICC International Arbitration Rules then in effect (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), except as otherwise provided herein and applying the substantive law specified in Section 16.1.  The arbitration will be conducted by a panel of three (3) arbitrators appointed in accordance with the Rules&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each Party will, within &#91; * &#93; after the institution of the arbitration proceedings, appoint an arbitrator, and such arbitrators will together, within &#91; * &#93;, select a third (3rd) arbitrator as the chairman of the arbitration panel.  Each arbitrator must have significant business or legal experience in the pharmaceutical business.  If the two (2) initial arbitrators are unable to select a third (3rd) arbitrator within such &#91; * &#93; period, the third (3rd) arbitrator will be appointed in accordance with Rules.  The Parties hereby agree to engage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in discovery of information and evidence that is or might be relevant to the claims, defenses, and issues in the dispute, including by means of &#91; * &#93;.&#160; The Parties further agree to the ability, right, and power to subpoena Third Party witnesses for both discovery and hearing purposes.&#160; The discovery provided for herein may commence once the Terms of Reference have been signed by the Parties and the panel of arbitrators.&#160; The panel of arbitrators shall address the time required for the completion of discovery at the initial case management conference and shall address any discovery issues if any arise based on motion and arbitral order.  After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators will be requested to render their opinion within &#91; * &#93; of the final arbitration hearing.  No panel of arbitrators will have the power to award damages excluded pursuant to Section 13.5 under this Agreement and any arbitral award that purports to award such damages is expressly prohibited and void </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ab initio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Decisions of the panel of arbitrators that conform to the terms of this Section 16.3 will be final and binding on the Parties and judgment on the award so rendered may be entered in any court of competent jurisdiction.  The losing Party, as determined by the panel of arbitrators, will pay all of the ICC administrative costs and fees of the arbitration and the fees and costs of the arbitrators, and the arbitrators will be directed to provide for payment or reimbursement of such fees and costs by the losing Party.  If the panel of arbitrators determines that there is no losing Party, the Parties will each bear or pay one-half of those costs and fees and the arbitrators&#8217; award will so provide.  Notwithstanding the foregoing, each Party is to bear or pay its own attorneys&#8217; fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the terms of and procedures set forth in Section 16.2 or 16.3(a), any applications, motions or orders to show cause seeking temporary restraining orders, preliminary injunctions or other similar preliminary or temporary legal or equitable relief (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) concerning a Disputed Matter (including, but not limited to, Disputed Matters arising out of a potential or actual breach of the confidentiality and non-use provisions in Article 14)  may immediately be brought in the first instance and without invocation or exhaustion of the procedures set forth in subsections (a) and (b) for hearing and resolution in and by a court of competent jurisdiction.  Alternatively, a party seeking Injunctive Relief may immediately institute arbitral proceedings without invocation or exhaustion of the procedures set forth in subsections (a) and (b), and any such Injunctive Relief proceedings will be administered in accordance with by the ICC pursuant to its ICC emergency arbitration procedures then in effect and applying the substantive law specified in Section 16.2.  In either event, once the Injunctive Relief proceedings have been conducted and a decision rendered thereon by the court or arbitral forum, the Parties will, if the Disputed Matter is not finally resolved by the Injunctive Relief, proceed to resolve the Disputed Matter in accordance with the terms of Section 16.2 and 16.3(a). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, this Section 16.3 shall not apply to any dispute, controversy or claim that concerns (i)&#160;the validity, enforceability or infringement of a patent, trademark or copyright&#59; or (ii)&#160;any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.1&#160;&#160;&#160;&#160;Governing Law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, and all questions regarding the existence, validity, interpretation, breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.2&#160;&#160;&#160;&#160;Entire Agreement&#59; Modification.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, including the exhibits, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to all of its terms.  This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained herein.  This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.3&#160;&#160;&#160;&#160;Relationship Between the Parties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors.  This Agreement does not create any partnership, joint venture or similar business relationship between the Parties.  Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.4&#160;&#160;&#160;&#160;Non-Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance.  Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.5&#160;&#160;&#160;&#160;Assignment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld)&#59; provided, however, that either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent&#58; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in connection with the transfer or sale of all or substantially all of the business or assets of such Party relating to the Compound and Products to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets or otherwise, provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the acquiring Party by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiring Party to such transaction (if other than one of the Parties to this Agreement) shall not be included in the technology licensed hereunder&#59; or </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Section 17.5.  Any assignment not in accordance with this Section 17.5 shall be null and void. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.6&#160;&#160;&#160;&#160;Severability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.  All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.7&#160;&#160;&#160;&#160;Notices.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice to be given under this Agreement must be in writing and delivered either in person, by (a) air mail (postage prepaid) requiring return receipt, (b) overnight courier, or (c) facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 17.7.  Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58;  (i)&#160;the date of actual receipt&#59; (ii)&#160;if air mailed, five (5) days after the date of postmark&#59; (iii)&#160;if delivered by overnight courier, the next day the overnight courier regularly makes deliveries or (iv) if sent by facsimile, the date of confirmation of receipt if during the recipient&#8217;s normal business hours, otherwise the next business day.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Licensee, notices must be addressed to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ipsen Pharma SAS<br>65 quai Georges Gorse<br>92100 Boulogne-Billancourt<br>France<br>Attention&#58; Executive VP, General Counsel <br>Facsimile&#58; &#91; * &#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">If to Exelixis, notices must be addressed to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis, Inc.<br>210 East Grand Avenue, <br>So. San Francisco, CA 94080</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>USA<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  General Counsel</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; &#91; * &#93;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.8&#160;&#160;&#160;&#160;STANDSTILL.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commencing the Effective Date and expiring on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary date of the Effective Date, unless such provision is terminated earlier (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Standstill Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), neither Licensee nor any of its Affiliates, without the prior consent of Exelixis or except as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided for in this Agreement or in any agreement referred to herein, or in any agreement executed after the Effective Date by Exelixis with Licensee or any of its Affiliates, will&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">make, effect, initiate, cause or participate in&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any acquisition of beneficial ownership of any securities of Exelixis or any securities of any subsidiary or other Affiliate of Exelixis (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) such that following any such acquisition, Licensee and its Affiliates then own more than five percent (5%) of the securities of such Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any acquisition of any assets of any Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any tender offer, exchange offer, merger, business combination, recapitalization, restructuring, liquidation, dissolution or extraordinary transaction involving a Exelixis Entity, or involving any securities or assets of a Exelixis Entity&#59; or </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as those terms are used in the proxy rules of the Securities and Exchange Commission) or consents with respect to any securities of a Exelixis Entity&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">form, join or participate in a &#8220;group&#8221; (as defined in the Securities Exchange Act of 1934 and the rules promulgated thereunder) with respect to the beneficial ownership of any securities of a Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">act, alone or in concert with others, to seek to control or influence the management, board of directors or policies of a Exelixis Entity&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">take any action that might require a Exelixis Entity to make a public announcement regarding any of the types of matters set forth in clause &#8220;(i)&#8221; of this Section 17.8(a)&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">agree or offer to take, or encourage or propose (publicly or otherwise) the taking of, any action referred to in clause &#8220;(i)&#8221;, &#8220;(ii)&#8221;, &#8220;(iii)&#8221; or &#8220;(iv)&#8221; of this Section 17.8(a)&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">assist, induce or encourage any other person or entity to take any action of the type referred to in clause &#8220;(i)&#8221;, &#8220;(ii)&#8221;, &#8220;(iii)&#8221;, &#8220;(iv)&#8221; or &#8220;(v)&#8221; of this Section 17.8(a)&#59; or</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">enter into any discussions, negotiations, arrangement or agreement with any other person or entity relating to any of the foregoing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the expiration of the Standstill Period will not terminate or otherwise affect any of the other provisions of this Agreement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing provisions, Licensee or its Affiliates will not be subject to any of the restrictions set forth in this Section 17.8 with respect to a Exelixis Entity if either&#58; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Exelixis Entity publicly announces its intention to pursue a proposed Acquisition Transaction (as defined below)&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Exelixis Entity shall have entered into an agreement in principle or definitive agreement providing for an Acquisition Transaction&#59;   </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the board of directors of such Exelixis Entity shall have adopted a formal plan of liquidation or dissolution&#59; </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if a Third Party commences a tender or exchange offer or bid which, if successful, would result in such Third Party beneficially owning not less than thirty five percent (35%) of the voting securities or equity interest in such Exelixis Entity&#59; or</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if a Third Party makes a public announcement of a bone fide takeover bid to acquire the outstanding voting securities or equity interest in such Exelixis Entity. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquisition Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (A) any direct or indirect acquisition or purchase of assets of the applicable Exelixis Entity at a purchase price representing &#91; * &#93; (&#91; * &#93;%) of the voting securities of or equity interest in such Exelixis Entity by any person or &#8220;group&#8221;&#59; (B) any tender offer or exchange offer that if consummated would result in any person or &#8220;group&#8221; beneficially owning &#91; * &#93; (&#91; * &#93;%) or more of any class of equity securities of such Exelixis Entity&#59; or (C) any merger, consolidation, business combination, sale of assets, recapitalization or similar transaction involving such Exelixis Entity representing more than &#91; * &#93; (&#91; * &#93;%) of the market capitalization of such Exelixis Entity.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Parties agree that Licensee or its Affiliates shall not be prohibited from (i) initiating private discussions with, and submitting confidential private proposals to, the management or Chief Executive Officer of any acquisition of beneficial ownership of any securities or any assets of any Exelixis Entity, including discussing a right of first refusal before a Exelixis Entity intends to pursue any Acquisition Transaction&#59; or (ii) proposing other collaborative research agreements or other commercial license agreements to Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties agree to discuss whether to terminate the Standstill Period on a biennial basis at the anniversary date of the Effective Date.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.9&#160;&#160;&#160;&#160;Force Majeure.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (other than failure to make payment when due) by reason of any event beyond such Party&#8217;s reasonable control including Acts of God, fire, flood, explosion, earthquake, pandemic flu, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, or any other event similar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to those enumerated above.  Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur.  Notice of a Party&#8217;s failure or delay in performance due to force majeure must be given to the other Party within &#91; * &#93; after its occurrence.  All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.  In no event shall any Party be required to prevent or settle any labor disturbance or dispute.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.10&#160;&#160;&#160;&#160;Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.  All references in this Agreement to the singular shall include the plural where applicable.  Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.  The word &#8220;including&#8221; and similar words means including without limitation.  The word &#8220;or&#8221; means &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subject of the conjunction are mutually exclusive.  The words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.  All references to days in this Agreement mean calendar days, unless otherwise specified.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  This Agreement has been prepared in the English language and the English language shall control its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.11&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i88c4de4c1ff646d2bb728e929f16265e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></div><div style="text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXELIXIS, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Michael M. Morrissey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Marc de Garidel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Marc de Garidel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  Chairman &#38; CEO</font></div></td></tr></table></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i88c4de4c1ff646d2bb728e929f16265e_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">List of Exhibits&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A&#58;&#160;&#160;&#160;&#160;Chemical Structure of cabozantinib</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B&#58;&#160;&#160;&#160;&#160;Exelixis Patents</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit C&#58;&#160;&#160;&#160;&#160;Approved Distributors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit D&#58;&#160;&#160;&#160;&#160;Initial Global Development Plan and Budget</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit E&#58;&#160;&#160;&#160;&#160;Press Release </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHEMICAL STRUCTURE OF CABOZANTINIB</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_01.jpg" src="image_01.jpg" style="height:156px;margin-bottom:5pt;vertical-align:text-bottom;width:298px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cabozantinib (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)-malate salt</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i88c4de4c1ff646d2bb728e929f16265e_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF EXELIXIS PATENTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#123;redacted Exhibit B content comprises approximately 23 pages&#125;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91; * &#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPROVED DISTRIBUTORS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91; * &#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit D</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GLOBAL DEVELOPMENT PLAN<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#123;redacted Exhibit D content comprises 2 pages&#125;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91; * &#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i88c4de4c1ff646d2bb728e929f16265e_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit E</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PRESS RELEASE</font></div><div><img alt="image_11.jpg" src="image_11.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:228px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;            </font><img alt="image_21.jpg" src="image_21.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis Contacts</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Community&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investor Relations and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">(650) 837-8194</font></div><div><font style="color:#0000aa;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">shubbard&#64;exelixis.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Hal Mackins</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">For Exelixis, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">(415) 994-0040</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">hal&#64;torchcomllc.com</font></div><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ipsen Contacts</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Media&#58;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Didier Ve&#769;ron </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Senior Vice-Pre&#769;sident, Public Affairs and Communication<br>Tel.&#58; +33 (0)1 58 33 51 16<br>Fax&#58; +33 (0)1 58 33 50 58 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">E-mail&#58; </font><font style="color:#0000aa;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">didier.veron&#64;ipsen.com</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Community&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Ste&#769;phane Durant des Aulnois<br>Vice President, Investor Relations<br>Tel.&#58; +33 (0)1 58 33 60 09<br>Fax&#58; +33 (0)1 58 33 50 63<br>E-mail&#58; </font><font style="color:#0000aa;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">stephane.durant.des.aulnois&#64;ipsen.com</font></div></td></tr></table></div><div><font><br></font></div><div style="padding-right:-4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS AND IPSEN ENTER INTO EXCLUSIVE LICENSING <br>AGREEMENT TO COMMERCIALIZE AND DEVELOP NOVEL CANCER THERAPY CABOZANTINIB IN REGIONS OUTSIDE THE UNITED STATES, CANADA AND JAPAN</font></div><div><font><br></font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib commercialized for medullary thyroid cancer (MTC) <br>and filed for advanced renal cell carcinoma (RCC) -</font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">$200 million upfront payment and subsequent regulatory and commercial milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> -</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">South San Francisco, Calif. and Paris, France &#8211; February 29, 2016 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis, Inc. (NASDAQ&#58;EXEL) and Ipsen (Euronext&#58;  IPN&#59; ADR&#58; IPSEY) today jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis&#8217; lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States, Canada and Japan. This agreement includes rights to COMETRIQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which is currently approved in the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). The companies have agreed to collaborate on the development of cabozantinib for current and potential future indications. Exelixis will maintain exclusive commercial rights for cabozantinib in the United States and Canada, and continue its discussions to partner commercial rights in Japan.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the agreement, Exelixis will receive a $200 million upfront payment. Exelixis is eligible to receive regulatory milestones, including $60 million upon the approval of cabozantinib in Europe for advanced renal cell carcinoma (RCC) and $50 million upon the filing and approval of cabozantinib in Europe for advanced hepatocellular carcinoma (HCC), as well as additional regulatory milestones for potential further indications.  The agreement also includes up to $545 million of potential commercial milestones and provides for Exelixis to receive tiered royalties up to 26% on Ipsen&#8217;s net sales of cabozantinib in its territories.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said&#58; &#8220;The robust results from the METEOR study in advanced renal cell carcinoma demonstrate that cabozantinib has the potential to become a key oncology product in Europe. This transaction will help Ipsen accelerate the growth of the company and strengthen its oncology footprint in Europe. We are excited to bring cabozantinib to patients and clinicians around the world.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future commercial indications for cabozantinib could include advanced HCC, the subject of CELESTIAL, an Exelixis-sponsored phase 3 pivotal trial for which top-line results are anticipated in 2017. Additional earlier-stage studies are under way through Exelixis&#8217; collaboration with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP), and its ongoing Investigator-Sponsored Trial (IST) program. Through these two programs, there are more than 45 ongoing or planned studies including trials in advanced RCC, bladder cancer, colorectal cancer, non-small cell lung cancer, and endometrial cancer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;In Ipsen, Exelixis has an ideal partner to maximize the potential for cabozantinib to have a positive impact on the treatment of cancer on a global basis,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. &#8220;Ipsen&#8217;s established international oncology marketing presence, late-stage clinical development expertise and shared vision with Exelixis for the franchise potential of cabozantinib will accelerate cabozantinib&#8217;s commercialization in its territories, while Exelixis remains focused on our launch in the United States. While our immediate priority will be on advanced renal cell carcinoma, Exelixis and Ipsen are committed to exploring and potentially developing cabozantinib in a variety of cancer settings.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cabozantinib is a small molecule therapy that inhibits the activity of tyrosine kinases including VEGF receptors, MET, AXL, and RET. Following positive results from the METEOR global phase 3 pivotal trial, the tablet form of cabozantinib is the subject of pending U.S. and EU regulatory applications for use as a treatment for advanced RCC in patients who have received one prior therapy. In the EU, the Marketing Authorization Application (MAA) for cabozantinib in advanced RCC has been accepted and granted accelerated assessment. With this designation, the MAA is eligible for a 150-day review, versus the standard 210 days (excluding clock stops when information is requested by the EMA). Exelixis plans to transfer sponsorship of this MAA to Ipsen. Exelixis also anticipates transitioning the commercialization rights to COMETRIQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> outside the U.S. from Exelixis&#8217; current international partner for COMETRIQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Swedish Orphan Biovitrum AB (Sobi), to Ipsen, in accordance with the terms of its agreement with Sobi. In March 2014, the capsule form of cabozantinib was approved by the European Commission under the trade name COMETRIQ for the treatment of patients with progressive, unresectable, locally advanced or metastatic MTC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About the METEOR Phase 3 Clinical Trial</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">METEOR is a global, randomized open-label trial that compares cabozantinib to everolimus, a standard of care therapy, in 658 patients with advanced RCC whose disease progressed following treatment with a VEGF receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial&#8217;s primary endpoint is progression-free survival (PFS), and secondary endpoints include overall survival (OS) and objective response rate (ORR). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patients were randomized 1&#58;1 to receive 60 mg of cabozantinib or 10 mg of everolimus daily, and were stratified based on number of prior VEGFR TKI therapies and on commonly applied RCC risk criteria. No crossover was allowed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As published in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the trial met its primary PFS and secondary ORR endpoints.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Cabozantinib demonstrated a 42% reduction in the rate of disease progression or death as compared with everolimus, with median PFS of 7.4 months versus 3.8 months for everolimus (Hazard Ratio &#91; * &#93;&#61;0.58, 95% Confidence Interval &#91; * &#93; 0.45-0.75, p&#60;0.001).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following a pre-planned interim analysis that showed a strong trend in OS favoring cabozantinib (HR&#61;0.67, 95% CI 0.51-0.89, p&#61;0.005) but did not reach statistical significance, Exelixis undertook a second interim analysis after consulting with regulatory authorities. The results of this second interim analysis demonstrated a highly statistically significant and clinically meaningful increase in OS for cabozantinib. Exelixis has shared these data with regulators and intends to present them at a medical conference later this year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cabozantinib&#8217;s safety profile was similar to that of other VEGFR TKIs in this patient population. The incidence of adverse events (any grade), regardless of causality, was 100% with cabozantinib and more than 99% with everolimus. Serious adverse events occurred in 40% of cabozantinib patients and 43% of everolimus patients. The rate of treatment discontinuation due to adverse events was low (&#126;10%) in both treatment arms.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Advanced Renal Cell Carcinoma</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The American Cancer Society&#8217;s 2015 statistics cite kidney cancer as among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Clear cell RCC is the most common type of kidney cancer in adults.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If detected in its early stages, the five-year survival rate for RCC is high&#59; however, the five-year survival rate for patients with advanced or late-stage metastatic RCC is under 10 percent, with no identified cure for the disease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">4</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the introduction of targeted therapies into the RCC setting a decade ago, treatments for metastatic RCC had historically been limited to cytokine therapy (e.g., interleukin-2 and interferon). In the second- and later-line settings, which encompass approximately 17,000 drug-eligible patients in the U.S. and 37,000 globally,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> two small-molecule therapies and an immune checkpoint inhibitor have been approved. The currently approved small-molecule agents have shown little differentiation in terms of efficacy, demonstrating only modest PFS benefit in patients refractory to sunitinib, a commonly-used first-line therapy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Cabozantinib</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cabozantinib is currently marketed in capsule form under the brand name COMETRIQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the United States for the treatment of progressive, metastatic MTC, and in the European Union for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. COMETRIQ is not indicated for patients with RCC. In the METEOR trial, and all other cancer trials currently underway, </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Choueiri T.K. et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> N Engl J Med 2015&#59;373&#58;1814-23</font></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Cancer Facts &#38; Figures 2015. American Cancer Society. Available at <br>http&#58;&#47;&#47;www.cancer.org&#47;acs&#47;groups&#47;content&#47;&#64;editorial&#47;documents&#47;document&#47;acspc-044552.pd</font></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Jonasch et al., BMJ (2014) vol. 349, g4797</font></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> http&#58;&#47;&#47;www.cancer.org&#47;cancer&#47;kidneycancer&#47;detailedguide&#47;kidney-cancer-adult-survival-rate</font></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> ACS Cancer Facts and Figures 2015&#59; Heng et al., Ann Oncol (2012) vol. 23 no. 6&#59; internal data on file&#59; Motzer et al., N Engl J Med (2007) vol. 356 no. 2&#59; NCIN (UK) report, April 2014, Available at http&#58;&#47;&#47;www.ncin.org.uk&#47;view&#63;rid&#61;2676</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is investigating a tablet formulation of cabozantinib distinct from the COMETRIQ capsule form. The tablet formulation of cabozantinib is the subject of the NDA and MAA for advanced RCC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cabozantinib inhibits the activity of tyrosine kinases including VEGF receptors, MET, AXL and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and maintenance of the tumor microenvironment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The European Commission granted COMETRIQ conditional approval for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Important Safety Information, including Boxed WARNINGS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WARNING&#58; PERFORATIONS AND FISTULAS, and HEMORRHAGE</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Serious and sometimes fatal gastrointestinal perforations and fistulas occur in COMETRIQ-treated patients.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Severe and sometimes fatal hemorrhage occurs in COMETRIQ-treated patients.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;COMETRIQ treatment results in an increase in thrombotic events, such as heart attacks.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Wound complications have been reported with COMETRIQ.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;COMETRIQ treatment results in an increase in hypertension.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Osteonecrosis of the jaw has been observed in COMETRIQ-treated patients.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Palmar-Plantar Erythrodysesthesia Syndrome (PPES) occurs in patients treated with COMETRIQ.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The kidneys can be adversely affected by COMETRIQ. Proteinuria and nephrotic syndrome have been reported in patients receiving COMETRIQ.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reversible Posterior Leukoencephalopathy Syndrome has been observed with COMETRIQ.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Avoid administration of COMETRIQ with agents that are strong CYP3A4 inducers or inhibitors.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;COMETRIQ is not recommended for use in patients with moderate or severe hepatic impairment.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;COMETRIQ can cause fetal harm when administered to a pregnant woman.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverse Reactions &#8211; The most commonly reported adverse drug reactions (&#8805;25%) are diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. The most common laboratory abnormalities (&#8805;25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please see full U.S. prescribing information, including Boxed WARNINGS, at www.COMETRIQ.com&#47;downloads&#47;Cometriq_Full_Prescribing_Information.pdf</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please refer to the full European Summary of Product Characteristics for full European Union prescribing information, including contraindication, special warnings and precautions for use at www.sobi.com once posted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ipsen</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ipsen is a global specialty-driven biotechnological group with total sales exceeding &#8364;1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen&#8217;s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult &#38; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">pediatric). Ipsen&#8217;s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care.  Moreover, the Group has an active policy of partnerships. Ipsen's R&#38;D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis&#47;Paris-Saclay, France&#59; Slough&#47;Oxford, UK&#59; Cambridge, US). In 2015, R&#38;D expenditure totaled close to &#8364;193 million, representing about 13% of Group sales. The Group has more than 4,600 employees worldwide. Ipsen&#8217;s shares are traded on segment A of Euronext Paris (stock code&#58; IPN, ISIN code&#58; FR0010259150) and eligible to the &#8220;Service de R&#232;glement Diff&#233;r&#233;&#8221; (&#8220;SRD&#8221;). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit </font><font style="color:#0000aa;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.ipsen.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Exelixis</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, COTELLIC&#8482; (cobimetinib), a selective inhibitor of MEK, has been approved in Switzerland, the United States, the European Union, and Canada, and is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad global development program under a collaboration with Exelixis. For more information, please visit the company&#8217;s website at www.exelixis.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Forward-Looking Statement Disclaimer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; the business and financial terms of the collaboration agreement for cabozantinib with Ipsen, including, the division of commercialization rights, development plans and Exelixis&#8217; eligibility to receive regulatory and commercial milestones and royalties&#59; Exelixis&#8217; plan to continue its discussions to partner commercial rights for cabozantinib in Japan&#59; the potential for cabozantinib to become a key oncology product in Europe and the impact of the transaction on the growth of Ipsen&#59; advanced HCC as a future potential commercial indication for cabozantinib and the timing for anticipated top-line results from CELESTIAL&#59; the impact of the collaboration with Ipsen on Exelixis&#8217; plan to maximize the potential for cabozantinib on a global basis&#59; Exelixis&#8217; plan to stay focused on the potential launch of cabozantinib in advanced RCC in the United States&#59; advanced RCC as Exelixis&#8217; immediate priority&#59; Exelixis&#8217; and Ipsen&#8217;s commitment to exploring and potentially developing cabozantinib in a variety of cancers&#59; the eligibility for an expedited review of Exelixis&#8217; MAA for cabozantinib in advanced RCC by the EMA and Exelixis&#8217; plans to transfer sponsorship of the MAA to Ipsen&#59; Exelixis&#8217; plans to transition the commercialization rights to COMETRIQ outside of the U.S. from Sobi to Ipsen&#59; and Exelixis&#8217; intent to present data from the second interim analysis of OS for METEOR at a medical conference later this year. Words such as &#8220;will,&#8221; &#8220;potential,&#8221; &#8220;future,&#8221; &#8220;continue,&#8221; &#8220;eligible,&#8221; &#8220;priority,&#8221; &#8220;committed,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; or other similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the clinical, therapeutic and commercial potential of cabozantinib&#59; Exelixis&#8217; dependence on its relationship with Ipsen, including, the level of Ipsen&#8217;s investment in the resources necessary to successfully commercialize cabozantinib in the territories where it is approved&#59; Exelixis&#8217; ability to maintain its rights under the Ipsen collaboration&#59; risks and uncertainties </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">related to regulatory review and approval processes and Exelixis' compliance with applicable legal and regulatory requirements&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion&#59; Exelixis&#8217; ability to judge the proper size and level of experience of the commercialization teams required to support the launch of cabozantinib for advanced RCC&#59; unanticipated complications associated with the transition of the COMETRIQ commercialization rights from Sobi to Ipsen&#59; the availability of data at the referenced times&#59; Exelixis&#8217; ability to protect the company&#8217;s intellectual property rights&#59; market competition&#59; changes in economic and business conditions, and other factors discussed under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 10, 2015, and in Exelixis&#8217; future filings with the SEC, including, without limitation, Exelixis&#8217; annual report on Form 10-K expected to be filed with the SEC on February 29, 2016. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis&#8217; expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ipsen Forward-Looking Statement Disclaimer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The forward-looking statements, objectives and targets contained herein are based on the Group&#8217;s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group&#8217;s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words &#34;believes,&#34; &#34;anticipates&#34; and &#34;expects&#34; and similar expressions are intended to identify forward-looking statements, including the Group&#8217;s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful.  If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition&#59; general economic factors, including interest rate and currency exchange rate fluctuations&#59; the impact of pharmaceutical industry regulation and health care legislation&#59; global trends toward health care cost containment&#59; technological advances, new products and patents attained by competitors&#59; challenges inherent in new product development, including obtaining regulatory approval&#59; the Group's ability to accurately predict future market conditions&#59; manufacturing difficulties or delays&#59; financial instability of international economies and sovereign risk&#59; dependence on the effectiveness of the Group&#8217;s patents and other protections for innovative products&#59; and the exposure to litigation, including patent litigation, and&#47;or regulatory actions. The Group also depends on third parties to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">develop and market some of its products which could potentially generate substantial royalties&#59; these partners could behave in such ways which could cause damage to the Group&#8217;s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group&#8217;s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group&#8217;s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group&#8217;s business is subject to the risk factors outlined in its registration documents filed with the French Autorit&#233; des March&#233;s Financiers.</font></div><div><font><br></font></div><div style="padding-right:-4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks,<br> and COTELLIC is a U.S. trademark.</font></div><div style="padding-right:-4.5pt;text-align:center"><font><br></font></div><div style="padding-right:-4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"># # #</font></div><div style="padding-right:-4.5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102firstamendmentto.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i276c78d6e70743419296d695eeb0b9b0_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of December 20, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ipsen Pharma SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties desire to enter into this Amendment to expand the territory in which Licensee has the right to develop and commercialize cabozantinib and amend the continuing rights and obligations of the Parties under the License Agreement, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">DEFINITIONS.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 1.30 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. and Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 1.55 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Market Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 1.69 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, individually and collectively, the following regions&#58; &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 1.71 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA, the EMA and Health Canada or other foreign equivalent.  For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority shall also include any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Health Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the federal department of the government of Canada having the authority to regulate the sale of medicinal or pharmaceutical products, or any successor agency thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unless otherwise defined in this Amendment, all capitalized terms have the meaning as defined in the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Canada Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any Regulatory Authority in Canada requires one or more additional studies to support any MAA submitted by Licensee for the Product in Canada that are exclusively for the benefit of Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Canada Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such studies shall be deemed Licensee Only Development Work and subject to Licensee&#8217;s applicable obligations set forth in the License Agreement, including, without limitation, those obligations set forth in Sections 4.2, 4.5(e), 4.6, 4.7(a), and 4.8.  In accordance with Section 3.2(h) of the License Agreement, the JDC shall prepare an amendment(s) to the GDP with respect to any Canada Studies and submit such amendment(s) to the JSC for approval.  Exelixis shall, as may be required to enable Licensee to be the Sponsor of the Canada Studies, be subject to Exelixis&#8217; applicable obligations set forth in Section 5.1(b) of the License Agreement.  Exelixis shall have the right to use the Data of the Canada Studies generated by Licensee to support its own Development, Regulatory Approval or Commercialization in the Exelixis Territory subject to Section 9.2(b) of the License Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Country-Specific Development Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The phrase &#8220;Canada or&#8221; in the first sentence of Section 4.5(e) is hereby deleted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">REGULATORY ACTIVITIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any Canada Studies are included in the GDP, the GDP shall specify that Licensee shall apply for and hold Regulatory Filings in Canada.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;PVA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as reasonably practicable after the Amendment Effective Date, the Parties shall amend the PVA as necessary to address the modification herein to the Parties&#8217; respective territories.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as reasonably practicable after the Amendment Effective Date, the Parties shall amend the Supply Agreement as necessary to address the modification herein to the Parties&#8217; respective territories. In particular, the Parties agree that the Supply Agreement will be amended to add &#91; * &#93; reports from the below-referenced tracking system detailing the distribution and sale of product supplied for Canada.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following is hereby added to the License Agreement as Sections 2.8(e)-(f)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; To enforce the Parties&#8217; respective obligations set forth in Section 2.8(e) of the Agreement, to the extent permitted by Applicable Law, neither Party shall, and shall ensure that its respective Affiliates, permitted Sublicensees, and Third Party distributors will not, either directly or indirectly, advertise, promote, or market Products, including via the Internet, to any Third Party or place of business, residence, or shipping address in the other Party&#8217;s territory for the duration of the Royalty Term. &#160;The foregoing shall restrict either Party, to the extent permitted by Applicable Law, from engaging in any form of direct or indirect solicitation, advertisement, or promotion in the other Party&#8217;s territory. &#160;Each Party shall promptly, without any right to remuneration or compensation, forward to the other Party all inquiries regarding the Product by persons or entities whose place of business, residence, or shipping address is in the other Party&#8217;s territory. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Licensee will &#91; * &#93;.&#160; In the event that Exelixis or Licensee &#91; * &#93;, Licensee shall &#91; * &#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">FINANCIAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Amendment Execution Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In consideration of the expanded license rights granted by Exelixis to Licensee by virtue of this Amendment, Licensee shall make a one-time, non-refundable, noncreditable payment to Exelixis of ten million dollars ($10,000,000) within five (5) days after execution of this Amendment.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following is hereby added as Section 9.3(c) of the License Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestones Specific to Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the remainder of this Section 9.3(c), Licensee shall pay to Exelixis the non-refundable, non-creditable payment set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Licensee, Exelixis, or their Affiliates, licensee(s) of Exelixis or Sublicensees)&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:65.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Event</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone A&#58; MAA Approval by Health Canada (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, receipt of a &#8220;Notice of Compliance&#8221;) for a Product for RCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line) </font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$5,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone B&#58; MAA Approval by Health Canada for a Product for RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line) </font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$3,000,000*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone C&#58; MAA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by Health Canada (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, receipt of a &#8220;Notice of Compliance&#8221;) for a Product for HCC (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$2,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone D&#58; MAA Approval by Health Canada (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, receipt of a &#8220;Notice of Compliance&#8221;) for a Product for the first indication other than RCC or HCC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone E&#58; MAA Approval by Health Canada (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, receipt of a &#8220;Notice of Compliance&#8221;) for a Product for the second indication other than RCC or HCC</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  *With respect to a Product, if Licensee achieves Milestone A, and as part of such Milestone A, RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line) is also included in the claims section of the approved label of Milestone A and allows Ipsen to promote the Product for use in RCC (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> line), then Licensee shall pay Exelixis the milestone payment corresponding to Milestone B in addition to the milestone amount owed for achievement of Milestone A.  For clarity, in no event shall Licensee be obligated to pay to Exelixis more than a total of $8,000,000 for the achievement of Milestones A and B with respect to any one Product.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subject to Section 9.3(c)(i), each milestone payment shall be paid once for the applicable events described above for each different applicable Product.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Net Sales Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Section 9.4(b) is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4(b)(i) Net Sales Milestones for Licensee Territory Excluding Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall pay to Exelixis the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in the Licensee Territory, but excluding the Net Sales of all Products in Canada, in any period of four (4) consecutive Calendar Quarters first reach the values indicated in the table below.  Once one of the values indicated in the table below is first reached and the corresponding milestone payment is paid by Licensee under this Section 9.4(b)(i) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Previously Achieved Commercial Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the period of four (4) consecutive Calendar Quarters to be applied to determine the reaching of a subsequent Net Sales amount in the table below shall only start at the Calendar Quarter immediately following the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Calendar Quarter which served as the period to determine the reaching of the Net Sales amount triggering the Previously Achieved Commercial Milestone.  For the avoidance of doubt, each payment in this Section 9.4(b)(i) shall be payable once only, regardless of the number of times such milestone is subsequently achieved.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.589%"><tr><td style="width:1.0%"></td><td style="width:71.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Aggregate Net Sales of all Products in the Licensee Territory Excluding Canada in Any 4 Consecutive Calendar Quarters</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payments</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed&#160;&#160;&#160;&#160;$100 million</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$25 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed&#160;&#160;&#160;&#160;$250 million</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$50 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed &#160;&#160;&#160;&#160;$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed                               $&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17.1pt;padding-right:17.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91; * &#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4(b)(ii) Net Sales Milestones for Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall pay to Exelixis the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in Canada in any period of four (4) consecutive Calendar Quarters first reach the values indicated in the table below.  Once one of the values indicated in the table below is first reached and the corresponding milestone payment is paid by Licensee under this Section 9.4(b)(ii) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Previously Achieved Commercial Milestone for Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the period of four (4) consecutive Calendar Quarters to be applied to determine the reaching of a subsequent Net Sales amount in the table below shall only start at the Calendar Quarter immediately following the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Calendar Quarter which served as the period to determine the reaching of the Net Sales amount triggering the Previously Achieved Commercial Milestone for Canada.  For the avoidance of doubt, each payment in this Section 9.4(b)(i) shall be payable once only, regardless of the number of times such milestone is subsequently achieved.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.589%"><tr><td style="width:1.0%"></td><td style="width:71.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Aggregate Net Sales of all Products in Canada in Any 4 Consecutive Calendar Quarters</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payments</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed&#160;&#160;&#160;&#160;CAD$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:11.3pt;padding-right:11.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CAD$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed&#160;&#160;&#160;&#160;CAD$&#91; * &#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:11.3pt;padding-right:11.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CAD$&#91; * &#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equal or exceed &#160;&#160;&#160;&#160;CAD$&#91; * &#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:11.3pt;padding-right:11.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CAD$&#91; * &#93;</font></div></td></tr></table></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(A)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the amounts set forth in this Section 9.4(b)(ii) refer to Canadian dollars.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.4&#160;&#160;&#160;&#160;Notice and Payment for Net Sales Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Section 9.4(c)(ii) is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  As part of the report in Section 10.1, Licensee shall provide written notice to Exelixis if (1) the aggregated Net Sales of all Products in the Licensee Territory, but excluding the Net Sales of all Products in Canada, in any four (4) consecutive Calendar Quarters first reach the values set forth in Section 9.4(b)(i), or (2) the aggregated Net Sales of all Products in Canada in any four (4) consecutive Calendar Quarters first reach the values set forth in Section 9.4(b)(ii), and Licensee shall pay to Exelixis the corresponding Net Sales milestone payment within &#91; * &#93; after the end of the Calendar Quarter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.5&#160;&#160;&#160;&#160;Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Section 9.5(a) is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.5(a)(i)  Royalty Rate for Licensee Territory Excluding Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the other terms of this Section 9.5, during the Royalty Term, Licensee shall make quarterly non-refundable, non-creditable royalty payments to Exelixis on the annual Net Sales of all Products sold in the Licensee Territory, but excluding the annual Net Sales of all Products sold in Canada, at the applicable rate set forth below&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.576%"><tr><td style="width:1.0%"></td><td style="width:64.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Net Sales of all Products in the Licensee Territory Excluding Canada</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;<br>and less than or equal to &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion greater than &#160;&#160;&#160;&#160;$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26%</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.5(a)(ii)  Royalty Rate for Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the other terms of this Section 9.5, during the Royalty Term Licensee shall make quarterly non-refundable, non-creditable royalty payments to Exelixis on the annual Net Sales of all Products sold in Canada at the applicable rate set forth below&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.576%"><tr><td style="width:1.0%"></td><td style="width:64.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Net Sales of all Products in Canada</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion less than or equal to &#160;&#160;&#160;&#160;CAD$30 million</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion greater than &#160;&#160;&#160;&#160;CAD$30 million<br>and less than or equal to &#160;&#160;&#160;&#160;CAD$&#91; * &#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91; * &#93;%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Portion greater than &#160;&#160;&#160;&#160;CAD$&#91; * &#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26%</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(A)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the annual Net Sales amounts set forth in this Section 9.4(a)(ii) refer to Canadian dollars.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;Product Trademarks.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following is hereby added as Section 11.6(a)(i)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  Without limiting the generality of the foregoing Section 11.6(a), the Parties shall use the trademark Cabometyx&#174; for the Product in Canada to the extent that such trademark is approved for use with the Product by Health Canada or other applicable Regulatory Authority.  If Exelixis is unable to obtain or register Cabometyx&#174; for use with the Product in Canada, the Parties shall collaborate to select another Product Mark to be used for the Product in Canada.  In accordance with Section 11.6(a), Exelixis shall own the Product Marks used for the Product in Canada and all goodwill in such Products Marks shall accrue to Exelixis.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as provided in Sections 9.4(b)(ii) and 9.5(a)(ii), all references in the Agreement to dollars or &#8220;$&#8221; shall remain United States Dollars.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The License Agreement as modified by this Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3&#160;&#160;&#160;&#160;Severability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><div id="i276c78d6e70743419296d695eeb0b9b0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXELIXIS, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">By&#58;  &#47;s&#47; Michael Morrissey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Name&#58;  Michael Morrissey, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Title&#58;  President &#38; CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">By&#58;  &#47;s&#47; Christophe Jean</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Name&#58;  Christophe Jean</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Title&#58;  EVP Corporate Strategy &#38; Business Development</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#123;Signature Page to the First Amendment of the Collaboration and License Agreement&#125;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91; * &#93; &#61;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103secondamendmentt.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id8db7eaf9dc14af4a94888d021473170_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of September 14, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ipsen Pharma SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1, dated effective December 20, 2016 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties desire to enter into this Second Amendment to amend the timing of a certain milestone payment under the License Agreement, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">FINANCIAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Section 9.3(b) of the License Agreement is hereby amended and restated to read in full as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3(b)  Notice and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall notify the other Party in writing within &#91; * &#93; after the achievement of any milestone set forth in this Section 9.3 by such Party, its Affiliates, or its Sublicensees.  Licensee shall pay to Exelixis the applicable development milestone payments within &#91; * &#93; after the delivery or receipt of such notice.  Notwithstanding the foregoing sentence, Licensee shall pay to Exelixis the Milestone #2 payment (First MAA filing with the EMA) for the Tier 1 Additional Indication ($25,000,000) either within &#91; * &#93; after the delivery or receipt of notice, or on &#91; * &#93;, whichever is later.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Second Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The License Agreement as modified by this Second Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, for any reason, any part of this Second Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Second Amendment.  All remaining portions shall remain in full force and effect as if the original Second Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Second Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Second Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:95%">&#91; * &#93; &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:95%">.</font></div><div><font><br></font></div></div></div><div id="id8db7eaf9dc14af4a94888d021473170_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be executed and entered into by their duly authorized representatives as of the Second Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXELIXIS, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; &#47;s&#47; Christopher J. Senner</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Christopher J. Senner</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  EVP and CFO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; &#47;s&#47; Fran&#231;ois Garnier</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Fran&#231;ois Garnier</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Executive Vice President, General <br>Counsel</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exhibit104thirdamendmentto.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9c35b08d49304e36b11b5bfdf5b3fa7b_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIRD AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of October 26, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ipsen Pharma SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1, dated effective December 20, 2016, and Amendment No. 2 dated effective September 14, 2017 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties desire to enter into this Third Amendment to update certain definitions and manufacturing responsibilities under the License Agreement, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Now, Therefore,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">DEFINITIONS  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unless otherwise defined in this Third Amendment, all capitalized terms have the meaning as defined in the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;&#8220;Cost of Goods&#8221; Definition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The fourth sentence of Section 1.19 of the License Agreement is hereby amended and restated to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Direct labor costs shall include the cost of&#58; &#91; * &#93;.&#8221;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The third and fourth sentences of Section 7.1 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;It is anticipated that Exelixis will supply commercial Product to Licensee in final, labeled packaged form.  Exelixis shall be responsible for packaging and labeling for all countries in the Licensee Territory.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Third Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The License Agreement as modified by this Third Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, for any reason, any part of this Third Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Third Amendment.  All remaining portions shall remain in full force and effect as if the original Third Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Third Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Third Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div></div></div><div id="i9c35b08d49304e36b11b5bfdf5b3fa7b_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be executed and entered into by their duly authorized representatives as of the Third Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXELIXIS, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Michael M. Morrissey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  President and CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Christophe Jean</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Christophe Jean</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  EVP Corporate Strategy &#38; Business Development</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>exhibit105ipsensupplyagree.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i690b7e7362d44960b1dcae8fef9529ed_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:right;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUPPLY AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUPPLY AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of February 29,  2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IPSEN PHARMA SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Exelixis, a biopharmaceutical company, is developing its proprietary compound known as cabozantinib for the treatment of cancer&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Exelixis and Licensee are parties to a certain Collaboration and License Agreement of even date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration and License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under which Exelixis has granted Licensee the right to develop and commercialize cabozantinib outside the U.S., Canada, and Japan&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Collaboration and License Agreement contemplates that Exelixis will manufacture and supply cabozantinib to Licensee for development and commercial use, and Exelixis is willing to manufacture and supply cabozantinib to Licensee, on the terms and conditions set forth below.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 1<br>DEFINITIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Capitalized terms used in this Supply Agreement but not defined herein shall have the meanings set forth in the Collaboration and License Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such party, but for only so long as such control exists.  As used in this Section&#160;1.1, &#8220;control&#8221; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance&#59; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Batch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the quantity of a Product produced in a single production run of such Product.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day that is not a Saturday, Sunday, or a day on which banking institutions in San Francisco, California, USA are authorized by Law to remain closed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;&#8220;Claims&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any and all Third Party claims, suits, proceedings, damages, expenses (including court costs and reasonable attorneys&#8217; fees and expenses) and recoveries against a Party. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration and License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means cabozantinib, having the chemical structure set forth in Exhibit A of the Collaboration and License Agreement, including any pharmaceutically acceptable salt form of cabozantinib. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.7&#160;&#160;&#160;&#160;&#8220;Cost of Goods&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;COG&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, with respect to any Compound or Product, the fully burdened cost to manufacture such Compound or Product, which means&#58; (a)&#160;in the case of &#91; * &#93;&#59; and (b)&#160;in the case of &#91; * &#93;.  Actual unit costs shall consist of &#91; * &#93;.  Direct labor costs shall include the cost of&#58; &#91; * &#93;.  Manufacturing &#91; * &#93; shall include &#91; * &#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Drug Substance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means cabozantinib, having the chemical structure set forth in Exhibit A of the Collaboration and License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency or its successor.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.10&#160;&#160;&#160;&#160;&#8220;Exelixis Indemnitees&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Exelixis and its Affiliates and their respective officers, directors, employees, and agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S., Canada, and Japan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expanded Access Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the administration of the Product to named individuals who do not meet the clinical trial enrollment criteria either outside of a clinical trial or after the completion of a clinical trial.  Expanded Access Programs are also known as named patient programs, named patient supply, and temporary authorization for use. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration or its successor. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all indications and uses in humans and animals.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Finished Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Product in appropriate final form, packaged and labeled and ready for its intended use (i.e., sale to the end-user, use as part of an Expanded Access Program, use in clinical trials or other development work or use as a sample).</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Distribution Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, to the extent applicable, the then-current Good Distribution Practice Guidelines issued by the European Commission to ensure that the level of quality determined by GMP is maintained throughout the distribution network, as set forth in Commission Guidelines 2013&#47;C 343&#47;01 and any and all related Directives, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.17&#160;&#160;&#160;&#160;&#8220;Good Manufacturing Practices,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">cGMPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, to the extent applicable, the then-current Good Manufacturing Practices required by the FDA and&#47;or EMA, for the manufacture and testing of pharmaceutical materials, as set forth in 21 CFR Parts 11, 210 and 220 and Directives 2003&#47;94&#47;EC and 2001&#47;83&#47;EC, as each may be amended from time to time, and comparable laws or regulations applicable to the manufacture and testing of pharmaceutical materials promulgated by other Regulatory Authorities. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.18&#160;&#160;&#160;&#160;&#8220;Governmental Authority&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any national, international, federal, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.19&#160;&#160;&#160;&#160; &#8220;Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test data, and data resulting from non-clinical studies), CMC information, stability data, and other study data and procedures.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.20&#160;&#160;&#160;&#160;&#8220;Laws&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all laws, statutes, rules, regulations, ordinances, and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city, or other political subdivision, domestic or foreign.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.21&#160;&#160;&#160;&#160;&#8220;Licensee Indemnitees&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Licensee and its Affiliates and their respective directors, officers, employees, and agents. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.22&#160;&#160;&#160;&#160;&#8220;Licensee Territory&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the world outside the Exelixis Territory. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to the period prior to the implementation of the Transition Plan as set forth in Section 2.4(e), all activities related to the manufacturing of the Compound and Products, in final, labeled, packaged form for commercial use, including in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing.  For the period after the Transition Plan, with regard specifically to packaging, shall be primary packaged bulk tablets, rather than labelled packaged form for commercial use.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has a correlative meaning.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Order Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.2(a). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product containing the Compound as an active ingredient, in any form, presentations, dosage, or formulation, including but not limited to Cometriq.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.6.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.5.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.28&#160;&#160;&#160;&#160;&#8220;Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a recall, withdrawal, or correction (including the dissemination of relevant information) of any Product in a Party&#8217;s territory that is (a) required by a Regulatory Authority of competent jurisdiction, or (b) is deemed advisable by the representative of Licensee&#8217;s Quality department in its sole discretion in Licensee Territory, or (c) is deemed advisable by the representative of Exelixis&#8217; Quality department in the Exelixis Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.29&#160;&#160;&#160;&#160;&#8220;Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all approvals (including MAA Approval, and Pricing and Reimbursement Approval, if applicable), licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of a Product in any country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30&#160;&#160;&#160;&#160;&#8220;Regulatory Authority&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA and EMA.  For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority shall also include any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.31&#160;&#160;&#160;&#160;&#8220;Regulatory Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications and authorizations (or waivers) with respect to the testing, Development, Manufacture or Commercialization of any Product made to or received from any Regulatory Authority in a given country, including any INDs and MAAs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.32&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Specification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the written specification for each Product, as the same may be amended from time to time by Exelixis, or upon Licensee&#8217;s reasonable request in accordance with requirements of Regulatory Authorities in the Licensee Territory.  Specifications may be required to be different for a Product for use in different countries due to individual Regulatory Authority requirements in such countries.  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.33&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stockout Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a period during which Licensee, as a result of failure of Exelixis to supply Product, has no commercial inventory available to supply the market in the Licensee Territory.  Inventory stockouts arising from Licensee&#8217;s failure to maintain the &#91; * &#93; safety stock in accordance with the Supply Agreement shall not give rise to a Stockout Period.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.34&#160;&#160;&#160;&#160;&#8220;Term&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has the meaning set forth in Section 10.1.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any entity other than Exelixis or Licensee or an Affiliate of Exelixis or Licensee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America, including its territories and possessions (including Puerto Rico).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 2<br>PRODUCT SUPPLY </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Purchase and Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Pursuant to the terms and conditions of this Supply Agreement, Exelixis (either itself or through its Affiliates or Third Party subcontractors) shall use Commercially Reasonable Efforts to Manufacture and supply Products to Licensee in such quantities as Licensee shall order pursuant to and in accordance with this Article 2, and Licensee shall purchase from Exelixis all of Licensee&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; requirements for Products for development and commercialization in the Field in the Licensee Territory pursuant to and in accordance with the Collaboration and License Agreement.  For clarity, Exelixis may perform its obligations under this Supply Agreement through one or more Third Party subcontractors, provided that Exelixis remains responsible for the work allocated to, and payment to, such subcontractors as it selects, to the same extent it would if it had done such work itself.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Order Forecasts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Rolling Forecast.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  On or prior to &#91; * &#93; of each Calendar Quarter during the Term of this Supply Agreement, Licensee shall provide Exelixis a rolling forecast of the quantity of Products to be used for commercialization that Licensee plans to order during the &#91; * &#93; period commencing the following Calendar Quarter, itemizing the applicable quantity for each form of Product (i.e., dosage strength and packaging configuration) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Order Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Order Forecast shall be made in good faith for budget and capacity planning purposes only and shall be non-binding on Licensee and Exelixis, except as provided in Section 2.2(b).  The Parties shall discuss and review the Order Forecast at each regularly scheduled meeting of the JSC established by the Parties under the Collaboration and License Agreement (or by a subcommittee established by the JSC to oversee the manufacture and supply of the Product).  The Order Forecast will be in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Binding Commitment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The &#91; * &#93; of each Order Forecast shall constitute a binding commitment for Licensee to purchase, pursuant to Section 2.3(a), &#91; * &#93; of the quantities for each form of Finished Product specified therein and Licensee shall be required to order such quantities pursuant to Section 2.3(a).  The &#91; * &#93; of each Order Forecast shall constitute a binding commitment for Licensee to purchase, pursuant to Section 2.3(a), &#91; * &#93; of each form of Finished Product specified therein.  For clarity, the numbers set out in the following &#91; * &#93; of the Order Forecast constitute the non-binding forecast of Licensee&#8217;s expected requirements. </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Purchase Orders&#59; Delivery Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or before the &#91; * &#93; of each Calendar Quarter during the Term of this Supply Agreement, Licensee shall submit to Exelixis a binding purchase order (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Purchase Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for Product to be delivered during the next Calendar Quarter as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;with respect to commercial supply, in quantities &#91; * &#93; to those set forth for such Calendar Quarter in the Order Forecast, and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;with respect to development supply, in quantities &#91; * &#93; with those projected for use in clinical development by Licensee as set forth in the Global Development Plan (as defined in the Collaboration and License Agreement), as well as any comparator drugs set forth in the Global Development Plan as to be supplied by Exelixis to Licensee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall accept or reject each Purchase Order in writing within &#91; * &#93; after its receipt of such Purchase Order&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Exelixis shall accept such Purchase Order, if the quantities of Product ordered in such Purchase Order are consistent with the quantities set forth in subsection (i) and&#47;or (ii), as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Additional Quantities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event Licensee desires to obtain quantities of Product in a particular Calendar Quarter in excess of the quantities specified in the Order Forecast after such forecast became binding, Licensee shall notify Exelixis in writing the Parties will discuss in good faith as to whether Exelixis may be able to supply Licensee with such additional quantities, provided that Exelixis shall have the right to accept and&#47;or reject such order at its sole discretion.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Delivery and Shipping Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Purchase Orders submitted for quantities of Product that are in accordance with Section 2.3(a) and&#47;or Section 2.3(b) will be binding on both Parties after acceptance in writing by Exelixis&#59; provided, however, that should Exelixis neither reject a Purchase Order nor provide written confirmation of acceptance within &#91; * &#93; of receipt, Exelixis shall be deemed to have accepted the Purchase Order effectively.  The Purchase Order will specify a single delivery date for such order to be delivered in such Calendar Quarter, but will in no event be a date sooner than &#91; * &#93;.  By way of example, a Purchase Order submitted on &#91; * &#93; would specify the quantity of Product ordered for delivery in the &#91; * &#93; Calendar Quarter of &#91; * &#93;, with a delivery date no sooner than &#91; * &#93;.  Exelixis shall deliver all Products &#91; * &#93;.  Exelixis shall be responsible for obtaining all licenses or other authorizations for the exportation of such shipments and shall supply Licensee with the documentation required for filing or claiming credit or deduction for any applicable taxes and&#47;or duties.  Licensee shall be responsible for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">obtaining all freight, handling, insurance, and shipping expenses for such shipments, and shall be the importer of record and responsible for all duties and taxes for such shipments, and shall be responsible for obtaining all distribution licenses for the Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Separate Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Purchase Order will constitute a separate contract for the supply of Products on the terms of this Agreement (and excluding all other terms and conditions including any set out or referred to in any Purchase Order).  In the event of a conflict between a Purchase Order and the terms of this Agreement, the terms of this Agreement will govern.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;Supply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Exelixis shall establish and maintain any necessary drug master files, standard operating procedures, protocols, and master batch records for the Manufacturing of the Products.  Exelixis shall, in connection with each shipment of Product to Licensee, provide to Licensee the certificate of compliance, certificate of analysis, completed batch records and any other documentation as may be required in the Quality Agreement with respect to such shipment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Traceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Exelixis shall mark the Product supplied to Licensee with a lot number for the purposes of traceability.  Licensee shall record the lot number of each Product used for each promotion and marketing event, distributed to each named patient in an Expanded Access Program, or sold to each customer, and shall retain all such records for &#91; * &#93; after the date of termination or expiration of this Supply Agreement to facilitate in the event of a Recall under Section 5.9 of the Collaboration and License Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Form of Supply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis shall supply Licensee with Finished Product in finished, labeled form at Licensee&#8217;s cost and expense. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall supply Product for commercialization in the Licensee Territory according to Licensee&#8217;s written instructions specifying desired quantities of Product in each of the available dosages and product configurations (i.e. bottles and&#47;or blister strips) to meet the requirements for the Regulatory Authorities in each applicable jurisdiction.  Licensee shall be responsible for ensuring that the Finished Product conforms with all applicable Laws and Regulatory Approvals for each applicable jurisdiction within Licensee Territory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Finished Product Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to implementation of the Transition Plan as such term is defined in Section 2.4(e), Exelixis (by itself or through its contract manufacturer) shall conduct release tests of the Product for Licensee, and Exelixis shall supply Licensee with Finished Product release documentation so that Licensee may fulfil its obligations as the Marketing Authorization Holder in the applicable Licensee Territory.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall develop, and submit to JSC for review and approval, a transition plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by &#91; * &#93;.  The Transition Plan shall provide for Licensee&#8217;s assumption of responsibility for primary packaged bulk tablets, including but not limited to labeling, Finished Product release, and QP release to market by &#91; * &#93;.  Such Transition Plan will take effect at &#91; * &#93; unless otherwise agreed by the JSC, and this Supply Agreement will be updated to reflect this shift of responsibilities between the Parties.  The Parties further agree </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Licensee will concurrently assume contractual responsibility for the abovementioned activities with Exelixis&#8217; commercial manufacturer, Patheon, Inc. (&#8220;Patheon&#8221;) by entering into privity of contract with Patheon.  In the event that Licensee chooses to assume the responsibility contemplated in this section through any other means of manufacture other than a direct contract with Patheon, Licensee agrees to provide Exelixis with at least &#91; * &#93; prior written notice in order to enable Exelixis to fulfill its own notice requirements to Patheon.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Product Shelf Life.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Product supplied by Exelixis to Licensee hereunder shall have a remaining shelf life of &#91; * &#93; of approved shelf life upon delivery pursuant to Section 2.3(c).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;Inventory Management&#59; Safety Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party shall manage its inventory in a manner that maximizes the remaining shelf life of its inventory.  Licensee shall carry a reasonable quantity of inventory of the Finished Product, and Exelixis shall carry a reasonable quantity of raw materials, including API, which may be used in the event of an interruption to the supply chain.  The quantity of such safety stock shall be sufficient to cover the quantity set forth in the Order Forecast for the next &#91; * &#93;.  The Parties shall replace and replenish the safety stock continuously on a first to expire, first out basis.  Each Party shall be responsible for the cost of maintaining its own safety stock.    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.5&#160;&#160;&#160;&#160;Inspection and Acceptance. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Shortages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall notify Exelixis in writing of any shortage in any shipment of Product within &#91; * &#93; of receipt.  In the event of an undisputed shortage, Exelixis shall make up the shortage at no cost to Licensee, within &#91; * &#93; if replacement Finished Product stock is available, or, if replacement stock is unavailable at such time, as soon as reasonably practicable after it becomes available.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Non-Conforming Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Licensee shall inspect all shipments of Product promptly upon receipt, and shall notify Exelixis in writing in reasonable detail within &#91; * &#93; of receipt if Licensee is rejecting any Product that fails to conform to Exelixis&#8217; warranties set forth in Sections 8.2(a) or 8.2(b).  All Product not rejected within such &#91; * &#93; period will be deemed accepted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If Licensee notifies Exelixis of any nonconformity of any Product in accordance with Section 2.5(b)(i), Exelixis shall have the right to inspect the Product in question and Licensee shall cooperate with Exelixis&#8217; inspection, including providing Exelixis with samples of the Product in question for testing upon request.  If Exelixis agrees with such notice of nonconformity, Exelixis shall, at its discretion and expense, either&#58; (i) replace such Product, at no additional expense to Licensee, as soon as reasonably practicable after receipt of notification of such nonconformity or (ii) refund any portion of the applicable Transfer Price that has already been paid.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event that Exelixis disagrees with Licensee that a Product does not conform to Exelixis&#8217; warranties set forth in Sections 8.2(a) or 8.2(b), or considers that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the defect was caused by occurrences after the delivery of the Product to Licensee, it may require a sample of the allegedly nonconforming Product to be delivered to a mutually acceptable independent testing laboratory for testing or, in the case of a dispute concerning compliance with GMP, an independent consultant for evaluation.  Except in the case of manifest error, the determination of the laboratory or consultant as to whether the Product is nonconforming will be final and binding on the Parties.  The fees and expenses of such laboratory testing or consultant, as the case may be, shall be borne entirely by the Party against whom such laboratory&#8217;s or consultant&#8217;s determination is made.  If, as the case may be, such determination is against Exelixis, then Exelixis shall either refund the Transfer Price paid by Licensee for such Product or replace such Product, at no additional cost to Licensee, as soon as reasonably possible, but in no event later than &#91; * &#93; if replacement Product stock is available, or if replacement Product stock is unavailable at such time, as soon as reasonably practical after it becomes available.  If, as the case may be, such determination is against Licensee, then such Product shall be deemed accepted by Licensee.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Sole Remedy.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding anything to the contrary in this Supply Agreement, the remedy set forth in this Section 2.5 will be Licensee&#8217;s sole and exclusive remedy and recourse with respect to the shortages that are not also Stockout Periods, or nonconforming Product delivered to Licensee by Exelixis hereunder. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Damage after Delivery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall bear the risk of damage to the Product after delivery to Licensee pursuant to Section 2.3(c).  If the Product is damaged after delivery to Licensee pursuant to Section 2.3(c) and Licensee intends to order replacement Product, Licensee shall promptly notify Exelixis of the damage and any orders for replacement Product, and Exelixis may, at its sole discretion but in good faith, accept or reject all or a portion of the order for the replacement Product. </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.6&#160;&#160;&#160;&#160;Quality Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Parties have substantially agreed to the terms and conditions of a quality agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) setting forth in detail the quality assurance arrangements and procedures for the Manufacture of the Product, which Quality Agreement will be in substantially the form attached hereto as Exhibit B and incorporated herein by reference.  To the extent that the terms of this Supply Agreement and those of the Quality Agreement are in conflict, the terms of this Supply Agreement shall control except with respect to quality issues, which shall be governed by the Quality Agreement.  For clarity, if there are any financial terms in the Quality Agreement that are in conflict with this Supply Agreement, this Supply Agreement shall control with respect to such financial terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.7&#160;&#160;&#160;&#160;Business Continuity Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Within &#91; * &#93; after Regulatory Approval, Exelixis and Licensee shall begin preparation of a business continuity plan that would address, as a result of a Force Majeure Event or otherwise, Exelixis&#8217; inability to provide the supply of Product or the volume of Product as forecasted, including a set of clearly defined measures that would allow a quick response and recovery to the disruption of Product supply.  Specifically, such business continuity plan will address, at a minimum, provisions related to rolling safety stock, Exelixis&#8217; holdings of API stock, and Exelixis&#8217; holdings of sufficient API stock to cover the period necessary for a successful transfer to a new commercial manufacturer under Section 2.(e), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provisions for technology transfer of API and Product manufacturing capabilities if applicable in the event of a failure in performance of the then-current contract manufacturing organization.  In addition, the Parties shall agree that in the event Licensee were to forecast that future sales of the Product shall exceed &#91; * &#93; in one Calendar Year, the business continuity plan shall be revised to include the set-up of a second manufacturing facility for the Finished Product.  The Parties shall submit the business continuity plan to the JSC (or a manufacturing subcommittee) for further discussion.  The Parties shall review the business continuity plan on a yearly basis (or at such other intervals as the Parties may agree).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.8&#160;&#160;&#160;&#160;Backup Supplier.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In the event that for a period of &#91; * &#93;, Exelixis has failed to supply at least &#91; * &#93; of the quantity of the Product set forth in the binding portion of the Order Forecast, upon Licensee&#8217;s request, Exelixis shall select a Third Party manufacturer (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Backup Manufacturer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that is reasonably acceptable to Licensee to Manufacture the Product for supply to Licensee to the extent Exelixis is unable to meet Licensee&#8217;s requirement for the Product as set forth in the binding portion of the Order Forecast.  The costs and expenses associated with the engagement of the Backup Manufacturer, including the costs for transferring the Manufacturing process to such Backup Manufacturer, shall be borne by Exelixis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.9&#160;&#160;&#160;&#160;Allocation in the Event of Product Shortages.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Section 2.9 shall apply in the event that Exelixis is unable to supply, with respect to a Calendar Quarter, &#91; * &#93; of (i) Product ordered by Licensee pursuant to Sections 2.2 and 2.3 for delivery in such Calendar Quarter, plus (ii) Product required by Exelixis or its Affiliates or other licensees for their own use with respect to such Calendar Quarter (such event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The purpose of these allocation rules is to permit Licensee (with respect to the Licensee Territory) and Exelixis (with respect to the Exelixis Territory) to independently make their respective long-term purchase decisions for the Product, with the benefits and risks of such purchase decisions to be allocated to Licensee or Exelixis, as the case may be.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Exelixis is unable to supply &#91; * &#93; of (i) Product ordered by Licensee pursuant to a Purchase Order plus (ii) Product required by Exelixis or its Affiliates or other licensees for their own use, then the available Product in each Calendar Quarter in which a Shortfall occurs shall be &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The &#91; * &#93; set forth in this Section&#160;2.9 shall restart for each Calendar Quarter, without any carryover of a Shortfall realized by either Licensee or Exelixis in the prior Calendar Quarter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If Exelixis determines that it will not be able to deliver the quantities of the Product specified in the Purchase Order on the requested delivery date, or Exelixis is made aware of any future anticipated shortages, then Exelixis shall promptly notify Licensee of such determination, and in any event, no later than &#91; * &#93; following such determination.  Such notification shall include the reasons for and the expected duration of Exelixis&#8217; anticipated inability to deliver such quantities of the Product.  Promptly thereafter, but in no event more than &#91; * &#93; after such notification, the Parties shall discuss in good faith the matters set forth in such notification and begin good faith negotiations with respect to an alternative delivery schedule or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">alternative sourcing for such Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any such negotiations shall not relieve Exelixis of its obligations hereunder.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.10&#160;&#160;&#160;&#160;Continuous Improvement&#59; Supply Contacts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Parties acknowledge their common goal in optimizing the supply chain and reducing the costs associated with the Manufacturing and supply of the Product.  As part of the supply chain optimization, the Parties shall cooperate to optimize, among others, an agreed-on service level measured by means of key performance indicators, as well as seek to extend the duration of the Product shelf life to at least &#91; * &#93;.  The Parties will discuss cost reduction mechanisms through the JSC (or any manufacturing subcommittee established by the JSC).  The Parties shall reasonably cooperate with each other to implement such improvement, the cost of which shall be shared by the Parties as mutually agreed. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;(b)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall designate one (1) qualified and experienced supply chain professional to serve as that Party's primary supply contact regarding the supply of Product within this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supply Contacts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and under the direction of the JCC.  Each Party may replace its Supply Contact with an alternative representative at any time with prior written notice to the other Party.  Supply Contacts shall be responsible for facilitating information exchange and discussion between the Parties regarding the supply of Product under this Agreement.  Supply Contact shall have decision-making authority within the guidance and subject to the review and approval of the JSC.  Each Party shall bear its own costs of its Supply Contact, which costs shall be excluded from the Parties&#8217; respective Development and Cost of Goods.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.11&#160;&#160;&#160;&#160;Stockout Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In the event of a Stockout Period, Licensee shall be entitled to certain royalty reductions as provided under Sections 6.3(e) and 9.5(f) of the Collaboration and License Agreement.  In addition to such royalty reductions, in the event that Exelixis recovers third party damages arising directly from a Stockout Period, Exelixis agrees to share such damages with Licensee &#91; * &#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in accordance with each party&#8217;s demonstrated losses.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 3<br>FINANCIALS</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The transfer price (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for Finished Product supplied by Exelixis to Licensee will be equal to &#91; * &#93;, which shall be calculated for each configuration of the Product.      </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Invoice and Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Concurrently with delivery of Product to Licensee, Exelixis shall submit to Licensee an invoice for payment, in U.S. Dollars, of the Transfer Price for Product included in such delivery.  Licensee shall pay each invoice, in U.S. Dollars, within &#91; * &#93; following the date of such invoice by wire transfer of immediately available funds into an account designated by Exelixis.  Financial audits shall be conducted in accordance with Section 10.4 of the Collaboration and License Agreement, and late payments shall bear interest as set forth in Section 10.5 of the Collaboration and License Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Other Manufacture Related Costs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall be responsible for the costs and expenses of any Manufacture-related work that is performed by or on behalf of Exelixis at Licensee&#8217;s reasonable request, which costs and expenses are not included in the calculation of COG.  Within &#91; * &#93; after the end of each Calendar Quarter during which such work has been performed by or on behalf of Exelixis at Licensee&#8217;s request, Exelixis shall submit to Licensee a reasonably detailed invoice, in U.S. Dollars, setting forth the costs and expenses incurred by Exelixis in connection with such work.  Licensee shall pay to Exelixis the amount invoiced, in U.S. Dollars, within &#91; * &#93; after the receipt of the invoice by wire transfer of immediately available funds into an account designated by Exelixis.  Late payments shall bear interest as set forth in Section 10.5 of the Collaboration and License Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Tax.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall pay any and all taxes (other than taxes based on Exelixis&#8217; income), duties, assessments, and other charges and expenses imposed by any Government Authority in connection with the supply and transfer of Product to Licensee.  If a withholding or deduction obligation occurs, then the sum payable by Licensee (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Exelixis receives a sum equal to the sum which it would have received had no such withholding or deduction occurred.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 4<br>REGULATORY</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Regulatory Inspections.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis shall cooperate with any inspection of its facilities by any Regulatory Authority overseeing the Manufacture of the Product for use in the Licensee Territory.  Each Party shall notify the other Party of any such inspection and shall permit the other Party&#8217;s representative to observe such inspection to the extent such inspection is scheduled at least &#91; * &#93; in advance and such observation is permitted by applicable Laws and any applicable agreement between Exelixis and a Third Party (such as a contract manufacturing organization) in the event such facility is owned and&#47;or operated by such Third Party. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;GMP, Quality Assurance and Other Audits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall have the right to conduct cGMP, quality assurance, and other audits (e.g., Environment, Health &#38; Safety) pursuant to the terms and conditions of the Quality Agreement, but subject to any applicable agreement between Exelixis and a Third Party (such as a contract manufacturing organization) in the event such facility is owned and&#47;or operated by such Third Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Inquiries and Customer Complaints.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Licensee shall comply with the Pharmacovigilance Agreement and Section 5.5 of the Collaboration and License Agreement with respect to all inquiries, complaints, and adverse events regarding the Products in the Licensee Territory.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Notification of Potential Recall&#59; Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will act in accordance with the notice requirements set forth in Sections 5.7 and 5.9 of the Collaboration and License Agreement.  In the event that any Recall with respect to a Product is the direct result of a breach of any warranty of Exelixis set forth in Section 8.2 and is not the result of Licensee&#8217;s, its Affiliates&#8217;, or its sublicensees&#8217; transportation, storage, marketing, use, sale, or distribution of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product, then Exelixis shall bear (and reimburse Licensee for) all of the costs and expenses of such Recall and the destruction of such Recalled Product.  To the extent that the reason for any Recall with respect to the Product hereunder is in part the direct result of the breach of any warranty of Exelixis set forth in Section 8.2 and in part the result of Licensee&#8217;s, its Affiliates&#8217;, or its sublicensees&#8217; transportation, storage, marketing, use, sale, or distribution of the Product, then the expenses of such Recall shall be allocated in an equitable manner between the Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Reach Registration.</font><font style="color:#0070c0;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Product is or contains any substance which has to be registered under Regulation (EC) No. 1907&#47;2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (hereinafter referred to as a &#8220;Substance&#8221;), Exelixis shall ensure that such Substance will be pre-registered and registered in accordance with REACH at the (pre-) registration date set forth under REACH, provided that Licensee and&#47;or its Affiliates do not qualify as an importer of such Substance under REACH.  Upon request of Licensee, Exelixis shall immediately provide Licensee with proof of the (pre-) registration of the Substance, and shall immediately inform Licensee if it becomes aware that any Substance was not (pre-) registered in due time or if the (pre-) registration is cancelled.  If Licensee and&#47;or any of its Affiliates qualify as an importer of the Substance under REACH, Exelixis shall, upon request of Licensee, provide Licensee and&#47;or its Affiliates immediately with all data and information that Licensee and&#47;or its Affiliates require for (i) the assessment as to whether such Substance must be (pre-) registered, and (ii) the (pre-) registration under REACH.  Licensee and its Affiliates shall be entitled to use such data and information to the extent required for the (pre-) registration of the Substance  </font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 5<br>CONFIDENTIALITY</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any and all Information disclosed by a Party to the other Party under this Supply Agreement shall be deemed Confidential Information of such Party under the Collaboration and License Agreement and subject to the confidentiality provisions set forth in Article 14 of the Collaboration and License Agreement.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 6<br>INTELLECTUAL PROPERTY</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;Intellectual Property.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Any and all inventions, whether patentable or not and including all intellectual property rights therein, generated by either Party in the course of conducting their activities under this Supply Agreement shall be deemed to be generated under the Collaboration and License Agreement and subject to the rights and obligations of the Parties as set forth therein. </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORCE MAJEURE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Force Majeure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding anything to the contrary in this Supply Agreement, both Parties shall be excused from the performance of their obligations under this Supply Agreement to the extent that (a) force majeure prevents such performance or, with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respect to Exelixis&#8217; supply obligations pursuant to Article 2, prevents the combined supply of (i) Product specified in accepted orders placed by Licensee in accordance with Section 2.3(a) and (ii) Product required by Exelixis and its Affiliates, and (b) the nonperforming Party promptly provides notice of the force majeure to the other Party.  Such excuse shall continue so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition.  For purposes of this Supply Agreement, force majeure shall include conditions beyond the reasonable control of the applicable Party, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm, or like catastrophe, and failure of plant or machinery.  Notwithstanding the foregoing, a Party will not be excused from making payments owed hereunder because of a force majeure affecting such Party.  If a force majeure persists for more than &#91; * &#93;, then the Parties will discuss in good faith the modification of the Parties&#8217; obligations under this Supply Agreement in order to mitigate the delays caused by such force majeure.  </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby represents and warrants to the other Party as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Corporate Existence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Corporate Power, Authority and Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Supply Agreement and perform its obligations hereunder&#59; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Supply Agreement and the performance of its obligations hereunder&#59; and (iii) this Supply Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium, and similar Laws affecting creditors&#8217; rights and remedies generally.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.2&#160;&#160;&#160;&#160;Product Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exelixis represents and warrants to Licensee that&#58; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;all Product supplied to Licensee pursuant to this Supply Agreement will be Manufactured in conformity with cGMPs and Good Distribution Practice&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;each Product supplied to Licensee pursuant to this Supply Agreement, at the time of shipment of such Product to Licensee pursuant to Section 2.3(c), will conform to the applicable Specifications for such Product&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;all Product supplied to Licensee pursuant to this Supply Agreement will, at the time of shipment of such Product to Licensee pursuant to Section 2.3(c), be free and clear </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of all liens, security interests, and other encumbrances&#59; provided, however, that Exelixis shall retain a security interest in such Product until Licensee pays for it in full pursuant to Section 3.2. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.3&#160;&#160;&#160;&#160;Disclaimers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  EXCEPT AS EXPRESSLY STATED IN THIS SUPPLY AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ARE MADE OR GIVEN BY OR ON BEHALF A PARTY, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;Indemnification by Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Exelixis shall defend, indemnify, and hold the Licensee Indemnitees harmless from and against all Claims to the extent such Claims arise out of, are based on, or result from&#58; (a) any negligence or willful misconduct of Exelixis, its Affiliates, or the officers, directors, employees, or agents of Exelixis or its Affiliates&#59; or (b) Exelixis&#8217; breach of this Supply Agreement, including the representations and warranties contained herein.  The foregoing indemnity obligations shall not apply to the extent that (i) the Licensee Indemnitees fail to comply with the indemnification procedure set forth in Section 9.3 and Exelixis&#8217; defense of the relevant Claims is prejudiced by such failure&#59; or (ii) any Claim arises from, is based on, or results from any occurrence for which Licensee is obligated to indemnify the Exelixis Indemnitees under Section 9.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;Indemnification by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Licensee shall defend, indemnify, and hold the Exelixis Indemnitees harmless from and against all Claims to the extent such Claims arise out of, are based on, or result from&#58; (a) any negligence or willful misconduct of Licensee, its Affiliates, or the officers, directors, employees, or agents of Licensee or its Affiliates&#59; (b) Licensee&#8217;s breach of this Supply Agreement, including the representations and warranties contained herein&#59; (c) the export, import, storage, packaging, or labeling, by or on behalf of Licensee or its Affiliates or sublicensees, of any Product supplied by Exelixis hereunder&#59; or (d) the commercialization of any Product supplied by Exelixis hereunder.  The foregoing indemnity obligations will not apply to the extent that (i) the Exelixis Indemnitees fail to comply with the indemnification procedure set forth in Section 9.3 and Licensee&#8217;s defense of the relevant Claims is prejudiced by such failure&#59; or (ii) any Claim arises from, is based on, or results from any activities or occurrence for which Exelixis is obligated to indemnify the Licensee Indemnitees under Section 9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3&#160;&#160;&#160;&#160;Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Party claiming indemnity under this Article 9 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promptly after learning of such Claim and shall offer control of the defense of such Claim to the Indemnifying Party.  The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense of the Claim for which indemnity is being sought.  The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense&#59; provided, however, that the Indemnifying Party shall have the right to assume and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conduct the defense of such Claim with counsel of its choice.  The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money.  So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle or compromise any such Claim without the prior written consent of the Indemnifying Party.  If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article 9. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4&#160;&#160;&#160;&#160;Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS SUPPLY AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTIONS 9.1 OR 9.2, OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 5.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 10<br>TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Supply Agreement will become effective on the Effective Date and, unless earlier terminated pursuant to this Article 10, will remain in effect until the expiration of the Collaboration and License Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Termination for Breach.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  A Party&#8217;s material breach of this Supply Agreement will constitute such Party&#8217;s material breach of the Collaboration and License Agreement, and each Party shall have the right to terminate this Supply Agreement and the Collaboration and License Agreement for the other Party&#8217;s uncured material breach of this Supply Agreement as set forth in Section 15.2(a) of the Collaboration and License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Termination Due to Termination of the Collaboration and License Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Supply Agreement shall automatically terminate upon termination of the Collaboration and License Agreement.  </font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.3&#160;&#160;&#160;&#160;Performance on Termination&#59; Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Termination or expiration of this Supply Agreement shall not affect the rights or obligations of the Parties under this Supply Agreement that have accrued prior to the date of termination or expiration.  Upon termination of this Supply Agreement for any reason&#58;  (a) Products Manufactured pursuant to Purchase Orders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will be delivered on the scheduled delivery dates and Licensee shall pay Exelixis not later than &#91; * &#93; after the delivery date (provided, however, that Licensee makes advance payment prior to shipment in the event of termination due to payment default by Licensee)&#59; and (b) all costs of unused raw materials, labels, and packaging incurred by Exelixis shall be paid by Licensee in the event that Exelixis terminates this Supply Agreement pursuant to Section 10.2(a) or that this Supply Agreement is terminated pursuant to Section 10.2(b) as a result of termination of the Collaboration and License Agreement by Licensee pursuant to Sections 15.3(a) or (b) of the Collaboration and License Agreement.  Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this Supply Agreement&#58; Sections 5, 6, 8, 9, 10.3 and 11.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:1.26pt;padding-right:1.26pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISCELLANEOUS </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.1&#160;&#160;&#160;&#160;Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Supply Agreement, including the Exhibits, together with the Collaboration and License Agreement, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, with respect to the subject matter hereof.  This Supply Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by an authorized officer of each Party.  No modification to this Supply Agreement will be effected by the acknowledgment or acceptance of any Purchase Order or shipping instruction forms or similar documents containing terms or conditions at variance with or in addition to those set forth herein.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.2&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice to be given under this Supply Agreement must be in writing and specifically refer to this Supply Agreement, and be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party, and will be deemed to have been given for all purposes (a) when received, if hand-delivered&#59; (b)&#160;if air mailed, five (5) days after the date of postmark&#59; (c)&#160;if delivered by overnight courier, the next day the overnight courier regularly makes deliveries&#59; or (d) if sent by facsimile, the date of confirmation of receipt if during the recipient&#8217;s normal business hours, otherwise the next business day.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Licensee, notices must be addressed to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ipsen Pharma SAS<br>65 Quai Georges Gorse<br>92100 Boulogne-Billancourt, France<br>Attention&#58;  Jonathan Barnsley, EVP Technical Operations<br>Facsimile&#58; &#91; * &#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;with a copy to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ipsen Pharma SAS<br>65 Quai Georges Gorse<br>92100 Boulogne-Billancourt, France </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Fran&#231;ois Garnier, EVP General Counsel <br>Facsimile&#58; &#91; * &#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">If to Exelixis, notices must be addressed to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exelixis, Inc.<br>210 East Grand Avenue <br>South San Francisco, CA 94080</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, USA<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Executive Vice President and General Counsel</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; &#91; * &#93;</font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.3&#160;&#160;&#160;&#160;Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The headings of clauses contained in this Supply Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and do not constitute any part of this Supply Agreement, or have any effect on its interpretation or construction.  All references in this Supply Agreement to the singular include the plural where applicable.  Unless otherwise specified, references in this Supply Agreement to any Article include all Sections, subsections, and paragraphs in such Article, references to any Section include all subsections and paragraphs in such Section, and references in this Supply Agreement to any subsection include all paragraphs in such subsection.  The word &#8220;including&#8221; and similar words means including without limitation.  The word &#8220;or&#8221; means &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subject of the conjunction are mutually exclusive.  The words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221; and other words of similar import refer to this Supply Agreement as a whole and not to any particular Section or other subdivision.  All references to days in this Supply Agreement mean calendar days, unless otherwise specified.  Ambiguities and uncertainties in this Supply Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  This Supply Agreement has been prepared in the English language and the English language controls its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Supply Agreement shall be in the English language.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.4&#160;&#160;&#160;&#160;Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly provided hereunder, neither this Supply Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent&#58; </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;in connection with the assignment of the Collaboration and License Agreement to a Third Party as set forth in Section 17.5 of the Collaboration and License Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.  </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The rights and obligations of the Parties under this Supply Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and permitted assigns to the extent necessary to carry out the intent of this Section 11.4.  Any assignment not in accordance with this Section 11.4 shall be null and void. </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.5&#160;&#160;&#160;&#160;Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates.  Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Supply Agreement, and shall cause its Affiliates to comply with the provisions of this Supply Agreement in connection with such performance.  Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Supply Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.6&#160;&#160;&#160;&#160;Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Supply Agreement.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.7&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, for any reason, any part of this Supply Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.  All remaining portions will remain in full force and effect as if the original Supply Agreement had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.8&#160;&#160;&#160;&#160;No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The failure of a Party to insist upon strict performance of any provision of this Supply Agreement or to exercise any right arising out of this Supply Agreement will neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance.  Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.9&#160;&#160;&#160;&#160;Relationship Between the Parties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties&#8217; relationship, as established by this Supply Agreement together with the Collaboration and License Agreement, is solely that of independent contractors.  This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties.  Neither Party is a legal representative of the other Party and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.10&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.11&#160;&#160;&#160;&#160;Governing Law&#59; Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Supply Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Supply Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles.  The application of the U.N. Convention on Contracts for the International Sale of Goods (1980) is excluded.  Any controversy or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">claim arising out of, relating to, or in connection with any provision of this Supply Agreement shall be resolved in accordance with Article 16 of the Collaboration and License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.12&#160;&#160;&#160;&#160;Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall comply in all material respects with all applicable Laws and regulations, including, but not limited to, those concerning drugs, drug manufacture regulatory requirements, or exportation or importation of Products, including but not limited to proper declaration of dutiable values.  Except as provided in Section 2.3(c), Licensee shall be responsible for obtaining all exportation and importation licenses or other authorizations.  </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.13&#160;&#160;&#160;&#160;Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with services to be performed under this Supply Agreement.  In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37.4pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUPPLY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXELIXIS, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Michael M. Morrissey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">IPSEN PHARMA SAS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Marc de Garidel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Marc de Garidel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  Chairman &#38; CEO</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF EXHIBITS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A&#58;&#160;&#160;&#160;&#160;Form of Order Forecast</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B&#58; &#160;&#160;&#160;&#160;Quality Agreement</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Order Forecast</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91; * &#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quality Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:35pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:109%">COMMERCIAL QUALITY TECHNICAL AGREEMENT</font></div><div style="margin-top:35pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:109%">Between the CONTRACT GIVER</font></div><div style="margin-top:5.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">hereinafter called</font></div><div style="margin-top:5.5pt;text-align:center"><font><br></font></div><div style="margin-top:5.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">EXELIXIS Inc.</font></div><div style="margin-top:5.5pt;text-align:center"><font><br></font></div><div style="margin-top:11.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:109%">and the CONTRACT ACCEPTOR</font></div><div style="margin-top:6.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">hereinafter called</font></div><div style="margin-top:6.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Ipsen</font></div><div style="margin-top:6.95pt;text-align:center"><font><br></font></div><div style="margin-top:6.95pt;text-align:center"><font><br></font></div><div style="margin-top:6.95pt;text-align:center"><font><br></font></div><div style="margin-top:6.95pt"><font><br></font></div><div style="margin-top:13.4pt"><font><br></font></div><div style="margin-top:13.4pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:118%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Scope</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Authorizations</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Duration of Quality Technical Agreement, Review and Changes </font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Compliance</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Quality Systems</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.1  Quality Responsibilities</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.2  Personnel and Management Responsibilities</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.3  Document Retention</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.4  Drug Substance Production</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.5  Drug Product Production </font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.6  Release of Product &#8211; Ipsen Territory</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.7   Post Release Issues and Product Complaints</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.8  Product Recall and Returns</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.9  Change Control</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">5.10 Annual Product Quality Reviews</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Drug Production Control</font></div><div style="padding-left:58.5pt;text-indent:-3.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">6.1 Deviations</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Components</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">7.1  Audits of Suppliers</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">7.2  Retain&#47;Reserve Samples</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Warehousing&#160;&#160;&#160;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:8.84pt">Quality Control (QC) and Testing&#160;&#160;&#160;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Compliance Audits</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">10.1Compliance Audits</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Inspections by Regulatory Agencies</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Channels of Communication&#47;Organization</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Product Shortage</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Approval of Quality Technical Agreement</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Appendix I - Change History Log</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:109%;padding-left:2.73pt">Appendix II - Contacts</font></div><div style="margin-bottom:12pt;margin-top:13pt;padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.0&#160;&#160;&#160;&#160;SCOPE </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;The commercial arrangements relating to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">development and commercialization of cabozantinib outside the U.S., Canada and Japan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be dealt with in a separate Supply Agreement (the &#8220;Supply Agreement&#8221;) between EXELIXIS and Ipsen. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;This commercial Quality Technical Agreement (the &#8220;Quality Technical Agreement&#8221;) is a required and integral part of the Supply Agreement.  This Quality Technical Agreement defines the responsibilities related to quality systems and GMP and GDP  requirements for the development and commercialization of Drug Substance and Product.  Duties and responsibilities are defined in detail as required in the US GMP Code of Federal Regulations and European regulations. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;All initially capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Supply Agreement.  In the event of any inconsistency between the provisions of this Quality Technical Agreement and the terms and conditions of the Supply Agreement, the terms and conditions of the Supply agreement shall prevail (except that the Quality Technical Agreement shall prevail in the consideration of Quality and GMP&#47;GDP Matters, including without limitation matters relating to quality control and testing). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4&#160;&#160;&#160;&#160;The appendices and enclosures to this Quality Technical Agreement are an integral part of the Quality Technical Agreement and are incorporated into this Quality Technical Agreement by such reference.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5&#160;&#160;&#160;&#160;In this Quality Technical Agreement, &#8220;authorization,&#8221; &#8220;approval&#8221;, &#8220;in writing&#8221; and &#8220;written communication&#8221; shall mean on official letterhead or approved forms and signed by the authoring party&#8217;s Quality Assurance (QA) representative. Transmission of such written documentation may be by mail, courier or a scan (.pdf) attached to an email.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6&#160;&#160;&#160;&#160;Tthis Quality Technical Agreement is made between&#58;</font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EXELIXIS, Inc.</font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">210 East Grand Avenue</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;South San Francisco CA 94080</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;USA</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Referred to as EXELIXIS in this Quality Technical Agreement, </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">And  </font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ipsen Pharma SAS<br>&#160;&#160;&#160;&#160;65 Quai Georges Gorse<br>&#160;&#160;&#160;&#160;92100 Boulogne-Billancourt</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">France </font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Referred to as Ipsen in this Quality Technical Agreement.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, in this Quality Technical Agreement, &#8220;Ipsen&#8221; and &#8220;Ipsen Territory&#8221; shall &#160;&#160;&#160;&#160;have the same meaning as &#8220;Licensee&#8221; and &#8220;Licensee Territory&#8221;, respectively, in the &#160;&#160;&#160;&#160;Supply Agreement.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:15pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.0&#160;&#160;&#160;&#160;AUTHORIZATIONS</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;Manufacturing License </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1.1&#160;&#160;&#160;&#160;Once EXELIXIS has been made aware of Ipsen&#8217;s proposed regulatory filings, and with sufficient notice, EXELIXIS shall ensure that the contract manufacturers used to produce Product have all necessary licenses to produce the Product for distribution in Ipsen Territory as mutually agreed.</font></div><div style="margin-bottom:15pt;padding-left:67.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;Product License</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2.1 &#160;&#160;&#160;&#160;EXELIXIS shall be responsible for applying and obtaining approval for the initial new drug application for the Product and for any supplements thereto in the U.S., Canada and Japan (collectively, the &#8220;NDA&#8221;).</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2.2&#160;&#160;&#160;&#160;EXELIXIS has filed the initial Marketing Authorization Application (MAA) for approval in Europe for the Product and the Ipsen shall be responsible for any other filings, variations or supplements and obtaining approvals in Ipsen Territory. At such time that Ipsen makes the idecision to file a regulatory application, Ipsen shall, with sufficient notice,  notify EXELIXIS of any regulatory requirements as a result of the potential application, where EXELIXIS may be required to prepare additional information.</font></div><div style="margin-bottom:15pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.0&#160;&#160;&#160;&#160;DURATION OF AGREEMENT, REVIEW AND CHANGES</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;This Quality Technical Agreement shall be effective as of the last date all required signatures are appended below, and shall expire at the termination of the Supply Agreement for the Product. </font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;Changes or supplements to this Quality Technical Agreement or to the Appendices and Enclosures can only be made by mutual consent of EXELIXIS and Ipsen in writing.  Such changes shall be recorded, approved and filed in the Change History Log (Appendix I) with each subsequent revision.  The appendices and enclosures to this Quality Technical Agreement are part of the Quality Technical Agreement.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2.1&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.0&#160;&#160;&#160;&#160;COMPLIANCE</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;&#91; * &#93;.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.0&#160;&#160;&#160;&#160;QUALITY SYSTEMS</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;Quality Responsibilities </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.1&#160;&#160;&#160;&#160;EXELIXIS shall ensure that the level of quality determined by GMP is maintained throughout the manufacturing, packaging and labeling processes.</font></div><div style="padding-left:108pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.2&#160;&#160;&#160;&#160;EXELIXIS shall ensure that the level of quality determined by GMP and GDP is maintained throughout manufacturing, testing and the distribution network as set forth in the Commission Guidelines 2013&#47;C 343&#47;01 and any and all related Directives and applicable regulatory requirements, as may be amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.3&#160;&#160;&#160;&#160;Ipsen and EXELIXIS shall each be responsible for&#58;</font></div><div style="margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.3.1&#160;&#160;&#160;&#160;Approving the Quality Technical Agreement,</font></div><div style="margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.3.2&#160;&#160;&#160;&#160;Ensuring that the terms of this Quality Technical Agreement are complied with,</font></div><div style="margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.3.3&#160;&#160;&#160;&#160;Ensuring that the terms of this Quality Technical Agreement are performed in accordance with cGMPs, GDPs and applicable ICH Guidelines.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2      Personnel and Management Responsibility </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:118%">5.2.1  Ipsen and EXELIXIS shall notify the corresponding Quality Assurance group of any relevant Quality organizational changes.  </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:118%">5.2.2&#160;&#160;&#160;&#160;Ipsen and EXELIXIS shall have a training system for assuring personnel dealing with overseeing manufacturing, packaging, development and commercialization activities are trained for their job function.</font></div><div><font><br></font></div><div style="margin-bottom:15pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;Document Retention</font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3.1&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4&#160;&#160;&#160;&#160;Drug Substance Production</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4.1&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4.2&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.5&#160;&#160;&#160;&#160;Drug Product Production </font></div><div style="padding-left:60.5pt"><font><br></font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.5.1&#160;&#160;&#160;&#160;&#91; * &#93;.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.5.2&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.6&#160;&#160;&#160;&#160;Release of Product &#8211; Ipsen Territory.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.6.1&#160;&#160;&#160;&#160;For supplies going to the Ipsen Territory, the following shall apply&#58; </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.6.1.1&#160;&#160;&#160;&#160;&#91; * &#93;&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:166.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">&#91; * &#93;.</font></div><div style="padding-left:166.5pt;text-align:justify"><font><br></font></div><div style="padding-left:166.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">&#91; * &#93;.</font></div><div style="padding-left:166.5pt;text-align:justify"><font><br></font></div><div style="padding-left:166.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">&#91; * &#93;.</font></div><div style="padding-left:166.5pt;text-align:justify"><font><br></font></div><div style="padding-left:166.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">&#91; * &#93;.</font></div><div style="padding-left:166.5pt;text-align:justify"><font><br></font></div><div style="padding-left:166.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">&#91; * &#93;. </font></div><div style="padding-left:166.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.6.1.2&#160;&#160;&#160;&#160;EXELIXIS has sole authority to release the material for use in the U.S., Canada and Japan.  </font></div><div style="margin-bottom:15pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.6.1.3&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7&#160;&#160;&#160;&#160;Post Release Issues and Product Complaints</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.1&#160;&#160;&#160;&#160;Ipsen shall comply with the Pharmacovigilance Agreement of the Collaboration and License Agreement once finalized with respect to all inquiries, complaints, and adverse events regarding the Products in the Ipsen Territory.  </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.2&#160;&#160;&#160;&#160;EXELIXIS and Ipsen shall maintain systems for resolving all customer complaints, adverse events, and inquiries related to the Product.  </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.3&#160;&#160;&#160;&#160;&#91; * &#93;. </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.4&#160;&#160;&#160;&#160;&#91; * &#93;. </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.5&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.6&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.7&#160;&#160;&#160;&#160;It is expected that most customer complaints, adverse events, and inquiries for the Product shall be received by EXELIXIS for the U.S., Canada, and Japan and by Ipsen for Ipsen Territory.  </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.7.8&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.7.8.1&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;padding-left:60.75pt;text-align:justify;text-indent:-24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8&#160;&#160;&#160;&#160;Product Recall and Returns</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8.1.&#160;&#160;&#160;&#160;Based on initial non-conformance information, both Parties will jointly determine if an investigation is required.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8.2&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8.3&#160;&#160;&#160;&#160;&#91; * &#93;. Ipsen shall comply with all Regulatory Authority requirements.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8.4&#160;&#160;&#160;&#160;&#91; * &#93;. EXELIXIS shall comply with all Regulatory Authority requirements.</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8.5&#160;&#160;&#160;&#160;&#91; * &#93;.  &#91; * &#93; shall support any recall decision and effort &#91; * &#93;&#93;</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.8.6&#160;&#160;&#160;&#160;&#91; * &#93; shall be responsible for the destruction of returned Product &#91; * &#93;. . &#91; * &#93;. </font></div><div style="margin-bottom:15pt;padding-left:60.75pt;text-align:justify;text-indent:-24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.9&#160;&#160;&#160;&#160;Change Control</font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.9.1&#160;&#160;&#160;&#160;&#91; * &#93; to ensure appropriate review of regulatory changes &#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:60.75pt;text-align:justify;text-indent:-24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10&#160;&#160;&#160;&#160;Annual Product Quality Reviews</font></div><div style="margin-bottom:12pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10.1&#160;&#160;&#160;&#160;&#91; * &#93; shall be responsible for preparing an Annual Product Quality Review (APQR) for &#91; * &#93;&#59;  </font></div><div style="margin-bottom:12pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10.2&#160;&#160;&#160;&#160;&#91; * &#93; shall be responsible for preparing an &#91; * &#93; Annual Product Quality Review (APQR) for &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10.3&#160;&#160;&#160;&#160;The data for the APQR shall be provided by &#91; * &#93;.</font></div><div style="margin-bottom:12pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10.4&#160;&#160;&#160;&#160;A standardized format and content shall be agreed upon by both parties.</font></div><div style="margin-bottom:12pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.10.5&#160;&#160;&#160;&#160;The APQR shall include all Manufacturing, storage, testing and release activities, as well as additional applicable requirements in Ipsen Territory as amended from time to time, conducted by EXELIXIS&#8217; contract manufacturer&#8217;s for a given time period.  The APQR data shall include but is not limited to&#58;</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Analytical Request Forms</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Batches manufactured and disposition status (including dates of manufacture)</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Summary of Drug Substance test results (including manufacturer lot number)</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">QC testing trends and data&#58; In-Process, COA, Analytical Report Form (ARF), Stability</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Product complaints, recalls, returns and any salvages as applicable.</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Summary of any production changes at EXELIXIS&#8217; contract manufacturer in the Manufacturing, testing, storage, validation, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:133.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">release process of the bulk Drug Substance, Product and Finished Goods.</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Summary of all deviations, deviation trend results, and associated corrective actions for the bulk Drug Substance, Product and Finished Product.</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Summary of CAPAs associated with significant deviations, investigations and trends and the status of those CAPAs at close of the APQR period for the bulk Drug Substance, Product and Finished Product.</font></div><div style="padding-left:133.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Status of recommendations from the previous Product APQR and status of corrective actions which were in an open status at the time of the previous APQR.</font></div><div style="padding-left:133.2pt;text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.0</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">DRUG PRODUCTION CONTROL</font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;Deviations </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1&#160;&#160;&#160;&#160;Ipsen and EXELIXIS shall utilize their Deviation procedure&#47;systems to ensure appropriate review of all Product events. A Deviation is an event in the manufacturing process and&#47;or support system that are outside of approved operating parameters, approved procedures, approved Specifications, or a departure from accepted GMPs.  </font></div><div style="margin-bottom:15pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.2&#160;&#160;&#160;&#160;&#91; * &#93; shall &#91; * &#93; inform &#91; * &#93;.  </font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.0&#160;&#160;&#160;&#160;COMPONENTS AND RAW MATERIALS</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;Audits of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMPONENT AND RAW MATERIAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Suppliers  </font></div><div style="margin-bottom:15pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1.1&#160;&#160;&#160;&#160;EXELIXIS shall perform, or arrange to have performed, audits or GMP evaluations as applicable of suppliers of components purchased by EXELIXIS and its contract manufacturers to ensure the proper manufacturing and handling of materials and to ensure appropriate quality systems are in place.  If requested by Ipsen, EXELIXIS shall request from its suppliers permission to allow Ipsen to review EXELIXIS audit reports at Exelixis&#8217;s discretion and within reasonable limitations,</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;Retain&#47;Reserve Samples </font></div><div style="margin-bottom:15pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.2.1&#160;&#160;&#160;&#160;&#91; * &#93; shall be responsible for &#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:115.2pt;text-align:justify;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.2.2&#160;&#160;&#160;&#160;&#91; * &#93; shall store &#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.0&#160;&#160;&#160;&#160;WAREHOUSING</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;EXELIXIS shall store and ship Product in accordance with GMP, GDP and approved Drug Substance and Drug Product storage and shipping requirements, specifications and procedures.</font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.0</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">QUALITY CONTROL (QC) AND TESTING</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;&#91; * &#93;&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1.1&#160;&#160;&#160;&#160;&#91; * &#93;. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:15pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.4&#160;&#160;&#160;&#160;Out of Specification (OOS) Investigations</font></div><div style="padding-left:126pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.4.1 &#91; * &#93;. </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91; * &#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:126pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91; * &#93;.<br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5&#160;&#160;&#160;&#160;Stability </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5.1&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5.2 &#91; * &#93; shall have the responsibility of &#91; * &#93;.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5.3&#160;&#160;&#160;&#160;For the Ipsen Territory stability program&#59; &#91; * &#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5.4&#160;&#160;&#160;&#160;Should specific territory tests be required, &#91; * &#93;.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.0&#160;&#160;&#160;&#160;QUALITY VISITS, GMP COMMISSIOINING, AND AUDITS</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.1&#160;&#160;&#160;&#160;Compliance Audits</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.1.1&#160;&#160;&#160;&#160;&#91; * &#93;.</font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.0&#160;&#160;&#160;&#160;INSPECTIONS BY REGULATORY AGENCIES</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;&#91; * &#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;&#91; * &#93;. </font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.0&#160;&#160;&#160;&#160;CHANNELS OF COMMUNICATION </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.1&#160;&#160;&#160;&#160;EXELIXIS and Ipsen have designated Quality representatives to oversee the respective obligations in the functions regarding the Product and the Quality Technical Agreement. </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.2&#160;&#160;&#160;&#160;Any Quality issue that cannot be resolved through the normal communication channels such as e-mail, phone calls, and team meetings&#47;teleconferences shall be escalated to the Supply Contacts for both parties and the JSC &#91; * &#93;. </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.3&#160;&#160;&#160;&#160;Should the impasse not be resolved at the senior management level, further issue escalation may involve executive management at both EXELIXIS and Ipsen.</font></div><div><font><br></font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.4&#160;&#160;&#160;&#160;Ipsen and EXELIXIS Quality Assurance shall review this Quality Technical Agreement in 2018 and make necessary amendments &#91; * &#93;. After 2018, EXELIXIS and Ipsen shall review this Quality Technical Agreement biennially and make any necessary revisions.  This review and any resulting revisions shall be documented in the Change History Log (Appendix I).</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.0&#160;&#160;&#160;&#160;Product Shortage</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.1&#160;&#160;&#160;&#160;EXELIXIS shall notify the applicable Regulatory Agency in the US, Canada and Japan of potential or known shortages in accordance with applicable regulations and regulatory expectations in those territories.</font></div><div style="margin-bottom:15pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.2&#160;&#160;&#160;&#160;Ipsen shall notify the applicable Regulatory Agency in the Ipsen Territory of potential or known shortages in accordance with applicable regulations and regulatory expectations in those territories.</font></div><div><font><br></font></div><div style="margin-bottom:15pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.0&#160;&#160;&#160;&#160;APPROVAL OF QUALITY TECHNICAL AGREEMENT</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.724%"><tr><td style="width:1.0%"></td><td style="width:43.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signed for an on behalf of </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signed for and on behalf of </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXELIXIS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPSEN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gisela Schwab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chris Masterson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President &#38; Chief Medical Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Quality</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APPENDIX I - CHANGE HISTORY LOG</font></div><div><font><br></font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon revision of this Quality Technical Agreement or any Appendix to this Quality Technical Agreement, this Change History Log shall be updated.  The Change History Log shall be maintained by EXELIXIS. It is the responsibility of each document holder to replace the superseded revision with the revised approved revision. Superseded copies may be retained for historical records, but must be marked to appropriately indicate the historical status of the document. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Annual reviews of this Quality Technical Agreement and appendices, not resulting in a revision to the document, shall be documented as a review and signed on the Change History Log.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is each party&#8217;s responsibility to ensure that staff is adequately informed and any procedural or documentary changes resulting from a revision are implemented in the areas affected by the changes.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91; * &#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APPENDIX II &#8211; CONTACTS</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91; * &#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>exhibit106firstamendmentto.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4ad43a00d390464aa62849b02d4464e1_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br>Exhibit 10.6</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO SUPPLY AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT TO THE SUPPLY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of October 26, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ipsen Pharma SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1 dated effective December 20, 2016, Amendment No. 2 dated effective September 14, 2017, and Amendment No. 3 dated effective October 26, 2017 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to which the Parties have been collaborating on the development and commercialization of cabozantinib&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exelixis and Licensee are parties to that certain Supply Agreement dated February 29, 2016, as amended by that certain Side Letter between the Parties dated August 26, 2016 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Exelixis has been manufacturing and supplying cabozantinib to Licensee for development and commercial use under the License Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties desire to enter into this Amendment to amend the Supply Agreement to reflect the expansion of Licensee&#8217;s territory under the License Agreement,remove reference to the concept of a transition plan transferring manufacturing obligations to Licensee, and make certain other changes, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The fourth sentence of Section 1.7 of the Supply Agreement (&#8220;Cost of Goods&#8221; or &#8220;COG&#8221;) is hereby amended and restated to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Direct labor costs shall include the cost of&#58; &#91; * &#93;&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.11 of the Supply Agreement is hereby amended and restated to read in full as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exelixis Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. and Japan.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.23 of the Supply Agreement is hereby amended and restated to read in full as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities related to the manufacturing of the Compound and Products, in final, labeled, packaged form for commercial use, including in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has a correlative meaning.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.25 of the Supply Agreement (&#8220;Product&#8221;) is hereby amended and restated to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product containing the Compound as an active ingredient, in any form, presentations, dosage, or formulation.  For the avoidance of doubt, the manufacturing and supply of product bearing the trade name Cometriq</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be covered under a separate agreement entered into between the Parties on November 21, 2016.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.30 of the License Agreement is hereby amended and restated to read in full as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30&#160;&#160;&#160;&#160;&#8220;Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA, the EMA, and Health Canada or other foreign equivalent.  For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority shall also include any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91; * &#93;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Health Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the federal department of the government of Canada having the authority to regulate the sale of medicinal or pharmaceutical products, or any successor agency thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RoW Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or Rest of the World Countries, means all of the other countries of the world except &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined in this Amendment, all capitalized terms have the meaning as defined in the Supply Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;PRODUCT SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.3(c) of the Supply Agreement is hereby amended and restated to read in full as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;2.3(c)  Delivery and Shipping Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchase Orders submitted for quantities of Product that are in accordance with Section 2.3(a) and&#47;or Section 2.3(b) will be binding on both Parties after acceptance in writing by Exelixis&#59; provided, however, that should Exelixis neither reject a Purchase Order nor provide written confirmation of acceptance within &#91; * &#93; of receipt, Exelixis shall be deemed to have accepted the Purchase Order effectively.  The Purchase Order will specify a single delivery date for such order to be delivered in such Calendar Quarter, but will in no event be a date sooner than &#91; * &#93;.  By way of example, a Purchase Order submitted on &#91; * &#93; would specify the quantity of Product ordered for delivery in the &#91; * &#93; Calendar Quarter of &#91; * &#93;, with a delivery date no sooner than &#91; * &#93;.  Licensee shall place Purchase Orders of desired quantity of Products labeled for commercial use in Canada for delivery by Exelixis in Canada, &#91; * &#93;.  With respect to Products labelled for commercial use in countries of the Licensee Territory other than Canada, a separate Purchase Order shall be placed and Exelixis shall deliver all Products &#91; * &#93; once the Finished Products are released by Exelixis or through its contract manufacturer as described in Section 2.4(d) below.  Exelixis shall be responsible for obtaining all licenses or other authorizations for the exportation of such shipments and shall supply Licensee with the documentation required for filing or claiming credit or deduction for any applicable taxes and&#47;or duties.  Licensee shall be responsible for obtaining all freight, handling, insurance, and shipping expenses for shipments upon and after unloading at the &#91; * &#93;, and shall be the importer of record and responsible for all duties and taxes for such importation in the Licensee Territory, and shall be responsible for obtaining all distribution licenses for the Products.&#8221;   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.4(e) of the Supply Agreement is hereby deleted in its entirety.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.8 of the Supply Agreement is hereby deleted in its entirety and replaced in full to read as follows</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;2.8 Backup Supplier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; Exelixis shall select a Third Party secondary manufacturer (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Backup Manufacturer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to Manufacture the Product for supply to Licensee.&#160; Exelixis shall engage the Backup Manufacturer, and complete, on or before the &#91; * &#93;, to the reasonable satisfaction of Licensee, the transferring of the Manufacturing process to such Backup Manufacturer, qualification of the Backup Manufacturer, equipment and all validation of Manufacturing process in accordance with applicable law and regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At Ipsen&#8217;s request, Exelixis shall also assist Ipsen in its applications for Regulatory Approval of the Backup Supplier by the relevant Regulatory Authorities of the Major Market Countries, to the extent commercially reasonable, and in accordance with Ipsen&#8217;s timelines.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following is hereby added to the Supply Agreement as Section 2.12&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;2.12 Canada-Labeled Product Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On a &#91; * &#93; basis, Licensee shall provide to Exelixis a report, in a form to be mutually agreed by the Parties, which specifies in reasonable detail the distribution and&#47;or sale of Product labeled for Canada by Licensee, its Affiliates, its permitted Sublicensees, and&#47;or any Third Party distributors in the previous &#91; * &#93;.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;FINANCIALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 3.1 of the Supply Agreement is hereby amended and restated to read in full as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The transfer price (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for Finished Product supplied by Exelixis to Licensee will be equal to &#91; * &#93;, which shall be calculated for each configuration of the Product.  The Transfer Price in effect at the time the first Purchase Order is placed as part of the binding commitment under Section 2.2(b) shall apply as the Transfer Price for the Calendar Year.  The Transfer Price shall thereafter be calculated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and adjusted annually in the manner set forth in paragraph (b) below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91; * &#93; Reconciliation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On or prior to &#91; * &#93; of a Calendar Year, Exelixis and Licensee shall review the Transfer Price paid by Licensee for the Finished Product supplied during the preceding Calendar Year and determine if the &#91; * &#93; is either lesser or greater than the Transfer Price paid by Licensee during such preceding Calendar Year (the &#8220;&#91; * &#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Reconciliation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  If the Transfer Price paid by Licensee during the preceding Calendar Year is less than the &#91; * &#93; owed to Exelixis, Licensee shall pay the difference for such amounts.  If the Transfer Price paid by Licensee for the Product is greater than the &#91; * &#93; owed to Exelixis, Exelixis shall credit the amount of such payment due by Licensee to Exelixis until such time that the reconciling payment has been fully credited to Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjustments to Transfer Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On or prior to &#91; * &#93; of a Calendar Year at the time of the &#91; * &#93; Reconciliation, Exelixis and Licensee shall review the most recent Order Forecast provided by Licensee, and based on quantities planned for purchase and expected annual price increases by Exelixis&#8217; Third Party manufacturers, and other related price factors, Exelixis and Licensee shall agree upon a new annual Transfer Price for the Calendar Year.  The Parties agree that if by &#91; * &#93; of an applicable Calendar Year the Parties cannot agree on a new annual Transfer Price, the prior Calendar Year&#8217;s Transfer Price will apply, and any additional payments owed will be remediated through the next annual reconciliation in accordance with Section 3.1(b) above.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 3.3 of the Supply Agreement is hereby amended to add the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;FTEs dedicated to other Manufacture-related work and billed to Licensee under this Section 3.3, such FTEs shall be billed &#91; * &#93;.  With respect to any Manufacture-related work that is specifically related to support Licensee&#8217;s&#58; (i) &#91; * &#93; in RoW Countries of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensee Territory and (ii) &#91; * &#93; in RoW Countries of the Licensee Territory, the Parties agree that Exelixis&#8217; direct labor costs of personnel to be engaged in such activities shall be capped &#91; * &#93;.  If Exelixis, acting reasonably, considers that Manufacture-related work mentioned in the preceding sentence would require additional FTEs, Exelixis shall notify Licensee and the Parties shall agree in good faith as to the reasonable out-of-pocket costs in excess of &#91; * &#93; incurred during the conduct of such Manufacture-related work for the purpose of this Section 3.3.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;EXHIBIT B &#8211; QUALITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.4 of the Quality Agreement set forth in Exhibit B is hereby amended and restated to read in full as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Ipsen and EXELIXIS Quality Assurance shall review this Quality Technical Agreement in 2018 and make necessary amendments.  After 2018, EXELIXIS and Ipsen shall review this Quality Technical Agreement &#91; * &#93; and make any necessary revisions.  This review and any resulting revisions shall be documented in the Change History Log (Appendix I).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly modified herein, all terms and conditions set forth in the Supply Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Supply Agreement as modified by this Amendment, and together with the License Agreement, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.4&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><div id="i4ad43a00d390464aa62849b02d4464e1_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXELIXIS, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Michael M. Morrissey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  President and CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Christophe Jean</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Christophe Jean</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  EVP Corporate Strategy &#38; Business Development</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>exel20210331exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icd4ceb468a9b4596945529429a8d89ef_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exel20210331exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9cb0cf52672e4b25b9c84b007391df87_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>exel20210331exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9747a4747ae342378f0ff5b222c930d5_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended April&#160;2, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In Witness Whereof, the undersigned have set their hands hereto as of the 6th day of May 2021.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>exel-20210402.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84867dad-da96-4e08-a2f6-a31b9b3022af,g:df225ca8-d190-43b7-90ff-2fc6e5818592-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20210402" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20210402">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210402_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210402_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210402_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210402_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangements" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements">
        <link:definition>2112103 - Disclosure - Collaboration Agreements And In-Licensing Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements And In-Licensing Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - In-Licensing Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2121104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2322303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>2424416 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForwardCurrencyContracts" roleURI="http://www.exelixis.com/role/ForwardCurrencyContracts">
        <link:definition>2128105 - Disclosure - Forward Currency Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForwardCurrencyContractsDetails" roleURI="http://www.exelixis.com/role/ForwardCurrencyContractsDetails">
        <link:definition>2429420 - Disclosure - Forward Currency Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2130106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2331304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2432421 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2133107 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2334305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2435422 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2136108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2337306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2438423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails">
        <link:definition>2439424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2440425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails">
        <link:definition>2441426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes">
        <link:definition>2142109 - Disclosure - Provision For (Benefit From) Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2143110 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2344307 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2445427 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
        <link:definition>2446428 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2147111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" abstract="false" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeAgreementsUpfrontPayments" abstract="false" name="CollaborativeAgreementsUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProbableMember" abstract="true" name="ProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeAgreementWithWuXiBioMember" abstract="true" name="CollaborativeAgreementWithWuXiBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_StatusAxis" abstract="true" name="StatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_StatusDomain" abstract="true" name="StatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_GlaxoSmithKlineMember" abstract="true" name="GlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" abstract="false" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductsDerivedFromCabozantinibMember" abstract="true" name="ProductsDerivedFromCabozantinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" abstract="false" name="CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeAgreementWithAdageneMember" abstract="true" name="CollaborativeAgreementWithAdageneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" abstract="false" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>exel-20210402_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84867dad-da96-4e08-a2f6-a31b9b3022af,g:df225ca8-d190-43b7-90ff-2fc6e5818592-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210402.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fc990aa-2268-4b93-9223-a8878b3847c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ab69677-4190-4015-856a-ccef8432e9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fc990aa-2268-4b93-9223-a8878b3847c2" xlink:to="loc_us-gaap_Liabilities_5ab69677-4190-4015-856a-ccef8432e9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_29734100-d561-4d7f-930e-27c830282ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fc990aa-2268-4b93-9223-a8878b3847c2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_29734100-d561-4d7f-930e-27c830282ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_576a8b7f-6b10-4f1d-870d-a27a7afae55e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fc990aa-2268-4b93-9223-a8878b3847c2" xlink:to="loc_us-gaap_StockholdersEquity_576a8b7f-6b10-4f1d-870d-a27a7afae55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c6fffb86-31bc-4674-aa17-517a5b40a76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:to="loc_us-gaap_AssetsCurrent_c6fffb86-31bc-4674-aa17-517a5b40a76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2cd0d7f3-b8c7-472b-b883-097ac61f3654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:to="loc_us-gaap_LongTermInvestments_2cd0d7f3-b8c7-472b-b883-097ac61f3654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_683114ac-2871-4242-8811-4dafcbc927a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_683114ac-2871-4242-8811-4dafcbc927a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f5b7ccfa-e8ed-4712-9138-eb950aaa715c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f5b7ccfa-e8ed-4712-9138-eb950aaa715c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5aa65f0f-e12d-4cd3-b9e8-8f8de0dd7796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:to="loc_us-gaap_Goodwill_5aa65f0f-e12d-4cd3-b9e8-8f8de0dd7796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30129247-d661-4078-b421-db19aed94ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc7e2630-59f4-4ca8-a84e-feb7ee6c724b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30129247-d661-4078-b421-db19aed94ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6403d3b5-79d4-4192-b40e-489bcd39a345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_54d735a2-5fc3-433c-b53f-3d96f84ffd5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6403d3b5-79d4-4192-b40e-489bcd39a345" xlink:to="loc_us-gaap_LiabilitiesCurrent_54d735a2-5fc3-433c-b53f-3d96f84ffd5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5b150b84-6632-4d92-8878-f73d306b2732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6403d3b5-79d4-4192-b40e-489bcd39a345" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5b150b84-6632-4d92-8878-f73d306b2732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e819b7f2-a580-49e9-ad97-4fc60943b571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6403d3b5-79d4-4192-b40e-489bcd39a345" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e819b7f2-a580-49e9-ad97-4fc60943b571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2a20c06d-6c22-40b2-abaa-8b4a2112320f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6403d3b5-79d4-4192-b40e-489bcd39a345" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2a20c06d-6c22-40b2-abaa-8b4a2112320f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_79ecee1c-829f-4221-b8ed-fef8f4b476bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9a49e641-d511-4fb9-a120-4faf68f5cc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_79ecee1c-829f-4221-b8ed-fef8f4b476bd" xlink:to="loc_us-gaap_PreferredStockValue_9a49e641-d511-4fb9-a120-4faf68f5cc74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_03f8cff4-2779-4d18-9da7-6e8ae48f2a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_79ecee1c-829f-4221-b8ed-fef8f4b476bd" xlink:to="loc_us-gaap_CommonStockValue_03f8cff4-2779-4d18-9da7-6e8ae48f2a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4ef4a216-01c2-4389-a779-a4e50facddb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_79ecee1c-829f-4221-b8ed-fef8f4b476bd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4ef4a216-01c2-4389-a779-a4e50facddb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_318f8b44-201e-437f-8fdc-e573879bcbb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_79ecee1c-829f-4221-b8ed-fef8f4b476bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_318f8b44-201e-437f-8fdc-e573879bcbb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1dab99c8-4057-41b5-b874-5036f024d37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_79ecee1c-829f-4221-b8ed-fef8f4b476bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1dab99c8-4057-41b5-b874-5036f024d37b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eee2fbcc-95a3-420b-b2be-e566770ea20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:to="loc_us-gaap_AccountsPayableCurrent_eee2fbcc-95a3-420b-b2be-e566770ea20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_160bba4e-efe1-4934-8bc3-d2890780323d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_160bba4e-efe1-4934-8bc3-d2890780323d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_cd302290-1cf2-442a-8be6-16b33f5ff6f9" xlink:href="exel-20210402.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_cd302290-1cf2-442a-8be6-16b33f5ff6f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_0f404a0c-7d46-4f4a-bee1-e081bce6cef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_0f404a0c-7d46-4f4a-bee1-e081bce6cef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_fc43cfef-2fa6-455b-90ff-07056be6f5dc" xlink:href="exel-20210402.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_fc43cfef-2fa6-455b-90ff-07056be6f5dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa46a0a9-3969-4a4d-8f6c-3e4ee5e28e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cbd336d-21b3-446c-b838-e9695630a44f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa46a0a9-3969-4a4d-8f6c-3e4ee5e28e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13729bba-ad3d-47fa-af87-fc968c8d21f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6078da22-6e93-4021-a89e-15768ebd0dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13729bba-ad3d-47fa-af87-fc968c8d21f9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6078da22-6e93-4021-a89e-15768ebd0dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f36da07b-2eac-43e5-a437-625515ad5940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13729bba-ad3d-47fa-af87-fc968c8d21f9" xlink:to="loc_us-gaap_ShortTermInvestments_f36da07b-2eac-43e5-a437-625515ad5940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_706b542c-8351-4625-bc9c-9fea4840873e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13729bba-ad3d-47fa-af87-fc968c8d21f9" xlink:to="loc_us-gaap_ReceivablesNetCurrent_706b542c-8351-4625-bc9c-9fea4840873e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e473b0af-67ff-4c33-9a9e-c8e74ab631c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13729bba-ad3d-47fa-af87-fc968c8d21f9" xlink:to="loc_us-gaap_InventoryNet_e473b0af-67ff-4c33-9a9e-c8e74ab631c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11fa6142-5918-4ef3-b7ad-4304590cea5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13729bba-ad3d-47fa-af87-fc968c8d21f9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11fa6142-5918-4ef3-b7ad-4304590cea5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f09101c-b58a-4c6c-82bc-70adeef43d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ef9636c3-4217-41c1-925b-c22983ecf4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0f09101c-b58a-4c6c-82bc-70adeef43d58" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ef9636c3-4217-41c1-925b-c22983ecf4a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_37aca377-9e42-405d-801b-f236e07e907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0f09101c-b58a-4c6c-82bc-70adeef43d58" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_37aca377-9e42-405d-801b-f236e07e907b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2bb4b5c-a0ac-4f21-8719-da5dc86b54f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0f09101c-b58a-4c6c-82bc-70adeef43d58" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2bb4b5c-a0ac-4f21-8719-da5dc86b54f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b03ea600-8c89-45b9-ab36-7ac011599437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5ac5fa23-7b9b-46ca-ae0a-f27677da45c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b03ea600-8c89-45b9-ab36-7ac011599437" xlink:to="loc_us-gaap_CostsAndExpenses_5ac5fa23-7b9b-46ca-ae0a-f27677da45c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e15406c5-c13d-4fdb-9bcc-c75b04bfc26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b03ea600-8c89-45b9-ab36-7ac011599437" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e15406c5-c13d-4fdb-9bcc-c75b04bfc26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e1e6192-110b-45a7-88fc-cb2955afe810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_abc1c517-ff5c-40db-9b5a-5a2abc47dbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e1e6192-110b-45a7-88fc-cb2955afe810" xlink:to="loc_us-gaap_OperatingIncomeLoss_abc1c517-ff5c-40db-9b5a-5a2abc47dbd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_5f8b231f-53c5-4975-82b0-a4ceff307c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e1e6192-110b-45a7-88fc-cb2955afe810" xlink:to="loc_us-gaap_InterestIncomeOther_5f8b231f-53c5-4975-82b0-a4ceff307c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_38b41009-bc43-4b75-a8d0-ffa493a6a276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e1e6192-110b-45a7-88fc-cb2955afe810" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_38b41009-bc43-4b75-a8d0-ffa493a6a276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14a99e9b-68cd-4d28-92f4-603372bd7dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3a5287d0-d7dc-4f6b-b19d-9597dcac42ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_14a99e9b-68cd-4d28-92f4-603372bd7dc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3a5287d0-d7dc-4f6b-b19d-9597dcac42ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3013bd00-abad-49d8-8fc0-34b75c3ffca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_14a99e9b-68cd-4d28-92f4-603372bd7dc2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3013bd00-abad-49d8-8fc0-34b75c3ffca4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fb48411-f942-44f8-a0b8-8474c034c5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9823b5df-9e9c-4e4b-9e2d-64771e727801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fb48411-f942-44f8-a0b8-8474c034c5c8" xlink:to="loc_us-gaap_NetIncomeLoss_9823b5df-9e9c-4e4b-9e2d-64771e727801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_72ac211a-78fa-43ef-b8ec-09646b516751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fb48411-f942-44f8-a0b8-8474c034c5c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_72ac211a-78fa-43ef-b8ec-09646b516751" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c4d43b5-7555-437d-9e03-12759f04cad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_70a94196-68b4-4ac7-bba4-2519c2610bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c4d43b5-7555-437d-9e03-12759f04cad6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_70a94196-68b4-4ac7-bba4-2519c2610bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d86f674c-0c5f-46e6-b8f7-b38bdb022ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c4d43b5-7555-437d-9e03-12759f04cad6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d86f674c-0c5f-46e6-b8f7-b38bdb022ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92c95b75-191b-4762-924f-1741a827267b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_013a4d2b-8ebf-43ea-918d-d9302a2804c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92c95b75-191b-4762-924f-1741a827267b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_013a4d2b-8ebf-43ea-918d-d9302a2804c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9f38706-f03c-4470-a800-adb34b13f297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92c95b75-191b-4762-924f-1741a827267b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9f38706-f03c-4470-a800-adb34b13f297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eda8c74-d483-4c01-afca-4d7d2a95aaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92c95b75-191b-4762-924f-1741a827267b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3eda8c74-d483-4c01-afca-4d7d2a95aaf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_618dc773-cc60-4db5-8479-7d13ef9ecfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c4bbb639-4293-4035-bd48-4cd4371c6022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_618dc773-cc60-4db5-8479-7d13ef9ecfcd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c4bbb639-4293-4035-bd48-4cd4371c6022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_6decebd3-c06c-4904-9c1c-338dc1c981ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_618dc773-cc60-4db5-8479-7d13ef9ecfcd" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_6decebd3-c06c-4904-9c1c-338dc1c981ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b1760820-942a-48ba-ad6b-eca460b05901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_618dc773-cc60-4db5-8479-7d13ef9ecfcd" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b1760820-942a-48ba-ad6b-eca460b05901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d531d32-f0db-47b6-809c-3dba020b4b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_NetIncomeLoss_5d531d32-f0db-47b6-809c-3dba020b4b18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c3fb1f59-35d1-48dc-a5fc-8243d809369b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c3fb1f59-35d1-48dc-a5fc-8243d809369b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_900f7304-6300-4862-9a67-14852af3d353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_ShareBasedCompensation_900f7304-6300-4862-9a67-14852af3d353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_91c01fa7-597f-47ab-83b6-1c5ca2b4f68d" xlink:href="exel-20210402.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_exel_NoncashLeaseExpense_91c01fa7-597f-47ab-83b6-1c5ca2b4f68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_24fe4a86-d81a-4e7e-8151-fa6d7738b3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_24fe4a86-d81a-4e7e-8151-fa6d7738b3cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_93f9396c-49ed-40c4-958f-c154c682695c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_93f9396c-49ed-40c4-958f-c154c682695c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9d3c099b-5d66-491f-b046-a7a340b605b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9d3c099b-5d66-491f-b046-a7a340b605b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d7f4549-3e44-4e5a-8d5d-6f2e0d26c45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d7f4549-3e44-4e5a-8d5d-6f2e0d26c45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bf777cbe-1512-4fa6-ba4c-5ebdf7f49d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bf777cbe-1512-4fa6-ba4c-5ebdf7f49d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a1e94f3d-cea1-45f8-b934-d67c0a132123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a1e94f3d-cea1-45f8-b934-d67c0a132123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8b16e27f-840c-475b-ba2e-367defabcfa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998f85d-c51e-41d2-b905-98fd0b41f11f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8b16e27f-840c-475b-ba2e-367defabcfa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210402.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_afa7668b-727a-4a8d-af52-2962b6199b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb862309-c21a-442a-a281-315d34f5ffe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_afa7668b-727a-4a8d-af52-2962b6199b73" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb862309-c21a-442a-a281-315d34f5ffe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17cb32f7-3c52-4896-aade-e0d296e1392c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_afa7668b-727a-4a8d-af52-2962b6199b73" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17cb32f7-3c52-4896-aade-e0d296e1392c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangements"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsGSKDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestments"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f689b521-d64f-4324-b2c1-1696a1f3f9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_305ab6ba-51b8-48dd-a580-d0790c0fdb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f689b521-d64f-4324-b2c1-1696a1f3f9fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_305ab6ba-51b8-48dd-a580-d0790c0fdb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_d43f4aaa-fe25-4317-b51c-d6a6dfae6303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f689b521-d64f-4324-b2c1-1696a1f3f9fa" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_d43f4aaa-fe25-4317-b51c-d6a6dfae6303" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cf2df82-50c5-4fac-ac45-4b0edf014b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_25fa5738-2366-4342-88b7-f0c705915cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cf2df82-50c5-4fac-ac45-4b0edf014b44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_25fa5738-2366-4342-88b7-f0c705915cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b7dc7c45-04f7-4416-b3ac-16475c88278a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cf2df82-50c5-4fac-ac45-4b0edf014b44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b7dc7c45-04f7-4416-b3ac-16475c88278a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1640f303-d4ea-4613-a040-abd11088d932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cf2df82-50c5-4fac-ac45-4b0edf014b44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1640f303-d4ea-4613-a040-abd11088d932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_db50045c-f6cb-4e69-b37e-25fc7dcd721d" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_099540ad-b23c-4fe3-8aa5-19068f7e4b5a" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_db50045c-f6cb-4e69-b37e-25fc7dcd721d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_099540ad-b23c-4fe3-8aa5-19068f7e4b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2daa7187-4533-4fc4-aa1b-ed31d1946383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_db50045c-f6cb-4e69-b37e-25fc7dcd721d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2daa7187-4533-4fc4-aa1b-ed31d1946383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfc0aa83-c8c7-48d9-9967-664ec7f099bd" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b5c80bd9-4e75-4493-964a-228939a238bb" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfc0aa83-c8c7-48d9-9967-664ec7f099bd" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b5c80bd9-4e75-4493-964a-228939a238bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c65cf84b-2ccd-4464-942f-304b5ca60d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfc0aa83-c8c7-48d9-9967-664ec7f099bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c65cf84b-2ccd-4464-942f-304b5ca60d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9a211327-d80f-4a14-8b41-0aa721828ba4" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f61597e6-0f43-43d2-95d3-f2f2df591786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9a211327-d80f-4a14-8b41-0aa721828ba4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f61597e6-0f43-43d2-95d3-f2f2df591786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0b3483a6-2257-46f5-8eda-dabfe0d6b167" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9a211327-d80f-4a14-8b41-0aa721828ba4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0b3483a6-2257-46f5-8eda-dabfe0d6b167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb590fc-de37-427d-939b-9ee79778a13d" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_ff457eee-5a10-4ef7-99f6-68352ecf4e27" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb590fc-de37-427d-939b-9ee79778a13d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_ff457eee-5a10-4ef7-99f6-68352ecf4e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46da2456-b185-4c1f-a225-598af27514f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb590fc-de37-427d-939b-9ee79778a13d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46da2456-b185-4c1f-a225-598af27514f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_27f17bf6-2896-40cd-82e4-55682ba58bb2" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_3cb20bca-f9f3-41c7-b935-4efe7182d395" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_27f17bf6-2896-40cd-82e4-55682ba58bb2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_3cb20bca-f9f3-41c7-b935-4efe7182d395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_fc560192-d8e9-4e03-b6cd-28ba3701233a" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_27f17bf6-2896-40cd-82e4-55682ba58bb2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_fc560192-d8e9-4e03-b6cd-28ba3701233a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_35bc86a3-1c6d-4527-983a-ea685016e754" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_27f17bf6-2896-40cd-82e4-55682ba58bb2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_35bc86a3-1c6d-4527-983a-ea685016e754" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_033469b0-6e6a-4d70-9d6d-2cedbdeeece5" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_2091dcbd-468f-4468-a577-fbc290e4d979" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_033469b0-6e6a-4d70-9d6d-2cedbdeeece5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_2091dcbd-468f-4468-a577-fbc290e4d979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f9a98196-f3a0-42ce-b9ed-49a84c96bfd8" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_033469b0-6e6a-4d70-9d6d-2cedbdeeece5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f9a98196-f3a0-42ce-b9ed-49a84c96bfd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a0d03a04-c2dd-40a7-97a7-e3e4acfc4a1a" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_033469b0-6e6a-4d70-9d6d-2cedbdeeece5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a0d03a04-c2dd-40a7-97a7-e3e4acfc4a1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b8c7491-cf75-4da3-ba37-b26cc5cb1299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_245ace45-173a-4f61-abec-68372b8fea0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b8c7491-cf75-4da3-ba37-b26cc5cb1299" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_245ace45-173a-4f61-abec-68372b8fea0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0cab9168-2c90-4f21-8816-20fc272f637f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b8c7491-cf75-4da3-ba37-b26cc5cb1299" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0cab9168-2c90-4f21-8816-20fc272f637f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ForwardCurrencyContracts" xlink:type="simple" xlink:href="exel-20210402.xsd#ForwardCurrencyContracts"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ForwardCurrencyContracts" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ForwardCurrencyContractsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#ForwardCurrencyContractsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ForwardCurrencyContractsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_de6b7495-7439-4e3d-8c53-429731452810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d3d68571-867b-4fba-b297-11073284437a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_de6b7495-7439-4e3d-8c53-429731452810" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d3d68571-867b-4fba-b297-11073284437a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_99c9aa82-3803-4a26-b3e0-3855e19c993f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_de6b7495-7439-4e3d-8c53-429731452810" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_99c9aa82-3803-4a26-b3e0-3855e19c993f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210402.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210402.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c006540d-c838-447b-8f94-7943af3b0234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_af35f589-3593-41f8-b442-71da9badd51a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c006540d-c838-447b-8f94-7943af3b0234" xlink:to="loc_us-gaap_InventoryRawMaterials_af35f589-3593-41f8-b442-71da9badd51a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_15bec0fe-e7bb-4d50-8148-8e6684c7752b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c006540d-c838-447b-8f94-7943af3b0234" xlink:to="loc_us-gaap_InventoryWorkInProcess_15bec0fe-e7bb-4d50-8148-8e6684c7752b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ce30022d-3b10-4904-b434-e09d24cb5c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c006540d-c838-447b-8f94-7943af3b0234" xlink:to="loc_us-gaap_InventoryFinishedGoods_ce30022d-3b10-4904-b434-e09d24cb5c40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20210402.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShare"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShareTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_791518c8-6d03-4547-abb3-0a3b8c97768c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_261d3e69-ff01-4a1e-9830-59802a6d2b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_791518c8-6d03-4547-abb3-0a3b8c97768c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_261d3e69-ff01-4a1e-9830-59802a6d2b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0a0a7992-90d8-4c31-b680-c6bfd251696f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_791518c8-6d03-4547-abb3-0a3b8c97768c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0a0a7992-90d8-4c31-b680-c6bfd251696f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210402.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>exel-20210402_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84867dad-da96-4e08-a2f6-a31b9b3022af,g:df225ca8-d190-43b7-90ff-2fc6e5818592-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210402.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" id="i6d475303839446d3ba41266f8e49d6b9_CoverPage"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="iee2fbf2f81bd4e6bb92a5844a9c9b9e8_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="if285cb7614734f579f907607602ec94c_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="ieabc6a6c8e094011b8a29d37b99c78d1_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_911127f2-84b6-4d60-b1a3-dba1ce0bd3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_RevenuesAbstract_911127f2-84b6-4d60-b1a3-dba1ce0bd3f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c272557-55e3-4f6d-b4d7-fbda87f7841b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_911127f2-84b6-4d60-b1a3-dba1ce0bd3f4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c272557-55e3-4f6d-b4d7-fbda87f7841b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_252906d4-0922-412c-8c34-253175a48713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_252906d4-0922-412c-8c34-253175a48713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_95aba419-1869-47b8-be87-4f7776fc5d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_95aba419-1869-47b8-be87-4f7776fc5d46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_786bce46-31ca-4090-b3ec-b6d4f1421e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_786bce46-31ca-4090-b3ec-b6d4f1421e19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9e10f0c1-95fe-4ad0-bd6b-5bc3f9902aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_CostsAndExpenses_9e10f0c1-95fe-4ad0-bd6b-5bc3f9902aa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bbee80fa-f5b6-4117-841c-34fdcb892687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_bbee80fa-f5b6-4117-841c-34fdcb892687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_b8639fd0-f336-4b9f-ace6-992c5d524261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_InterestIncomeOther_b8639fd0-f336-4b9f-ace6-992c5d524261" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13a65e6e-5513-49c3-aef5-752f99391282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13a65e6e-5513-49c3-aef5-752f99391282" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ae1b4ec-7dce-4845-8f3b-f2555fbbd32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ae1b4ec-7dce-4845-8f3b-f2555fbbd32c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_64ec8374-1680-47f0-8d5c-5edc7c13cf4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_64ec8374-1680-47f0-8d5c-5edc7c13cf4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be1dae87-1054-40e3-a531-84497575c617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_NetIncomeLoss_be1dae87-1054-40e3-a531-84497575c617" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a178a92a-9ce4-44ad-9ee1-891ceb67e3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:to="loc_us-gaap_EarningsPerShareBasic_a178a92a-9ce4-44ad-9ee1-891ceb67e3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_defc1483-127b-492d-8cb2-2d1b414ca434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_defc1483-127b-492d-8cb2-2d1b414ca434" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_376dae27-2e75-44fc-934d-eed17f4c5710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_376dae27-2e75-44fc-934d-eed17f4c5710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e0dc832-a161-405a-8f5d-c996987b0e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e0dc832-a161-405a-8f5d-c996987b0e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:to="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82850b75-0037-4134-8c5a-bc3cce11b263_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:to="loc_srt_ProductsAndServicesDomain_82850b75-0037-4134-8c5a-bc3cce11b263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:to="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_40c96fa2-51fb-4992-982f-6cd5ed42aaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:to="loc_us-gaap_ProductMember_40c96fa2-51fb-4992-982f-6cd5ed42aaa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_dd4a0ad6-2c68-45e1-9026-e3ea74c1afcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:to="loc_us-gaap_LicenseMember_dd4a0ad6-2c68-45e1-9026-e3ea74c1afcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2bf985ef-7ee3-4eef-b1c9-98348507a3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:to="loc_us-gaap_ServiceMember_2bf985ef-7ee3-4eef-b1c9-98348507a3f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="idbd166f12f0646439135e1253096da07_CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="extended" id="id8dae653af3a446191a2528bbaaad1d4_CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i6e8336abdd554268ad5e9d9c50718868_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_be9afe31-f5be-4788-bb38-5ff241a6b55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_be9afe31-f5be-4788-bb38-5ff241a6b55c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8fbf4292-b431-403e-8af0-631aff0ac347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8fbf4292-b431-403e-8af0-631aff0ac347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_571c3f90-0040-431b-abee-e5a086add5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockholdersEquity_571c3f90-0040-431b-abee-e5a086add5fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df8c04e8-cfa4-4717-9afc-7041fb187e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_NetIncomeLoss_df8c04e8-cfa4-4717-9afc-7041fb187e37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c8ad6aa3-a821-4dfb-a986-11f62ea450ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c8ad6aa3-a821-4dfb-a986-11f62ea450ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1245f78f-d258-455a-88c8-77b5e46092d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1245f78f-d258-455a-88c8-77b5e46092d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2085c712-84cd-4a06-8ae2-4994223add00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2085c712-84cd-4a06-8ae2-4994223add00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85006369-be1f-4ccd-b66d-fb85eb97b4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85006369-be1f-4ccd-b66d-fb85eb97b4a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d09287c3-bc35-4d62-9d41-fb03ce8f1647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d09287c3-bc35-4d62-9d41-fb03ce8f1647" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56797cbe-1040-494a-a36f-1e20a1a274f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49bdf1d1-c7b3-466c-8d29-a9ad0d837c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_be9afe31-f5be-4788-bb38-5ff241a6b55c" xlink:to="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1ea9ba7-dec8-49f8-8399-40bf8fd24235_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:to="loc_us-gaap_EquityComponentDomain_e1ea9ba7-dec8-49f8-8399-40bf8fd24235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:to="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_03dd8cb5-8449-4cf3-8869-1d80757e4041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_CommonStockMember_03dd8cb5-8449-4cf3-8869-1d80757e4041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f8f50dac-2951-4b20-af45-0fc0d152a4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f8f50dac-2951-4b20-af45-0fc0d152a4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1c033901-1486-461b-b614-78b359587a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1c033901-1486-461b-b614-78b359587a61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_184b60c8-51b4-44ac-96c6-be6e65cfc0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_RetainedEarningsMember_184b60c8-51b4-44ac-96c6-be6e65cfc0fe" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i88e242181e4a43e291895a2a43d093b4_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="ide6daf7e32384819aaf85e91f982a1a8_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i35c4e5dd2303475ebd9da8102a18f9ad_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="ief37c7f8cdf74ff6b032972e1a597249_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:href="exel-20210402.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_f799e067-1525-4f8f-ae86-1ac7bfc3d70b" xlink:href="exel-20210402.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:to="loc_exel_NumberofProductsinCommercialMarket_f799e067-1525-4f8f-ae86-1ac7bfc3d70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cf8b9e46-1c35-4f60-a5ae-ec91a88898ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cf8b9e46-1c35-4f60-a5ae-ec91a88898ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:href="exel-20210402.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:to="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2fa3d40-3fbf-4242-af4c-bc7631790846_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:to="loc_srt_ProductsAndServicesDomain_f2fa3d40-3fbf-4242-af4c-bc7631790846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:to="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_7892cf29-6e95-44cc-a241-896cd4abf3dd" xlink:href="exel-20210402.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_7892cf29-6e95-44cc-a241-896cd4abf3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_8497a651-c167-4e6a-968f-814207336103" xlink:href="exel-20210402.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_8497a651-c167-4e6a-968f-814207336103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_8e79fa7a-b1b9-4e8c-b108-b3e75c7d573e" xlink:href="exel-20210402.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_8e79fa7a-b1b9-4e8c-b108-b3e75c7d573e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210402.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" id="ie4a5184baa0b4d0caf2de220afa3be18_Revenues"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" id="ice9193983eed4e1ab237bf07d07b5b96_RevenuesTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i7a05a61c2f534271b585ede9fb5cdbd6_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2eb86a55-a47c-4415-b6eb-1d8dc24b15f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c324b7d1-6a89-483a-ab11-d62208bb0091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2eb86a55-a47c-4415-b6eb-1d8dc24b15f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c324b7d1-6a89-483a-ab11-d62208bb0091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2eb86a55-a47c-4415-b6eb-1d8dc24b15f2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:to="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2e41810-3d1b-48c7-b56f-88b4d1827eab_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:to="loc_srt_ProductsAndServicesDomain_e2e41810-3d1b-48c7-b56f-88b4d1827eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:to="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_0774c287-7283-4a42-9182-f1068c99031e" xlink:href="exel-20210402.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_exel_ProductGrossMember_0774c287-7283-4a42-9182-f1068c99031e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_bc821888-0231-42d4-ab8f-9f9fe5f62b5c" xlink:href="exel-20210402.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_bc821888-0231-42d4-ab8f-9f9fe5f62b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_15eb0280-f07b-4356-b327-2005933e8286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_us-gaap_ProductMember_15eb0280-f07b-4356-b327-2005933e8286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3ddb75db-cd0e-4e23-b9a0-eca6fe269f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_us-gaap_LicenseMember_3ddb75db-cd0e-4e23-b9a0-eca6fe269f3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9887070d-1b2c-457e-9969-b0d201fef916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_us-gaap_ServiceMember_9887070d-1b2c-457e-9969-b0d201fef916" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_8194174a-ec0e-4519-a020-56c2c8816d11" xlink:href="exel-20210402.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_exel_CollaborationMember_8194174a-ec0e-4519-a020-56c2c8816d11" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="ie09076ef553c4d10b36e40c5e0e8a27f_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_abeae467-84cd-4dea-8d70-105a17f6e76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a3f31024-6d87-48f1-997d-c9a8524998cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_abeae467-84cd-4dea-8d70-105a17f6e76c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a3f31024-6d87-48f1-997d-c9a8524998cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_abeae467-84cd-4dea-8d70-105a17f6e76c" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b65255cd-f5a8-40a1-b448-2177705488d5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:to="loc_srt_NameOfMajorCustomerDomain_b65255cd-f5a8-40a1-b448-2177705488d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:to="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_91ff67a2-47a5-4fec-b258-b8a972895f9d" xlink:href="exel-20210402.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_91ff67a2-47a5-4fec-b258-b8a972895f9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0652357d-ede9-4a39-8636-d5ec0843095b" xlink:href="exel-20210402.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0652357d-ede9-4a39-8636-d5ec0843095b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_6b72ca0c-b6c2-46c4-ac19-3fc33aebcea2" xlink:href="exel-20210402.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_6b72ca0c-b6c2-46c4-ac19-3fc33aebcea2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_f7c62b59-a8c3-4bde-8615-ea118547d6df" xlink:href="exel-20210402.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_IpsenMember_f7c62b59-a8c3-4bde-8615-ea118547d6df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_e634a93d-c379-4e8a-bbab-f25d9e4b1aca" xlink:href="exel-20210402.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_e634a93d-c379-4e8a-bbab-f25d9e4b1aca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_52d32c97-dc8f-4eb2-a18a-6480700c22e7" xlink:href="exel-20210402.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_TakedaMember_52d32c97-dc8f-4eb2-a18a-6480700c22e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4df9d581-0e74-4274-aa23-6c90422ab5db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4df9d581-0e74-4274-aa23-6c90422ab5db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dfcfe7cf-4900-436e-91c0-032931495c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dfcfe7cf-4900-436e-91c0-032931495c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3c54de27-2011-49d4-a0a1-8bb812248d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:to="loc_us-gaap_AccountsReceivableMember_3c54de27-2011-49d4-a0a1-8bb812248d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a437ce13-4220-4b23-b794-4a6a9a45773b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a437ce13-4220-4b23-b794-4a6a9a45773b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_da4e2209-aba7-4b34-bce6-e4afe67ccbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_da4e2209-aba7-4b34-bce6-e4afe67ccbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_629ed300-da04-4acf-a1c3-56ea25374124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_da4e2209-aba7-4b34-bce6-e4afe67ccbee" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_629ed300-da04-4acf-a1c3-56ea25374124" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="i958347512aa94b70aa002891539be17b_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_11e83cbd-e86c-4185-b3a1-209688b3e618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb54d41c-c8a8-48c1-ac62-8671e6d2ea4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_11e83cbd-e86c-4185-b3a1-209688b3e618" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb54d41c-c8a8-48c1-ac62-8671e6d2ea4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_11e83cbd-e86c-4185-b3a1-209688b3e618" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:to="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d369f74e-3ce6-4ef2-9931-a08ea3bb0872_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:to="loc_srt_SegmentGeographicalDomain_d369f74e-3ce6-4ef2-9931-a08ea3bb0872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:to="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6393574a-45b7-48a4-8653-61d253f405af" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:to="loc_country_US_6393574a-45b7-48a4-8653-61d253f405af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_33509f69-0d0c-45d7-838b-c98c81dcba40" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:to="loc_srt_EuropeMember_33509f69-0d0c-45d7-838b-c98c81dcba40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_a7b0d6cc-fe12-4940-aa2c-ee4e9aafdf80" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:to="loc_country_JP_a7b0d6cc-fe12-4940-aa2c-ee4e9aafdf80" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i09e0290363e84bdba5e8c4eac1c8bceb_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_687f3fdc-f2c7-488f-adf7-521244168e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44a9b80a-1b28-4caf-b50b-aa0ad5277438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_687f3fdc-f2c7-488f-adf7-521244168e00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44a9b80a-1b28-4caf-b50b-aa0ad5277438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_687f3fdc-f2c7-488f-adf7-521244168e00" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:to="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_446860dd-16a4-4467-b498-74d7408792a6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:to="loc_srt_ProductsAndServicesDomain_446860dd-16a4-4467-b498-74d7408792a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:to="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_1ad12eba-6f11-4446-8184-b3feae04482c" xlink:href="exel-20210402.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:to="loc_exel_CabometyxMember_1ad12eba-6f11-4446-8184-b3feae04482c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_04452d88-edd6-46da-903c-2a263f5ee3b5" xlink:href="exel-20210402.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:to="loc_exel_CometriqMember_04452d88-edd6-46da-903c-2a263f5ee3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2fe1b9fd-5658-4ffa-b344-8fe23a26d6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:to="loc_us-gaap_ProductMember_2fe1b9fd-5658-4ffa-b344-8fe23a26d6dc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i1d20b5ad2ab54618b09740b2e43b750a_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e53fd0d0-2ed4-4f43-b903-6fc9cca6cbc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e53fd0d0-2ed4-4f43-b903-6fc9cca6cbc0" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_792f63e2-2c94-4cde-b2e7-cf53e1fe2567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_792f63e2-2c94-4cde-b2e7-cf53e1fe2567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_de7b2635-3c38-4de6-b675-868d2a899ebc" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_de7b2635-3c38-4de6-b675-868d2a899ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_6e549c5c-e7f0-41f0-92fe-77c2afac901b" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_6e549c5c-e7f0-41f0-92fe-77c2afac901b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_685ddb5f-5f12-4e7b-9fac-fde7e493b6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_685ddb5f-5f12-4e7b-9fac-fde7e493b6b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b362eb2e-694e-4aca-b0d8-d88320d609df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e53fd0d0-2ed4-4f43-b903-6fc9cca6cbc0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7baffade-7717-4367-aba7-6dc520c95e22" xlink:href="exel-20210402.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7baffade-7717-4367-aba7-6dc520c95e22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a349107e-be5f-476e-8e78-7aec57a12e0d" xlink:href="exel-20210402.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a349107e-be5f-476e-8e78-7aec57a12e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_9ad6e22d-cf8e-4318-9ac6-2aea30ead34b" xlink:href="exel-20210402.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:to="loc_exel_AllowanceForProductRebatesMember_9ad6e22d-cf8e-4318-9ac6-2aea30ead34b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i718d7d4f504c40ca819bd79ecd38cbf1_RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangements"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements" xlink:type="extended" id="ia3b8b49414904eb49a447c9e67faa657_CollaborationAgreementsAndInLicensingArrangements"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables" xlink:type="extended" id="i3288f559fb0d4354bede95e5562efdf5_CollaborationAgreementsAndInLicensingArrangementsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i382ce77674414b0aa13018c42175f4de_CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_258a931a-da92-4cdc-b4e0-340fdcd01596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7d411fa3-a436-4208-97d9-9c70e15e8ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_258a931a-da92-4cdc-b4e0-340fdcd01596" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7d411fa3-a436-4208-97d9-9c70e15e8ed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_258a931a-da92-4cdc-b4e0-340fdcd01596" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:to="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d48c671a-6fce-4196-900a-e152c6bc57b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:to="loc_srt_ProductsAndServicesDomain_d48c671a-6fce-4196-900a-e152c6bc57b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:to="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_faf4d425-8352-4bf1-8bdb-5a7b71871489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:to="loc_us-gaap_LicenseMember_faf4d425-8352-4bf1-8bdb-5a7b71871489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_56886e30-e077-40ad-a709-10fc771ef6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:to="loc_us-gaap_ServiceMember_56886e30-e077-40ad-a709-10fc771ef6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52b0db55-e45d-41ab-b9a1-841cd381753a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52b0db55-e45d-41ab-b9a1-841cd381753a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc0b9c0-df99-4292-8349-2348c2719752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc0b9c0-df99-4292-8349-2348c2719752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_40fc7aa7-aaae-4740-b519-bffb20be68ed" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc0b9c0-df99-4292-8349-2348c2719752" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_40fc7aa7-aaae-4740-b519-bffb20be68ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" xlink:type="extended" id="idc9cbc57fd55456bba5b4cdfd5d1ec8f_CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_788f5401-ffc5-4440-a72b-af3ffa6c88b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6df8afdc-501c-4368-b624-bf1bf8279744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_788f5401-ffc5-4440-a72b-af3ffa6c88b4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6df8afdc-501c-4368-b624-bf1bf8279744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_788f5401-ffc5-4440-a72b-af3ffa6c88b4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_089331e3-0a00-4783-aa04-d7bdd46e91fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_089331e3-0a00-4783-aa04-d7bdd46e91fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98d7fa66-8c0c-426f-b26f-b8ae0ae3023d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98d7fa66-8c0c-426f-b26f-b8ae0ae3023d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_54ef9f4c-3fa6-4182-8da1-a01e981c2aa0" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98d7fa66-8c0c-426f-b26f-b8ae0ae3023d" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_54ef9f4c-3fa6-4182-8da1-a01e981c2aa0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i98e072342df2447998d6c520516070a7_CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74d4c550-93df-45bf-8359-f9a60df6ed47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee1d3d1b-a7ef-4b0e-b860-ca0cd3c3a73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74d4c550-93df-45bf-8359-f9a60df6ed47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee1d3d1b-a7ef-4b0e-b860-ca0cd3c3a73a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74d4c550-93df-45bf-8359-f9a60df6ed47" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:to="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6891bf85-b0f1-4299-bcc3-ce42d96a7f46_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:to="loc_srt_ProductsAndServicesDomain_6891bf85-b0f1-4299-bcc3-ce42d96a7f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:to="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_fb7720d1-136d-46c8-b2ca-bc1a5f12223d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:to="loc_us-gaap_LicenseMember_fb7720d1-136d-46c8-b2ca-bc1a5f12223d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1a02df98-f0a0-48a9-ba57-94c3ff0c863f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:to="loc_us-gaap_ServiceMember_1a02df98-f0a0-48a9-ba57-94c3ff0c863f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91168aba-936b-4cde-884d-1745c07d0260_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91168aba-936b-4cde-884d-1745c07d0260_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d5130d4-59a4-4f2b-8777-20be1ae5012c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d5130d4-59a4-4f2b-8777-20be1ae5012c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_210fe078-d4b6-4023-8910-858b2c89681a" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d5130d4-59a4-4f2b-8777-20be1ae5012c" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_210fe078-d4b6-4023-8910-858b2c89681a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" xlink:type="extended" id="ib67c8b3be5a0434e9095c2dfd94ce5bf_CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb374aac-4318-46fc-bb3d-8c97a9d3c135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_536ec375-9a7e-4ec6-8dc4-e57f9081cb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb374aac-4318-46fc-bb3d-8c97a9d3c135" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_536ec375-9a7e-4ec6-8dc4-e57f9081cb30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb374aac-4318-46fc-bb3d-8c97a9d3c135" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a10e20b-49a4-401f-9304-8f6128265af9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a10e20b-49a4-401f-9304-8f6128265af9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9a4f0ac-c285-4bac-9cd1-b97d2aecd887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9a4f0ac-c285-4bac-9cd1-b97d2aecd887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_ab0b1dc7-7ff2-4223-9487-78572a87a745" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9a4f0ac-c285-4bac-9cd1-b97d2aecd887" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_ab0b1dc7-7ff2-4223-9487-78572a87a745" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails" xlink:type="extended" id="i0f3980e617744fdf9a20326ed68f9985_CollaborationAgreementsAndInLicensingArrangementsGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_fc449fdb-d964-42ce-b254-72b3623a96f1" xlink:href="exel-20210402.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_fc449fdb-d964-42ce-b254-72b3623a96f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1616fa0a-8b98-4a45-b923-2a856383e8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:to="loc_us-gaap_RoyaltyExpense_1616fa0a-8b98-4a45-b923-2a856383e8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:to="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_54a0bfe5-8d38-402f-869a-ae587de58a2d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:to="loc_srt_NameOfMajorCustomerDomain_54a0bfe5-8d38-402f-869a-ae587de58a2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_840c026f-c3e2-4db0-ba56-449630261114" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:to="loc_srt_NameOfMajorCustomerDomain_840c026f-c3e2-4db0-ba56-449630261114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_903b687d-5192-4d2c-be3a-57f86aa1d05a" xlink:href="exel-20210402.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_840c026f-c3e2-4db0-ba56-449630261114" xlink:to="loc_exel_GlaxoSmithKlineMember_903b687d-5192-4d2c-be3a-57f86aa1d05a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8aacf83b-aa8f-4ba1-8eac-7f321c218280_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8aacf83b-aa8f-4ba1-8eac-7f321c218280_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eead4279-e83d-4b1c-9fd2-185cde22b14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eead4279-e83d-4b1c-9fd2-185cde22b14c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_e98a5a5f-f789-4daa-b369-06cdfdad833e" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eead4279-e83d-4b1c-9fd2-185cde22b14c" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_e98a5a5f-f789-4daa-b369-06cdfdad833e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="i2bc67c8dd68e453e8172b48b8df12613_CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_df6742b2-f467-450f-9643-112a1a2d2aba" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_df6742b2-f467-450f-9643-112a1a2d2aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9ef3b0d-55e8-438e-93a4-acda93da3a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9ef3b0d-55e8-438e-93a4-acda93da3a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c9e3135-f107-402d-aa68-92a2da242a2d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c9e3135-f107-402d-aa68-92a2da242a2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c0dba2-3120-4fc2-b7b5-15f1e7d38d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c0dba2-3120-4fc2-b7b5-15f1e7d38d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_1c44d8f9-4e09-44ae-ab4b-76d4bede25be" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c0dba2-3120-4fc2-b7b5-15f1e7d38d08" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_1c44d8f9-4e09-44ae-ab4b-76d4bede25be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" xlink:type="extended" id="i4bc31ce5605b4fcaa1a9c226a93ee7cf_CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_5cdd6bfe-8475-4bdf-9289-466edd89a4a1" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_5cdd6bfe-8475-4bdf-9289-466edd89a4a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_799f419f-b751-44c2-ab43-183ec4d7fbe1" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_799f419f-b751-44c2-ab43-183ec4d7fbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_9ff68fe5-95b0-40aa-8710-5046c0e5a666" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_9ff68fe5-95b0-40aa-8710-5046c0e5a666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_58a268fb-c9e1-471f-a403-35bceba63bee" xlink:href="exel-20210402.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_58a268fb-c9e1-471f-a403-35bceba63bee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ff844c88-685a-4180-818f-b0a79f0bf7d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ff844c88-685a-4180-818f-b0a79f0bf7d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithAdageneMember_ba8a058a-4a62-4f53-9f4b-3c98eb5c78dd" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementWithAdageneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:to="loc_exel_CollaborativeAgreementWithAdageneMember_ba8a058a-4a62-4f53-9f4b-3c98eb5c78dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithWuXiBioMember_3b1fd4c1-c911-4e39-b655-c2aaff85c89c" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementWithWuXiBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:to="loc_exel_CollaborativeAgreementWithWuXiBioMember_3b1fd4c1-c911-4e39-b655-c2aaff85c89c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestments"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended" id="i01bdcb2f909748c0b95420dc7bde1b3c_CashandInvestments"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended" id="i9dcfcd1b5fb7422e8e6c6da59a67e937_CashandInvestmentsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i7c17fcd12e634b01892a62585baea461_CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i59c7ce17c71b436b901b5808d74abd6c_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fc5d33f-1869-416c-91b4-48b875ddec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fc5d33f-1869-416c-91b4-48b875ddec44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411d7b1a-e6ae-4831-9e69-7611ad0aa9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411d7b1a-e6ae-4831-9e69-7611ad0aa9f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ae919f2-8609-4f2f-8f10-caf15ce2df2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ae919f2-8609-4f2f-8f10-caf15ce2df2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a407a98-030b-428a-bc48-4a99aa01181f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a407a98-030b-428a-bc48-4a99aa01181f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2c7de892-6d03-47b2-acfb-4670938219f3" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2c7de892-6d03-47b2-acfb-4670938219f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b46bc388-b074-4cfe-aeff-e9cd49cc66da" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b46bc388-b074-4cfe-aeff-e9cd49cc66da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e8e93772-c5e2-4369-a66a-0ab85b3852fa" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e8e93772-c5e2-4369-a66a-0ab85b3852fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_dccce1e4-2cd3-4b11-8fb6-907d293f7ea4" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_dccce1e4-2cd3-4b11-8fb6-907d293f7ea4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_6ed89b16-87e1-474a-94c3-dc874405b36c" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_6ed89b16-87e1-474a-94c3-dc874405b36c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d632a439-1548-4bc2-b5ce-806801445c3d" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d632a439-1548-4bc2-b5ce-806801445c3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5774602c-6506-4264-a6d3-d252a1cf9082" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5774602c-6506-4264-a6d3-d252a1cf9082" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d8b4d418-e36b-4f9b-a159-2f1343f915f1" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d8b4d418-e36b-4f9b-a159-2f1343f915f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_758723ca-81eb-45e1-b1ba-972188968beb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_758723ca-81eb-45e1-b1ba-972188968beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2b46a9bd-f454-4577-97ff-cea2269170ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CommercialPaperMember_2b46a9bd-f454-4577-97ff-cea2269170ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af5f2cdd-f101-4d56-ab72-3616ae01494b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af5f2cdd-f101-4d56-ab72-3616ae01494b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_28d9f632-b461-4c6a-b6fb-d1f200a3e0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_28d9f632-b461-4c6a-b6fb-d1f200a3e0d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c82e9fa5-53b1-4210-902b-753b9d13da89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_MunicipalBondsMember_c82e9fa5-53b1-4210-902b-753b9d13da89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_df43b3ef-34ef-489c-9227-b8f614081b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CashMember_df43b3ef-34ef-489c-9227-b8f614081b8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4af78c0d-0bac-4f51-b56a-a98395771261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4af78c0d-0bac-4f51-b56a-a98395771261" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e6b9f6d9-66cf-4223-81b5-57ed7acba656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e6b9f6d9-66cf-4223-81b5-57ed7acba656" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="i2a6b8e8742b94708bd48cc80d146f0b7_CashandInvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="i4ac496140e8c48a0817c4db8e9e507d4_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9365512-9bfe-4e75-a2fb-8ab090cc89c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9365512-9bfe-4e75-a2fb-8ab090cc89c0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_13c32623-6ea3-4ae9-acd1-523b0c392377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_13c32623-6ea3-4ae9-acd1-523b0c392377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_1986aae7-0823-47ab-94f2-93ebcaab139f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_1986aae7-0823-47ab-94f2-93ebcaab139f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9365512-9bfe-4e75-a2fb-8ab090cc89c0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f340e25a-bd14-4f52-9e29-25558bde943b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f340e25a-bd14-4f52-9e29-25558bde943b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79b05ce4-f017-4421-a3eb-53926adcf62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_CommercialPaperMember_79b05ce4-f017-4421-a3eb-53926adcf62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ec2f6460-a14d-405f-8bd6-bd3db5cffc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ec2f6460-a14d-405f-8bd6-bd3db5cffc42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_89845ca5-ea57-46c6-9491-b72e9d839599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_89845ca5-ea57-46c6-9491-b72e9d839599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2fadc601-2e77-45ef-9634-16c018dccb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_MunicipalBondsMember_2fadc601-2e77-45ef-9634-16c018dccb99" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended" id="i4198928534204de3b23c3c04ea252049_CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ForwardCurrencyContracts" xlink:type="simple" xlink:href="exel-20210402.xsd#ForwardCurrencyContracts"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ForwardCurrencyContracts" xlink:type="extended" id="i21260970f3e14ca9974d2b034301d870_ForwardCurrencyContracts"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ForwardCurrencyContractsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#ForwardCurrencyContractsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ForwardCurrencyContractsDetails" xlink:type="extended" id="i17c2ed0289cc4ae895262a89e3c58a9d_ForwardCurrencyContractsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_60931c8c-bba5-4c32-8e5c-31e0aeb35c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_60931c8c-bba5-4c32-8e5c-31e0aeb35c85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ac326b3a-7b80-465a-b45a-3dd6aaa13d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ac326b3a-7b80-465a-b45a-3dd6aaa13d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_9ee556b8-9ab9-4001-9ea5-4f3b82b5af21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeTermOfContract_9ee556b8-9ab9-4001-9ea5-4f3b82b5af21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_f0446c53-35dd-422d-a5f6-1d815c80f45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_f0446c53-35dd-422d-a5f6-1d815c80f45e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e94546e6-1dd0-4145-9139-e1e8a0f59fa9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e94546e6-1dd0-4145-9139-e1e8a0f59fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8e953268-e854-490f-8518-5bd321bbbcf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8e953268-e854-490f-8518-5bd321bbbcf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_0716688e-1e6e-4c9f-bfc1-a574981ef6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e953268-e854-490f-8518-5bd321bbbcf9" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_0716688e-1e6e-4c9f-bfc1-a574981ef6f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" id="i2f61459ce2774c2aa9f07c5087fb4f77_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i03fce698e1134197b707763118a5c02f_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ied49456cfb2b454abf692e1a698c22d3_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad48337e-d786-497b-88ac-7d057216c6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad48337e-d786-497b-88ac-7d057216c6d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb2ee2b7-4a92-4af2-be0a-20776426e3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb2ee2b7-4a92-4af2-be0a-20776426e3fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_39027328-f548-4c25-93d6-d9db779cf847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_39027328-f548-4c25-93d6-d9db779cf847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbf1d01c-351a-46c7-a073-efcda22a556a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbf1d01c-351a-46c7-a073-efcda22a556a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1452d4a0-0388-4aca-85d6-0791eb86342f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_CommercialPaperMember_1452d4a0-0388-4aca-85d6-0791eb86342f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_58dbce8a-768c-472f-821e-9b15f519e2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_58dbce8a-768c-472f-821e-9b15f519e2de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_065fa0d6-aaf5-40f0-aacc-6c9793b9ee9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_065fa0d6-aaf5-40f0-aacc-6c9793b9ee9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c99e574e-96da-4a19-b196-a15872d4cbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_MunicipalBondsMember_c99e574e-96da-4a19-b196-a15872d4cbb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4227da4e-7fb0-4f69-8903-db3f44aaf60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4227da4e-7fb0-4f69-8903-db3f44aaf60a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b96c2847-a533-42c5-8683-7aaa937a1f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b96c2847-a533-42c5-8683-7aaa937a1f00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f849717d-ff7c-472d-8f2e-6988f686fc74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f849717d-ff7c-472d-8f2e-6988f686fc74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_133164c8-2383-4063-9d9a-b70828263e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_133164c8-2383-4063-9d9a-b70828263e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b4e9d422-3a95-41ce-9cb0-eb9c958e2b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b4e9d422-3a95-41ce-9cb0-eb9c958e2b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_de676252-2e7f-4fbf-8b78-4e7c798907e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_de676252-2e7f-4fbf-8b78-4e7c798907e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9529f2b4-8180-40c2-aba4-019cf9c149f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9529f2b4-8180-40c2-aba4-019cf9c149f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cf51be7a-3faa-4ee4-80ef-99c2e9c039ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9529f2b4-8180-40c2-aba4-019cf9c149f7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cf51be7a-3faa-4ee4-80ef-99c2e9c039ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210402.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" id="i0122a9016b8d4ea6b8c529faa1b2768d_Inventory"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210402.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" id="i9944a9e89d604c96a0d41dc7872f9ded_InventoryTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i0a8e0f811868426cb0659db82577c0fd_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_61ede8db-5dd5-46fd-97fe-618ef9528bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryRawMaterials_61ede8db-5dd5-46fd-97fe-618ef9528bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5b2cb892-684d-4d99-a6a2-5b4a472608ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryWorkInProcess_5b2cb892-684d-4d99-a6a2-5b4a472608ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_95b60ecb-5513-4cfa-af2a-b52c637b1942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryFinishedGoods_95b60ecb-5513-4cfa-af2a-b52c637b1942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e52788a7-3e7e-4452-a020-1a590f711703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryGross_e52788a7-3e7e-4452-a020-1a590f711703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_90f816e9-bb2a-4be5-af38-eb2b90adf158_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_90f816e9-bb2a-4be5-af38-eb2b90adf158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_76125ef1-f719-4133-a383-508ee57abfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:to="loc_us-gaap_InventoriesMember_76125ef1-f719-4133-a383-508ee57abfb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_8630f0b9-99a9-4131-8c5c-11632be8d562" xlink:href="exel-20210402.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:to="loc_exel_OtherLongtermAssetsMember_8630f0b9-99a9-4131-8c5c-11632be8d562" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" id="ie80f7255c95245eaa3290e065344f31e_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" id="i6d0253c0eb8a44858149b78b3dece231_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="icdc42d9f67154a8085bca2945d9fb476_StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89bb5d90-2aef-4ad7-8bc7-f33bddaf1363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_285f5b6f-f63a-4c4f-a903-342cedccd36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89bb5d90-2aef-4ad7-8bc7-f33bddaf1363" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_285f5b6f-f63a-4c4f-a903-342cedccd36a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89bb5d90-2aef-4ad7-8bc7-f33bddaf1363" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6730f330-f2c3-4a0c-8bf6-fb486b301310_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6730f330-f2c3-4a0c-8bf6-fb486b301310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9fdac25-0ab3-4092-9f2f-41ac70a3ea52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9fdac25-0ab3-4092-9f2f-41ac70a3ea52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e82aa5f2-1fdd-43d6-b152-37ccc6cb6272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e82aa5f2-1fdd-43d6-b152-37ccc6cb6272" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended" id="ia9f5a0aca4e14cb4a9de8c34fd6f8362_StockBasedCompensationBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d71607-e127-4b8c-b402-abb5483a4072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_17017657-d9af-41d7-acb0-5c0d0f6aa508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d71607-e127-4b8c-b402-abb5483a4072" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_17017657-d9af-41d7-acb0-5c0d0f6aa508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d71607-e127-4b8c-b402-abb5483a4072" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:to="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835d685c-5628-4298-a503-010baf5a7aaa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835d685c-5628-4298-a503-010baf5a7aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88ef57f2-ed46-4562-a7df-f2de706c8387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88ef57f2-ed46-4562-a7df-f2de706c8387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00d57011-6adc-49bc-bb96-ab71f36fdca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00d57011-6adc-49bc-bb96-ab71f36fdca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2c5f2b44-85fd-45ea-af6d-46094e8b3a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_PerformanceSharesMember_2c5f2b44-85fd-45ea-af6d-46094e8b3a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9df09d4e-2e96-40f0-87d6-0c097e190d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_EmployeeStockMember_9df09d4e-2e96-40f0-87d6-0c097e190d1e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ifdc4219d7cb846c0a4addab5c58727d2_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c0bca40-4a49-40fa-8b2a-771ea50f092b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c0bca40-4a49-40fa-8b2a-771ea50f092b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_aff5ec57-13a6-4825-a9ca-e5b5b4508640" xlink:href="exel-20210402.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_aff5ec57-13a6-4825-a9ca-e5b5b4508640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_331fa9d4-9333-4503-bea6-5382eae5b20e" xlink:href="exel-20210402.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_331fa9d4-9333-4503-bea6-5382eae5b20e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210abbf9-5914-48d3-9b6c-233cb2e491f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210abbf9-5914-48d3-9b6c-233cb2e491f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3867442-430d-4a90-9115-e279f8f1cea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3867442-430d-4a90-9115-e279f8f1cea5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8c50a38-3534-4d1a-a2b1-c8a60cee3619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8c50a38-3534-4d1a-a2b1-c8a60cee3619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d4aa55b-fbbe-408d-a373-b4041506ffc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d4aa55b-fbbe-408d-a373-b4041506ffc9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bdca0b6a-52d0-4b3b-a703-43d0d606911d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bdca0b6a-52d0-4b3b-a703-43d0d606911d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f466f9a3-27d5-49d4-adf6-9628978c2d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f466f9a3-27d5-49d4-adf6-9628978c2d38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68d92644-8e50-4de2-91ea-238af0af2f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68d92644-8e50-4de2-91ea-238af0af2f3b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6bf53319-9462-4c05-bdc7-34c0ed844036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6bf53319-9462-4c05-bdc7-34c0ed844036" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c21b3415-3f8c-456d-bd7d-b924415b250c" xlink:href="exel-20210402.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c21b3415-3f8c-456d-bd7d-b924415b250c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9d362c40-1335-40fe-9b44-55c2ec77c629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9d362c40-1335-40fe-9b44-55c2ec77c629" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9c54d3d-87a3-4064-9beb-2608dd7be8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9c54d3d-87a3-4064-9beb-2608dd7be8f9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ac2250-7e84-498d-af7a-7328584b6039_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ac2250-7e84-498d-af7a-7328584b6039_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_486ccfe6-4116-49fb-a62e-05657736099f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_486ccfe6-4116-49fb-a62e-05657736099f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2c940a28-c9a2-4422-bd06-8beecb25952d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2c940a28-c9a2-4422-bd06-8beecb25952d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cdfdeb4e-7b5f-48b0-a4e2-b52eb46b4144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:to="loc_us-gaap_PerformanceSharesMember_cdfdeb4e-7b5f-48b0-a4e2-b52eb46b4144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:href="exel-20210402.xsd#exel_StatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_13cdaf91-2d2d-483c-820a-3e56d6de9304_default" xlink:href="exel-20210402.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:to="loc_exel_StatusDomain_13cdaf91-2d2d-483c-820a-3e56d6de9304_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_f10ac21b-b97f-4f51-8ca1-a504f80638d6" xlink:href="exel-20210402.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:to="loc_exel_StatusDomain_f10ac21b-b97f-4f51-8ca1-a504f80638d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_65d0e329-b69b-47b3-ba7f-545261688f73" xlink:href="exel-20210402.xsd#exel_ProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_f10ac21b-b97f-4f51-8ca1-a504f80638d6" xlink:to="loc_exel_ProbableMember_65d0e329-b69b-47b3-ba7f-545261688f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:to="loc_us-gaap_VestingDomain_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:to="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e3b89cb0-b13c-4455-8e56-491d647d932e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e3b89cb0-b13c-4455-8e56-491d647d932e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_afded97c-a39d-417a-9c66-d00e8af4a97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_afded97c-a39d-417a-9c66-d00e8af4a97c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended" id="i62a81a1570444536a2e7cb95b34afa00_StockBasedCompensationEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d696778-ef19-4f08-b63b-21d1fc69fb95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d696778-ef19-4f08-b63b-21d1fc69fb95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d5ffde4b-4a62-445e-852c-97206855b77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_SharePrice_d5ffde4b-4a62-445e-852c-97206855b77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3724b1cd-1074-4630-9388-013b1e9a01dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3724b1cd-1074-4630-9388-013b1e9a01dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c17b9bc4-5c0d-4e40-9093-63345d203610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c17b9bc4-5c0d-4e40-9093-63345d203610" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bdb2b647-d078-416b-b59c-ff3f83ef3ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bdb2b647-d078-416b-b59c-ff3f83ef3ef3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:to="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df53aca4-d37f-4cb4-b5fd-eca49274d4a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df53aca4-d37f-4cb4-b5fd-eca49274d4a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58c5c27d-e52a-406e-8f97-dcd20a6c2c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58c5c27d-e52a-406e-8f97-dcd20a6c2c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_99ac08b0-1379-4aa2-ad52-db70880efaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58c5c27d-e52a-406e-8f97-dcd20a6c2c85" xlink:to="loc_us-gaap_PerformanceSharesMember_99ac08b0-1379-4aa2-ad52-db70880efaba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20210402.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended" id="ib5c4d58fade84c479da396dcd7dc4c8e_ProvisionForBenefitFromIncomeTaxes"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShare"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" id="ice0835c5f5db48289630cb4a9cfec49a_NetIncomePerShare"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShareTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" id="i5a294a64ea2e4f0fa1a34560b4a406aa_NetIncomePerShareTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="i50d818e0db51474c811624800e1ebe57_NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended" id="i7658ab122d704c4aaf280f9efb5100be_NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_07c516f4-97a3-424e-a8d3-681a87eeef9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4bb9ebb7-4e8d-4cc3-a505-c6de5e722b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_07c516f4-97a3-424e-a8d3-681a87eeef9f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4bb9ebb7-4e8d-4cc3-a505-c6de5e722b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_07c516f4-97a3-424e-a8d3-681a87eeef9f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1356fda1-4379-4eeb-8d8b-40a85c43f010_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1356fda1-4379-4eeb-8d8b-40a85c43f010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ca089ad-6dc9-4697-9575-900c9c88d8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ca089ad-6dc9-4697-9575-900c9c88d8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1fe5fbd4-5901-46a8-82fc-89796ef4e838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ca089ad-6dc9-4697-9575-900c9c88d8dc" xlink:to="loc_us-gaap_StockCompensationPlanMember_1fe5fbd4-5901-46a8-82fc-89796ef4e838" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210402.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended" id="ifb46ff748ec74eed956c783e1775349f_CommitmentsandContingencies"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>exel-20210402_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84867dad-da96-4e08-a2f6-a31b9b3022af,g:df225ca8-d190-43b7-90ff-2fc6e5818592-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f024e2c6-b27c-4f80-b6e6-42d6a4b62f06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0be7ff87-be8e-4d9a-8a2d-64cd5ca478f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3181cf5c-eefd-4821-9890-bb0a2afea6f6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c0655cf3-0f08-47dd-99c5-e95437fe6167_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_af2abc3b-1690-494b-9f05-24dbf2d84516_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProbableMember_c176a3a3-160e-43b9-bc25-e06fad7fceb8_terseLabel_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_label_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_documentation_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember" xlink:href="exel-20210402.xsd#exel_ProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember" xlink:to="lab_exel_ProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fa64574d-52cd-40ed-be56-14592d07e1d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cdd5ab1b-2e20-45fc-b4bd-0777115785de_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3e6421ae-a7cb-4efa-b279-510504487c65_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_43e71bb1-2eec-465a-8dfa-17256ddb1e16_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7812822b-3d01-46d3-9c5d-12c2843d5529_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_cb1156a8-8d8c-435f-850c-628f8217fc94_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95377c2e-c02c-471f-a13e-3b09c06d53f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6126137d-705c-4870-a9b0-43bfb0b2de5f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_210f1e5c-b412-4abe-9d53-3fb10b7e735f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d26bae24-73e4-427d-b768-3529387ee00b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9ba96ff8-ca3e-41b3-9e9f-23be7d07058b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_a50c9f9e-f149-4495-b2f2-e54aa469aa9f_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_86461050-bbac-4d03-af9f-91c85d20e2b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_358018ed-10c9-4fd2-b3e0-e2057ae9fa47_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b05fc542-10e8-4832-a1d5-906ef4ffaec1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_3241f83e-b659-48ec-8142-f3c321948ace_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_17a39802-9d14-4004-a0cb-56bbdc745707_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a536e525-c136-4458-b0d0-1afa28007a19_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_aa5d04cf-7c4b-42f2-ad46-3ae458fd6c51_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9d2dc09d-6aea-488f-9e24-b81a4642ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_a7533a69-e84c-41c0-a29d-8d2aade7aeec_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20210402.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_ce163fe7-de27-464e-90a5-2db11136ad35_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20210402.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_1ba7343b-1527-43c1-82c7-0cad0928288e_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9078ef6d-4863-40a3-b15b-4b157b030845_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_524c155f-721b-4e8b-9cd8-affe2c00232a_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20210402.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_ee84331d-0b3b-45c8-a770-33cefcedab4b_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20210402.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21fa7efb-0346-4609-bfa4-1ad18b2017e0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1968ece5-0f78-4776-b819-19a6feae595f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0a128765-a7b2-43a6-9810-6c28c67a2010_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FORWARD CURRENCY CONTRACTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_3883f413-d1e2-4b92-85c9-b975dafac1b0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_01df6f3c-f7a3-4e42-adf9-41830586f46f_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_82534ddd-01b3-4416-ba8f-ad3881559414_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_a95ffd2e-ba16-4123-8ad5-67460a5af759_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_28dec196-7e2c-48e1-8ef0-2dae13af20c8_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_de378970-7f01-4a3a-8e7d-b060cfedfaf1_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64e7cc58-64c3-431e-900a-97c602c90b02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_13b28630-ee45-4f6c-abee-07dee40e38b9_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c3dbde5f-5ecf-4765-a247-9b7257769388_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a2dd63ef-ae34-4a13-a085-7418cd0982e8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fb2f75bb-304d-4cac-b753-9dbea61181b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d7f1dd7-f8a8-4ad9-bab5-f3e105668610_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_31744a9b-34fd-4f95-8e25-0c455fc2cb27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_bdf7a7b2-922b-44b5-b4f5-ff22d989b21e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_a9f06138-37c8-44d9-b398-5a911383926c_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1306028d-6a4a-4c07-97a9-1b353a197932_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9458c437-7386-4247-8dd6-1c6c415b6149_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_88271bb1-3fb1-4b03-8a8f-e94b215e7596_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e54bef66-cb6d-4175-ac1a-eabd298c702f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_8de2126d-9ed3-4e17-89a4-b5bfef7604c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1ba03546-a7fe-4804-b438-13769bcc62db_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_807cf446-6204-4016-a472-4086082dbcdf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7ef9edd7-e363-4345-a1c1-b532c9e3545c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_df8bd815-7d4e-40b9-a9bd-88d47754bb89_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_09ad5d1b-cd57-4f33-8f9e-0f3663072ff0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_52a9921c-f222-4640-b20d-432d704b011a_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f27b16e8-31ae-4997-aeb7-7e06dd192105_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3021a61c-0bc1-4269-ba09-16fe2e54c5fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_6ed453ab-eba7-4183-ac2d-643b1db349c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5f0a64eb-9e7c-4570-a5db-441456f7b300_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bb4b1156-6678-4792-bd05-06bbf1dda619_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_32d68cc3-376f-4abc-a61a-2c693b490f2c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_38bf760b-f681-4dbd-8019-f65d9a6e40a7_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e2c2d66e-cad6-45f8-a63c-17b9c051f86c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_54e848ae-7487-4c3b-b7d6-5bbdde9882b3_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20210402.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5f43f3c9-335b-49d2-adbd-6c49e7e861f1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b9e174db-ce2d-4cca-ad61-939dcf820536_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_bde3ee8a-1b94-4a38-b368-d41d1c6bfc82_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20210402.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2cc4be8f-cefd-48df-a12a-ff0ede1e4e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34b34bc7-b081-4620-a6de-23d1a822433c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_d888d3ef-3ff2-4ad3-a694-02b472e08a75_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20210402.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_da18d1c8-3294-4641-ad71-54c3591201e2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_7c5527b6-d0c6-4a83-b0e9-5ef9789933e1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6029323f-e484-48a0-a156-6e13f90cc668_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_73f8a064-e90d-4123-b838-c6aa2b21ab91_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_5a87caec-0239-4c07-8661-5e7a625e9da7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement maximum amount eligible for development milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Maximum Amount Eligible For Development Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Maximum Amount Eligible For Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_76ef7dd2-7ecc-4f41-a07a-0dd5bb83239c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_845daa1c-1de2-4000-adab-18a515a9499e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c0b93aa-e8d8-45df-bafc-a581fbe0626d_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1fcd83b7-2bee-4d1f-a1e8-c02a3d798f5a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_8abd2f22-f678-44c9-87aa-5f1a4ce2138d_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:href="exel-20210402.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4aba4921-5005-4f37-b975-e057e91865f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_d2e77c6b-6b97-46a3-906f-152ff112aac2_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fc82c841-ba3e-4df3-9824-778ba6893d8f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_7b869147-37c5-49a5-acc8-55a7f97bf884_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments, pretax</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6f5f7ce5-e7a2-414b-9365-e261ac825944_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181d1ba9-1538-41fb-b295-8e08c2117aee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b4cb12cc-88d9-4dd2-9dff-5142f27b2530_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_966875d4-c1ca-4dfa-8e86-0b8ed04ec8b7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_ea704a51-5670-4bc1-850c-5f18ba6bad76_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e8140bcb-433c-44e4-bd2f-3a811ed34447_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_04a70baa-ca6d-4693-a172-7e7298453e11_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4695f69e-17bb-4162-b871-e1a32b6722d6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_121d59ae-3d3a-435f-aeab-87424f05fb17_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember" xlink:href="exel-20210402.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_GlaxoSmithKlineMember_1ee9df49-c7f1-4c1e-b76f-99073c79ce84_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember" xlink:href="exel-20210402.xsd#exel_GlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember" xlink:to="lab_exel_GlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6fd5633-91ee-4397-8f6a-2c5d5f4fd457_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4fb53119-231a-4a9a-8a5d-05421d0c7d89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1c07fd54-1848-4714-b634-8350086bf9b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_23da408c-6249-4693-8fae-a7bb63173b72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e9e2276e-182b-4fc6-80b2-37a6d5d471a8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1be7092-763f-4009-9204-4ed91f6b93e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_554ea019-a3d4-491c-8089-a4e452c47aaf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_789f5eb2-fbe7-4bf3-9aad-d448be76a036_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash short-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5f9d3a7a-5fd5-46b4-89f8-710284718d96_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_07d3ad0f-55d9-433c-8521-70b2b1b94bf2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_96323083-12a5-4290-b5bc-57b00b5f7ea0_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef2fb121-dc44-4f05-9c7a-b450e138c791_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e1fd558-a579-4bd8-8b16-7f4b9f4986ab_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eef8355d-0a24-439a-a3e4-bbe1be85f6eb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_02b4a3c2-6c4b-4030-b406-69997e92a950_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_a2da2cd0-3259-4098-b8be-3a3502d727da_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_011bb8f6-1e44-429a-a019-bbe9beac5d59_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7a400886-537b-4f93-b3aa-04ee3380b30e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_7d6b3c27-ded4-43fb-b859-99322b7c549f_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20210402.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5dfb0051-a64c-404b-8571-386c2a649684_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7d24f6fd-c366-4817-ab50-191d33b140e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7874e07b-172c-4859-b1fe-46293563f571_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b24ef5a1-a0b8-47b5-9a01-9a492c1cf8da_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_f5cf056a-3759-44ff-a601-4c5ba0ea3631_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20210402.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2883d509-125e-465a-87c2-686a4bb298f1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1d8fb681-a997-40ea-bce2-7a2158616853_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8804b5c2-f2f4-41e7-81c7-d9f216a638e3_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7bc8dbeb-1c05-48cf-a3f3-e429d3ff5f2e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e780b4a2-7975-4f63-b575-97e5af1f7ca9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c6c0aed3-92c8-44cf-9684-4f7a5a84117d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81b2c7fc-b14f-49f8-a385-cdde2a50e3c2_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e1f0e245-7cc1-4b12-8d1f-152352d1c1e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2206540c-8116-46e7-882c-4b137678f559_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_36fa416d-af45-425e-8b4b-1221550a3221_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9f497416-00f9-41ce-8bc8-38baf46d80cf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b6824806-2e32-4a4f-b20b-2dbc4e077d34_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cde536db-77fb-425b-8c6e-01b5dbfdb0fb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf39c79e-a358-4824-883e-2e81dd1dbb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_4af91064-b187-4848-9c15-a1184cdb08d0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_35f9f4b0-e2c8-4497-8be1-ca367b44629f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a4de6b7d-842c-4cd0-9136-8c64e4d53a76_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8b78aac-1e06-4129-b3d3-f84b30d9713b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_9adada51-1bbc-44d8-a86b-2ead5ebf5a69_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20210402.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2025a922-6e45-4cc4-9031-4bccb4d43192_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8afd7f1e-5689-4907-9df6-d44d1a0723be_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_57b38deb-d274-497d-9cf9-6ac5f58fd3e6_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_127210f4-65cf-4251-b665-5b67423812a9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a81a44f3-6e46-4a1c-b7c2-86c776d577a1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_e652de5a-3878-40a7-890b-81bfca83828c_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20210402.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6ed81d4b-64e2-44fb-b609-d88846f5853c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 313,262 and 311,627 at March&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_d9b3684e-7fba-497d-86d6-35a2ac3e6a04_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_568d483b-699f-4391-9596-72f58c417e7b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fe001ede-3604-4fa6-8c32-e7bc6ee9f642_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_056cadb8-59eb-4934-a0f2-55df6e2002cf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7fc4339c-d35d-4de2-836b-89b1550c18b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_96015086-239e-4d83-8a83-903851bb48bf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5dee933-11a2-4737-87b8-9f0216bf773a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4aaeb2de-2625-427b-8570-0b3b59589a09_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95281df6-e093-4407-b5fb-9643ea009a36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_33e3da13-c1d4-4108-963d-9df0e06a10c8_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusDomain_b418f55c-761b-4360-9bb8-42c3103e8e73_terseLabel_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_label_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_documentation_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain" xlink:href="exel-20210402.xsd#exel_StatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain" xlink:to="lab_exel_StatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_bd174612-15a6-4b7f-b727-ad961068a61c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8df910d5-f4da-4c5d-a0ba-e1d2d4979f38_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0da41581-ebe5-4589-9055-172691349108_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_6cb35bbb-429d-48b6-a0f2-4ecb4ea2584b_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20210402.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5d266744-c2ef-4aa8-894d-f68dca9c31ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_068b178b-3a93-48a9-a56e-646cc8a850f0_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20210402.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc482657-75c6-45de-988a-4bd14914eb7c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_3c075bb6-e310-444b-b94b-556de1b28d91_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20210402.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_45f40e26-ba88-4c01-86f9-ff3fb64a90e5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_629b1434-a263-4070-abd5-6544ce6211f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a389682c-b488-48d4-838f-a4128925f76a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c6a6189e-521d-40d9-9d1e-dd9334144fdf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS AND IN-LICENSING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_948d0295-11e2-43f1-96ea-1667200bfc40_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_181134e0-7d45-4dfa-9ba2-57b97b869d4e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b78e546-260b-425b-b0c7-f331111534cf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_35ff0099-8626-4068-afb9-643c58780430_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8ea15c0f-de9b-4d0e-8d19-36d256f0bd51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0ec2f06f-8a28-4478-8d9c-3ed652de17b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_2ce49313-c4be-467d-b6b0-0915539ac0a4_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20210402.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_71c81a7a-062a-4b75-a1f7-4548f5e7aa77_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_8d6e43dc-66e7-415b-9114-c3b272b4c0e7_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20210402.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa79fd17-fe07-4b7c-a73a-528b4ed56143_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_47f97309-b6f8-42c3-b8fa-eb66cc2c0d01_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaMember_142e0951-a268-47bb-88e1-b4b5bc9748b5_terseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_exel_TakedaMember_label_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_documentation_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember" xlink:href="exel-20210402.xsd#exel_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember" xlink:to="lab_exel_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3ccf26cb-9e09-49f1-9de5-a3a9b5d53420_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_1740bec3-4844-4660-8c10-0ca80377ff91_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_7f66e0e7-1a22-4d72-bd4b-d42b75e19a3c_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20210402.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f92e100b-f4d4-4dc7-bea0-aa912c6241f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_82f0f637-c05d-43a5-be1e-7ef98ffd6292_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6c5abaf-fdbf-4be3-b56f-e3ccdf53dd3b_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53580c8e-caf8-47d1-bb4a-f0d19dc7c977_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_dc0808b7-89bb-40d6-b94a-9aac33e2187c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2c5071a8-c6dc-4944-b8dd-9a2689d0f660_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7f9b5d05-ad2a-472b-bdef-2c87d70631d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d6394bb2-297e-43a0-b5b0-3e389ad78b94_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_5a144e2c-2cbe-4dce-89ce-65fb22a8727b_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20210402.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e69647c2-288c-4ee9-b213-15c89bb6a658_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20210402.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_81859e4a-0f9b-4020-a1fa-e320295c996c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_787ac4b5-0478-4167-9640-3158a15b36a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_094a9362-cd95-430f-bf43-1669af58a0dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR (BENEFIT FROM) INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_be88cbcd-db2a-46f7-876e-fd38d4abde8f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_17653a29-cc8b-4383-82b4-f3cd5b296334_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Contracts for Non-Designated Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d0f5853b-c009-42f1-bfac-4982a9777a5f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_98c7f92c-41e8-4435-acff-3b01e4ca2bb7_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_45c4137e-1486-4e09-9aa6-e0777c1f232d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c15ee5b-408e-43d2-92df-4232e5907179_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_16bc2d49-fc45-42a7-a6f6-7e76eeab74b4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_8159969e-907e-4b88-807c-7f4524571de8_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c80acc6d-0aba-4490-8ee6-471fb185212c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b3125764-23fb-4eb0-9f1e-8e23a9d031cb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b8a06fc5-fa80-4a93-b985-4a8b8d7acbe5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_30d64df0-9752-4c9f-9a21-772c09eb4581_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_038b661c-9d22-4fcf-9646-99476a1609ad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_f6008fe4-0fd0-4723-99bf-a0fbe46370a7_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20210402.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c18906ba-f046-4f63-ba4f-caa8707e995c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_7c3e35f9-354d-4957-9162-d4c09a907639_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20210402.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_80f1745e-3535-44ed-bb5f-4b2bb8243fd5_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_31a6735b-8635-4290-96c5-0e57468d48a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_773385b7-1101-43ff-b392-aa822cd243f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_f2c966d5-9e9f-422e-a809-2f17331c2cac_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_88eb369c-0abc-4182-b3ce-961faba17eb5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_c21e7003-e944-450c-bba9-016f8fa1c653_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f2067fb0-b110-4711-a7cf-cfacbf03368f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_99f763d1-d62d-416d-a4fa-2c371ffb2709_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_f9f4642a-2aad-49e4-a165-7b2b758ff333_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at March&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_067c6833-5a24-4cd3-87ec-45d5f4465627_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_976b26d3-aec0-4606-96fd-729f707d7d08_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_dbb8062f-27e7-4a11-832b-9f37b7e76f9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_c4bb674c-a2fa-4fb1-b974-ebfa398075e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb341783-c56b-473f-88b3-f229550a4b12_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e35bdeb2-fb1d-4ab9-8993-c1c6d431a9d2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_edf6d1b8-9dc3-4fa1-bf87-6978881449b5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_5dc7baa9-4ad6-497e-a9f4-d6ae8e7cd4c2_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fccd32bb-560a-4919-b082-ad01b8ae326a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d3ab2d67-7b0d-476b-8293-d39be7b101cc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d5a785fe-bd54-420a-9ebc-7b193fe4bd16_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8fd2bc0d-43e4-410d-9034-78bf1d291e6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_29e6d8a8-fa24-4e83-8f5d-d205f3a770e9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3c4bca96-42f0-4cc8-b8cc-6af03c4b4ca9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3feb65ca-debc-4ccd-915c-bae60b2fbee8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fc44014b-12a9-44c6-8094-d5e34194947f_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0bc8c2dd-5b9c-44e3-be31-db789bdf7b8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_9e3e3e6a-8d0a-462d-86b5-859ab9a27c9b_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20210402.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d48ae8b3-7c5f-4075-af82-9f28adb7f218_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_107f5ad9-26e3-4eec-a787-f707ad7435ca_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_10162e94-81a1-4fee-baac-e6c76825497f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_25e85d13-da2c-4795-8de0-6ad202ec7288_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3dee9df6-26f9-417f-9487-d2e2e795ed5b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_887d46ae-f3b0-4c7e-b5ff-c6ac11bb6b35_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_24a925c7-6eb8-4521-9d27-2db6f944a0da_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ca32555f-330f-466d-b53f-78d385eabb2f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_91b34949-7883-488f-9bb0-8ba5055cfd80_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7681767f-0e78-4657-8b8c-a6b36daad097_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_94086320-7da8-48c6-bf55-db40ab59fda9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_c2dee283-781d-45fe-8cdd-759e684081d6_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20210402.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_95bab5e9-66e9-4594-b3d4-f3b9334cf1b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_128270aa-f796-4605-a35b-096f225afc45_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_860870d1-5b09-4a06-bba6-72395f5c618f_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8d3aa30b-8424-45fd-aee1-c303f3f910cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0377c3ec-0e47-4abf-b2fa-38cb20f6db02_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_733cd533-3c09-4aab-a45f-369e19ee9c10_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_efe23730-c6ed-4160-b058-23841113232b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ee8e646a-e2a7-4588-b99f-7bd04c74b5c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on available-for-sale debt securities, net of tax impact of $499 and $941, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a760eb2-6a4c-487e-9652-cff3f34605f7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_107cf0d9-1da6-4512-abad-ad870c4688e5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_2f048b98-c1df-49b4-b71d-425a005065c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on available-for-sale debt securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4dc03de6-f923-4157-8840-619bfc93a0b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_ec8acfcf-bd6e-437f-b218-2a32edfd2c5d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_e056ad44-313b-4677-a9b9-ac8b56cbc8c6_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bddef29c-c4f6-4b3b-a172-46ab6ce5078a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c314f75a-8243-456c-9c5d-0889363fd1c4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_36fea939-6726-4c46-a47c-d26bec228a44_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3bc84539-a4f1-4a28-a5c4-a92cf0685673_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_92f25948-416a-4e6d-a35d-554a07792c04_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_f39eefb4-74c9-4ec5-9581-bf82f0d12a2a_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_0df7d0eb-0ca7-44d0-bc27-57ef86802725_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_0049cecd-5a8a-4f46-8e2f-6bd0a7e010fd_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20210402.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f9cfb689-4c4d-4fb9-b9ce-21e8aca411a9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0447a042-4bb4-4d57-8d37-93f4f7686fe8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ddda521-ab3d-4986-a632-609ed2b2cfca_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_63ec254e-c0ca-4194-9165-ca80ffbf1597_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_98e2936f-346d-4e78-a2fa-6c96c5010102_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusAxis_811d5ab0-9625-4cdb-bb86-545d67d8db6d_terseLabel_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_label_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_documentation_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis" xlink:href="exel-20210402.xsd#exel_StatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis" xlink:to="lab_exel_StatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_f26d7409-b1ae-45bb-be4a-8e14a4c0c71b_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_0d1d02be-93af-4e98-b29a-2a3d9745962f_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_be65f81a-7663-4151-a574-de109bf30c85_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d9aafe14-bd8f-47a3-a002-1be8e7e2cee7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c58a073a-5f05-416c-b2c2-901663db9646_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_998fc20b-8a6b-49e4-bf52-3b461b7262b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_089870e7-c566-4edf-8a0e-f48d75864aa5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_b1dc9949-3c71-42b5-8f45-0ec0e1daa169_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a19deb42-47b5-449f-a40e-4e25810e9767_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de5fd223-3aa4-4daf-a5bd-d8aaceb5e234_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ee93d45a-06b2-4bb7-a839-3d9685f3737a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e8620e4d-1bd4-48c7-a3ed-91744ce2d279_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_45101007-44cf-451b-8625-32e945c85717_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_28430a6c-e850-4865-92ff-318947fb7a0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementWithWuXiBioMember_74e9a852-6820-49f3-a888-f4b9d9d2a1a2_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementWithWuXiBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With WuXi Bio</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithWuXiBioMember_label_en-US" xlink:label="lab_exel_CollaborativeAgreementWithWuXiBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With WuXi Bio [Member]</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithWuXiBioMember_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementWithWuXiBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With WuXi Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithWuXiBioMember" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementWithWuXiBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementWithWuXiBioMember" xlink:to="lab_exel_CollaborativeAgreementWithWuXiBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_04f1859c-a6ba-4781-bd89-9faf0796f06d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_46d6134c-8bd9-4948-9a0e-ca967470f4e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_50e49731-3938-4dbf-ad6e-5e58126b032a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_988434c1-8bd6-4649-ac4a-3409cef656bd_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2114c4c9-352a-41bb-9f87-6b59702e0fa2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a3c163fb-020c-4a52-b4c2-6234d0c69634_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_ac052b0d-1567-48db-890a-cdd7b2b96403_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_d129b88d-b190-4c1f-947e-cc6122c66fda_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_e16c740f-edec-4da1-b064-65523deb1380_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_bb5fb62a-edb0-4008-a065-b4117a288479_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_71546bf2-60e5-466a-9801-5b052b1be1a4_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_e95aab39-5cd5-4792-a216-071553b20d92_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ee803be3-2354-4cdc-8c9e-e7f612a0355e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_97a54937-0ebe-45be-9d5f-793452c6acf5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52fa7508-27b1-4134-987b-a720cf77829d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ceb95fbd-63ac-4c0c-a6b1-f5a48c2bca5e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0b22df89-cb40-4216-876e-4c51e78bc55f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_16410239-f7b0-4399-9b52-e2d716e8907d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1719c1ce-b3db-4882-adf4-fdfd85005227_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_470f0320-6d93-49e4-bbd0-49fbd37cd226_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b80eb55d-a820-4396-9833-3644d1ceb157_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_67691495-a517-4982-acd8-60baf0062121_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fe79347a-6b0b-48a3-ae67-1cedbd57f389_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d47b0a25-8946-4cb7-83fb-02a5fd12445a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a4631061-c4ab-48d3-a19b-52ee4660bd95_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_b45240f2-a9c7-48e1-a38e-7598b071b011_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6114955e-dc57-432a-9935-c3036702756c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_68b5b08b-7473-4c70-9c76-5c04ff8a2077_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_30ce53d8-3e60-4da4-9f2a-9ec5d85e535d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dcdf4ab3-d77a-4d6d-995c-882f0b2625f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_794df445-67f3-47ed-a15d-e0a868288fc5_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a760fd3a-b568-4964-ae72-20383fd85962_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_aa0e4159-3840-4ff0-ba5e-cc7d5860e801_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_44d79e98-ce5c-4506-9a94-2b3de48c1dfe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1dda770d-114f-400b-97e4-2bc628f1e23a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_67aa48d6-c5d5-4f92-b808-44fd38f2abc1_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_label_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementsUpfrontPayments" xlink:to="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_43796e8f-d8ce-4bfa-ae69-6a311c1de4e6_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:href="exel-20210402.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_095a9a33-2a75-444d-b128-fbb4cf5f9e50_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3a726da0-19c5-4539-82dd-5b02eeaf49d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3153222b-ae06-45bb-9316-6990c941f5c8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d596979b-0927-435e-bab3-4b5cb6111811_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_9d5d6a1b-a583-40da-96c0-300f967e6363_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3a635586-a939-4b22-afc3-5a861e195ede_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20210402.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c27146a5-dd93-47c8-ac6f-5db646cf62dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_253998db-5485-414c-a2cb-111a225ebd02_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc5259bc-1725-4ea5-ac88-b9ceb0723477_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f49054c6-fc41-4b85-afa4-573f5c396b2d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_670a87ad-f70b-4575-92fa-e6f388089993_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_734e8339-bdff-4631-aafc-9b71b60856da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0d6431e5-b984-451d-9f28-a63bcc329409_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a63076c7-2e3b-465f-b2f8-8cc64ce5f920_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aaaeb057-6ab5-47df-9f15-4bc5b031db87_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_bdd71293-e712-48b7-b508-3ae5f37b2ef6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6fd49d73-f06e-4e06-a4cc-f48cd7264fc0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_125b36a2-e08a-44f7-bd2a-cd1b3403e12c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7cbc9bfe-d33d-45c8-ae43-0eef7d15ce59_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_eef7c9ea-d091-4c89-8e8b-cec79abe049d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7f8b581b-0e5b-4b03-9b5b-6f4dd509e547_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_625d9e99-2c5f-4b29-927f-14f4623f55b6_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_33aeb574-12d0-47ad-9288-a08e1eb43a27_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_0dbf0d54-9c83-408f-84a7-76f14fdc3673_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_be9a1d2d-8598-440a-9d32-d4a6f5bb40a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_79af805f-e113-4918-b581-e550776e7530_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a39cf903-ca58-4593-9ed6-821e49c056f5_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0bd0f373-d434-4cd1-ad32-53e89ab48b15_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_bc0a47cb-1ed2-492b-9fdd-7445e566733f_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20210402.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_c994d91d-fd8d-4e88-93d9-eef0d4c7ff03_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20210402.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_3cd281b5-df68-434f-ae51-e7c6adf05468_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_29860094-4bee-46e8-bc98-39cdc89e8ac0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_00a25d16-69f9-4fd2-9787-5c06081c84eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e2ccddb3-c07c-45e8-bf01-c61a6b031443_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_94416b7f-ff99-4b01-ab26-817b733772a6_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_ea41279b-b634-4c30-9465-5dcf6a3c0415_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_05dcfe72-41af-488d-b8dc-30ad1158d9f2_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3cc66763-cc77-4249-8635-c75c58e61eb2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_6da35283-fda6-4a51-ba71-d56ed9f3f2c5_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement maximum amount eligible for regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Maximum Amount Eligible For Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Maximum Amount Eligible For Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_24525b89-fba0-410e-9759-30e4100e93c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_0f1d9ade-eb87-4a07-97eb-e115ce95bdd2_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20210402.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26869030-fadb-4800-afee-ae7966c0a296_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8d02b60f-fc3b-468c-a933-c0c05bb1e7d4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7469b559-26d6-4c62-8f94-d1eceb385460_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e6efb867-08c8-4058-a4bd-d504577fc63c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b238b94d-b7cc-4423-811f-3bbbc0b4351a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_2e5acc7d-b5b5-406b-9d81-a7683557be4e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_11f3ae5f-e81b-417f-8a56-807c5ec77a54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86b123e2-279c-42ee-ae12-f8862e0f551f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementWithAdageneMember_d04e77e8-b50d-4edf-9b34-204e459d27b3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementWithAdageneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Adagene</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithAdageneMember_label_en-US" xlink:label="lab_exel_CollaborativeAgreementWithAdageneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Adagene [Member]</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithAdageneMember_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementWithAdageneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Adagene</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithAdageneMember" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementWithAdageneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementWithAdageneMember" xlink:to="lab_exel_CollaborativeAgreementWithAdageneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7ddc7fc-7fab-49f1-a0d6-9ee4ad37dd7d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_0f47bb1c-d7a6-48ef-8638-77ee2bef1d9a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_35a89ec1-062d-4145-a3db-247ad730615b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd90e4df-02e3-49af-bf09-22022ffaba17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_063d1ff3-13e2-41ff-b5fb-26561e4df9bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9a68f770-a78d-4058-bfc2-6946445c7514_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_7b091ce2-bd0d-4415-9ac1-b4b4a37f63e8_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20210402.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c5e24419-721c-4369-9afe-60c0f7e127db_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b749b950-845d-42ef-91d0-a4876ddb91ca_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_333e8509-ed6a-4c67-a1c0-2adabc9f1caa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2c028244-e7e9-4e7f-9b68-eff8e012e5ea_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5d7af390-aab3-4e20-b14d-6e5401f21adc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2f3f775e-176c-4d6b-81fc-3cc0608c0996_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_47c9f56c-fe6e-40e1-881d-a27feab60406_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_10be73b5-ea9c-4520-815b-044b47242137_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_c580339b-55bc-46eb-a8df-1729d3bee49e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a85ab017-1f4d-492f-9605-e75ef90d317d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6e3ab79a-14bc-43fb-ac9c-f8b08ed4374d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_057b8c7f-b406-486e-9642-eb00e67c7407_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28bd1eb5-7c89-40ec-9349-a476c444e960_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1b271824-bba9-46f7-83a0-8896f1f45de2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_731bb33d-f83f-4b1a-98d3-f311819ca96a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d1e86efb-1e04-472e-a047-99b2625f06b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fc9dc0e6-6dea-43f9-9732-9e3d91c02937_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_958d754d-8e07-4a12-9e4b-f7fd0f119f2b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_fe83d948-296c-40da-b03a-997b31c2979d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3b6c7022-40db-4e70-b490-69ee8656478f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1e40b960-255f-45db-a9a7-7b92fd025dc5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_9cde91bb-df9b-49e9-aa3b-3c5ba54a6188_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>exel-20210402_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:84867dad-da96-4e08-a2f6-a31b9b3022af,g:df225ca8-d190-43b7-90ff-2fc6e5818592-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210402.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_faaa6cba-ff64-4660-8361-51a91e1a0ed1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_DocumentType_faaa6cba-ff64-4660-8361-51a91e1a0ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_824306a8-aaae-46eb-91a3-8fca4618dc83" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_DocumentQuarterlyReport_824306a8-aaae-46eb-91a3-8fca4618dc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_04991da7-768e-4362-80fe-d6c18fccf915" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_DocumentPeriodEndDate_04991da7-768e-4362-80fe-d6c18fccf915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_78c94f69-d67b-4e61-b31e-de754a3d3fd1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_DocumentTransitionReport_78c94f69-d67b-4e61-b31e-de754a3d3fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fb3f1148-6dc9-435b-b3d1-494b1b4edf65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityFileNumber_fb3f1148-6dc9-435b-b3d1-494b1b4edf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_84ea682f-8bf0-49e9-91e6-0caa3f2f41fb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityRegistrantName_84ea682f-8bf0-49e9-91e6-0caa3f2f41fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_af4d9607-c86f-48a9-b9bb-bfdee5510a7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityIncorporationStateCountryCode_af4d9607-c86f-48a9-b9bb-bfdee5510a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1562d811-3336-448c-93d0-c23dca5795b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityTaxIdentificationNumber_1562d811-3336-448c-93d0-c23dca5795b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ec0bda39-587f-4ad8-9e9e-6f4b0b2de0c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityAddressAddressLine1_ec0bda39-587f-4ad8-9e9e-6f4b0b2de0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8380764f-5fa0-44c8-8374-02353acfcfb3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityAddressCityOrTown_8380764f-5fa0-44c8-8374-02353acfcfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_99d53660-06d8-4004-aa03-db4df953dfea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityAddressStateOrProvince_99d53660-06d8-4004-aa03-db4df953dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d6b280d5-ffe8-4f05-98c8-37f9b0078165" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityAddressPostalZipCode_d6b280d5-ffe8-4f05-98c8-37f9b0078165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_11cd3dcb-1035-4cd8-83e1-196165f7aee9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_CityAreaCode_11cd3dcb-1035-4cd8-83e1-196165f7aee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_56e41437-3b8d-456b-99bd-4ef5f3c90f97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_LocalPhoneNumber_56e41437-3b8d-456b-99bd-4ef5f3c90f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_28dfded4-c3b3-462c-9722-f2b14fce6935" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_Security12bTitle_28dfded4-c3b3-462c-9722-f2b14fce6935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f46741ac-a5d7-4309-b15e-6db322a5c89c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_TradingSymbol_f46741ac-a5d7-4309-b15e-6db322a5c89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ebc4884a-b7fb-4a4a-80eb-595cb8961578" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_SecurityExchangeName_ebc4884a-b7fb-4a4a-80eb-595cb8961578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_17bafac1-5205-4de6-86bc-775168a1ca8c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityCurrentReportingStatus_17bafac1-5205-4de6-86bc-775168a1ca8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6777e9e8-d0bd-4b33-8960-97a4bd667ed9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityInteractiveDataCurrent_6777e9e8-d0bd-4b33-8960-97a4bd667ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b4221f46-a283-4b0e-ace0-8ec257ed745b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityFilerCategory_b4221f46-a283-4b0e-ace0-8ec257ed745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_46c31878-c8d7-4c44-b421-a2322bc236bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntitySmallBusiness_46c31878-c8d7-4c44-b421-a2322bc236bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_17a47b7e-b58f-4a96-985d-718de630a02a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityEmergingGrowthCompany_17a47b7e-b58f-4a96-985d-718de630a02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_452781d4-7001-4b49-ad68-cc93ea3098c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityShellCompany_452781d4-7001-4b49-ad68-cc93ea3098c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_db35a973-d4e5-43c2-a5f0-4326c325adba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_db35a973-d4e5-43c2-a5f0-4326c325adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c7b70133-b73e-412c-b871-8c72a2ed1db6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_AmendmentFlag_c7b70133-b73e-412c-b871-8c72a2ed1db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b3304e09-1b11-426c-bf29-63b84daca7ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_DocumentFiscalYearFocus_b3304e09-1b11-426c-bf29-63b84daca7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f275de83-62c4-4783-93e4-92cbcb963b15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f275de83-62c4-4783-93e4-92cbcb963b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fadc9693-1a65-4b49-922f-7401e2f8d4af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_EntityCentralIndexKey_fadc9693-1a65-4b49-922f-7401e2f8d4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bd6b6c18-7e32-458e-bfbd-74b0900bddf5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_172bdd71-f821-4b64-8dd8-56af350b67da" xlink:to="loc_dei_CurrentFiscalYearEndDate_bd6b6c18-7e32-458e-bfbd-74b0900bddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fc4df407-475e-40ae-9e82-b7e23fb1036e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc4df407-475e-40ae-9e82-b7e23fb1036e" xlink:to="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb969e1e-4c5f-4960-ba6f-b612b6712e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb969e1e-4c5f-4960-ba6f-b612b6712e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c17bb48a-1203-45c0-9251-d9df151358bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:to="loc_us-gaap_ShortTermInvestments_c17bb48a-1203-45c0-9251-d9df151358bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_4d8e3aad-a8a2-48ec-a4f8-cbb5671e871e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_4d8e3aad-a8a2-48ec-a4f8-cbb5671e871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5487d318-13ce-43f6-9d65-028613236c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:to="loc_us-gaap_InventoryNet_5487d318-13ce-43f6-9d65-028613236c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_57427634-f917-4b7e-9b46-21be4e307ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_57427634-f917-4b7e-9b46-21be4e307ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e158878-738f-488d-aa7c-f35a5b69eb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24d6df90-64b9-45df-85e6-00dd6684856d" xlink:to="loc_us-gaap_AssetsCurrent_0e158878-738f-488d-aa7c-f35a5b69eb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_03b90e30-449f-461f-a468-42f85f84f390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_LongTermInvestments_03b90e30-449f-461f-a468-42f85f84f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0bca4883-4cd9-40bb-ac24-862318b934e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0bca4883-4cd9-40bb-ac24-862318b934e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_23b695d4-e4f2-4fa9-b987-985d6f50abd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_23b695d4-e4f2-4fa9-b987-985d6f50abd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c2323eb9-7475-48d4-9c16-747875001e4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_Goodwill_c2323eb9-7475-48d4-9c16-747875001e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1ef7adb2-ab5d-488f-b3d1-3a29605ac3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1ef7adb2-ab5d-488f-b3d1-3a29605ac3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a6c4c5e-1a66-48d1-af76-7e312c5c5ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9bf5e9d7-55d3-4758-af59-ab2a633eebe7" xlink:to="loc_us-gaap_Assets_0a6c4c5e-1a66-48d1-af76-7e312c5c5ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc4df407-475e-40ae-9e82-b7e23fb1036e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9ac8a0e3-ea44-47ef-86aa-67eeb4de3fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_us-gaap_AccountsPayableCurrent_9ac8a0e3-ea44-47ef-86aa-67eeb4de3fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_055a8e35-5b80-4ed3-90a1-38086e845431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_055a8e35-5b80-4ed3-90a1-38086e845431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_32845a25-821a-47ad-9da3-22d4bd589186" xlink:href="exel-20210402.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_32845a25-821a-47ad-9da3-22d4bd589186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_c6700ca2-2da7-4855-abe6-3da682342640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_c6700ca2-2da7-4855-abe6-3da682342640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_f2ed880c-fc3e-4db9-b6dd-fc566b4d0e1a" xlink:href="exel-20210402.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_f2ed880c-fc3e-4db9-b6dd-fc566b4d0e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_662501ed-f1ee-4fb4-8531-3df557cb89b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_662501ed-f1ee-4fb4-8531-3df557cb89b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cb100ecf-0f2c-46a6-b7eb-2aca07b44d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6556063b-a11f-42cf-bd71-e808dc80a960" xlink:to="loc_us-gaap_LiabilitiesCurrent_cb100ecf-0f2c-46a6-b7eb-2aca07b44d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20c40fbd-1259-40df-9f11-67eaffbd1925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20c40fbd-1259-40df-9f11-67eaffbd1925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1aeb6b00-bf79-4efe-a85d-42bddabe9f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1aeb6b00-bf79-4efe-a85d-42bddabe9f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_03f4aaeb-1198-4472-942b-8fb04bd1375f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_03f4aaeb-1198-4472-942b-8fb04bd1375f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_655029af-a258-47c4-8d80-9919800ed58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_Liabilities_655029af-a258-47c4-8d80-9919800ed58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1ff52e22-7ea3-4ea0-99a7-f715bb67377b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1ff52e22-7ea3-4ea0-99a7-f715bb67377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5f323f48-929a-41d0-886b-775ca2140386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:to="loc_us-gaap_PreferredStockValue_5f323f48-929a-41d0-886b-775ca2140386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_352d9d65-3f12-4890-b572-42afe8a23e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:to="loc_us-gaap_CommonStockValue_352d9d65-3f12-4890-b572-42afe8a23e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0fcb7cd0-7d57-4334-844e-e6cf8e7081bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0fcb7cd0-7d57-4334-844e-e6cf8e7081bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48440467-9baa-4031-b2f2-473c5d9c980f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48440467-9baa-4031-b2f2-473c5d9c980f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f915fa4-b080-4fb6-9cec-06cd12807848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f915fa4-b080-4fb6-9cec-06cd12807848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a7b71a0-bb0a-4be1-85a9-fb671e83bf70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_243295b4-0dd1-47ad-aadb-bb4a77a035ce" xlink:to="loc_us-gaap_StockholdersEquity_1a7b71a0-bb0a-4be1-85a9-fb671e83bf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_365ba4a2-84c6-4fa4-a58a-99b63ca2b470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_486f203a-5006-4eff-a67f-56c9c15d185f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_365ba4a2-84c6-4fa4-a58a-99b63ca2b470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3867e7a8-07a9-4a47-ac57-e3f1c482da51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9de4d8a-ba0c-423b-98c6-f0f3a71424b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3867e7a8-07a9-4a47-ac57-e3f1c482da51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9de4d8a-ba0c-423b-98c6-f0f3a71424b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7a6c9ac8-b893-455f-bfaa-860e70de32a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9de4d8a-ba0c-423b-98c6-f0f3a71424b1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7a6c9ac8-b893-455f-bfaa-860e70de32a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_312aa57a-a1e9-4efa-a693-024270602179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7a6c9ac8-b893-455f-bfaa-860e70de32a1" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_312aa57a-a1e9-4efa-a693-024270602179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d21a184f-7425-4293-99cc-7959d2c31033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_312aa57a-a1e9-4efa-a693-024270602179" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d21a184f-7425-4293-99cc-7959d2c31033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ac03bcef-36b4-4bc4-9583-6b8c3a368fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_312aa57a-a1e9-4efa-a693-024270602179" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ac03bcef-36b4-4bc4-9583-6b8c3a368fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a1474f8c-929e-4218-8b69-820e6f478224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_312aa57a-a1e9-4efa-a693-024270602179" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a1474f8c-929e-4218-8b69-820e6f478224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_da06003d-a172-4ba9-976d-e25ff892dbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7a6c9ac8-b893-455f-bfaa-860e70de32a1" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_da06003d-a172-4ba9-976d-e25ff892dbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a114d68b-4760-4512-ac24-06915aadd84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_da06003d-a172-4ba9-976d-e25ff892dbe7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a114d68b-4760-4512-ac24-06915aadd84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4098b1b6-5cb8-4431-b9db-8b553c487bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_da06003d-a172-4ba9-976d-e25ff892dbe7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4098b1b6-5cb8-4431-b9db-8b553c487bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b9524b39-5e72-45a8-864e-4e958f556b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_da06003d-a172-4ba9-976d-e25ff892dbe7" xlink:to="loc_us-gaap_CommonStockSharesIssued_b9524b39-5e72-45a8-864e-4e958f556b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7c04eae9-4fc8-412b-997f-87bbc31c077a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_da06003d-a172-4ba9-976d-e25ff892dbe7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7c04eae9-4fc8-412b-997f-87bbc31c077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_40f62b45-54c2-40ee-9cbf-d3b33b274dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_40f62b45-54c2-40ee-9cbf-d3b33b274dae" xlink:to="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:to="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_82850b75-0037-4134-8c5a-bc3cce11b263" xlink:to="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_40c96fa2-51fb-4992-982f-6cd5ed42aaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:to="loc_us-gaap_ProductMember_40c96fa2-51fb-4992-982f-6cd5ed42aaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_dd4a0ad6-2c68-45e1-9026-e3ea74c1afcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:to="loc_us-gaap_LicenseMember_dd4a0ad6-2c68-45e1-9026-e3ea74c1afcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2bf985ef-7ee3-4eef-b1c9-98348507a3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e05bc08-8bc3-4301-87eb-13fcdc484a9d" xlink:to="loc_us-gaap_ServiceMember_2bf985ef-7ee3-4eef-b1c9-98348507a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f982c826-fffe-46c7-9059-4267600b6d10" xlink:to="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_911127f2-84b6-4d60-b1a3-dba1ce0bd3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_RevenuesAbstract_911127f2-84b6-4d60-b1a3-dba1ce0bd3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c272557-55e3-4f6d-b4d7-fbda87f7841b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_911127f2-84b6-4d60-b1a3-dba1ce0bd3f4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c272557-55e3-4f6d-b4d7-fbda87f7841b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_252906d4-0922-412c-8c34-253175a48713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_252906d4-0922-412c-8c34-253175a48713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_95aba419-1869-47b8-be87-4f7776fc5d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_95aba419-1869-47b8-be87-4f7776fc5d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_786bce46-31ca-4090-b3ec-b6d4f1421e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_786bce46-31ca-4090-b3ec-b6d4f1421e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9e10f0c1-95fe-4ad0-bd6b-5bc3f9902aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5857a59d-1c88-4485-85f6-cbdee161327e" xlink:to="loc_us-gaap_CostsAndExpenses_9e10f0c1-95fe-4ad0-bd6b-5bc3f9902aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bbee80fa-f5b6-4117-841c-34fdcb892687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_bbee80fa-f5b6-4117-841c-34fdcb892687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_b8639fd0-f336-4b9f-ace6-992c5d524261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_InterestIncomeOther_b8639fd0-f336-4b9f-ace6-992c5d524261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13a65e6e-5513-49c3-aef5-752f99391282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13a65e6e-5513-49c3-aef5-752f99391282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ae1b4ec-7dce-4845-8f3b-f2555fbbd32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ae1b4ec-7dce-4845-8f3b-f2555fbbd32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_64ec8374-1680-47f0-8d5c-5edc7c13cf4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_64ec8374-1680-47f0-8d5c-5edc7c13cf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be1dae87-1054-40e3-a531-84497575c617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_NetIncomeLoss_be1dae87-1054-40e3-a531-84497575c617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a178a92a-9ce4-44ad-9ee1-891ceb67e3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:to="loc_us-gaap_EarningsPerShareBasic_a178a92a-9ce4-44ad-9ee1-891ceb67e3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_defc1483-127b-492d-8cb2-2d1b414ca434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10f04696-f11e-45a5-be57-8cbebbfb63b5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_defc1483-127b-492d-8cb2-2d1b414ca434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3241f066-6779-401f-8296-064035b59e9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_376dae27-2e75-44fc-934d-eed17f4c5710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_376dae27-2e75-44fc-934d-eed17f4c5710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e0dc832-a161-405a-8f5d-c996987b0e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6bf2ce8-7954-411a-9d0a-137f669b62c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e0dc832-a161-405a-8f5d-c996987b0e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e3469a-643d-43f9-8b29-a0078d5e2c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ea7de3c-87d8-4042-a0bf-eda612bd137b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e3469a-643d-43f9-8b29-a0078d5e2c99" xlink:to="loc_us-gaap_NetIncomeLoss_8ea7de3c-87d8-4042-a0bf-eda612bd137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2030fb75-85ae-4a91-a179-5b5522fcf869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e3469a-643d-43f9-8b29-a0078d5e2c99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2030fb75-85ae-4a91-a179-5b5522fcf869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_97237199-c361-407b-88d9-8e7e3909d507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2030fb75-85ae-4a91-a179-5b5522fcf869" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_97237199-c361-407b-88d9-8e7e3909d507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e3f1b76-f4e7-4795-ab74-99642847062f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e3469a-643d-43f9-8b29-a0078d5e2c99" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e3f1b76-f4e7-4795-ab74-99642847062f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f73bef83-0286-400e-965b-f087a8e6a0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96bcfc86-ed90-4277-8d22-f8cebaf3807d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f73bef83-0286-400e-965b-f087a8e6a0eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96bcfc86-ed90-4277-8d22-f8cebaf3807d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e90c8127-510e-4904-90c9-0df4ccbbc619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e90c8127-510e-4904-90c9-0df4ccbbc619" xlink:to="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1ea9ba7-dec8-49f8-8399-40bf8fd24235" xlink:to="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_03dd8cb5-8449-4cf3-8869-1d80757e4041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_CommonStockMember_03dd8cb5-8449-4cf3-8869-1d80757e4041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f8f50dac-2951-4b20-af45-0fc0d152a4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f8f50dac-2951-4b20-af45-0fc0d152a4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1c033901-1486-461b-b614-78b359587a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1c033901-1486-461b-b614-78b359587a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_184b60c8-51b4-44ac-96c6-be6e65cfc0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91fbebb6-bb07-49a7-b92d-68f47d9c156a" xlink:to="loc_us-gaap_RetainedEarningsMember_184b60c8-51b4-44ac-96c6-be6e65cfc0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_be9afe31-f5be-4788-bb38-5ff241a6b55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7ab2be2-aa04-4c43-aec8-d0f8a1658d2c" xlink:to="loc_us-gaap_StatementLineItems_be9afe31-f5be-4788-bb38-5ff241a6b55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_be9afe31-f5be-4788-bb38-5ff241a6b55c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8fbf4292-b431-403e-8af0-631aff0ac347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8fbf4292-b431-403e-8af0-631aff0ac347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_571c3f90-0040-431b-abee-e5a086add5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockholdersEquity_571c3f90-0040-431b-abee-e5a086add5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df8c04e8-cfa4-4717-9afc-7041fb187e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_NetIncomeLoss_df8c04e8-cfa4-4717-9afc-7041fb187e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c8ad6aa3-a821-4dfb-a986-11f62ea450ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c8ad6aa3-a821-4dfb-a986-11f62ea450ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1245f78f-d258-455a-88c8-77b5e46092d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1245f78f-d258-455a-88c8-77b5e46092d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2085c712-84cd-4a06-8ae2-4994223add00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2085c712-84cd-4a06-8ae2-4994223add00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85006369-be1f-4ccd-b66d-fb85eb97b4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85006369-be1f-4ccd-b66d-fb85eb97b4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d09287c3-bc35-4d62-9d41-fb03ce8f1647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d09287c3-bc35-4d62-9d41-fb03ce8f1647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56797cbe-1040-494a-a36f-1e20a1a274f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56797cbe-1040-494a-a36f-1e20a1a274f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49bdf1d1-c7b3-466c-8d29-a9ad0d837c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4abc1db-5798-40d7-8285-646ce77099a7" xlink:to="loc_us-gaap_StockholdersEquity_49bdf1d1-c7b3-466c-8d29-a9ad0d837c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210402.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dfda7df5-61a3-45d9-97f4-32015a60ca00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_NetIncomeLoss_dfda7df5-61a3-45d9-97f4-32015a60ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4d13df67-51a4-476c-ab2b-14ecaae503e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4d13df67-51a4-476c-ab2b-14ecaae503e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5a7bc60f-459c-40c8-b69b-2209060c61ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:to="loc_us-gaap_ShareBasedCompensation_5a7bc60f-459c-40c8-b69b-2209060c61ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_a32ce445-fa68-4bc6-93f1-48da84a1d67e" xlink:href="exel-20210402.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:to="loc_exel_NoncashLeaseExpense_a32ce445-fa68-4bc6-93f1-48da84a1d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7b5dc3ca-bc00-4c16-96ec-7e58451fdd1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7b5dc3ca-bc00-4c16-96ec-7e58451fdd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_22478987-4dd0-4b25-bde3-59943ce714f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_22478987-4dd0-4b25-bde3-59943ce714f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a3119786-63df-42a1-b764-7315985fa4d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de64accc-2f70-4e03-bdda-e9a2c67ecaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de64accc-2f70-4e03-bdda-e9a2c67ecaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c0ece7ca-aa74-4fa3-b57c-aaf715e059f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c0ece7ca-aa74-4fa3-b57c-aaf715e059f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3b7a871-be4d-492c-a3f8-5b7cc5625c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3b7a871-be4d-492c-a3f8-5b7cc5625c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8648ae2c-d104-438a-b220-a212a0738774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8648ae2c-d104-438a-b220-a212a0738774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7f3c4a5b-aa78-4468-9fab-61cdc4755756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9701552e-8f05-4b8f-ac0f-3862f36e4eae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7f3c4a5b-aa78-4468-9fab-61cdc4755756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac347d67-f0a9-4bc6-8bf6-86f7c18fbc09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac347d67-f0a9-4bc6-8bf6-86f7c18fbc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b887bb52-9147-47a0-b832-4ec0a4674292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b887bb52-9147-47a0-b832-4ec0a4674292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_61b2d1fd-221a-4558-b1fc-4220a10a57da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b887bb52-9147-47a0-b832-4ec0a4674292" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_61b2d1fd-221a-4558-b1fc-4220a10a57da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_3469ce89-0a1d-4284-a0a3-a2f1c182fae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b887bb52-9147-47a0-b832-4ec0a4674292" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_3469ce89-0a1d-4284-a0a3-a2f1c182fae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0ce7cbcc-5261-4928-a5b7-dbfe80af0d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b887bb52-9147-47a0-b832-4ec0a4674292" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0ce7cbcc-5261-4928-a5b7-dbfe80af0d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d8f01a8-92e9-45c9-9773-00a130f3d0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b887bb52-9147-47a0-b832-4ec0a4674292" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d8f01a8-92e9-45c9-9773-00a130f3d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48c4bd40-bac3-4734-9c28-901d5c32c562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48c4bd40-bac3-4734-9c28-901d5c32c562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_294a75f8-f8ef-4b58-a435-5a41f9890e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48c4bd40-bac3-4734-9c28-901d5c32c562" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_294a75f8-f8ef-4b58-a435-5a41f9890e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_96f67292-a0e2-45fe-bb61-658e98f19a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48c4bd40-bac3-4734-9c28-901d5c32c562" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_96f67292-a0e2-45fe-bb61-658e98f19a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_311b547c-4962-4b49-963d-e74f9b44fd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48c4bd40-bac3-4734-9c28-901d5c32c562" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_311b547c-4962-4b49-963d-e74f9b44fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78530a68-ccf8-4b59-b343-964e7851cabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78530a68-ccf8-4b59-b343-964e7851cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8351637a-b49c-4992-aa91-c18bbd7e62fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8351637a-b49c-4992-aa91-c18bbd7e62fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73553fbe-12cc-42c9-9e72-ebe777848ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73553fbe-12cc-42c9-9e72-ebe777848ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f7de3e2-dfde-4689-a597-9e87b017aa5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c563a16-54de-4d1c-ae70-e8f1535510d2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f7de3e2-dfde-4689-a597-9e87b017aa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_cc71e028-ac7e-46c3-ab2b-889b073cd07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f7de3e2-dfde-4689-a597-9e87b017aa5f" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_cc71e028-ac7e-46c3-ab2b-889b073cd07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_369e5e52-4f77-4a72-bf44-0500f2de2162" xlink:href="exel-20210402.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_cc71e028-ac7e-46c3-ab2b-889b073cd07e" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_369e5e52-4f77-4a72-bf44-0500f2de2162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad934952-d1b5-4c4b-abcd-6038d5de7c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_001ade84-c764-478c-b8c6-168f78635767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad934952-d1b5-4c4b-abcd-6038d5de7c3c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_001ade84-c764-478c-b8c6-168f78635767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8241aee1-9aaa-4b96-a0e8-fde5437e5ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8241aee1-9aaa-4b96-a0e8-fde5437e5ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_555acb1f-e6ec-4084-8cc1-97d8924fb2c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_555acb1f-e6ec-4084-8cc1-97d8924fb2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_9ae5f687-b7f3-4d04-8205-41d1a1a3b0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_FiscalPeriod_9ae5f687-b7f3-4d04-8205-41d1a1a3b0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e291a269-b7ec-4562-a216-730c6e1408fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e291a269-b7ec-4562-a216-730c6e1408fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c4846d41-caf5-40d9-a75b-5bdeb1d80710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_UseOfEstimates_c4846d41-caf5-40d9-a75b-5bdeb1d80710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_75a3dcb5-de21-42c1-9acb-138f0f63f63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_75a3dcb5-de21-42c1-9acb-138f0f63f63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6b0c44f9-17a8-416c-a0cf-f84a6f6487fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_6b0c44f9-17a8-416c-a0cf-f84a6f6487fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8428b7db-aa50-4677-a553-fedc3dd72324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8428b7db-aa50-4677-a553-fedc3dd72324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4171eb11-36bd-4329-8d70-c82ef5094ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ac10f3-47b6-4b1c-8a90-730b761c6774" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4171eb11-36bd-4329-8d70-c82ef5094ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876776c4-131c-4df0-ba6c-d172d7cf7b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:href="exel-20210402.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876776c4-131c-4df0-ba6c-d172d7cf7b9a" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:to="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f2fa3d40-3fbf-4242-af4c-bc7631790846" xlink:to="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_7892cf29-6e95-44cc-a241-896cd4abf3dd" xlink:href="exel-20210402.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_7892cf29-6e95-44cc-a241-896cd4abf3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_8497a651-c167-4e6a-968f-814207336103" xlink:href="exel-20210402.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_8497a651-c167-4e6a-968f-814207336103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_8e79fa7a-b1b9-4e8c-b108-b3e75c7d573e" xlink:href="exel-20210402.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e15f2c2-5162-4e2d-a549-ffd60f3d59e5" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_8e79fa7a-b1b9-4e8c-b108-b3e75c7d573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:href="exel-20210402.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9f115010-b1c6-4f9d-9510-92dfc2493cd8" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_f799e067-1525-4f8f-ae86-1ac7bfc3d70b" xlink:href="exel-20210402.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:to="loc_exel_NumberofProductsinCommercialMarket_f799e067-1525-4f8f-ae86-1ac7bfc3d70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cf8b9e46-1c35-4f60-a5ae-ec91a88898ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b5b4945c-15ae-44e8-b2c7-6eac41e2481b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cf8b9e46-1c35-4f60-a5ae-ec91a88898ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210402.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6a3d13c-d3cc-426e-9ded-172bf0626678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_efd14974-c9e2-4b8f-bbb1-324aff84dd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6a3d13c-d3cc-426e-9ded-172bf0626678" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_efd14974-c9e2-4b8f-bbb1-324aff84dd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e43a1777-5d54-4bc7-9949-de97c12eeba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_56193569-bec3-4115-9fb8-f783917b1a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e43a1777-5d54-4bc7-9949-de97c12eeba6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_56193569-bec3-4115-9fb8-f783917b1a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a97f8752-529a-4843-a0e1-86965a78276f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e43a1777-5d54-4bc7-9949-de97c12eeba6" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a97f8752-529a-4843-a0e1-86965a78276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_8bbe2c93-3c34-46eb-9bf1-8c0be6c92c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e43a1777-5d54-4bc7-9949-de97c12eeba6" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_8bbe2c93-3c34-46eb-9bf1-8c0be6c92c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_b8f6b863-95e9-4c34-8785-3fc275f49b2b" xlink:href="exel-20210402.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e43a1777-5d54-4bc7-9949-de97c12eeba6" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_b8f6b863-95e9-4c34-8785-3fc275f49b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ace1e5de-a893-4890-8d54-877e776b0df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e43a1777-5d54-4bc7-9949-de97c12eeba6" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ace1e5de-a893-4890-8d54-877e776b0df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e66d832-1501-47f5-96a8-3e3f3766669c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e66d832-1501-47f5-96a8-3e3f3766669c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:to="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e2e41810-3d1b-48c7-b56f-88b4d1827eab" xlink:to="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_0774c287-7283-4a42-9182-f1068c99031e" xlink:href="exel-20210402.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_exel_ProductGrossMember_0774c287-7283-4a42-9182-f1068c99031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_bc821888-0231-42d4-ab8f-9f9fe5f62b5c" xlink:href="exel-20210402.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_bc821888-0231-42d4-ab8f-9f9fe5f62b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_15eb0280-f07b-4356-b327-2005933e8286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_us-gaap_ProductMember_15eb0280-f07b-4356-b327-2005933e8286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3ddb75db-cd0e-4e23-b9a0-eca6fe269f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_us-gaap_LicenseMember_3ddb75db-cd0e-4e23-b9a0-eca6fe269f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9887070d-1b2c-457e-9969-b0d201fef916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_us-gaap_ServiceMember_9887070d-1b2c-457e-9969-b0d201fef916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_8194174a-ec0e-4519-a020-56c2c8816d11" xlink:href="exel-20210402.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739b9f83-f04f-4dde-a44f-453c54126524" xlink:to="loc_exel_CollaborationMember_8194174a-ec0e-4519-a020-56c2c8816d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2eb86a55-a47c-4415-b6eb-1d8dc24b15f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_247a8e39-54cf-4292-a8c2-9c12d6ff272a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2eb86a55-a47c-4415-b6eb-1d8dc24b15f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c324b7d1-6a89-483a-ab11-d62208bb0091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2eb86a55-a47c-4415-b6eb-1d8dc24b15f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c324b7d1-6a89-483a-ab11-d62208bb0091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b48c0e0a-d2a7-4e83-aaeb-a5aff52613a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b48c0e0a-d2a7-4e83-aaeb-a5aff52613a1" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b65255cd-f5a8-40a1-b448-2177705488d5" xlink:to="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_91ff67a2-47a5-4fec-b258-b8a972895f9d" xlink:href="exel-20210402.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_91ff67a2-47a5-4fec-b258-b8a972895f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0652357d-ede9-4a39-8636-d5ec0843095b" xlink:href="exel-20210402.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0652357d-ede9-4a39-8636-d5ec0843095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_6b72ca0c-b6c2-46c4-ac19-3fc33aebcea2" xlink:href="exel-20210402.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_6b72ca0c-b6c2-46c4-ac19-3fc33aebcea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_f7c62b59-a8c3-4bde-8615-ea118547d6df" xlink:href="exel-20210402.xsd#exel_IpsenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_IpsenMember_f7c62b59-a8c3-4bde-8615-ea118547d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_e634a93d-c379-4e8a-bbab-f25d9e4b1aca" xlink:href="exel-20210402.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_e634a93d-c379-4e8a-bbab-f25d9e4b1aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_52d32c97-dc8f-4eb2-a18a-6480700c22e7" xlink:href="exel-20210402.xsd#exel_TakedaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eeb8d5dc-842b-447c-b9c8-13387a015f92" xlink:to="loc_exel_TakedaMember_52d32c97-dc8f-4eb2-a18a-6480700c22e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4df9d581-0e74-4274-aa23-6c90422ab5db" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dfcfe7cf-4900-436e-91c0-032931495c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dfcfe7cf-4900-436e-91c0-032931495c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3c54de27-2011-49d4-a0a1-8bb812248d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b1561d9-72be-4824-87c9-c7c1de77b9ab" xlink:to="loc_us-gaap_AccountsReceivableMember_3c54de27-2011-49d4-a0a1-8bb812248d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_da4e2209-aba7-4b34-bce6-e4afe67ccbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a437ce13-4220-4b23-b794-4a6a9a45773b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_da4e2209-aba7-4b34-bce6-e4afe67ccbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_629ed300-da04-4acf-a1c3-56ea25374124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_da4e2209-aba7-4b34-bce6-e4afe67ccbee" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_629ed300-da04-4acf-a1c3-56ea25374124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_abeae467-84cd-4dea-8d70-105a17f6e76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8dd6e042-4253-4f6b-aa7c-35700b621a67" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_abeae467-84cd-4dea-8d70-105a17f6e76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a3f31024-6d87-48f1-997d-c9a8524998cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_abeae467-84cd-4dea-8d70-105a17f6e76c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a3f31024-6d87-48f1-997d-c9a8524998cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_becadcc5-32e7-49f8-be64-e04469bb7529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_becadcc5-32e7-49f8-be64-e04469bb7529" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:to="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d369f74e-3ce6-4ef2-9931-a08ea3bb0872" xlink:to="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6393574a-45b7-48a4-8653-61d253f405af" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:to="loc_country_US_6393574a-45b7-48a4-8653-61d253f405af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_33509f69-0d0c-45d7-838b-c98c81dcba40" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:to="loc_srt_EuropeMember_33509f69-0d0c-45d7-838b-c98c81dcba40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_a7b0d6cc-fe12-4940-aa2c-ee4e9aafdf80" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_53bea7c9-1c9f-4342-8648-7c85699f7818" xlink:to="loc_country_JP_a7b0d6cc-fe12-4940-aa2c-ee4e9aafdf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_11e83cbd-e86c-4185-b3a1-209688b3e618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9f208bec-70dc-4f06-a4f8-e137da0b1712" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_11e83cbd-e86c-4185-b3a1-209688b3e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb54d41c-c8a8-48c1-ac62-8671e6d2ea4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_11e83cbd-e86c-4185-b3a1-209688b3e618" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb54d41c-c8a8-48c1-ac62-8671e6d2ea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_227f0590-2d70-4d70-a1ad-8b1b7a1a268a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_227f0590-2d70-4d70-a1ad-8b1b7a1a268a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:to="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_446860dd-16a4-4467-b498-74d7408792a6" xlink:to="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_1ad12eba-6f11-4446-8184-b3feae04482c" xlink:href="exel-20210402.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:to="loc_exel_CabometyxMember_1ad12eba-6f11-4446-8184-b3feae04482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_04452d88-edd6-46da-903c-2a263f5ee3b5" xlink:href="exel-20210402.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:to="loc_exel_CometriqMember_04452d88-edd6-46da-903c-2a263f5ee3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2fe1b9fd-5658-4ffa-b344-8fe23a26d6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aec1da4e-c502-4089-9080-0447aed195ca" xlink:to="loc_us-gaap_ProductMember_2fe1b9fd-5658-4ffa-b344-8fe23a26d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_687f3fdc-f2c7-488f-adf7-521244168e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9d6b45e6-1b4e-4d99-abb3-d96173ed7ff6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_687f3fdc-f2c7-488f-adf7-521244168e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44a9b80a-1b28-4caf-b50b-aa0ad5277438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_687f3fdc-f2c7-488f-adf7-521244168e00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44a9b80a-1b28-4caf-b50b-aa0ad5277438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_331bb4d1-2140-4fac-b1fa-6014c03fe01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_331bb4d1-2140-4fac-b1fa-6014c03fe01b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b1bb8cdc-0bf2-4fc2-b62d-febd1f601e9d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7baffade-7717-4367-aba7-6dc520c95e22" xlink:href="exel-20210402.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7baffade-7717-4367-aba7-6dc520c95e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a349107e-be5f-476e-8e78-7aec57a12e0d" xlink:href="exel-20210402.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a349107e-be5f-476e-8e78-7aec57a12e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_9ad6e22d-cf8e-4318-9ac6-2aea30ead34b" xlink:href="exel-20210402.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0108ecdb-2e04-4343-9a8f-a605c0800ba7" xlink:to="loc_exel_AllowanceForProductRebatesMember_9ad6e22d-cf8e-4318-9ac6-2aea30ead34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e53fd0d0-2ed4-4f43-b903-6fc9cca6cbc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_afc50e3b-b27b-4746-9da6-585d07840e36" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e53fd0d0-2ed4-4f43-b903-6fc9cca6cbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e53fd0d0-2ed4-4f43-b903-6fc9cca6cbc0" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_792f63e2-2c94-4cde-b2e7-cf53e1fe2567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_792f63e2-2c94-4cde-b2e7-cf53e1fe2567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_de7b2635-3c38-4de6-b675-868d2a899ebc" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_de7b2635-3c38-4de6-b675-868d2a899ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_6e549c5c-e7f0-41f0-92fe-77c2afac901b" xlink:href="exel-20210402.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_a92355fa-63de-4f10-8f31-419b7e0b6ac6" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_6e549c5c-e7f0-41f0-92fe-77c2afac901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_685ddb5f-5f12-4e7b-9fac-fde7e493b6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_685ddb5f-5f12-4e7b-9fac-fde7e493b6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b362eb2e-694e-4aca-b0d8-d88320d609df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_51c783a8-2b43-4573-b743-7cd7b8120228" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b362eb2e-694e-4aca-b0d8-d88320d609df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_4b5a13d3-6005-485d-b038-ba6775395777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_4b5a13d3-6005-485d-b038-ba6775395777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_157a0f29-05ea-4353-8aff-41c397832451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_157a0f29-05ea-4353-8aff-41c397832451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d6c1fcb-4c71-4b58-98d1-a687f6902f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d6c1fcb-4c71-4b58-98d1-a687f6902f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c8e17972-151b-4eda-a182-e92295996c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c8e17972-151b-4eda-a182-e92295996c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_07004dfb-8756-47ca-8f76-7d9a39afa053" xlink:href="exel-20210402.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_07004dfb-8756-47ca-8f76-7d9a39afa053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_11f788f5-70b3-4c17-af6c-203d1b0aeb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_11f788f5-70b3-4c17-af6c-203d1b0aeb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_9e792875-1fe9-42d2-b985-30dfe4abd03f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4718dba-4f62-4ffb-bf4e-82acb535ab7a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_9e792875-1fe9-42d2-b985-30dfe4abd03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a070bd9f-0a9a-4bf6-bad4-6984e0fe9d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7d6c838c-cae6-436c-9b1c-b827d3056ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a070bd9f-0a9a-4bf6-bad4-6984e0fe9d77" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7d6c838c-cae6-436c-9b1c-b827d3056ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3604554-b69d-4728-811e-4cfb45a135a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0c2f441b-a7dd-4842-a6a0-01f203183ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3604554-b69d-4728-811e-4cfb45a135a1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0c2f441b-a7dd-4842-a6a0-01f203183ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_644f7f80-09cd-4d9a-a073-8ee8c71afeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_644f7f80-09cd-4d9a-a073-8ee8c71afeb0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:to="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d48c671a-6fce-4196-900a-e152c6bc57b8" xlink:to="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_faf4d425-8352-4bf1-8bdb-5a7b71871489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:to="loc_us-gaap_LicenseMember_faf4d425-8352-4bf1-8bdb-5a7b71871489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_56886e30-e077-40ad-a709-10fc771ef6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1957817a-6ca5-4a22-82f1-df600d031d98" xlink:to="loc_us-gaap_ServiceMember_56886e30-e077-40ad-a709-10fc771ef6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc0b9c0-df99-4292-8349-2348c2719752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52b0db55-e45d-41ab-b9a1-841cd381753a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc0b9c0-df99-4292-8349-2348c2719752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_40fc7aa7-aaae-4740-b519-bffb20be68ed" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc0b9c0-df99-4292-8349-2348c2719752" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_40fc7aa7-aaae-4740-b519-bffb20be68ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_258a931a-da92-4cdc-b4e0-340fdcd01596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d00eba9-c153-4a5e-94f9-b115376295cb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_258a931a-da92-4cdc-b4e0-340fdcd01596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7d411fa3-a436-4208-97d9-9c70e15e8ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_258a931a-da92-4cdc-b4e0-340fdcd01596" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7d411fa3-a436-4208-97d9-9c70e15e8ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c1fb9080-2d57-4869-9029-0cbf849518f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c1fb9080-2d57-4869-9029-0cbf849518f4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98d7fa66-8c0c-426f-b26f-b8ae0ae3023d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_089331e3-0a00-4783-aa04-d7bdd46e91fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98d7fa66-8c0c-426f-b26f-b8ae0ae3023d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_54ef9f4c-3fa6-4182-8da1-a01e981c2aa0" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98d7fa66-8c0c-426f-b26f-b8ae0ae3023d" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_54ef9f4c-3fa6-4182-8da1-a01e981c2aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_788f5401-ffc5-4440-a72b-af3ffa6c88b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_824335d7-1feb-442f-acf1-ce79e8e4b2f5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_788f5401-ffc5-4440-a72b-af3ffa6c88b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6df8afdc-501c-4368-b624-bf1bf8279744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_788f5401-ffc5-4440-a72b-af3ffa6c88b4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6df8afdc-501c-4368-b624-bf1bf8279744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f90130-5e3b-49ee-99e4-819b96e6739c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78f90130-5e3b-49ee-99e4-819b96e6739c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:to="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6891bf85-b0f1-4299-bcc3-ce42d96a7f46" xlink:to="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_fb7720d1-136d-46c8-b2ca-bc1a5f12223d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:to="loc_us-gaap_LicenseMember_fb7720d1-136d-46c8-b2ca-bc1a5f12223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1a02df98-f0a0-48a9-ba57-94c3ff0c863f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_586bc641-93b3-4485-977e-b22b0382c0ce" xlink:to="loc_us-gaap_ServiceMember_1a02df98-f0a0-48a9-ba57-94c3ff0c863f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d5130d4-59a4-4f2b-8777-20be1ae5012c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91168aba-936b-4cde-884d-1745c07d0260" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d5130d4-59a4-4f2b-8777-20be1ae5012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_210fe078-d4b6-4023-8910-858b2c89681a" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d5130d4-59a4-4f2b-8777-20be1ae5012c" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_210fe078-d4b6-4023-8910-858b2c89681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74d4c550-93df-45bf-8359-f9a60df6ed47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_34381092-02f8-429b-8620-1421d5bd8ea7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74d4c550-93df-45bf-8359-f9a60df6ed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee1d3d1b-a7ef-4b0e-b860-ca0cd3c3a73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74d4c550-93df-45bf-8359-f9a60df6ed47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee1d3d1b-a7ef-4b0e-b860-ca0cd3c3a73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_afdf9576-7a60-4476-b56b-3e4a061a8a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_afdf9576-7a60-4476-b56b-3e4a061a8a82" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9a4f0ac-c285-4bac-9cd1-b97d2aecd887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a10e20b-49a4-401f-9304-8f6128265af9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9a4f0ac-c285-4bac-9cd1-b97d2aecd887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_ab0b1dc7-7ff2-4223-9487-78572a87a745" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9a4f0ac-c285-4bac-9cd1-b97d2aecd887" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_ab0b1dc7-7ff2-4223-9487-78572a87a745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb374aac-4318-46fc-bb3d-8c97a9d3c135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a7663ae-0c4b-453f-8787-b9235baed37c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb374aac-4318-46fc-bb3d-8c97a9d3c135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_536ec375-9a7e-4ec6-8dc4-e57f9081cb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb374aac-4318-46fc-bb3d-8c97a9d3c135" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_536ec375-9a7e-4ec6-8dc4-e57f9081cb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ada30a30-fef5-4281-bc9a-016765abc54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ada30a30-fef5-4281-bc9a-016765abc54b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:to="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_840c026f-c3e2-4db0-ba56-449630261114" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_54a0bfe5-8d38-402f-869a-ae587de58a2d" xlink:to="loc_srt_NameOfMajorCustomerDomain_840c026f-c3e2-4db0-ba56-449630261114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_903b687d-5192-4d2c-be3a-57f86aa1d05a" xlink:href="exel-20210402.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_840c026f-c3e2-4db0-ba56-449630261114" xlink:to="loc_exel_GlaxoSmithKlineMember_903b687d-5192-4d2c-be3a-57f86aa1d05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eead4279-e83d-4b1c-9fd2-185cde22b14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8aacf83b-aa8f-4ba1-8eac-7f321c218280" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eead4279-e83d-4b1c-9fd2-185cde22b14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_e98a5a5f-f789-4daa-b369-06cdfdad833e" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eead4279-e83d-4b1c-9fd2-185cde22b14c" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_e98a5a5f-f789-4daa-b369-06cdfdad833e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f7fc212-6390-4026-a31f-4425a7ca2b03" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_fc449fdb-d964-42ce-b254-72b3623a96f1" xlink:href="exel-20210402.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_fc449fdb-d964-42ce-b254-72b3623a96f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1616fa0a-8b98-4a45-b923-2a856383e8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b008064-56e3-4186-9d11-74b7b04300cc" xlink:to="loc_us-gaap_RoyaltyExpense_1616fa0a-8b98-4a45-b923-2a856383e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12c1c71c-b3db-4403-a16a-2fdae55b30d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12c1c71c-b3db-4403-a16a-2fdae55b30d4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c0dba2-3120-4fc2-b7b5-15f1e7d38d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c9e3135-f107-402d-aa68-92a2da242a2d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c0dba2-3120-4fc2-b7b5-15f1e7d38d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_1c44d8f9-4e09-44ae-ab4b-76d4bede25be" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c0dba2-3120-4fc2-b7b5-15f1e7d38d08" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_1c44d8f9-4e09-44ae-ab4b-76d4bede25be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae7cc7e0-b3f1-4c62-a0c7-835edc6d2b73" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_df6742b2-f467-450f-9643-112a1a2d2aba" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_df6742b2-f467-450f-9643-112a1a2d2aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9ef3b0d-55e8-438e-93a4-acda93da3a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53e80edd-d094-43a8-9e65-81a89ca9f21f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9ef3b0d-55e8-438e-93a4-acda93da3a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd4fd62e-ae6b-4021-b221-bf53acafed82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd4fd62e-ae6b-4021-b221-bf53acafed82" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff844c88-685a-4180-818f-b0a79f0bf7d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithAdageneMember_ba8a058a-4a62-4f53-9f4b-3c98eb5c78dd" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementWithAdageneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:to="loc_exel_CollaborativeAgreementWithAdageneMember_ba8a058a-4a62-4f53-9f4b-3c98eb5c78dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithWuXiBioMember_3b1fd4c1-c911-4e39-b655-c2aaff85c89c" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementWithWuXiBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2cf2076-5b25-4c69-813a-edad1441baf5" xlink:to="loc_exel_CollaborativeAgreementWithWuXiBioMember_3b1fd4c1-c911-4e39-b655-c2aaff85c89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7153863-eb33-4f76-bdcf-9dce866bd39a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_5cdd6bfe-8475-4bdf-9289-466edd89a4a1" xlink:href="exel-20210402.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_5cdd6bfe-8475-4bdf-9289-466edd89a4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_799f419f-b751-44c2-ab43-183ec4d7fbe1" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones_799f419f-b751-44c2-ab43-183ec4d7fbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_9ff68fe5-95b0-40aa-8710-5046c0e5a666" xlink:href="exel-20210402.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones_9ff68fe5-95b0-40aa-8710-5046c0e5a666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_58a268fb-c9e1-471f-a403-35bceba63bee" xlink:href="exel-20210402.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7aff8e10-bbec-4858-a8fd-bfafcd7a5452" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_58a268fb-c9e1-471f-a403-35bceba63bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1735df04-d28e-4de3-976d-c5fb6aa597c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_7fc236f2-b3da-4642-8498-f2dfde9d5b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1735df04-d28e-4de3-976d-c5fb6aa597c1" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_7fc236f2-b3da-4642-8498-f2dfde9d5b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d679f88e-e58f-4ef1-981e-896e47fff87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_177c07f2-f891-485a-a5e9-fd0bc4176b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d679f88e-e58f-4ef1-981e-896e47fff87a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_177c07f2-f891-485a-a5e9-fd0bc4176b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_711fb3b8-f628-4462-afe7-5842db36edbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d679f88e-e58f-4ef1-981e-896e47fff87a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_711fb3b8-f628-4462-afe7-5842db36edbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_f6edf1cf-0e39-429b-bf59-a07c15a9324a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d679f88e-e58f-4ef1-981e-896e47fff87a" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_f6edf1cf-0e39-429b-bf59-a07c15a9324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_33be8323-82cd-4d39-a366-08204eccf219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d679f88e-e58f-4ef1-981e-896e47fff87a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_33be8323-82cd-4d39-a366-08204eccf219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_43c777c5-8544-4859-b19e-477cff74c5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d679f88e-e58f-4ef1-981e-896e47fff87a" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_43c777c5-8544-4859-b19e-477cff74c5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59df51cd-bde6-4957-aa80-efc329fa134c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_1b96f900-833b-4e98-9fc9-41d51d7d3b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59df51cd-bde6-4957-aa80-efc329fa134c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_1b96f900-833b-4e98-9fc9-41d51d7d3b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84f1fda1-7494-4640-8092-36eb876396f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1b96f900-833b-4e98-9fc9-41d51d7d3b89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84f1fda1-7494-4640-8092-36eb876396f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_a937fe51-8d0e-4de0-8e77-5226a21d0911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1b96f900-833b-4e98-9fc9-41d51d7d3b89" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_a937fe51-8d0e-4de0-8e77-5226a21d0911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_729a9c9f-25ca-4429-bf5f-5577fd5d45bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1b96f900-833b-4e98-9fc9-41d51d7d3b89" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_729a9c9f-25ca-4429-bf5f-5577fd5d45bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d72344bc-5c03-40c3-8128-40adc5934a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d72344bc-5c03-40c3-8128-40adc5934a1e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_758723ca-81eb-45e1-b1ba-972188968beb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2b46a9bd-f454-4577-97ff-cea2269170ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CommercialPaperMember_2b46a9bd-f454-4577-97ff-cea2269170ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af5f2cdd-f101-4d56-ab72-3616ae01494b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af5f2cdd-f101-4d56-ab72-3616ae01494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_28d9f632-b461-4c6a-b6fb-d1f200a3e0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_28d9f632-b461-4c6a-b6fb-d1f200a3e0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c82e9fa5-53b1-4210-902b-753b9d13da89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_MunicipalBondsMember_c82e9fa5-53b1-4210-902b-753b9d13da89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_df43b3ef-34ef-489c-9227-b8f614081b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CashMember_df43b3ef-34ef-489c-9227-b8f614081b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4af78c0d-0bac-4f51-b56a-a98395771261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4af78c0d-0bac-4f51-b56a-a98395771261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e6b9f6d9-66cf-4223-81b5-57ed7acba656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_566b4588-e127-4780-a636-93beca8c46ba" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e6b9f6d9-66cf-4223-81b5-57ed7acba656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a90f0ba-ef24-4f03-bbb5-00eed069cbf9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fc5d33f-1869-416c-91b4-48b875ddec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fc5d33f-1869-416c-91b4-48b875ddec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411d7b1a-e6ae-4831-9e69-7611ad0aa9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411d7b1a-e6ae-4831-9e69-7611ad0aa9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ae919f2-8609-4f2f-8f10-caf15ce2df2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ae919f2-8609-4f2f-8f10-caf15ce2df2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a407a98-030b-428a-bc48-4a99aa01181f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4dcfd76b-ccff-4946-ae93-bb2c5aeaffa8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a407a98-030b-428a-bc48-4a99aa01181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2c7de892-6d03-47b2-acfb-4670938219f3" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_2c7de892-6d03-47b2-acfb-4670938219f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b46bc388-b074-4cfe-aeff-e9cd49cc66da" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b46bc388-b074-4cfe-aeff-e9cd49cc66da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e8e93772-c5e2-4369-a66a-0ab85b3852fa" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e8e93772-c5e2-4369-a66a-0ab85b3852fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_dccce1e4-2cd3-4b11-8fb6-907d293f7ea4" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_62a3cf0c-9c00-42da-9ce5-2e2ac20461be" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_dccce1e4-2cd3-4b11-8fb6-907d293f7ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_6ed89b16-87e1-474a-94c3-dc874405b36c" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_6ed89b16-87e1-474a-94c3-dc874405b36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d632a439-1548-4bc2-b5ce-806801445c3d" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d632a439-1548-4bc2-b5ce-806801445c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5774602c-6506-4264-a6d3-d252a1cf9082" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5774602c-6506-4264-a6d3-d252a1cf9082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d8b4d418-e36b-4f9b-a159-2f1343f915f1" xlink:href="exel-20210402.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_63f97cb7-7405-4c44-bc94-c6c673d412e8" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d8b4d418-e36b-4f9b-a159-2f1343f915f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eae4b40b-9a26-4a10-a700-761f66706702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_7859413f-2569-4f8b-b96e-4e3301d2327e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eae4b40b-9a26-4a10-a700-761f66706702" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_7859413f-2569-4f8b-b96e-4e3301d2327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_213c8df8-98ac-4dd9-a3e6-40027bd23c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eae4b40b-9a26-4a10-a700-761f66706702" xlink:to="loc_us-gaap_InterestReceivable_213c8df8-98ac-4dd9-a3e6-40027bd23c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e7bdfbc3-c0ca-4318-9f4e-33a689a08343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eae4b40b-9a26-4a10-a700-761f66706702" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e7bdfbc3-c0ca-4318-9f4e-33a689a08343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_884e618b-7df3-4763-9fad-6e338debc6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eae4b40b-9a26-4a10-a700-761f66706702" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_884e618b-7df3-4763-9fad-6e338debc6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c97e89df-3a68-4293-9343-94f6ce30b15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c97e89df-3a68-4293-9343-94f6ce30b15f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f340e25a-bd14-4f52-9e29-25558bde943b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79b05ce4-f017-4421-a3eb-53926adcf62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_CommercialPaperMember_79b05ce4-f017-4421-a3eb-53926adcf62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ec2f6460-a14d-405f-8bd6-bd3db5cffc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ec2f6460-a14d-405f-8bd6-bd3db5cffc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_89845ca5-ea57-46c6-9491-b72e9d839599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_89845ca5-ea57-46c6-9491-b72e9d839599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2fadc601-2e77-45ef-9634-16c018dccb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a834e1ff-dcb8-4aee-8a17-2cb1fd01d466" xlink:to="loc_us-gaap_MunicipalBondsMember_2fadc601-2e77-45ef-9634-16c018dccb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9365512-9bfe-4e75-a2fb-8ab090cc89c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3698e65c-bb57-404c-be6f-47f117949671" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9365512-9bfe-4e75-a2fb-8ab090cc89c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9365512-9bfe-4e75-a2fb-8ab090cc89c0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_13c32623-6ea3-4ae9-acd1-523b0c392377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_13c32623-6ea3-4ae9-acd1-523b0c392377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_1986aae7-0823-47ab-94f2-93ebcaab139f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5362eb30-3f03-434e-aa4b-93ce8d44c495" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_1986aae7-0823-47ab-94f2-93ebcaab139f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da71a838-80e5-4af8-b58a-b97508def1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c8489e8a-48ab-48c5-a2e3-0b1e0104bf7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da71a838-80e5-4af8-b58a-b97508def1ef" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c8489e8a-48ab-48c5-a2e3-0b1e0104bf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8c7c5081-be89-4a9c-8639-1f5d60d2ca08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da71a838-80e5-4af8-b58a-b97508def1ef" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8c7c5081-be89-4a9c-8639-1f5d60d2ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49117321-e881-41e2-ba63-f7e5377fe868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da71a838-80e5-4af8-b58a-b97508def1ef" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49117321-e881-41e2-ba63-f7e5377fe868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ForwardCurrencyContracts" xlink:type="simple" xlink:href="exel-20210402.xsd#ForwardCurrencyContracts"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ForwardCurrencyContracts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7fca6d29-fb06-40a4-8b4d-941f57bba024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_41075ae0-d2c3-4334-b9f0-4905a04797c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7fca6d29-fb06-40a4-8b4d-941f57bba024" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_41075ae0-d2c3-4334-b9f0-4905a04797c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ForwardCurrencyContractsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#ForwardCurrencyContractsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ForwardCurrencyContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f35de987-42b6-4698-b7b5-010d7f830d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f35de987-42b6-4698-b7b5-010d7f830d55" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8e953268-e854-490f-8518-5bd321bbbcf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e94546e6-1dd0-4145-9139-e1e8a0f59fa9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8e953268-e854-490f-8518-5bd321bbbcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_0716688e-1e6e-4c9f-bfc1-a574981ef6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e953268-e854-490f-8518-5bd321bbbcf9" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_0716688e-1e6e-4c9f-bfc1-a574981ef6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3d766847-cafa-466c-853d-e8e22204f630" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_60931c8c-bba5-4c32-8e5c-31e0aeb35c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_60931c8c-bba5-4c32-8e5c-31e0aeb35c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ac326b3a-7b80-465a-b45a-3dd6aaa13d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ac326b3a-7b80-465a-b45a-3dd6aaa13d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_9ee556b8-9ab9-4001-9ea5-4f3b82b5af21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_DerivativeTermOfContract_9ee556b8-9ab9-4001-9ea5-4f3b82b5af21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_f0446c53-35dd-422d-a5f6-1d815c80f45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0ff6a77-c1f7-4125-81fd-ed3fbe60d584" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_f0446c53-35dd-422d-a5f6-1d815c80f45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_53466d6c-1ea2-4cb5-b3ca-447eac7376c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_00e54380-a231-4380-81ab-35610cddee7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_53466d6c-1ea2-4cb5-b3ca-447eac7376c0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_00e54380-a231-4380-81ab-35610cddee7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7eaae344-75da-4a00-9ecb-c12c312e62a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cd829f29-b3fe-4ac4-8f6f-b1d98b672e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7eaae344-75da-4a00-9ecb-c12c312e62a4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cd829f29-b3fe-4ac4-8f6f-b1d98b672e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b0f174d2-77c9-4c5e-b285-230880c03971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b0f174d2-77c9-4c5e-b285-230880c03971" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fbf1d01c-351a-46c7-a073-efcda22a556a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1452d4a0-0388-4aca-85d6-0791eb86342f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_CommercialPaperMember_1452d4a0-0388-4aca-85d6-0791eb86342f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_58dbce8a-768c-472f-821e-9b15f519e2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_58dbce8a-768c-472f-821e-9b15f519e2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_065fa0d6-aaf5-40f0-aacc-6c9793b9ee9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_065fa0d6-aaf5-40f0-aacc-6c9793b9ee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c99e574e-96da-4a19-b196-a15872d4cbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_MunicipalBondsMember_c99e574e-96da-4a19-b196-a15872d4cbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4227da4e-7fb0-4f69-8903-db3f44aaf60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4227da4e-7fb0-4f69-8903-db3f44aaf60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b96c2847-a533-42c5-8683-7aaa937a1f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8bd37a0-f23a-4baf-aa0e-3731f9f59932" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b96c2847-a533-42c5-8683-7aaa937a1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f849717d-ff7c-472d-8f2e-6988f686fc74" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_133164c8-2383-4063-9d9a-b70828263e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_133164c8-2383-4063-9d9a-b70828263e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b4e9d422-3a95-41ce-9cb0-eb9c958e2b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4525685-b259-4030-be46-08d820b807c4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b4e9d422-3a95-41ce-9cb0-eb9c958e2b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9529f2b4-8180-40c2-aba4-019cf9c149f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_de676252-2e7f-4fbf-8b78-4e7c798907e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9529f2b4-8180-40c2-aba4-019cf9c149f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cf51be7a-3faa-4ee4-80ef-99c2e9c039ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9529f2b4-8180-40c2-aba4-019cf9c149f7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cf51be7a-3faa-4ee4-80ef-99c2e9c039ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c9b99d7-f184-4ae4-9c25-3c0e27ca891f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad48337e-d786-497b-88ac-7d057216c6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad48337e-d786-497b-88ac-7d057216c6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb2ee2b7-4a92-4af2-be0a-20776426e3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb2ee2b7-4a92-4af2-be0a-20776426e3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_39027328-f548-4c25-93d6-d9db779cf847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d922a863-da9b-479c-87d2-f177864f86d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_39027328-f548-4c25-93d6-d9db779cf847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210402.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_40c42949-0816-41dc-ab5a-756a99a58a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b1e5cfc1-602c-4e8a-8e81-5c3c822461dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_40c42949-0816-41dc-ab5a-756a99a58a88" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b1e5cfc1-602c-4e8a-8e81-5c3c822461dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210402.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_56ee67b1-4880-4526-8d3e-09d627b426af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4c861299-8eee-496f-996a-de85c8fd9cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_56ee67b1-4880-4526-8d3e-09d627b426af" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4c861299-8eee-496f-996a-de85c8fd9cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b2735ec8-4af2-4518-b80e-7629cd412bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b2735ec8-4af2-4518-b80e-7629cd412bb9" xlink:to="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_90f816e9-bb2a-4be5-af38-eb2b90adf158" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_76125ef1-f719-4133-a383-508ee57abfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:to="loc_us-gaap_InventoriesMember_76125ef1-f719-4133-a383-508ee57abfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_8630f0b9-99a9-4131-8c5c-11632be8d562" xlink:href="exel-20210402.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66bab63-9458-450a-98de-1b7df7cc246e" xlink:to="loc_exel_OtherLongtermAssetsMember_8630f0b9-99a9-4131-8c5c-11632be8d562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_ec945d35-e14c-4bf5-b8d7-f574e898795f" xlink:to="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_61ede8db-5dd5-46fd-97fe-618ef9528bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryRawMaterials_61ede8db-5dd5-46fd-97fe-618ef9528bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5b2cb892-684d-4d99-a6a2-5b4a472608ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryWorkInProcess_5b2cb892-684d-4d99-a6a2-5b4a472608ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_95b60ecb-5513-4cfa-af2a-b52c637b1942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryFinishedGoods_95b60ecb-5513-4cfa-af2a-b52c637b1942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e52788a7-3e7e-4452-a020-1a590f711703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2d8035f9-63c5-47f4-9012-4efec59fde70" xlink:to="loc_us-gaap_InventoryGross_e52788a7-3e7e-4452-a020-1a590f711703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d81029a3-c14e-4422-84e4-ba2211a3168d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b2735ec8-4af2-4518-b80e-7629cd412bb9" xlink:to="loc_us-gaap_InventoryWriteDown_d81029a3-c14e-4422-84e4-ba2211a3168d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c0669de-e06e-4b1c-8137-5ff59a43638b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0c19270d-d6af-4022-a8a5-691e390a8dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c0669de-e06e-4b1c-8137-5ff59a43638b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0c19270d-d6af-4022-a8a5-691e390a8dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_132e7e05-0c4c-4a9f-ad1a-ecd12a44daba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b69c6584-b310-4fd1-9f38-55d2ac70b9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_132e7e05-0c4c-4a9f-ad1a-ecd12a44daba" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b69c6584-b310-4fd1-9f38-55d2ac70b9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_d3177938-c063-4f0a-a9f8-682696997452" xlink:href="exel-20210402.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_132e7e05-0c4c-4a9f-ad1a-ecd12a44daba" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_d3177938-c063-4f0a-a9f8-682696997452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44149cfd-d3dd-469b-bcc8-83b8305be54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44149cfd-d3dd-469b-bcc8-83b8305be54d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6730f330-f2c3-4a0c-8bf6-fb486b301310" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9fdac25-0ab3-4092-9f2f-41ac70a3ea52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9fdac25-0ab3-4092-9f2f-41ac70a3ea52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e82aa5f2-1fdd-43d6-b152-37ccc6cb6272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9035a2d4-6dff-4262-af00-af8de15fea87" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e82aa5f2-1fdd-43d6-b152-37ccc6cb6272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89bb5d90-2aef-4ad7-8bc7-f33bddaf1363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4adb064e-db28-46e3-a2ef-f6488dfeb3fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89bb5d90-2aef-4ad7-8bc7-f33bddaf1363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_285f5b6f-f63a-4c4f-a903-342cedccd36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89bb5d90-2aef-4ad7-8bc7-f33bddaf1363" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_285f5b6f-f63a-4c4f-a903-342cedccd36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43d9e4ea-cc62-4036-9873-fdf934b08fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43d9e4ea-cc62-4036-9873-fdf934b08fd8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:to="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_835d685c-5628-4298-a503-010baf5a7aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88ef57f2-ed46-4562-a7df-f2de706c8387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88ef57f2-ed46-4562-a7df-f2de706c8387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00d57011-6adc-49bc-bb96-ab71f36fdca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00d57011-6adc-49bc-bb96-ab71f36fdca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2c5f2b44-85fd-45ea-af6d-46094e8b3a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_PerformanceSharesMember_2c5f2b44-85fd-45ea-af6d-46094e8b3a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9df09d4e-2e96-40f0-87d6-0c097e190d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2493b8fa-a0cc-4fd6-81e1-4051b47f0f1a" xlink:to="loc_us-gaap_EmployeeStockMember_9df09d4e-2e96-40f0-87d6-0c097e190d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d71607-e127-4b8c-b402-abb5483a4072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a913a18-9176-4579-be80-970b6137fcdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d71607-e127-4b8c-b402-abb5483a4072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_17017657-d9af-41d7-acb0-5c0d0f6aa508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d71607-e127-4b8c-b402-abb5483a4072" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_17017657-d9af-41d7-acb0-5c0d0f6aa508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6437500c-7cc9-43cd-969f-2839f386c76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6437500c-7cc9-43cd-969f-2839f386c76b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_00ac2250-7e84-498d-af7a-7328584b6039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_486ccfe6-4116-49fb-a62e-05657736099f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_486ccfe6-4116-49fb-a62e-05657736099f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2c940a28-c9a2-4422-bd06-8beecb25952d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2c940a28-c9a2-4422-bd06-8beecb25952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cdfdeb4e-7b5f-48b0-a4e2-b52eb46b4144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a262303-deff-4420-8eca-f589cfac42c8" xlink:to="loc_us-gaap_PerformanceSharesMember_cdfdeb4e-7b5f-48b0-a4e2-b52eb46b4144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:href="exel-20210402.xsd#exel_StatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_f10ac21b-b97f-4f51-8ca1-a504f80638d6" xlink:href="exel-20210402.xsd#exel_StatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_13cdaf91-2d2d-483c-820a-3e56d6de9304" xlink:to="loc_exel_StatusDomain_f10ac21b-b97f-4f51-8ca1-a504f80638d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_65d0e329-b69b-47b3-ba7f-545261688f73" xlink:href="exel-20210402.xsd#exel_ProbableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_f10ac21b-b97f-4f51-8ca1-a504f80638d6" xlink:to="loc_exel_ProbableMember_65d0e329-b69b-47b3-ba7f-545261688f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1170fc76-94b2-4c7e-92f4-0dfbce0e6b92" xlink:to="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e3b89cb0-b13c-4455-8e56-491d647d932e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e3b89cb0-b13c-4455-8e56-491d647d932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_afded97c-a39d-417a-9c66-d00e8af4a97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_12d0c6b7-77c1-4ee7-9926-4a7b90eda3dc" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_afded97c-a39d-417a-9c66-d00e8af4a97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0b03b3-ad4d-414f-9f9d-e6ae05a4795a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c0bca40-4a49-40fa-8b2a-771ea50f092b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c0bca40-4a49-40fa-8b2a-771ea50f092b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_aff5ec57-13a6-4825-a9ca-e5b5b4508640" xlink:href="exel-20210402.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_aff5ec57-13a6-4825-a9ca-e5b5b4508640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_331fa9d4-9333-4503-bea6-5382eae5b20e" xlink:href="exel-20210402.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_331fa9d4-9333-4503-bea6-5382eae5b20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210abbf9-5914-48d3-9b6c-233cb2e491f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210abbf9-5914-48d3-9b6c-233cb2e491f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3867442-430d-4a90-9115-e279f8f1cea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3867442-430d-4a90-9115-e279f8f1cea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8c50a38-3534-4d1a-a2b1-c8a60cee3619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8c50a38-3534-4d1a-a2b1-c8a60cee3619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d4aa55b-fbbe-408d-a373-b4041506ffc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d4aa55b-fbbe-408d-a373-b4041506ffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bdca0b6a-52d0-4b3b-a703-43d0d606911d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bdca0b6a-52d0-4b3b-a703-43d0d606911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f466f9a3-27d5-49d4-adf6-9628978c2d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f466f9a3-27d5-49d4-adf6-9628978c2d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68d92644-8e50-4de2-91ea-238af0af2f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68d92644-8e50-4de2-91ea-238af0af2f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6bf53319-9462-4c05-bdc7-34c0ed844036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6bf53319-9462-4c05-bdc7-34c0ed844036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c21b3415-3f8c-456d-bd7d-b924415b250c" xlink:href="exel-20210402.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c21b3415-3f8c-456d-bd7d-b924415b250c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9d362c40-1335-40fe-9b44-55c2ec77c629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9d362c40-1335-40fe-9b44-55c2ec77c629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9c54d3d-87a3-4064-9beb-2608dd7be8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_307d2ef0-473d-4618-bc97-b9b920d771e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9c54d3d-87a3-4064-9beb-2608dd7be8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc2d3df6-469e-4fbb-828c-0289a5f6e89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc2d3df6-469e-4fbb-828c-0289a5f6e89a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:to="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58c5c27d-e52a-406e-8f97-dcd20a6c2c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_df53aca4-d37f-4cb4-b5fd-eca49274d4a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58c5c27d-e52a-406e-8f97-dcd20a6c2c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_99ac08b0-1379-4aa2-ad52-db70880efaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58c5c27d-e52a-406e-8f97-dcd20a6c2c85" xlink:to="loc_us-gaap_PerformanceSharesMember_99ac08b0-1379-4aa2-ad52-db70880efaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ccf17cb6-b5a5-4c44-ad1b-1bd83726d687" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d696778-ef19-4f08-b63b-21d1fc69fb95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d696778-ef19-4f08-b63b-21d1fc69fb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d5ffde4b-4a62-445e-852c-97206855b77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_SharePrice_d5ffde4b-4a62-445e-852c-97206855b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3724b1cd-1074-4630-9388-013b1e9a01dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3724b1cd-1074-4630-9388-013b1e9a01dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c17b9bc4-5c0d-4e40-9093-63345d203610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c17b9bc4-5c0d-4e40-9093-63345d203610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bdb2b647-d078-416b-b59c-ff3f83ef3ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9034d6b-41c5-4522-a66a-cb2c51a2238a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bdb2b647-d078-416b-b59c-ff3f83ef3ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20210402.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4948556d-3f51-4e52-9335-e5edd962f763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c37360eb-8267-4aef-a996-6d450503a08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4948556d-3f51-4e52-9335-e5edd962f763" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c37360eb-8267-4aef-a996-6d450503a08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b600a232-b718-4000-ba23-e2667349f1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b0e36f27-e923-4e65-8bb4-74d98e934692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b600a232-b718-4000-ba23-e2667349f1b9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b0e36f27-e923-4e65-8bb4-74d98e934692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aa098a04-af2c-47b1-97bb-99695b4abd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d875d515-915e-41d6-9b0b-5caeb4c15a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aa098a04-af2c-47b1-97bb-99695b4abd16" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d875d515-915e-41d6-9b0b-5caeb4c15a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9adc4000-6c42-45f2-9810-24127f0183f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aa098a04-af2c-47b1-97bb-99695b4abd16" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9adc4000-6c42-45f2-9810-24127f0183f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4fe0367c-9ed7-4835-a033-4637a45cb6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_380b3c6a-ef69-4c4d-ba13-0ede3401228f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4fe0367c-9ed7-4835-a033-4637a45cb6e3" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_380b3c6a-ef69-4c4d-ba13-0ede3401228f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f64fd2d-ebf2-4535-b192-cc7190b02f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_380b3c6a-ef69-4c4d-ba13-0ede3401228f" xlink:to="loc_us-gaap_NetIncomeLoss_2f64fd2d-ebf2-4535-b192-cc7190b02f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c3547fe-a5a7-4c82-8d24-e27709eac1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4fe0367c-9ed7-4835-a033-4637a45cb6e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c3547fe-a5a7-4c82-8d24-e27709eac1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dbfb4524-f422-4cfe-b118-378233ee8e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c3547fe-a5a7-4c82-8d24-e27709eac1ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dbfb4524-f422-4cfe-b118-378233ee8e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a7525787-2f70-4658-8ecc-e3f19b239be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c3547fe-a5a7-4c82-8d24-e27709eac1ba" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a7525787-2f70-4658-8ecc-e3f19b239be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c26eaef3-c174-484e-80a7-f434a0528686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c3547fe-a5a7-4c82-8d24-e27709eac1ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c26eaef3-c174-484e-80a7-f434a0528686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c3ace621-ac6a-4fb1-bd0f-73e60a44ffbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4fe0367c-9ed7-4835-a033-4637a45cb6e3" xlink:to="loc_us-gaap_EarningsPerShareBasic_c3ace621-ac6a-4fb1-bd0f-73e60a44ffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b65dcfbe-6260-49e9-abf1-a8871c223800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4fe0367c-9ed7-4835-a033-4637a45cb6e3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b65dcfbe-6260-49e9-abf1-a8871c223800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20210402.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_19d36c2c-f8b1-4e7c-b758-41e2cb9faa91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_19d36c2c-f8b1-4e7c-b758-41e2cb9faa91" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ca089ad-6dc9-4697-9575-900c9c88d8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1356fda1-4379-4eeb-8d8b-40a85c43f010" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ca089ad-6dc9-4697-9575-900c9c88d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1fe5fbd4-5901-46a8-82fc-89796ef4e838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ca089ad-6dc9-4697-9575-900c9c88d8dc" xlink:to="loc_us-gaap_StockCompensationPlanMember_1fe5fbd4-5901-46a8-82fc-89796ef4e838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_07c516f4-97a3-424e-a8d3-681a87eeef9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c7f3a68-8e94-46b3-8ea6-d217f34d2c9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_07c516f4-97a3-424e-a8d3-681a87eeef9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4bb9ebb7-4e8d-4cc3-a505-c6de5e722b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_07c516f4-97a3-424e-a8d3-681a87eeef9f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4bb9ebb7-4e8d-4cc3-a505-c6de5e722b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210402.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0ab3274-e311-435e-a6b1-9dd9d628f8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f8ecfd8-d7ff-40b2-a5b3-f996c40fa564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0ab3274-e311-435e-a6b1-9dd9d628f8db" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f8ecfd8-d7ff-40b2-a5b3-f996c40fa564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exel-20210402_g1.jpg
<TEXT>
begin 644 exel-20210402_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
MU0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9
M 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"
M# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@
M NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #
M[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<
M!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&
MC :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?
M"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)
M^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY
M#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.
M20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y
M$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3
M@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L
M%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9
MMQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>
M'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@
M\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:
M)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I
M."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK
M+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,R
MFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><
M-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,]
M(CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U
M0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(
MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBH;FZBLK>2::1(88U+.[L%5%'4DG@ 4-VU8*[=D345R/A/X[^"O'
MWBF70]!\6>'=:U:&$SRVEAJ$5S+%&"%+,$8XP2!SZCU%==6-'$4JT>:E)26U
MTT_R.C$86OAY\F(@XNU[--.SV=GT"BBBMCG"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_C5\9-!^ /PTU3Q
M5XCNOLNF:7'N8+@R3N>%BC!(W.QP /?D@ D8UZ].C3E6K-1C%-MO1)+=LZ,+
MA:V)K1P^'BY3FTHI*[;;LDEW;.1_:_\ VN?#W[(/PU;6M8_TS5+S=%I6F1OM
MEOY@,]?X8UR"SD< @#+%5/Y'_M'_ +8OCW]J/7);CQ-K5Q_9WF;H-)MF,5A:
MCMMCSAB/[S;F]^U4OVHOVE->_:I^+5]XIUQC&LA\FQLE<M%IUL"=D2?3)+-@
M;F+' S@=Y_P3=_97/[4/[0]G#?V[2>%_#>W4=78K\DJ@_NK<GUD<8Q_<60CI
M7\J\4<79AQ9FD<KRUN-&4N6,=5S=Y3\NMGI%+:]V?WCP-X>Y1P#D4\]SF*EB
M81YYR=GR=H4[];VC=:RD][61]V_\$F_V5!\!_@,GB75;4Q^)O&Z)=R!Q\]K9
M]8(O8L"9&'!RZ@\I7U=2!0JX' %+7]-9'D]#*\#2P&'^&"MZOJWYMW;]3^).
M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#\U_\ @OU^TS-INF^&?A3IMPT:Z@G]N:TJ'[\:N4MHCCL725RI
M[I$:_,+YO:OHS_@K-XRG\:_\% /B#),6$>GW,&G0H?X$AMXD./JP9O\ @7;I
M7SG\WM71#8QEN'S>U'S>U'S>U'S>U62'S>U'S>U'S>U'S>U !\WM1\WM1\WM
M1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-
M[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^A?_!O1_R67XB?
M]@6W_P#1YK\]/F]J_1__ (-X/#[S^,?BAJVQ_+M;/3[0/_"3(\[D>Y_=#Z?B
M*BIL5'<_4:BBBN<V"BBB@ KX[_X*S?\ !/1/VKOAU_PEGA>S!^(7AFW/E)&/
MFUFU&6-N?61<LT9]25_B!7[$HIIV=PW/YFY8F@E9'5D=&*LK#!4CJ"/6D^;V
MK]&_^"TG_!/#_A&M2O/C%X,L?^)??2;_ !/90)_Q[S,?^/U0/X7) DQT8[N=
MS$?G)\WM73&5U<P:L'S>U'S>U'S>U'S>U,0?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U %WPUXEU#P;XAL=6TJ\N-/U+39TN;6Y@<K)!(A#*RD="" :_<W_@
MF_\ MVZ?^VQ\&EGNFM[7QMH*K;ZY8KA0S8^6YC7_ )Y28/'\+!EY 5F_"7YO
M:O0?V7OVD_$/[*'QETOQEX<E_P!)L6V7-JS$0ZA;L1YD$G^RP'7&5(5AR!43
MC=%1E8_HDHKB?V>/C]X>_:;^$6C^,O#-SYVFZM%EHWQYUG,.)()!_"Z-D'L>
M""5()[:N<V"BBB@ HHHH **** "BBB@ HHHH **** ,?Q[X\TCX8>#-3\0Z]
M?P:9HVCV[75W=3'"Q1J,D^I/8 9))  )(%?A'^WU^VIJW[;'QMGUR=9K/P[I
MI:UT+3G/_'K;Y^^X!(\V3 9R"<<*"0HKW#_@L#_P41_X:&\:3?#SP??;_ _A
M^XQ>W4+_ +O6[M">01PT$9X7LS OR-A'P]\WM6U.-M3.4N@?-[4?-[4?-[4?
M-[5J9A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U>Q_L._L=
M:U^VG\;;7PWIYDL])M<7.LZELRMA;9P2.QD?[J+W//0,0M@/:_\ @D;_ ,$\
MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
M8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4?-[4P#YO:CYO:CYO:CYO:@ ^;VH^;
MVH^;VH^;VH _H%_X)^_\F0_"K_L6+'_T2M>P5X__ ,$_?^3(?A5_V+%C_P"B
M5KV"N0WCL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ H90ZX/(/4>M%% 'X[?\%?O^"=_P#PSGXWD^(/A&QV
M^!?$5Q_I=O"GR:)>.2=N!]V&0Y*=E;*<#8#\1_-[5_27\0_A]H_Q6\#ZIX;\
M06,.IZ+K-NUK=VTH^65&]^H(X((P00",$ U^$/[>G[%NL?L3_&NXT&Z\Z\\/
MZANN=#U)E^6\M\_=8CCS8\A7'KA@ K+6U.5]#.4>IXE\WM1\WM1\WM1\WM6I
MF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5[+^PK^V/K7[%7QNM?$EC
MYUWHMYMM=;TU6XO[;.3@'@2)RR-Q@Y&=K,#XU\WM1\WM2W _I)^&WQ'T7XN^
M ]*\3>';^'4M%UJW6YM+F(\2(?4=0P.5*G!5@0<$$5N5^-G_  2+_P""AQ_9
ME\>+X'\6WQ7P%XDN (IYG^31+ML 2Y/W87X#]E.'XPV?V35@ZY'(/0^M<\HV
M-HRN%%%%24%%%?'_ /P5C_X*$K^R9\-O^$7\,WB?\+"\3VY\AD8%M&MCE6NB
M/[YPRQ@_Q!FYV8+2N[!L?/7_  6E_P""A_\ ;U_>?!OP9??Z#:.%\47L#_Z^
M53G[$K#^%3@R8ZL G\+@_F_\WM2SSO<S222.TDDC%F9CEF)Y))]:3YO:NF,;
M*Q@W</F]J/F]J/F]J/F]J8@^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO
M:N__ &8_V</$/[5GQETKP9X;AW7>H-ON+EE)AT^W4CS+B3_94$>[$JHR6 /&
M>'O#M]XNU^RTK2[.XU#4M2G2VM;:!"\D\KD*J*HY))( 'O7[E_\ !-G]A&Q_
M8G^#:QWBP77C;Q J3ZY>)AA&1DK;1M_SSCR>?XF+-TP!$Y6148W/5/V<?V?/
M#W[+WP@TGP;X9MS'I^F1_O)G \Z]F;F2>0CJ['D]@, 8  '=445SFP4444 %
M%%% !1110 4444 %?F__ ,'$/_(F?"W_ *_-1_\ 0+>OT@K\W_\ @XA_Y$SX
M6_\ 7YJ/_H%O51W)EL?EU\WM1\WM1\WM1\WM728A\WM1\WM1\WM1\WM0 ?-[
M4?-[4?-[4?-[4 'S>U?IG_P;I]/C%_W!?_<A7YF?-[5^F?\ P;I]/C%_W!?_
M '(5%3X2H[GZ94445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O_266OYU/F]J_HK_ &H/
M^3:?B)_V+.I?^DLM?SJ?-[5M2,Z@?-[4?-[4?-[4?-[5J9A\WM1\WM1\WM1\
MWM0 ?-[4?-[4?-[4?-[4 >F_L4_\GD?"7_L<M'_]+H:_H8K^>?\ 8I_Y/(^$
MO_8Y:/\ ^ET-?T,5A4W-:>P4445F6%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\R_\%BO^4<?Q&_[AO\ Z<[2OIJOF7_@L5_RCC^(W_<-_P#3
MG:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-
M[4 'S>U=/\%?^2Q^$O\ L,V?_H]*YCYO:NG^"O\ R6/PE_V&;/\ ]'I2 _H^
MHHHKE.@**** "BBB@ HHHH **** /SO_ ."S7[(.QX?BUH-M\K>79^(HXUZ'
MA(;H\?2-B3_SR]6-?GG7]!7BWPKI_CGPSJ&C:M:Q7NF:I;O:W5O(,K-&X*LI
M^H)^E?B+^U_^S7J'[*GQTU;PK=&2:R0_:=+NV'_'Y:.3Y;_[PP5;L&1L<8)_
ME_Q@X/\ J>+6<86/[NJ_?MTGW]);_P"*_=']P?1W\0O[1P#X=QLOWM!7IM_:
MI]O6#T_PM6^%GE]%%%?B9_3 4444 %%%% !5[PUXDOO!WB*QU;2[J:QU+3)T
MNK6XB.'@E1@RL/<$ U1HJH2E&2E%V:)J0C.+A-73T:>S78_<7]C7]INP_:O^
M!6E^)K?R8=24?9=6M$/_ !Z7: ;P!_=;(=>?NN,\@UZO7XU?\$W/VNF_97^.
ML*ZE<,GA'Q,4LM74GY;?G]W<X_Z9LQR>?D9^IQ7[(PS+<0K)&RNCJ&1E.58'
MH0:_LSP[XM6>Y6IU'^^IVC-=WTEZ26OK==#_ #?\7_#^7"V>2IT5_L]6\J;[
M+K#U@W;ORN+>K)****^^/RD**** "BBB@ HHHH ***R?''C?2OAMX0U'7M<O
MH=-TC28&N;JYE/RQ(OMU)/0 9))  )(%14J1A%SF[):MO1)=V:4J4ZLU2IIR
ME)I)+5MO1)+JV<G^TS^T;H/[+GPGOO%.O2;E@'E6=HC 2W]P<[(D]SC)/\*@
MGM7XJ?'3XVZ]^T-\3=3\5^)+HW&H:C)E4!/E6L0^Y#&/X44< =3R3DDD]S^V
M_P#MAZM^V#\6)-4F\^S\.::6@T;3F;_CWBSS(X''FO@%CSCA02%!KQ>OY$\2
M..I9YBOJ^&;^KTW[O]Y_S/\ ]M71:[MG^@_@SX6PX7P'US&Q3QE9>]UY([J"
M??K)K=Z:I)LHHHK\Q/VT**** "M7P1X,U+XB^,=+T'1[9KS5-8N8[2UA7^.1
MV"CZ#GD] ,GM657Z#_\ !%G]E;[1=7WQ7UBW.V$R:=H =?O-@K/<#Z F($=S
M*.U?2<)\/U<ZS.G@*>B;O)]HK=_HO-I'QO'W%U#AK)*V:U;-Q5H1_FF](K[]
M7VBF^A]L_LT_ ?3?V:_@KH7@_3-LBZ7 /M-P%VF\N&^:64]_F<D@$G"[1T K
MO***_N#"X6EAJ,</17+"*2271)62/\P\=CJ^,Q-3%XF3E4J-RDWNVW=OYL**
M**Z#E"BBB@ HHHH **** "OF7_@L5_RCC^(W_<-_].=I7TU7S+_P6*_Y1Q_$
M;_N&_P#ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F
M]J/F]J/F]J #YO:NG^"O_)8_"7_89L__ $>E<Q\WM73_  5_Y+'X2_[#-G_Z
M/2D!_1]1117*= 4444 %%%% !1110!^(_P#P6B^*;?$C]O#7[-9"]KX3L[71
MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '\_/_!0/_D]SXJ_]C-??^C6KR#YO
M:O7_ /@H'_R>Y\5?^QFOO_1K5Y!\WM75'8YP^;VH^;VH^;VH^;VI@'S>U'S>
MU'S>U'S>U !\WM1\WM1\WM1\WM0!_0+_ ,$_?^3(?A5_V+%C_P"B5KV"O'_^
M"?O_ "9#\*O^Q8L?_1*U[!7(;QV"BBB@84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"?M)?M"^'OV
M7?@_JWC+Q+<>78Z;'B*%6 EOIR#Y<$8/5W(Q[ $G !(Z_7M=LO"^B7FI:E=0
M6.GZ?"]S<W$[A(X(T!9G9CP% !))Z"OPY_X*7?MXWO[:?QB9=/DFM_ OAV1X
M-%M&^7S^SW4@_OR8& ?N)A>I8M48W9,I6/*?VE_VBO$/[5'QDU;QIXDFWWNI
M/MAMU8^386ZY\N",=D0'ZL2S'+,2>"^;VH^;VH^;VKH,0^;VH^;VH^;VH^;V
MI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4LD30MM960[0V",<$9!_
M$$'\:^H_^"7?[ -U^V5\5_[2UB&:'X?^&9D?5)L%?[0EX9;.-O5A@N1]U#V+
M)G['_P""O7_!-JV^)_@ ?$/P#I,-OXB\*V2PW^FV<00:E81* IC1>/,A0< #
M+1C:,E44QSI.Q7*[7/R4^;VH^;VH^;VH^;VJR0^;VH^;VH^;VH^;VH /F]J/
MF]J/F]J/F]J #YO:A6VG(X(Y!':CYO:CYO:@#]D/^"0__!0T?M+> E\"^++[
M=X\\-VP\F>9OGUNT7@29_BF08#]V&'YR^/M6OYM/AM\1M:^$7CS2O$WAV_FT
MS6M%N%N;2YB/S1N.Q'0J1D,IR&4D'()%?O'^PM^V3HO[:OP2M?$5CY-IK5GM
MM=;TU6YL+G&3@'DQORR-SD9&=RL!A.-M4;1E<]HHHHK,H**** "BBB@ HHHH
M **** "BBB@ K\W_ /@XA_Y$SX6_]?FH_P#H%O7Z05^;_P#P<0_\B9\+?^OS
M4?\ T"WJH[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J
M/F]J/F]J #YO:OTS_P"#=/I\8O\ N"_^Y"OS,^;VK],_^#=/I\8O^X+_ .Y"
MHJ?"5'<_3*BBBN<V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .%_:@_Y-I^(G_8LZE_Z2RU_.I\WM7]%?[4'_ ";3
M\1/^Q9U+_P!)9:_G4^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:
M@ ^;VH^;VH^;VH^;VH ]-_8I_P"3R/A+_P!CEH__ *70U_0Q7\\_[%/_ ">1
M\)?^QRT?_P!+H:_H8K"IN:T]@HHHK,L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KYE_X+%?\ *./XC?\ <-_].=I7TU7S+_P6*_Y1Q_$;_N&_
M^G.TJH[H#\-/F]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH
M^;VH /F]JZ?X*_\ )8_"7_89L_\ T>E<Q\WM73_!7_DL?A+_ +#-G_Z/2D!_
M1]1117*= 4444 %%%% !1110 4444 %%%% !7BG[>W[4,7[*W[/6I:S!-&OB
M#4LZ?HL9PQ-RZG]YM/58U!<]LA5/WA7M=?C?_P %,_VJO^&F?VA;F+3KCS?"
MWA3?IVE[&S'<-N_?7 _ZZ,H /=$3OFO@?$;BK^Q,IE.D_P![4]V'=/K+_MU:
M^MNY^L>#? KXFX@A3KQOAZ-IU.S2?NP_[?>EOY5)]#YWNKJ6^NI)II))IIF+
MR2.Q9I&)R22>22>]1T45_&+=]6?Z0*R5D%%%% !1110 5>\-^'+_ ,8>(++2
M=+M)[[4M2G2VM;:%2TD\CD*JJ.Y)(JC7ZC_\$JOV!_\ A3>@P?$3Q=9JOBO5
MH<Z9:3)\VD6[K]\@_=FD4D'NJ''5F ^JX/X5Q.?8]82CI!:SETC'_-[)=7Y)
ML^#\0^/,'PIE4L?B/>J/2G#K.7Z16\GT7FTGZS^P)^Q78?L@?"T1W'D7GB_6
ME2;6+U1D(1R+>,]?+3)Y_B;+<<*OOE%%?VEE>68?+\+#!X2/+""LE^K[MO5O
MJS_-G/,ZQF;XZIF./GSU:CNW^22Z)+1+HDD%%%%>@>2%1W%O'>020S1K+#*I
M1T==RNIX((/4'TJ2B@$VG='XO_\ !1#]DJ3]E'X[W%K90O\ \(KK^Z^T:3DB
M-"?GMR?[T3$#N=A0GDFO Z_;S]MW]ENS_:Q^!&H^'V6*/6K7_3-&NGX\BZ4'
M )_N."4;V;/517XFZWHEYX;UF[T[4+>:SOK&9[>X@E7;)#(A*LK#L001CVK^
M._$SA'^Q<S=2@K4*MY1\GUC\NGDUV9_HGX*>(2XER14L5*^)H6C/O)?9G_V\
ME9_WD]DT5:***_-S]E"BBB@ HHHH *]@_8C_ &I+S]D[X[:=X@5II=%NO]"U
MFV3GS[5B,D#^^A =?=<=&.?'Z*[,OQ]?!8F&+PSY9P::?FOT[KJM#S\VRO#9
ME@JN QD>:G4BXR7D_P FMT]T[-']"&AZW9^)='M-1T^XAO+&_A2XMYXFW1S1
MN RLI'4$$$'WJY7P+_P1I_:^_MW1)OA/KUUNO-/5[KP_)(V3-!RTML,]TY=1
M_=+] @K[ZK^X.%^(*&=9;3Q]'[2M)?RR6Z^73NFGU/\ ,3CCA'$\-9S6RK$Z
M\KO&7\T'\,EZK1]I)KH%%%%?0'R04444 %%%% !1110 4444 %?,O_!8K_E'
M'\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\
MWM72<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-
MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**^,/^"N/_!0[_AEWP#_ ,(7X3O OC[Q+;G=-&WS:+:-E3-[2O@B/TP7XPH9
MI7=@V/GK_@M!_P %$/\ A-]9NO@_X,OC_8VFRA?$E["_%[<*<BT4CK'&P!?^
M\X X"'=^=WS>U*[M,[,S%F8Y))R2:3YO:NF,;*Q@W</F]J/F]J/F]J/F]J8@
M^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:O1_P!E+]F3Q!^UQ\:=+\&^
M'HRLMT?.O;MEW1:=:J1YD[^RY  R-S,JCEA7#^$_"FI>.O$^GZ-H]E<:EJNJ
M7"6MI:P+NDGE<A551ZDD5^ZG_!.K]AS3OV)O@M'8R+;W7C#7 EQKU^G(>0 [
M8$/_ #RCW$#^\2S<;L")RLBHQN>H? +X%^'_ -F[X3Z/X.\,VHMM+TB'8&('
MF7,AY>:0C[SNV23[X&  !V5%%<YL?D+_ ,%BO^"=Q^!'BZ;XF>#[';X-UZX_
MXF=K"ORZ->.WW@!]V&4GCLKDKP&05\*?-[5_2CXV\%Z7\1?"6I:#K=E#J.D:
MQ;O:7=M,,I-&XPP/Y]1R#R,5^$W_  4&_8CU7]B7XUS:2WGWGA;5R]SH.HN/
M]?#GF)ST\V/(##N"K8 8 ;4Y=&9RCU/!_F]J/F]J/F]J/F]JU,P^;VH^;VH^
M;VH^;VH /F]J/F]J/F]J/F]J #YO:O6_V*_VN]=_8S^-MCXITDR7.GR8MM7T
M[?MCU&U)RRGL'7[R-V8#J"P/DGS>U'S>U+<#^D/X3_%30_C=\.M'\5>&[V/4
M-%URW6YMIEX.#P58?PNK JRGE64@\BNBK\7?^"3'_!0I_P!E/XC?\(EXHO"/
MA]XFN )))&^71;IL*+D>D; !9!Z!6_A(;]H(I5GC62-E=' 964Y# ]"#7/*-
MF;1E<=1114E!1110 4444 %%%% !1110 5^;_P#P<0_\B9\+?^OS4?\ T"WK
M](*_-_\ X.(?^1,^%O\ U^:C_P"@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S>
MU'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_  ;I]/C%_P!P7_W(5^9G
MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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MQ1?.1\,0+U)(30=./ET1UJ-AH#;0SRUA/1H&"@/]  @-Z = 1(%^ (0&]+,
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M>0&2$/H_(2&0!Y-^7FO7;JV<ARF2;:,* 8 S',7DJ79S&FNY@"?/W2Q,Z#D
M=O"5D:>*]Z>0F]4)0T!"$!#6 G*H77\U[>D8%3R$)\\!R$D(U9.R)WB'.4/X
MB^+)<P!<$EK=4+EGV9N,$)E<G@?L'"20D(N&MG =CE$R0I@DI H!DD-4]".L
M8),>,MQ@" &2@(+ZF7J3YP;T P%14S_+$/* ?L ?T"\>(8"20+]XA% 8Q:;)
M\P3TBT<(55%OFCQ/0+]XA% 5]:;)\P3TBT<()5%RFCQ/0+]XA% 2):?)\P3T
MBT<()8%^T"\>(91$._EDFR8O@D"_>(10%;9I\J()](M'"%5AF"8ORD"_>(10
M&'G3Y$4?Z!>/$$!)U-0O]1?RGK.C2 T!U$9!_5(&:'OF# &20%3T(^S-U*>\
M$'JWT"\XR=R9F.N%+$20SA-.8D\EHC73F8_][E*\@)Y8K@[WJ(!^+,'L-?!7
MRIZL8 @!_ ']#MYD=.K4J1\_?NB-*RLK>7EYJ;]O.++#S3<FW92L^[+V;87=
M,MKPFYJ:3"UBX,:%4T=QWDC@$NAW4&VUM;6#@X-ZX\.'#T6+LWXYOS'IJ5YS
MUK?E EZMR%Y8&WYA8>'$Q(2Q11\XQ),']#NHMB=/GK2TM&@MOW__KJJJ2J?3
M>A7V]O;6U]<7%!1<OGSYQ8L7VOLW';XQZ;MD[=8*+IY=5]KP.SL[&QL;C3M$
M&SC$DPKT.ZBVU=75_/Q\\5.TC(V-B4/?S,R,5H5/GSZMJZL;'Q]?6UN;FIJZ
M>/'BRY<OG;\Q&;!D+8L^17H-9M)/G$67EI:.CHYFK/3S%P+D!/H=OMVVHZ/C
MT:-'HJ6MK4T<P;3V[]^_EY24B,_Z\D-#0Y<N79+]E2V[@QOYX4@?OACRU:M7
MQ9:;3CZ!5*#?0?U-3DY65U=O;&R(PZ"XEM/:Y^?GQ<^3!HJ*BHX=.[:PL"!5
MOX.MM(>D_XQA^-O;VV5E92,C(U'0+_N-W\:M4FF.,.AWD&EQ15=34R.N %M;
M6_7VN;DY\7-Z>OK34<11D>T;DY+$TS 6>G=W=T-#@W[631O(]U896\16*39'
M&/0[S/3CQX_%YS=OWNCM6UM;Q<7% P,#V5TP?V-24FZ,PQ?'D(J*BJZNKBCK
MI]@<8=#O,-._?OW:W-S4;FSJ^>[IZ2DO+W_UZM7R\O+2TE)_?[^6:36^,6DJ
M]&?/GA46%D96OV_?OBDV1YC44YO(8JV?$>/%1E]?WY4K5PH*"L3547-S\^O7
MK[5E%/C&I&GXXDARYLR9B.AGNN36KP68)RF2:D72]0,11--O<7%1O]@>'A[F
MUT^J&]FWTY(CH?HCC#7.)Y\,=[QDNV'9H9M #G=]G6\71PKH%VD<*HGACI=O
M-WQW;K> :1GGN[[0#]#@4$E2[WAY<D-&_Y9+Z@L[W_6%?H &YTIRN./%[P9Y
MYW9KY7PS!/0#(>-PYN9R+7^QR#<INX><?^=H=[L8^@%6W%=\0#=RKAY0/",N
M]<N^70S]0 BPN6$9B% \C9QOAL#))X@<EAJ0NY')DI"\_TRNOW.$?B"B,+B1
M'8B\<^>[OM /1!>I[MGI31[+X:XO] /1Q6A"?/53 ^R.Q&'4 /J%"W9'XH!^
MT0&[(W&8SCP)E<CI'O0S@=V1.*!?=,#N2!S0+SI@=R0.Z!<=L#L21XCZ4052
M!NR1Q ']H@/V2.* ?M$!>R1QR-//V#_T<P/V2.*0K9\:DR#Q /V2A7!#4TZX
MH7V@G9%5F4F0>(!^"8+AM1#*3(+$ _1+$+)?"Z'2)$@\0+^DD-.-X*@T"1(/
MT"\IR'X1JIL0,9H$B0?HEQ08]%-I$B0>H%]2R.D&"<I,@L0#]$L0#*^%4&82
M)!Z@7X+@>1&J&I,@\0#]DH4"+T)5">@'0&A /P!" _H!$!K0#X#0^#]H1KF6
0;SQ4>@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
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M$,AG-Q'\3^=7TS5=4]/=,PPPP,SP>CYX#'U45U=W57?7J^I=[]+H=#H!
M        YNG3TPD           #L'8AG          "@#2"> 0        "
M-H!X!@          V@#B&0          : .(9P          H T@G@$
M    @#;HI>)9=7;KCDUY38^2':N,JLW(+0<PMU=V]C:3 0        "@ VAZ
MI[XB5ZW1:/@%?A?YK;Y]2ZO55E96DN5OOOZ&;.S;M\^C1SH/#_>! P<^^=13
M8\>.#?2?R,>FC,KRV57#YQ><O7GCYL^__'RO@7"/!N[?WW6(EQ=9]O?W?_'Y
M%P:ZN;%T*N.Q/AD          *RD-XIG"_*RM/SBR;R\TM+2AKOUZ@?3 Z6;
M%A@<%!0<'!41206MN;,PH2O;11=NU%3GG\Z_>/%BU94K\G/)<D?<XCUTZ#B?
M<5'3IP=,\%>]%NAG         + MO5$\RR!WH/FGG_Z\?W]N[@EUS6Q&Q/*K
MDR9/?NL/;TT)#1,L=FO+SEM07'3D\)&RDA*K3JK8Y3UL6-3TJ,4+XUF$T,P
M        T!7T.O&L5)@)JU?EY>:UMK3H5RQ(5BL8Y^N;OBM]S,A1YDXM2/W/
M9PH+]F5E7;TL=34KU+AAE2[(5DW#> SVC(V+@X0&        @*ZCUXEGGOR"
ML^O7K9/W-IOJ6!\_/[*!CG:F@Y#KZ^_6_WA7_1!Q84Y<;.K6;>84;&-3T\J$
ME<5%Q4H9S):)'O;P\"1K[NZ#R$E)'K7<OZ_5:M4/D=))=/OH$2/9%JAH
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M@ODYGR7</3WBYLU33NQ,%F;/B3%.@B4>>"K_M#F?X0          K,1IQ;/
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M$]CL7*HJEP8;Z.9FU,_BEH;ZAIV[TODSKEBVG/<97O+%%^QPYS8W
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M(Z(BUR<GD5^#)A<#DQAVI*6QHTCDH40\<]#SLAYO3\_!+'W?2+-5 0
M  !H%__3TPGH*HATK*FN,=@SZW2N_?OS+KX:&N[IET13YW'C?/@#CQP_UG+?
M*'$GAX8</I3#CMV;E;DI*9GM_=.^?9E[,UBTXWQ\B@H*:<SWZ"D$NJ:7LM]]
M]QV?OM^_]AK?@7S^W#E#DD3E?.POQR>^.($&2!8'/#?4-]"]Q9P+<7)@P 1_
M$I[-R'7SYDU!4NSDU]O;R^ U3:-Y].A11VXE         /1ZG+;G61"]7K.>
MY\&#!_.[;M^Z95C2Z8R.OD2H^*004;I]^W8V:)D0/W^!OO]9'+%,5NOJ[K#
M),S33S]-3T?76;\TC4$_!IL+S=ML-__T4_V/=]EJ1&0$D<3,V-MMP( 5*U<*
M7#<U]?C-#,(-1NEJ\VGUZ]>/I8=.T 4         H+WT#C6ETSWYY)/\!D,_
MK:2!>>[4U;%E(DJ)Q.6=?A&>'?<L[<V6':MA7;M2R#MW[C#OUH88I$-\GS.Q
M *_XLM*0'A'_B4;?9E0>SYH1S9^)[9+<=!LNDVSBTZ_W0D8$,WQK P
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MIJ3H)YV6\!CL.?'%">RZ!''>+*;G^[OV%[A^:<.H;'&U3Q],4@4
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M*;R:I7;7_(7(M.Z>S(R91 ES<TH'!@?QRKGY_W[*R\UC%MWN'NY0S@
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MA1PY<B3O1"ZOBND5'3U^C([$IERLK)@V)9P/</GR9;<! P1T.P,       !
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M@JF:);\9^\A)"Z]>OF+N=!3OH4,CIT>]$S5]P!-/F)TQ2V+QTO?7)ZY5/3L
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MRMB755A02$K6HT>Z/GTTY-?ABIE#0VYVXMJU@?X3>SHA      # L?F?GDY
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M) L/6ENUVKK;MVZ1C-,'53KEIEOHQLZX[)8=:Y_>OZU/I!7IUT@^PQS%G 0
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MIL[VW'8F,V4?Z.9&2G7FWHQ_?O==3.Q<%U=7P[ZV"C,YEHAMIWS> 0    !
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M# YB,J/E?LNJA(3FGW[JYN0!ZS%F)1.'0(&/CZ^)PS#!<+LT!E/W7NK[
M  "@EZ#:ARK8R'C;D<0S[^_G8F6%<JAST,0 <QWTK+^Z=Z+:XK(O:Y^[ASOK
MH*NKU:Y8N:+;DP:L@F\Y8IM@MJTD*#A(_X_OF1<;&G[XX0<!LAD     P'GA
MK;6O5]\\4UAPMJBPL:F)[>W\*?ZG\U%T!MH 8*$90-4 F]R"A0L6\+,Z!P8'
MK4M,-!</:LRJ=V"@FUMF5M9;4Z>Q+<6%^L'/BQ?&LRV\Q7LG;Z.Y&#!UD#7
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MLGP13'-6>?-E!YIK$P&@\_!E;]2H4?I_:IW/*'4      $X E1[E7U:N6IE
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MC8N-E6F-IYYZBD9;7E[^9DAHFV?OB+=M>J:FYN9I4Z?IY]?B*J.1TZ,VK-_
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MC]>N63,O+F[3YDVY'YU@(<G3-25\RI<5E>Q \H"%A(4626]Y\CS0SN<NNT0
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MJ4YI^T:I5D$$B^K.W+$]@C5JWS07[MRY(W07*LJ93Z2%6F#[SV2,BH_<2KI
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M'24X^/-.[L#8L6,=Q42"(E-*.])VZ-L]E<TWIO,@V _,<H\LZ]ON+3\X#"[
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M[(6Y)'Z1?CH-06W8$OO^:33R#X]4W2$/:?3,F3WU>E0][Y9MV[ZNJI)K9ND
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M3#GG%YRES79."?^9(>_,B*A(D]U\)8P^5KR,T9FX.R(?T?C%BUB<W?;4R&S
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M"2,M7"PMXZW .F\6Q'=Z'3E^3#\ BO^P*AHWERY?'N@_T=SP5W/NQT#WPW]
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MDT].T;E_*;6U^BH4>[Q9=[P%U_FRD+)3R (#.X'/8M7F20LY+G#OZ#6X:#0
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MC?,;X(^2=<_>LAFS9GKW-3@&:[M^G5@6X%3CAY>E&]MOW<;SWK%B//Z%%_5
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M\9G1SZ+$35^T,#LO-SXQ$6W[^/@LRURJU)PC(B,K]Q_ QW#BHBR$2BDG'>+
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M,W*%F5R#-.>B#1L'#ARX=M5JZI3RZ4JC/[3;?KL]+C[^L^/'*5^2]OHHAL=
MNE>4?KR0FH:RT+H-&_:\^RX_Y;8'<YZI>Y'^_(M?_,*]G 2;4IY5U5>R6[*K
MN*NK2USR1#A1=ZSV^K7K&XLVP0%&? M2G\BZ1&;?R- @2H?RY-2HX2/0?WBQ
M65_SC2W-J2DIO* &Q??HJ+R<'/@$AWP)@]$+("7H2.TQF<A%N:(0M@," O;O
M*T>;DR.C%F=DO+UMFYFGP]LY@_K7=OWZFV^]^?&''W&L,K<<I;SK(L+"P@X?
MJG9U*!@,3P96C#M+BF4E3JT20'(1GNRV*"W][)DS!I';&%2U+%7[@O.P-"2W
M2U<Q$8NA#M2?X8@F!J]EE;$DPV#+9N7359N\1>D+'W_\<4IYU#+F'8:9 ,E;
M49.E<4(A(I#P-#UF6E9N#C81(1B;:*%J-\*,25R+TB5CY]V[2 0_6E<+%S=7
M7DPPH3FCC)&=EXLRB3C$ 31GN'@5<]O+L O&LI#'9RU<@BY=:45MDLID9O#Y
M?OY^-34UI,RBIA$51O(4]:<KYVA(OTT-C:C^-QTVCX]\JW%%A"A3X=5)D\0M
M)E4S&#W#A'"+?T7WVB8)&#)D<]%FLHMD)-INUD11500 *>JJSL/,!IO1VZ!,
M@"F&#QGZV?'CBS,RH/<KHUF1\G5G9/8^MES#*@;G#OFP1\HSBM;RO?L,DI9$
M>=G>5UYY9<WZ=7 5*^5")JKZU8&JRL0Y22.?&>73O[^/P#.CGXU/3,3>:!CV
M J8"U;5!NIV0Y(W2XJFGGQX^;%ARTAST?]3(4?_]U%/3WWB=. =2+5IDY!D>
MQ&KSN''C]NTIPZ\AIV;,FHDU9[?S&<#0.)1K%K*AG/JE_<I:%1,]DKP?FGGS
M13\TQ/V,O$SU\?(J*2W%$RM(7"%Q;7!@@,'+HR6.Q "H4:"J:V7D6_XTAB-0
MK5WY*3-*9T4,!L-Z5&LY(@E?OGHECAAC&BEK2#.I^>03:M9;946%'UXN%&-A
MLR55YMNV;"7.PRP/-H,!P9ED>6YN;7W=F.!@'6DUU"XU:,NFLY9@N9::F@I?
MH65ZI#QSPA?NWU>^.",#[Y"CMW[X8>?VMY&FE)"45'&P2FGQ2^G2#<U-J>EI
M2&=>NB2COK:NXW8[><7M'VX=KZ]'QU^-B$#%WDUE7*T!#3-4!XI1<KP4%H[2
M0K9(NEY_O[N[\40#2@Z46.F+%N**F!JLA@]$$CR2I!.2$D>,&('49L.25,(M
MWGV]\U<5ENPJ5@YW*]5O!L-FC-4_Y)3V*VLEJBH0.;(@):7MVC5XM>%78LVZ
MM<10BA0W)*X=J3G2AS@/@[JW"4#7,G8>I@PDLRC1",:LAY0.(-VQ7# 86N#!
M@P?4$5P9(J%HWMSD^WBA5DY=ZT":<T55)=2<R7(G):6ELA$_2Y J\.[N[I0%
M"\BPEMD ,Q@4L"M\Y+#A?_CTTT3LB)OTSD//=M ]F.EV'YMCG&BH?.\@]2)M
M8FK.LPF@@H0M_<+"P[*798E+H4C?C#0EI/<>KZO+7+QD4,#@H4.']O?U)0]!
M-_[XXX]_^>Z[*ZU7[M^_+Y//U+S:G#U].B$NKJ*J*G1\B&W!9A"H\7^H4:#?
MI+ESZH[5\J=5,[V0(AWM'=7O'T+_43T^=-C008,&B16ZE(XWVMK:;[>C7Y4R
M(!P)&#)D_8;U$T/#./D(H>I$"P;#!HQ-W5'M,'(O8P?3H4U)2Z.\\?' Z48Z
MW<+%BZ K"O@T)*(AT6WZM->,>?A0?[*T@4VP:FIJ\**#5%#=*)(]&%C3D@3R
M'^#/-^*@\67R-(-A ZA,/?SPPYQ:[^&RK&6BJ R15Z&9RY8JG0?A#70\8VGF
MFE6KK7.7('6>=DC.PZC0HN>C +M7(\AP#E2NH*2I3>LW1$='BVZ,8&ZDO-^9
MSJO"6?3,E<M73/K-J\3SM&:Q47E6CM4@A?9D2TM6;L[A0]6B'S:Y3YJ;-V[>
M;+NA?!#_JXQ9U03@N*Y[7;&_FWWJU"D<LZR<VPQ5F\/M[+Q<7G.FS"V4?H9(
M7V97UYE3I]%_\A1591L>0&IV\KQY*_+RJ%"I^O1F,&Q&.>:IFO.-'=$R2LV?
M'-]94OS!X<,J]X#!Y\BHR)5YRTT\'XEH*PORQ5EY9J4T11V.I,.W%KSU\8<?
ML5I:FU#]E7A[T*!!HN]?J:K'"@"#P; *7*8>/'A E2 D)!N<?AD1=.?,2TY/
M284%DYKPLC U[?O_^9]RP<NC56'"^LG9TZ>A\S#\9!Q45E<SE$#Q255P0M+"
M'__XQY24E*;&)G55V6POCS1[#BD42Y<MA2Z0M$E/S;;)C%E,T8:-7WW]5=*<
M)'X0DJH7E!$'-3%.9A,?-C%\T9(E9>7[5A864-YK[G=W+TA9P#1GNZ <$VYL
M:2[?NP]>X3]PP(K\E2@M]NS;NV7;5M%%'+;-4+7GA"8#U!&.\_7WFSMO'LHD
M6'.F L!,M1F.@,QJ5M88GI3?<,,F^J%1=F"!W\&! :AQ4LZ5H$ BFLPEI+DY
M2U39Q\[#6"VM693"T".//$K.<<S&GL'H&41SQN5H9TEQ>=E>5?<3(CI=1&3D
MIO4;.,7 !E61%FW<%!8>1NLGI@'>/0Y7'\;.PT@!9]UD#!.H>C*"9_WZ^W[\
MX4=)V(2;X^B<:4D[(I6+^MHZTS/SM8 M(\_&1F_P<12#J%2C_SN*=S4V-)XY
M?5HV:5;^(.I 0$! 9%14<O)<7Y_^\,D-S4WQL7'\%!'AE8TG&I!,AMWW,WH"
MU0=QI[,3Q3.4DI'HO%_>NYD0&W>Q]?*1FB-U=;4WKK?QAXR5"G"\CY?7Q)<F
MOO2K7R7&Q8/S,HM!9JK-< 0FS!D\HP,.FJ:+?FCDYMF4M8B?OQ\JOYR:U8D2
M5/Q?C8@0%Z4PVW,,S54$D*0X<N1(8ASN&1'N,2C-,48],\IPFJG-#(9-J)JY
M(GU@VY:M*I4S1MA&,O"6S9OA$_ &',$FIW:7[HZ)B6EK:[/.?EMZRIK"5:-'
MCPX+F: :VA[& ,/S,)$QR'&DESWYY),HG_-Z'[$LMG)F ?K9\?;;&E^VRA;E
MV6ST81:EI:/_G+#0:$MS<T='1WM[Q[T??R23/?P&^ \8,-#;VVO0X,'#AP^/
MG!1!O"/ D2+T&SXA=/7:-4N79.!SZ$U()@L)"7&O-;6U"4RUN/AXL:=#FI.\
M7\TN:-3P$2.'#5^1EX>4[>.??7KY\N4+YR^@X]>N7B4=)0&!@7T?><3?WP\E
M[C///*-,*4JEH11I!L->*',4$F*FQTRCI(V@L6.I:6!N!"X[G7?OSD^>)W8R
M<NI=OUY>7J6[=U-^:$P7NLJ*BI=__;*XMIQI%(XJ$/DK5C[UU%.X(62E6R.H
M>G%#&R\^_T)9N<'R"!UY8=SSK@DB@^&V4!6=3G 2%C<[EJZ<Y>Z4>/?:@I\(
MJGCJY;,G2(%%5VXLVL0_%OL,LAYT[ZE3IRB'WJR69E!0,PA,YY"%J6G//OML
M0ER\T7%3$TB20^.)ADM76I&B85-XG8&-<YZM BE.UFJY4*W"OPFQ<=]\_35<
M4'Y1^L)!@P:-&#J,*5UV(34]#2YZCNKQ=_>\:^QB'-NHSD7I8MOKE*V+\B"#
MX0@:&QKY/_+>^M%C1KLR3#8!C370K[H?&NE2_'?5FM64PT750@<[LU Q+RXI
ML:XM!)(<=![&&6]Z61WN3(Q-^$=IQ+JD&0S[@C3GF)@8T;VV$?^I?;R\L'MM
MY9(0JA4C/A@6,L$PL*2*R1%I%"04L),M+:SZ99C $B,U2/B$T .5%8GQ\5WW
MK-2?0?_[[M)2O!"/-G-F3^<\.Q,4CP&!@:0N0#+9_.1YU.BEBX/H;I 1_HJ#
M58>K@8<AG:YP]:J1PX:S*&5X'O5U"G\M[CG9'LY!DOFA@7/JP'<M6K($]G:9
M^&12KV*O%J@MS%B:"4^KO,@X;6UM<?'QG#F[+W=, @:#P5"%N 0R=&L:]QR!
M*EABGH-OM%!GB)\=RR\62]7)(!"F;T<!2TA*I#R3,1@]!,D,^RLJO/M:LZ8:
MS,-Z?9T@SVA6,' GY1GQ\2<?>WEYD2CFU]1.3R-GM=D_H65POFPZV9*_8B6T
M($J:DY08%Z_9+A\&PW*HFO=.9R<OQU!:GUX_<.! IP?-#N 2RONAD?OY,_Q*
M1$1%0?_V9DLWY=\U/25UQJR9^)4R:T/%BU2?A?V[DH80_BK?Q6 P&&X-,0N2
M=6MRZK5E4O)</,D18Z'S%U)MYN7D1$9%&IYO946*@K>KM 3ZSK#J=@9#%6'\
MN;(/4=DL<6BGTQ$!H[NKZT!5)2=?&,*A ;8*-U.>_?K[[MBU$]8^AP]58Y^!
MG,9BUEWHO'LW)RN[&TS%&1,<7+1Q$\=D689'0-6\APY7XQW*GNVIIYYR0>#L
M@>B'1NGE'NP.#@RHV+^?DZ]H9?JQU)Q8]%N\<U?8Q'"#YJS7TUJTD0?AO[BN
M5D[)89UT# ;#P\!UVO[*"H-[;<45^#<R.JIHPT9*?#4KS5+SHC<7;4:5/#DG
M>X4%85U=4$C\&[/:F&$74!;%TPI4>_-E8)V9H[V+??/UU["'75,YTYV49QR)
M4Z,G+UJR!!Y'@F-#<Q/'RKQ-+%TF&!1)O95^ _PK*@YP\D7(6*\$PZV!5G G
MOOB"PW6%/%<__OCCK@E<#\!.PN)FQ\IF(U.2DU[OZ^]W],A1.+IK88FF*@$=
M/PUI-S]WAKP%]!.K(S^+ZNJFDRWDL599)S(8#(8;@>32POP"?DMU02E!Z!+<
M:V_AC'B!,0%5D_OTZU>V=R^_1BSU"LZD"@VF]B3&Q]_I[&3"'L->$']5_/I5
MIO,ST)D-.5^G.W?V'#&%T-KD7'=2G@DK\O+X 1 ))#CFYN2B8H]WM1.YVF=G
M2?%Q//]3)RZ<4%):ZM??EU@<,7-*A@= K."0JMDD> O3*Z0*C:^+0('#?_<?
M_Y@R=0KO:A5".G$%D#A5NGMWOR>>L-;G![5T''$HM6'3QCY@[HQ55H*HKDY9
ML  %FW*$PRIM!H/A22")-#TMK5M:8-5P@MBF"FL?U-34(+T75H!658:P?AXQ
M=%B%8.8JTYE-=VZ"*[ON=<7$Q%C^:@;#&-3 6]'&34'!P>8[<2CU6*_'G@*L
M%5V<@]LHS\3[*][=7;K;?^  <K;MVK5E6<OPMG8B5^,T-#>)JPYR8AVZ:/%B
MN*(,&Q1BN#O4W-KWJP]13BE<%; >@BM#5.GQ:ZTKAIH-5E(ZW:HUJU&AA@79
M0HL28YHM7CA09O=N5C@#M-^Z/3N67_;YP8,'Y"VLGF$P&)X$4D1O_W!+I6Z4
MJDW*O79/.A#)O:BJ7UE88&@(S+9Q\$J=#NDJ_" A@]$SJ#YWQ-9M6WE_5<8P
MEE=UNB.UQ\!5&A+8W$9YIF0LO'H*O*"^MHY,?F:8Y4YG9VY.+F_M*67'R&B9
M/R&.2;0,]X=:QZ[A1 ,'^C7)1:(ILEN1G9=;=ZS6L*_6]BQ:O#A^=BQU4-FP
MF49Y64)LW,(EBZWN>I!ZE\^=.9.V,!VO7$KU;C 8#(:[DY"4*%LU$)KG2!V.
M2[.6A8X/@8L"XO.6*-+4!;"*7IB:-BDRPE)K(-@:"H%$;<JNTA*3]S 8YJ&R
MZ,AAPT6'H\9O,&R#PO+O?_^;/%!3*HG;*,]*Q#XV@DZW=?,6XO. 8P(90.F+
M@E\[X=HU<@0I#YLV;7)ZN!A68% S6,:VB?8['8TG3ACV007=]Y%'7!$B2U%6
M914'JPQ^:(#Q" 1WASFHO5F9MSPB*LJ4(QPE8)BZ^OU#N*^3$AP9;@1K89T)
M<T'B%J#46;M^O<R]MG0"[B4ESTU/227S8FR;\&R,ROT' @("E"^%]QM^%8&$
MSL,86L/:CA5705FNH=^E&9E]3 P^0\ G7+Y\F7J@1G ;Y5F9(="1A:EI2$ D
M^_?OW\_)RL:3GWMN">-)4%/M=Y66\)6[E!>]O+TW%FW"4YU=%D2&.4@KJWO(
M;8JM%B#UP.$//J#GGDGX^OHZ/V"60ZWPA"0;?FTYDU;3@P,##I3O=VBHMF[9
M,CA@L*DK3+9VV[=NQ2*:UAI%A@E@/M2:!Q</!LHSRO+"DD +X%2H?._@CNW;
MQ4.J.JH1]]KV#0:_JJNWM^S5U'PEDQ;="7%Q[7<ZX ,96L!T1S/E@%,["8=#
MY=.O7_3D:-D)BYM^#5JHN8T4KLPQ^,CFHLT!0X:(AX3YY5G9620#,;$,@F-#
MG.K,&63NS&5+PT(FL/$?=X%Y<;,6+'<>>N]]==,@CO,?X*^I>AD" X8^Y$YG
M9VI*"N^'QGB _0<..%)SQ-%!0FWAGK(R[[[>AA/4&+C)*.VZUX4^A#AZ9+@%
MRH:5J-":+4$>@*H\0RT[Q^+?^5"5<V-+\\KE*\B^K'-34J0'!PS&5GX.4G)P
M8^?7W[>BJE*<92J?V&S>4850.;\V[35.>[:RO1R<N"3#7+K2FI6;0_[G+,\C
M,X2UDW#$]S#ZG3EKEHK3&;..N,6_6ODBS'^Y.@!60\5@?Q^?C9LVQLV.O8^D
M2>$XGK.!36)<%TS-@>.-G^J<G6-8V$:GBXB,1''%,65,\U Y7V^).Q"&%&]-
M)UL,D] 4=LY]O?NZ2_Z/F3:M_=9ME1-29O#R]MY57(PT6\>%@;2%(X<-W[YC
MQ[PY<\43L"VT(&>VWVZ/BX__[/AQQP6582]4^^SV5U8LRUP*![(NM[:B1MDU
M0>P%P"FRN%H[=NP8/H&EU+BX.%0J71W,W@)TK8J$J[345,/:!V2>,U!6D39[
M],C1?D\\P8$&W>Y-#\XA82$3,I9FKBE<96%O)@5J+A.2$AUMOL2P%MCG@DHZ
M/WM+.H$.=;2WQTR>PFE2GL=YTM?/MZ.]@X/3#\WYM-.:VHQQFY%G#C3>5$==
MZ/B09=E9^ J<#-NW;FV]=E7U]MX&[)P6ISH#/Q:# P9OV;R9NI*A0>AI"!;K
M)PQ<[>[;NQ?OB%*^/.I&/3/*)6&S!#@KF/=# UP5J%JAKUJS.GQ"J*,;&](%
MCIIJ@^\)RMVWV:4I]/JS9\ZDIJ=IT"B+00'7+2/PJZ;+>_&8YNP(J$%F_(NT
MM;C9L4AZYO_OW8=^Z^OJ^O?S8>7(:<"HCHN/I]UK2UZX<'6'W6O[].OG!+M(
M_/#TE-29OYT%CQI^+:"^MF[M^O7V#QS#5BA+!P[LX(QW]NQ9C11_I4\['.#@
MX&!#OY)TSH8'NAQW4IX)2N<*:0M2PB9.)/M=][KFS4WF3&2U7@/\Z@-5E?5U
M]637NZ]WT>;->(1*FUT[# )L;J&/=(8E("GSBS]_85";%3*$UNIE""F;,C\T
ML/<$?,CBC(R$V#CJ=L>%#0?,X'N""H^)5X-AF<.'JK%_5U8%:1:EMRJ])*L9
M+M+I^&F6# >@ZL!E0<H"@Q&9<-&\^?/[^_BP<N0T2+L<GYAX]O1I%34 ]-62
M^7'.#-ZN'3N#GQLK[E.OMB"?[-B^'5L":[F)[#U0MH<(,7&E]O3V#[>:OSSI
MJN!!C/F<\O/WY_]8;J0&;&TTE0G=1GDV$7?XX.[24K\!_N1@V_7KJ>EIK!4A
M7+K26IA? +M\YB;/"QT?0FI_3>5+A@ENW+AI>><Q [%EVU;>F@[:T4&+=YUN
M_ LO:C;_XQ)ZH*J2]T,#]5)*1Q7\T.3EY'!.$70HQR0'RO</#@RPPB!"/N-@
M^]:M#<U-#@DHPQY \U1R!"49/]0&&#ILJ&;+D5M#8IY$[]KUZQM/-(BGA5.^
M?KX+4]-<%,!>S8[B7<?KA6$)I78J'4E*GHM3Q]C$=;N@?!IZ7<6!"M$Q$-7E
M:MFK%Z:E(^F1R=*:@DS<,"R>+"5KPXD&C53"JFK%L&'#\#G^UX)PCA@YDK*[
MT0ANHSSK%(;O5(3V]_$I*2W%)_#QPX>JC];5:B0;N9SYR?/$7FI![ Z;&$Y6
M=68.J-P(O07>/AB0.YV=U>\?HKVDR(WKB"F=-D%:2L'*?$KAIVR? @)X]]JP
MGG1HN8;M(G[%T2-'^_3I8VFWCMR)3M>]KL3X>.+?E:%-J+QTN+J:FM6))]ZZ
M(F@>#NRSX 1_^P:7SIP8_V^^]98K@M;;.5)[;.VJU2HM,JBN(Z.C-JW?H+S7
M[A9_2G4%[6+'0+QG1\JDW#+NW[^/I$?FV5%3D(0>-&@0.<3_ZO75U8>T,QBF
MS-Z//_XX_P<&SV01>/311U5G#+D<MU&>.35K;>J"L) )BS,R8$HL3$N_^X]_
M."-PVB8K-T><ZBQ$CI^_W^[2W62>H0;S)<,8]JT6-5+#.@+R:?RP<W<WOZ5J
M4R?XIG9JR"R#A!_[H1%M]8G!N;POP&^ ?TU-#:4M.V':,]SUZ=>O\F"5%[60
M(Q4&RF >? 7Q[TKAP5G4@#0K4N-0:='8V$CUX#P[^EFG!\K34"H_U"ZJ$'*R
MLL5]*?(# @.QXT_GA*J70V*CH;EI\<*%AA-J3BA0TFPNVJQ:&SNBBE:5DT/'
MAQ2N7FW#L_A?816;95G+5"]A&<-58%%PX)-/BOM25=Q^N[VQI5F9M;2;4M1L
M+WG(8R9/@2Y1M/,5[J0\6\+RW-R@X&!^"\\.[>Z>'1MK[&+M)(.]4/VB([7'
MRLOVZH#!ZMIUZ_!0F^?%0&_@H8=ZW.)*MOH>UF]"^3C @N;A0]5X7Z6S4SCB
M[S] :_$ 1X]E[K6ASBR%V<O;N[BD1 MS'<-")BS)S%"5(&6[BJG:&.S?E>N%
MOBK@5'RM F=.H5\DGR$I#9^PUA$1PQC*Z6EP<@3>7;H,>/V4BE)V;HXS0]7+
M(0[;<K-SNNYUX4/\KZ*)Z>/E55-3XW(O>BC ";%Q27/GD("9*:T*GQK0>9C[
MY@0/&S%"7_'TTT\;]J7F572/:CBL5\[[<!47O[U(YT XF4Z>+@&!@1SP+*"I
MA/,<Y9GDB<J*"MYMB92-SITY8\QAH.>U!\J,U7ZG8\7RY1R.'R%K)LU)FAH]
M60>6NW!%2!G6 3/J?_[SGQY)JY(:J?_I)_L$3C- X1[O+DA)D?G4X52D'&]O
M^6"IBU"5F)&X(W.OS:FXXRI<O2I\0JA4U2<E   @ $E$05030F@"$OA%:>EO
MS)AA9L 9-I:<+!LC$6UG23%QY>WP<&L$*D(T#)%C>)MM. E"J%5&C!CARL"Y
M/R8$1'P0E8[C=754/AD]9@QJTQT1'FC,HA'A6SO$Q,30O1@0O=Z[KW?EP2JD
M.6LATE 8BC9N"IL8;I'!-IR2(VT3YV%.F!;D(.CRY5:!QU N&U\8][QX GQ+
MW;':BZV7R2Z6\S627O>Z[I'V@A;&<"<RZ+(9$S0&WNORP$,\1WDFF0-554B:
MQ(?P;]F>/8TMS:KUE^?ISQ#T::FIJ7#8:DQ0$*I .=8$NANDN4+<N-Y&S^"U
MYD'DKHX.CYUBBJ-K?V5%XXD3U GEL.>@P8.=&39C*!N&K-P<U K2I^2)OC@C
M(S$NWO&ALPA<JY3LVB6:_X 3XJ^RL>1HI7%-X2IL=>;9E;,,9<QH#RI_UM76
MRDX+(1?GLS'L@=)@&Y6+;5NVTD8T')>^,-U!G4W*2@D=>>@ASY$;K85TSO*K
M!H)5/WE %P/>7I*9&3H^A-.&T(_#4%)2@D?SS%<U1$,&7[0H?>&E*ZU$#7.[
M^IEHSC_AD0-W"S\'1$&\@9?+X3CZ6\@:M)S&NCENM+6)6ZK&@/)3XYY_'MZK
MJ?SF(94@E3F0-#ECUDQRKKNK*R<[!ZH?\%Z-9"E[ ?NE*M\[:'#(*9AW[MBY
M V\KQYPUE2\9JJ DNWSU"MFQY1$@E=O;.Z1CGI/TI$6_T]G)NY<GAD!4=P-0
MV+10 \ DP-L[BG>5EXEK4^N5=L["-G&O[7+@V!3ZK:RHX&>2*P)LB'^2+FKF
MCG&S8[%_&BTDC<.1QX V15)JOMG.DF*9M:K$8X\]IL' NQ>4<$SHO'LW)RM;
MMDZA4(B"QHZ=$A7-.;&P/'CPP#DOTAHD4=(6IAM6#<00>RYI5 V[UZ:,H5P(
M#H!??]]WR_:(2\J9SC!J/7HH^\V?-Q]E1<X]C?F)31/LXW!'H&<35 .0H^2W
MOJ[^TI56ZF*,:Y/LVK5K8F&AI!H]O8"(=U]ON.ZF=BS/,1ZB/"N;C8+\@L$!
MA@$EO'*5ZI6>!&QQ+[9>SE^QDM^2CJQ:LWIH0*#9&QE:YKOOOA.W;*M!@,$2
MORZE)X)R,FK=8V)B1$'3F#6L='SX\.'.#J("V+6'MI'FS'MP51VGE;8# @.Q
M>VWGA]88I%7SZ=>ON*2$=[X-SO&_L'6$W1GRH?7[]^^CY'-"@#6!/'^B.-3@
MR![L'$'4"@812CN.L) )FLJ0[HLR&A>D+) -=4H":-[R/,XI?2[D^1K,G\X$
M5<ZB'PT,K*6E;>)>FTA6KBT74, ;,738CET[\5&SMRF/M5V[AIV'P9FH=@VL
M8Y&-&[E5R#$XMND.+-P9#9M4O;X@/U]Y(^?2K-C8TMQQNYV29&3;.L.TY[#P
M< Y\*>PO<$I@S>!1E2 LP_U]?(J W0(ZA^J[([7'2&^9>Q5X2Z ^+6O9,L/:
M5"@C3IP(>W&4-SHQI S;:6YN[E%WJ5P3.U!5Z3&I#TOTFV^]R0N:I"/6F'60
M</RQQQYS5AA-07P0-#0WO;UM&SYD."U/([\!_D>.'(%C&BZOT&#',-I >M3J
MM6OHO*H,)!$]Y5<2YV&] KGEE,N3TC0UQXZ>.WM6W)%K#A[9L#H39>SA(]EY
MN="(#)_@A*7=B;\#!U7C2IG[G__\IR->I'U0#.PL*39T:V+D:C/:&!P8@-UK
M:V>L# Z H^TI4='\PC3F[H%=[? SZVOKL@0'=9JR![8<MQYYQB'''5@X_ODU
M#M0&"1H;&I& 1]WHVJQ8?>B0+%-1R$6UUZ9/1Z%]^.&']1*<FNVPJ_ HY9DJ
MPZ'C0Q8M60)3:,7RY9UW[WJ,MD!!.@(1:]:O.W/*,*[H/W! 24DQ9Z2:\\C8
M\%2:&YOLV%WZY\\_=[N>8V/@;'RGLW-\2$A30R-_B)I2J[00%OCE+W_IS' :
M R=$8TMS0ER\:!/+J1LU>7E[EY26DK6IM3"RP0'YC(1$].^JVD8J^_X5O=%$
M1.LED.F%?_WK7UT=%E/L+MUM*%E I X*#E;.!F)8A>H<8Z2P[=M3IKP41?ZR
MK"R\YZ >-%7UK[6UU;YO<1=00JPI7,5O4?&L,W@_\O+R.GKD*':OK:FQ,JC,
MH]_EN;F1T5&F;B"EFU,QX2XOVXL].SHRR(X"!?O;"]^Z.A0] J;F(WT?$8]2
MV5*O+UB9WWZG@]/&L#-'5C?$J!F=$?TY^+FQV+$Q)RDU.HTY.?8HY9D"1?2*
MO#R#ZQJ=KOW6[56K5T%9TS/4!@SYEDM76O?*V]HU:]?Z]?>E+F-H$-74@2D+
MU^NV$7 OTD_0,V%EI)WLH1Q6-1TYB*:3+3(/J)2&9N331@YS@=DV]2UX%X4_
M/C9.YAY<:=3$<1E+,\-")C@GG%:A;-6*-FR$:P>*0+',).5[]^T4>OW<"Y*X
M>.:VM=RZ=<O)U@0F7D2=.E!5:9CN(;?L$/YJI?:P&B,UJLO-.AJ:FW@G84KT
M^HBH*%)W.;0'S2ZS6ZFRX'99I;&E6=2<E9$,VI>*JDJ##R>- 85>]+NY:+/H
M/$Q^D?K-)+VD4H\].Y)T=*,$14'E?3YS%IMM2[V]>!:Q1KZ4%/91SXRB3I!-
M)$LD)B9RQFL&9S8QJ"DW>"\&)PS;8.1Y04J*\B$:49LQ'JL\DUZ9K=NV>O?U
M)JER^%!US;&CU#6> ?F6S(Q,*'_/F#43.Q2A+F-H$%49A219T:8B8V:N5B"_
M=W[R/"36:*1C$D+UE'-&PD8&G+-R<UZ;&M/6UJ8RJFD<+V]O)X^]JYJZ86OM
MA+@X>F$M^47HYJC)T0M3TQP=2#NR;?LV<>U &[*67K]FU6IH>\9I1G8Q 4G<
M+[_^RKH[@6FEHYLG&(W*%T$C3[*+2EG!RGQ\ SW%CN,&#1JDD2YI$H#;MV]9
ME.MT*D[X83EUZ'>9>"RJ$Q+CXU7K!%2FLG.R'1$>",F'/<V-.MU7WWP-32ZU
MT] 8 Z9+Q<&JN-FQ_!889!8!VTG)<[%[;8V#4Q,I^1N+-BG/F;V9E!?48#6=
M;*%:-)<7?Q.0H,H":3HKZ@S>K6[>O,EI+.NB#T$5+W4(FD:?.74Z.R^7G"13
MB!UJ<J\<&[C[CW^H=P+*K^.$, 6-'>N@M??LB,<JSR1/C!PV?$YR,CF*?E:N
M6(&U!4V5@9XC3G7.R3Y[Y@PY.#@PH""_P"WJ-0;&F*!VZ4HKO\(G$?)L34J=
M_-ZVZ]=C8F*(_TS;GND(5"T&E=OM=SJ0VCQNW#C>-S5HY\PC/'S(T*&<<YM#
MZEWX*QI;FI&4S%MKFPB)7N\WP)_O0'$K1@P=EKELJ:4Y%AK82_U$A?GY*'XX
M>7NO99>_))?^[6]_L_IFG>[FC1N<XQ4V2H*D7H27<J'L3M]:\);!CX9"VQ1=
M^&I N"0!N/W#+3.]-M 859Y%J6$ZSF'?I9H0Z!>I);(9')PLMF?,FHE*EB/"
MHPP>)__V\^?.6_T4O?Z?__RG=DPN+8%D@)TEQ9F+E]SO[N8XE0%8<B3XN;%%
M&S9J_P.A!2Q2]9'";W6WIO3)*'/&S8YM_O(D]7Q[!=7ND+#A.I:R15>] 58@
M__[WOUTK(\%Q?E(I\>8G5%\\N ']["O;NZ-X%S[P\,,/B]<X,IFHQ@OM+EVV
MU-3  $2O7[YBN>/"9B\\5GF&K,Q;'AHF.-7 TC8PWN8TIC#T!/1%2,0LW[L/
MBC6;BHKP]!MRC:N"Q[ *G<+[SOSD>?A$#Y^K5S3_2']&RB=20;$*37!MT5"=
M,$:V&YJ;-FS:^-KKTT>-&(G49KY>MK9#00,%'TLP2#B+CXT3-6=C/>+"]IJU
M:U%Q=J\J"X4V/25U3% 0OV,V]Y+!3' EBIF$N#B\^#,G94LB!&@0$LYK5Z]:
M?@^1Y,Z</L/)%3:[I[A2(Z*:!A*]Y-4)28F\*P&B,RCDSI___.>."*IMR()A
M(DAZF7]73C!TY.1BGX-"*+V?3F6\?:R^+O9WLPWBIMS@R,O;>UGF4H<&3!E(
M C^>;SVGOOG&Y3;P-K"KM(2VUH9=M* QS<W+<T4 ;0>W/DLS,OW\_0Q'K<SP
M]^_?1_HS:H[),^T80@>! GD=S^U2]  J+X67??W5UZX5H:%0!"N-@(  F#_I
M5-#KUZY>0_1G<%AF<F_?M(/]LTC"X9=V,SO"+UR0E#Q7F[/2*/[+U0%P(-#<
MZ)W=[SS__#C2B7OX4/4KO_E-S.0IG*?HD_@SUZU=!P\I<Z'GC;=[,#"E$N<D
MM9'JO@?#S@:U1-[\(RD-J:#H?\"0(6/&C$;"V8@1(QY__'&7MX4H$O @V,F3
M?/=V^^WVCHX.]46VJ.$CRV)I\.!!G$O+179>KL$;D*+-@]O!SXUUQRH+5\+I
M"]/G)"2:S[WP++@85=WQL7$92S/QTJG2>:W79DU-399>"N($%48D;: OA=,6
M'/JQT,I#!QR_X=T[G9T+4A:(WIY)HD!=0CB.E&<MI(A><BISI/:8196 O+HX
M=_8<![19Q\TEUBN<WY (7[-^W<[M;ZO<(\7\C%DSG3FQ%L;&I2NM*A,7+>#<
MN?-V,P)W%@E)B8;UG*EZ"1[1Z2(B(XG;<VU"Q3E)T_X^/LGSYB'E"E]DOKQ0
M94JO1_550ES\@<H*% -ND;B7KUX1\[ EIFHZP_R4\^?/:^'K8!APA/=]Y!%X
M6J7>$_1G]'=16CJGJ'P<D6JDYC0X"["@W0\(#"S:L-&.P7 <GJP\PPR!*HC"
MU:N7+C%XYU^Y8L7X%U[$H[):* \]!(5_[?KU2*D@HL_@P !E+G3WS^PE0%FV
MH_-.0D(BKRY2:6>S"@U'GJDGZ'1MUZZA_[8\UNZHJL&J&9C2N#B#E&FVOL:V
MILXO%RAE.^_>->@DJLB_ LEGS@N?G2"-].3(*-0N\C/236=::N!=KE*N6;7Z
M^^^_Q]6:]BOMHW6UO-DP9UE1E8OC6S=OF35CIM.,ABC-&>X>J*K<LGES^^UV
MP]50?P:B)S0'=5Q0S4("W]+28JDF !*H[?IU).V%A4R '^*TCT*OWK!^/38]
M, 2/DXV >7EY.7/8F8!CH**BPK;;4;."%&]H:N[RK&("I%_-FYLLKG<(<PB5
M(AB]?F[R7$[;7Z1:-O$N4JC>WK9-Q?1)[2DJ5;1.A_5GJG-3L_!YV!*U&0/Z
M2E >;O[RI,NGM2L3<?#@0;(1!5493]"?;]VZM6G]!O@$AV9:5*'QS@+,YBOA
MK'=?[]_O>==!(;$[GFRV34WK2HB-"YL83LYBXVU.V_6=Y:!FJ6S/'HZ87NAT
MFXK$N9$.M<U@. *<(=OO=.0LSWOA^1=$S1G7]4J#,>N?KK*KZ$I7N=+)*'OZ
M.2-=X\:.F*VO=3H\7-;3H%H)>F/E>P>?>^ZY1KRDEA*8'%+P?CMSEG."9T=@
M#1P:'F800$W>P__J56;5HB/E97M_,VD2Y2)>4Y!J=M/&3>20);>)^5SXKOO=
MW2__^F7HV])!@82[4+R^V'IYW88-SXQ^=NF2#'Z4AJ2%6L[$3(V>[/+&%)I;
M'Z^OQUNF;U#J SE9V0W-33#KVOVCE'/.#U153G_C]==?F\ZO,6G2=B9YWKR?
M/?ZX?<-C(7<Z.P\?JK;Y]H+\?)C'-%N$4<Z/BHAL@Y:]JC9!4BOIY>V-AYTU
M^T48G=*@5P =# L/IRU*5"$74/6 H#^O*5PU_8TWH/]1#8*"]T%UM?DOQ2@:
MHS5XB-YUJ%;=_!B ZN<H\NV^/663(B/P^E48QQ7&G27%TZ>]QCL+L" _(,VY
M_,"!4<-'V#T8#L)#EGBU!#S4,V[<.#AMO:Q\GQ::_)[S:D0$7$$D:4Y2T4:#
M'T4/^,!>Q9':8W_X[+/ZNCJ9MQ@E-@P^FQV2M63,UH50H] ]#N2>?7NQ+;33
M0(E;6E*J;GG.F8K_3IO6/=(.6;DYO%,WTUB6IGV\O&;^=M;2C$PX-JL=4'V;
M-'=.W;%:2V\PGJO]!O@'!07Y^OD]TO<1>DD2.X%;!WZ<5N#"^0NW;OW #S5;
M6;@TE3_7KE^_8_MVVVLSG6Y,4-#H,:,=%^TXPI$T<N/&3:.U@0+_@0,N"/;/
MC@B2*D1X0%J';"% JY"28$5!/C8<U2:H<MZT8:.UWX@2Y=OS%QP4).>0E9/-
MN\LQB^D")1ESX2%HNP?2+LA$9:N0OGK1DB4K-#"_'4KU*-\F)\TQ>JFB?4%I
MM&K-ZH38. >%C1_XR<FQH@7DN)6%!9K-,ZKT(N49(YM-I-/Y^OE>^O:B2T-D
M"Y0RO+.DV.#30J_W@*K<?;&\GX)<V7GW[LFOOOS;W_[V_???(\GUVM6KMKB_
M8MC$WOWE<"$W>Z&:#5 YK3U6>PXXP^>Q.*$79V0LS\TU?YWK.LM,3&A$!T-"
M0WLZ(P"*;CJ=EY=75'34@I04O-JMJM5QCUYG$Y>NM&9F9(KR6:\IQ0&!@2<E
M]=MQ6)BFC2W-]'KIGH*#1$RS$8MR]?QY\VTOOZ @)"7/+=JPT=@;'3$IVNS3
M4!/\?O6A/>^^:]MT;DX:AC'[.I=42L8J9'(0J3J_^<UOQ#DF/0&DLM\ _XC(
MR/CX>+(4N8G . [X.CX/)\^SL?='SHQ9,TMV%2M?8>R(HT$UWO28:;)#%C0]
M8X*#5ZQ<@?TB&?L*T[-75$LKDG-4BI+)#A>WTYRY7J@\<[CG"<FOI"J?.X<,
MTFI_A%:9E5'%]\+S+T!!@>@#VO\<CR0U/>W&C9MF+[M]^Y;YYJK7"-^N0:>[
MT]'10UF-NA<J;YPP=^[SSS]O;&@X<_J,46G>DE06KD%RIV:'6TUPH*KR][O?
ML8O4PD-,Z:1X\Q\X(#0T=-SSSP<%!4&[+T<KT@\>/,!>J<GTX#]__KG!PU!O
M(FCLV,^.'^<<$-56R:9W.CNW;-MJ,'!PQ_K3V.">3N?G[_?M^0L.:M-)9H:@
MJ&[^\F39GCT-)QIZVAE!ODCXD%FS?CMEZA2D64%YAC-I/FIWC;KI9$MC0^.Y
M<V=-.9XPBS24-_.WLY8L7NS7WQ>^PA(MVH[?9?J-G)IW X.JTT.C,R/F,X,#
M U"UC"KGB%<GX:4BG".4PA>AA#::AVW]7K\!_C-GSHJ9%J/:=:L:#(?B@Z4"
M92J8,S.,C(YZ;?IT:EUE8U*-\A2DXF 5^J<RL&^\3O/R\MJQ:Z>J_:_&]9?>
MJ#Q?NM(:%1$IKMK'\>GWYQ-?N)&I/96/$^<D&<0UG6[&S!FX2TSC.<_S(!$N
MV@596"F[HWCG0=RY<\=>Q83W[LMQ?__[W[___OO;MV[?N=/!3U\TV>%J]3N$
MNY"B\NRSSSSRR*.J!J6//_XXY>[("2"EY>177S[TT$,__?03EB%X[^AZ_84+
MWXJ6%';'N&0P)CBX;]^^@P8/0J=")O#=ZH,&#:(&0)2H]DM^_<TW)FZY^.W%
M'^_]V'Z[O;/SSNEO3JF$D.N!;P(W0O V7+%_O]T?3!(%M=HW;]Z4WJ;#FIY>
M .W^ZU__:FUMO7GC!N]$@)HP[(X5K!$]9,OV;=C2TNZEN^;8451XR73*2Q<O
MH8S][07>#,K,U*&>H-,%! 0$#@GLW[__SW_QBY___.<D#*C CA@ZK.<]7T2E
M.5K'6Y!B\ZZ.=H1BR08[Y1.^<A[]++'VUPFK1>"*$?T^^NBCE%-NU3Z+G@/[
M#2]?O7+CQ@T2!EQ8[OUX[[OO;O(M%*&'1<9(IH43K;V\O8<,'>KGYPOGH8Q_
MX<5^3SS1\_R,VU\"KIP-IGRJ(;1'3T% 8&! 8("?O__ @0.?>NHI\K&DT7%.
M6SSJV6<,@[TP*3G.DF0-&#(D(C)BVK1IQL)LS'X!_39_>?+8L6/'Z^ME/LPI
MU"+?U\^WI+14XV[JC=$;E6<.SKZ3A%'<:\ZYB<Y) DE-=? ;X/_YGSYWNX$I
M3P(E3414)&Z3C/GG4(&J;E3K/H:]&1P8\&7+R1X^A,CQ2 0T'#7=-LO-CVWL
M9#%R)/BYL9_6.V0,T 1\131G+J>7NW:CPME#\5191C@UL4"M*&%+41//5HTK
M4Q/)J(^"][JOSM8#2 P[(M>A9V;GY<HFS%,ISIFL)-TK+53+BTX7%!S\:7V]
M@THT/VQEHCJR2P2:?HC\K-*TV^9\A6\T?*"%X;$0RRLW>>7L.)21IN)LPD2%
M:1N6?;[J&7NY'?%1RKU4Y6S?3Z;>H@#E8<JOM4.9%!DAZZQ7S>U4&5>[)B P
M<$S0F*'#ACW[[+.AXT.4!1!OH,;Q;W_[V]DS/ :S!>4SX=OEA(:'O;/[':6V
MXA8J&.?92U69 -7+38V--ZZ+ZZ:</7T:KZO) :LA+2<AR<0KEB^'QY<N6P8-
M8[3\"1Z)U,\M5A:V]$SA6H;<V"L%<:?QR"./]OPA>-Q 5M!(>AEKK55;=-,H
M<X(175K(/K)5')U4#R@E;]7,;,?7*5^A5 "DJ#8="<3B#EIBFW\[V5#5ZGLX
MN.%6D+AU1$Z#F5FET\2LK.9>\:]:Y^OU*:DICBW%)O*J7<;K3&OFBN-VU)P-
M :!>:FS7FA>8OYU\H" ;.-HU@T[NSUR]'E-MF'J8N(IPJ)1!M7XN!^9J8Y^C
M[/>T652CW@*>)JNU'$]_/%^ !$:U'82ME3+IA=VVZ]?%"5;2!4%CQTK/X/,5
M[<Z#BD!EUE*4-2\OK]5KU\3/CE5^A1LI+[U1><:U26Y>WMRD.211MVW9BM?5
MA/6.*T-I'!+"[-P<."D_;&(XMNERE\SG>:BWTQ;<9DK!Z!W"M[,18M7/S]?\
ME18@EC72BIANK8T=L0$C[9.QV4H.1ZTQEAU1;EOU<.6-1C0-PT'IE-E(P!?
M.<QFPJ,,C&IG06\HO#K=BR^^Z+C'ZV%'I FMV(1TZ';("PN27ZEI@0XIUV:C
MJX>=02:*L +X=3:[I9#UN9C0'WJ83XPH">(ID'6%5D+V+8XPTZ"B3A8D$Y'?
MD_X^U5Y+M<#1%_?L\RD/([+ *-](7=##I%>-.G"03"JQ\?G6A47OY^\G"YC9
M@F96RY6VU2<XF-"6J>/RAT=$1F[9O)D,.)O*KMK&D]=Y-@;N$)H<&35CY@R\
MCWZZN[OQLL^4W.FB,)H"AY!?<;'Z,#GHY>U=N(H//YFVY$:YT&,QG03XK*H(
M#M%D)G1[A%CU\_>W2QG703G)6*(;$ZTL?SXE;9!=^9-)#4#N=4$]9JS[P-A9
MRQ]+1:^RVQMV8%DL!>KE$6B+YLP!*8'Z]7A415B[/5MF1F'Z4G'#YM$DC4"5
M<8Y+24WA0+<XYR ITZI(MNWYRC)BZ:VV3WO6J]8//0@,%3+9T^##%?65]$)#
M#XB-+S45'.,?8EK2X'K0.:)7C+XJGT]%E'1+3V)#I0]"&0S.B-&!74H0;&X4
M87-:XXM>-'+D2$-XI&^,C(Y:65B0E#R7C![+OAK6DY9$B^EZU?3M0@_@QT=J
M*O;O]^G7#X9<[5J]:^06:^B-(\\8E#8K5ZZLJZT3?0GH]8</51?D%Z!T=:@%
M6L_!&>O=/7N@&YX9,V=@GV<:'S;O#1CBWG3A5^WX5&V#&8[!L:,W5/\Z==R:
M5-:K9A4C'>>PU;%"\7 73/2F*R/6XK)C=>>WL>YVY0!7;RC".MWSX\8Y[-F"
MQOC33U8,B[E[A,L';<(FAD-?N(XU<Y7>832'VXQR/-":Q]I<5^LHB=_81@]'
M(/5&QEU-/M;F$763P3'W0%@[<7*M2:]F-F7QBV5/XXQD)T7]3$9H>Q(/>KUB
M[->TCF<L>%:A.F8K55-\E>5$4?S11X4Y:"!ER\KW38F*A@$X6E?[Z?%/SY\[
M)QIFJZ:[B:B UZM&FI%Z ^GP<Y.3\9I8G$F%F5R@_?$_K2OW#H(DC&&%9($M
MV[?%SX[5>)IA1/<  GX#_"]>^-:UX>GEP(E,C2W-__[WOWMGR7(O7GS^!3MZ
MUZ.\?;H*[&W;R2^]T]GYY==?::JW&(6$.)C]Y2]_:=;;-KP1?TCGW;OHHQP:
M2(^!DM+L#O2VW7O ^="^U90J&JF["*C XL$ >\G02&W0@E&>,RMG\J476R]_
M]]UWSGFIA1!A"6=O.&1E,UK+PY8L\6!?4 R01#>=TU![?>AP]>E3I\^=.ZN^
MMKF)?@'5*]5.!00&1D9%)2?/]>OOJWUEV%HT).LX&9*63SW]-!G"G3,O>=/Z
M#2X-ET50KGT7+5FR(B_/A>%A4'A>3>%YV'<"(4MQB-9BPZKP$+-8K7V%QG%<
M=/6VA.AMWVL:N\2&9J/400'3[/<Z"&U^KS9#17'YZI4__>E/Y\Z>O7[M>EM;
MFTQ5YHQ8TE&04\+U8X*#0\-"7WOMM1%#A^'S;A$/UM(;S;8I$Q'_ ?Z\VVTA
M^;&AA?8=OLGF0'+<(X\^0DY1OAP9+H$E@?;1*;R2]B2]-)+6RJ]P9CZT8WS:
M%ZM"HO'*7[,X3@>P8R>7]G&X5S#WP5Z?3SU'"['J'#E-"U]J#/OF<TU])N5U
MV"5-L.77(Q47:KE'ZVHO7;QT^_:MMK8;5Z]<N7__OOK$!&F[CY?7T&'#_/Q\
M P("1STS"DXP(=W0FDH=>]$;E6>8D(TMS3?:;O!;0C(_^NACL%+3<I('! :*
M\Q8X[M#[AUYZZ24RYUG+-:8'PZ+=[?"\]%(6?V=6",1L6PN59\_[0%F)MA#8
M:-K7G95.;5$?STX7\HV<)U90%@(%L)[48*J=+RZ/54JY<O3SM5E>M!PVFR$9
MS%65E;6%1:?P_8ZT7SP'AQQ7G3*#3JE.AJ*>!@]Z6%KW4K-MG(K9>;G[RO;"
MKI0//_XH?$*H2X-F'ASXU/2TPX>J^7VA!\B[K_?<Y'G8>-O#\JA;P.+<3?&P
MA%.V4D[^0$TUDU;%@T;"[.XX-!I[B4JIJ4+D*NR2UJIQ2-9R=RV.Z&Q2OL)Q
M#^\Y&K0(Z#FNBG,;8D^U?:1Z0NW5:'I&XD)ZJ?)\L?7RF_/?;+MVC=^1S ^"
MQH[][/AQ%X?,'"1/7[YZ)3HRJKN[&RK_H6&A[^Q^Q]'.11BFZ24C).Z.?9-)
ML_*NTR1%365[U3 P_=GNJ&9[.T:C;>GH 6BJ-+F0GG^^!C4TY^2K/,X  "
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MIT\]_3?ZA=[<MG7;^^^\J_^+^UJC<KZF7]\639LE1B9/F3R%+,/ZU[9M#ZB
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MO7K.FS,W?*=+MZY??/[OQ VT\OSPX^%///;X :;@8K ;E$U)N:9?WQ>?>[Y
M?+(6L??=>Q_4N++TNJ3W2R^^%.82"Y-F#QIT]P$FY4,Y.H8QO_*/5YHW:9KX
MYO;L[,NON")SY<H"9UJ4]9MA&(9A&(9A&(8Y%$X(\:R9,GW:S3?>%+?Q2MFS
M5\\/WGN_@.+54O;5UUX;^:\1!:W!1:C9GKU[/?#@@P44K-[5])]FWG#=];_^
M^BO]'GZ4UJC1"R^^0/')B3G 1H\;.W3(T/ESYQZP]X,\M.EU6EK:M==?=_?
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M%4[6E<U4^?!^Y@  ( !)1$%4)"A-L9)VQG[0$?66N!]ESA>R'OD1_9Z*4.=
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M ^P!UR[?%'4?^>@53?K;PULS(@HL'AD]$_."J-X65HOTC0X]"4/,US<"#K@
MSCJ*QQ7V8L5HF:,0[#BA.X6N&L@E2*_MTE73X]D%-8DM+W'<4IHTZ<9B^=%H
MDA?$(HY=83$K"[2"$R\9K3^R*R#_@SK2.$)@Z,6D$X&K%WCZN>K#VY*>/Z%L
M%")&=Y9RG' E3T%^]2+%(3P_83#H"^/24\OV"5Q4W+^#VY@U3O.0Q[4&N,U
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MMSVCE//M\OEGO?+LO$WK;;B$,F9;90=MV#.TL!6^KX?Z#]]>/N19&J(FQ9?
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MIE,W*?GZMF>]<56_?__ASB]NN_.A\WOV;MJB:H4*Y,U^5FI#(8Q1&%:M2C5
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M %FU8T?.WEU5RV$.9\Q/@V]#B:EO%_\LJ+B45/&YE/%E]4<OF#&@2R_C4.U
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M+\]6J379A@(J@H7C#494E91RP^^X#_H%'*<CV$N8@2Q<;CB(15O6;MGSJ]$
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M7Q)<W<7B:9@M655RH]K 6F"5;^%M;D];A,#',C";IKEY__]>SOW<=FG6Y4R
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M'I;YSP0TL_VB-C4^]QIP[*;1(A[FD6/J;/D#GG1=N%=PHSJK>4.WRA!6 P
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M^X(L0(2P%P  .'^ > 8          ** :4(          " *$,\
M $ 4()X!         ( H0#P#          !1@'@&          "B /$,
M      !$ >(9          "( L0S           0!8AG           @"A#/
M          ! %""> 0        " *$ \ P          48!X!@
MH@#Q#           1 'B&0          B +$,P          $ 6(9P
M    ( H0SP          0!0@G@$         @"A / ,          %& > 8
M         *( \0P          $0!XAD          (@"Q#,          ! %
MB&<          " *$,\          $ 4()X!         ( H0#P#
M  !1@'@&          "B /$,          !$ >(9          "( L0S
M       0!8AG           @"A#/          ! %""> 0        " *$ \
M P          48!X!@          H@#Q#           1 'B&0
MB +$,P          $ 6(9P          ( H0SP          0!0@G@$
M    @"A / ,          %& > 8          *( \0P          $0!XAD
M         (@"Q#,          ! %B&<          " *$,\          $ 4
M()X!         ( H0#P#          !1@'@&          "B /$,
M  !$ >(9          "( L0S           0!8AG           @"A#/
M      ! %""> 0        " *$ \ P          48!X!@          H@#Q
M#           1 'B&0          B +$,P          $ 6(9P
M( H0SP          0!0@G@$         @"A / ,          %& > 8
M     *( \0P          $0!XAD          (@"Q#,          ! %B&<
M         " *$,\          $ 4()X!         ( H0#P#          !1
M@'@&          "B /$,          !$ >(9          "( L0S
M   0!8AG           @"A#/          ! %""> 0        " *$ \ P
M        48!X!@          H@#Q#           1 'B&0          B +$
M,P          $ 6(9P          ( H0SP          0!0@G@$
M@"A / ,          %& > 8          *( \0P          $0!XAD
M     (@"Q#,          ! %B&<          " *$,\          $ 4()X!
M         ( H0#P#          !1@'@&          "B /$,          !$
M >(9          "( L0S           0!8AG           @"A#/
M  ! %""> 0        " *$ \ P          48!X!@          H@#Q#
M        1 'B&0          B +$,P          $ 6(9P          ( H0
MSP          0!0@G@$         @"A / ,          %& > 8
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MN;Z03I6S)IO\>WGRE/_[W_^@EWX/R/XS>^X<H9R#WY9+%B\AXAD] 0  0-E
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M[[[S+G4V)"$I<>*D26J$"P]C(?_(:V'(T-M5SXA%"Q9VZ]Y=]@$$/P, 0$4
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M95#.FO(6JE.[]I(E2QRIXP(=0 M^%S%();PW=T[[:Z\U#$/]JVZ49;SAKI"
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M\#69$2ISW+?P1MRP#1^V&%$D:'UA6XE&^CBIN?A7G@*VYJ[B8(<(%K(<8L
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M'CQX\-___O=GGWX&;A(2XJ'6IZ>GLU<'HSB<47BX^////S]SY@P3%R2 TO7
M P\(AQMQL7$9<&D<G&#.H.9"[+[ZZBN(';L/VGG=N@^U:]_^\4<?<YH^]80]
M!3EU\>)%-4:&$O^;W_SFM[_]+7\3V--GH9 7%!<5%19=OGP)VAEVDU6-QHT;
MIW5.Q3NE^1_/"@_>*>COE!H-47*'%+QM(>Z\_$16<./Y%"L)[V[=P@50M#7
M-7_U*W:=G))<>.@0=P]&Z;7KUW$=B2+'CQW'7UNVU-^X=BF?/'UZ].CQVK)7
MV2WV3-[^_ %]^_DLU>!@S.@Q^FOG6F'+'C*$#6$H@MK@##?"S?ESS?V3'3O:
MRB!$"HI?^Y3DXD)UAVKV;&%AH1"$V%S8#7DK=O6"AU6C1BR6+5!-G/-C+B$6
MZ@%4/,J!P.^??-)/8D+9@#*,)_ +"@H\GR+N<<AX)H@J!V^R03G6;QG]0>ZN
M7/]VBQ*BI1$P3HI^9=&B0P</"0<M<M;GK/U+C=CVR2D37IK@7YC<O7N&#!J,
M \M9MQ;O+B.+S87?FY\W>,! [&#-NK497;IR,T#1]CL!P42/#/F/'3T:9Z<_
M#<P>O&C^@I!2"2+R^NK7A4,[V=?9,V:F=4D?-WY\2'GD"<2Q:;-F_ O['TQW
M9CP+MJAMEV^KP-F&!:;%7U]_'70@045F\&B"MMK[V6?DLSV=Z)R66O*).?.P
M(W<76W;.RYNP'9JB;4(+G].GO9S9.VO<F+%.,R%5D[A:M11#H6S9JM4'^_>S
M- <]?M;L65O?W:*[TQR N247F*#VHOO.'3L*#A68*C*"'=\]-A  :Z'_@ '"
M#OQ.BB]4&5P18F)CO_SB"QSBZE6KA3DB9A^L7[NN=GSM(4.'LJ-6(^&MS9OV
M[-Y=<K1$'0BP#@DQLC5S*#4MK7N/[DT:-E*,^2A6PO66!&G)+BT)!M1KVY*F
MJ(7M$$10T5:30F+Z\4V*T1[U<%J(D6RQ@&&CO16<FIJ:T3W#O7%@N0;E9/&2
MQ?OW[Q=V/S*D5:O&^#%C0>GOU[\_'\I4*E[CW_C66WPDEUW,FCU;'@Y3_ W=
MRK]Z6HQLM+0 S&.4R-"\<!F>R>H]9^8L_-36[=M&#AM>$<EB.?1849):M0I(
MBV6<QB@;-VAH.9@Z&-1'D>R>DID[?_[QDA+V(+ANF91DTQK[6YUTX, !X3X;
MLK3-':&C:=DRB35$+*PKEZ] #P(=DSQ@K4:6UW=%N7SY$A? ?:+^YDW+QI]M
MVK11K.6<7:BQ0&T"7/!3OCT3\Y%'6F+C^>KE*R'-4A#W(+1LFR"J(JP[24I*
M4K^@4=N<-6O8XB[9L=-7_R&"SP,&#?Q]<@KHE[=0/Z>#>J";/]S<GY<'+L%D
M=1<&/1T0W(4DFY-OHK?\JWM_Z3 0[LZ5:U=[]NH%BOLQIK5PKP+F&U-Y>_=!
MLKRV:J5_;_W YS3T$+7=67!)$'16_*SG)#,#U 7(_2=3.FS;LE54V9E[]!1H
MC6!"=^K<&=+$C_PQ,3%<&OCX]MMOF0R@ K+R9LDO= W*)5@U3W9\LOBC([:Q
MJR#\A.+B1H^OYH#9HLQRSLC(T"UGUPFWW?OV/I6:FCUP$*2,J5X[" %JW^ !
M T>,LJC.+F9)#%\&J24OBP7(!KD/(9JC0CAVFC(*.B68)4^E=@;'@O"VU_PK
MOPGUHOG#+<:-'E/(1@3L+&<&%+#ERY:]/&V:[*T>$;Q>U $<.K14>DE3%+/"
M2I]@"4 B0 0%R6U]!E:L7M6L17,M1MIHHS.EY\]#C*:_/-W6'QP0B/KHHX]"
ML3<'L!R 9 1I>_9Z6L@1=YE#A3\(H12"I812OF6K5F $LF^A6L)AP$<6L*D#
M=._>G3O0)A([X%_9GMN1MQNX2 2UP[H$X1YXX '%=ZS!67WKF547M;>"G0H>
MOE-TY#"4)?X56INERY:&$4&6+&9WIOD >>K^B(*,WN8MF@M2?O[YY]@9_TQJ
ME82GQ(\=.R;X:2L;Y+4P3OW$8X_C1WBL2\ 9*IE)K=UB(="L>3/SB^9S65F9
M_\>)>Q RG@FB:H%7,35MU%CM ]!K/.7EY5V[=<6JDN>DHKL6R('^N.,?.HIF
M#,=N.D719J';M&W+Y<'+NGS%-NKX4*G-7PT=VH^T8*GVZ-Y#7Q"(WR5CDS!X
MI9PV-RO;SV&D"2\,4!(>82,I1NA@>W3KUHVEO,O(O?^9J ,'#H#E;Y_[QBR3
M<!O4&D@3H33:>EZW7CULHC#%"*PU4P5T66JHF6U]G^O#M-6*FEBS:F-AK#C%
M-&C84+ASY=I5L)S-J:J@_JXF3A >^LX=.TR54; 54:!8@&U;MD)ZXD-BG"J^
M(!NSZKME=+.9DA7&F+2O)9\<A8@XO9\9D)*13[EWZMP9ZH5Z(JX0A'.]2.G0
M :]&]E^#L&#PV6_  ,NR%#YQBF-G>)[<(<5]F0..T:SI,_0#?GA$Y'82I5[[
MY/:"/X8KW2P$/T%4RXB)M;&2 4L2C&VA=LAF>7@5!PNY9=M6(7;MV[>O_*6M
MJAB(Q 8-A$G"E XI"DI82!](V,CM9SR5"I_??OLM_T']#-WS^O43]2OMV9O:
M2%; VB 8OUM:FPGCQ^-AXC'CQH;]NA \==1Z@E2+AUOX>8J)9"YX,9KWP\7%
MLC-%J\NFRV"P[$(I=)&VN@J^6+QT">XXTKJDLQ<K<!#L0K7&41UIWL([%APU
M%M;6X*.//KI;5CD1=P0RG@FB:B%H/\-'C&!?V&^LU\GHWIT/>SM-*@HZDWO/
M"KZ!<:+KM4BMC*^3D-D[:V#VX$'9@^$S&2DEW%EI:2EHWJ!,XR58\L!S9> 2
M1R>;T)]Y^=UWWX&EJEH^1D<>$Q/3LE4K^!..Z^ Y!78".VDLJ*&$I;SBW+3L
MXZHE/L@#9DS1D<,N Q9^ F4/9O;JQ7V&OWKU$T%3>?$O?\E9OV[MAO5KUN8,
M&I(M3TJ #,.&#\/!.<Y#(M/B]NW;+TV>I-KJ5EG!_\3$1/X5_UA>7CYB^'#/
M*<$P">CO#?H<:\!%W:<DLV?/MFS,*ZU]P(JF^LXA<I#4NA54PVDSID->Y*Q;
MNWC94JB,4#>#0<N&0)">"Q8M0G&R,<LM43;HVZ^?_KJ@06R-6,B+VO&U+0(;
M91LB,O3/?^:>V\XVXZ8 BFCKUJV%4UY-/Z5U#?S7WIE9H0[&,7EP.7QK\R9U
M<REKQ,'B&CAXT$#X-R0;TE:?IS*T?'GQK56N #288*\>X^MF%>N FFUT-&?/
M]GX&^X-_9PL3+*M:-" O4M/35&GA+WLP7*MK!ZQA@;'=OV_?@N(BQ2[]W5/,
M'9R2%]@VSLALZ]ZC>R2>APJ3I("-8!K%)C4U5;&6$'7S,*.LLOMOKEFC1)P4
M'H50ZGD]_:G.UJ<8$3E_[APN[?*8%%]#H=;6H'E&UPLC1D82M:N7KV#+WWQ9
MS!4N4FP-=&9U,'CUJKD6"3>G4)?U<FM(ON25Q<*^UD*AA5_5,2_4<8R?,,&V
MB8:;ZC*-H+DS2./&C17?[09X6+UZ=7;%[ERY?+GR1X6(NPAZYYD@JA#R7$27
MU+3D#AT*"]#1(*"\GC_?,Z,[:%'0E_!!=Z%3P<NK%*3NRUW"J;-G^O7I:ZXY
MU!R [31I\F0(7=;PEBQ;NFY-#@N2?9:5EG7MUO6CPT<4U.7C0?1HI(T'_?KU
M:].F3;5JU< P@\\%\^;KMJXF))AD+TV:R'5]/I%5MVY=/^*]\=<WN&^=T]*R
MAV2W;].6/P@)N&CA(HN"K@6Q8/[\;NE=HA+]@'8*RT:\KXD6K[+2TA[=,B)\
MT9I)&%^K-I2H@D,%:>EIPX8/YUM8\7S,Z-)5T5843YTR!:_K!I'@INV62!9;
M&LTQ[MJYD\US,@=RDFY\>_-?5[]NSM-JST*@,V;.7+URI1+U0F649)_>"G-0
MBNV:"V1M0@E1CU$-F"^+)J<DJ[/QVN-0"+&WBO;.X>)77H&+K*S>V=F#:\?5
MDJ=H%LU?,&?>O)PU:_ LY9HWWQP\>!#;-TBH@&+U-^3L/W" /LNMZ<&]LK*@
M*O'<A_K^[M8M2Q<ON<7.]34>+"XJ J,4Y!2BKTA9 W:FV;R@)0SJP%Q65DI*
M"MN'C,=K;W[>B<].Y.7M"P2JU8J+XUN%R3Z[9 V^6+)X,790+['>PD6+>*!\
MT\$KUZ[FY*S=MFTK:/GN.C>+D;R<OG9\[6>>>;9]<GN\LYJB[9)P^M3IO'WJ
M4!';N<JV';8L3-" [!@]=BQ_EQ4_]=JJE9 I^DND^KQE^8!^_?;LV\>V0E"L
M)3,20YK[<_'B12:'+EYL#'LCO=( 22";]#;0*$L9W3,4:_&.JUE3WP+*J(#Y
M>7E3)T]VZ01]ALZO6=^!:S1\_NM?_U)\)++%0<!<L,!+%!=2R#N@H+C(7$,1
M#$(E>GWUZC#BPF/!7H?!POSB%[_P[T- 77S>4!\7T]*![RZI6#,%2OZ0H4-?
M7;J4!0PWH4GI^UR?["%#IDR:A*LM>P1JS5]>>!&'-3![,)]@%S+1-,*-'/GE
M+W^)H^F9*0T;-3J&%G[C6!"$#4&"(*HJ8 ?"Y]5KUYYHTZ8F(RZNII5^ _J#
MZ2(\(GLB?,4W__344X*???KW<Y<*NO ''GS0(D]<W(1)$YV" Z O%$*!.S[3
M(8QG_]BID^DZ+@[B*,LF"^D4'//DP=\]N&O/;J<0EZ]<(6907-R&31N9_TY!
MN\.?8A=@R3S>Y@DY%/852H*0+"$%^G__]W]@%5R^>L7S\1.G3^FY;]#CZ9["
M4T(Q&__2!+$ :Q=0L*$L.44<[#J+>^T/JH/_2+EC9K01"D] ]Z3S+$AJ\4-Y
M!%F#TNIIVT26"Z$?2:" ":5T]MRY[@);ZCM*7LA$+%A0*Q+L0F^"F&/C$^ZX
M",8?;-J\F5"3H/"P>F$+%U40AN/>&@@%3T\?0V:HPB?/G):=88$]I3)C9%0]
M'B.GW+3U'#N&QE.(%"0O=R_XQO+%DBD&4/!D_R.$^R,4&"A(T0K"/Y9FUKD0
MZLZ02Y;O$2+$5ZA$4,U#\F3\Q)>$))6#P%AJD_:4;3_H4CMDY-KDIX'%0G;J
M;-$?6%?K!&X).<U:-(?\XFZ@FS/["X.^_?O+0?-KZ)<%]^")4,==$A9^TEM%
MH[3@>D00,C3S3!!5%SYDNWOW[J[=NI:5ELDO5N7GY>?ORZMS__V#L@=G96;J
MAU4X3_P*TU K5J^R;,@1"'1.3=VX80/V)"C-:2>W;??J:\O5/6_1>O*M[V[I
MV[>O,/]9.=/.0>=W+]G/_&90&H0.HCE#1VFU"&[8N#&E77M%2A8V>?7"B)%?
M??65.BV )A/V[-[-9^?"0! ,.O8]N_=8%I"CA6I0#* P3$V('S)TZ#-9O=E[
MFWY""1K[,+,=L/D=VSE5N&[6N$EF5B;;G9A%MO!0P?5OOF$'Y]C.=NKGBZ#)
M9[B(B8W-S<WEAP,%I=G+#>O6@TYS_-@Q,YK:"LRIDR>'EYXN2<!"W;ECQ^'#
MA[U<&S/JH OV[X\+/(]%M6J65WGY5@)37YXF[%8M3[FP3SR3']34.WXJ&Y\L
M#6H[RK[S]CMX?^S\_'P\DX-#L2GAAI!)K9)V;'_/^DN0APAYM'/7SL<?>]S<
MY2L8A$)8=.0P+S/\*1S$K-FSU$4**-\3&S38N7.'W$PIUE*G:$LA^'V<4$$?
M2S&YXW_^XQ]Z-#49DE-26'[9KAI0C)EA 5P%YLR9(VQ$GUB_/B[&7 "A5,.%
MX#EW?/K<67TMCP%+)>Y>\(WE"U0W"/>QQQZ]^8.Y&?OQDA*V(L!6AO!@/GSS
MG__@E%2G/>-K"WD7=A#^*4#'4$&HJ6EI@@,F2>_,+'5F'A57=E!%Y$F!0VG9
MJI4Y71D(%%BW,?/T1#\L#?6ABFLG-7/63'/)3S"8]4QO88_]4 %OO_ON.RR9
M(I52VZ=P.L3PQ>>:_/)[!]C]6^LW]!\X0&\/C8I\^>M+LV?,A/R"Z@FW]?,%
M$.Q0#*%]P#7KQHT;I@S:9\U?_4K0?USR'7Z*C36V>-0>/R[%@B P],XS051=
MN)H(>M)'AX_TRLQT<GGIZZ_GS)SUQ../3Y@TD6W@%$ K9FW53>;@S3?>P#?C
M$^+9>E&LL&*O^$\97;I"E\8\8ET.='A\"9D?!3>*X#[5#%W2/[@JB9T%_*QI
M# 9?'#V:6<XX4';!;8SQ8\>IK[&AN)<<C:@/ELT&* E'#A\&M0G;D_@!T*Y
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M7HY@L1"V&>-Q[Y;>);-W%K;/61"T!KAJ(F[F9]Q47%ZX( B"(.XJR'@FB+N
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ME7PV+"PLS*=Y$J]9Y!NW1^H=%\>\;>T3>>F5E_%'J(&BTA+^L2;*#>)>K*C
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M"'(1E*=]%*\=1!:@J+1$]\A5B$N(%W8P%HCAHP"27+""_'R\6Y(E5ZNK\T"
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M; #7/X*+/K2*^+Y]# EB*6N\;A02LGGK5C8GCY=%,.5L=NYE%Y!%7(*QQ?+
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MU=^R:=/2%<OU_<.L!CO@::8.'_;9/S[C1W#SI%!8%W]>0C/+6K\!L@#MS2W
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MZM>_'VZWN$3P\>&''[891=J=G\='M2#*4T\]9?,[!I9_^^VWMV_?AO+"7PB
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MA16>.(KYVI,,\V12#662I?;#3P3_K=U<S %P[C44[9Z>BWU(LU7F;_E-_CK
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M&*]UJU;XJ]<G3'ACVC1/4>Z6@01!$ 11&[@)@@@D;M^^[>FKDV=._[%+EP9
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M>-MP\^0MQM,.0Y8U"5DO6K@(WY'=4]&!3PYGNH0UX?QZZQ9M%$:1B)ZFG?T
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M$)ZL@W:8ECKL[PGQT CQ+"Y8E;EVS?*E2V_=O,GNR([?\7%\'R8_,,M(=N?
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MEPO4K_GW1VA:T ST]=(*;+-NN%B [[M<@Q('>=HKGB (@O@]0S//!!&@J/U
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MF7[FI>/%'SEBA.ZYK?C<;ERW?E?>'EP$\^-@-V5G3MZ3=KN#ZP5/&#_>'!@
M>R!-GCMV!;<4;Z#YU;I%N7._:TOUA1-1IYVU+^(2XO'Y6SX!]0:U!W58D%\
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M,@01WB<N7J@E;OS08:D%?+)14D<'-F=M8F+2N8RTG)]D'R&IM!$C<*NK**\
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M/ ,     $('P#     ! !,(S       1",\      $0@/ ,     $('P#
M  ! !,(S       1",\      $0@/ ,     $('P#     ! !,(S       1
F",\      $0@/ ,     $.%?BD$T=8^,FB\     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_21.jpg
<TEXT>
begin 644 image_21.jpg
MB5!.1PT*&@H    -24A$4@   .P   !7" (   "(O#[U     7-21T( KLX<
MZ0  $Z!)1$%4>%[M70E\3%<7GTFM$80DI!%!+"&6VF)+@BC14((*@EJ:I)9&
M6WL7/I1T06-?2M**EJ*(I7:U5*HM6JD]@I9H+%F$1F*)Y/M/C^_V?3/)>V_>
MO)G,U)W?_/S>O)Q[[CG_^W_GW>7<2UM04*#A'XZ +2-@9\O&<]LY CH$.(DY
M#VP> 4YBFV]"[@ G,>> S2/ 26SS3<@=X"3F'+!Y!#B);;X)N0.<Q)P#-H\
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M*+[IVR.Z_T"R[83@L#E)EU(R,N]._. +_$SY\S9^XB)\_!)<XXL+_(0 OKB
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M\2+6A0 GL76U![=& 0*<Q I XT6L"P%.8NMJ#VZ- @3^"V?9+A??$ R)
) $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>exel-20210402_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exel="http://www.exelixis.com/20210402"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20210402.xsd" xlink:type="simple"/>
    <context id="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="icbcb1d3131ca4167a7ff2b8ca6254b1b_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i048e6e9f5b9b4e0ba2126e2a863f1d6a_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i592bc5a3806f402f856d8fbd3249538c_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i9f00123ecb754d409c9d6be859b4fdee_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9d09b08c1f784f428f462bef31987f4a_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i9858fc09c7b54fd1845c5fda3918a98a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icb9a0be4715d45f2b1b8c059009f2389_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if75411ce18e84324abc3dc776c48c674_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic6bf9d2f48e04ceb99b9304f3f84faf4_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic410500a0c8b410381c4e4bbee8f365a_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i8cacc83750d84b399462ea235ec6323b_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i713d2897e6a74b35aa381b133355de13_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i06c195dc608249e3bf58c4e4e2307058_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="id9e566d0502942fca3c3b78c08b2698f_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ia914428f35354de39626e9a26f516c1a_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="if1462009eba74249b8e6d01c54abade3_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i89a6170ae38049f98a1b0f885593db8a_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ic669bf72aa434685b03e7f33f063bc4c_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="if985cb26685e42e1a5a365f3817d1a89_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i0c78236539674a37ac21c6d6337ead9c_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i366dca17411041bebbcc3bc9f6af0ebb_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="id9391bb26733440a8f33658cba5d97ee_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i5b86543d8f8f4ff3ab021af4701ad04f_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i22aa948226244f6fb9cc2d1dfb676393_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="if452b79a99af416fa1fe1c2fc78ecba7_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="iced95de5963448ac971de4994c5ac45a_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="i91abab7d19a343a4b06202fe09657540_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="ie272ec5d42f9472290f2325ef65b788b_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="ic99cda1e69634b08b343ceeb851e2c7f_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="i58866e6deacc4148bb07d20840bf1d70_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i408f9d80116040c38606e6e6c337a915_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i982d3bb2ce4643ee9cc102ef593e25a7_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i91deeede7b214054b29b855842eef51d_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i8898a28def344c1f9498ba826c92cd6c_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i3baa2e8821bd4cfabd0848feb53fa5c3_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i5d240db1d02c4ee0bf2a46143b9f379e_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i4e133af899104a37bb4e10ef4a36a743_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ic4ca58c530c04c0a90377ee5dad43da3_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="id6dc7e8bd8ec407b89698d13a23ff3a6_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i3353acb8df5349fcacfe665fc7964fff_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i29eb60ff6b6e4824ac262e719a07f775_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i0dd90892a68449c1be0d524436467c64_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="idc9d41e68f324a95b996b386418e5c09_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i924eb348cf9042fd9031133e05c98fe2_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="ic2b621907fd54e6ab9fb72223fc3cce0_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9b4979a471ca488b9d64b5802fd2808f_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i96161bc61bb64082ad9bfe6554af5de8_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i275fbd17545d4f8b807507bd55e10fb3_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="if932bb37d2414b9980b74b899a1de12f_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i0267ecf78e1743a6a1a623e79ad10130_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibbead320fb374843a5973991f2729b28_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9aecec8e5f714843bc680fc320329bea_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i41350dbef7e647b68e40059774e4ab18_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1a15f998b54b45e38f5eb360f2fd42ea_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iaccc2e4b26604b8ea916b910ab9dd639_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="icfc54d6c3da5453e9ed0a4216e6a54e7_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i033f4863b9914aba94c5752bddff7dbf_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="idee8f86874504109a2f7f134f40a822f_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ide2d347c3248461bbac83c443362c76d_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i4440cbe5c8ee44e8b1840c7f93915a2f_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i7513f3df79784ca184d5576f5feaa6d9_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9833f33d37c343598d92bce315de9ef6_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i117710a18dd3442b82fba13f802c6502_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i5d143f3e9b8641a0a4577a8bac49ef18_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i2cacac77f313426ca97a1e07efbf2a65_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i174d54dbbfea4b6bad9fae3f525eccc8_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i056bc3d8fccb421993c4071a717225d5_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ib97002ec6f9544a39132f917c4592192_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="ief5a426a6b1946c89b6817f64c12e299_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ice3ee77a9cff45ac9945571ab644d883_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i935fa856289043ebb8784c517f1d2af2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0fd7e209de56458d92e416e590288a81_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="icda8e5037b204db3976ae10c6e028ac7_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i7fb298ecd26c450db75de5a5f0fb2155_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i81f81bce7d9042b5bcbe2a95f60b3a9a_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ide9d86fd3b5944978f4a854f4a7afa13_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i8d78f7d5227d4a02aff49883e41f93ab_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i91ea16dceb12421a8f3ad991f4018890_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i5be727a8bd4c47ed98837d53bd0c5424_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i36eac876d5c64caa8af0b1d90f8647d5_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ifd260ef2e89045b09b489e3188306512_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i2257faa0011b4db494f9ed2b1349487b_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ic0598c8e5e7946afbf373a833d52f32c_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i58c953dc7f8e45ca83f3d4357a8d0e6a_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="ibcc59cc9f93348c6a6d15ebba27b76f9_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1338ac5d655940fb81117935b0c226e0_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i1a72e61479e84a879347cd4381d1ede0_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="iaff5cec481d74bcea3ef68f582e81de0_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i64b66b3d22614d23aa88f2b13229ca74_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ic42981c9c0704111836c5dcbda3df875_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i3ea0b7048aa4459185b0dda8013edb1c_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9805e61daf3145378cc62ee23939e9ff_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i40279315ce444f11a37ef540f6d742b5_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i1c01c5a5d8f54262b32390c82a09e601_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithAdageneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ib4664d16060941379ab6fa2d61b74a13_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithWuXiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i60c52c8abd6f4b608764f83a27cbc14a_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithAdageneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="iad6f1409c99d4cb69907fadf7fd41180_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeAgreementWithWuXiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i32119146b8b54758a862a6fc16e21509_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ia88ed0d294474275a7e78a0ec710c85d_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ief9769920780449fbdaf815855b16f9c_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i4e0b6bb63ed24207bf551f83d299b039_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="iccd209a5a49a4d98986e05725389c2fe_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i079f6e55e7604e41981bb55d026449bb_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ie4bdd567b1f84314b22e6f47db7ed986_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i8bcc7386ed5c43fd9b000593557060ec_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if66c4113d53e4bb3957023006b998620_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7ab172e9d9f744789028b9b209c7b067_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7dea8d433b994133ad734c5e0261047a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ife3bfc70915c45dc8a4ed22128e381e3_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iaf9c81849c224cf1a0586e1bcd1d2538_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i9c90e1d818864936ad88a7d0eecd505d_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i9921b8f98f46428c8230f8cc4d5b8de5_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="id9fef9dd01c3463884a549e712c67975_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i9b066d94ab5d48e4a3165fe4d64c48cd_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ie79ae71b4d194663b3217ba40d89497a_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ie91a81478309419e9d65e9da67aa5b90_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ie9a6af5ad3d6491eb55e7a02e03ca7f0_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="iba1677dbd26445dc9bd4d84baffd67f6_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i8e586cbac7b74f1d80c273b7797e092d_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i6350986f2c204a2488862f0ace5acbcd_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i554b0eab7ff4477ca7fd008d3dd2c260_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i415a1c2ee7384eba9691f7dbb9a64ac0_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ibccddea8bdc34321a373d4b211f85366_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i0a320379c33746e8a62505863f507b0b_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i02f8f448a7e44f71893357d3ac2b9a60_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i7e178b46a658489fb7b95d67e5ac005c_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i5966995df7754c27a0b4f6cf9ddfcf30_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ifacaab7c5ee54a3d9ae628433835e5b2_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i39e3fe01255048d58bc6c48c899a44f9_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i14575a1b1fbe41f2ad3f7b52e297ed34_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i1fe4c382d26c42ca9aab7aae9c0d74cb_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2cc15096d7544af483700aaf508a964a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iec009171117540bdbb58c1be5851a2d7_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3fe21729df9640cdbe357f4ec3f1d02a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i320b4929fd414ebf96f80e9078a55169_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i82d730819e3d4d3c9dde3eeeb9a8b9c9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i61fc1e1e560a449a9311f3bf3efd3e52_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i08c476589a9744e4a0a2d5a9ec2bb854_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i317939be92c5441a8c74c4d69f167550_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9c07b0da2b0d43f8bd7ff0a0f78a9545_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i68847f2d1e1d4718a5bda4b12d840afe_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i85f1822a756341a984f6f5e493514983_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ie576c7303b774e12a574df1fb982d1f0_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6a800e8408eb4e51a4f63612b53ab204_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2191e1eb15cf4c0385b5db4eb3d8d740_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ieba91e88df5042f390aa570d7bc9525f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ibaa26564d1144ad68101916a752c72c5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2c81d2dc86224957b76780b9b01b05fc_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i12afb5247d4341d8b3086641b3b17606_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if81956f5ad624fb3a34af890cb926767_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9234350c43af4d5fa786ab8abc166d55_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i504de91fc7df4dbd9eba09e75fabc924_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i22ff09f3344f4de1a78249a095f43788_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i02becf95ad41458a9f42b2d89fbc17fd_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ifb144073f9ec4ff78af65d49175c7cbe_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ib3ddda20eb4846618e6298bc462af14b_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i1369691551dc4fafb80d4de87f27c595_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="ieed02b22b90b48f3b8a0903941c79c91_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i0bcfe7378fa74f1399955c024d098430_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="if18980bf9a07498daf97936c223cd8bd_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i408345112b514492b8672264d5e9495e_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="ie3af9d6876ad41e9a9459ff5b52f0864_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i666a5e9b8134485fa80a9e4de6771543_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="i949dcc93029c4d24bde4a783adbeeacb_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i2fa0e1f1fe17409098662f0eaa3cf7f2_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="ibc8c9c247bbf4f2fa55811d4b33ba5b9_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i677b05d55bac4440b27c7ed808660a68_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i8622ebd208ee40748f3badc2d3baff8b_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i21631f07cfc643bd9432ab5a17b6267d_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifcf3d4993c944a21a332310247496165_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9911c9d99e354292b6c84ef2ea046b40_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i6017a4101e7f412f89057676d1636d3e_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ibc070254d7a9427b9acaf2c3ca6a6317_D20210102-20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-04-02</endDate>
        </period>
    </context>
    <context id="i103b70fa1d1e4257bec9058596619e69_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="forwardcontract">
        <measure>exel:forwardContract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl8yLTEtMS0xLTA_ed5f2441-310b-4cfd-92ce-4f1d62bf81e0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl80LTEtMS0xLTA_05548c55-4828-4baf-910b-75dad4531f91">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl81LTEtMS0xLTA_b7a5dfc0-cded-4ea1-b5bb-5ebd46851c75">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl82LTEtMS0xLTA_fd984d31-3fbe-4aea-bee2-9a7e522ca59f">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80L2ZyYWc6MjRkYjQ2YTUzZWViNGQ0MThkMTc5MGU0YmRmZTRhNTgvdGFibGU6Y2JmZWM4ZjYxMWRlNDc4MjllMzM1ZDA0M2YyZjI2OWYvdGFibGVyYW5nZTpjYmZlYzhmNjExZGU0NzgyOWUzMzVkMDQzZjJmMjY5Zl83LTEtMS0xLTA_d9b2bd72-338c-46e4-8bbb-341d5bd1e39c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6NTVkZjJhOTE4ZGQyNDUwZTlkZGIxM2ExNzJjNGU4M2UvdGFibGVyYW5nZTo1NWRmMmE5MThkZDI0NTBlOWRkYjEzYTE3MmM0ZTgzZV8wLTEtMS0xLTA_ec4f9e49-22f5-493a-8a7b-3e3bc86637e2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGI5MDA4M2IzM2FlNDY2NDhhN2I2NTIxZjE2NDA5MjQvdGFibGVyYW5nZTpkYjkwMDgzYjMzYWU0NjY0OGE3YjY1MjFmMTY0MDkyNF8wLTAtMS0xLTA_a2b5cb2a-9f79-4177-bd1e-06a9925f41f2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl81NDk3NTU4MTQwNzg4_b36008d2-f858-458c-9f22-04df5a796361">2021-04-02</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6OWIyNTY0ZmUyZDIxNDNjZWE0Mjg1MjNjMTE4NmMzOGIvdGFibGVyYW5nZTo5YjI1NjRmZTJkMjE0M2NlYTQyODUyM2MxMTg2YzM4Yl8wLTAtMS0xLTA_65272f7b-975f-4c59-925e-f3e4ecfd217a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg5_4b1a1a8c-b85d-47d5-a2da-0bd70e328e19">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6YmQzZWVjZmE2ZTJiNDRlNDlmNzUwNTIwYWI5OGQ5NTgvdGFibGVyYW5nZTpiZDNlZWNmYTZlMmI0NGU0OWY3NTA1MjBhYjk4ZDk1OF8xLTAtMS0xLTA_353b1a24-d74d-4863-9944-764cf5256094">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6NmU5ZjdhNmQ1NDEzNGU4NTkyZWRhNTcwZDgwZTI4YzMvdGFibGVyYW5nZTo2ZTlmN2E2ZDU0MTM0ZTg1OTJlZGE1NzBkODBlMjhjM18wLTAtMS0xLTA_ce43d3bc-d448-4a03-8c7b-9c1adfab5c94">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6NmU5ZjdhNmQ1NDEzNGU4NTkyZWRhNTcwZDgwZTI4YzMvdGFibGVyYW5nZTo2ZTlmN2E2ZDU0MTM0ZTg1OTJlZGE1NzBkODBlMjhjM18wLTEtMS0xLTA_b065a031-a9c5-4f6a-bf14-2d399ea140f4">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODkw_af7b6426-9909-4fa5-8a44-16c395d68328">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg2_6401d7e7-7c9b-4255-9e55-3bda5a481f6c">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg0_747e367b-a660-4709-9e94-9d27369db50f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg3_5ed3ab37-bbed-49d0-8083-3abbe16b5340">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg1_6b9c2dd2-61c0-4de1-8d0f-5a0b59cec956">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODg4_2c993a3b-291b-4817-9d1a-5586a77ce69e">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGJjY2FjZTU4NDEzNGY3MTgyOTVhZWZhMDAzYzk3M2EvdGFibGVyYW5nZTpkYmNjYWNlNTg0MTM0ZjcxODI5NWFlZmEwMDNjOTczYV8xLTAtMS0xLTA_c0096cab-0e17-45bd-b865-cdef170e8c8c">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGJjY2FjZTU4NDEzNGY3MTgyOTVhZWZhMDAzYzk3M2EvdGFibGVyYW5nZTpkYmNjYWNlNTg0MTM0ZjcxODI5NWFlZmEwMDNjOTczYV8xLTEtMS0xLTA_12cbdff2-1df6-4ba6-a1ea-41e781d1d2f7">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZGJjY2FjZTU4NDEzNGY3MTgyOTVhZWZhMDAzYzk3M2EvdGFibGVyYW5nZTpkYmNjYWNlNTg0MTM0ZjcxODI5NWFlZmEwMDNjOTczYV8xLTItMS0xLTA_e1f76463-9362-4f25-9b00-939d6786f6d9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODgx_f21d7a36-6061-43f9-b572-0e02d622991d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODgy_611a5b0b-772f-4d17-9d2e-1a69bed9a390">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZTEzNTQwNmE5MjU5NGE4MmExMTM5MDIxMDU1YWFmNWIvdGFibGVyYW5nZTplMTM1NDA2YTkyNTk0YTgyYTExMzkwMjEwNTVhYWY1Yl8wLTAtMS0xLTA_beb9fcba-e2e7-46d6-9092-ac5281be238f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZTEzNTQwNmE5MjU5NGE4MmExMTM5MDIxMDU1YWFmNWIvdGFibGVyYW5nZTplMTM1NDA2YTkyNTk0YTgyYTExMzkwMjEwNTVhYWY1Yl8xLTQtMS0xLTA_ca9a9d65-d20b-4da2-b1d9-dbdaacc5a038">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGFibGU6ZTEzNTQwNmE5MjU5NGE4MmExMTM5MDIxMDU1YWFmNWIvdGFibGVyYW5nZTplMTM1NDA2YTkyNTk0YTgyYTExMzkwMjEwNTVhYWY1Yl8yLTEtMS0xLTA_8c894180-4478-4efe-833e-064c7315c217">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODgz_111724f2-6f0c-48a3-b9eb-b8365c9baf3f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icbcb1d3131ca4167a7ff2b8ca6254b1b_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xL2ZyYWc6MmQ4YTVlZTc2MWRkNGRkZThkMWY3NzIzYzQ1NzNmY2IvdGV4dHJlZ2lvbjoyZDhhNWVlNzYxZGQ0ZGRlOGQxZjc3MjNjNDU3M2ZjYl8xODI2_f6f2149f-0d46-4078-ab06-76e14286e259"
      unitRef="shares">313387205</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNy0xLTEtMS0w_99532cb1-38c8-4646-b6ac-f5656df49233"
      unitRef="usd">370209000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNy0zLTEtMS0w_ed7320c4-eea6-4d35-bebd-855b549655d7"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOC0xLTEtMS0w_042ef8d7-dcf5-410a-a9bf-04f2cabb8141"
      unitRef="usd">815285000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOC0zLTEtMS0w_0968542e-a935-4a8d-be74-680b765e1c47"
      unitRef="usd">887319000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOS0xLTEtMS0w_b607b521-880d-4f03-894c-48c7a84afb23"
      unitRef="usd">177673000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfOS0zLTEtMS0w_eb431aec-2d8b-49cd-86d5-350e117dc91e"
      unitRef="usd">160875000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTAtMS0xLTEtMA_ebbe1a7d-fdd5-4cfd-862a-7e9f9c7656ad"
      unitRef="usd">24757000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTAtMy0xLTEtMA_566e3229-3b40-4921-aa74-23e958aa5a5b"
      unitRef="usd">20973000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTItMS0xLTEtMA_e69e0a31-693d-4c45-993a-b0eabea5cf4c"
      unitRef="usd">46341000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTItMy0xLTEtMA_ccd68666-b51d-4ad8-9ca4-2536a8de0c89"
      unitRef="usd">57011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTMtMS0xLTEtMA_1fbb92d1-d862-48d5-8543-ed6ae1d34a16"
      unitRef="usd">1434265000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTMtMy0xLTEtMA_d7028ea5-ae87-47da-af85-e4706f4c1b7f"
      unitRef="usd">1445395000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTQtMS0xLTEtMA_3d254d2e-f56d-4bdc-b7e6-ab84b4ed955c"
      unitRef="usd">328860000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTQtMy0xLTEtMA_3c2d41be-9dc2-4d3a-899a-9bd159b72eac"
      unitRef="usd">330751000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTUtMS0xLTEtMA_272fa8b3-d37a-4a15-b9b0-004d8d7b839a"
      unitRef="usd">78453000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTUtMy0xLTEtMA_cba9e055-bf71-4e1e-a7a5-269f40ac0910"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTYtMS0xLTEtMA_4ab4522f-0f11-432a-9e3a-2a5600ac3037"
      unitRef="usd">160598000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTYtMy0xLTEtMA_76bf92c1-5c6f-4636-8f2c-22d8daeb87eb"
      unitRef="usd">156711000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTctMS0xLTEtMA_7ba06e73-7790-4855-a6eb-6eeba5eaf1a3"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTctMy0xLTEtMA_6cae87a8-c126-4985-ba41-927427e73409"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTgtMS0xLTEtMA_81495862-a801-459a-8c7a-a4b263fe7363"
      unitRef="usd">124682000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTgtMy0xLTEtMA_f6a767f8-67e3-4757-a7f7-60fb7167fd17"
      unitRef="usd">73408000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTktMS0xLTEtMA_f5ee10e4-bfb2-4ad1-9c98-b7d5b0d0e747"
      unitRef="usd">2190542000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMTktMy0xLTEtMA_d1261ee1-6b10-4874-b5eb-8db06a2a2bf9"
      unitRef="usd">2137333000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjItMS0xLTEtMA_5c12d6aa-13ae-4ffa-af9a-01f6a19d761c"
      unitRef="usd">13821000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjItMy0xLTEtMA_c9889a19-c09c-497a-a959-1029a7e24411"
      unitRef="usd">23632000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjMtMS0xLTEtMA_effae359-52b7-4432-a0b3-b39d00d3f4cc"
      unitRef="usd">37945000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjMtMy0xLTEtMA_5cc3ab74-b272-4d5f-8858-5211a66657fc"
      unitRef="usd">51189000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjQtMS0xLTEtMA_68170948-5a3a-43b6-971b-633bcf697ec0"
      unitRef="usd">59762000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjQtMy0xLTEtMA_3e616397-8453-45b0-b122-765c7968108f"
      unitRef="usd">52251000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjUtMS0xLTEtMA_9e890a30-7aed-42bf-a398-60da4e0848ae"
      unitRef="usd">31468000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjUtMy0xLTEtMA_087356eb-3cec-4d4a-9f74-73894c99929d"
      unitRef="usd">20683000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjYtMS0xLTEtMA_a67be957-d6f7-4d96-829f-d43f842a6947"
      unitRef="usd">13461000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjYtMy0xLTEtMA_e2d563d9-f945-4d99-90e1-f5102c53c67a"
      unitRef="usd">12456000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjgtMS0xLTEtMA_0f1efba4-52c8-40ca-b34d-f3a9a6d1f36c"
      unitRef="usd">56880000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjgtMy0xLTEtMA_0632f5b1-938f-4c6e-bc13-0076ca57a88e"
      unitRef="usd">44447000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjktMS0xLTEtMA_ebb98a2a-e0bd-462d-8e61-3b8c8a4e2e32"
      unitRef="usd">213337000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMjktMy0xLTEtMA_f1501017-f61b-4886-bc2a-067a5043c426"
      unitRef="usd">204658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzAtMS0xLTEtMA_db614917-7007-4144-90fb-e66813cf45d4"
      unitRef="usd">9760000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzAtMy0xLTEtMA_20e803bd-3745-4d1d-b5a3-942c270b40a5"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzEtMS0xLTEtMA_6cd94a8d-86b4-4e84-8da4-8b52d1c74f75"
      unitRef="usd">52837000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzEtMy0xLTEtMA_4db5f8fa-6033-43ca-aa4c-5c54e135c332"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzItMS0xLTEtMA_3639eec4-98b7-4e86-b9dc-9b75c2bb6d9e"
      unitRef="usd">3421000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzItMy0xLTEtMA_93fca196-b6f9-4dd9-9ef6-98163983019e"
      unitRef="usd">721000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzMtMS0xLTEtMA_6d0b0ea8-b45d-4597-852b-6b112f0a4d36"
      unitRef="usd">279355000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzMtMy0xLTEtMA_e774782d-eaf7-4235-82ad-20a8e09ebb72"
      unitRef="usd">258220000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzQtMS0xLTEtMA_7c43127e-fbea-418b-b5ec-c35ddb00ef38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzQtMy0xLTEtMA_4ea24791-f7a4-4e68-98e9-6cc0f35ecdc4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzIx_52b59cd4-6952-4735-9568-c74ff6e453b9"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzIx_fb3d2a04-24f3-471e-a446-66191f8540ef"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzM1_b3cc8fe4-b0b9-48e2-8025-2853a60e3982"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzM1_e01cc99d-83e7-4856-8dfa-3bc5fd44aa74"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzYw_b07d48e5-cc1a-469f-a64f-2ac793d2d93c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjU4YzQ2NDNiNWE4YTRiYzJiN2Q2ODJmYjI3Njg3OTBmXzYw_e46db632-e0d5-423c-9610-ff35865e0df2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMS0xLTEtMA_fed92670-a004-419a-8b0e-f5913bb62291"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzYtMy0xLTEtMA_1f351ffd-233c-47ff-a4c6-7743d788dc79"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzE4_859fa434-ba6d-41ad-80d3-6ab017042098"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzE4_b10351e3-fa50-4a99-829d-0be069d42b61"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzMy_643ac0c0-4107-4d7c-8b9f-a50c95de7247"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2XzMy_bc4aecf8-c5d1-4b80-91ae-761aa57af019"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzc4_526e4ad0-02d5-4165-bb7c-7c49902bd681"
      unitRef="shares">313262000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzc4_da30f299-1ff7-4df8-9029-1fd8388827cc"
      unitRef="shares">313262000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzg1_16ab2b83-69de-400b-84e9-f18755c30e4a"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NTJlMzFjNDQ1MjRiZjhiMmY1ZTFlMzIwNmViMWY2Xzg1_86fec39b-96b4-4ebf-b94b-8bdaf070bb0a"
      unitRef="shares">311627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMS0xLTEtMA_100a4098-1b35-44d6-aa3e-b8b49e6f856f"
      unitRef="usd">313000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzctMy0xLTEtMA_4c6f62f1-f292-4936-8453-84ee3343ab84"
      unitRef="usd">312000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzgtMS0xLTEtMA_ffd6a70f-3d57-4a1d-b079-1f58f55d50bf"
      unitRef="usd">2354103000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzgtMy0xLTEtMA_d80e21ba-e555-4c17-b88b-258fb5e92a82"
      unitRef="usd">2321895000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzktMS0xLTEtMA_83ac758f-e9e0-4b6a-9404-b7c9d673e952"
      unitRef="usd">2740000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfMzktMy0xLTEtMA_93e15a1a-54a2-430f-85ee-7d701c79868c"
      unitRef="usd">4476000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDAtMS0xLTEtMA_6993c995-98e0-4486-9fc8-c3cdce8c73f4"
      unitRef="usd">-445969000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDAtMy0xLTEtMA_e340e0a9-55ff-4168-9d73-1ad3882470ec"
      unitRef="usd">-447570000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDEtMS0xLTEtMA_71452c8e-583f-4abc-9b22-3b3cc3d83bd3"
      unitRef="usd">1911187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDEtMy0xLTEtMA_82498784-112a-452e-89bc-b1675167cbbe"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDItMS0xLTEtMA_6e70e6f8-de50-4cb7-b252-1f7cf34ce46c"
      unitRef="usd">2190542000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xNi9mcmFnOjgxODEwYmQ3MDI5MzRhM2RiNTQ4YTUxMzNmNTU3MmZlL3RhYmxlOmY5MzcxZjJiMzFkYzRkNzJiYzJiMGNhMTc4MTBjNTVjL3RhYmxlcmFuZ2U6ZjkzNzFmMmIzMWRjNGQ3MmJjMmIwY2ExNzgxMGM1NWNfNDItMy0xLTEtMA_c67fce0c-9898-4f62-b1bb-01fa3abc9a88"
      unitRef="usd">2137333000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMy01LTEtMS0w_644a7c62-b311-4238-a192-2a8ea241162d"
      unitRef="usd">227212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMy03LTEtMS0w_38fe9dc1-20f4-445b-9f44-07153e0b30c0"
      unitRef="usd">193880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i048e6e9f5b9b4e0ba2126e2a863f1d6a_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNC01LTEtMS0w_572bf001-769a-4272-985e-76a2260838e5"
      unitRef="usd">27528000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i592bc5a3806f402f856d8fbd3249538c_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNC03LTEtMS0w_759186dc-6ed0-40f1-bbdb-16e47bc3c5e1"
      unitRef="usd">20879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f00123ecb754d409c9d6be859b4fdee_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNS01LTEtMS0w_96079154-1930-450b-8dcc-60005844b8a3"
      unitRef="usd">15490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d09b08c1f784f428f462bef31987f4a_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNS03LTEtMS0w_e605fa22-94c2-4252-809d-8396d0bcad01"
      unitRef="usd">12156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNi01LTEtMS0w_f2c0b6aa-ce66-4fd2-91c7-dac3cb92ec95"
      unitRef="usd">270230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfNi03LTEtMS0w_90f7b23b-5b2b-4de2-8b61-0c5379ba1560"
      unitRef="usd">226915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOC01LTEtMS0w_b26da604-ec60-4478-88b2-2aca1cdaf3b6"
      unitRef="usd">13198000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOC03LTEtMS0w_505a4bf5-e1cc-43b6-85ff-dcc29609cbcd"
      unitRef="usd">9289000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOS01LTEtMS0w_a7cd087d-9131-4d2c-85c0-ad11340cef68"
      unitRef="usd">159288000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfOS03LTEtMS0w_daeeba09-0092-4c90-b962-0f23d244c35a"
      unitRef="usd">101877000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTAtNS0xLTEtMA_b3697842-8947-4657-9841-6978517cdfee"
      unitRef="usd">102351000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTAtNy0xLTEtMA_516be175-2778-4ec9-a1cd-6b8178a31aaa"
      unitRef="usd">62940000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTEtNS0xLTEtMA_16915667-8880-41c6-afa2-3771e883733e"
      unitRef="usd">274837000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTEtNy0xLTEtMA_9a48c3ec-f1b1-4e9f-b465-3184888554d7"
      unitRef="usd">174106000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTItNS0xLTEtMA_cfe08af9-93a5-43f4-9330-66c8e5855aac"
      unitRef="usd">-4607000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTItNy0xLTEtMA_00ff71c7-114e-4561-8ee0-7fbabb91b8d1"
      unitRef="usd">52809000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTMtNS0xLTEtMA_fadeefce-ba6a-469e-b2db-1080dbbf924c"
      unitRef="usd">2682000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTMtNy0xLTEtMA_7bbf7c14-ae24-4292-9ae5-7ad5b743becf"
      unitRef="usd">7220000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTQtNS0xLTEtMA_f2ece92a-2812-4d20-987a-645b683947a7"
      unitRef="usd">-90000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTQtNy0xLTEtMA_4561af3c-2f4f-406e-a6ee-b3d05d4290a9"
      unitRef="usd">6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTUtNS0xLTEtMA_c4f94103-f0e2-4091-be7b-d0f6ba7eb4f4"
      unitRef="usd">-2015000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTUtNy0xLTEtMA_554fcefc-faca-4801-ad9a-05025c825160"
      unitRef="usd">60035000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTYtNS0xLTEtMA_608fb8ca-0060-42c4-b560-863c77d74a81"
      unitRef="usd">-3616000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTYtNy0xLTEtMA_698825c0-531d-434a-8b59-b1214eab3842"
      unitRef="usd">11423000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTctNS0xLTEtMA_ecd714ce-eb21-40a9-a879-48e71daa1ad0"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTctNy0xLTEtMA_0ea809f2-6783-488f-8721-7b546a97a932"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTktNS0xLTEtMA_8837b32e-dc83-4ee5-806b-ba1cee33e6a1"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMTktNy0xLTEtMA_740a180a-c9c6-4f24-b5e1-b2c8efee53c7"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjAtNS0xLTEtMA_74a03a98-91a0-44fe-82d7-22b29dbaa525"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjAtNy0xLTEtMA_abb427d7-1f97-46a5-b120-899ea61f714a"
      unitRef="usdPerShare">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjItNS0xLTEtMA_a936ce71-94fc-45ba-a4a5-bbce48f3a549"
      unitRef="shares">312473000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjItNy0xLTEtMA_3c79c02c-5009-4846-a1b4-331cdf843814"
      unitRef="shares">305388000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjMtNS0xLTEtMA_62a1aecf-4b5c-4d87-88a0-dcc49bcc3e2a"
      unitRef="shares">321287000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8xOS9mcmFnOjlkNzJiMGE4OWZiMjRmN2M5ZjFkNjVmZGE3MTliZGZhL3RhYmxlOmFmNTkzYzQ5NjllNzQ5NDA5NTI1NzFiZmMzOWQ2OTNiL3RhYmxlcmFuZ2U6YWY1OTNjNDk2OWU3NDk0MDk1MjU3MWJmYzM5ZDY5M2JfMjMtNy0xLTEtMA_7f75f5a3-d781-41a7-a322-6e4ea27bdd24"
      unitRef="shares">315839000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfMi01LTEtMS0w_ecd714ce-eb21-40a9-a879-48e71daa1ad0"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfMi03LTEtMS0w_0ea809f2-6783-488f-8721-7b546a97a932"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC0wLTEtMS0wL3RleHRyZWdpb246MWM0OTkzMjBmZmNkNDRmODg3NTIyYTBlY2ZkNzFlNDhfMTAy_e1a8e360-978d-48c6-af63-06a9191aff46"
      unitRef="usd">499000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC0wLTEtMS0wL3RleHRyZWdpb246MWM0OTkzMjBmZmNkNDRmODg3NTIyYTBlY2ZkNzFlNDhfMTA5_e3654b6f-d849-4835-adb2-a61144805f60"
      unitRef="usd">941000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC01LTEtMS0w_e428168e-5d3d-49c6-968b-e6962fdbcedf"
      unitRef="usd">-1736000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNC03LTEtMS0w_6a713bd4-8923-4e21-9c9e-e702c258bceb"
      unitRef="usd">-3291000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNi01LTEtMS0w_89788ef8-640e-4020-9819-43401993ab1c"
      unitRef="usd">-135000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yMi9mcmFnOjAxMGZkYjlkYTU5MTRiNTRiYzk0YTU3ZTRhZTg1NDU2L3RhYmxlOjliMGVlYWM5MzE0ODRlZjJhMjk4ZmNhODc2M2M5YTgxL3RhYmxlcmFuZ2U6OWIwZWVhYzkzMTQ4NGVmMmEyOThmY2E4NzYzYzlhODFfNi03LTEtMS0w_78210514-fd56-4ae9-8333-2317731649f6"
      unitRef="usd">45321000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9858fc09c7b54fd1845c5fda3918a98a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtMS0xLTEtMA_0a2f1f33-93bf-4ecc-92e4-3783404acf0d"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9858fc09c7b54fd1845c5fda3918a98a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtMy0xLTEtMA_34815454-8fda-4e4b-8156-21ef43120df8"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb9a0be4715d45f2b1b8c059009f2389_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtNS0xLTEtMA_a056316a-fc24-4dd6-9e82-9ec0106ce7fc"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if75411ce18e84324abc3dc776c48c674_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtNy0xLTEtMA_d8364554-9913-4d70-a265-a0d0d211c721"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6bf9d2f48e04ceb99b9304f3f84faf4_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtOS0xLTEtMA_bf141971-bfae-445c-895b-de704e4df683"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjMtMTEtMS0xLTA_e26dd80d-fdce-4e19-b08e-46a409098d48"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic410500a0c8b410381c4e4bbee8f365a_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjQtOS0xLTEtMA_70b25710-e9e2-4619-80b5-1299b7930a3a"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjQtMTEtMS0xLTA_d77ab880-7a05-4c2b-b65a-45c9c594f729"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8cacc83750d84b399462ea235ec6323b_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjUtNy0xLTEtMA_874156d7-69b4-446b-bf2a-745d13f70e80"
      unitRef="usd">-1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjUtMTEtMS0xLTA_3dd2b08a-e4d7-426a-961f-bdb483b4d953"
      unitRef="usd">-1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i713d2897e6a74b35aa381b133355de13_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtMS0xLTEtMA_b81578bf-a064-4c82-93bb-53624c3f89aa"
      unitRef="shares">1635000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i713d2897e6a74b35aa381b133355de13_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtMy0xLTEtMA_16e9e401-eb30-49e3-9fce-c46659b2f9d8"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtNS0xLTEtMA_057c0280-93fa-476e-badc-c20c5f3dc5b1"
      unitRef="usd">4201000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjYtMTEtMS0xLTA_7723e242-e74c-4389-b154-ccbab2552b0b"
      unitRef="usd">4202000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjctNS0xLTEtMA_baec149f-6904-4774-9960-827a98d8130f"
      unitRef="usd">6646000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjctMTEtMS0xLTA_e6330b0f-9121-4052-b5a0-27a2580078d7"
      unitRef="usd">6646000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i849f8abf76d84d41be6b2a0084e8e7f1_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjgtNS0xLTEtMA_cabfe078-687a-45a3-ba71-51fc856745df"
      unitRef="usd">34653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjgtMTEtMS0xLTA_efb7beed-ca4b-46e7-a949-14a29b2fb0b3"
      unitRef="usd">34653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i06c195dc608249e3bf58c4e4e2307058_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktMS0xLTEtMA_ece2acf2-2266-4ad3-a3df-3928e55ca1cb"
      unitRef="shares">313262000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i06c195dc608249e3bf58c4e4e2307058_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktMy0xLTEtMA_a6bd9508-5175-4415-9995-db285b22cca3"
      unitRef="usd">313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9e566d0502942fca3c3b78c08b2698f_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktNS0xLTEtMA_c789c3a4-d8b9-41ac-8130-378a80bbafff"
      unitRef="usd">2354103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia914428f35354de39626e9a26f516c1a_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktNy0xLTEtMA_21d97a67-af00-4220-b03f-f11dfb029f5b"
      unitRef="usd">2740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1462009eba74249b8e6d01c54abade3_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktOS0xLTEtMA_48d2c8bd-af98-420b-bd4f-2f66d34578ca"
      unitRef="usd">-445969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOmQwMzcxZWFkNDU3OTQ5ZDdiZWY1NWM5YzEzY2ZhMzcxL3RhYmxlcmFuZ2U6ZDAzNzFlYWQ0NTc5NDlkN2JlZjU1YzljMTNjZmEzNzFfMjktMTEtMS0xLTA_362522f4-b982-4e07-b808-a6748724fcae"
      unitRef="usd">1911187000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i89a6170ae38049f98a1b0f885593db8a_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtMS0xLTEtMA_1f45860c-8dcd-4a1b-bc89-4bd145f40033"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i89a6170ae38049f98a1b0f885593db8a_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtMy0xLTEtMA_957b19ef-705a-49e2-8be3-fd7b37b5f68e"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic669bf72aa434685b03e7f33f063bc4c_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtNS0xLTEtMA_a5ae91a1-5d3f-4e7e-80fc-37dd2d3f5403"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if985cb26685e42e1a5a365f3817d1a89_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtNy0xLTEtMA_74e3d9cd-c40c-461c-882a-17146d1dcc8a"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c78236539674a37ac21c6d6337ead9c_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtOS0xLTEtMA_685e52f2-9eac-4f9e-ab66-438532aec8ef"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i366dca17411041bebbcc3bc9f6af0ebb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjMtMTEtMS0xLTA_bb5cd0a0-b288-44d1-a3ce-024b64576887"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id9391bb26733440a8f33658cba5d97ee_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjQtOS0xLTEtMA_94cad7e6-adb8-4125-a07a-bbd1aeb8817e"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjQtMTEtMS0xLTA_69b0e731-efe2-42b1-9eab-309377cc8547"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5b86543d8f8f4ff3ab021af4701ad04f_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjUtNy0xLTEtMA_e1da9733-6950-417c-8de0-3fb71d2ba428"
      unitRef="usd">-3291000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjUtMTEtMS0xLTA_ebedf0e2-9600-4ccf-aec5-4122cbc63468"
      unitRef="usd">-3291000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i22aa948226244f6fb9cc2d1dfb676393_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtMS0xLTEtMA_d923ae3d-a4ae-493c-9ea9-e4d705f513d6"
      unitRef="shares">949000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i22aa948226244f6fb9cc2d1dfb676393_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtMy0xLTEtMA_0a5934bc-5344-45f1-87ee-953463bd2eee"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtNS0xLTEtMA_0c589369-7b80-4c9e-9dc3-f1f6578fd98f"
      unitRef="usd">4171000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjYtMTEtMS0xLTA_e5d37143-f410-4ff8-b9fe-b8f54079de11"
      unitRef="usd">4172000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtNS0xLTEtODM4_feceb6b6-b53e-47a8-93e4-96f96dadfbe9"
      unitRef="usd">1793000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtMTEtMS0xLTkyMA_c561ea6b-0eb2-44b3-8f0d-cb3548774d77"
      unitRef="usd">1793000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia15042be01684841bd946ab9cdc23ac6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtNS0xLTEtMA_faa74b57-07d2-459a-8a71-ab0b083c27b6"
      unitRef="usd">13982000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjgtMTEtMS0xLTA_51f883e2-159f-4c7b-8cb0-10fe94432db9"
      unitRef="usd">13982000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if452b79a99af416fa1fe1c2fc78ecba7_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktMS0xLTEtMA_59261b44-5e58-47e6-903b-289a4363136e"
      unitRef="shares">305780000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if452b79a99af416fa1fe1c2fc78ecba7_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktMy0xLTEtMA_b77d3ce0-d17d-4b30-b2aa-dab3541b8c48"
      unitRef="usd">306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iced95de5963448ac971de4994c5ac45a_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktNS0xLTEtMA_98fc26e4-929e-484b-931e-ac4adec0f297"
      unitRef="usd">2258307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91abab7d19a343a4b06202fe09657540_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktNy0xLTEtMA_31139447-3469-4430-8afb-deedff7b344d"
      unitRef="usd">-222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie272ec5d42f9472290f2325ef65b788b_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktOS0xLTEtMA_bb6e1080-e317-49af-b4df-af42096fff56"
      unitRef="usd">-510739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic99cda1e69634b08b343ceeb851e2c7f_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yNS9mcmFnOjg1ZjZjZjIwMjAyNjQzYzg4MmNiMDYxOTJjMWQ3YjA5L3RhYmxlOjA4MTY2ZjZhYmZjYjQ3Y2JiOTQxZWZiMDJmMDVkNGQ1L3RhYmxlcmFuZ2U6MDgxNjZmNmFiZmNiNDdjYmI5NDFlZmIwMmYwNWQ0ZDVfMjktMTEtMS0xLTA_44fd4f14-3cbc-4dec-b61c-36ff9dc5e2c2"
      unitRef="usd">1747652000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMi0xLTEtMS0w_ecd714ce-eb21-40a9-a879-48e71daa1ad0"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMi0zLTEtMS0w_0ea809f2-6783-488f-8721-7b546a97a932"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNC0xLTEtMS0w_bf6cd119-a3dc-46f0-b728-66fb3aaff426"
      unitRef="usd">3227000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNC0zLTEtMS0w_00eee545-2843-4434-a2e4-eb6736172387"
      unitRef="usd">2175000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNS0xLTEtMS0w_704a062a-c98a-44a8-9efa-7716e520e0c5"
      unitRef="usd">34653000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNS0zLTEtMS0w_a8bc7b04-c35c-44ad-9b0a-1fc667081240"
      unitRef="usd">13982000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNi0xLTEtMS0w_140a58be-99ea-4554-b07e-63b4c35ee55f"
      unitRef="usd">1221000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNi0zLTEtMS0w_47413064-3a0f-44dc-91a4-800ca97dee04"
      unitRef="usd">1174000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNy0xLTEtMS0w_87eecec3-4911-4631-9eaa-a4c502b78692"
      unitRef="usd">3388000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfNy0zLTEtMS0w_aaaff98d-5901-4a8f-b890-12ede3fb1231"
      unitRef="usd">-10128000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfOC0xLTEtMS0w_ed3cb637-2c52-4dd1-8a92-bb123ca8b894"
      unitRef="usd">-6578000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfOC0zLTEtMS0w_233c125e-f9d8-4354-ad77-1e9a4873e1c6"
      unitRef="usd">888000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTAtMS0xLTEtMA_dba27a53-d3d3-4e6e-a5dc-384401f0ae8c"
      unitRef="usd">17690000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTAtMy0xLTEtMA_802ed9d3-c894-4bc2-a2fe-854840aceeb7"
      unitRef="usd">18270000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTEtMS0xLTEtMA_71785a28-50b9-4d15-8f8f-ecd518dc6485"
      unitRef="usd">2090000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTEtMy0xLTEtMA_4258f58f-1ab6-4c1b-aad3-993c63815d5d"
      unitRef="usd">4695000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTMtMS0xLTEtMA_04b3ab29-1ee8-44a9-8398-e06692bdb853"
      unitRef="usd">-1872000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTMtMy0xLTEtMA_952be2c8-082f-48c8-a7b6-70bb7591ae67"
      unitRef="usd">2863000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTUtMS0xLTEtMA_77e77e2e-a940-408b-842f-daad943ae142"
      unitRef="usd">13422000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTUtMy0xLTEtMA_f0705669-b0b7-4656-9ed6-9dc1152d7a86"
      unitRef="usd">8850000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTYtMS0xLTEtMA_f3309004-d7ce-4ba9-aeb7-00599d958bb4"
      unitRef="usd">138000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTYtMy0xLTEtMA_f03e4685-659d-4807-b4f3-81cee7831791"
      unitRef="usd">-2131000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTctMS0xLTEtMA_a0be747d-7b09-4f6a-a923-1520ff14f488"
      unitRef="usd">39544000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTctMy0xLTEtMA_f3658d52-baec-4a19-9884-378d68f0e704"
      unitRef="usd">56074000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTktMS0xLTEtMA_58cc7ed0-340c-47e2-a320-a982caab32eb"
      unitRef="usd">13557000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMTktMy0xLTEtMA_a7a56cc1-d0a6-4db4-a7ea-41adf2fd2e1a"
      unitRef="usd">2961000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjEtMS0xLTEtMA_5538bae0-978e-4a4f-9458-d299749496ba"
      unitRef="usd">331612000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjEtMy0xLTEtMA_dc1fb49f-5eee-4b7c-9fc8-4c3f46d046af"
      unitRef="usd">251505000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjItMS0xLTEtMA_464b38dd-669a-4839-8c41-f39b5ac36e96"
      unitRef="usd">407424000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjItMy0xLTEtMA_b2294f40-dc8a-4ae5-9e85-152c0fb8909c"
      unitRef="usd">287086000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjMtMS0xLTEtMA_10d6e668-2765-4c5b-a973-6a41b404ff19"
      unitRef="usd">62255000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjMtMy0xLTEtMA_1063115d-3f24-449f-bcec-ad80d0acd714"
      unitRef="usd">32620000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjUtMS0xLTEtMA_636a1f00-68b6-494b-9ecc-41754de0e3f5"
      unitRef="usd">2791000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjUtMy0xLTEtMA_a7242f68-a7da-498c-b38d-cffd1ab11a74"
      unitRef="usd">3938000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjYtMS0xLTEtMA_dbe8372f-36cb-406b-aa61-447d0bafc19f"
      unitRef="usd">5441000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjYtMy0xLTEtMA_e292c693-373e-46a2-ba5a-f5196110442c"
      unitRef="usd">1793000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjktMS0xLTEtMA_38f55cbc-a467-4571-b13a-2791b92866d7"
      unitRef="usd">-2650000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMjktMy0xLTEtMA_2cc569cc-6715-4c24-80e6-e2330e4b52bb"
      unitRef="usd">2145000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzAtMS0xLTEtMA_45499fe2-6c6c-42d5-a8a8-0ad3cd23f9d7"
      unitRef="usd">99149000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzAtMy0xLTEtMA_653e94e9-014e-43f3-8096-9e367efef60a"
      unitRef="usd">90839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzEtMS0xLTEtMA_7ebb6327-858b-4b4b-91f5-9ef989ccfa1b"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i366dca17411041bebbcc3bc9f6af0ebb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzEtMy0xLTEtMA_4194218f-1838-4462-a3cd-599e077830bb"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzItMS0xLTEtMA_a7670021-75dd-4b6c-94b0-f55e7fcbf491"
      unitRef="usd">419921000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic99cda1e69634b08b343ceeb851e2c7f_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzItMy0xLTEtMA_aad2d564-b965-44a2-a139-7831f102ca83"
      unitRef="usd">358976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzctMS0xLTEtMA_737903a5-d7c3-4025-b885-7d7cfaa3144a"
      unitRef="usd">4893000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8yOC9mcmFnOmVmMTkyMmI4MDM0YzQ5MjM4ODdjMjk4OTZjNGU0YmRkL3RhYmxlOjcxYzI3MjVlMjhhOTQ2MGRhNzQ0MDQxMjk4NWZhNDI5L3RhYmxlcmFuZ2U6NzFjMjcyNWUyOGE5NDYwZGE3NDQwNDEyOTg1ZmE0MjlfMzctMy0xLTEtMA_7c0d73a6-3995-4eca-9b76-bf35cb71cad5"
      unitRef="usd">576000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE3NDM_7492e6db-c118-4138-811b-a7c753595077">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#x2019;s OPDIVO&#xae; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple regimens to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the three months ended April&#160;2, 2021 and April&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended March&#160;31, 2021 and March&#160;31, 2020 and the year ended December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as compared to the significant accounting policies disclosed in Note 1 &#x2013; Significant Accounting Policies included in the our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Forward Contracts for Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into foreign currency forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our foreign currency forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i58866e6deacc4148bb07d20840bf1d70_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNTcw_4f267372-0e22-40ea-be70-9c2fc460ebb0"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i408f9d80116040c38606e6e6c337a915_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNzcz_7e07f5fa-3694-4935-b945-b02fa79bf310"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i982d3bb2ce4643ee9cc102ef593e25a7_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMTQ5NA_777b9cb3-cae7-47fe-9841-abc0ca5c1dc2"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE2OTg_813acd03-9fc5-475f-8aa6-8497ea7951d4">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE3MDc_16db90be-a60b-443e-ae68-717d4603e98e">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE2OTE_b6f71811-567f-4d32-9ade-abef54c643c5">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the three months ended April&#160;2, 2021 and April&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended March&#160;31, 2021 and March&#160;31, 2020 and the year ended December&#160;31, 2020, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNjA0NzMxNDAyMDc3MQ_d9ec6f86-c8ec-4e73-baec-515a22b15e7e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief &lt;/span&gt;&lt;/div&gt;Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNjA0NzMxNDAyMDc3Nw_773d80b1-4ce0-43d4-adc7-672b847969eb"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNzE0NjgyNTYzOTI0NA_5b01ae5d-553d-4cf4-8306-ddae5bab2efc">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNzE0NjgyNTYzOTI0NQ_7f833ce4-c158-4387-ab11-ec0685569c41">ReclassificationsCertain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfNjA0NzMxNDAxNDk5Nw_f9d3464a-1be5-4005-890b-9fdc320dca2e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Forward Contracts for Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into foreign currency forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our foreign currency forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNC9mcmFnOmE1NDU1ZjMzZDhkMjQ4Y2VhMDE1MjU3OWY5YjU4YmI3L3RleHRyZWdpb246YTU0NTVmMzNkOGQyNDhjZWEwMTUyNTc5ZjliNThiYjdfMjE3MTg_52719e8b-57e6-422f-adbd-62ee0b043427">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg3Mg_d7d13a56-2ef1-4ea3-aa50-5f7a07b5e8e6">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers or as other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)   Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)   Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, we recognized $2.5 million and $1.6 million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, and 2020, we recognized $27.8 million and $18.8 million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda Pharmaceutical Company Limited (Takeda), Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Genentech Inc. (a member of the Roche Group) (Genentech).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $87.3 million of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements - Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg4NQ_9b0143a9-3570-4700-a835-3157e5f95f70">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91deeede7b214054b29b855842eef51d_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMy01LTEtMS0w_fcfa880f-97b1-435f-ae78-f2338ebfbac3"
      unitRef="usd">314205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8898a28def344c1f9498ba826c92cd6c_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMy03LTEtMS0w_aaffad51-61a8-4802-b658-b71b59bd44ee"
      unitRef="usd">252566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3baa2e8821bd4cfabd0848feb53fa5c3_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNC01LTEtMS0w_b5d1fdc4-e0c2-44c8-95c6-1371c864fd1d"
      unitRef="usd">-86993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d240db1d02c4ee0bf2a46143b9f379e_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNC03LTEtMS0w_036ac31e-e28e-4438-9b63-c8b50ff398c5"
      unitRef="usd">-58686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNS01LTEtMS0w_644a7c62-b311-4238-a192-2a8ea241162d"
      unitRef="usd">227212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNS03LTEtMS0w_38fe9dc1-20f4-445b-9f44-07153e0b30c0"
      unitRef="usd">193880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i048e6e9f5b9b4e0ba2126e2a863f1d6a_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNy01LTEtMS0w_572bf001-769a-4272-985e-76a2260838e5"
      unitRef="usd">27528000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i592bc5a3806f402f856d8fbd3249538c_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfNy03LTEtMS0w_759186dc-6ed0-40f1-bbdb-16e47bc3c5e1"
      unitRef="usd">20879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f00123ecb754d409c9d6be859b4fdee_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOC01LTEtMS0w_96079154-1930-450b-8dcc-60005844b8a3"
      unitRef="usd">15490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d09b08c1f784f428f462bef31987f4a_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOC03LTEtMS0w_e605fa22-94c2-4252-809d-8396d0bcad01"
      unitRef="usd">12156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e133af899104a37bb4e10ef4a36a743_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOS01LTEtMS0w_1422036a-2626-4d8a-8c40-05e1c88f54c9"
      unitRef="usd">43018000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4ca58c530c04c0a90377ee5dad43da3_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfOS03LTEtMS0w_60d000c4-af3a-4ed1-b28a-e94d6f51fdd7"
      unitRef="usd">33035000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMTAtNS0xLTEtMA_f2c0b6aa-ce66-4fd2-91c7-dac3cb92ec95"
      unitRef="usd">270230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmQ5YmVlMDRmZWY0NjQzNjBiM2YxOGM5ZGFjNTlhMTBhL3RhYmxlcmFuZ2U6ZDliZWUwNGZlZjQ2NDM2MGIzZjE4YzlkYWM1OWExMGFfMTAtNy0xLTEtMA_90f7b23b-5b2b-4de2-8b61-0c5379ba1560"
      unitRef="usd">226915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNjA0NzMxMzk2NDY1NA_115666a1-7d26-43ca-a0b3-f298102d4b17">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id6dc7e8bd8ec407b89698d13a23ff3a6_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMi01LTEtMS02MTg3_48af7235-fbcb-47a9-af1f-36e6ff53b07a"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3353acb8df5349fcacfe665fc7964fff_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMi03LTEtMS02MTg3_05ef8cae-2a83-4177-820b-e25ef41a7c47"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i29eb60ff6b6e4824ac262e719a07f775_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMy01LTEtMS02MTg3_9193e646-5078-4e31-9f6c-801a8587a244"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0dd90892a68449c1be0d524436467c64_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfMy03LTEtMS02MTg3_b6735d49-c5c9-4b5a-b0e4-457bae0f69bc"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc9d41e68f324a95b996b386418e5c09_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC01LTEtMS02MjA2_48296832-2533-4e72-bfae-7906da8bd506"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i924eb348cf9042fd9031133e05c98fe2_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC03LTEtMS02MjA2_4e1d14b6-4dc4-455f-b180-b3ebf2ec1f0a"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic2b621907fd54e6ab9fb72223fc3cce0_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC01LTEtMS02MTg3_ffc72d6e-002f-4d9b-bf55-f0d3beb90b95"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b4979a471ca488b9d64b5802fd2808f_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNC03LTEtMS02MTg3_7a25973c-058f-45cd-be28-aa7bde236d19"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i96161bc61bb64082ad9bfe6554af5de8_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNi01LTEtMS02MTg3_4849d6f0-1b48-4128-a801-9bc7d58a1c42"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i275fbd17545d4f8b807507bd55e10fb3_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmI5ODUzMjY5MjI0MzQ3YzE5NjM3ZjYzMjRiODU2MmZkL3RhYmxlcmFuZ2U6Yjk4NTMyNjkyMjQzNDdjMTk2MzdmNjMyNGI4NTYyZmRfNi03LTEtMS02MTg3_2c639bd5-2f74-4000-bdb4-470aff1a9852"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if932bb37d2414b9980b74b899a1de12f_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0xLTEtMS02MTg3_0c2069cb-ccae-4dd5-808f-11dc5f2927a0"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0267ecf78e1743a6a1a623e79ad10130_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0zLTEtMS02MTg3_eef8984d-dec1-4123-9e27-8d3000221203"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibbead320fb374843a5973991f2729b28_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0xLTEtMS02MjE2_f0d92438-b6f7-4380-b032-b8508fff411e"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9aecec8e5f714843bc680fc320329bea_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMi0zLTEtMS02MjE2_1e807d41-29da-4d18-8ba0-cb12e77b81a2"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i41350dbef7e647b68e40059774e4ab18_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0xLTEtMS02MjIw_4ebac690-19a4-473f-b52d-85c5e7f79fde"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a15f998b54b45e38f5eb360f2fd42ea_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0zLTEtMS02MjIw_500a5e59-a86f-4534-8934-1e662306fb11"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaccc2e4b26604b8ea916b910ab9dd639_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfNC0xLTEtMS02MjIw_95da7868-bb89-41e7-bbdc-7625710e8101"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icfc54d6c3da5453e9ed0a4216e6a54e7_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfNC0zLTEtMS02MjIw_86526894-9d8f-4eee-9be0-84fc54c00d4f"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i033f4863b9914aba94c5752bddff7dbf_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0xLTEtMS02MTg3_6745193a-b4be-45c6-bd87-9f87013f6350"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idee8f86874504109a2f7f134f40a822f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjc3M2ViZDQzYzRhZDQ0NTM5Nzg3Nzg1OGU1YWU3YmIxL3RhYmxlcmFuZ2U6NzczZWJkNDNjNGFkNDQ1Mzk3ODc3ODU4ZTVhZTdiYjFfMy0zLTEtMS02MTg3_1cfa4cef-6de9-4025-b4b9-83c548aea7f5"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNjA0NzMxMzk2NDY1Nw_49a5516b-1eb0-4f71-8542-de91765a6c79">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide2d347c3248461bbac83c443362c76d_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMi01LTEtMS02MTg3_1266436d-a9be-45f9-b5e3-7eeffe35f7ab"
      unitRef="usd">229957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4440cbe5c8ee44e8b1840c7f93915a2f_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMi03LTEtMS02MTg3_86c46b3f-2a29-4035-b8bb-8d7ddf421da1"
      unitRef="usd">196596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7513f3df79784ca184d5576f5feaa6d9_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMy01LTEtMS02MTg3_bc01c24b-bf6a-4a46-86db-319b34186fe3"
      unitRef="usd">33806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9833f33d37c343598d92bce315de9ef6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfMy03LTEtMS02MTg3_59cd9517-d00f-417c-8872-9a10f4ae04b6"
      unitRef="usd">29036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i117710a18dd3442b82fba13f802c6502_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNC01LTEtMS02MTg3_33797359-c973-4db2-a032-5f67c78b8757"
      unitRef="usd">6467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d143f3e9b8641a0a4577a8bac49ef18_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNC03LTEtMS02MTg3_60c22d8d-97ed-4b1b-9636-9aab98de8f7f"
      unitRef="usd">1283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNS01LTEtMS02MTg3_065f5b8b-25fe-4887-bd23-8009e603ec96"
      unitRef="usd">270230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOmE2YjAyOTcwMTVlZDQ0YWM5ZGRmZDA0YTU4YThjMWU2L3RhYmxlcmFuZ2U6YTZiMDI5NzAxNWVkNDRhYzlkZGZkMDRhNThhOGMxZTZfNS03LTEtMS02MTg3_a0efa8a9-5b78-4bd1-915a-dad5f96a63ba"
      unitRef="usd">226915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg2NQ_39672e54-7dbe-4131-b3bd-bd0b78ba2088">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.&lt;/span&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers or as other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cacac77f313426ca97a1e07efbf2a65_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMi01LTEtMS0w_5682a390-aa68-492e-8367-5e091936e8d6"
      unitRef="usd">223595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i174d54dbbfea4b6bad9fae3f525eccc8_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMi03LTEtMS0w_9fb1a7f5-90eb-4454-933c-f22b388710a7"
      unitRef="usd">189216000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i056bc3d8fccb421993c4071a717225d5_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMy01LTEtMS0w_fd5aa277-365b-4ff2-a322-5f7f114fcb78"
      unitRef="usd">3617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib97002ec6f9544a39132f917c4592192_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfMy03LTEtMS0w_6f8d23f0-bf27-45c8-a981-c5b54b6fdb0c"
      unitRef="usd">4664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2befcfa9ea420caf2c953fcc12bf06_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfNC01LTEtMS0w_a17265e9-6fc7-43ff-ac7e-5e670e0171c1"
      unitRef="usd">227212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f99122317154b2d86f38a464938c4f1_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjBlMDRlNDljYmI0NjRkY2U4M2MyYzFmMmY3NmVjYTk5L3RhYmxlcmFuZ2U6MGUwNGU0OWNiYjQ2NGRjZTgzYzJjMWYyZjc2ZWNhOTlfNC03LTEtMS0w_5b220c95-5796-40b7-b4d9-ad8266c13fc0"
      unitRef="usd">193880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDg4MQ_8dfafcf2-6817-4809-ac8a-cb880de60e53">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ief5a426a6b1946c89b6817f64c12e299_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS0xLTEtMS0w_d51af9f0-6ec5-49e6-ac22-50ef2bd73668"
      unitRef="usd">9853000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ice3ee77a9cff45ac9945571ab644d883_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS0zLTEtMS0w_6033bbd7-7fb9-4e93-ad54-0bdd7205a0cf"
      unitRef="usd">3279000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i935fa856289043ebb8784c517f1d2af2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS01LTEtMS0w_03559544-62a2-4a67-b8c9-ea1a10f29c92"
      unitRef="usd">17404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMS05LTEtMS0w_d906359c-7def-499a-a306-117ba2b67a6f"
      unitRef="usd">30536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i0fd7e209de56458d92e416e590288a81_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy0xLTEtMS0w_ce87c7b0-a9fb-467d-92bf-2e8a161c2c70"
      unitRef="usd">52470000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy0zLTEtMS0w_b2a380ae-d5f4-4c09-8666-4957564fbfd4"
      unitRef="usd">8054000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy01LTEtMS0w_27964001-4bf7-4f41-9416-13a1c42bf9ff"
      unitRef="usd">25232000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfMy05LTEtMS0w_7ab114db-bd5c-4b21-8ac1-7050b737ac9b"
      unitRef="usd">85756000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i0fd7e209de56458d92e416e590288a81_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC0xLTEtMS0w_e4ba5c57-0edd-4021-b987-2720846c9fbe"
      unitRef="usd">-27000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC0zLTEtMS0w_05baf70a-6230-4c80-86ad-dce0f2807a43"
      unitRef="usd">-2000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC01LTEtMS0w_5889d589-93be-45fd-8d37-66574f430113"
      unitRef="usd">1266000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNC05LTEtMS0w_4dfa62da-be56-4b0e-840a-e2e8f0ce19db"
      unitRef="usd">1237000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0fd7e209de56458d92e416e590288a81_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS0xLTEtMS0w_7f58952a-d263-4338-8270-e3d1ae205d39"
      unitRef="usd">49636000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia7d2be502e90468c86f4d575c7534482_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS0zLTEtMS0w_b5c603ff-4da0-4a85-b9b6-8e9c920be5d1"
      unitRef="usd">5622000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i37a026ee4e9d4f2fb685eebe01bf6f2f_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS01LTEtMS0w_eef30bcf-7bd1-4342-b216-6a6be4a02ff9"
      unitRef="usd">15935000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNS05LTEtMS0w_db0fcfd8-6123-4310-b6d9-8c101050a03d"
      unitRef="usd">71193000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="icda8e5037b204db3976ae10c6e028ac7_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi0xLTEtMS0w_4611de01-f58b-47d6-b730-06771bb972f9"
      unitRef="usd">12660000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7fb298ecd26c450db75de5a5f0fb2155_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi0zLTEtMS0w_533f556b-a28f-4944-9400-b4343294d387"
      unitRef="usd">5709000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i81f81bce7d9042b5bcbe2a95f60b3a9a_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi01LTEtMS0w_efef02a4-43bf-4c46-9205-dfbd5a169d0e"
      unitRef="usd">27967000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjNlYTYyMWYyNmZkMTQxZGQ4YmM4NTViYzIyMjM3ZDdmL3RhYmxlcmFuZ2U6M2VhNjIxZjI2ZmQxNDFkZDhiYzg1NWJjMjIyMzdkN2ZfNi05LTEtMS0w_0f339c0d-2143-450a-93ff-cb94bb4972c5"
      unitRef="usd">46336000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNjA0NzMxMzk1OTY4NA_d25ce27a-8f28-4e9e-a199-dafcd20ded3d">Contract assets and liabilities were as follows (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)   Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.  &lt;/span&gt;&lt;/div&gt;(2)   Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfMS0xLTEtMS0xMjgy_7861c0e2-b16e-4e9d-9cf4-fc2143c86781"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfMS0zLTEtMS0xMjY3_74ef7304-a525-4bee-a337-08cf30b71ae3"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNC0xLTEtMS0xMjg4_4a779bfb-2e75-4913-bb08-6cc89a54a058"
      unitRef="usd">9207000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNC0zLTEtMS0xMjkz_e016cc03-da36-4d6c-b98b-2073982627c0"
      unitRef="usd">1790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNS0xLTEtMS0xMjk5_66070cf3-d09d-47d4-8dc6-ec2d09e7f762"
      unitRef="usd">9760000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNS0zLTEtMS0xMjkz_5775389d-c4c2-4eee-859c-906d93284748"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNi0xLTEtMS0xMjk5_d414ee41-9698-4af8-9eca-1ad8181443f7"
      unitRef="usd">18967000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RhYmxlOjZhODgwNmVlNGVhMDQ3ZGU4MmFlYzU2MjU5ODlmYzhkL3RhYmxlcmFuZ2U6NmE4ODA2ZWU0ZWEwNDdkZTgyYWVjNTYyNTk4OWZjOGRfNi0zLTEtMS0xMjkz_8ccedbd0-d5c5-4516-9e5d-7cdd2deca1b1"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMzg0Nw_fe77015a-9cde-438c-b78f-0cd43979aecd"
      unitRef="usd">2500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMTA5OTUxMTYzNDI2Nw_b6722ea4-ba96-49b5-90f9-76c2d0c7efb1"
      unitRef="usd">1600000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMTA5OTUxMTYzNDM2Mw_4001a7d2-051e-48f3-8ce7-ff267d60c2cd"
      unitRef="usd">27800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfMTA5OTUxMTYzNDQ5NA_35763dd0-18f4-41ee-ab64-d0e123efbf80"
      unitRef="usd">18800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF8zNy9mcmFnOjNiYTE3ZGZjNTM3YjQyMTVhMWEwZDY3OTAzOTQ4NjU3L3RleHRyZWdpb246M2JhMTdkZmM1MzdiNDIxNWExYTBkNjc5MDM5NDg2NTdfNDM1Mg_fd738657-84de-47a4-b2ff-2a8a7f5610ba"
      unitRef="usd">87300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMTEyOTY_453f2f59-2677-4c40-8389-b4193bc79333">COLLABORATION AGREEMENTS AND IN-LICENSING ARRANGEMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $44.8 million of the tr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020 to, among other things, modify the amount of reimbursements we are eligible to receive for costs associated with our required pharmacovigilance activities, modify the amount of milestones we are eligible to receive, and modify certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02 clinical trials. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.940%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, $42.5 million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK &amp;amp; Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $10.1 million and $8.1 million during the three months ended March&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations and In-Licensing Arrangements &lt;/span&gt;&lt;/div&gt;In the first quarter of 2021, we entered into additional licensing and collaboration agreements in support of our preclinical pipeline with Adagene, Inc. (Adagene) and WuXi Biologics Ireland Ltd (WuXi Bio). As part of these agreements we made aggregate upfront payments of $14.0&#160;million in exchange for licenses to develop and commercialize products. We committed to make payments to Adagene for potential future development milestones of $55.0&#160;million, regulatory milestones of $200.0&#160;million, and commercial milestones of $525.0&#160;million, each in the aggregate, as well as royalties on future net product sales. We also committed to make payments to WuXi Bio for potential future development milestones of $18.5&#160;million, regulatory milestones of $30.0&#160;million, and commercial milestones of $80.0&#160;million, each per product, as well as royalties on future net product sales.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMTEyOTA_a5fd9fdb-69ef-4a63-8edb-b5b3a521c9f4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.940%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide9d86fd3b5944978f4a854f4a7afa13_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMi01LTEtMS0w_1c48e2f2-0f37-4397-95af-5b9fe142aaa0"
      unitRef="usd">22451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d78f7d5227d4a02aff49883e41f93ab_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMi03LTEtMS0w_1090f217-a0ea-4d5a-b635-f66520f9caf7"
      unitRef="usd">17949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ea16dceb12421a8f3ad991f4018890_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMy01LTEtMS0w_e0d1ee04-a854-45f1-a6cb-8c35dabfd486"
      unitRef="usd">11355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5be727a8bd4c47ed98837d53bd0c5424_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfMy03LTEtMS0w_3e0d5263-1591-47ee-9a80-ab9f7a792de4"
      unitRef="usd">11087000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36eac876d5c64caa8af0b1d90f8647d5_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfNC01LTEtMS0w_c695e3f3-8acb-4b24-9c94-222481a8085f"
      unitRef="usd">33806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd260ef2e89045b09b489e3188306512_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOmNlYzIyNmQxMjUwYTQyYTQ5MGRlZmU4ZmJmNmFhMTgzL3RhYmxlcmFuZ2U6Y2VjMjI2ZDEyNTBhNDJhNDkwZGVmZThmYmY2YWExODNfNC03LTEtMS0w_5f045c1d-2b27-40f0-a7e8-0e761cd6d012"
      unitRef="usd">29036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2257faa0011b4db494f9ed2b1349487b_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMzYxMQ_22ab2cd1-414f-463e-919a-e8c4a5d0420c"
      unitRef="usd">44800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0598c8e5e7946afbf373a833d52f32c_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMi01LTEtMS0w_7cab5ba1-4475-4101-aac9-6b7d1aceec62"
      unitRef="usd">1301000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58c953dc7f8e45ca83f3d4357a8d0e6a_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMi03LTEtMS0w_1caff836-9c63-4da5-b1fb-95562170d340"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcc59cc9f93348c6a6d15ebba27b76f9_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMy01LTEtMS0w_c8160674-30b6-447b-9e82-5d964f6f679d"
      unitRef="usd">4135000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1338ac5d655940fb81117935b0c226e0_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfMy03LTEtMS0w_ae43622e-78de-4c43-8771-d425d275c0ee"
      unitRef="usd">1069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a72e61479e84a879347cd4381d1ede0_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfNC01LTEtMS0w_5d2d089d-2c82-4493-a684-51620f33b001"
      unitRef="usd">5436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaff5cec481d74bcea3ef68f582e81de0_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjU2MTA3YTZhZTU5MDQ0OWY5ZDI3YmY2NDk3ZWVmYWEzL3RhYmxlcmFuZ2U6NTYxMDdhNmFlNTkwNDQ5ZjlkMjdiZjY0OTdlZWZhYTNfNC03LTEtMS0w_0da1d0a5-d271-4f6d-b65e-351922a0eaa7"
      unitRef="usd">1069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i64b66b3d22614d23aa88f2b13229ca74_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNzM5OQ_62d30e24-e3dc-4e41-9386-7bb8348058b5"
      unitRef="usd">42500000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="ic42981c9c0704111836c5dcbda3df875_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNzY4MA_51ea31e1-78a0-439c-97b6-864f308d2193"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="i3ea0b7048aa4459185b0dda8013edb1c_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfODAzMA_cf1df6fe-d3be-43d5-a733-011d91f62509"
      unitRef="usd">10100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i9805e61daf3145378cc62ee23939e9ff_D20200104-20200403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfMTA5OTUxMTY2MDI1MQ_e029cae5-8ed9-472e-897c-ba6d19d937f6"
      unitRef="usd">8100000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMi01LTEtMS0w_698d9f27-49d0-4986-81c7-38e7ce6243fa"
      unitRef="usd">1794000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i40279315ce444f11a37ef540f6d742b5_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMi03LTEtMS0w_b8e43d23-dabe-4ea3-893b-dc4d57c46c48"
      unitRef="usd">1407000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMy01LTEtMS0w_ab3d9376-a9d2-4cf7-a8f8-6f22dfad7d94"
      unitRef="usd">951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40279315ce444f11a37ef540f6d742b5_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RhYmxlOjMzOThlOTQ0ZGFkNzRmYzY4ZjQwNTU4NWJiN2M3Mjk4L3RhYmxlcmFuZ2U6MzM5OGU5NDRkYWQ3NGZjNjhmNDA1NTg1YmI3YzcyOThfMy03LTEtMS0w_813555e0-6f05-4de4-8068-ad6fb378b6b1"
      unitRef="usd">1309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeAgreementsUpfrontPayments
      contextRef="i1c01c5a5d8f54262b32390c82a09e601_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5Mzc5NA_81f21a08-7982-47c6-8ead-81f7eeb1b047"
      unitRef="usd">14000000.0</exel:CollaborativeAgreementsUpfrontPayments>
    <exel:CollaborativeAgreementsUpfrontPayments
      contextRef="ib4664d16060941379ab6fa2d61b74a13_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5Mzc5NA_fc4c68c6-94b3-45ea-8900-cfb8dce72945"
      unitRef="usd">14000000.0</exel:CollaborativeAgreementsUpfrontPayments>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones
      contextRef="i60c52c8abd6f4b608764f83a27cbc14a_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjE4Mg_fb08d053-6640-46f6-b362-b03434b00187"
      unitRef="usd">55000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones>
    <exel:CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones
      contextRef="i60c52c8abd6f4b608764f83a27cbc14a_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjE5Nw_4592764e-e5e0-4e7d-a607-8ed48cf71f8d"
      unitRef="usd">200000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i60c52c8abd6f4b608764f83a27cbc14a_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjIxMw_b72c3ce2-28ff-4f9d-b160-052ab5112d0e"
      unitRef="usd">525000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones
      contextRef="iad6f1409c99d4cb69907fadf7fd41180_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjIyOQ_88d1f17d-ca58-41a1-89fe-a8a7f45079a4"
      unitRef="usd">18500000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones>
    <exel:CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones
      contextRef="iad6f1409c99d4cb69907fadf7fd41180_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjI0NA_3307a5f9-2188-4862-b838-844463ca17bf"
      unitRef="usd">30000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="iad6f1409c99d4cb69907fadf7fd41180_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80MC9mcmFnOjU3MDM1ZmM0YWU2YzQ4Y2U5MDJjNjEzYjk3MDA2NTM1L3RleHRyZWdpb246NTcwMzVmYzRhZTZjNDhjZTkwMmM2MTNiOTcwMDY1MzVfNjA0NzMxMzk5MjI1OQ_9a3fecc3-354f-4242-92e4-a1dcae965113"
      unitRef="usd">80000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjI0Mw_a13a2a94-2997-4f41-bfbf-236efa3d5b9c">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of March 31, 2021, restricted cash equivalents included $48.2&#160;million of short-term investments as collateral under our standby letter of credit entered into in January 2021 as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,560,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $3.6 million and $4.5 million as of March&#160;31, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All securities presented have been in an unrealized loss position for less than 12 months. There were 53 and 14 investments in an unrealized loss position as of March&#160;31, 2021 and December&#160;31, 2020, respectively. During the three months ended March&#160;31, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjIxMg_1efacf07-0412-465f-a518-40beb9eb8c88">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjIxMw_2696d6b5-2af2-4948-be64-118e8745e16c">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMS0xLTEtMS0w_99532cb1-38c8-4646-b6ac-f5656df49233"
      unitRef="usd">370209000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMS0zLTEtMS0w_ed7320c4-eea6-4d35-bebd-855b549655d7"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMy0xLTEtMS0w_e6e5a5fa-d420-4cab-9a6d-d37bd1dfcfb2"
      unitRef="usd">49712000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfMy0zLTEtMS0w_9755c214-3335-44c5-967c-8cbacbb7fa5a"
      unitRef="usd">1555000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfNC0xLTEtMS0w_22dff960-d997-437f-8ce8-e3bdabb6e1ff"
      unitRef="usd">419921000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjA2YjE4M2Y2NDJmNzQ2NTc4OTAyNzViNGRlMWM3YzY3L3RhYmxlcmFuZ2U6MDZiMTgzZjY0MmY3NDY1Nzg5MDI3NWI0ZGUxYzdjNjdfNC0zLTEtMS0w_4bc7bbce-78f0-470c-814b-bbdb6d3f1e4d"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTA5OTUxMTYzMTQzOA_2b16dd5b-5060-4338-ad2b-bce21a952cd4"
      unitRef="usd">48200000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjI0NQ_ad0f1bfc-4702-4f22-85b9-aed43ff0cfb1">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,560,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i32119146b8b54758a862a6fc16e21509_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy0xLTEtMS0w_0b4a6dfc-7b96-4132-a56e-eec9c2dd67f3"
      unitRef="usd">667071000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32119146b8b54758a862a6fc16e21509_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy0zLTEtMS0w_7d0e5884-308a-4aad-a1ef-d1a153e435ce"
      unitRef="usd">219000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32119146b8b54758a862a6fc16e21509_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy01LTEtMS0w_3dbb1272-80d0-40c0-b040-e65b904559b2"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32119146b8b54758a862a6fc16e21509_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMy03LTEtMS0w_5c2b8a1f-b2c5-4f4f-802b-a1cfeb8b77cd"
      unitRef="usd">667289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC0xLTEtMS0w_4f2ef425-cd73-4fae-be15-afad71b7f956"
      unitRef="usd">495490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC0zLTEtMS0w_75ed31fa-44cf-41ee-92e4-18f4df1917b1"
      unitRef="usd">3609000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC01LTEtMS0w_e629a624-d42d-4c3e-9c17-cdb5da70a711"
      unitRef="usd">275000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNC03LTEtMS0w_113d8af6-ea51-41b9-9c5a-88a52a7e944f"
      unitRef="usd">498824000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS0xLTEtMS0w_afe93cdf-69e3-4dc2-81c2-06b1faed2318"
      unitRef="usd">148208000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS0zLTEtMS0w_1c4ffc23-9081-4b8f-b8c0-70f6d2e1e490"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS01LTEtMS0w_fb8b6e50-bf52-48f9-ac90-bad957701b08"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNS03LTEtMS0w_538f896c-4af9-4645-8987-812623d91cb5"
      unitRef="usd">148284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi0xLTEtMS0w_2460de61-e2b6-4dd9-919b-851a27fac6a4"
      unitRef="usd">27776000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi0zLTEtMS0w_b01acb66-3245-482a-a957-95aef0d3eb2a"
      unitRef="usd">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi01LTEtMS0w_d5480fd7-51b6-4ab9-aca2-de52e431abca"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNi03LTEtMS0w_9eb2284c-8564-4ebf-8b98-e144d7e7d5ae"
      unitRef="usd">27832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy0xLTEtMS0w_db4e53b8-acd6-4c7d-a79a-ea1264d009c1"
      unitRef="usd">1338545000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy0zLTEtMS0w_49440462-10eb-466b-9aec-19430994c96b"
      unitRef="usd">3975000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy01LTEtMS0w_7d1f7344-0721-44ff-8ace-03993bbb1695"
      unitRef="usd">291000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfNy03LTEtMS0w_1facc5a2-81e6-4c72-bcf4-8ab2da7a2bf5"
      unitRef="usd">1342229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC0xLTEtMS0w_f7638261-7674-4ce2-bfb4-fb442d586afd"
      unitRef="usd">52757000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC0zLTEtMS0w_894c1e43-8fec-48ae-8089-8a19f76ea50a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC01LTEtMS0w_8c71271f-28e4-4e5e-ac58-2b65cf93cce2"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i4e0b6bb63ed24207bf551f83d299b039_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOC03LTEtMS0w_ba73e551-35b5-40fb-a24f-204f3e0b7815"
      unitRef="usd">52757000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS0xLTEtMS0w_29a76942-b4af-47ab-83ab-0cc1e73ea0d3"
      unitRef="usd">105775000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS0zLTEtMS0w_4c744441-9096-498f-84cf-6fb8cbd8c76a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS01LTEtMS0w_2c1fd28f-539e-4231-b45d-34146957935d"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="iccd209a5a49a4d98986e05725389c2fe_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfOS03LTEtMS0w_18d6688f-dc24-413e-8844-071fe190bfd5"
      unitRef="usd">105775000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtMS0xLTEtMA_42997821-0641-4b93-9ecb-749ed6fde9a5"
      unitRef="usd">63305000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4bdd567b1f84314b22e6f47db7ed986_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtMS0xLTEtMA_ac0af483-b36c-41f1-9e8c-8e825da06254"
      unitRef="usd">63305000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtMy0xLTEtMA_7159dd5e-8b94-41b0-ad20-08385e77e8bd"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtNS0xLTEtMA_91f8a3ec-5d7b-4aab-941c-7ca5051f2db5"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTAtNy0xLTEtMA_d06e3bf9-33d9-4f5c-8cb9-9405586d84cf"
      unitRef="usd">63305000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtMS0xLTEtMA_04852853-587e-4647-8a29-ddfc81567a74"
      unitRef="usd">1560382000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtMy0xLTEtMA_a598b9cf-218e-495e-a1e9-8ac454e3bb7a"
      unitRef="usd">3975000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtNS0xLTEtMA_eafa71b0-747c-4902-8cd9-35db3564b94b"
      unitRef="usd">291000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmNmYmRhMzJjOTBhNzRiYTk5NmE4MWY5NDQyYTUxM2E4L3RhYmxlcmFuZ2U6Y2ZiZGEzMmM5MGE3NGJhOTk2YTgxZjk0NDJhNTEzYThfMTEtNy0xLTEtMA_4783b3e9-b7ba-4184-9ce8-424efeb0764a"
      unitRef="usd">1564066000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy0xLTEtMS0w_c5114268-8f6b-41f7-81c8-3eb8c3bc9a43"
      unitRef="usd">569456000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy0zLTEtMS0w_686ff8ba-e160-408e-b530-ba7f25ea625b"
      unitRef="usd">372000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy01LTEtMS0w_5c8af7dc-5bb0-4938-9741-e99bed037e14"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bcc7386ed5c43fd9b000593557060ec_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMy03LTEtMS0w_4c4dd548-3ab5-4dba-9c0f-ce4fa1323edb"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if66c4113d53e4bb3957023006b998620_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC0xLTEtMS0w_f6989159-6530-4ff3-9fa7-21c676028738"
      unitRef="usd">543520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if66c4113d53e4bb3957023006b998620_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC0zLTEtMS0w_d4a6fc97-7ec4-4cf7-89b5-432ae5d996c9"
      unitRef="usd">5244000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if66c4113d53e4bb3957023006b998620_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC01LTEtMS0w_e94538cb-78dc-49f7-abf2-9afab69e0107"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if66c4113d53e4bb3957023006b998620_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNC03LTEtMS0w_eaa54624-a5d5-4322-bce1-bcc3b6b2be77"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS0xLTEtMS0w_dfcd3748-81d4-476c-9000-7452e65506b6"
      unitRef="usd">208326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS0zLTEtMS0w_73ef982e-5155-4782-b1d9-17a696c57f36"
      unitRef="usd">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS01LTEtMS0w_00f7ac4f-47e5-4693-b605-9e2685f1d019"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNS03LTEtMS0w_584bd6e3-c464-4f77-9fb8-67135c6f4532"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0xLTEtMS00MjY_66c6db85-a8ca-4bd1-ac0d-7267353905f9"
      unitRef="usd">28680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0zLTEtMS00MjY_974824dd-cfea-4824-abe0-8ae20c742c7f"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi01LTEtMS00MjY_ad982cd7-e3e3-4ffb-824a-aae35174056a"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi03LTEtMS00MjY_4d747ef4-7cf6-4cef-b74c-28d0cdd14189"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0xLTEtMS0w_b6759153-7da0-4ae4-b9d7-335c8d6b44b0"
      unitRef="usd">1349982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi0zLTEtMS0w_b92bbf52-236a-4a72-829e-f72a97324f5c"
      unitRef="usd">5931000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi01LTEtMS0w_b6582cf3-9619-451c-86fc-786ff57a7fef"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNi03LTEtMS0w_e6d4eee1-1a2b-4534-91a4-61c30749a3f1"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy0xLTEtMS0w_b5bcd41d-a072-4a53-a4db-6f2421872e23"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy0zLTEtMS0w_f1666bd5-455d-45cd-b6a1-6e8f22c6d905"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy01LTEtMS0w_3bdd837b-df5b-4d09-88d0-1fcf1685798c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i784076a3cbca4f4bb0b6ef08a6282e96_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfNy03LTEtMS0w_86b06b9b-9832-4803-931c-c94c1f734a71"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC0xLTEtMS0w_5d349c87-331a-46d3-aeac-53d090bcf65b"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC0zLTEtMS0w_54182645-2898-49fa-95b2-598d5b777222"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC01LTEtMS0w_8ec1666a-a2a1-4385-93a2-af5a88fba911"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i7dea8d433b994133ad734c5e0261047a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOC03LTEtMS0w_dac9d2f4-aa08-415a-b2f1-4d3489c2dacd"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS0xLTEtMS0w_5b814ef2-87b7-4ea2-b767-ff5278ab32d7"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS0zLTEtMS0w_08fa9a33-0e5c-4143-8457-34a79541543f"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS01LTEtMS0w_85d24f03-46c4-472c-9ada-6f368534d05a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ife3bfc70915c45dc8a4ed22128e381e3_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfOS03LTEtMS0w_81eb5e7f-54d9-49b9-bd3d-6f9bd2c0c9fb"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtMS0xLTEtMA_1c60b128-e214-418e-a095-134650a82614"
      unitRef="usd">1532923000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtMy0xLTEtMA_2d8ea918-743b-4a85-b3d2-0fb2e331aa18"
      unitRef="usd">5931000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtNS0xLTEtMA_9e2d53c6-6de0-4266-aae7-b8af7d0948e4"
      unitRef="usd">12000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjRhMDcyN2Y4ODc2ODQ3MTA4NTA5OWYzNjNmZWQ2YTM0L3RhYmxlcmFuZ2U6NGEwNzI3Zjg4NzY4NDcxMDg1MDk5ZjM2M2ZlZDZhMzRfMTAtNy0xLTEtMA_21e7d68f-e67d-4527-a6ba-477790042d66"
      unitRef="usd">1538842000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfNzUy_9269b779-3aa9-4e84-8f18-032167f91433"
      unitRef="usd">3600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfNzU5_3c115c82-8fe7-45a2-bdbb-ac553fb137de"
      unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjI1NA_4fe2d56b-12ea-4adf-8ff9-1ef808d5d1eb">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i32119146b8b54758a862a6fc16e21509_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi05LTEtMS00Nzc3_cdb8662e-70a2-4484-9e28-db6c91130a14"
      unitRef="usd">4722000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i32119146b8b54758a862a6fc16e21509_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi0xMS0xLTEtNDc3Nw_9ff8ab77-ef4f-4528-b4d3-2647d80ebca5"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi05LTEtMS0w_ee15c480-e59b-4133-8785-0559a5013e2e"
      unitRef="usd">131468000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i74fdf685ce7e48f880b68e3b4ca4ba29_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMi0xMS0xLTEtMA_ecc82ac6-961d-40cf-a0de-ea1a9a7a7fd0"
      unitRef="usd">275000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMy05LTEtMS0w_12977306-e283-4921-a4fe-5f522fcf1374"
      unitRef="usd">31981000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia88ed0d294474275a7e78a0ec710c85d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfMy0xMS0xLTEtMA_cd97f2e8-b033-4095-8703-1e489df828e5"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNS05LTEtMS0w_73dd2e68-5bed-4584-ad13-24a9d90860be"
      unitRef="usd">12120000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNS0xMS0xLTEtMA_fa2de607-fca2-44c3-ac20-c7523a29aa56"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNi05LTEtMS0w_808fa3e4-bb04-4703-85c5-5d35aa0fca71"
      unitRef="usd">180291000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjllYmY3YTE0NDRmMzQwZjNiODYyOTdlNWIzMGU2MzljL3RhYmxlcmFuZ2U6OWViZjdhMTQ0NGYzNDBmM2I4NjI5N2U1YjMwZTYzOWNfNi0xMS0xLTEtMA_10825a9c-3c59-4d98-90ac-3ebabb43259e"
      unitRef="usd">291000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if66c4113d53e4bb3957023006b998620_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMi05LTEtMS0w_d8c4aa74-1cb4-4932-87b1-62cf456f8bf7"
      unitRef="usd">28445000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if66c4113d53e4bb3957023006b998620_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMi0xMS0xLTEtMA_ce490e8e-3975-4273-afb5-0f738da5c974"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMy05LTEtMS0w_b8d35914-53a7-4020-8a2d-e7f3538afbfd"
      unitRef="usd">21989000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic28cb51d76f14b04b9a5dde949a1e5c8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfMy0xMS0xLTEtMA_849993de-c201-4918-acf4-e25de069081d"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNC05LTEtMS0w_b23b5dbf-f144-4a10-8265-45ef802145ab"
      unitRef="usd">5865000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7ab172e9d9f744789028b9b209c7b067_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNC0xMS0xLTEtMA_7631a1c0-84c9-4098-a2ea-8abb84fdd2c6"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNS05LTEtMS0w_1da02aff-df2a-40a8-ba73-85d70454379e"
      unitRef="usd">56299000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOjQ1ODhkY2I4NDNhMTRlMThhODRmNmZlZjg5YmM1ODBhL3RhYmxlcmFuZ2U6NDU4OGRjYjg0M2ExNGUxOGE4NGY2ZmVmODliYzU4MGFfNS0xMS0xLTEtMA_d1a52c4c-a53c-4e33-9935-1dbcc032b835"
      unitRef="usd">12000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTQ3OQ_5442b978-6cbf-4b48-b5db-ce01b412124c"
      unitRef="investment">53</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTQ4Ng_3f2ea138-0a15-4232-964f-c1ca1fa1bbd1"
      unitRef="investment">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic99cda1e69634b08b343ceeb851e2c7f_I20200403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTU5NQ_230f8040-9e0d-45ef-bcb9-5a2d17299141"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMTU5NQ_ce9fb230-30ce-4cd9-a87a-0f1dace9effb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RleHRyZWdpb246OGIyMGRkZDIxMDFkNDE5ZTlhYWUwMTljZmJlZjVlMmZfMjIyNg_dc3def0e-ab43-4953-b081-389078161239">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMS0xLTEtMS0w_8e9e3f9e-4dd5-4da6-9d7a-a0a4264be305"
      unitRef="usd">1021369000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMS0zLTEtMS0w_a04f7a37-c398-4487-830e-18c3893091f7"
      unitRef="usd">1034150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMi0xLTEtMS0w_6bf4064a-c570-4c93-b80d-073cd95043eb"
      unitRef="usd">320860000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMi0zLTEtMS0w_ba6f2c93-33b8-4ca4-b348-674d22a0bb0f"
      unitRef="usd">321751000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMy0xLTEtMS0w_209fe46e-3a55-4b0f-a609-623e93fcf3d9"
      unitRef="usd">1342229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80My9mcmFnOjhiMjBkZGQyMTAxZDQxOWU5YWFlMDE5Y2ZiZWY1ZTJmL3RhYmxlOmI2Mzk0OWYxYzFjZTQ5M2E4Mjk1MzYxZTBiZjE5MTI0L3RhYmxlcmFuZ2U6YjYzOTQ5ZjFjMWNlNDkzYTgyOTUzNjFlMGJmMTkxMjRfMy0zLTEtMS0w_6cd528a1-8323-4269-9a74-c71a84c4d385"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzYwNDczMTM5NTM5NzA_620f164f-6696-4822-83f4-069373a51aa8">FORWARD CURRENCY CONTRACTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, we had one forward contract outstanding to sell &#x20ac;9.3&#160;million. The forward contract has a maturity of three months, is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The fair value of the forward contract at March 31, 2021 was not material. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the three months ended March 31, 2021, we recognized $0.4&#160;million of gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="iaf9c81849c224cf1a0586e1bcd1d2538_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzU0OTc1NTgxNDAzOTQ_3e697086-04a4-4174-9d09-99b9817ece67"
      unitRef="forwardcontract">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaf9c81849c224cf1a0586e1bcd1d2538_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzYwNDczMTM5NTQwMTM_5c23c78e-f1b8-408e-bb88-79cca4b8558f"
      unitRef="eur">9300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i9c90e1d818864936ad88a7d0eecd505d_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzU0OTc1NTgxNDA0MDI_7c2c74cd-44fb-4beb-8de8-d9f89741f02f">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i9c90e1d818864936ad88a7d0eecd505d_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF85MzkvZnJhZzo2YmIwNDFhYTI1MjQ0ZmQ4ODkzNGQzYzhjNzY1MDJlNi90ZXh0cmVnaW9uOjZiYjA0MWFhMjUyNDRmZDg4OTM0ZDNjOGM3NjUwMmU2XzYwNDczMTM5NTM5ODU_01585ab4-5cb1-43ad-ac83-1644e681a6fe"
      unitRef="usd">400000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RleHRyZWdpb246OGExMjkxZmZjZjRiNDI1NThlMjM2ZDEyZmJmNzQ0OWRfMTUzNQ_8b827ee2-b4a9-41aa-83ab-f37b72115506">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RleHRyZWdpb246OGExMjkxZmZjZjRiNDI1NThlMjM2ZDEyZmJmNzQ0OWRfMTU0Mw_ae652e74-65ef-4b8b-a444-977e04553209">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9921b8f98f46428c8230f8cc4d5b8de5_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMi0xLTEtMS0w_4177d0b6-6e6c-40ca-9f6d-b1843d52710e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9fef9dd01c3463884a549e712c67975_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMi0zLTEtMS0zNjc1_892ffd24-56ea-4dc6-922c-8752ea874a06"
      unitRef="usd">667289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b066d94ab5d48e4a3165fe4d64c48cd_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMi01LTEtMS0w_358d127f-106c-4ebc-89cf-c90ac72c900f"
      unitRef="usd">667289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie79ae71b4d194663b3217ba40d89497a_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMy0xLTEtMS0w_d2e59e0d-37a5-469b-8269-1dcce3b0c432"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie91a81478309419e9d65e9da67aa5b90_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMy0zLTEtMS0zNjc1_0995fb8f-cea7-448c-bc47-b4a5aceb8381"
      unitRef="usd">498824000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9a6af5ad3d6491eb55e7a02e03ca7f0_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfMy01LTEtMS0w_d23539eb-4329-4224-8f58-f46e3027b4cc"
      unitRef="usd">498824000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba1677dbd26445dc9bd4d84baffd67f6_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNC0xLTEtMS0w_c3d1b9d9-11d2-47fb-a6a4-3fc15ce3ba34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e586cbac7b74f1d80c273b7797e092d_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNC0zLTEtMS0zNjc1_9e1dd71c-9748-4404-8b8d-feb33ad45647"
      unitRef="usd">148284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6350986f2c204a2488862f0ace5acbcd_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNC01LTEtMS0w_51e4eb01-9266-4f1a-902a-cb8d322a04d8"
      unitRef="usd">148284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i554b0eab7ff4477ca7fd008d3dd2c260_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNS0xLTEtMS0w_4cda96ad-e3f0-43da-a2c7-c81e950412e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief9769920780449fbdaf815855b16f9c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNS0zLTEtMS0zNjc1_9eb2284c-8564-4ebf-8b98-e144d7e7d5ae"
      unitRef="usd">27832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i415a1c2ee7384eba9691f7dbb9a64ac0_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNS01LTEtMS0w_323ae705-21d5-4cc6-98d2-695a475b6fce"
      unitRef="usd">27832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibccddea8bdc34321a373d4b211f85366_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNi0xLTEtMS0w_105604e1-5248-44d4-941a-55680ae0577b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a320379c33746e8a62505863f507b0b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNi0zLTEtMS0w_b1c85175-d269-440a-b69f-469949949945"
      unitRef="usd">1342229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02f8f448a7e44f71893357d3ac2b9a60_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNi01LTEtMS0w_26620e2e-56a9-4332-b8a5-db3026d23c46"
      unitRef="usd">1342229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e178b46a658489fb7b95d67e5ac005c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy0xLTEtMS0zNjc3_2bb36dc2-6526-4afe-af68-578b957eeaf1"
      unitRef="usd">105775000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e178b46a658489fb7b95d67e5ac005c_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy0xLTEtMS0zNjc3_b4be7724-23db-4c99-ba5d-4996f67a16cb"
      unitRef="usd">105775000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5966995df7754c27a0b4f6cf9ddfcf30_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy0zLTEtMS0w_2cc43d76-2234-4ce4-b602-2a9f8ee7eaec"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifacaab7c5ee54a3d9ae628433835e5b2_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfNy01LTEtMS0w_0f6afda4-8732-4fcb-94b3-a45759713880"
      unitRef="usd">105775000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i39e3fe01255048d58bc6c48c899a44f9_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC0xLTEtMS0w_8a321a8a-9320-4fb6-bbee-8493400bb2be"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i079f6e55e7604e41981bb55d026449bb_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC0zLTEtMS0zNjc5_42997821-0641-4b93-9ecb-749ed6fde9a5"
      unitRef="usd">63305000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4bdd567b1f84314b22e6f47db7ed986_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC0zLTEtMS0zNjc5_ac0af483-b36c-41f1-9e8c-8e825da06254"
      unitRef="usd">63305000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i14575a1b1fbe41f2ad3f7b52e297ed34_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOC01LTEtMS0w_89fa8ac3-a013-48bf-9763-32bd97e6f427"
      unitRef="usd">63305000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibccddea8bdc34321a373d4b211f85366_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOS0xLTEtMS0w_8cdc3bba-b700-487a-98ad-cd93cdc10887"
      unitRef="usd">105775000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a320379c33746e8a62505863f507b0b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOS0zLTEtMS0w_ee8a8e60-5952-45a6-a567-cdd448c813fb"
      unitRef="usd">1405534000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i02f8f448a7e44f71893357d3ac2b9a60_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmE0MTMzNzdjMGQzNTRjMmRiYzg2NjhkZmVjMDdmNDBjL3RhYmxlcmFuZ2U6YTQxMzM3N2MwZDM1NGMyZGJjODY2OGRmZWMwN2Y0MGNfOS01LTEtMS0w_69474720-c7d8-4c1e-9f69-aa9fd5f06c7e"
      unitRef="usd">1511309000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1fe4c382d26c42ca9aab7aae9c0d74cb_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMi0xLTEtMS0w_0187c235-c33b-4140-bc79-0bec77e5df3c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2cc15096d7544af483700aaf508a964a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMi0zLTEtMS0w_dba637f4-b6f7-4dfa-a182-12b79946e06b"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec009171117540bdbb58c1be5851a2d7_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMi01LTEtMS0w_c65cdcc4-d903-4218-b6e5-ff4e9a8e2b14"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3fe21729df9640cdbe357f4ec3f1d02a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMy0xLTEtMS0w_52614c7d-dc35-4f78-acc8-c8d70cb5de67"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i320b4929fd414ebf96f80e9078a55169_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMy0zLTEtMS0w_41eee934-6c34-4f17-88be-95cee831d370"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82d730819e3d4d3c9dde3eeeb9a8b9c9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfMy01LTEtMS0w_90b44f78-2dbd-411c-93c4-1a2d7db9fc20"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i61fc1e1e560a449a9311f3bf3efd3e52_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNC0xLTEtMS0w_cd03de6a-e52d-48cf-9740-f5872d8eb1dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08c476589a9744e4a0a2d5a9ec2bb854_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNC0zLTEtMS0w_dc5d076c-708c-4203-9463-13d11894d44b"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i317939be92c5441a8c74c4d69f167550_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNC01LTEtMS0w_08367f66-04cc-4800-a436-ce6ef315e3d5"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c07b0da2b0d43f8bd7ff0a0f78a9545_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0xLTEtMS00NDk_6dab7d8e-53bb-4b3d-bd9a-d54363f12909"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68847f2d1e1d4718a5bda4b12d840afe_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0zLTEtMS00NDk_3cda3cb8-ea44-420a-ae51-3cf7d65c64d0"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85f1822a756341a984f6f5e493514983_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS01LTEtMS0zNjgx_ae84191a-a124-43a6-9067-2b59d0746fad"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie576c7303b774e12a574df1fb982d1f0_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0xLTEtMS0w_afbd4c89-4b42-4ca1-8c3d-385e73e50582"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a800e8408eb4e51a4f63612b53ab204_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS0zLTEtMS0w_491596d4-8d2a-4f8b-9ce1-d629f6abf60c"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2191e1eb15cf4c0385b5db4eb3d8d740_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNS01LTEtMS0w_dfc5df8a-cd79-45c5-b919-a0fb1e9117d3"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieba91e88df5042f390aa570d7bc9525f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNi0xLTEtMS0w_92a428fe-8c8a-4bfd-b587-6308f62d89b4"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibaa26564d1144ad68101916a752c72c5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNi0zLTEtMS0w_d22bb3f8-9632-4033-8130-2add4d6af006"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2c81d2dc86224957b76780b9b01b05fc_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNi01LTEtMS0w_69312c38-8f7e-408a-8b68-0ac1c669950e"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i12afb5247d4341d8b3086641b3b17606_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNy0xLTEtMS0w_04deb7d7-ae0b-40fb-a694-b677396e88c1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if81956f5ad624fb3a34af890cb926767_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNy0zLTEtMS0w_5a8b91f6-5daf-4594-b4b0-75fb71301f45"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9234350c43af4d5fa786ab8abc166d55_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfNy01LTEtMS0w_1e32cadd-3d25-49bb-839e-383177fab871"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie576c7303b774e12a574df1fb982d1f0_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfOC0xLTEtMS0w_e37bb0f1-1fef-445e-8b78-467683b93c9b"
      unitRef="usd">40761000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a800e8408eb4e51a4f63612b53ab204_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfOC0zLTEtMS0w_d352e0fa-8d45-4574-bd54-3d120c93e408"
      unitRef="usd">1415905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2191e1eb15cf4c0385b5db4eb3d8d740_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80Ni9mcmFnOjhhMTI5MWZmY2Y0YjQyNTU4ZTIzNmQxMmZiZjc0NDlkL3RhYmxlOmQzZDc0MTk2ZTBkYjQ2N2ZiN2M2YzQ4N2FlZmE3OWI1L3RhYmxlcmFuZ2U6ZDNkNzQxOTZlMGRiNDY3ZmI3YzZjNDg3YWVmYTc5YjVfOC01LTEtMS0w_63fa2e0a-5426-4550-affe-07535135c2bc"
      unitRef="usd">1456666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTky_18da5085-d31d-48b0-a76d-e163f070bd58">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-downs related to excess and expiring inventory were $2.1 million and $0.2 million for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTg1_c3043ad5-b780-41d5-af03-c0c1e9f7298c">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMS0xLTEtMS0w_a8e57614-2214-439e-b063-c13653a5e485"
      unitRef="usd">7988000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMS0zLTEtMS0w_fe678d94-8b37-4bad-a2d2-381f0fb4e504"
      unitRef="usd">7773000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMi0xLTEtMS0w_9ff29431-804c-42cd-8ead-5afa46214204"
      unitRef="usd">21873000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMi0zLTEtMS0w_9888630f-7aaa-4034-b0d7-99cb82a350da"
      unitRef="usd">20610000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMy0xLTEtMS0w_fd95965d-d52a-4cd8-97cc-76e923a5fdfd"
      unitRef="usd">5786000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfMy0zLTEtMS0w_83af9f83-382e-4579-b065-6e5051547014"
      unitRef="usd">7291000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNC0xLTEtMS0w_7f96b4ee-32a6-44b2-bf34-2af30f22e1db"
      unitRef="usd">35647000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNC0zLTEtMS0w_82acf29e-9e65-495a-b8e6-248cb88c21a9"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i504de91fc7df4dbd9eba09e75fabc924_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNi0xLTEtMS0w_29167b26-2a29-4ee3-8792-e71746fd095a"
      unitRef="usd">24757000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i22ff09f3344f4de1a78249a095f43788_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNi0zLTEtMS0w_76ac6aa8-32bd-4f7d-bd39-2feb0643f575"
      unitRef="usd">20973000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i02becf95ad41458a9f42b2d89fbc17fd_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNy0xLTEtMS0w_3242afee-c1d1-43de-8141-c98df966b2cc"
      unitRef="usd">10890000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ifb144073f9ec4ff78af65d49175c7cbe_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfNy0zLTEtMS0w_8e9968d2-f94b-4945-b670-403bb33a63f6"
      unitRef="usd">14701000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfOC0xLTEtMS0w_f526b0e0-d703-4922-a422-fdaa60ff0cf5"
      unitRef="usd">35647000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib3152fd72d2e45c78ae6f5d34c980d50_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RhYmxlOmU4YTVhYjhhOWQ1MTQ2ZjQ4ZjA3OWJiODlhMzk4Y2Q1L3RhYmxlcmFuZ2U6ZThhNWFiOGE5ZDUxNDZmNDhmMDc5YmI4OWEzOThjZDVfOC0zLTEtMS0w_acdc804b-abc1-4461-82a1-6f722ac8af5e"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTM2_55ddfba7-af7e-4324-b4a6-1c94778cf2aa"
      unitRef="usd">2100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF80OS9mcmFnOjhhNjY5NDQwZWUwNzRmMzA5YzM4NTViNTJjZjRkNjk5L3RleHRyZWdpb246OGE2Njk0NDBlZTA3NGYzMDljMzg1NWI1MmNmNGQ2OTlfMTQz_fe3cf5da-7367-439a-ac7a-af6eae66ff1c"
      unitRef="usd">200000</us-gaap:InventoryWriteDown>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNDI4Ng_a582709e-6d78-49ae-a025-6e990fd0363b">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 9,272,614 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, we granted 881,440 stock options with a weighted average exercise price of $21.75 per share and a weighted average grant&#160;date fair&#160;value of $9.88&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of March&#160;31, 2021, there were 15,688,044 stock options outstanding and $30.7 million of related unrecognized compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, we granted 3,059,698 service-based restricted stock units (RSUs) with a weighted average grant&#160;date fair&#160;value of $21.43 per share. As of March&#160;31, 2021, there were 8,282,867 RSUs outstanding and $155.9 million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and RSUs granted to employees during the three months ended March&#160;31, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we awarded 1,027,650 (the target amount) performance-based restricted stock units (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to employee&#x2019;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#x2019;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;March&#160;31, 2021, there were&#160;8,767,305 PSUs outstanding and $161.2 million of related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended March&#160;31, 2021, we achieved additional performance targets for 461,532 additional PSUs granted during 2019. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNDI3OQ_85d18aa5-e328-4812-90fd-47648040d5a2">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3ddda20eb4846618e6298bc462af14b_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMi01LTEtMS0w_81e4398b-5c89-4a35-98ae-24d1d25851e7"
      unitRef="usd">12396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1369691551dc4fafb80d4de87f27c595_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMi03LTEtMS0w_ebb6e8ae-9036-4827-b5ca-600f8fbb02b8"
      unitRef="usd">5086000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieed02b22b90b48f3b8a0903941c79c91_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMy01LTEtMS0w_e3b9b737-32d0-4340-af32-0b78d81b91a4"
      unitRef="usd">22257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bcfe7378fa74f1399955c024d098430_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfMy03LTEtMS0w_ffd1b04c-5bc7-4972-a6b1-62221100315e"
      unitRef="usd">8896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfNC01LTEtMS0w_0c78a9f5-951f-49ca-aa8e-4dd1b2072ac6"
      unitRef="usd">34653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjFhM2I4Y2VmNWY0NDQ2MTVhNGNkNDcxYzhkYjljMTI3L3RhYmxlcmFuZ2U6MWEzYjhjZWY1ZjQ0NDYxNWE0Y2Q0NzFjOGRiOWMxMjdfNC03LTEtMS0w_a08409b5-b20a-4689-9066-22b1deda0a3d"
      unitRef="usd">13982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMi01LTEtMS0zNjkx_42ab78f2-3810-421a-b8de-7dba36ed3c52"
      unitRef="usd">4694000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if18980bf9a07498daf97936c223cd8bd_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMi03LTEtMS04Njc_60a8e3db-299d-4c6c-99a8-db5bf0cf1845"
      unitRef="usd">4994000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i408345112b514492b8672264d5e9495e_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMy01LTEtMS0zNjkx_dd4bc807-decd-4cb0-972f-4a6a374faf5a"
      unitRef="usd">11669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3af9d6876ad41e9a9459ff5b52f0864_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfMy03LTEtMS04Njc_54da0e9b-efe0-4693-9800-65213c176742"
      unitRef="usd">7797000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNC01LTEtMS0zNjkx_3d6d92bf-9be7-4542-b655-4a191abede39"
      unitRef="usd">17947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i666a5e9b8134485fa80a9e4de6771543_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNC03LTEtMS04Njc_b700cdf2-19d7-410c-a26f-d22bdf05d691"
      unitRef="usd">496000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i949dcc93029c4d24bde4a783adbeeacb_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNS01LTEtMS0zNjkx_3e675927-2800-465e-ad70-fb3b11b6405b"
      unitRef="usd">343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2fa0e1f1fe17409098662f0eaa3cf7f2_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNS03LTEtMS04Njc_22317178-1168-4984-9203-9352f4739261"
      unitRef="usd">695000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNi01LTEtMS0zNjkx_df53770b-99be-4ce0-82a8-1324e26e8c7a"
      unitRef="usd">34653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjNhOTUzODkzMjRkMjRjYzlhMjFkNjMwZjUyNmZkY2Y5L3RhYmxlcmFuZ2U6M2E5NTM4OTMyNGQyNGNjOWEyMWQ2MzBmNTI2ZmRjZjlfNi03LTEtMS0zNjkz_f3b251ac-aaec-4351-afdc-d7611298ae0a"
      unitRef="usd">13982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjA3_932485a6-aeb1-4e05-a5d2-47c727c973f9"
      unitRef="shares">9272614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMzY4_d1693d9b-b302-442d-bce9-14dba6bf48e4"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNDU4_c130a5eb-0b5c-44de-afa1-2bb0361c0c65"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfOTI4_804942e6-7f71-4472-ac0d-437f530d082e"
      unitRef="shares">881440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfOTg3_2eaaa0e3-6aaf-49d8-88fc-4a9a61d6e38b"
      unitRef="usdPerShare">21.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTA0OA_2c43834d-3ce4-45d4-a4ff-c47544bde9ad"
      unitRef="usdPerShare">9.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc8c9c247bbf4f2fa55811d4b33ba5b9_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTA4Mw_c29d5f1d-827c-4d44-9532-ad83c8bbcf27"
      unitRef="shares">15688044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibc8c9c247bbf4f2fa55811d4b33ba5b9_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTExNg_a6af9723-3f0d-40f5-87fa-ebb98bddaadb"
      unitRef="usd">30700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i408345112b514492b8672264d5e9495e_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTE4NA_6e6c7cf8-c915-4cf0-9b21-b107a7fe1ef8"
      unitRef="shares">3059698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i408345112b514492b8672264d5e9495e_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTI1NQ_ac45e4bf-3aa5-473e-b0a1-873645016e01"
      unitRef="usdPerShare">21.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i677b05d55bac4440b27c7ed808660a68_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTI5MA_833f81a4-4ea4-43b2-a3ab-c0c349a370b2"
      unitRef="shares">8282867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i677b05d55bac4440b27c7ed808660a68_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTMxNA_c6ceb304-fb14-4499-a01d-355eff0f8a45"
      unitRef="usd">155900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8622ebd208ee40748f3badc2d3baff8b_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMTA5OTUxMTY1MjY5NQ_a52ecb3f-468c-468a-8278-505e6077d491"
      unitRef="shares">1027650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i8622ebd208ee40748f3badc2d3baff8b_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNjA0NzMxMzk3NzUyNw_0ce3c7a5-c04f-4046-ba44-291eb9b73e4f"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i21631f07cfc643bd9432ab5a17b6267d_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNTQ5NzU1ODE2NTkxNA_1436b797-3828-4982-82ac-a7fcb53b560c"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifcf3d4993c944a21a332310247496165_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNTQ5NzU1ODE2NTkzNA_0e7716be-e403-47a2-a6f4-b0c10d561e75">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNjA0NzMxMzk3NzUwMA_e1795d02-33df-4935-a0ad-c89075a70dcd">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfNTQ5NzU1ODE2NTkwNg_16f1bb99-c80d-4209-b185-de9fc11bacef"
      unitRef="usdPerShare">24.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="i9911c9d99e354292b6c84ef2ea046b40_I20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMC0xLTEtMS0zNzU0_4e8f99b5-ba8b-4252-ac18-c799c6be69f4"
      unitRef="usdPerShare">21.31</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMS0xLTEtMS0zNzU0_11ac59bb-316e-437f-b8a6-ff62e04aa878"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMi0xLTEtMS0zNzU0_299106d3-afa7-430a-9654-afcbec9a917a"
      unitRef="number">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RhYmxlOjg1NzcwNGRiMjgzYzQ1ODRiZDc3OTBjYmQ5OWYwMmVhL3RhYmxlcmFuZ2U6ODU3NzA0ZGIyODNjNDU4NGJkNzc5MGNiZDk5ZjAyZWFfMy0xLTEtMS0zNzU0_5ede2eb4-bda3-4888-a53e-652c6819ed3d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9911c9d99e354292b6c84ef2ea046b40_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjE5OTAyMzI3OTIzMA_78f2ff64-2ac2-440d-91ac-3a20ffc4bf1c"
      unitRef="shares">8767305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9911c9d99e354292b6c84ef2ea046b40_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjE5OTAyMzI3OTMwMQ_7c9ffd0c-17f8-4c15-bfcd-1fa0810f186c"
      unitRef="usd">161200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6017a4101e7f412f89057676d1636d3e_I20210402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81Mi9mcmFnOmZkZDE2Nzc5OGIyZDQxMjQ4MmRiNDI1ZDc0MjRjNTgyL3RleHRyZWdpb246ZmRkMTY3Nzk4YjJkNDEyNDgyZGI0MjVkNzQyNGM1ODJfMjE5OTAyMzI3OTc3MQ_24f83694-a3a0-4f5e-89b5-b672b6bdfbf4"
      unitRef="shares">461532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81NS9mcmFnOmVjYzg5OWI3NWFlZjQwNWJhOTkzNmM3MjNkNWM4ODA5L3RleHRyZWdpb246ZWNjODk5Yjc1YWVmNDA1YmE5OTM2YzcyM2Q1Yzg4MDlfNjk0_f90d3a0e-ade0-4b38-8601-906b061a0fb0">PROVISION FOR (BENEFIT FROM) INCOME TAXESThe effective tax rate for the three months ended March&#160;31, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period. The effective tax rate for the three months ended March&#160;31, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RleHRyZWdpb246YmIyY2I5YmI2OTY3NDBlOTllZmJjMWRjNjhjMTU0N2RfNjg2_7460e692-181d-412b-a6ba-cffb567ad596">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options and PSOs, unvested RSUs and PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RleHRyZWdpb246YmIyY2I5YmI2OTY3NDBlOTllZmJjMWRjNjhjMTU0N2RfNjcz_5aa0bc62-fc1e-4dcc-b9b5-bf05415dd0e8">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfMy01LTEtMS0w_ecd714ce-eb21-40a9-a879-48e71daa1ad0"
      unitRef="usd">1601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfMy03LTEtMS0w_0ea809f2-6783-488f-8721-7b546a97a932"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNS01LTEtMS0w_a936ce71-94fc-45ba-a4a5-bbce48f3a549"
      unitRef="shares">312473000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNS03LTEtMS0w_3c79c02c-5009-4846-a1b4-331cdf843814"
      unitRef="shares">305388000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNi01LTEtMS0w_edfdc474-86c1-4aa8-86c6-3eac1d790b01"
      unitRef="shares">8814000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNi03LTEtMS0w_f9287e95-e9ab-4150-b10a-e8b41b4cb7b7"
      unitRef="shares">10451000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNy01LTEtMS0w_7106682a-f312-46f6-b47e-3b88af616a2f"
      unitRef="shares">321287000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfNy03LTEtMS0w_2926b046-776b-44a2-bbd5-3f1c59a07826"
      unitRef="shares">315839000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOC01LTEtMS0w_8837b32e-dc83-4ee5-806b-ba1cee33e6a1"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOC03LTEtMS0w_740a180a-c9c6-4f24-b5e1-b2c8efee53c7"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOS01LTEtMS0w_74a03a98-91a0-44fe-82d7-22b29dbaa525"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i743f2228fb564d7b9dcc12b8f607efd6_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOjVlNmMzMjcyZmIwZjRmNDRhMDU1NDllNjZlZTcwMTZiL3RhYmxlcmFuZ2U6NWU2YzMyNzJmYjBmNGY0NGEwNTU0OWU2NmVlNzAxNmJfOS03LTEtMS0w_abb427d7-1f97-46a5-b120-899ea61f714a"
      unitRef="usdPerShare">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RleHRyZWdpb246YmIyY2I5YmI2OTY3NDBlOTllZmJjMWRjNjhjMTU0N2RfNjkw_7658ad91-c5e8-4169-9fbe-52719d2a026c">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibc070254d7a9427b9acaf2c3ca6a6317_D20210102-20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOmVjOGZiOTQ3MzA5YTRhZjRiZGM3NzNmNmFiNWIwNzkzL3RhYmxlcmFuZ2U6ZWM4ZmI5NDczMDlhNGFmNGJkYzc3M2Y2YWI1YjA3OTNfMi01LTEtMS0w_91504a61-c4d4-4adc-a76d-60034bfb5da1"
      unitRef="shares">10007000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i103b70fa1d1e4257bec9058596619e69_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF81OC9mcmFnOmJiMmNiOWJiNjk2NzQwZTk5ZWZiYzFkYzY4YzE1NDdkL3RhYmxlOmVjOGZiOTQ3MzA5YTRhZjRiZGM3NzNmNmFiNWIwNzkzL3RhYmxlcmFuZ2U6ZWM4ZmI5NDczMDlhNGFmNGJkYzc3M2Y2YWI1YjA3OTNfMi03LTEtMS0w_a8a96556-0894-4853-b5b9-47effaa868e9"
      unitRef="shares">12014000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0ZWEwM2QwYjE1ODRjYjE5Njk1ZDZkMmM1NjlhOGM4L3NlYzpmNGVhMDNkMGIxNTg0Y2IxOTY5NWQ2ZDJjNTY5YThjOF82MS9mcmFnOjg0ZmUzNjMzODY1MjQxMDQ5NzY5ZDg5M2Q0NDVmYzhhL3RleHRyZWdpb246ODRmZTM2MzM4NjUyNDEwNDk3NjlkODkzZDQ0NWZjOGFfMzEzMg_6bce8432-85e3-4e77-a16b-14f25081b280">COMMITMENTS AND CONTINGENCIESIn September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received a notice letter from Teva Pharmaceuticals USA, Inc. (Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#x2019;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. We are reviewing the details of the Paragraph IV certification notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095076986808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  02,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,387,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994152120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 370,209<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">815,285<span></span>
</td>
<td class="nump">887,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">177,673<span></span>
</td>
<td class="nump">160,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">24,757<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">46,341<span></span>
</td>
<td class="nump">57,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,434,265<span></span>
</td>
<td class="nump">1,445,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">328,860<span></span>
</td>
<td class="nump">330,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">78,453<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">160,598<span></span>
</td>
<td class="nump">156,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">124,682<span></span>
</td>
<td class="nump">73,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,190,542<span></span>
</td>
<td class="nump">2,137,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,821<span></span>
</td>
<td class="nump">23,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">37,945<span></span>
</td>
<td class="nump">51,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">59,762<span></span>
</td>
<td class="nump">52,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">31,468<span></span>
</td>
<td class="nump">20,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">13,461<span></span>
</td>
<td class="nump">12,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">56,880<span></span>
</td>
<td class="nump">44,447<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">213,337<span></span>
</td>
<td class="nump">204,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">9,760<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">52,837<span></span>
</td>
<td class="nump">49,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,421<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">279,355<span></span>
</td>
<td class="nump">258,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 313,262 and 311,627 at March&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,354,103<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2,740<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(445,969)<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,911,187<span></span>
</td>
<td class="nump">1,879,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,190,542<span></span>
</td>
<td class="nump">$ 2,137,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095068045096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">313,262,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">313,262,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094995123768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">13,198<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">159,288<span></span>
</td>
<td class="nump">101,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">102,351<span></span>
</td>
<td class="nump">62,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">274,837<span></span>
</td>
<td class="nump">174,106<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(4,607)<span></span>
</td>
<td class="nump">52,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">7,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(2,015)<span></span>
</td>
<td class="nump">60,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">(3,616)<span></span>
</td>
<td class="nump">11,423<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="nump">$ 48,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">312,473<span></span>
</td>
<td class="nump">305,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">321,287<span></span>
</td>
<td class="nump">315,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 227,212<span></span>
</td>
<td class="nump">$ 193,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,528<span></span>
</td>
<td class="nump">20,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 15,490<span></span>
</td>
<td class="nump">$ 12,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988577480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="nump">$ 48,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized losses on available-for-sale debt securities, net of tax impact of $499 and $941, respectively</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="num">(3,291)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (135)<span></span>
</td>
<td class="nump">$ 45,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094992894696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized losses on available-for-sale debt securities, tax impact</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994847352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 2,241,947<span></span>
</td>
<td class="nump">$ 3,069<span></span>
</td>
<td class="num">$ (559,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">48,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(3,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">4,172<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(1,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Apr. 03, 2020</a></td>
<td class="nump">$ 1,747,652<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">2,258,307<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(510,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2021</a></td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">4,202<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(6,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 34,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 02, 2021</a></td>
<td class="nump">313,262<span></span>
</td>
<td class="nump">313,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Apr. 02, 2021</a></td>
<td class="nump">$ 1,911,187<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 2,354,103<span></span>
</td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="num">$ (445,969)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095067068104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="nump">$ 48,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">3,227<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">34,653<span></span>
</td>
<td class="nump">13,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="num">(3,388)<span></span>
</td>
<td class="nump">10,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(17,690)<span></span>
</td>
<td class="num">(18,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,090)<span></span>
</td>
<td class="num">(4,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="num">(2,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">13,422<span></span>
</td>
<td class="nump">8,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">138<span></span>
</td>
<td class="num">(2,131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">39,544<span></span>
</td>
<td class="nump">56,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(13,557)<span></span>
</td>
<td class="num">(2,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(331,612)<span></span>
</td>
<td class="num">(251,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">407,424<span></span>
</td>
<td class="nump">287,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">62,255<span></span>
</td>
<td class="nump">32,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">3,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(5,441)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(2,650)<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">99,149<span></span>
</td>
<td class="nump">90,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">419,921<span></span>
</td>
<td class="nump">358,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 4,893<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988562440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple regimens to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the three months ended April&#160;2, 2021 and April&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended March&#160;31, 2021 and March&#160;31, 2020 and the year ended December&#160;31, 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity. </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the significant accounting policies disclosed in Note 1 &#8211; Significant Accounting Policies included in the our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into foreign currency forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094992968456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers or as other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)   Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, we recognized $2.5 million and $1.6 million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, and 2020, we recognized $27.8 million and $18.8 million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda Pharmaceutical Company Limited (Takeda), Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Genentech Inc. (a member of the Roche Group) (Genentech).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $87.3 million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095095457544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS AND IN-LICENSING ARRANGEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS AND IN-LICENSING ARRANGEMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $44.8 million of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020 to, among other things, modify the amount of reimbursements we are eligible to receive for costs associated with our required pharmacovigilance activities, modify the amount of milestones we are eligible to receive, and modify certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02 clinical trials. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.940%"><tr><td style="width:1.0%"/><td style="width:62.693%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.613%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, $42.5 million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK &amp; Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $10.1 million and $8.1 million during the three months ended March&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations and In-Licensing Arrangements </span></div>In the first quarter of 2021, we entered into additional licensing and collaboration agreements in support of our preclinical pipeline with Adagene, Inc. (Adagene) and WuXi Biologics Ireland Ltd (WuXi Bio). As part of these agreements we made aggregate upfront payments of $14.0&#160;million in exchange for licenses to develop and commercialize products. We committed to make payments to Adagene for potential future development milestones of $55.0&#160;million, regulatory milestones of $200.0&#160;million, and commercial milestones of $525.0&#160;million, each in the aggregate, as well as royalties on future net product sales. We also committed to make payments to WuXi Bio for potential future development milestones of $18.5&#160;million, regulatory milestones of $30.0&#160;million, and commercial milestones of $80.0&#160;million, each per product, as well as royalties on future net product sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094993400744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of March 31, 2021, restricted cash equivalents included $48.2&#160;million of short-term investments as collateral under our standby letter of credit entered into in January 2021 as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $3.6 million and $4.5 million as of March&#160;31, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.376%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were 53 and 14 investments in an unrealized loss position as of March&#160;31, 2021 and December&#160;31, 2020, respectively. During the three months ended March&#160;31, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988339144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Forward Currency Contracts<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">FORWARD CURRENCY CONTRACTS</a></td>
<td class="text">FORWARD CURRENCY CONTRACTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had one forward contract outstanding to sell &#8364;9.3&#160;million. The forward contract has a maturity of three months, is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The fair value of the forward contract at March 31, 2021 was not material. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the three months ended March 31, 2021, we recognized $0.4&#160;million of gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095077044632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405,534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988339144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $2.1 million and $0.2 million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988644600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 9,272,614 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we granted 881,440 stock options with a weighted average exercise price of $21.75 per share and a weighted average grant&#160;date fair&#160;value of $9.88</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of March&#160;31, 2021, there were 15,688,044 stock options outstanding and $30.7 million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we granted 3,059,698 service-based restricted stock units (RSUs) with a weighted average grant&#160;date fair&#160;value of $21.43 per share. As of March&#160;31, 2021, there were 8,282,867 RSUs outstanding and $155.9 million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the three months ended March&#160;31, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we awarded 1,027,650 (the target amount) performance-based restricted stock units (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2021, there were&#160;8,767,305 PSUs outstanding and $161.2 million of related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended March&#160;31, 2021, we achieved additional performance targets for 461,532 additional PSUs granted during 2019. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094992784712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR (BENEFIT FROM) INCOME TAXES</a></td>
<td class="text">PROVISION FOR (BENEFIT FROM) INCOME TAXESThe effective tax rate for the three months ended March&#160;31, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, in relation to the generation of a small pre-tax loss during the period. The effective tax rate for the three months ended March&#160;31, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094992920312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options and PSOs, unvested RSUs and PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988596584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIESIn September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by <div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a notice letter from Teva Pharmaceuticals USA, Inc. (Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. We are reviewing the details of the Paragraph IV certification notice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095095809976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the three months ended April&#160;2, 2021 and April&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended March&#160;31, 2021 and March&#160;31, 2020 and the year ended December&#160;31, 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief </span></div>Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">ReclassificationsCertain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Foreign Currency Forward Contracts for Non-Designated Hedges</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into foreign currency forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers or as other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div>We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988388568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.  </span></div>(2)   Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988556584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.940%"><tr><td style="width:1.0%"/><td style="width:62.693%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.613%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>License revenues under the collaboration agreement with Genentech were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094986670392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.376%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988648744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405,534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988658696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094993037256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094993523080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094993940664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 02, 2021 </div>
<div>product </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products derived from cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994084072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">314,205<span></span>
</td>
<td class="nump">252,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(86,993)<span></span>
</td>
<td class="num">(58,686)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">227,212<span></span>
</td>
<td class="nump">193,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,528<span></span>
</td>
<td class="nump">20,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,490<span></span>
</td>
<td class="nump">12,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 43,018<span></span>
</td>
<td class="nump">$ 33,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994925304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095068104472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">229,957<span></span>
</td>
<td class="nump">196,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,806<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,467<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094995785416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">223,595<span></span>
</td>
<td class="nump">189,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="nump">4,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 227,212<span></span>
</td>
<td class="nump">$ 193,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994889448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">$ 30,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">85,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(71,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2021</a></td>
<td class="nump">46,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">52,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(49,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2021</a></td>
<td class="nump">12,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">8,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(5,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2021</a></td>
<td class="nump">5,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">17,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">25,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(15,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2021</a></td>
<td class="nump">$ 27,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095067884424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">9,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">9,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">18,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">27,800<span></span>
</td>
<td class="nump">$ 18,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 87,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994855688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,806<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,528<span></span>
</td>
<td class="nump">20,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22,451<span></span>
</td>
<td class="nump">17,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,490<span></span>
</td>
<td class="nump">12,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 11,355<span></span>
</td>
<td class="nump">$ 11,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988631944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - Ipsen Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 87.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 44.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094995021240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,528<span></span>
</td>
<td class="nump">20,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,490<span></span>
</td>
<td class="nump">12,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4,135<span></span>
</td>
<td class="nump">$ 1,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094986680408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 87.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 42.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094985999080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988688776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 270,230<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 951<span></span>
</td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095067884584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And In-Licensing Arrangements - In-Licensing Collaborations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeAgreementWithAdageneMember', window );">Collaborative Agreement With Adagene</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones', window );">Collaborative arrangement maximum amount eligible for development milestones</a></td>
<td class="nump">55.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones', window );">Collaborative arrangement maximum amount eligible for regulatory milestones</a></td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">525.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeAgreementWithWuXiBioMember', window );">Collaborative Agreement With WuXi Bio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones', window );">Collaborative arrangement maximum amount eligible for development milestones</a></td>
<td class="nump">18.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones', window );">Collaborative arrangement maximum amount eligible for regulatory milestones</a></td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">$ 80.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Maximum Amount Eligible For Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Maximum Amount Eligible For Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeAgreementWithAdageneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeAgreementWithAdageneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeAgreementWithWuXiBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeAgreementWithWuXiBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988714568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 370,209<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">49,712<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 419,921<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
<td class="nump">$ 358,976<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095069648296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,338,545<span></span>
</td>
<td class="nump">$ 1,349,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,975<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,342,229<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,560,382<span></span>
</td>
<td class="nump">1,532,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,975<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,564,066<span></span>
</td>
<td class="nump">1,538,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">667,071<span></span>
</td>
<td class="nump">569,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">667,289<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">495,490<span></span>
</td>
<td class="nump">543,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,609<span></span>
</td>
<td class="nump">5,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(275)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">498,824<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">148,208<span></span>
</td>
<td class="nump">208,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">148,284<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,776<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,832<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">52,757<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">52,757<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">105,775<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">105,775<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">63,305<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 63,305<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094986627480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 02, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Apr. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash short-term investments</a></td>
<td class="nump">$ 48,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994909736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 180,291<span></span>
</td>
<td class="nump">$ 56,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">131,468<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(275)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">31,981<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">12,120<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988419800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,021,369<span></span>
</td>
<td class="nump">$ 1,034,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">320,860<span></span>
</td>
<td class="nump">321,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,342,229<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988540152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Forward Currency Contracts (Details) - 3 months ended Apr. 02, 2021 - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>forwardContract</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | forwardContract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on derivative instruments, pretax | $</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094995807128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,342,229<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,342,229<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,511,309<span></span>
</td>
<td class="nump">1,456,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">105,775<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,342,229<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,405,534<span></span>
</td>
<td class="nump">1,415,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">667,289<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">667,289<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">667,289<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">498,824<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">498,824<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">498,824<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">148,284<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">148,284<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">148,284<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">27,832<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">27,832<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">105,775<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">105,775<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">63,305<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 63,305<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994742984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 7,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">21,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">35,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">24,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 10,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095077171048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 34,653<span></span>
</td>
<td class="nump">$ 13,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,396<span></span>
</td>
<td class="nump">5,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 22,257<span></span>
</td>
<td class="nump">$ 8,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095067210856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 34,653<span></span>
</td>
<td class="nump">$ 13,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,694<span></span>
</td>
<td class="nump">4,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,669<span></span>
</td>
<td class="nump">7,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">17,947<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140095092550152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,272,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,688,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,282,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="nump">1,027,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,767,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988418360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details) - Performance stock units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 02, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 24.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 21.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094988322440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="nump">$ 48,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">312,473<span></span>
</td>
<td class="nump">305,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">8,814<span></span>
</td>
<td class="nump">10,451<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">321,287<span></span>
</td>
<td class="nump">315,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140094994984936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">10,007<span></span>
</td>
<td class="nump">12,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5TZW0:I+YD\.I>063M9/>%RL:4U?N;W=T+*_HSJL.,]R-<@]H%25W]OM_![
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M<M%>OX_=[V/W0A)VL??-"/&I-X"]U1@2.+'_S9U+-N@I&PEQEZLL5GX<$CJ
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MHW":* #\?\NY?+Y1;][:E[^K?P!02P,$%     @ S(.F4BFP+,4?!@  .!<
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MU=RZ:+)5Q5=5YLI:5QL55SHJN!9E'%1TJ.@,U>WA>'QD5&Y#YNZ-WXQ0EO>
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MM[S^ 71B>@"0"JTJX%,(U&:9AJB%MCY1M'Z28G:U0[<.RH!=UN6A?9#H0I=
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MC#@8](_:+PWUT8ET<K(1T]7RL+ RH 0C@XX2=V^SE1F*CTC<Z?$KPEAU.@9
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MO7U"V]V%K73!\^:D8 =3WLH<NTD$P[S$ R=F-Z%IQC3/B3+<V>I$M8F^6;+
MO_K0-HX;P76=J8=EA ;)W'WDM5FY4)6K:.(;Y2)Y (%%R:]JTV[J>G["+;UC
M7]2N.U\J,SK&IN^QU"VC]+N/ENW3]I/OU'WIW YWWXL1BL P@T*[Q%2_-QJ>
M.5K6W)2JL-\]%ZH$I;67=/XI- W ^Z5"+-0WM$'[(?S5OP%02P,$%     @
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M!#3M]#]>#]%I"2J[ ]XI?!034Z$SPX7^MB^-M6CSQVP)(0]"?ZE<VZ7:95^
M:1 "Y<@$+ @2'U2>$,Z\\(%(HA$&\4"OI])"6"TN'[#'4+^.)5 90Z;X!$1J
MP1($95JYRHAU'I$J0R('%#'B6)F)VKXOW>NNE_"1(\>[#17ZLO'F9I2/*S=$
M&S<81$*> .;GEK:,Z[(;2"NY05'[:NCO[#,QA0C*'$,, 6Y19-+<Z&HV1W3_
MHQ%F9IT0AM*)$),.O[PR7J(R2R/);%M-FH=VC>KAWZPB3#RA08/%]GO!B_8
MP5*857)0YW1B)E-PGPE#VWYD, KM7"^$YT,WYXZ2TPB'H9--)550)E))@^)&
MP;_Z8JC<7!OB4@\RF+R$2!^ %J8K2]1,T[86_EU4_ZU0%5RLFHQ\1@4L4#&^
M]K%4+RQ[)2FTNK+PT;Y^@\!@T]HTQ#[[)A/)H^\9A(7!B[R,1KQ@@T$RVNKC
MHK^3[(WV[A0P-6[LL:L=_7XRW-JB?[W='7:C'7!ZP8;#9+>W3>+VDMYPFXU]
MA=TQ(6$O1J/N+B;./(\#CR](L):R/ S4R :TM@65'SQ-/;E&PFT:)\6UG=.-
MD8B\ISS?'9$^LUA4/KASR%3:@6(="!.86CRU4RDRY#7_*C)^G[P^<E5SU\XS
MN MVY1'A.U$,"B!B+N$ N8=\M^);A17YLJ8:*B;A3Q01.NC=37#M+=CS"JY%
MZ4)?\!%U&EQ5(--BXW-S9)Q-6*$S.5UZ?/&X"I5OA"PF%>HGD#W\H:K%T#"3
M$XQ2<"F27* %;:FNK=6I]''PGH1(?*LDP1 [,:II)G,/NS\022*(1VQ \%'<
M6HFG]"?>U;@?@X2O2;*'66BDFFJ'UXB\SA/2Y:ER@TI33JGN6YGRL$O'%^<W
MX^.;C5[?JVU^#EB*><K/& XDE8, +X%>A3H/NJ1]3@:L-Y.8:I2-?VDCD2H
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M#FB^\2@52:QI@4T*K+G-_<"\.O7YEH5%,ZUQ%,5Q,0N4A62 781CK,_T)T1
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M#(!I^_G9#1JUM)]\IZII5&4?%X*C\:<%>#]3JND'=,#F?P W_P%02P,$%
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M/KWM"NM03M1L4.K(X0:-2RW_P^Z/@_YH=V@A2HGB14VTJ1P>5 S_;=T#K9)
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M(J#L6AC&62'Y2A;2[9A4=%:;3)ABUQSA32VMA+L30H&(YBL45=PXF<J*$P0
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MQ5C@-HI[T-90,#EM;OV)^$E<:W?S=DG302-F:E8@/P2[[80>7^JMSH@8>ZT
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M*V6I\_EA3I\:U"Z ]C.E[&'B!.J/5^\W4$L#!!0    ( ,R#IE+C%=D,UP,
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M=X@=[VXCQ_*.&38=*[D%9:T)S7:<5.=-Y+BPA[(RBE8Y^9GI(YW[O<ADC;!
M!:N2*1P'AI#M>I#U*#<=2GP")8$'*4RI82YRS-_[!\1H3RO>T;J)SP+.&C6
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M[9FO7/\VTTR"N-*/:E]D=OA<,!KRM"E%1R:H7,,44,J:("5%(27CI'26"1U
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M]Y6E!?A.M^#M QV0?@7VXK]02P,$%     @ S(.F4F#@1 *"!@  >!$  !D
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M+/59/ZWI84/M#.C\H)0]+5R \:E<_P-02P,$%     @ S(.F4K\&X,PS!@
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M9405NQ/%[WRL9U>]M(?&;$*;0C^*Q:^L]2<R]G)1*/N-%NU<KX?R1FE1MLJ
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MX'1.>6':F#/H7,\4 +^ )<J2R9S3 M6T!I[U41PGV$O,#A+?\/7$/VVE),U
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M(SCV=Q1:\4%&>MCSPEU&.O%_S,B 0+T(S%Y:M_O.<?<*CI'P: %)N@*2/+N
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M9;.3UAEAPYF.X1W<<_UXM;&ER<EG.GH,**O8[<1V^R/?\1RIQ@\<10X.,OX
M[U[+?71RH96HMN[:MNR:ROB[K5UM7P9S?R'^*^Z?%=096T[U+W!#JMW.D#*F
M_%7M)T;6[GI<2T.7K1L6]+I!905H?R.E>9Y8@/:]-/L'4$L#!!0    ( ,R#
MIE+2DD(4:0,  %D(   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)U6
MVV[;.!#]E8%:% F@6#<[\;JV 3OI8@ML Z-.MP^+?:"EL46$(E62BM._WR&E
MJ$[K&$%?+%YFSIR9.20]W2M];TI$"X^5D&86E-;6DR@R>8D5,P-5HZ2=K=(5
MLS35N\C4&EGAG2H1I7%\&56,RV ^]6LK/9^JQ@HN<:7!-%7%]/<E"K6?!4GP
MM/"9[TKK%J+YM&8[7*/]4J\TS:(>I> 52L.5!(W;6;!()LN1L_<&_W#<FX,Q
MN$PV2MV[R<=B%L2.$ K,K4-@]'G :Q3" 1&-;QUFT(=TCH?C)_0_?>Z4RX89
MO%;B*R]L.0O& 12X98VPG]7^+^SR\01S)8S_A7UG&P>0-\:JJG,F!A67[9<]
M=G5XC4/:.:2>=QO(L[QAELVG6NU!.VM"<P.?JO<F<ERZIJRMIEU.?G9^2WW_
M*'-5(:Q0P[ID&N'LCFT$FO-I9"F$,XSR#F[9PJ4OP&7P24E;&O@@"RR>^T=$
MK>>7/O%;IB<!%[4>0)R&D,9I<@(OZ_/-/%[V MX'IB67.W.0[;^+C;&:Y/'?
M"?QACS_T^,,7\-=T:HI&(*@M7*NJ;BSSZJ/IDAF> Y,%W'#16"S@H/AG?RMC
MSG^P.E;ZDY'=Z9V8FN4X"^AX&M0/&/CV\C9"3=#&)WSA=-Q1*5HJ(>R1=G+/
MF)@Q ULEZ,0:..,2;*D:0^8F!'S,L;8':*Q2C;3F? )WI49\)@#XQ'1>0I:T
M_7,_,=PV%6IFE9[  ;VWD(27<4+?X3B\3%*X0:E(\*WA5W^ZL+A@#^2[\TPK
M*JNG8(!N&V.)'W46WKT9ITGZOLLQ2])P>)5!%H_";#QN2T_W !C,&\TM)^]Q
M.$Z&D,3A<)3\3J2NAI"E29B.KRCF*!QG?\#1XC^G]Q;B@4\Z'B27IQV>HGB7
MN'49P0G)CGK)CEXMV96R*"UGHE6AZ63L"K"V*K^'6^4E*QK77:\,_%GGOZGN
MDR2/J_N.@N]_[E?=I_"\<R3<EO56JXKZJ"%G(F]$R]O+_R75OU[;"XI\41S1
MF#MK.7F3;HB=^ [<F,;=LK_0(QW&\160;F-2Y;'^1@?7/1VEG7_4#,'3.6QO
M_GZU?S<7[7/QP[Q]="F''9<&!&[)-1Y<41=T^Y"U$ZMJ_WALE*6GR ]+>OM1
M.P/:WRHJ=S=Q ?I_$_/_ 5!+ P04    " #,@Z92&IWMNML"  !'"0  &0
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M!C 3D.(5871/L*<=Q>FK)'O<\8^?F>S=/B(FIX9@BD%!0KC /A FRQ(4X[3
M\ZCNP%0%97!,A/%?(@R/BS#I/)ST>KC<^96 PCLM:;1@="T?J#VC?-V3AK..
MY.Q59 B#_=44O*P0+=^A$M%Q)<*#^S/\#RTD.J:L9Q7>FDG?J0BC/5/T.H+L
M;\%P\,*"#/XIB']0VQ U<Q5<$U>-FC+7C7:OA'E3&_?+FR?&-549%YH4D*)I
M<#)&7M54[:9C9.4JY5H:K+NNF>-+!Y1=@/.IE&;7L03=VVGV!U!+ P04
M" #,@Z92&(>:=W0#  "7#0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6RUEUUOFS 4AO^*A7:Q2EO!=B!0)9':=!^5NJEJ]W$Q[<(!AZ !SFPG:?_]
M;$. $D"9HMPDV)SS^IP'<SB>[!C_(U:42O"<I;F86BLIUU>V+<(5S8BX9&N:
MJSM+QC,BU9#'MEAS2B+CE*4V<AS/SDB26[.)F7O@LPG;R#3)Z0,'8I-EA+_<
MT)3MIA:T]A./2;R2>L*>3=8DID]4?E\_<#6R*Y4HR6@N$I8#3I=3ZQI>S1'2
M#L;B1T)WHG$-="H+QO[HP5TTM1P=$4UI*+4$47];.J=IJI54'']+4:M:4SLV
MK_?J'TWR*ID%$73.TI]))%=3R[= 1)=DD\I'MOM,RX1<K1>R5)A?L"MM'0N$
M&R%95CJK"+(D+_[)<PFBX:!TNAU0Z8#:#J,>!UPZ8)-H$9E)ZY9(,IMPM@-<
M6RLU?6'8&&^539+KQ_@DN;J;*#\Y>Z1;FF^H .]!=;EX ;>)('',:4PDC<!<
M_<:,OX"WMU22)!47ROS[TRUX^^8"O %)#KZMV$:0/!(36ZJHM+8=EA'<%!&@
MG@@P^,)RN1+@0Q[1Z+6_K;*I4D+[E&[0H.#UFE\"![T#R$&P(Y[Y,>[8N#L#
MX>"*,#9ZN$>O@5+O6[;<@P:_[I4IN),T$[\'%AI5"XW,0J.>A;XQ25+U:A5/
ML>M!%/Z>\=?O]W:&Q@["*LMMDT^'&?("Z%9FK\)SJ_#<P? ^<28$6',6;4+9
M$^8K8:\2]LX+>%PM-#X1<.'O-LAA.$*.VP)\:(9<Y'I>-V"_"L\?#$]Q"-DF
MEP*H%Q&05%5HDH>#B(-*.C@O8NC4]<@Y$7(IT,3WWO>" +<H=]FYON?W8(:-
MD@D'0_RJOJ[_L8\AJH71F3'710GB4S'CPUV*Q@BB-N9#.QA@WW=Z,-?E# [7
ML_LD5.T"/0IQ782@>V;$=5F"WJF(O4/$8Q?Y;<(=9HX_#GH U^4,#M<SU?JD
M9,%X@4)0OE7$Q5&\ZYH$_3/SKFL4#$[E'1QN57<4M+]_768(NCUU ]6E#1U3
MVL)7U(^ C>K"A.!Y8:.Z5"%T(NQ2H-E&C+ #VYN[PPQC![>;#;O1XF:4QZ;S
M%\!\\(K6L)JM3A?7IJ=NS=^H4T=Q1JAEBB/+%\+C)!<@I4LEZ5R.U0;@Q2F@
M&$BV-HWT@DG5EIO+E3HY4:X-U/TE8W(_T M49['9/U!+ P04    " #,@Z92
M3ZZJ-D<$  !#%P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6S-6-^/
MXC80_E<LI$JM=-W$#LO^$""Q<-5M>ZNNENOUH>J#-YF M8F=VF8YI/[QM4.(
M89LXRXD'7B!Q\GV>\>>9B6>X%O)%+0$T^I9G7(UZ2ZV+VR!0\1)RJBY$ =P\
M287,J3:W<A&H0@)-2E">!20,!T%.&>^-A^78HQP/Q4IGC,.C1&J5YU1N[B 3
MZU$/]W8#3VRQU'8@& \+NH YZ#^*1VGN@IHE83EPQ01'$M)1;X)O9Q&Q@/*-
MKPS6:N\:65>>A7BQ-_?)J!=:BR"#6%L*:OY>80I99IF,'?]4I+UZ3@O<O]ZQ
M_U(Z;YQYI@JF(ON3)7HYZEWW4 (I767Z2:P_0>70I>6+1:;*7[2NW@U[*%XI
M+?(*;"S(&=_^TV_50NP!#$\S@%0 \A;0;P%$%2!Z"QBT /H5H%^NS-:5<AUF
M5-/Q4(HUDO9MPV8ORL4LT<9]QJWN<RW-4V9P>OP$K\!7H-#/J+Z<,447"PD+
MJB%!SQLT9PO.4A93KM&TM DD^G$&FK),_62@]>!4\!BXEK04]8FIEV&@C9EV
MLB"N3+K;FD1:3(K0@^!ZJ=!'GD#2@)_Y\9AX" *S/O4BD=TBW1$OXZ20%R@D
M'Q )"6XP:/H>>%3"PR9__/!?*3=PW#3[@3=1+7E4\O7;S$E3EC&CK4(B1=.O
M<_0):*:71CQ9B$JZ?W?;P3-AOYZP7TX8^??8!W3/F68T0Y.BR,QN*B=Z!,E$
M8G90OLJHS0'H8YJ:I("^2&JR2_G.7Y\-([K7D*N_/?9<UO9<>A? 3&DWJ?5>
M"VWLD=7.;]JK?BI\>1&&/S1MB0[<]?]Q![X,:E\&IQ!S$L=BQ;4RJL; 7NES
MYA/VJI[\ZBR$O:[MN3Z=L'XJ3%J$G77@<(>P-[4O-T<(.S')E2FQ,O[=@5P
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M$#E!*#"SCH'1;X^W*(0C(AD_6LZ@N](!C]<']@_>.WE9,X.W2GSE&UM,@TD
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M5"G=/!Y-8%7E!W:M+(V_7Q;TWJ)V"72^5<H> O<&="]X^@M02P,$%     @
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MZAWW,&*JZ*:*B9%IWL',I,%^*!_&V(&"L@=P?R&E64\L0=73CGX"4$L#!!0
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M.NC34[QWTETH6%NUH*U:8.V%7U5MOQ[HS^T":@'7[^\1-V'K)K1NHJ_<9&9
M_KOI*E]MJF]-F>ZT2<,!J!TF[F:W3!TP?QCX@Q;V(=*HC30Z&NG."=R/%<Y=
MQM8Y[, !%+H@$C'!5Y>:R!)AI4BWG-I?O!-G-!SXP9Z:0Y0?QW&WEKC5$G^9
M]=Z!C/JFR2,ZL8+M2DA=2P6ET(8S45:8OU&^0F/!<VCPYI(*K@2C.3;0N89?
M?>^;:X[NX?7H3$I\4+S('P[-A?J0E4-8&'B#P5[R)AVP^'HXZ'^$30]A0?_:
M#_=/C+O3!,T3]P/+%>4*,;($HG<U #NR?C;JB1:5[8L+H:'+VF$!+RV1!@#[
M2R'T^\2TVO;M3O\!4$L#!!0    ( ,R#IE(O6*+0$P8  .4@   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;,6:6X_:.!3'OXJ%^M!*98AON50,4LML
MNUUMI:K3Z3X',$/4)$X=PW3VTZ\3,ACBRX!@M"\S!,YQ_C['YV=SPOB!BY_U
MBC$)?A=Y65\/5E)6[T:C>KYB15I?\8J5ZI,E%T4JU:6X']658.FB=2KR$0J"
M<%2D63F8C-OWOHK)F*]EGI7LJP#UNBA2\?B!Y?SA>@ '3V]\R^Y7LGEC-!E7
MZ3V[9?*N^BK4U6@WRB(K6%EGO 2"+:\'[^&[*<6-0VOQ(V,/]=YKT$QEQOG/
MYN+SXGH0-(I8SN:R&2)5_S9LRO*\&4GI^-4-.MC=LW'<?_TT^L=V\FHRL[1F
M4Y[_DRWDZGH0#\""+=-U+K_QAS]9-R':C#?G>=W^!0^=;3  \W4M>=$Y*P5%
M5F[_I[^[0.PY0.)P0)T#.M8!=PYMY$9;9>VT;E*93L:"/P#16*O1FA=M;%IO
M-9NL;-)X*X7Z-%-^<C)-ZQ5(RP7X7&Y8+56"9 V&!U>S1W#+YFN1R4?P_;%B
MX/4-DVF6UV^4X=WM#7C]Z@UX!;(2?%_Q=:T&J\<CJ;0U=QC-.QT?MCJ00\?[
M2ER! +T%*$#0XC[UN_^5ELH=VMQ'*B*[L*!=6% ['G:,=\-F$M3;66>L!NE&
M33B=Y6RH*F=8ISE[Y[D+WMT%MW<AKDD77,CL7[8 4UY+6]"V_F'KWU3D9@(Q
MCBFAX]%F/SHV.Y(D,=K9'0@D.X'$*_"3X'4-[DH%B+S5^4F!P9K=[3AT3P!.
MHKY*TX@F&-HETIU$>IK$O]4ULVJDQNV'*($]C18CZ(ABN),8>B5^3#,!?J3Y
MFME4A<8-5>H00DE/F,V.TB1PQ"_:B8N\*[T!P%O08N"/7^MLHY:V*OJWX)NJ
M?Y'-9;,XGQC1?V_/P5,-\4Y)?&8UQ&8(:!C@O56^#97-#J,$87NHDIW Y$+5
MD!Q3#::1NQI@H'D>7*H>NI&>*0B;E:LBX-ZV \^HB<ZYEVD2A&%?G,T0QS%Q
M"=0; $1>@5->%$S,LS0'55HQX5G@4/,>XA?<5J#&-O1S^_E2@B:+PS *(B/[
M%F:'":&A([X:V_!$;CN+"9I(1K!/1XL1CER+0(,;^LE]2C&9?!X:P31M H=$
MC6\8G5-(D2W-*#;"9]JI-,<H=LC33(=^J$^YJ+A()0,S;AP,#\?4&(;)"U81
MTBA%?I0^7T7(9"-)*$F"7G@M=I1@BAS91QJCR(_1XZL(F:3$8=!?!Q8KB@AQ
MR-P[3?MA>D(==2,=;DK&WFFSBAPJ-9V1_SCN+Z7.^3#7<8Q(7YII1TD<49<\
M#77DA_K=U>T5^*Y"6*_%8WL>N^<;)LKF6]JPKGA9<Z%"JZZ8J$1FQ/?PMAK4
MB+YDM6G6(C]KCZ@VRQ&8Q"B(^QDP[9011HX]"VG6(C]K3Z@VDZ<Q[LLT;1!V
M;%E( Q?Y@7M*J9GGY+TBZD1:;%PXT !'_H/T,X5F'HR;-,=&H9EV*LV4.N1A
MS7WLY_Z7=9G-LTJ=_)[;L[ &-88OV5#0I,5^TA[14C#1B:(HZI^L;69Q&#MV
M++S7\O!#]O@:PB9(P_X:L-C$CF]Y6(,6G]CU<)<0-H_'PSZ.;#:.KWE84QG[
MC\_^$L*6(W,4X_[W9)M9'(4.!F&-<NQ'>=,<\*UF#5S\?S<GL 8K/K<]@4U6
M4K2_\7=1-\UB!"/'[H0U5?&EVA/8)&?_Q.HU.>PE:JZ2B[4FB'E@[BOTFAPJ
MU)0FYW0EB.UP;.;78N;)+]%H)WZT?^$E>P1%*GXR"99K_\Y$-)")OR?Q\C5&
M]MK-Y_8MB E3&-#(;#6;=B2(0@=WB>8NN53;@IAP-9:PS^10H&8ON5C+@OC:
M$9W"HSL61$.=G-.Q(.:IV)Y@T\Z78(UY\DS#@JD5N,SFJ52G-+X$"U;Q.I.^
MY:T)3?R-BY<O-:IA3,]M;E 3L"'&03\1-K,@"!RG<*I93"_5VJ F</OKV&MR
M*%#SF%ZLJ4'-P[2AT&=RJ%"CG9[3T*#F0T-K?BUFEOR.]IY!-S\ ^)**>Y4O
MD+.E\@NN(C4SL7VFOKV0O&H?2\^XE+QH7ZY8NF"B,5"?+SF73Q?-D^[=+QLF
M_P%02P,$%     @ S(.F4C ZF<BJ @  "0<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&ULC551;YLP$/XK%MI#*W6% &%5E2"ER:9UTJJJ4;>':0\&
M+L&JL:EMDG;:C]_94)8V"6H>@@WW?=_==]9YLI7J09< ACQ57.BI5QI37_J^
MSDNHJ#Z7-0C\LI*JH@:W:NWK6@$M'*CB?A@$B5]1)KQTXM[=JG0B&\.9@%M%
M=%-55#U? 9?;J3?R7E[<L75I[ L_G=1T#4LP]_6MPIW?LQ2L J&9%$3!:NK-
M1I>+Q,:[@!\,MGIG36PEF90/=G-=3+W )@0<<F,9*#XV, ?.+1&F\=AQ>KVD
M!>ZN7]B_N-JQEHQJF$O^DQ6FG'H7'BE@11MN[N3V*W3UC"U?+KEV_V3;QB:)
M1_)&&UEU8,R@8J)]TJ?.AQU -#H""#M ^%Y U &B-X#P&"#N +%SIBW%^;"@
MAJ83);=$V6ADLPMGID-C^4S8MB^-PJ\,<2:=4UT2*@IR+3:@#3;4:/*1W%"E
MJ.T(.5F H8SKTXEO4,^B_+SCOFJYPR/<LUJ=DR \(V$0CNZ7"W+RX93U,@?X
MYL-\WZA OM'[^1;OR2]R?$'']YK%1S=[2\/>TM#11D=H=YP\(PO(C//W\V/#
MS#-90MXH9AAH\FN6::/PX/\>$(UZT<B)QD=$[U!2L=Q 07+;4EU*93X:4!7Y
M;Y$^U,.6-W&\=DALTO@"AP;^)O[F0$9QGU$\F-&U0'44QN&0 ]O0C,,A^7A/
M/DI>J[='8S\N'@]D.>ZS' ]F>=-4&2@B5[LVX1I[1AJ!@Y2S/^@IEUJ36FKF
MAM5?,GCLKEK)\4ZNX^A-.?LAH_AP)4E?23)8R8SC"*<B!X*7 <D5%,RXO.%@
MVY,]/]\XOAB*:#/T=^:.O22^4[5F0A,.*\0$YY^P/M4.WG9C9.U&428-#C:W
M+/&N F4#\/M*2O.RL=.MO_W2?U!+ P04    " #,@Z92)'W/THP#  !'#@
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M,:KCK>4X,3(K/OQ7TL UHACNX*;'E#6 ]8V4YGYB[Q+5W7'^%U!+ P04
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MR.CTC(ATW;;JB54K?_-GRE(?\<.".CUJ%T#[N5+V?>*:2?OO&/T%4$L#!!0
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M"S>EX74<#Y)DZ+]N)L-A%,=A:[2EK-<JZW4J>])5P%RJ4O 9D4YM-4%OPVV
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MI1,KLE!"-KC,U"/??R>UH%#SQ3R3YHOVM:UCH;B4BN<U&#S(*:O^^+4.1 L
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MP0CR0E2W>]51O# 7Y)HKN&Y-,X47$1': .8WG*M#1R_0O+&F?P%02P,$%
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M2,,D+ L:]V"] YUO#+WU9N,#M'\@TS=02P,$%     @ S(.F4LZ='0TX P
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M2A(_ IA?011A"#R-.((I  T8$D75/KBS'X7K?2IL_UT;_0)02P,$%     @
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M"](M!'8+XBT$>BOJK01Z*^JM!'KKZ&&;0&]%O95 ;T6]E4!O1;V50&]%O95
M;T6]E4!O1;V50&]%O95 ;T.]C4!O0[V-0&]#O8U ;QN]+"'0VU!O(]#;4&\C
MT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#;46\GT-M1;R?0VU%O)]#;1R^[
M"?1VU-L)]';4VPGT=M3;"?1VU-L)]';4VPGTCJAW)- [HMZ10.^(>D<"O2/J
M'0GTCJAW)- [CCY6_J?>N9QV*5][OM=X_?^DNIS/3=?+7Y;?.T<WU 7G #\W
M/'X!4$L#!!0    ( ,R#IE(4U''DT $  *T@   3    6T-O;G1E;G1?5'EP
M97-=+GAM;,W:R6[",!0%T%]!V5;$> @=!&S:;EL6_0$W>4!$$ENVH?#W=<(@
MM:*HB$J]&R)B^]T76SJ;9/2VM>1[F[IJ_#A9A& ?&//Y@FKM4V.IB2,SXVH=
MXE\W9U;G2STG)@:#(<M-$Z@)_=#62":C)YKI515ZSYMXVY>F&2>.*I_T'G<3
MVZQQHJVMRER'.,[63?$MI;]/2./*;HY?E-;?Q D).YG0COP<L%_WNB;GRH)Z
M4^W"BZ[C++:IF _;BGQZOL2)'LUL5N94F'Q5QR6IMXYTX1=$H:[27=&;\\DA
M[C#M?OG5^5V9<X%QYM09Z^.).;H\[G D[>J^C87(A?+\(QX38^FKGX_:TRZH
M^&5VW-X/XY;=>7C67:[?XZ]G?*Q_81\"I \)TH<"Z2,#Z6,(TL<M2!]W('W<
M@_3!!RB-H(C*44CE**9R%%0YBJH<A56.XBI'@96CR"I09!4HL@H4606*K )%
M5H$BJT"15:#(*E!D%2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP*
M15:%(JM"D56AR*I09%4HLBH4616*K I%5H4B:X8B:X8B:X8B:X8B:X8B:_:?
MLKX;L_SK%^CM-:UUV1SR6?>5PN034$L! A0#%     @ S(.F4@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #,@Z9271E)/^X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #,@Z92F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,R#
MIE)UK#[N.P4  &P5   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #,@Z92E;"#A*<&  !\&@  &
M        @(%^#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ S(.F4FW'W9FH @  W@@  !@              ("!6Q0  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,R#IE+Q$%G8!@4  &<3   8
M              " @3D7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " #,@Z92]:^=E=X"   [!P  &               @(%U'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ S(.F4ADE,[-Z @
M>P4  !@              ("!B1\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( ,R#IE+W"$OX,@4   @6   8              " @3DB
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #,@Z92*; L
MQ1\&   X%P  &               @(&A)P  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ S(.F4HQ<>O<2#P  -R<  !@
M ("!]BT  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,R#
MIE)NT LZ= L  !0?   9              " @3X]  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ S(.F4M[B%)<)"@   QL  !D
M         ("!Z4@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " #,@Z92S R[F+4(   /&   &0              @($I4P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,R#IE(_/$=FPP,  % (
M   9              " @15<  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ S(.F4B)6)Z;)!0  " X  !D              ("!#V
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #,@Z926E'4
MQ0(#  !+!@  &0              @($/9@  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( ,R#IE)Z>+_J10@  'T5   9
M  " @4AI  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MS(.F4OR*TZ35 @  R 8  !D              ("!Q'$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " #,@Z92XQ79#-<#   *"0  &0
M            @('0=   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( ,R#IE+&>E .Y@<  '85   9              " @=YX  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ S(.F4OC$&LYN#0
M$28  !D              ("!^X   'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " #,@Z928.!$ H(&  !X$0  &0              @(&@
MC@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,R#IE*=
MF7*&&P,  #8'   9              " @5F5  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ S(.F4K\&X,PS!@  ?14  !D
M     ("!JY@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,R#IE(:G>VZVP(  $<)   9              "
M@>FM  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ S(.F
M4AB'FG=T P  EPT  !D              ("!^[   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " #,@Z923ZZJ-D<$  !#%P  &0
M        @(&FM   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( ,R#IE*BE+^5U@(  "D)   9              " @22Y  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ S(.F4ER8 ;S; @  6PD
M !D              ("!,;P  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " #,@Z92N7AX0(L$  !1$P  &0              @(%#OP
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,R#IE(F^S&G
M4P,  ,,)   9              " @07$  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ S(.F4BAWJ*%; P  R T  !D
M ("!C\<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #,
M@Z92.)X2'T@"  #-!0  &0              @($ARP  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,R#IE)(\2H'50,  ,,-   9
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M970T,2YX;6Q02P$"% ,4    " #,@Z92X/.<L=@"  #'!P  &0
M    @('OW   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M ,R#IE(O6*+0$P8  .4@   9              " @?[?  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ S(.F4C ZF<BJ @  "0<  !D
M             ("!2.8  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " #,@Z92)'W/THP#  !'#@  &0              @($IZ0  >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,R#IE)#8SJ=FP(
M $<&   9              " @>SL  !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ S(.F4M_Z/W6? @  =@8  !D              ("!
MON\  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #,@Z92
M4E7:^*L&  "Q,@  &0              @(&4\@  >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,R#IE)[:HBI.0,  )4*   9
M      " @7;Y  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ S(.F4M Q.P[T @  !0D  !D              ("!YOP  'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #,@Z92PW41 AT#  #="P
M&0              @($1  $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( ,R#IE*]#YIQ' 4  /D6   9              " @64# 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ S(.F4BE,5SGF
M @  30<  !D              ("!N @! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " #,@Z92)J(T%"@#  !O"0  &0
M@('5"P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,R#
MIE)UKX15MP(  $P&   9              " @30/ 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ S(.F4LZ='0TX P  :A,   T
M         ( !(A(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #,@Z92EXJ[
M',     3 @  "P              @ &%%0$ 7W)E;',O+G)E;'-02P$"% ,4
M    " #,@Z92MC(ZOVX$  #-)   #P              @ %N%@$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ S(.F4KP!UL'@ 0  ["   !H
M     ( !"1L! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ S(.F4A34<>30 0  K2   !,              ( !(1T! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #\ /P P$0  (A\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>190</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements And In-Licensing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128105 - Disclosure - Forward Currency Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ForwardCurrencyContracts</Role>
      <ShortName>Forward Currency Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133107 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Provision For (Benefit From) Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes</Role>
      <ShortName>Provision For (Benefit From) Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2143110 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements And In-Licensing Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2334305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - In-Licensing Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements And In-Licensing Arrangements - In-Licensing Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2429420 - Disclosure - Forward Currency Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ForwardCurrencyContractsDetails</Role>
      <ShortName>Forward Currency Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ForwardCurrencyContracts</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2432421 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20210402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20210402.htm">exel-20210402.htm</File>
    <File>exel-20210402.xsd</File>
    <File>exel-20210402_cal.xml</File>
    <File>exel-20210402_def.xml</File>
    <File>exel-20210402_lab.xml</File>
    <File>exel-20210402_pre.xml</File>
    <File>exel20210331exhibit311.htm</File>
    <File>exel20210331exhibit312.htm</File>
    <File>exel20210331exhibit321.htm</File>
    <File>exhibit101ipsencollaborati.htm</File>
    <File>exhibit102firstamendmentto.htm</File>
    <File>exhibit103secondamendmentt.htm</File>
    <File>exhibit104thirdamendmentto.htm</File>
    <File>exhibit105ipsensupplyagree.htm</File>
    <File>exhibit106firstamendmentto.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20210402_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20210402.htm": {
   "axisCustom": 1,
   "axisStandard": 17,
   "contextCount": 190,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20210402_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20210402_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20210402.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20210402_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20210402_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20210402.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 384,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 27,
   "keyStandard": 261,
   "memberCustom": 26,
   "memberStandard": 34,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20210402",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements And In-Licensing Arrangements",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128105 - Disclosure - Forward Currency Contracts",
     "role": "http://www.exelixis.com/role/ForwardCurrencyContracts",
     "shortName": "Forward Currency Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130106 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133107 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Provision For (Benefit From) Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes",
     "shortName": "Provision For (Benefit From) Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143110 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements And In-Licensing Arrangements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i91deeede7b214054b29b855842eef51d_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "id6dc7e8bd8ec407b89698d13a23ff3a6_D20210102-20210402",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "id6dc7e8bd8ec407b89698d13a23ff3a6_D20210102-20210402",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "ide2d347c3248461bbac83c443362c76d_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i2cacac77f313426ca97a1e07efbf2a65_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "ib3152fd72d2e45c78ae6f5d34c980d50_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "ib3152fd72d2e45c78ae6f5d34c980d50_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i36eac876d5c64caa8af0b1d90f8647d5_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i2257faa0011b4db494f9ed2b1349487b_I20210402",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i1a72e61479e84a879347cd4381d1ede0_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i64b66b3d22614d23aa88f2b13229ca74_I20210402",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i3ea0b7048aa4459185b0dda8013edb1c_D20210102-20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i3ea0b7048aa4459185b0dda8013edb1c_D20210102-20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i4bcf7689215a48c0a219dff8c9bb6d92_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i1c01c5a5d8f54262b32390c82a09e601_D20210102-20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements And In-Licensing Arrangements - In-Licensing Collaborations (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails",
     "shortName": "Collaboration Agreements And In-Licensing Arrangements - In-Licensing Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i1c01c5a5d8f54262b32390c82a09e601_D20210102-20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "iaf9c81849c224cf1a0586e1bcd1d2538_I20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forwardcontract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429420 - Disclosure - Forward Currency Contracts (Details)",
     "role": "http://www.exelixis.com/role/ForwardCurrencyContractsDetails",
     "shortName": "Forward Currency Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "iaf9c81849c224cf1a0586e1bcd1d2538_I20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forwardcontract",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432421 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i02f8f448a7e44f71893357d3ac2b9a60_I20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "ib3ddda20eb4846618e6298bc462af14b_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i3929c6d9a6184d01ad46b0fe7cc0e21b_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i87fc02e15b3d473c95d1a9bd7c4c5c3b_I20210402",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i792d4649242c47c88975f6fd3dca0e7b_D20210102-20210402",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i9911c9d99e354292b6c84ef2ea046b40_I20210402",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "ibc070254d7a9427b9acaf2c3ca6a6317_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "ibc070254d7a9427b9acaf2c3ca6a6317_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i89a6170ae38049f98a1b0f885593db8a_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i89a6170ae38049f98a1b0f885593db8a_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210402.htm",
      "contextRef": "i08c0c72d46f74e849870a739472ff9fd_D20210102-20210402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementWithAdageneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement With Adagene",
        "label": "Collaborative Agreement With Adagene [Member]",
        "terseLabel": "Collaborative Agreement With Adagene"
       }
      }
     },
     "localname": "CollaborativeAgreementWithAdageneMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementWithWuXiBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement With WuXi Bio",
        "label": "Collaborative Agreement With WuXi Bio [Member]",
        "terseLabel": "Collaborative Agreement With WuXi Bio"
       }
      }
     },
     "localname": "CollaborativeAgreementWithWuXiBioMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payments",
        "label": "Collaborative Agreements, Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Maximum Amount Eligible For Development Milestones",
        "label": "Collaborative Arrangement Maximum Amount Eligible For Development Milestones",
        "terseLabel": "Collaborative arrangement maximum amount eligible for development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentMilestones",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Maximum Amount Eligible For Regulatory Milestones",
        "label": "Collaborative Arrangement Maximum Amount Eligible For Regulatory Milestones",
        "terseLabel": "Collaborative arrangement maximum amount eligible for regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products derived from cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20210402",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r161",
      "r232",
      "r237",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r161",
      "r232",
      "r237",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r157",
      "r232",
      "r235",
      "r378",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r157",
      "r232",
      "r235",
      "r378",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r232",
      "r236",
      "r409",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r232",
      "r236",
      "r409",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r51",
      "r53",
      "r54",
      "r397",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r307",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r252",
      "r254",
      "r277",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254",
      "r268",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r84",
      "r140",
      "r149",
      "r155",
      "r179",
      "r303",
      "r308",
      "r339",
      "r381",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r47",
      "r84",
      "r179",
      "r303",
      "r308",
      "r339"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r164",
      "r186"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r169",
      "r171",
      "r392"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r169",
      "r170",
      "r391"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r163",
      "r165",
      "r186",
      "r385"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r256",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r80",
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r340"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r296",
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS AND IN-LICENSING ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r205",
      "r386",
      "r402"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 313,262 and 311,627 at March\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r63",
      "r388",
      "r404"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r161",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r161",
      "r336",
      "r337",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r161",
      "r336",
      "r337",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r128",
      "r129",
      "r161",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r161",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r210",
      "r212",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r210",
      "r211",
      "r233"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r210",
      "r211",
      "r233"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r210",
      "r211",
      "r233"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r66",
      "r378"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r127",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r166",
      "r186",
      "r192",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r175",
      "r187",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r176",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r174",
      "r190",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r177",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r138"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r318",
      "r319",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "FORWARD CURRENCY CONTRACTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r315",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r87",
      "r311",
      "r313",
      "r315",
      "r316",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Forward Contracts for Non-Designated Hedges"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r110",
      "r112",
      "r113",
      "r114",
      "r118",
      "r119",
      "r389",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r110",
      "r112",
      "r113",
      "r114",
      "r118",
      "r119",
      "r389",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r121",
      "r180",
      "r208",
      "r209",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r329",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r328",
      "r329",
      "r331",
      "r332",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r244",
      "r245",
      "r250",
      "r251",
      "r329",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r244",
      "r245",
      "r250",
      "r251",
      "r329",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r190",
      "r191",
      "r194",
      "r195",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gain on derivative instruments, pretax"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ForwardCurrencyContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r198",
      "r199",
      "r380"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r86",
      "r140",
      "r148",
      "r151",
      "r154",
      "r156"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r289",
      "r291",
      "r293",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR (BENEFIT FROM) INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r106",
      "r107",
      "r139",
      "r283",
      "r290",
      "r292",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r84",
      "r150",
      "r179",
      "r304",
      "r308",
      "r309",
      "r339"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r84",
      "r179",
      "r339",
      "r382",
      "r399"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r84",
      "r179",
      "r304",
      "r308",
      "r309",
      "r339"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r59",
      "r62",
      "r79",
      "r84",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r111",
      "r140",
      "r148",
      "r151",
      "r154",
      "r156",
      "r179",
      "r339",
      "r387",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r140",
      "r148",
      "r151",
      "r154",
      "r156"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r94",
      "r134",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r57",
      "r60",
      "r301",
      "r302",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r51"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized losses on available-for-sale debt securities, net of tax impact of $499 and $941, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized losses on available-for-sale debt securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r73",
      "r271"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r200",
      "r401"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r19",
      "r26",
      "r400",
      "r419"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r280",
      "r431"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r3",
      "r12",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash short-term investments"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r81",
      "r421"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r209",
      "r275",
      "r398",
      "r414",
      "r416"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r180",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r147",
      "r152",
      "r153",
      "r157",
      "r158",
      "r161",
      "r231",
      "r232",
      "r378"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r128",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r222",
      "r234",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r254",
      "r267",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r254",
      "r267",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r12",
      "r81",
      "r379",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r256",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r126",
      "r128",
      "r129",
      "r130",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r259",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r253",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r16",
      "r383",
      "r384",
      "r394"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r121",
      "r180",
      "r208",
      "r209",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r121",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r209",
      "r255",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r84",
      "r162",
      "r179",
      "r339"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndInLicensingArrangementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r244",
      "r390",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r88",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at March\u00a031, 2021",
        "periodStartLabel": "Balance at December\u00a031, 2020"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r114"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r114"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r432": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r434": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r435": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r436": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r437": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0000939767-21-000045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-21-000045-xbrl.zip
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M#JYAFOVS3P>FVS+N[+4I^U3 FT@>K<>2,^Y95%8AR9&TGO. 4;1%F"TLE;V
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M-S($:Q^C<MI:X761EN0^=0#]$-KP*;B#>31CD!=X,1B(+V,L8FRH#)&#ARR
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M2BL1$)>$4Z4=B6$.I%'MM,-9U72/0O_]H#AV@J2.(G >I$ L,*P5MI9SCX@
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M*C'%,*7&2\H<#^!> &N59@ZD,6G';UP,(% ;G40: S7CWBG#@B<$$Q6HPJ$
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M.#<*/"LZDVIX6N0-@3^,1F6]C!$9%,%7T9SQ NA,H4;M5[\2>5QL4RDF(_'
M.#V3&!QKZPVSF'C%D+E,%C_+>COOJE*.T7=YUCQB18B17% 8HK5B440>F*8<
M,ZWF(:-BT?5V5E0E<"F<I"CMFV4!$\,E\Q%'JQ7@7BP"G9NIH?G5*9 P"J$
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MK,(];;?Q?Q9[IMW+>J#MHQ-ZC?.PI* U^;>3D2HB]$>N'B/53/HX;*X/+B6
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M[2U'<6%Y=65J,OK4 5>JN=<X+JQ?]"P)T6\\>&HLE9FUP6=,>Y0II&@&/]J
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MP[%I^$HX/4X%=(;)LSKYGG-W8X53&0"9 L$926=]*)R5ML^S :SD BE]JZ>
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MDB3*U63/P:+/UTD']80S&#/2KA=P@:QWF95!9,8J9EGPFG.7BH"I1270#/E
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MCVUBHU2?&58?BQ&,#H$">'&4,:-URISM,V0#$MHS8@5^0DSZCQF,25_3PS*
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M/?VMC_1CKD(>=!166P[2:H!%Y '(1<XB\;FI>>/RP')K<X8W"IEX/R9(YMH
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MO[+> "M^9;T!5OS*>@.L^)7U!ECQ*^L-L.)7UAM@Q:^L-\"*7UEO@!6_LMX
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M%ZK2DUJF=#[&GGPV4[9Q A;W;<1XCEEYQ$M_0VTG]G.WUPV_OGM]Y7)>66^
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M_EZV^R;;W-C[=_;F[]U/>UEE'^1ENPMXW!O!/?S@576'.>J:D6^#@KAYC+?
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MFB,SR&R >0J)8K7'OQ2)":"18="F[\L/]\-:]E<XZY5@D^+1DQ&",@?$*UC
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M^:/C7G_Z)XPIPCRZ<-.Q/>D &<%6M0O"'=-XOAZFW1VDV,\WM$ :M-O1#T?
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M79BKORY9B#%=!]2J!ONL/3COM "<WFJHRPLHOF\QX@5L>+3TWAOC3L>'LP>
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M;?SO_]&4T-\?N^U!F9(1*E![Q:"VG&XN%:@]&:B=SD%MEWU3/";%,$=64('
M'HO(,J80UCZG5BFP#-EJ@=I$M3SGS)DX%\K=O>/IG_'R]? %E^']&MO</1/O
MZ9_QU'E#TP<OGJ8]YBGA%7L\;<'2ZV<TFN[N4H8@U\4MQG")>SBC&F+%W>=A
MR@[BV+OX"_GU?ME.+U%?NFQJ*Z\5/4%4T66JT>S JM*-[JX;+=26S08?_\:M
M4L8EAVA4N;$[8<@YK)'T7ALKN,6B:.Q.<9EJ4CU1S'L%12L"14_0;K."HN5#
MT8*9=G3Z+6("J(,9"I9)Q(/TN=0U(!-6S&@JJ?(XE\=39EGICR4JC[=B:NE?
MO>X^&L9^9P454WJ%8OI":X.LD$;7['5]A:1W1](S7OPC\4U*K+!/@*38A)Q)
MSI$.7J+H*7P255*29J5./3R1O,1E@UXM&S^W-E2Q\7W9^*Q"))023 ,' _Q2
MQ&.,2.>.Y ;+8!C5.:9H;8/5E;A8^&OEVQ!=4(@6%1ZJ+DKXI_>_[O2&MCV/
MO5[PPBXUU^:5G2TN<TE6'LJ?6R.K /PN -XZIX<%3@"U<\]):33B-FEDHK>(
MV*"))IRSI,"BU4^53%V24(O'K$11@>7K!<OGUGLKL+P;6)[5=C7HH,$%C(+P
M G%!)("E"$CY$"ALAR6N*%@M^(.UW1)@Y26YS0O.O<D;4$:D(H7SC/:+B%Z>
MP^]\I//E:3/?+OF_*]-J2S?Z7\BOM5KM[YR=W!V.TT$?)='X+CF[I5NDR_-?
M;LYG^85>6-R\?NWS'N*<NG,^J_,AJWU9&N7M$KV?.T%Z:]3/T\SS'A[T8ZQU
MX):#02UV<_+K)65CB[S G%]0S]FV\\3>VO]ZPKK/XK;-I:Z5D1^ZOCW*A-^,
M/Z87?AH3PZ?9O&:"5*ZF(+UW&FKC=!\W?WQ+42E,A$7&AX@XTQXYI1/"/G!F
ME+' D&L;=/VB(,QIVNU,")EB[D(="FP12JE.3D@>E#/!>T*=3A*KF((LJ ,#
M=7!4_,(QJZCCJ:EC9U-L[WSYV=C9/87K*%"*DXK2:#ERUDC$C1/(X&20DMG5
M[V'KLM)$UB\6A9E22CT7[3B./I^?M4_J&9!GX%QDT1<YR*UB8^;H[B+@:5'R
MXR*DNPE.IUE>_J17]_I+Q>?ZR@#T=7;,W_,""=NS^@B?X><@M6+(/0#C]U9O
M-#C7!O!U<V&#-GY\ S(BN7L2PH( 7NO$D/91H92H5$%B3PN\5NMZM0"[HI8E
M4\M'T=S\QH22+("A2W3BB).<CN D1P%'0AD@=M(YSD5?0RW7@791Z.GR6B>U
MP71_\AW'DQV:P7/M<Z[(,GM0 ?S'?2"(/F!KK0BR&!>.Z?=.;'MX,J\$DRM0
M^>FWA?;?\EF#OW(@>9 7ROK *X' :A^.P9*H_7U@X;[:Y\W/M5^*3WZMUW;L
M40QV\I6/H\*\!B.AL!QJ?[4ZK3R$7\:7P?5;MM7R!ZW:9]L].NE-+ZS/KSQ[
MP:\%$[Z/W6S(P$J -K)>^\76.N,DWTFMGD\]#S_?]WNCXU]KO\RN_G55I-OF
M(,_DFN84BX.YTG?RV*.LWPD,[WE,<A<,G*FADUIGE^+?JX4Y$(2DL?\M!<6T
M% IIG@T7E1534%X0M=JJ)"3!SJYM:+5^L1?-3!!F-EMJ--DM*:XHP]5Q\'G(
M!>^Z@PG9 0+Z.$>L,3IEH)B@T7D(*TKV+.+A51@XJ5$5:MW>L'82AZ!4PY-G
M$ UP#*IGSDJC^/=F;QAK;!T@;+$,VN8^:*=C!$:U-_#YJ<WND)8[>UW^=H%<
M:]L+@R@FLC#;OV^8[=D'%Z,CO^=9YJO/N&O>M;KPMA8 ].<A?# >YJ(=D>_8
M['9SS;-/166M7%?K7:XC1C#ZS\1\B+ RMC]1O:?U%L[@%BZN;'7'G%RH4JXW
M*FIPU>+/+"3S-@#B9Y6^-UG?DTE5LBOV9OTVCKQQ79F;*M=PO%:VRH/-[9VW
MF9@>O>K8C%2^Q\UY^;>MUL"W>X-1ORS5QG#CS10MOS! -0*(AW>_?J&[IQ_Y
M+OT"2 ?7'[X]W3T\@N\W ?$:Y#Q:-G?\C\;I/YW=TT\'>SN MEL'AWL[1S]@
M;+2QTVQMY^^W=@%)_P&E\.T)C.4;%Z##)V$0F DJ%]O&2#-MD./$,.>588R=
M+S#$1,+"T.@$!MK#P>'(A28F4064E\B%$F/;?_VU^<?VI\V=#]O-VN;[3V_?
M-MXV=S[7-IM;M0]-]->'-V^;GS\TW]<V/WW:;+X??WM]9;%+/<4W#^Q<I21-
M'74AYJ,ZKK36CF("? TVC#3*JS)77?T:Q\4%%VM,S@H-7J;3MJ/-;JW:\5G5
M=>ST;DT =UP)L@,KGF&S=3I!LUPR==0OSBM"+B#8.RZJMX*<+#3H1=A/P&2@
MSP[B>FTS3,M19@/AQW3 N71. ;\9"N%I?1A%=MT7I7S.C3R_&=9\K,OGT2_6
M<,Q8.AU6[!Z,$13& T]JGR!8EWU U]9Q$71=/ FPN"@X"]=,O'U%#<I<H!:&
M49_.;=Q^?6$5(LA'^":O3M\>%U7Q\HKFQ=KOP>AA'8[[O>^M8GV[\0<([VB'
MXR4ZGEL;/H\0+".8VZS+.SRC!1\=G Q:\"Z _5PHLRC:>6:=)F=%]]W6Z>V=
MXZQ'C]\,(][OV\Y@*@>S^$L@.GNWKE;[W"QP!^6D%%I"?5)A>,Y* ]]O.;C>
M =G]J!=/LC.F.:-0]";E8Z<L=V:>=JZ$7<LPM[4/G[H,\=5J8WDHL7C2;ZTA
M7.YO,:>QUGJ6',LSF6O9JO8!J#NZ_LCV3X!NB2RP^PP<V:L(<-%]<B]YLBA+
MUFM?IM5[:_D8=S"O57SIR^M%)>).P8+UR2 FY9PS]@-##W)EYXOC*8(E)A@]
M.8XO$+*7BSQF8$BC(>B*9P4=;! @[1B)0=G/Q9BGX_NR_GF]>,*?%O:M@/1"
M]!6X7@PWC$LX3Z<1%]>M-S[?N&9A;A[IPN#6:[E >RY7#=*@J#"B?J_%!(^8
MU#S>S\*O,#D/^KW1_@'L[F$/MAGH+<;B&"*O6&L(?Q4OL\<@.L DS<,>C-SL
MR[/UKF%^^Z.\)H7$A3<,8KRX>9/QP H>3TM9%W69AWE1]L$B"*U^+,S"WR<B
M-F_M0>]'+ 3VY'0(=GEH :A3*\-F]IX,X [4L4<% HZ&![U^%O;%(D_<EL4&
M+*SI?"3=_=[X5&FV_K>RQ5Y[5=OSG66KJK:OHJKMC3;4.9O+&4:-]-2Q:+BD
MRMKDDP;C3'BM#=&S<,O'\@E\GA2UWTY7>0=RVYB<0'3%UPN^JD&9*I8_DP]A
M\YL5*<#:.R1-3(A;R9".\*<3CEE!B3?I0I%BPYE3*< &><V=218;9I*PV!.@
M3Q[/^Q#*JRY]FAY6S5H-W$8YNK&L^AU4Q7.H7[X"SH+>NM+R)='[#VY@]AA7
M/G^A:<'YXQ2:EL^V5\LK7KT\2C K4P]ZTHPI1PLUQM%";^?10KD^]%U*0S_+
M6C_NE7=I%E;.S;UEC?-;3?0VQ?%>PH+A6RS8HZ+6LLJO/$OJTU^3()II1,ZC
M+^93]S"]J5;J2\W:N_.\5SXU+T03M$R!.6$X-THG;K7@\%/99 F[*;;U+CEZ
M$YO@7;_7N2QP\>W/28QYKK$,_Q]V[,^R9.[=UXH<9^YU\OL^G#0['W\V#K_\
MV-WY> +_B<;[3^V]SA>^U_FST^R\.VCL[)^>S]S;I?_DYJ,PGK<GS9T_#II;
M?\)_1S_VWO_3V=LYZ.QV=NGNU[<_M[>:J;'8+YIXKB--%.'$%,K9"<@(FY
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MB#L=.0N4H6#S 7>T#&G#' J>!Z$\EY[K#'<</[@_VPN($7^1%3.FL36S@Q?
M@/AS'"54A+>\./W\MOGTI=FBV\NDRZ:V^F+GX5IVE8;TI")FL;Z'=2R'RTAD
M3:"(PU8BJY-&,E$:D@TJ&+ZV8<2#2]"5K[I'A4 O!8&>0/&MP.G)P&FN_VK"
MA! 1 QIA@7B('&DL-;)!)L>4=M*1<87,5U&D9):B=C%4IE2AAY^F"45G(@_'
MX?P?NF@<2Y2#+Q=LQT'M#O$^Y8I5O#P^XN:8BP_CV+74Z@^&M?^.;#^'YO?2
M)!/A0CNA>1A<>[: XZ#'2^.OBAXO@]'Q<:]?Q*'E$/CC?IPU;SEN'<<\EW&<
MUF:P^[$;Z[ _?KWVR^3/7XL7?!W]OU;MCQ:LXG[+#VH?<F 5?/P74.\OT^]^
M+9(Q<E#])$-AL<5-T<NG8T/^"#[;S[U81L>I#VN6\X3&E\!M=XG#)AX3+ZP(
M&I">2NH8909[32TV46*RC*C[2YP=LRE]&8__[\GP7VUP=O-P$S=/&S\;IT>B
M<>I%<Q-0.U%BL4;*Y'H>RDNDHPT(/E<Q.N(P5W<K+LBEY"'7H<.&$Z:,!1:R
M-$CB%+>$57O];'N=//=2PPX;[ACB(EJD#<;()Z>#CXH:+D!"\W5\04!?(;&G
M\?FM[.?P!UD^%(&UD\#O(KEP$O=](>8[3G.M!NNUK_-.4$6F:\<>Q3G:P <3
MC"L>?J%QUF)D^4)/LCN"E,1>4*^M WV%.T!_)7G2S%+EG2?</B"G^EI';,/^
M;'5&G<VBK=K;20.U=[W^UGQ6C=FD*G+.Y'SXEC?VOR6'=<""(0 <C+A,$CDF
M*7*8<<9S(2(-T"7$)>1\AGISBLC^J&V'O?[)"Z*?3[-)5>1SGGQ$\\<W+@R%
M+8HH9J.%1Q60E5CE+"6N?5(DZ9!C5O#-]',6VDI,0U?1RIO9X.>T\B4'2Y\U
M"BZ>$KUN.OKPL_'CFU/4,Q]!G=$I(9Y,0 ZH V%!K1.$T(#!,A3T%C@4+=AA
MDRR9F?9=])S\$=OM_.^9?.6)^+N0MES(TR)]YGJA.K4''E.J9NN?<&R\,8%[
M)XW!*MF05 J<$(TKJ5HB<C[9_OA-ZT 2 3#T5FC$B26@)*:(K+8J<8%!H>>@
M).I+2IH\AE0M&_U44O5J\L%@8S"&E17)($HTD(_.^IAF&FG.N63>$N72V@9[
M2J'ZV"14"=7EDA$!%#*6I>@]0TSD)O.44V1HY,B2X&TT$N0J6]O0MR"C0J8>
MQ_Y41-Y#G%Z=[KCHN;S23?W8+LU+<MH+\KDQM8VSM;)YHYO;.V]K?'U:BZ@Y
M @YJ^;/\C+7'7M$ %I_B47.C%;:*&:YH2B:%2SU,9P^&/G2_ T,6BM"'[E9T
MP\UN>/O?46MX\J$[&/9'Q3=O[.  /L__Y.^^ RUD_U*W'POW18#O/DU^?6];
MW4&.I8J#'1CG'^V>/WIN)CZ9,O%!JW'XQ]'>^X\GC9W-GWM;'W]N?_TB=K^^
M:S>VWHI=NM?:^[I+]G;^[)QGXNWW'TX:[S\=[6V!IKOU[J@)U^_MM \ #'XT
M=MJ'>YT_VWN'_[0;G;V4\1^T84O 6K&&(VJ, FV8$^222X@R&9-E03CCSV<\
MDH!#\BIR+ARGRAG!9>1@!C$N@Z9FK18!&8]A_V!K0)=^L_GY_]8VFUNU#\U_
MWG[>:;QM[GR>PL"$8LZE9U[J]+_YM6>'R4QNJ0"38)IQ(H132L0@L$]$"I5/
MWDO#1IEFZ[7\L[9 NN/Z/T#XL$#9)KCP_8K4FWAL=/CL#V(8M>-VNAP"BGS@
M5\SG/QO[WPAPLT]8(<P)15R*A*P@H/%A%YV)#N3+A<QF,(@I[(:D#&O.DM*<
M)&J"4XX&B1,]S^=/MLUSGKABPU_S7O_X1J6103J!J$VPUX9KY*+D")3GJ!47
MD<@+F,Z-EU@;CY,Q'#1O[20%U=LKP2)LE#V_UYNY"%ROZUOMUKP83(%B^6<M
MSC=C;!GTYS!V_@+X+I^CS@N66 ]V!.#323Z%?=/+N)6+TL!O1<AL4:7C#]LN
M*F9^/HAQ[!TI[BQT^OD#\_'K'1[Z>0C_S$Y,"[A]5]33*$I[7E]>XXPLNTZV
MW:WBQ:62\$;&O.*^&S>YC&4%I&*/DP'_&.GZS-SOJ3<.5MWJL<M-H>ZT0FC'
M\J=0WSF9=C:Q)TRFG>6\UVZ9AWR'5..56(!9R;')&N"[)/^O=!IP(4@*]]@Y
MR?=X^58O)*+V]>69:94\II$(QP)7S!L1B#4N*,^]\,Q=X?R\2Y3MY3KSYO"-
M[?>S=O2/;8]B>>)J[Z=#3^)J-^EN#CZ@N<_(GYWFZ4?:W/%\>V?SI'GZ3ZOY
M_E.[\;7!=D]WV86XVJV]5F-G_S3W&6ET=EES:Y<T3_=%8^L#:W[]@/?>?_FY
M>QH.FX<A-3[CG[.X6F,$H]X1Q,"F DN+2^2D]2@)*61(W%"6:STK7*</CZRM
M$FDK@"O!A.\2;\B(H"DH&FAN/Z^TC3*)P, >T3B(Z>D._*\"N#(!W.D,X&)0
MC&+/48Q6(AZ80"ZZ@+003G CA0@* (Z8.B4KDSI[@_Y9OBS/%YV7>XVS:+&>
M?6]X /9$N]?=1T7]?CL8Q(M:]6QU7FVCZ2=0*L^Z9!=@M]GK^E&_7ZI2!:N
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MIUW]HMGQK6&(^>2K..W%4PM &G^<QDX_CD[$NH/CV"M@+^T!F,&3^W&0OU7
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MI95?K4*Y-X9RKTY3*Y1[+,I-6*CT05!M"=*,,L2I-,CDNLE>$:NYYX'I\O2
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MJW2#'=IDO": ?)Y2[A.Q6&@9B?.!!"J8GE-&T"5&7J8D3F'E_\166)3$Q%>
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MKU?&#IV7H4-'N;]8)\?-H?YI3A?),47E2>=IK]F/C[,3[IB1U0$G9XE4*KA
M)><B>.,"#YH[FU*0*LG*3E@X7&J\F[(3/ O$F0"& 0D4<94<@MV&(Y8\$=E2
ML(S/^_!I@1RPE0+K*+3T\-+**9Y(T-A3Q9Q21D5L:.5_7%PMOFXGF$A"4,0C
MHWBN,H^!83@=4(J.,1NXD#D7BW!=H_K)#*/2Y,739,D$-CJ7ZZ686\JUUI(F
M##8BV(FN.DE88$V>V F"1!X=)LA0*1$ LD4&4XL\J#++!9>!72VB%J_R84$=
ME"ZG8[:JPX*[D4<([G"T3J7$N5+9*Q$P!H$- <!(/M!#41D!+PDZT\VYN \V
M9QBAR!)&G 6++/4*>4UB;N5 :#358<$**W!,1DEC*%8:<VZ2"S;I7.M#."*3
M\15U6%@MOFD$.)K+-B -=#\'(B0P HQ&D7 >5%1!V+BV055-,UHI\NHI,B?"
M$D]C5$S#Z@.JY^9BP3EC);>^.BM87$6>BB:BS$:%!:(D]\KT.5Q2!XJD$98K
MX63RBZC$\VRY0N@Z7;66*[-X*)X6^+F4T.6\#R%:[8)GG%%BF6*!.TI(TH+)
MZB1A 5%K.HV%8"$QCP0)6OH? T>&$XN$D!K;B(52[JVFL<Q%]5=4[[%E%#-E
M/&.*RZBMI"(7V&5)8.7PFVQ#M"3*/]4FCG@MB!(HY"!#SK%%3IJ4 P\-'_V?
M>,$V1"NG^RNL_C3IQ+FV*G*>%-&&,:$"LYYFHZ6R6!97_2<6"Y62XD@C$C)7
MN&2,(J<MH(%CF,I F<\%49>N"]E*'VIT._'\LL!8&E;G&G=@DXI$:<>EE4)S
M;9)3+M?Y5?E %6,Q#[?H.[!5-CLA_^?]?X;-[X _G4'_CB*Z%3C- DZ35(CL
M%V6'U#DF@Z=("BH1MRDBFZ1& M;7"!6C3:02C3<I&HZ[J!3EB++@<B-S@YP5
M 0%GE4DJ2Z0'NQ6LVYI2XM;.M4#^M\J)/J_C;"/!;!$AP8)S3Y7%CB?I<RF"
MW%#UB<?9E5H_DUI/K%'J/6=!240IXZ#2D8,UF@N76I-TC"K:Z*OS[!76X&2]
MM4YY$:/@E@5CHZ0:[!+-1!2.5KOSXJKQQ*K$2=H4+$=:@4')DW?(<,>0Y4()
MHPC3&O]\9U[Z@["%-!O?Y3&4I7MCV3DEQ--NOSFH$F-N0A SD:6("14"<QV$
M=E[F@A[:&,MY,A6)6#STV9G.C-$V'T)JBPRC&-#'2>1<C$ASPT ZG*-N[F79
MEM1MO9H:C)5),N9DVWRNR8G1Q#DA LZI;L8]Y6 J_HBM4H=O*/!N[ ]Z33^(
M8:S@U_]AZLK-=A<F\P+^O=L?5$H^FY)/Q\R)0TZ-4:#%"$M.$'>&(1.!:RAN
M8I I1&/%;-&4W(4@I'(D ><DW%$:9>(J.!6#T0^,9*C8Y^N+AO78)JX9<BS7
M=2*)@&AHCW345 2+)15\;4.R&L/S=PU5>\+B[0DDFQZ6@&8[V!$2M8$EY02-
MU(!N,UZI]N*J]L2PU"8!L?-@26+"$-<N(:,D0XRZ .L(6$W53]5ZZ7.LEB3
M\E:[%V][O>;-MBZSVO=OKJ+FS.^]]!@]GT#27T>4E!)98?(3,7DZ!TU[6"[G
M+'(*@[FM%1C>VH(8!\/@(X*U5O-V]BU,^.@]#OU'O\>;1+05@[.7B(^MX&P^
M<#8Y@HRP4#I*C(01%'%A);)"*H"SD$OX:<)2CBJH<0 TP>95\6LQ F*?"\W>
M*J"M(*:]0-!OA6GSP;2)V2P-5UQ1C+P*&G%/8FY48Y"U)@61L/0J9DP3A(#E
M_.0HWY<B:6.S^G(@8YEF)6;-LXL@W+$(W6'N"OJ(WFZK]\QRWO]5=CR]:N=V
MK4'QZ.]Q)UP[\JE.=:,;+Y3@N2%U/H2&"W[KQ9;-+:TG#5/_?KV'W6CM?\.3
MKU@',C4<_/PK#VCV^D(X6W:_).)&#[RIG\>]R=H=1>1ZT7Y#-L$@?[.M,WO>
M7_O7]5>#]YJ>QP=, 1&_:AJ<TBQOK!_28+N<[Y";^I8R\!M 1.SEJV 4]K6'
M4!SW\H[VMV;BT6(6L"-"<^^(D3D>.% OI+% ^ [!>MTK6P)W4_$N;X:=0?^_
M_V4W[EK,&V(_VJ>D46 (:X$95ARK9#V.2OL8?10IY.)N,PKMG4^YM]5TU=EX
M49L%+]5@J\[&=V'[%BASV\7>97-C7#4WKIH;+]:T5LV-GV5NJ^;&57/CJCW>
M[8"+%+EGF@8J/:?>FAS7;VTT'@<%/'OL*8+_555A[O49?;HXV/*XOO>-'NS]
M_@V^0QOTH-F@=;I_\8DWZ(?60?L]V_FZ36[ZC Y@?(V+3S"N@U;]XVZSL;7/
M#MK;;/_BX*2Q=<3VO_[5WM_S8O_DK^O-C3'1RE,FD&?,(4XX1LXK@["+7JDH
M0F+S2\59LJHP%;R]>7BCWA.!C0Q*<%Z&&@([L#8)K*V1W#X,WJKJ%Z^ <9.S
MON"L9"KE),.D$ _)(DLT180Z90R7$4NWMB&DJ6FJ*XRK,.YM85ST&!NB""$
M<M@%YX3VQ$6A!;$TJ KC%A;C)F=_7@H?O.<H&,P0IT0#VD6!4N+16!VI(WSI
M,&Z5Z_M4'8[O2]!,D1)%34A M+ /+C(!FWCT+)& Z0.I5V59OB0B37<X%E02
M[E5 P8-YR9/2R'JOD==!8>]$B%)511Y668$I=MQ0DP(GN=*]D4GC:+#25@@B
M3<4K%E:+)[83)S%&PSB2/I=J240AK5U$1@ 'T(P$,(B!5W!=4T)56KQZ6JS!
M F!8$Q-9X(%Y$T)D(!,.6*4SOM+BQ=7BB75@ (G+'9@&%Q GN0LA V.AM.^"
M,\G3A=3B53Y<J[H;SZ&E(DF>1!*%Q)9S8PTC)#&76$R!14$K&V'A<.EZ=^.
M&=@!%L%: 2YIGQ-].49):$6#CHZ$N9\^+9#SM5)@K#U74FA07<5YY!;#CB2L
MB9XZIP6OV,7":O'4^8H7 2OID8+E1)QBA@R7#!$6"-&&!Y[#4BG6-2$6J2=J
MI<7SLO2),LRX:*@7G!.KO>*>!VD2D4H(7&GQPFKQ5#5'S:1*4B+,/6BQQAA9
MSB3R4<;$B #[3RRB%J_R(4'5V?@>Y#$^YU@'2^$'9TF[H%+"%H.M:XW@HC(
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MTH%:Q)-VR/A(4)#4)&E=DMB7K4V%J!E,*MVO=+],[ *"&TET1/C$/89]PHD
M*.!8T$'QZLAB<75_<F01DA<A:8M\4+#U"R^0,\0@BY,CT1"B ELVW5_IXXRJ
MI_']EHBS@$Q:AR0PIXD9;,$8P4$Y;P05:0[ ]-8Z&+P0,DVGU1MJ.=4I@A4"
M\,1="L@)K9!D6"=)@S:.KVUP7%/RR;!4^4(73XN=M50*R0,AG-L@->BK(=(J
M0;VB_HGGDI4"/Y,"3\4TT=R2/&ED9.YMB1E#FC",*(@K#](FC&5U*KG"&DR]
M)H$&KR6EW CEE%0:.^,P<5@D7^W#BZO&TR61&:&>::23BJ#&L!EK)S7"UA-?
M=A''<0'WX57.>Z@ZU#ZTM!:UR0G*5>",DZ =<$<I.7',$26QK#C$ H+/= 8T
MYB$Z%12R$3L G^20E2:7H5&*&0E&GB=5=L,*:W#2Q B9!!@ E"?'+.,V:8.]
M,U0"GZ@XQ.*J\<04$#G1E22)1+ )<9$UF#N,E$A.@4U $A=K&Q+7,%ZDN.A*
MB^<58TP99P)[SFSB022KM+1.6^>)E$$\T):OM/@UM'AB"9#(J ?Y1"Q0@7)_
M<*29B8AI1I1*L*"*+* 65SU%JYZB5<.J%XK?>M,-JUX&DW>FT[\C4\[A1!!)
M$9@5%Q%IIS3B0(XU<X9YX^;LG5F8NISW.& K3'OSF/82X6D5ILT'TZ8.CIB@
M$2>+=.# ,V$?0BX(#K234.P-B[">96-1DF-2JD[)%:R],5A[B<B["M;F VM3
M!VDL6< UBP2G$F!-8&13B@@KP01APE-7AMER(6M2RF6!M:JWZ"+T%KW51734
M7^F>;HG-3H@=6"SYJWZ7S]+A\^MQ[$P2KFK%61PY)HIFYWOL#W(%MW[A;#^&
M K#P/\/N 'X[[35][&<0*P;'W7Z<<G8T._U!;UA^#6YVW/3'1;-?V&+<)@T^
M/QT.UHN=8:_HQ;9M=F ^KSW+]L8C",6PGS\<'#=[ 9W:WN"\?'#^MWYWV(,1
M7#YA"$/H.IB![V6[R'%4YFB4-;C[(/;@_D6O/*?-Y>G.F[$%ZS_L?<\'MY-O
MV@$(1;O=[;3.+]^U_#8,:/2Z_2;,O>U=^G3LM6^7[S:Z;CS0.Z: CJ?@>O^M
MA96/O>-8>J[.\[3;-@#;()]T=Z^MWRU?5Y[C5M.Z9JL,"[^:AHYO#4.^8?^X
M!M_WL5G.W.@+I_:\_*-6V-/37O<';(>#",L?F[TICUF_"""=@^[X@_YQMS=
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MW"IB7"+::.R2L5AQHX--1ADF/:7,!^U"Y25?=(R[])+SQHD_E-CJR()#U)B
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M@\/=<*#WH-FK]4#=J/7KG4&]X[CUX:#^D\I]!L4958FFXW6;PA=M%^L\6L[
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M2"G2XDXF27R+ Q9C"V[JBYC"WF@$(Q V<-541JJ.#M]=G)U<__$?BWC>-#W
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M8+;!_[*"OX"SZ\U07]Z]P^P22$GOF[2D>>8<C/?D]I1PXQ9D6D1S6@8+C7Q
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M>Y0KI O)KCY=_&)=.>UZG6IW$CA<C*:3ZE'9D&"7(Q^,M"NXK]$=^@IS]"%
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ME_#;)![/$RVAHAZB90XI6_HN$@7F(#3D9"+QB&H+\[@6_ES^8B*F 0'5GT6
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MSV\#8B@ FF]Q&'S+QNX UA?$YW'"WHUXFZ_2-%=Y=W957",*;N.0%J#IAI,
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MD_T AK^GM,H3T&,1@KN"'-QX7(!@T67&*SP;4I&#\QL^#N F0.=C*GEU<["
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M3]PEL*5I?\0\PNL]"[-R/F5/7* .D'M_$Q)PX2Q@\H? 47%_J60%M#89Y9+
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M! N"4?/&G<8/'_VU&K\'%.1M5$/1LQE]<_K7M]]:C( &9])>9Z@!6>)L"F"
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M!(T.)?U4NF#:#4;G"]Y6=":'-N";LV[@$HLW:GE$-P)@>*88Q/XW5/W2N>P
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MKO.EFH_RO]>KYF',LG^^W2WO\J;TTWZ]D]O.XO;JH4Y&VE_:$N)',F=?)C=
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MO[GCEFDH5C>=2 Q-?*US#8C-B\>N&!R%<H,5)D@I1D._EUJ.X;DFQ++\I[8
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MBX.YO;WF=CBK_,KH+BBX?<&=Z2^DJ_Y_CIZ&%1$CO)N%IER!0TXL+#?9TV=
M?7TPOP?S^U6:WZ\JLWPPOQ\C(C\<4LM?@^U]3&GF!]_?L_!VG"QM'5\A+ ^)
MYH/M/=C>0^C[\>\<[>Y#,KV/#Z;W6J6(1P?3>\=,;_LQMO?!"?W[P8_)]I9L
M2*,=;=B,[H%+_\Q,N0=+>BC9?G66]*LMV3Z\1X;TP?_?WMG_IHV#<?Q?L39I
MZDXT)0G0=KNKQ&A[QXG;=4UWVJ\F,<6ZD.3RLH[__I['#A26MD!+J!,L31LS
M3T+LV)_'K]^GI(S7S)&V=EA!M"-]C>U1,'(].1;5QSQM+28=-O$/)AKI#WBK
M3L1<#EZ4]*2,OB.T6!>&J'OL-9U#L_'K,#XZPY@XLJ>Q?URU[</3CKV'7G27
MD%0FST?'X$6;>I/Q>A/GAOF+]J,5\J/Y<X KY%'" A>5"(?".I_*O4_(PPL-
M.-2VA)'N;<QD !!/C#$OV3#.:#PEUFF#6$VSTT!M'Q&GA:5W&!5@>>PIONKC
MCY(K$<"+.%VG;->J3<LQ59-) N#?EGA4"\9:FK&59*PUXG&2TMER6!I*QEYB
MZL(JF>3I.7-%R"5@Z8RG>2!+S61MJIFL2'YF3+8UDRO)9#O!V+S>/90EDQV1
M6H"RPZ)44MEL":(>:RIK4TUEU?(SHW)+4[F25&ZE8QY[A9[R#:86H/RWFX:B
MH]S12-:F=4?RD8@*<E94&-U9;*Y5H5J4"-AE_=02%_XN*_36RT+8O%8\KNTZ
M@@H%Z=*A>IYSI0[5HY]5/ZL.U5-E36X=JF=?7[D.U:-#]2A2MCI4S]Z$@-"A
M>G2HGOTI>AVJ1X?JJ63%W56H'K7GG6=+9VV]=%;)I;.VV,B;9%'D3RDN<^4;
M&D2"7OC2IJH#J*Y[$3H:J)4$:F>37;N/[D70_-6FU>!5W?@K#VV:^H!WQ?"+
M^IZ6V;1M<ZYY4M#3SO7!KF(>N#RB/M+2S7##2RZ<'9.K+$XR"L 5&IZNU-[N
MNBFYSGR6$-.FAV;K@+Z7BBF01LRV)Y,T5ZMIJC"':LA5';ZO\EPM""<7N'K)
M PH?X9/FZMZ:*LRAVG'5,LQW;T\LJ_U1X[7B>+4>ZK8FJ_JMB,UU^6N>D*^&
M8_0,XC!7P-NTVTV-V6J:*HRENF'6;)I&_[.C &)W.1G][=/U@/2#) 6D,'(>
MNAG.2&ZC$*SC*KW]FS$CHBSXK"R\O"S@ _1A@S E-(H8C<%"S.+V\<'!WR"H
MSVE*B=AG,F0NS1)&>)K(^Z7T-B$T9@3/"GLHQXJ;J>;WP">1AK/?,VK8KIS>
M'PJTJZ>Z+J4TKL77>T-_A$$XF8)[3UF0H&-VW#&;T&*CT_ZY,J8*M[LZ^N=>
M=Z Y4N (_(:;^7*F9L"#?X<T><"5:ZI4QE3A5EA'JIQ?7&JJ%*ARSD8\X!HJ
M=3%5N!'6$2J#[B<-E0)4!G3(_$0#I0ZF"C? .@+EZOI" Z4 E*N8)?"2]."G
M-J8*-\,:827?B5Y25%MEESMZX7=<+Z6WC\S?[V[A0XWRP//(-,7=YS196HW
M)6<7+J>0@E'/R4PU 5W1!DIDRR)+D+LR))4@+T93:G!MJJG4,D[:UO8%6BSC
M=$W=EQ44F15$$(H=#T_4RX<L:WOS"L!UDR,^RO+A*HSG.U32,4](OI&%C.EW
M7.QD 0DG? :0(8/,$#X!I,#/45]0Y"[,?#S" OF?1"SE"%Q_2O#$RBCS"1^1
M*!OZW(4TJ BN'R;,J]L:Z.;;MY2M$3=8"]REW:'4Q5=+ \X264F^9#2&<O=1
M)":"&D3 "#T-.(_#+PW"Y7*ZAZ>?/#)"\1.Q*"X/1UWT1+7)C=(0JPZ?B\^
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MF#Z7IL]"WQ&?B#<@O(7P0*A="&>M@(<0O,G7Z:E O!JY3UVU^2PA5V]:/9T
M&7.>U-NQG)#'B6P1@BP:A/+;-6?AY*P5%:<!\5HH>IE6].K54X=YF/HW\$!R
MF;UTKU#1^4>EH./:\.=N&!]\N_.A<\N]<=D*#[$KTAK7YK/^FD.U)Y&\"O7^
MA%^I%WI]3UX"]M&E(PJZP+1$]A%@ A[Q$X7H*V ^$5_D8;_\2:RTAJ4-LCX!
MBULJ>OMHD#P:1%>@G;5L#@-,4+']HE_ \X.GYM,*3=@?#M7!"SFX?;)_)T(P
M_X+Q25P%?0^I2+Q+_>.99$[JS<9FV;D7FT-M/G5J_EUAGW/.)W_(I__VU$^F
M)#Q+-]Q>13N$+\D@B#?Q4WGGH!UZ<H0@;S<;7P-@YW);L<P_E+?S;FBWJWU6
M72VC[YFY(EOO?UD_<?''X_^@N8/Q4EY&1[W]:B874,H1(K[L^$)9@K@B) K^
M[O&T+P2-7C2]H-[+LMMZ0^3]9'IJ^LMDR"%:!9WCC8Z5W&PY^<YZ5YF\3A='
MHRM)(X\E+S<5?<=10;"(O9.X\>]!97ZO%"]ME=68_NAM]<32Q',_;I^R?K,*
MQ[5WG>@7.53YHYHN)+W6>2!]7W5?,9]NZTX!U!I(!19.NG*EMJ[V?&?TE0;C
MK^&?])PR?7TJDV^]HBK'4]S>,8MRSZ>S(K$3[LO=_ ]$FAN4O?%5@;BG78;D
MB:G\T]U$/KWCZDM_,N'$CHYZ*_)2A[<]A3;E!51V;NO1^9;"[E7B:8<,-C@7
M*IG5Y>XKJM/+%[#8>D^_ #L<P>A@?Y.HI9>H1T.'-TDBK 55KL=DZY6.1T4U
MXZN4]\N5W+KZV9>"]=-WD-UEWT&6O 1,+3F65:X^GS54W0E.QU.9U@L'Y&;Y
MX$B^WS(4_5<JRFJ7+;$>O1WJR5N<F+^"WBIK?,O\44"X%]UPK[= #<'6#7%;
MN1F97=O=S-$;[79UI(,QRB/!]'6!:W];;.M&]SF4BK!ALB1#_4P&'O-OI#QG
M6X5T0_$>A6%_1'BE$ 3:F]._%T49^5+;AX7Y-G2A6P(1>+S3MAR'>657R$IL
MM*/4&"5OJ:_&M-(Q:3E>VTY$1"/II;($_6B;E-FZ->J"\ HI\\KD.UW1Z,;E
MY6N:I]]Z5:]=_,H>/5#L=Q<ZA[Y>)86W7HG9 L;=L ]##Q4LY#8Y)S"!6F:Q
MM1J7K5?[@8[&P=WPBR JA+T;!$!'G!O_XZL]EC8',98:#I(W/4U+!X]E6.WJ
MV%*EA^Y8+UPIJIX3*6\F?)\K:&<C\14J.CN2D6X,VTR+SA6THRV:OT04PBNY
M"):DI?K9]Q>^>?VA2G,\D=?@W&7VMW(7M"[^F^K-02*B>C(L5P>1JT2E%%D%
M^NW[KOB&(;GDDJRBIZ-$M"D6(N+/Y"4I&%\/+_&& !T<B6:=>G76.[LN"U8<
MNG)GJ=S2I#!^)GSZ<3AD?%'ZJA+IU@WCT1X3)W0)=.6YJTC2#TH8H8:AVG"@
MLG)/$&Y$RT=BMLXL1.A%OU5T)M]%]BXXFKYM@VPGMRTR[2+1+6#EJ9MJQ+NZ
M2ZMLEB74HE"=><TRG+;>O3:<B?7 ET@/>L%$((_9;&M5<YXB.QHAS=G/+C.]
M_V!Y@( .:F^&GT?\8YO=G.V@WV6J<ETQ@;8=1U9[XUGLFM>]G^T-VYV-G))A
M"]PQM;&;>8]UU0%/0[FK1E(V1I6=H'@@([F0QOAT=H*B]K[[>LQ_C*;+;A'K
M.WA$ZD4'&O+M^^::,%["=,EE$U5D_492PGU7K41-% :+=\,-:L\EX@9*3Y$^
ML3^@-?3;\KZK(EL^998]?P":AM[C1.X7=(/I/=33P_:T^OD%/?W6>^A&MEPJ
MF%6I\LZ[><%;W].9G<56]N@[M)RSVCPJ.TW:T%0M+V+;DS!U2%G88^+A#S_]
M'U!+ P04    " #,@Z92 NF'9OD=  !R0@$ %0   &5X96PM,C R,3 T,#)?
M8V%L+GAM;.U]67-;N9+F^_T5'O=KHXQ]J;AU.[S6.,95=MBNKNXG1F*3.$7Q
M: XIV^I?/PE2DK50$D4"Y)'OC:AP2=3AP8?,#\@%0.+O__'M:/+D2^IGXV[Z
MRU/V$WWZ)$U#%\?3@U^>_O'Y#;%/_^,??_O;W_\7(?_UXN.[)Z^Z<'*4IO,G
M+_L$\Q2??!W/#Y_\&=/LKR>Y[XZ>_-GU?XV_ "'_6'SI97=\VH\/#N=/..7L
M^E_[GZVTVD2()(+31"9J"?"L"0CFG1>4<\C_?O!SS)RK )9$YBB1PAOB:,Z$
MYZ"3LLPJQQ<OG8RG?_U<_O$P2T^P<]/9XM=?GA[.Y\<_/WOV]>O7G[[Y?O)3
MUQ\\XY2*9^=//SU[_-N-Y[^*Q=/,.?=L\=>+1V?C50_B:]FS__KMW:=PF(Z
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MRMV;3QZBA8I7^![W*8P70L&?)VDA\6E\?M3U\_'_+!.J063/LG)$J,APO,9
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M[)..;3.A#]'[ $;UJC@A!Z4I<QPCEE0RNE00KU&B)501AC(NQ X6QG_<D'$
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M)F]3KKI_G'E%L&\H!-,$JP85%K?ENY3N8L9L(U_+SNOW"7B8)NS]PGHO9WK
MI$DO[GOD=%$8*W)@3M;;+;S4S+L46'))9'0NAJW*YA\(9^YIU'Y8RG2!H@%5
M[CE+=+&OYI(*NGJ8(/!ZL:Y%%D0BA)4,2NA@DFURG<]6T@V?*.T7U&ZGNW9
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MEHOE/',E<NA[O3C6$\K](]]%N0TRLN=NVF4<O@#Y=5H:YI6AW3:6>O=+CLR
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MD=\F2W:!HN5:\OS+-37\/,/_/JN-8)8+:T;KK#2R=M8JY%W&VM3/^=ID/+E
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M-X,XF(3B\,8230^ <H*WP1C9U')%W$6"FUP*,W,J[6-D9R:5+$M.'.Q'(FB
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M<F6Z;914EUCUDTRYY"J8_4E"J[C*I+](5.JN:L)O(?2VRZ@&>GLHJ8JY$#+
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M.9M::3G8<BM"-:!6 BJ7K%D/J*0'HG.-P!LI7/$64#:E<!H64SREK!PNT99
MD.5K>#+IP^NLAQ;%M*6:2=4AD,MHB5R]$6V%\QF^J*4]B68GY0+8 I$.%1$0
M[Z.E.*"H&((Q-9)WN?"4.==RZ*E:K!5ED]E66E'\><U3(.ADC"6*]1A3M,#^
M*APIP80G&RC9\QW?ZV3-C@Q,QUMIO2@QMH+ UHA<TMXV*Y*4D1K- D96#6?(
MK];RDI]QA TZXX$XM,9Z@$?6=%^":G+II ,/Y3N_&14"@'I[Q9'WI6U"B;."
MK*_DIBDQ[L-B-J2<*@N)0,IBKH=R;*R9B*95/:4'_'R;BEO(? 41R_8LJ;E#
M05>Z#3P2Q*5AI>E(PS809=P5C]QB,JK?[FMYL&;##OQ>U4&72K4L@D5C%6<S
M*Y(Y*UJA"W# W0:!IQSRE)P9LS,GER&@O:KD++!F2!']D-JV)3'.;(EGT:1F
MCZ&%O)H-(9B_[-32M315+4D6S HTR"^T8-S ([8"X$8C);: 6JE-S0>T-]J$
M$4_,ZBIG2R G;'=T3@*24=VY"%PK-T6\2%<I)D5WO'F'XRX%+0.,00_<#L6!
ML[:4*$WP 2FV0>V,%M.^(@N\!B.F["F2%MINAU; 8Y3(>R)IBX:VBP*"-<.I
M?)NPB$PC*WJ4@M;*^LPMD)192E:X4&QJ8@ N.L7>'G^UJ.?3Z:BE%$W%-"*K
M.I/96",NNRP^U5H*1HQ@*<^!?3E%:Z 6UX-.A&J*6#H/$W \QHEJI"(445\1
M#=AL4F\/EO:'G+EX2?/Y,0^@4&I4X7@QBJ:5@B]@J]<-SH?*9BA.:P5#-(JM
M,"Y6L8;(V30<%0#\#V9JN($GWVFF0%OM<,D']F I(&VX0.? 6S(;C)5!^$)P
MQ9;&JN9F+HS3<C%/"TA=(0+-:I2Q^RH:S*8;4BW0#("8U6C%<3LKV+U(OH#X
MB22EU"P$6VKX:(-M5&N<ROHSO,#R>KA@B>E""FEFTJ#\%LJ%9B3!(S01,1=<
M>9L%BL/ ZHNL)K)*2;6DM +OS:9"!;[.MC@E4<U8<HY*15)(.QRN1ZF8RZ$8
M]$ YV0G7F!/&RVW- H-0301;)2/OS'2T-PZD6S>#Q+:2*L=MC: YR#==<M23
M8&.ZTU:R4V&RXJN(L-_6:#E@+*=%H"AI@4-AEUKSLA&(%95V*A23S*!>,.H6
MI6Y7U(P2#,J2XD^%[7ZGV0N":B02]#98L1Q6+-Y*VHX'!&#2/K24@;-1IR5;
M,!M^*,/S2"G5"$>*"4N@W-MC1C"^3NDQ),Y1-9;VEEHZ F5;<8^MR8F*F'6W
M8K42F8P4HQ$'%;*DY(8_VG F8+N.EMU6NZ,5]&@:EL22>,O6VU/#PGC398MZ
MD]94, 1G(TF!)<Q"*(]FR)ROROE]9KB,5E/>JBT+W&0F)H""V(\KN7JXF<RC
MV7@UJJ3B6!L.!X!'(H+%2 58BCD'.YAJ*N8F&]$([<-T(5;SXYHMJR%V(>+C
M4V8JEG6Z_88[2=OR,;=$Q5FA$WM_X&8G+BC1$-R.@ZRNY6ZU,2"-=L 9BFAD
M.QY%[4Z01X9\4=E?L#->9\!HX[@()1PJ*%&M(N*CG<XL#Z5]6 E4\R0.ZE.6
MUX2R)==,JPV;I5*N!@L2AV&^M%5-%.P!-\'4JBKP!$E$5.T@ZM3,H.B2<W"Q
M!(HN?Z2-E0HEO,#R$9)MMD EC@?*@IID+46JZ5)E$-" H_#'V0+<=HIX.V&H
MC$,&1I3)1 )0/AW68@DVZC1JUC9D\:.M $Q""-?DDR5OP-OY-@_WM*%VC>3C
MQ0(P31USZU#88:UA%*ZE&T4X3><JCFPAHU%9GJG'JVF^T'*$XG#0 L*I.=L6
M"N9J+1K&Q#BHV@*6!FMA$R%/GLR(Z634QV.PVYZNX_5BBJP7:YIN!!Q1-F!V
M$\YHU!<O- E?/!?6PF&Z8" V(8XAOD@P&R&=#AY0*A9!_A,25=2&UVWVB(9K
M=-+=KFGU$H#'W6*D*HKA")(JA;U9690@C2^Q*,A"Y Q$V0L([.,<.AP0VUPD
M"'+RO)^VZ)5D*09B 0\J' 5&&2_<2(<5.PCFLF&!RAR,- A'G2_":M6BP74L
M5W!0D,\"BF&L1<&6@AE$4*H%?*\/)C,X2O!4&E3U=MC>M&%P4ZG!$-7*J$RI
M@>7%(I83DHYH.F:/F3T.T5]I<'C)2GN]EB0OQ5)^.X1:TJ0S!SR2S0T):=4%
MYQ.LD@WYZR*J*$DM8^MD@K17B\!.?Y!-F6MP4,?;$0HM"TF['L_%&%;C@4UD
M/*F048TG4350KP []3OJ8=B<D?PQW '[W7%==N PRV4DP:.WZ[0E[5!)1DHZ
M0 W1,%MC4D0K@>C5^08O1<'%)$;7&R%43=74'*#4G])3.*Q[,"+E]#E5K0;K
M&28I\*+#A=O:,,+KP'_1GD:^Y@F#_>8%/@O;ZD@-:+)L:=;8+(VY85J!TC5.
M!IFJ##>0NI;+A!SIO,Q4&K3JQXO90H,A[0F#U&,AX ]Q4&"6BC:'[&)+[AR;
MSA%>%^*OQ[*NB*P(H'ZL1@@Q: 49?L4"I2-8(@6KK+V(N!REF ,A"_E<N*(F
M9:9@E?UP+636K6*$5%E!LI*-2*1-P'Y_&V^G#23<JD<SK&2X+!Y0UV/1EME#
MM!,4Q181WE&E_/YDHV7%\U &]@?-. EIC$50+00HO/UZ7E%]4;->JX>*N%AN
MTDFZ$8:QD*V$R;@9\*U>-6P%M]/#"VI3YGT!M]F:*(1BH5I+Y9BD!C*>'UG5
M"HANUFR'";\'0TIPQ8["(/8'1"\"/!>4[O@WVE>#_5XEEF+3SKHN6Q5'REKR
MXT0<))E)ML80[B:L270,Y!!&I%5 ?.T()HO)3 #R6@JL/QPQ8V2FEG3&:M'>
M'MDE@P00)YA&N IB:!*M-:!HSII+*=$,N ]'0A8'6P@Y*KB()$AO-)-!L6K8
MZLQ(KD8!9(\!$"S:=KP9H8,6$ &!1V!M\6R[B980UAK+ICB/:HTV&[ZF)^(0
M28_?#:BQ@-XJX.4(9TD@%@?7T-6HKP5J3=KK;E$$3=,!MPXT)"87@Q"?M=O;
M.M:2@>&GD%P@WHI&0D@T;0.N-P[%[2X(;K=!#N=/:6VWSZ?Z<++!.50F7P[Y
M.2ANP_ \@N?QWAXA"V<<C#D2S;FC?#!OMC7C>:<KK$%FN\\>KPI8!JOC86\X
M3!5\BD\)I2L:F-N*AS'80\&!M#?3QJQX 16+13/@6U03*PB64XHNS(4["@[-
MZTE6-$A ,ZF:F6E+O"L,-*(E(!H;CH:X1)9K0FJAH;KQ:@U$F4"QUF3SG@H7
M:(*,*U,O$WH!H8JV E:H1,1@),:7LL%@DXKYBO9X+5"SNRM56LK$&F6^)A?3
M6!%B NUVWJGA?(UOHEH55;(%2@^U'+T]C-\9+\ 5K"X!3R(W6G9<,J"X(URG
M(GJT;J_8^71)M>(>@B']%3U95^.--*GZ:=P",9% HU@AW0G !+XI*Z'>'KN+
MJ58*!DU163&;QRL95&_!B0C$"34VQL!E>S+'LN&& :<\2CX4$26Z&BIKV9W:
M(Q:=&!, ]4+8G)?U.O!(A%)D2RT^$X7"(3V.I%LYS&N.M[1LR*G95 RK>+$Z
MYO?&F$(Y5)<+U7(KI&7=O_I%?&_//_NB/N9N:SK?UNH*I&JV(J@QF)Q-U\PQ
MF T6"CRLR+ G81?"F6*U[27]A=X>!U>3[(%J(]9L8;E23<[;-%_+WBBT4E"L
MX??4L)RYRB!D#8Y$[2AF4RW YAK-=,T!B[ZH+9')(# I9..H#KQO;T\R&\ 8
MG[F \RD&4^O5__KWAE_\6E%1$"T7X32N01;29$S-8#$BE4Q!9@]M2]K-+5H.
M-"IMP$(Y(T&*PY.F@[Y=?YD!,OV?^YGG?_0W([L'5)3_<\B [_T?1 9R\O]!
M9/^V%&"0G,R9\^.Y@YWG"[X_(?$OCI_\VC&+V0,GA691I6J-+7$"Y9X+'LR4
M97Y6#C.S(,-"^S$';^NWHF:^/V<7\7Y<0'"S(&*\E>,&</YT^JY8W66NWCGW
M]!U6_C_$NLOT7;&&=5F22ZRZR^MZ':#&W*@9=Z!6A\7I<3L1Q(%8"1QSF-T6
M!#/C+OQ[M+\R?U?T4:'$RYWS72Z5K5;G:GJY+'8.&WT__6?O?T*OH,L-@??H
MY>*_.J8R>^#,U2SY1\8-T)#C.0N:L]C[K2S.]B.8%>D'"8#8CZ.BB-A%SF[M
MG#+ZQ=R?X.1_R74'(MIM#C'7S]K,>+\5<*6?S=GM_0X4$WC$YN!$!_\]6OYG
M;/D>;?F_9OL_G/\3_/H_Y/NOOO]1IW_*^)\(Q"=7:V6]M>N)HIA0^<]/% V<
M<9O%<IWEYU99L%1G5[L\^QFD_$MS$JTY!\XB]GY4M)O[K9C-WI_#.',_T'G4
MBMA$5!!_0/H+R?Z V,@+I>_.:F']*!Y'T5D6;)89_?ZLUBY0/YM9+8LU@]4%
M0@*\_W>/:_W:U)_AY?)L21+XN?#WT-\_^'6G]+_+]'_/V_P'3/_5 W+_GV?Z
MSML?-/][J_F)=<S>Y9SEK%B-!?FJ%M'+HJP*<R,ZV-QL^)] [$0!K'46>,+7
M.4'_CMJ(V].GRCF=U5M]"#:SPZZ?0 T<K(5_=K)VX,@N_-V9W<YQ8?B'\\+@
MKN]_H>U>9/<BNQ?9O<CN178OLGN1W8OL7F3W(KL7^1]H/_[!(%#.SYEN3)\W
M=\<[H]*4RS4_$@U[J !IZNHRF4;Y G*I/&A/DZE8JNE1K[,OG<GV#7O.-,@T
MPC34A)A,+%?5@C%/O/-WBRC2U5<%0*:?M*]>-G5U/E?U^R)]?:;_K(WA-+UF
M,G5%P-C"@]($C$\%8]6H:9WG&\!X7$[IC <-[HQUL$$PGM 92SO'APW [!P?
MT1GSQ1(/QIT]:WR1[XP?!>/?-NH"&'<'P/CTABP88+P:C ]2ZT49C#=WYA8%
MMFHR#1[5>5X3N#P8F\%XE!Z/NL!XMLDT?)2TRSBWR[@F-&L=HEQEK:5W_JI)
MWPSND#[$X<#[?(*A"K5:?P0(A=7Y/E>YJ+&EELFTD^:!ME>'MWV R3;$8;/U
MHS.171CU3U_^FZTCVYVC+Y@!F76-?^;'9[\&5[[*9,*_!+SYW8_/<A>;3'>>
M9C)->.W'9P?]T60:#>1VQ_.[T#.^HR^[_/DG6>!F=ACZ0_N7 /]&VV6]F1UT
M/["GS[WSSP;U=?C&E=5R7>^K IL0^OI_KL3_]<1?W\=A44$4=*$$9B2!ELDE
M"8C[NR_5^N32/Q+B?SGM9VVG7H,V]IKMIG'S9YKV?'Z<J?O39TR#QXXT=1]U
M.7C3]8/< B.2IH[EI:9\L%/O!UK7+[$.6MRY5&5I8)XK&N_CZGICY[N.69J&
MF'I,HTWC3/N:)IL.-,TP]9M0D]UTN.D($VFB36%3W)0Q'6/B3'E3T:2;#-/Q
MII--IYL6F7YG^KWI$M,5IFM,UYMN-MUFNM-TG^DATU],3YO^:GK)]+IIC>D]
MT\>F#::O3%NZNKJ&=?5VC>W:MVM*U[0NJ OMPKOF=I%=@:YH5Z;KV"ZIJ]15
M[SJ^ZS==B[J6=%W2=677]5VW=MW=]5#7DUTO=+W:M;;KHZ[/N[X=U#UHU*!Q
M@R8-.G@0/ @?1 SR#XH/.GJ0-*@RJ#WHU$'G#+IHT%6#;AQTQZ"'!CT]Z*5!
M:P9]/.C+;E/WR.[QW0=T]W?CW:[N<'>V6^S6NT_L7MA]0?=5W3=WW]/]>/>J
M[C7=GW1_,WCHX+&#^P;W#SY\L&]P8C WN#+XQ,%G#;YD\)\'WS'XT<&K!J\=
MO&'P]B&]0R8.@8;,&D(-20^1AAA#3A]RP9!KAZP8\MB0EX:\-^2KH4.'CA\Z
M?:A]J&]H9FAAZ'%#SQKZAZ'+ACXX](6AZX9^.6S8L'V'0</F# L/8X?5AIT^
M[.)A-PY;.>S%8>\-VSQ\Y/ IP]'AGN'9X:7AIPR_8/@-PQ\8_N+P#X9O&;'G
MB&DC9HT(C^!'M$8L'G'-B'M&/#_BO1%;>L;T3.^9TQ/O*?2<W'-1S\T]C_6\
MT?/%R)$CIXYTC&1&RB-/&GG1R%M&/C%R[<AO1NTUZM!1KE%'C:J/.F?4=:,>
M'/7JJ"]Z>WL/[CVB-]M;ZSVG]_K>1WK?ZMV\Q]@]9NY![<'OL6"/2_>X8X\7
M]_AL](C1TT83HX\9W1Y]P>CEHY\?_<F>(_8\>$_7GNR>)^YYZ9YW[_G*GE^.
M&3L&&1,>4QQSUI@;QCPYYL.]ANUU\%[D7OQ>I^YU]5Z/[+5N;/?8 \>ZQG)C
M?S/VFK&/C7UOW-!QT\=1XPKC%HV[:=QSXS;LO=?>UKV3>S?WOG3O^_=>,[Y[
M_,'CJ?'J^,7C;QO_\OAO]YFT#[&/L,^9^]R\SXO[?#UA_PE'3! F+)RP;,)+
M$[[=MV]?<E]EWW/WO7/?-_<;O-^A^S'[&?M=OM]C^WVR_[C]#]^?VW_A_K?M
M_]K$01,/G1B=>-S$JR<^,_'+29,G>2=IDRZ>],BD3R:/GWS$Y,+D\R<_,/FC
M*6.GS)TB3SE_RLHIZ_OV[B/ZU+Z+^A[MVW# Q -\!]0/N/* YP[8,G7ZU,34
M4Z8NF_KF@3T'X@>*!YY_X,,';CAHRD'!@XX_:.E!KTT;,0V?EI]VX;3'IWU]
M\/2#4P>?<?"=!W\X?<)T:GI[^M+I;\SHG3%O1F7&53-6'S+T$/P0Y9 _'/+7
M0P<=BAV:/_320Y^'!D$V2(;^ +UPV)##'(>5#KOJL%?Z1_43_8W^I?UK9XZ?
M&9AYRLP[9WX&'P1GX7/AQ^'M9LRLFJ\QOX[LA=#(*<@]R.?HH2B'7HJNMO1:
M/)8%EKLL&ZV05;!>;OT;-A8+8F=@#V/;;':;;KO9]I'](/NQ]LOLK^#C\ A^
M%OZ$8XC#Z5C@N,_QS2S;K-JLVV;]_?#^PY7#;SC\P]G39PNSKYF];L[4.>R<
M*^>LF=LW]]BY?YR[9MX!\]AY5\U[YX@#C^"/N/:(#XA#B )Q(_&9T^S4G2N<
M7[MFN4YP/>CN=GO="]W/D7N1"?(2\BW/5(_D6>K9X,6\QWD?] WQ^7WG^EZA
M)E$<=3VU@;;3)]"/^D?Y8_Y+_.\$#@WH@7N"@X)T\+S@&Z%IH5+HSK I3(7/
M"[\9F1ZI1.YEAC(1YE+F_2@2/3[Z>&QL;'[LAMA7<6=\<?SUQ(Q$/?%P<G3R
MJ.3UR:]3[M22U)HTG#XA_71FOXR<N2L[+)O,7IO]\DCRR-\?^=Y1V%&G'_7R
MT=./;A[]Y#'[':,><__\T?/9^<N/'7)LZM@;CMW*AMFKV"]S5.ZRW ;.Q5W(
M?<P?P9_/?R3,$98('XASQ"7BA](<Z3SIH_R\_ 7Y3V27?(F\L> K7%'X6@DK
MURD[U)2ZK#B\>&SQ[M)>):7T:'ERN5E^08.TT[4UE5F5WU<VZ'[]VFI7]>CJ
M7;5Q()EZICZC?EI];6-NX]+&9B-I+&^.:9::S[0.;9W9^J#M:?_IN,''<<<]
M?/P!QY]\_-H3B!.N/+'KQ-R)#R\X<,&I"]X[R7O2GT_N.5DY^=E3S*<L.673
M;U*_N>?42:>>=.JZT[RG+3U]C]/UTU\YX_ SKOCMX-_*OWWN3,N9%Y^Y?2&_
M\*E%YD47+-IZ%G?64V<C9U]T]HYSQ'.>6VQ;?/GOAOZN]+N7SYUW[I^7C%G2
M7K+NO.!Y=YS?=_["\S?]?O[OG[S >L$5%_9<6+]PS46!B^ZZ^*"+?W?QUDOR
ME[QTJ?/299=-O.S,R[[^ _^'%R\_XO*;KYATQ:(KOOVC_,>_7>F]\HZK#K[J
M@JN'7MVX^OUKDM<\_B?\3]=?N]^UBZ[==EWINC5_CO[YT>OMUU]_P\0;%B\=
MM+2^]*,;C[KQKS>Y;[KKYOZ;KUPV?MFB6TRWU&]9?^NQM[Y\F_^VAY?CRV^^
M?=KMEZT8NV+A'5UWM.[8<&?^SC5W9>YZX6[Z[H?O.?R>%??.O/>Z^PZX[]+[
M][Y_\0,]#YSZP(Z5[95?/J@]^,E#TD/K'I[_\.N/I!]9_2CSZ'./^1][XB^>
MOSSR./'XRB?F/''?D[.>O/LI_*D[G[8]?<<SV#,KGL6>7?&<[;D[GK<_?]=?
M'7^]YX79+SSPXKP7'UKE7O67U=3JIU\*O?3"RXF7__;*4:^L^1O_MP]?55_=
M^%KCM2VOG_3&D#<6OKGGFQ>\-?&MJ]X^Y.UE:VQK[E_K7OO,.[%W7E_'K?OX
MW>J[6]\[]?W>]R_X8,H'UW^(?GC?1YZ/_KK^R/7O?:Q]O.63TS\=\^EEG\WX
M[/:_'_'W9S:D-[RW4=^XX_.SOMCWB^LV63<]_&7DR[>^*GZUY>N%F_?=_.=O
M\&\>_S;U[0=;C*W#MEZT[9!M]VSW;W]C1W''CAVOFURF05U=G?_?M>XAW9TV
M=/#@[B'#AH)P!?KP$2-'#!_>,WS8L)[>GIZ1HT ;-F*/T;VC]NB,.T@ZTSNS
MP/]1PX<-'_4?MQT/FL8,'[1I^!W=75--@\9T=8_IVO&H:0K(:89T#;3O$YJN
M0=V#APP%6^H9"0!6[ FVW]T]"&QVR&"0SW2= -Z;!H\9LM<!"#%T+,,.FUH9
MAYY\[I7##W3>^M#>T1<V'&3)Z:>,Z!F_SX1]]YMV\/09AQS:^:D1=\QRN4F/
MUT?1L7@BF0*)%L<+HI27"]5:O6$T6^W?G'K:Z6?\]LR%2\X[__<77'C1Q9=<
M=?4U?[KVNC]??\-MRV]?<<>==]U]S\.///K87QY_XLFG7ERU^J677_G;JZ^M
M?6?=N^^]_\&''ZW?^/D7F[[\ZNO-WWS;H:O+U-WU??M5NL8 N@8!&0P>UJ&K
M:Y#1 1@S>,@!R-"]"&886QD[%3UY^#CGN5?>^M"( RW1#7OG]!=ZQA]D73MM
M8X>T <K^/<).^:\H^X&P'^EZS32JNPL(KWN,:9YIV]:K%LXP[>Z[^^Z^N^_N
MN_ONOKOO[KO[[KZ[[^Z[^_]_^NGOKX>@UL&7N$^?L'KYO;<DR$G4]).&]+Z>
M[/GTU;',48M/W7[X9NCQMPZYT/77XS-KWU22IX^=?<<%^YV:0A^;<(#?[,$?
MZJNNGT/67SI[(GGH"^__:=JT%:O"G\]")F0WMS[/];WSZ7'65<M??753SXRK
M[G \O'#&'P?M[KO[/^S0>9M?VG@>L;E[PZKXQM1O/WO@Z6OERF?'WH6&/CAM
MH=GWQB>:Z>MW3QHQX95EH;,=R1M7<^->+[N7O+G\ZI&GW73F31/G3IX9NY0^
M!+KC]=LH0WUW@;+#]-H'C[Q]V^A'DB^O6+SIV>@7M6SRXOT_O6#[L997-G-'
MG?*<UW02^EA\NW?["SM,=\"+%Q3FZ$<N'JNDIKSZEOBA]5(126?/>9U[;L+B
MO]O>__K3^,H"_%KLF&TWG-@_OWG=4=Q^3QQ_Z?[3]!?DEQ_\P[G35QVT_-A2
M[O%N?-('6\<:7Z7FK1C]Z6BI=]N]U-H%O9^NKC>@S^D_;E__QA69B=R4-S+#
M/YK_U'W,8Z^>,5X\]ZG/7U[GB;YW5OVH-]^;-_..-MF_K+&@N<%^QMU>T[NQ
MYZL779]C)[>>?/7SQFF'?WG_U?4;K_EZQ;E?E[?N5?XJ/J5K>_?T,^M'QJ:<
M>5_I3*.O\L5KKWYY"IQ[\.()FKY^]"'S4]$A/7=-[/+/7Y69''9!#[[X(+M]
M M1^X*9O[FQL"[\3FO'.8<GC+DD^6UG\]M*#/WVA_^J]W]N;O^]W#+GWQY.'
M,^0XT^[^?T,_H+CTO ?'F58\N36S^;VU4T[.[O/5A8ON(Z_-VVX<$;[]Z2U/
M;ESMG?#T$Q[O\!'+?K?#5-QAV@S==,4C3R]Z?N36F4M6I5Z^LG_OY^Y:XY?$
M1TXY8$I#FO*6XZP%=SXQY;++9V\^[>;C(QOG_&7%._W9':;L2Z7%?R_=_#[Z
MQ(.U?>>,:W2;]KAHV>/->Q_[9/R1]M.>SBU-9.T+*O,2-UZQY+;M7VZ:=]5]
M<[^=\W[K67S=\HMGS]FW<'7Y+<I8_N*(3?J]VS^]\?D7WEZT8,-1\X9_.)8J
MKWF[9_U;4^M/[)-:-7*X9?T-W?>._OJ4*1\<L\\[RS;WG_'8V6)RO\:E:[9-
MGKCU\J//7^X;-BGSWJ'';6)>V;AL<7[98Y;18^]:O ]TG^N43P=?=>&S,\OW
M+__VR!D;O+_1]F32&+/#A'G>?_O)!^;?,^/;)?#FP^Q_>?3N)>%/C^Y].="U
M[XNYUR?/09Z?^^[VO?_6M&\?>?+&*=3O/7>N?7[$Q^9S'@A4LX$%:XY\<\'&
MIS;?O/"+#RM?CXE>:*V<]\T#PM>'7_WR8TWFH2_7/CG[GB7SWUP,;5DG;;YB
MZ;RA*]?</J]W]G&5WF5GWEA?,.1HZN3WGUE97#YXXV(4N>^$P+%[O)MZ:?M>
M&R\X;]VVH;U'NEZR;N,"]^R[</U3]<L/F7O6-8LW+/O@K7N7G;S@]L5GSY-&
MC[WY^K63](_]Y_[6\OH')]STMTT7'/CYRM5GG?/H9&53:/+&Y?O3A<O+P?CB
M+TC]R=;K:T]<=.'JK6<L>N"L;\2IERW5ODQY3CC ]MZP]Y[=^/A+=W\[Y;YX
MZIF5M_Q]Z[BK'UFPHNVZ<OVM#ZU]>^*A_-\NW&'RKM;09]5G=-]#!UN^Z/KK
M+8,77[OTV_UG/&=N7;X??M^HU6N^O7GQ\B.OO=?RS;#?X@;R)'+;TU_0H3_X
M-AV'O7#M[?*FPH<SKEJXZ?EQX&KZ1_WZFY3QET]\X;,5([=<I'ZBLL<M6G3F
M90=I?_GC<LO8!TV#J&6/+]X\8\&G]QM;CCK>O\5VZ;3'5IY2.V1?Z[WBM!-7
M;]MO/;G]"WW<E'NNF[C7JU\NVPP-^W3C#M/(Z:E[-G-K]W]F\X+@I:45QXW<
M>L_Y'S9/]GT\3D7#&_%)YX_?7%IYT=;DNK_?O+IEFP^_26[Y?'[!?]7V3^:_
MM77)RJ\^..F!<0O$%Q:/>?^OV[:^\MD[VQ^=_]H)UTV[\_/'G[W]BE']E4,?
MW^_V)3[G#7]^(WWY2:-C\V]?N2&\[-7* F'QJQ^$5\V\,K%Q\JUG>S/:T/<N
M/C\W\5OW7?.#KS^QY:4-R[;NM<]7B7D3MMOL9]>/7&!YY*WAYPJGSGJOM.QY
M!-ZV?(<I?<+PQ<M3Z[\\8=@I6Z%//O+/?K1?:*[:M"7ZS?W[+#EAW\_G43-G
M?_72VD<F4,?=<OOZUV^\_)8SMMUSA>4C8_*M("];>?R\\YW_KT?^W?U_K:]T
M+%AS_=L;&/^B-[W1S?/7'/GW0U_L??FMOM5K%EQB?/C5N;=\>/4UI^JAV$G[
M&R],V1!;_-K+X5?/6'/XD1_9)X<7S4X?\WA0F#?GAJXM'Y_\V<*GQGUEN)X8
MNG+2FZ]Y#WMT.?+D09\'3QS]S@<35S^\[)/ J)L<T.HE;TZ_/75I=B4T\\;M
M?_YV[N;Y_DGPEY=:S\#P>Z.+LC3UL>V>/]]_X+9WWW[5E;]JX79EWNV[[G;$
MIFV>==[5!]R[_'+ER*7R^+1XVC.Z>[V^;UH?CO>=0YYXRX*'T!VF\I?;_K35
M.GO:.Y>>.G]2?D-IK&V<$H$G%\ZYO'"*?=F"!_ W]OD\=\<#DYL[3,G-J75G
MPX^V)[W^M_6OS7GXS2,#*Q]^JCWF3=\3?1N(OG?WVS)YY#M;/<0YB;5&*!N:
M\\J"C?VKOE%?_>;M,X^9O&;S<NB"\3<P-^U_3_7C?1L+WKS@Q?G8#=Y-0TAM
MWO)YCY]]^%>_WWS(E<U'@LQ>Z[7<^V\WULG:=>JM4[Y.3QQ[ULVK3K[D[TNW
MA$<N_-.95T\DAST[XJ!5GUURC_3-TG,>?.6A=PHL@E2N#X70<&W5\OD'CV/(
MVL0KR7&1KI_W^7OO,#V4F%>^8G/L\BEW;3;60L\TER5_L]\?WH"_D,=_9KE]
MS(ORN(UO1CY;_Y3R$F#-\Z]G'__JB,W9%X_$[G_[+.Q/^=L737<,;^]_YK#Y
M_7/FG7G+ ]><:&^>]ZBQW;QQR&<WW7#T\R=<7XC=_^Q+SSR3I=[5,Q<OUBEL
M\[*%EYWP94]XQH/^KU<=LV5^#KYJ^Z8+WUCQYK4K_W3?L U7;\G>USS#=L:6
M.?8M=ZW\IH6]]/6I\Y^*KN)779T]9LR&:Z]<MW+<1]_./$^9]OYU2X^:]J<;
MQYQU^VV'#XG,VVON[R^=?\*"A\;O, GS/[WIQ"WO7'MK\=*C#WO@BBN7GC-9
M1ZSKMCUV>->'_I7U91]LWWOMMW<_)_F[_/+A3WZU\,UMKQN-H\,?AV:]\]1$
M^Y+DLTO7OW/3WEM7M3WS3KSY==+^URW'?979=L6F':97SUO3.&/MR"DSJ<.F
M?@'?O.>"Q]];]<5A#]S5__ 'O[O26]A$SUCVV6&3QU\P_E3SZKVO'+SDZ"5)
M[S>_N8C[>%T%0RZZOAJ_?OHA]I?N;&S?<-5"Z(_K@,\\:7?_OZ'?G%JW8/&\
MM8FM^VV<?Z;GS=?V.+=^XDF;I',.%J8L,LW;[ZG[\\QUAZZP+2Q^VY]Y8)_1
ML3'9"6WZ\_.H]IW"YBO.O6)#].W%^O&M;3<>3QP4N]AZ1>\3M> <XAOGPX_Z
MUMWZ-GS1JY_=>\*0YA!J]N='AS[W/7O0$D1J''[QF>\N.>[]JY>M.>MU9.GB
MOR3^\O+F&Z@GM[[UUB+AW05+6WN$78<\G1?N$CZ+GI6[[Y.;%B2_/%$%&=$7
MSZ=_GB-M6;Y]^)D;UP='OF/_[=Q);X6WG['LB'IPSH0-%R*F@Q*3EXV?L.6(
M>5-6]6R%MBU^X( ['U[YVN('VQ^>]]0YSV?O])\^Z8_G/AK=87K7WMZV>MGZ
MYX=\T<K=EF$//?P>]+8=IE$KYB^V/[&]]UM*VVJ>38UZ>,EMCQ+V[?AQRW:8
MIKU7?NX3L/ZVD[:W?L'2-2OET:_M0VR[Z,2QZR=#&P>OO&O%Y*-7W'97IOS9
M\,,/6+SMVH<<V_<>]?A)RO4;+SSK]I5G/#!N-?9LX?-)\Z@7URB7+OT_[+P'
M5%/KMC:\%!4%%:6*"E&Z5)6JE-@0$!$! 0$A*B "0D1!6D@4!*0+2+$1 1&0
M$NF=T)L@G=!)Z)V$$@)I_W+O;^^[S][GG'ON]XW[W?O__QUCO0S>$7C76^9\
MYO/,-5>";O"*&$3YT)]/1@'-*I@&V% JN;$7^@@2<A;&V.ZN/:KCH6"Q!SJ?
M+/[VCNN:395,^'/)R:5F"L<AE<'8B[[TD8^>(Q>?K8A/8OF^X!PW(O8AY#'U
M;]$K\.,R8A]UW)?V8J?C3,DF90,:'!,SC7K>Y'!*2KH'ILY4T);\J5_[-5JR
MZ^3FR5#!5Y_H.B(?HG0F'B9AP\\<"2X.SLTROV$8[514!G_6OF[-ZI?\,G&_
MTE')T[X&P>8BL4%R5]S0+)4<\VB(AO2LU>'...7!D:XJD:$2IPEJU[5::MJ+
M>.HIS# 3\$<?<,7XH0^ZPMEGO]'1NAU+AGV[H9[/YUN]\\Y(ZS^IPS6BB5=A
M T:,0VC DG:]=XD\GR!VM:#+&!<O'1,P=^XXOR48Y.XK"@<J;HJB;GEHUF '
M!N#D,#?J(-FQ!6*+&AKC6IU:1.VCGU19H<+.,1IK6M9/9Z4ZI1C90ZGN!$NT
M\E4P]B#+4>K^W 87=O]/^_]'\X#3N&/)NAS]J'&NFB&S3.%0)E"Z>5B*HX[+
M:LI*F GL%NR:[H/>A[QZ75/V46'JPP94^JF6L"MDQ(CAB>$(PM C0@S&!FXQ
M@2ZS=1KG>'$(,%-4E(+2M^<B70V6P.#7Z 9_#V5%?)\5?!0->RL2YB?%XOOY
MR5[,K*HVEM';Y>1<Z(EZ&"0Z]&%I>$<#ZB@#L9@YV0,_6>2/:$YU.2JKU5J'
M/^BSL'VP6YI/MSMKZ4V>3+DN9^S\I>?G,+/P'5N8L"4J%CL&C43&W(G]SC=(
MWQRA)M5S&\ Z&E?_)JUER#M8HK9#%\8"TBHSD"^A*%<?P35X*!I$U$/+QBE*
MP#8?$XBXW8]J3(JD/=H[ZBWWO?<]_$5=N:9_\VG.QOL)(5=*6RR%*E"[W3NV
M?[#C:>Z<T_FKY6Q]YBV6)WG*T5&SI66B&6IP!EL8U9L)U%Z@9.OOHABNN?OF
M@[?KDA6"QYF7&&VNC7(+3RXVRC4-1$3,)F&#\Q;7>-Y/V(4WJ+; GEAR+L;1
M^#+LMHUKRL^\(-!R$TSC&CI\QS+19CH;3BNKUYI%>.91.8V+8YY4(QJBLUR*
MXZU@@L62U^<Y)B#;%_G:!IYA(\0$\A>&%*=BMI>8P*[/]!@L <W8D5WQU<+3
M2HR4ICOT?&%M</#Y]4/4XV>>S3[!0XJE9A'J!/>$!QW)BM0T[^YUF!UCU,N]
M8.SR).+.1$HM_^[K>N+4[80I1?IT0=QGW@J,S:;&^TX%"_W]LX5>SF@X3THX
M>J>%Q<5#-9<Y)8PU!9[?!+:-2R4P2T?J-9]D1:P],'SS>4K\64VPQ%>1?R;W
M_Z?]?ZM)?:3DX6\SQ&DR)/& Z4%AW'K91[7H3D3_6WF*<SO!DH?GHX-!AE[W
MN](H^VWUMF\;,Y<R'0V?O3&W)]N/0-KUZ*&#MNM]N,/YRKRK"H;";E>-?#F*
M3_0HKL?1>"Z3D=%XU))9!LRBQKH386-AEOM8PT 8O?Z*D639%OY=R+2M@,;S
MT=;MR:+;G0/PX _O-@K;.[-,HZ&]X<?:)6;X+?=W<Q![@^.2'8T7^%QI'0::
M/-."'7]*F.Z81^>(UP9I2#'ZK'9T&N^/;,ZH=7L,_+CW?&L5-1'YC>:X*80]
M!\6_@N;1XL[/!&F(PB[4C/9!%RVEOQ$FG3"J$9NWKGX*YXB?R,%TEC*^$>'B
ML5PB'E^#?^1_B*.8A)#*K/0@54Q >UDHX%[==Q;-496'$EC2]]&XX0]&B]T@
M<F+O0-$U__;DY#O*,6(P^@H]6N/PJ$?(K8?+<I];CUJAL8_>^3>H& Q+S+?U
M>T7MF&JT?GA/0I\G*"KT1/;0;-S&FFIN:Q%7_/TY_./'3],-TNIEAE!]&)L"
M+T$X"/E"]!("_0U2\("PYCO^<K?QO;=O-[X>&^CXD%[F1C[QDC7@KO[)(Z:3
M@HEI^ADP?3<WA2(^T[,*W;K"O)Z6X6;Q"3HB43KS>LZ(VY3T+-HC2N!7C^0Z
MTS#O#(=N_B_(X(J80R@VR>=?54%[P$QHJ$P<W6) AU0;WC@G"GXO8ZPM#&EV
M@#N@)D=<.%!C9EB;<:U"]WS>\K8FZMGYE#&SAR.^P9*ZCO9RLL(!1R9CS6Z+
MN"0MVXD_!P1T,,'7MB$I3AD:ODS UX'1@B5VH_/5T>2PHH\$^'ZG'C>G[_$S
MU?3>DD5$X_'PV5Q7%<S S413EN=2==B[^@//H -&9*]N5^]7K\&M;$C,TCX'
M??@8ZO8!':NX0T5%1'Z_L^)2+SV.@&4#J9;MF3!CAUZ94YN6R4S &5.?1R.0
MHL.90-\CQM-$*<+L*#=5 5T!I?K,HU?3QNZ"&G*=9?5FTG_YL]__:?^7&TLU
M%I\XENO%Z&4"P'+F(^O+XSY["QBADQ.(%X^)7'-"H<^.^7)581ID+NNC=2H3
M^N;YG9:S/C_\$JPI23K_X>PW-=^])_PZ@AG^&00(19*#QA4 ?_5D#*%#%$"_
MS1;R+.V+8:,-OA)P%F+)K/*9A"#V1Z!/,H'#).L7DM8$>L[SL'E-<Q>+%JD'
M9<7D^<+!]NVG57+<<[;&T-[%042^@VIW]""7=WUE9'2O^AN,C\@@K3/IP]5N
M7Z68^5,%M!J4\]\01C?('HU#"S!!#;&'#.X.F;:&E,P;0C<.-IEFM,SD"OG6
M;;/@@IN)<2\+] 4]HMJU.A_)%N@9W7RMZ>3HQ!]E%D\&O&VH@+X#'50KON[(
M&EYTKMR+]X:]?:,KC>:3)]W87Y[L:Y!>YNU4_G2"3WCEM,"E+)_&G<0'PM"&
M-+.O9^Q_6,%:L.7;S\S7H6=(6G6AXONFPE-Z<N3UC +=:5VP[X(58Z4%[E;-
M1"G\<AR1E2 62#@@@.IPU;VW]W6H8MW+V"@3R*B[=.-(1G92,.-'+6&N(^6H
M@G$R=Y2N350N3 3UOKC<^)&QY[@+YY,/0V_>CQ0N#ZW!0;>5LO[P:QA++"\/
MO)[W;GS\8=;24N?G6+/CDE>>V^1Q50'[HSSJQ98RCNJ5"?.-H^I&^/ SSPOT
MN3R"R>I0K:Z3\NU2&^MLR92W06Q?SSTX<;" DD>]R^@MQ2VYD)QGZH[&+E@J
MC9VV/__X48I_I8?@\C"?\\P7;@G!&!"1Q>EE#^CI-!]ZX*=A[026C@=0&X"'
MT?W!YEB<P#/\ZV"O4^*^=1QQ"UNZ]0<U/ M0BXO<V '\AN-2LQL38*.J;R[!
M5Z LY:?,]O#8\7^ #LYG<3&!N)L^:JER!0/>V+8G(%5OTI^]@,F!XB/&<M,I
M9:0H?0&'PL5M5E\;T\)1K.B/3U=GJS96 T34:X^4'=U2K:X\U*.&&A]1OMSE
M-+ABU"=KG5?@[]4L_,U8<#BR_2*L!)K'4:4.)3^D""=2H/JKD^==5;.7>1[#
M92VF8XW&8L7Y)R4,^DWG1[F(&'*"_4;+_'J:6>4/F"VB4GPV>I@&:?RAQJAM
M8@)YWW(+$,;C6>7WR%-3WJL8$UR-%VB)L+[&+0:H6('_O:;G?COR;;QD6K,(
M<3=P/G@-\@I:&%$#\P\3\=JL@[/V#U^N'6("#IHR-60F<,L?O8Z!D-QIO&@R
MBEBK73@JVNO6&'$B*R#"I9D?SV^BJ'[>SR^R3<.DWM7'4A,AG EJBBKH/B>Q
M(6L"_!5?\+[]*X[V;.A+V+E=']9Z]J.D(917IM78]1LT/2;PH@/EKV$B:X,,
M,( EH$B','ZHV8^4]TR Y1-X=GE?P+%JK';$H8;46"?VG@E+N-[7M;SP82I.
MH )U<$;JH WR12>,<Q9*M!KS+<W[.F*/U.C:WHD[ZE26U@[;>)I3M?V@C GL
M0U7?@]JU\ZJY,(&:)X,V7=:;[MN6PZI/PS%3\0W[&D<7O9]J24'.:KQ/*M^L
MPA:DUC"!H,R@3XA+1.<,^8E#%S.J[&:^6(^4(X4+O#B_N35-"@;V?;[W]Q+5
MOS?/B,;V(2E"W&(]*\VD4JYK_7V2LFAPWAVKIKU-0GMK=?P:6V_)J6LBBB;D
M*"JL!&2D1^?#2F[2E]RT?OEKL>3(;QMWFMKF>DVQJ8HM_9803P,8VDN?=EP8
M?PIC#"]GG6#W1HU[B!6];52/>;MCA79Y&X=%[ %A)87&1?^$^933C; \&)%Q
MYU#ZO:R&1R+/U'DLL:Z+7DZFXE"#Z)B0MY#+(,43_@^G!ZLI<:3+M6.L:GR>
MXW+<#F1SP9#4[+GE9;2#W">!@8@+7]G/X'=ZI&N<I%WHTN#Q.&9,$JOP%D0G
MSQ:VN[F[B&MW7M47:)X%?J:R%"FF5$_D2*4(O1 IH>?CJ5@?\7)]R\S5\@AT
M>2EY<I\-2\#;0.GA"=6KW&QI#9,M)AH8>AH67^G>/3ILC]Z'@!ZH^!KE9]&7
M/"9=3I_-JMZAQ;_G4IU?RRG,Z_*?/.X898ZT<R-;KE*"4CKRMLBI6^[&.[_9
M0L;M1H*5S)JWP9JWR?PI_C7Y;A2AH/(LJM.<\I8)^.MM,@&!9,8QBPEQ.@\F
M"$VY-88B#:[)O1^,>#_X\75V.VBS 7V49B:@Z3ANQ^!1'J,]BZ XP4/1ZR:5
M8BB"D0\3:'1LK80[:, =I'T7U\?^_.'#OPY0_GV:G#Q-3FJ2_9_A_WL-7SD/
MNA0OPH/46#\6(GB^B&072C,=#_%6%]MW(L2D=UG.D%7^;FZ0@&^42M,,SU;D
MFK?I+(QVK),)B,:-B]-?.#&!=<^TCYDJ14\W'((E,@_XIB^4JB%/=LI)B\4N
M'\'<\Q#4M0@L2CC=<O&4T*'96K6SKR]6[SIL*O&)HVYE*'=E8G/1F%2Y4%LT
MQEMYRG+6O2P[7UV;\H[JM%'HQ35MW7;=WVWQ,7+AE,89)G @BQ3-",;5M=,D
MX5C*$G*$,8C.%?.G/J!Q5A(K,X4+>H3;?D2F+;:^<^N 2'F]@9<NC.C?YXZH
MC@B!L&V,^<(.%Z#8/*(:]*#F'<M'!^=Y)VV>\.M?O6K(?_MQ2U7X :<];]]D
MA^?]V3>@?W$?S-FMBK2MB@Q=(>?_\R-SF'Y!]:(](HYL#UL@3$BT*+F+;EG#
ME@TH/&>>W)R5WB^>;&##9S<$8X'BRZ"\&A#+6HY0&5>XH/W7"Z^_L_5;3=#?
MWML)I<Z+B>.RD"'(IC&B@5P ME S=XCB?LL'6J<CN)4OHRVM_!7XKG"7,S=M
MYHW("]_J)[N1K+317KLK.#F$?*;Y_%&WD39_^IL0Q8KZ\H!S=]W.[<\LEKRX
M?"X]1J'A<R==U@!V  Q6DEA\^@&JKA;?<X2W"YPC/.L>&$I\R$JRV*.G9"+#
M,LZ_B-K#$OIZ3Y?4\K7JC(=.Q:"N?OZ/TP;E&>0&>J8K1_\$/C9QO.UA5GU5
M6V5<:N"06*KKQ5.'U @>TFU^!1=5Q('G'C,T'FL&VV&^Q3!B$\6]UMV@J [*
M=>&[?7Z D^#PE/E2X&;IJVK\-YFF2QR33("F5-2@ORT%XX(2TRN9P$1!*\*&
M4HVA>5'>9E"*ZG!9/EF.1F]3HX_<6DSSHQC<VFTL /"T@AO2>>1SJ*W8?^A@
M,TY:)KS_BX%"B(-C_-#9+,1U,"I_H3*!<-Q;Q&@/>)GM'IC#_N73SK^,X!G7
MMJ35MJ3Y^N\-;]Z!=8P(UY#H6UP?41X/K-==NGSSK4Q6%IXD0VU6"Z\VYKGR
M5EH'V-'S;A6$=JPQ%!\*(=X@X)UXN\<WPZ2AXV[IE[&USXQ2E926H1-++YA
M;-2I+?5#,U$3CUJ:[[B4::317S)V4O+P6M7LM]7<QU<X/6H;S N'*FXXF9HF
M,%1YA:<* UN?L:4=Y(];*=372_3Y$BSUH?_W?- $=.@R@UT1#QNH-2@G,H&7
M^(C&!,D":^[Q?;2*\S477YOH/->P3I^/]%4Y41H9O JA2$-IW UKM8.QR<3
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MG]\88Y](6=8K,81_+GJC+DJ26Q$KBB3I<1O VE+)=_]8G+P-*M1=7G0,EO
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M.%*/W0.7(I ^.Y8)BE<[:E+%D>UYI?)"[%IQ?0'5>S"B -8/OW&O>#56^K.
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M]OS[OW.JX8YZ>B]XQ1%R"((WZ\6LQ9C3/8#=H /^JCW[ICPJ$$4Z,P_;TI5
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MU"FR!;ASVPQWL\L3T,E)%[LC\.8U)X+.O\Y]&G0J[8>_MT/__]5.Q[;-:&6
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M=2 [C\8O<V,ZG&HDBFQF:D4(<I*G/\[?$H@VI?1^&W:PGI/RWU1:BJ!,:CQ
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M%"%S29=C(;I3[.;P6<#UX#KYJQ-B_QL&_O]G&/C'$D-L.')W<?@PW[A(R;B
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MW@H-1S V/>ZO2^-XV!57#-H[Q4!.$2.1#[=KY?>X11=K:"HH+HI>+OWBGN/
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M'(;(AJ(92U%+()3"<'( E)[#33='T89@[PSU.X]]TYIV_MGS4NG'>QB@[";
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M5(%TN3=L=23HDZK0MA2,$-'A&:3X/7C8U)9."NH?:>,K61 8B)4>3=W:/\L
M37"3Y!UHH2'1[\DQ>;[)!K:8DQ(GJ)N6+V16EH).H;]Q4#Y]'U2GW*#OW:!8
M ERG@/Q"M,'WP<(]_XFLAKE(;:Q$^B9H%\GL\7[ZUCO5U:,T3?1,TO"TKE+@
M]'.M(-O7R@^$N.[>_G@L[)D)?KO:@E0<3LHGLSM[^$@CZXW&::6*G^!,0OZ;
MDB Z/F@?7H&9Z;'XEFY=K12I.$DK*+:&K])Q/>RG4EXA<N><P/ARWT+^J0\M
M7Q/TL[=+>;=TQY%C.O-3G7  >S92-Z_\QV<X_^KU@ $ZK+K/6VF2-7:(:C(.
M8R>'2509VBO"34Y"1B73LC9V';+0X-RQ FF"D$]X?4 %/M61I8F:$_S;J<UZ
MX.N^Z9B%-Q.&3$,7B7/]M:[D9 #9UAR.I.C N8D<>K7SUT?,"Q[=J7W<?B@*
M CMC,B_'=?-3DB'B,-P$(,WZ5&^RSK2.*^[&XH//RA.3ZA%R( 9(>U)$G_P6
MO6. >C[3V\ PLL6PH+K'^?:$[J/,H[P&\[D[P-%(7;F 2=3S) %RXCO?@,;X
M/<$3^U61KEEF6AY@"/YCFM'I\"S5S@+JR$\10(H-,8"^MXH@,_'J0>OME'E+
MUMHHT<XN*3,#K_M-4G$\@FTY$5]=M%J1@'>*>VQYCE#9Z8&#<,[23Y?=+!S"
M)O<LLZ=DM3>VC,8Q=Q<;'5(.(?^T)?D#DU+XR4G,T((Q!1RJ+)[G[6G\(*+5
MP^D21\1 ^ZM[YQ4%]0/SQ:=)V9<"_@&7B@V-@S75J.,4FB&LY!;=>]RU KTG
MJHU8RSX;.2=)(ROG*MB+CM*#JL4F'D'XO&_H]1</^3<GY@PW/7(X-7?F^C%W
MYR93<#,F'ITPC'$!OBP,>X1O(@//-VX8#U5<K5_I3+XZ-'O<MXO]OIJP$*'S
M85O*O!VT8)V+4]\T_@_EY@\N<&?GK^2)K ,\[!28FC33!*/PHC%K#B8O@>WI
M$PC[68OEW^GYL3U:Z!=M]*H!=Q=PND34"3GTIF P[7 )GNNCL\!V-//V'PR^
M_\WKINCB2<I%\B.2!1F2X]W>6"9H$98@>,+?=)]SQK%-%TUVDP=G\3M$08<5
M:8\L"@FU+WRR[$VNF<YMP:7<W%R5GH7M_7+$YI[R;M!AG5EQP@R=Q8+B/48?
M1O+$N6^*E!&D NYZR][0W(33.SV.T:FO>9B71+BS[O3QC$:)F:Z@AF&D("+[
MHCXQRIB8\4($^RA+=="Q+SSJME/%"B[$\Q+S?&,1?]%A;ZF_HO\!]3]]$G2]
ME>/BB)D9VY=!(?Y#+Y$'U:@.\Q#R22R>R8-B#3>A=_<?CP<'T'GCP(8)NY'%
M)\=C/LNOWWXZY=NK$BR": 'TM@99)Y]7*TH&P=4);%&LF,!J\;OOL7.EKKN.
M1C^[O/-UE_?J<;4/3!(\P])&G"V*5YL>5-VDOOINB_]@C(*_8X;0T_.[//\2
M*AYB)PM#J)RRB.ZQG;"=Y$**5[BRPGWEN&EGU(UBRUUQ=+&7MR">/(@'9(HQ
M)@'Z''NH!/W,4OG'UN2;Q1T.&N4_MB;OX MK=#^MJ2[VT5J8_ZD&@DBOQY9>
M#:;84P^7$+G"H^SRS!9+^M?ZG.Y+ND8]]CF+.1/Z65/32_PO ]Z&3WT_X.W?
MY&#09!@@/_<M.,"ZRZ7H4^*K,M,D= ^$K #-:):B/ 4H]L64C'I#+\B5S)2@
M&?D_9)?_)<?_"G)L*49YA.@]BVC#%O6GY];).DRPZBHB@GD;.![,(WV*UTU[
MN54*N:!C7(L>9"P U3*T;,SX.Z3MC=?%"^$*]6.<V R[1WQGO\HO8V^R;\VV
M@52Z.&H=<'#-"33^RCN#- ;HD<%H@#O FD?-MT8JMEK\X"SDA,#C5ZN= U+M
M>O'="#QD<2,=$ZVSINI561FS-:_S+E+G75QPJU#!O8@7K<)).J(U6AI<U#NC
MZS9;%W*C7W[709L,<(!FP6.%W>Y5.LLE$C^=2^GJ*(==S,Y<TCF1.3 /H1[.
M(3$S0/X*;^N('$W]]K7B?<F?X^RDX<,:56CL,=I0VG6UI4S7OM?LV3@Z5^/,
MX/JSU+0C1;':+=2Q5@^$3A&.JC[Y"<QB?;UE0F4^_+++PGE$Q(W6-4M'T07(
M>U&\R6W*,;C$H:\^W$E2_=$B_5*&=X_S!WMWPB2D?>@B[:[UZ%I]#:2=M<\]
ML%1] _.S\#/'<F/G*:7KSCF0CC>KBLWWR/-Q8:KP=7NELDWA2N%BW12=[4#\
MDRE_+5=G@:G#ZK(.9Z2SM+0LVN:]C_GU@B]'!NV03^PB;X?H#M(BTVBO$$I?
MS8<N AH;M$!!%]N=/R$K.E,F2NDZRU0Q>"U)!\V$'ND<\2+=**+E(G;9JX*M
M@U3L!V@RFI4(Y>!T9A!JZ=Q)OJ&B/@V$R,+#DS//UQ-JE*Z5Q7_>:K8I*W]J
M-"(L??QT6T/!KD/A]G^MZKS^M(2E[!4<94JM])$;0LVBGB8=ESS9RG7&$/TB
MV;:S.G8(1:N.1FU$#<D: 21SU8UT[:\6YQ8MD &RU^T<4IHL39S8;9?>Y83Y
M4I)P=Z:SY([T!?K600'? 0&>F9;9_$\8,&SWB__%WGO'-=5E;</!!HJ**!TD
M*DTI@@(B-2@B($(4I9>H2.\@'1(%*5(5%!2$*+U'I(0>Z0A"I'<(A%X32@B0
M\H7;F7GNN<L\<\_[S#SSOM_\L?\X/TX.Y^RU]EK7VFNM:P>+']VV.I0 M=M8
MJ<AG EUIQ0W&'2G8S\EKZWX.*S!%6^U(\).E3C*#M<\H_,437RTU<%GP6A.%
MI0R9+#C*TUEV-"_-_<"):UNY;W#B).9,0@UEM%.0"$:8.E9U]ZY4@?@C8Z5X
MBDOK%;OC[Y*[R/N.["Z@RJY"0L];&3HH^ .+\P5(GXT1\=KSF3U4P*6KV.<N
M"M+O^UH+Y=8JFR#M]+BO/OD_=7>RW(4H^[W\OZF7X7?&>6)L/9=3Q!/-2!F#
M[B5WTROS'F [[WWH VUS+5]RF;(0M.^PBR:>A0=0!(U'%L:/.K+7RLT?I **
M,JP2-2OM9_?+>C$IZKL>!9QP1U1E9:3UU=K!.\2;X,\HPN1D/YCG!)S#>LOH
M8J'5US#=UF_/7_)'-K?Q6]$?30L,'.%QA?]T;F-I_)+=!'Q8;4*@.60SZU%I
M;WYO>N>F1;2D33P')FJ9^P'][8F0U(,/B>)XE8F"0ISG)&_1A#^T9W"1Z]CP
MX*AJ#_V]B,!1]5KZCP>XQBZ71Z2:,_X,:.3R_VW?I47S7=X*UOWP8Q0!KR<M
M'C85;Y)30L&<96'J ]&D0R84UFV+O3V_:!)W6Y8"C+6&WRB@QF1(*RW-4T#0
M&;0AN1T6!C]\=X1\GR:!]P/_"$_RSP<%"ONM.AK$[W3<%60MN?V=N)UICOW7
M&!1+,R;@\>W+P" (0=2 !@K>(!X4J'CM->_L_Z/*]&,@(D"8 A#NSBK18IP6
M*=6Q3\A_J5'"BY6/2CFL6Y=&OI'TO44\![K-CCW"F>[Y8&![D<*XUSEY@@IX
M/FY8001AVK#DR(Q6]H;X3RAVY!%7,9:HPJ8O[)3UIU<9/*&>M$53L"Q9),EF
M*<O_/F;O?-WY"/N\!Z-_56;T^PSN>ZZTDPJP$!^,;0"6-#<EB=?6\$;D(=4Z
MJBLM1MF2;-.\8U&?IP"7922%HPSTF29 1VS-Y/!*\%1K@CY77&Z.B4!^>AYC
MA<:T*ZNN6C:__DHFZ50N@:<;]<@IH'.@I73+3*)_GXE=_WR+-T#^@0H5H) Z
MHDS!BXXX?GG1VI+5-)OEMX_(/D$%#%9.*$5C5H\.A3N(JX<\>$3_SNWL],S+
MZ*J50?Y=S , O84J:X<]]/I/F4E,4C-&+3R#^ ZS>[KF6'\!:-+*[@BI0AJ+
M' /X#U@(1;5.(>A>ZM?MK:A;2E=P9O%X]CJCN,#\096L>:[&RB'3X=N78V]B
MCS+-]K@R\;$2:6I_\! Y=!,R$(\U&=+TWDIFZVT;F9,+C][$S;Y]O[%NWG)4
M/B#_*0==B>P32]?H>[64G]?[?/N;BVH3-8 @5/;#S$&1I4H7NF['R_F]+>W=
M6-XU[W'0:+NP=!JZ)F.Y/TN4*>:'%43NWU$A@O'W5(BCN$4UO'[PJGF/E*GK
MJ*-#AMEQIH,&,,;<?7F9;RS.K(FD(!K'B?S-)!8:<K.@657<"Z\47'3(F&#9
M/@U^IWC5"OOSY;RO/M$]YGUF3%1W&F)(-\0:\ED\<>8TU%;9_SW09"WR7;&%
M2\]OE5S]!AA>W A R=#BTDG@]BDE-BJ@?R:5"OA@W*OF:E&X[?Y799NA?[/E
MXQ?[Z?HS5C0,FP'#.<+!$9 MFD4="5(%/\]:@;[;Z]&R_Z-%><ZH$GI2(K@!
MO,OF+DX6B$,ET; E*@7U&\C96$<RZ^>I/5O+WZ\)\G'Z#2B,2H8-9%+ ?!/B
MY"@C$"5>!?*]\>&?&A$-X_[;[H-?(F%$1NXO=Z!T3W\'!L-_]B)/WD_\3<;&
M7Q2YE$?_*A__^BDEFA9]3,O]NB1'N#0[>]@ZP:)Q>0HW-#C8T(V6RF.[>O?F
MC*704\"!&/\+MS1$JL,B3."BGDHVM- R"]H+P:&!1:2*F_&NC_"@R -Q;$'<
M)XV&L:<ZF.Y<_Z2J<*)KG](\HD5X$SUL18@OHP%IZ].0AL1TTW-\!#%>>DR]
M]?.EEJ4.#8_3[UKF#GJ?AK%[A32*R[>GZR62>Q0'?,2FJ0 G17_1"N"\T'.%
M(V7F(?/?\_+-$*A[*$DC-<J(D0=*TCB(AD*.0--^S"M$!5:K"'O$C1Y:G+1*
MRN(G4 Y_G]+O=8P7=C3.&6H:'W>:Y%LIT':]#U2[T(J7C;O((<KOG2GS&*4_
M*#8\%\VGA'8VO+(OP^(M..Z-M <5P!^O-_;"W;&Y %9['O8 1C0T:D0VC+,/
M!N-6DB[(B;W^^J8G4R50<I_$H\AG -BIP$%UI^Z<S(]SI5#.3@>I9:4^1A%N
M!IVQH3&6PSS,'XYDY5P] @ P7=,7V04_]X(<>XGA"_R8AWQ?T6I*9OOZQ,S3
MB=2'WQ]56*6;T";1:',P_2I$72UEW<E;"?&5/^Q\2LT'HO-_!;)HHBARZ1DY
M,*\1;WZMI#'YPU<[1#/7 Q40(VOM_B)<A-=V@/M%NXVH0I(GQE]\$A+H#F9:
MU,OV3K=C0]NX,\)X'"6<?9E[F%O.,+<@WDVN<*<G6\1^Z>DRIBU.T3AT=^J:
M_:X3DU<W<]WVJ&C'FQ$H9_/V!XK 8A]H3/,CB=QI]F)7!XJ6RURJQB/T<5'I
M-;I%L"M-<P6=OK8-VSK161QGK([F239ZC\).8"7>.)?,!O^\+?,S"0H\'9P9
M4??U5M*-=+92F]P,F@S=DO[,AG((]4S!)<=/"I\</WF,;3YOTY1W^N*R)03S
M1);S=.W<-4S M19!E#/, C'$KDG.4CH\1[G8[7&S_\4TQ"AXQ+[@-=,5O@VA
M,\DYK;[]$XK^--]Z $E&H"82*5<NAN29>D.9\<]?V'F8UFB*1"R'80<>+[M]
M&1J4'1#9%&>\6K_+=WFGX)Q>JM%70D3--Y3:U H!= S?73^^&2*X0S@ITS#1
M_=JAZF/5QQE*CU^WYJ35XC1-^_K5MM?^_1?ZWS%0YV 8%)!1K$ID5Y/HU,C6
MF>8PV<[=5M%L:%7JGX@F?_;2GS\-K=2?CB?QR$^^=:2<\[O4R1J_S 5-\O=;
M?/:RJ.W(A<VI8>24_\+\7NN.[,^]YMQ_<RJ ,@@S1E9,(W^H<G<O]U"9F J-
MFJK^]A@V1[_.NDT%[#'3,I&X*VG8 =0(8=ET0.$7;3*-]KFAWVX=5S[-M/-Q
MY;*BU@W*'C7MBW^$FO9?2_0 _"Y..K5%N1TRH4\.9P/M"-@-B#3OG<'YRV*0
M8/P>JC[TQVO53:B 1G 8%[#6*:0"&>:GX<^;E#)7NNSB+D^XVWG?W?+1]9PH
MC3/'B^EF84CVY? 4:"/\0 %)(\M;WZ>ZPZ'85*J4^TXYWU.7EDBE=>3#+]OO
MKI&XB7"\I#'Q*WZ_'EXM=#6]IZ3:=:+ <85_8<D+<#PL!Z![MRX+\  @T@ER
M9!H^94(NKI$Q\TK467=XDN@W;%UA8U\ MSVNK!@1N954B02ZWV?BI0'2%.;/
MEUX7_-SS&OX=? 3Z(W"<&IPH%$*28HK $B.QC$#)6B7>,BI N20)Y)EO=G:%
M:2Q8LLW#DLZ;KE%(1"2@9X>/PM!/,P@X*B!(?B)42=BKJ=XJK*0-1HP9TH8K
MQ5ICWQD *Z5RH#DA/.P60+].53<93[>/(C]1I%;5$RK)<5),P_LQ&>D8LKL>
M6^+6CC].N<L&>>OXU]CUL\$WIRTY.=M]_&F:,TER(HI/,@TN3L858J@ %L-$
M17/5MXW"43JZ"FFAL!>GU2T4:X&WIO=",.2>4X75@AZ2/U%H&,O!F@V':! _
M6M>>6;HO28<NSD[-R2_NNM=Q=8P\,_&=K\651&_IZH;+PR/&E6JB.F?U(Y_5
MZC"="6 XL\90$-HZ<SDR].>K[K/*WTIE('K@Q'-;))8;1#BXB"B/U5Q:8+O[
M!M>^L>;F=C*"'/F"PL^Y1K[O@+4-W'98][V_<Q/A/D$VZJ,TS?C*#W/&3(Y-
M'C[J6GON1.M"_9L'RF>BKJ6?'S6P&:#$9R'>TK3Y[3BR';&<BHM>&BK^I((=
M/];TRHYM81]CXQS2!;$%(3Z=@/ !6-'=;]H*R_ZWV?;^BO?Z[KT)87EXQOW?
M/(3QOQG_87[[GV)^0X2!,)]!)?HDD>A@MO'C3\(C*YK#4]?=3X;,(#\=B,SL
M;G?6!XU&*?N$[6Q-"D4_006-'>JM4LTW\4_4['1X7%4>F\WP- :PTOQA?XSZ
MZ44<FA!,',Z!=D(X2M <MHUQ6/TR<1;Y+;$TONDH <(-@.]+L([=&H2-F+LK
M([H31&];LE+5H]2]31+I';X/I0(VH!CP\OO577U6[N]UQ9M#NDIU5  2*C23
MDAPQ:9T21M$"U5S_R9F*&'])/M1;(^C5K/7]B;QLR3%CO22'90<L4"H*IDS/
M'_L%$*-\H+<[4SCF3D"EXU>Q85]^*Z/B"]=Z<WK,68:=;L3TENX(]"8Y+=7O
MRMBA2F0:*YF.S-E-;S>W5U?1 G6X(\.XB _V#-VK\E >*SY"$2:^UI^> "7:
M9'C=JX_;(YP9( 2,+U[D65MK@;T86 -C) #[@_=V)!\?$R$H$35X7S'%>D\>
MTW1H*LG*67>7H&=(6Y]6BV%QZ4T$%"(L$8OCQXALLKRG%CG>^*FJKL+<8<*D
MJ9UJ:0U)TA8^L?$"_B9HX>T%Z< 4<B]2H=3-#A?F*_;$U9KFJL@2I%]EVK=]
M*4=>[9ZE NK5_4XZV*F5KBL88HA3%<4,*,7E&DEI5/F7D=38<F>E;43++4J(
MR)H:Y0AR]PSM?A#)D@IXGKI7 GX!>\'LR7T3-7/OK?20[R)NYXY?%?WP4&1[
MM<F,J<*0P.JA>W(W59Q<0@4,UUAM]G?6-XC(U)7->[YAHVRKK+^'+:_R^Z72
MD,%Z.=GOYZX26DJS!A= =JM$:Z9 $"Y\4<;,*ER!\^0U/GF_K3Z8QX7J09?I
M\JDIOE/QB-Q%G"_!GKB9"VV'<$I!V.=%VP63+EYTV'KH)#;\XJ&3I0EF/?C(
MJ#)B!!2,8GX"#X?2=?EI?AS)'XO--\[O+0[DK*6P<4Z\GE9?^A+52W::T*<9
M(#N+\7L-MS:STN#>:M9MO?:DI;%9&N+!-H>@!CB;"5''K]0_,K8=ON[;JJ1!
MNKM6 3E<O==^F8F9^+=NN12!$Q/Q^O6P0U5\+@BO7./N)\=X^\D6O4MU4F@+
MSNFW!-T#L=^YUFGB4B.TX=!+]W#)8&8[U'Q"4#>'5)+@A>O@[&^77A[NZ#$)
M6 U@8:ZUU'5J  ^%$(KPB&5W_"$MWR:NQ!$'4=&\<P*B&P-HG"JOL[Q%E.&G
MRUKWS5TM1( ?(<7T)/;=>BA/95DAT6E"'G%2X7'.0D)Q<$=OM*6Z\N4*."%"
M;:C&%@\BL;-C.U"^,T,+O)S?L5^5M.*BH@+Q;UO&\_V>_31)>JT,Z'=P0VL8
MSEA\:+]&V8L5!=64A7!>&8&.<,=<H?[6^Z!7I^W&H PT&=3V7U_CAH6.'41:
M<TQJKC+=;NG<H +BO=^NK%(!8FK:[_';V3\FOR7P';Q3?(F\J^/%1$BAF:?,
M9R15\WPU#J U4L>\HDBH^-.GXTE?^!]@,*_:?0["KJ".4P2\ B>$PAW<T4?M
MN*("\PS?-WI:7 I6I<]J6<C\>.^EV@$N,@LY!H:IUF+QJ  UG19(4Q B\<O=
MYA,B9R\'TY=;HQAV^UPS=M@YMT!:607@":9F,#W)']>ZR'L,S_MF4DRQL'Q9
M\"@NEG3Y;'W3^%(9_5!%Z[=/OTZJVE4T1'RKU;VI(?3T/!TR_N5\7\R(B2;/
M%=S'& W^!]E<SV(T% #TLM)$3IH",9,SV D%Y#P%C4E?0RZMDZ/]MSMIDE=Z
M.:T;0G[R: VSL>XR5$/3I8!B6.W]/))%NBV0$<JY<'T6#'='A4I7>I)'N_")
M=I[T,RHMKW8DMF_>+P0E_M2/IWA[]N*SG^FS7L;#OQE$+4:3N'<Q-SMAEDYL
M=FN"_?T*R@[=?*N-3@>\0%LCGYF^4$"O: ^&;N]5S]:<DJF-'@B9F(F6@NJ.
M[#SH6;D?_5;C2;NSBF_62W'2H:+L0N>1+>'S*9^D_[$-XY]QQ,/AOU%ZL4@%
M_$:_:8X\S\\CQ7N_WV:X?Y.)8$:;U@&2"%%H5XXH4B>'"*&<,;$UX^Y<WMC-
M=A"U'Z*/D3K2R&@JPMJ"%6;Z5+!..0?8HUJ_CFY D]@-J( U4^@/RL->WG;6
M#C0-0A-#]V/&R8R@4R"<J3D-CSR!-2@##]'\NR&1!JT"%H$4343+CT@HODAE
MUHKV%:0;=#@G2A#\!9QXD1;;3%6 )L\P!<(V1$E[I,[N-,PBT#_U)ZQ3=.V/
M_I=HR\ D.((*P)^@KT7ML$$%89@*6C@5,T<%A#Y5.D8%?"_"2]+TL ]$BH>\
M_&'<>-OIY4&T4.Y7[]%)!3 #_&@F]*/5I!6%,0^V?1%UY@><5DPX[@%%40&_
M>I'4WYVT'E\IGB4R[#=>1.U7<T+Z4R<IP5IV<(<*^/5[1/]R3MRW_Z3@2]_=
MBC:I@%^_AJ_0D@/M'Y[%@99K)QVL;N&2WTQ6*V%52C3+A_5*D4&G.4N?9LBF
M\<_V'!?9H_Q&?$<195(IFN(-X-U]P[2/7+]WGC^$4QZ>2T/#CZU_[CFO&.HQ
M#&EPWCW!9FG^](,[?S\61&*MI!QA&R\1:I#$C!\9NT2$320&* P,3_>M] M;
M*14*G;LT+DI:N8-2@=5:PS I0%R0C0R$9J?](\WOA#N]<'H(M?_P\)5U&JQ-
M@R5@EG@G:*I\>-MT#R5C>]]UF/Z]W8M_N2A(Q2!KVWVQM&CX&+!.B;/(;M3<
MZ+W*$:9*CH4N60J+ZL&WA"/6^[NH@ ? @4P]<BGTRK64QME!HIWFL'O!PGD0
MMN\HGNM4<^+9@_?=.A,/7$",HNF([!I$"TR[>/W.L0@YQ^C4X?3\]&(5QJ.V
M$O39BE]E^6.T-03+0 -;A'O?0>:H !_/YT^D#3,@&Y':I(Q!:9$,@$+^W-4C
MN;$ENFH*L0NZ[;\^[6>OTZ+6AA9")7,'S38Y'1QPVR+I6NR#3:UED=*;:882
M?1/1+1Q,:#VMTVKG&_JH#%EV,\H@3?FK,'- 'M.!$\[7,(&ZG(8C6B84ZQ^J
MN]-,.4(+.@[L)M+PWP=I---P*Q7 Y >6YSX$^-0U*VM9[#8?\?;K]$OFKS>%
MIE83ARK.K3S8^#NW,TXCEO#XK090D5#C*+#)C+-L35I,T*38 2ZXQM?P4ET^
MM>#:RE6^HW3 ZO'/5,"RT,3J4#UF+!XK?ER3$NU7>='!]%DBN.R.0@L_%6"C
ML=CY3(^'&=(QV[X,H06 M5=!CODJ!"$B^G1C&]@=4^T=,VY:J*VN[(R\%+T]
MSZO1C+]@@3T;+]NT,'U3#^29E</+@5>"8\''#19VM*:X@N.SO\3K(26NS,V^
M^&)AH?3\A"WYP5\E&5BW:6N:_@05T/(.AZ2@I('D?6,H]=_@J;GO*6@,C(?\
M?,_N[=],8$-H!J;V_!X]@-(Q<A!J0I&&9I%:^"NI5,!A, $V"/HLADELVP4-
M(5?7+:,YU[LY.IP'FPY!E7]4VDG['TJ*_F.F,'4PI?Q_S'@ ?VE0%]?^M+(&
M/_S'K/\C9GWW @9$O!A?!PZ%7NWT UE,C(=VFMG%XVP(JXI!"0V?-<\UI;=4
M\)\7E7RJ+<_[AA )DX-_WB*]1]2C=CF+Q\G"8:B4B@X7S4=8$5I4?^?/YV3_
MTV@O^TATQ" [7#P6%>"G[WMTZPJ4HS_/W68BD->^L-:%)R\WYM#DB6<QA\"V
M9!!M,@*5:'#O>SP6L3M#$W54_Q3\)]GK3"9/7Y NW!FDR>"0'VVF/HHW0[;:
M::(]39OBHWMD_-<A4:C51 A%'A+SHZE0W)(&C_/A^!-6]:"=DR1W*L!OB*8*
M0S0-0P?#-@2(BY1M6K"'+=D6^HL62VX6_?)Q-'%PXM"4YZC3L/$K*)('BI_R
M9YE;0DMA#=?@1VDBU\3WD]?MJ(!FZ]__")H"?T/WH8FADA-P\F&H'!50XP C
M+@-_]8:DV+_(^]T?^F2:[DJ"C'_Y@<6_>DF[-?"?5^&,U6K(DLJNKY<38;Z+
MI.H^,0HT[NRN=ZUEP=YEMKQWWO7*MN.H0M%[;!;"_:?-,QE?R@UT&&1S.Q,V
MQ\ZZ<\W@J^% G_S>F>L2_W[-P29JR\SXRMOD).BQQ3&)7N?O-FS3DX$>?97O
M:@P^WEM8N6_U?A]8V>ZHGF R;T1NGU]AF .R4\QX-^H][_%2<>:C%[DNWDN\
M&V9<.AICED=,I#""=W6G!DA"G04U*^UJD$M(TA%&MYU;7W8:_%6AWGWH!G%>
M6SB+@DNN5[A1F8Q108F[P&A/V1<KM]AG@VK*<@# LD$O2;&Q2E5?OEW8?,%^
M-*52U1ZE/S-(2?:"U;%XV?&EOM$I>JT[TS^42(2G;T!&-9[L\:O;[^YUL=)U
M-G6W9(5]^^:<<TA#*0!EL+=%"OKTB-*A=!S"[I70RQ0E/7=H(,GUB9WE;"MO
M#/(@^NZ6[R4G'IHUTJ1\&1_J9X.Q5ID_SK<[O*X@:RYGU>%"!8A'91+U*8:!
M/222PW78S=P=E3I'.L+=*.^W:F.P^O Y^##4:8E@M*E'D<;O-CKE:?N)OP:/
MA)?8B!?WDRK!GV% SY6EI-;S*2@_T.OKOY46*@,-@3%78G=OD;CZJL[F"N?Y
MO#8L+1N.*RHS>_3.O[?PI5RVQ9R6YVM])1%&S5,W#7SP,Q&Q6DK9<YV]SYKU
M:R?/AM=K-*5QO38:E5J!?X6C:786'N*#K ,#;<>X^\42NO4Z'8WZ9I1<RGTN
M)R_4'\VL>.G;=QH:3U.\Q[#'0.)M/Q'V1K%#_1[9'QO$-ENPVHYB]"/OL;DW
MM _/3CUL8>Z?"8*=Q,<?[6U9E\5DYGD&KK(CV^U)W7.PC&0>?/[Q\U\O6-Y?
MRL3UA.U*&B/4TE*G^G_*'PO[?__+9O,H''>3"AC>3Z&! -:O.*19Q7"&G2OG
MABR_H]@*6IQ>D>W.Y=1=3,0I 3\A/:EJG5F5GN55^]F$OK4.W>3#*8\01\-4
M1"[P!# <X&W0KZZ7)?LE7LJ,_D@PR]U.V0+W.@P.;BCI1WJ!&1O>*=IGLA;W
M5UXL3" ^KN8E]_9]HP2=1["0 V&VE; A-$8ZJHBO(?E<MXMYOG(9]T46IC&Z
M07Z.AP.GVSJZS?HA([*.#U5.!P5+'ET]G-:]!LL9+(B@ B36(S)9WV!SI@<&
MUGHRA3C%I8<K?#-[#6G?:9J9\&^7E2Q4XB.I=%).$D_IX85"Q5.ZBTW9!E<*
M5OCGN<XOR<4I %)CU/?S/S-VW]ZC@$\CU\ FG(D3%%:BWI9G$$G&I=*@+(AB
MJKU]F-=,S6!"EC=24/MX@_3=R(%T$;Z9Z&$[ K(/9(^.&@H)VP1>Z=<";Y@"
MP9:M\X0PC1O8@.68#M\BWEKEM?^JSF<+IOL[XVG(%RK@A/1X,/1LB!YNI2C'
MVB@=M5-9R9B)?*<8>):>OKO:/QI'3V$LPFM.?%:QPIX&:> )<%ZZN+L$;A*L
MWZ#G(Q7P[(;&)B(4^I,;,LE>D1H"65-H]K;6D7+$[U;4>??<:O-:&72]8+9E
MUW <%6!IX!GA6Z:=E#L?'0+B(;'C?48?XQ#A"K*3 @\KN3Q26>O/;^D^NK][
M@@$Q>VJ&D![@69H@R^<1I3YP^?/[RZ]:SNST0=O9ESG)E^]"T,  E#TB''2\
M[F(XGJ^I3Z)YZP%7PS)@#M9;Q+(\3[;K(LG39MR'_+%*CE5_\D#_*_'[E5UY
M&:--LI8A,-38XF*'U6#A[@WH7"<DS .",QZ/CBMMC;'CY2U_"!_32+W!006,
M7P6FTT1/8EO%3D]QF_?Y@6P'.XC%UIK^2@[U&ZF#A>NIA-(//24B_KQUQKEM
MH0X.#W36VB5#L9%JKLU/E4J(=R?11.&MY8/8JT/RT:$[;_(<WHL%)>6_4G;[
M8IVBAU74$!JK<FH>Y_ SQAO-=N#5PA14)B_0M3B [R;,91/6.;"XU,'/_A]W
MM7:5:;-J0CE"8D F<)#4:R[U8B?L_4#AG\"[]Z:N?^!%R3XD=T,28:5.)-;$
M2?%E*R?WE*$RG%5@ 9U:U\;VN_0JL.8+')?RM5I=AN?N]R+ZVWY ?QLNFY-3
M S^'4(__9A3P5PD<3A)#/.$U.=./&S/]8JJD5_J W1JJU@:X*F1/( ]=Y9TZ
MODEF5#U9R]7,E7,.D),CP7+\Z1'2+,T'T%/:Q#X0]<V(A;E&;^!&':\^QINI
M5EQQ%.!%GTO9W^,M/IB[85N^H&COP/J!%DT>_/?L$?K?NNC=8=_K?8-]M=C+
MP#TPAI%Y[=:[]S8\]E!1<I<:L03/Y9SY-5J])#*Q,\'R#%3>>"TKN_#N"%GO
MKZI;169@Q OQR\M6NZRDLVL;@V?*\300/]&9SSVS>WG#MYQ^ZQ3H/,@?)TO7
MNM._++VKYN5)N$^4R?5"-\0Z%'7W/V:;^Z*597+%K^P<?6XA_>!]21[A&- !
MD/7J$&,#J(2^D6S<9"98MBY][!8XAE_H:]%S%YY+@9TL+@O:&E_Y$Y\[95]^
M$Z5BTK>JH)5ONB 7U-,?O[6NV-C8T&&F,>5JF/1B*D:#?R<A_R\[_-?^9G7>
MS\"^0-+[H: 1/0)>0Z&[+.HJ5@?-=^KIA^,:_,^>]:%L:6CE]5[%;!;L,2@8
MA'OI%=9WA1@TZ<6*8 0T:R"O6A3?(Z]$GN5A [B>.+4^2V(VIQS&7+0H(K9C
M-7F:.<<G[#B[5R5:9+YE=J>9;4-;>G?<#.['J_PX=NW=+X]=HVOU<R!>^@#]
M#F,LB6;P2FAWDO*WW7\TMXF8F',KA/CX)MUKPAGW>4@ O&1V"8&@-(]S2XLS
MV(5UJ0%W;B;YL=O[O,D]>=*"%/J0))HGVP3>$#-CHEFV@^073Q##=ICW0S>2
MM3+#I)*VY(ZG8"F*,V<<(Z,APLK[/BU=+SVL+)PJ<NK\".GD#X +;J(<Z87R
M>*%TOKNW<4?*Z'==Y.U;&;(8PK5D'@#B>9@#+C-(O_O53/\-EF4R'6T]2\)J
M;\ F](C!XQ,RD>*E1">#MY&'")[;3]HR0?B5AHTPO=WJ.)6Y*<2B $SRUK"V
MV@%7AF5((1"G+DX\'TV2\@R(G: "PE<#O1;K2VDH.OZ43'O^X(?]'N"QA$M/
ML;D7@?#W$;9J.5(1%4#'SI\?;??_ %W;[UQX0GX5+5/<01:KV[*0$!A!T@:U
MH\L*4W4/4KGU4)5%S_+/=6?TC+]-F+8C0LX"30U!S\$&BK)A\Z(EI 7:%)3P
MR?V!E,._Y()^09S$7;TGT$;Q'5(W:H,QC";0#@A1)JQ.G<+KIUTA[U=>PLT1
MG^SZZC:8$@PR(G,5V,*9BSUH\4G:AW]AZ-=+8BB*O4N<P Q[Z7]+P)H61DFW
M<+\=.;-?:.PEL+/WUTSYT\TD-A5"-A40] JO,S[1%^MLK(J+2+9,N5MCG+AV
MJ9B@I'.R? E]9DED!3'L1GB+)+]!62T;-T ?.^3=1CWJ_. 'E%NN'7 9O;-O
M2?XY7S8K\57V@CY77[J+M[<44D;?M;B[G8_-V_2%Z#<P?XR&4$__A)(D7O]3
M?3-_/<HGLQIT?EQUKR05$K.$7G!*==KG;\6N)-C8/)+NU8TR+%G5I(QJM[77
M%(K0EABI"V;S@W%MK_2PCQPD2,[V\R57(XR+H0=PI$5"_B!D62.8P_@"9?7Z
MU!,=>KT#WH@EV.Z%14@)NG'8B<FF,O_)P"6E_*PWK3:$[:G=2O\>LR7ONN"'
MNUJXRHFX<)S3%R.K8#]Y"UYXZOR)4(<),VVY.//>=[27]^:/\>E?'&/'G6K/
MI0*LL:D4-'T*S%&3%A^:K8ZN.LVB>/ST# \Q3VT_I@*&%O*-J(!X9W^_3/&B
M7G%?L,>NGH?S?)SS\' ]:W5UA:B+*M=!]9='#]ZY"J![2L^1G96"RHW1, 36
M1I:N[+'\_1YGYT&'>[=+^S;:PD5:SE845;WXD,QY7\J-[UA>WH_C"OHGD<O8
M7>$1Z%<XKWBQ5YP^CI"9N,SFL8T<+@*.QJW@WV>O1N8W34!*=2?&D:M+'^F7
M+7!<6YK(*!!1H]B_?X>_^<@-C-MA\TX!R.LIS.D(MV+]62@_+JQCK6D.,=Y5
M]7%T*QJ=F6!FM<3+2 P@6LG?;6@C)U2GWBN&Q<$(BSY4@'M-*8CU?#9BR;)K
M-:.D/%C3-]S3.CU,51A?\9[US!K#F8C[TB3G;NUO5,#-4UJF?SDB>X]UWYG\
M%&6[304\'H_6\TEOB $>7>2V=V_1Y_<^@)>XVSOI]/;!XX)-CA$[0ES3SFF=
M5NY<F]0R9)EJW 6^!U^%)5H>J!TX<>T0*CF'+$/S ++0_G'<>Z(P.&AGNF_9
MN+Z3L]CJ57EY$?W,<Y_B&SBYI0?T#'9;L$/$^@$];]X+NT6>&>,:[M'DZ@K*
MYDX+Q7#GII?O9M[E2;^C_CLV-W-,'W9!/PW2/C"S&%R^5Y#R!A1^_=^2>9$N
M$*]2AQR3([H56%>8E;A/C*K=+TSH&[Y7JKQNH#ZG:W''-UMV@>DC_0$8"%2,
M6D)/K@[>FXR<#2*9/B!LW2FT\TT[F%_"4:G%^&K] JEG2N(H [!3P!N^K+LK
M2 01OA!MA())QN8S#%L:#_V9VMPS;M]4:$E<:WV?"[A\_)#PY<++D>C9Q)\^
M#V%-+J+9)Q@7M)%7S@'4P#:SJU+U*C@^?_CCKMC.)H *0,LJ[W;&OKQ6:U$/
M9*<9O8\<_PA;P+_P J%-CD99GC8G5!(W4X@RMPSY@N=)Y%OX>Z[S!&NUQ$O+
M+QETZ>F27GFU.RN=Q"5G8M&G#.8JQ"+[,G-MW<2J\_.K+#6L7D7MRSJM@1A!
M$06WEH3,=T^2>-BV(%95^(RJDUB3Z@@+W:?;#JF*?F5KWA1!T9%]+#>F']\W
M=QNIHL-HB4^$!$C!C\_%95ND67N\&C121JUU2-W)1;LU\Z]I\*_9/?J?:!?[
MY[:,_:\)KQ=(E$%,O!Z"U(N'FEU,N&*PF71S6!-IR=%2&CGE6M,P<AY].[,0
M\0UXT$OR/C$<>TSR6J?]3(^TPZ-IT:7E%*!45^7!._+'P?>^\+S7WV#=%8"B
M2V&?QY?P$]$'#-]..?#V^']V!^(WGTQ5=?E@6MHC-NZD?LK+T=1D/X96W^/I
M^JF)-<>,#\\:_5R*<53_?B6R>V/T"GUY17E2G:K3R7W?EL  P&&AH8+^:2")
MS9=RY#05P,AM6D%4PPPO#QV/55)0\68D502URI!\]\DUGP(8[W8QW3B8<ZGR
M4V(A!H73@0U7[!+ZB$UH"X%&9(""TNJA%Y:#$"FK8^[G:,M-0^(JR-VYVO/4
M^E]$9<JL)_%WYB+WLFZZL%HQ$ ;>31F@ EAA)27#WJE$WXEW;S:%IF'%,QP6
M13=YUB1,HG2OMHAF5 42;I'C2-=V(7XVW7[ #^)O9N%RE.W8)T8..:]F;F,C
ML%=U6T8:]?ED@=7P?93#7KX$=Z)AFA>HCO (K=XYP9SA_#@)+2X:2=*1MWB[
MDRPA<<A=P('9);(CI:[NF' 3M['!0V0),O)1,,=+?I=S$<(Y/TYU.ZBEROHL
MZ_>JSW&(O9VZO4/Q&!?K3OK=P@5%40&<1.@X5V3>X?B^_!/N /_Y%,[AT5B1
MK_?WKYVBZ<U\'(H/AOD,Q&GC<<:-;GYW<0[1\1.G?; 400(MKDTS+:<"##[X
M#UB8=Z>4\SUM235RG?LVRYM9^_/=/ON_T1"U]V>2(C$PS^\"OBE^$LPTKI6Q
M:"1=-VIDT@"U3H)=9SH3^/+:F:F3(MP_:7,:_2IJB7W7VIH**$75BOC[]'\M
MPA^"E_:;=NN6?RYK'KOCO996^U@!_^:KA;VO.TP)5AB];%< ;1KGSE/03UTI
M*[(WMJWP]L_.&HIA;/+G,'>5P7TZ??,:>99X#>]TC;B,&U;#6P4[Q=[I=,]U
M<7$Z/Q%?Q!<]X?Y ]_4:I_JRR5ID9*I(DAC+79T[_V\'/;XHTBFAB>)Q%I C
M.IC@W- EF)@K6"AY=%*JN+U)@PKPD=[?\^GTXE8%2@&&"1S_K-@<X,>>ZV?0
MEV_$C3ZE2DY*$0T/9KLUD9[(&Z.>Q?ZQX<8:C_Z<NUN/IV7GGI4.^#/Q]#^3
M</I?<5& P@!K%>T(X<3:#T1)Y>=?L^V0UP\ZI,>-RGV5Q!*9]U\BW%-GZ@,3
MS\K4:_AQ[K*UYXVHE8+9%I$RWPLYQ [8QBU2 ='U%TAVR\*S-2Q^4EV48WY2
MWZLNI#0]["*!+%@C/YG'"8>QN_$N#8B"734*@LL3*\N_%]/ LLX_BWNW&D$Y
MW(SK<J*A."1]O>GEJT/JRR59[AH4DZRP'G+ZED<ML\/6"+V.2.->NX$F#00>
MH[2L>T'J?9"-[;:]J7"3%\75!Q^;0;_Q<,[N)Y<SWP73,Z/NU&7H?!:6*]JP
M#3M?8/[@O^K^MILI1^QV=6'U4E"TOL0\4HPI3,$0I=W5>J4?:<(DA_'D9GYZ
MX(FGRD!_8N+,Z\LCK+<]!(98NITV--LK!6;0YB%K"GIN[^ZVXFPWA;^J>GLZ
MM0HO;PONY>4/:N^1;J2 K"\4)UW&?L.A AD'#)?LT[]M\_I1MBT8JEZ52MR4
MX=J."A,A6LFUY\YX+;PE:6YEK,X/BO/GQ<> >K2Y6R3*!0W5A&MSK[_6,7/*
M@[]/&EZWIVGP&MI9)(5X#X<T)G;CZ35QZ!#[H5V]WHP3]1P3^N4>H+JPR]^:
MG]))ASQ\J)3M?ZRD6-+$U$2]4)5%W4S#-(I55XT_1AG@J@6MAM7*P!ZJ@RQ
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M;[]^>& DT4-#S-CILYKG+A.T.0&Y_ S_2.R*=')WO8^=Z$[?AU3R#<-)*:%
M$4P0#S;N3)#TKBPF^J -[+B"0*:UW.D(+L?8=.520NGW"%%KU+?DM/<Q&D+\
ML2:92^A=66O@Y]6Z<."1N4ND3]%7UI;C3XZ/G)#Y-MN#?=:I#'B"N(98<F(J
M$TR^%E"M*;<I.K,+<_>^6#U6G4]Y0BR?M' 4_9:O6C9A<R6[&>7]%295(?ZY
M>&SY]5U5Z%/HK3].H/D_.QX3,[_X */$2$EVJEWNH2Z1\:6O1B[*+F&B9M>E
M9VH$R$^5#A,+!Q%*;,2SAAV&^<59^8;1"K$G[B6#^W&L2RQW/>C;N9I)S%0
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MF=5 TXR?^"I63_S(4VUV/Z_@UK?2;%/>=D16Z=M.Y/*;JD'Z T@S(3.]\3L
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M<LF)'D=E$SOM=_G$\BTW1I'?]'?X2Y8RRA;R9VE<R#..XH@&--#TX4ES^IQ
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M!!FG/$0E-)"EU*6O*"U\1?5!+RTT<#1)+$; TCSI%]6A394*SDK<AN>ME'@
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MZNKGJ\_W=^#R\P=P_1E^NGY_]?GN^O-/X/+V]O+S3^5?7=.MVP^-'1<.!/C
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M1P3]PC@PQW5"L'N.A=.8#))6H:7;M\FD<!J'H\D3+%[MQCFW,E]E<ZZ7^IT
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MMM-.5SO49TU21K?S=09VH28J_6V%M3<XALE*^]:8VTW=^,1FZ=3'78AS3)"
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MS93H44499A(A V+*(<*$0$8YA4SD/,."BUPX204>?/K8F*,R#OQ>FN?)$MO
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MR==25ZEA=)'D72D$@0?3JA_+^W6(&X/W!G//[+RCDUO%F-D8PR;>OQ?V ^L
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MFN <:Y6[U(P]\&ROKWB XJT/M@TPW1CHMS?<1,UM+[@C%CU_LK\X ."]S7O
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MAOAK87Y5[,-^FBS%=+Y\72C/E) S6AC1^[OQ C3<*'8B*D? QA.P<:67])(
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MC_'-8I8GTLC ;=:,!RGKF4=B/BG-I%'"&=#>B285PP^3-*YM&DCG=XZ=!E%
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M!.@F&>,6DH^/M".4TD6C_%=DH9=7@Y)FL%IM@L.-#*_ZS7V/J[2<;FJ )\Z
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M_O9F8E6@0$<#TR96)Q T44QQD!69PJ&BR<F\IW?VZA(=*TQ_?;?X^.WV$R\
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M<%=DGT9.;2_P''2/=A]-?C59M -KS]_";YCA"93WWR3T2=7W/R+CKG)USI?
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MY&;RUWI\Z,%9JP 93YHB&:/(*#GO6*P#7B-@5JY)$/CG\>&QZ#Y%J?\>X.C
M%;H_5O<@.%+@Q/0FEN*BT ;,-?/%"NFE-5":M.?Y.RGUWP<B.V7=]M%7!Z#;
M-[0'XJIP2"Q);\@KH^]"RH($YK($3-G[)L'G5Y!UVPL91V;=]E'3D\FZ0>11
MY.28*T52C"T5"YH6J_/&2? .G#9?\H2_XJS;7CH_*.NVCP(ZL&V#AK\8E=,
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MZ&; :ZG'W+"^OJ-<XZP>)I\OJ] G%!BZ@D8PG_GFD(.80N>8D=*"%)D'T>3
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M^6*U_@Y6T]5$EF2R4H4);VN=AB6_5L1:&AZ],SDC"?04(/P2H2,W21T8*%_
MX:!:&ZS:I1DJ4SH_J\V),/^T7*Q6-Z^@?8=EL<0ZH4,+D5T4M-=80&)5B3H1
M)#!GA8#, 4)Q(T!U-^I'[L@Z*GX;Z+=_4_L@T_6BV6>F!0E9A"*9MW7"79&%
M^2(X2U"$22AS:3-V=1#JQ\UY=PKJP_6[/ZC#!:CG^*X2TMAQO2F B03-'03/
MN.*1PD,/Y'AISS2$ ,"%\&WF$^Y*X+BY\1.#<Q M=6!4CRH"OI*LE:!2X>04
M)<Z)Z0ST'1HF44*27%MQ>WIK!X7=>P5?)VAVW3KX.KVJQVYA>1S'UZ. B4PN
MHP^2V5P+2EV4#%*A!6X=#\I+VG+4380_U(]U,)K&OZAU8C0MQE?MB+'=\6S?
M$PQ,HK8Q*>]9Y(["V53JC"_:'3&DK$-*UN8=1[\.3-GX]\*>*KJ/5?.3MMKW
MQ 83].3E.2=9,BB95A3B@K7 .$1OHO)&EM-CO%(V_M6RKP3C>ZOYV,CO;0=0
MOVJ:\_UTE6:+U?D2)SFEA (UDRG37A:%H.@W6A:XRS*HXA!T>ZC?0]G(/;>?
M,-2/5?.3-N?TVMZY>HO9AR@L\V[3D5R3FG12+"?O-(5-4=D=9W^=F/)QMX/V
M@6C_<'C2[OV7A;/CN4"V2H)6@0E3$U?Q_[;W;<UMW4JZ[^>_=!W<+R]3)>\D
M>Z?*L5V.9W;-$PN7ALV)3&8H*8G/KS\-ZFJ)E+G(!2Y03E5*T85>JX'^NM%
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M.P=<&'_RC'$=3^O&@=LP%"DHU9C<]6Y(53K7Z!B"-<*GK+B(L0D+WS&"F8>
MGF'R2F>I ;FBY3,630.M9WVUMMEY9[UNZV(?2M.O3QF"AZWAR]X3W\&F^U4X
M#XN$OWY"O*.87:?>/"L4T:&'&$4M-D4-H4@'&$7T+.3"=9.P?YM G6!H?UTO
M&TQ\IP"ZK5TQ)H98:Y>4)@O3+(!W&8%'FXM-B8+X)D>*VT6:%D3CJ'P''.TQ
M_QT@Z=;&[J\?6@K%-!8.Q7)/FTLI(=2".,TH.M,VQ!*;'CT,NRQZ5-SLH^(M
MZ]=^\STA8&I<.7M[^0E7KY>+C_2\S[?44.M1."-98=%3X![6H^#@DD[ N9$B
MHLO:B&^%O\^_8MI4Q,AP&'$V.W(B7^X/N$5V3.KBP<BD0=FBP#-.T1Y)F+0O
M&6V32TE/19F^Y>^X,<R!D]T37-Z'/W\)]-QY.+^8&8ZTW\\1=,XT"%,R>%L0
M#'=8O!8NYB;] #9*TTG@NZ>*MR%F[_GN"33_7JY^^WGQ;K5,>'$QTU&DZ+P
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MNB[C]CZRPZ)M$8!95?NOYSXV4SPOZ@4/DYQLDPC8*M'$CG5RL&P[53A(<QU
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M*J^]B[OY0_U26</_X__\?U!+ P04    " #,@Z92<&9O"O<'  !,(   &@
M &5X96PR,#(Q,#,S,65X:&EB:70S,3$N:'1MU5EK;QNW$OU^?P6KX*8VL'I:
M=BW9,:#(FT: 7[7E)OU44$NN1'BUW))<R>JO[R&Y>MB2'1EM4SM 9.V2',[,
MF3DS%(]_.+WL]G^["LG(C!-R=?OQK-<EI7*U^F6O6ZV>]D_)Y_[Y&6E6:G72
M5S35P@B9TJ1:#2]*I#0R)FM7J]/IM#+=JT@UK/:OJU94LYI(J7F%&58Z.;9O
M\,DI._G?\0_E,CF543[FJ2&1XM1P1G(MTB'YPKB^(^5R,:LKLYD2PY$AC5JC
M3KY(=2<FU(\;81)^,I=S7/7/QU6WR?% LMG),1,3(MB'DHA8,^*#YL$A;0V:
M^ZV#5G-_O]%J-EKTD!VV>/Q['4I6,=VOT6:6\ ^EL4C+(V[W;^\W,W,T%<R,
MVO5:[?\E-^_D.):IP68*B_U7+V--DN'WIDP3,4S;SIZ27SH?CF0B5?M=S?T[
MLB/EF(Y%,FO_V,6J@1(_!AJ^+VNN1.PG:/$GARY0RSU.O9X_87TB4C[7N]ZP
MRH;W(S$0ANS5*_6'FJY:2]40!AN9M5N0NJ)R! =S]9UU[H;7_=ZG7K?3[UU>
MD,M/Y.JZ=]'M777.2/@U[-[V>[^&>(T9X?63-OW71ES=7M_<=B[ZI'_Y:G4,
MOW8_=RY^#DFGVR?7MV?A#:GOT7*]N4-W"4T9J>\S_Q2\6ALZ-Z1S>GG5#T_)
M6W#Y3=AU4;U7:]C([G\.R4WG^F/G(KPI7WX]"W]S6&"D4:LUMDS8?\V$YD83
M>@$Y%]&(\H2<5\BY5$IHS6<!N1I53BL!B;@R(IX1,Z+F_;O]PZ,7\8Y(&7!I
MUP^_NUWU"NF1$9UPHOA$\"E*DQD)33Y)-2;U6OD7(F,2WO-$W L=D%X:56!>
MZZV8UZB0CU3#*)F2\8S<I7*:<#;D@;=2\4PJ0YCDFJ02U1D"J4A! S.2IT;E
M'(JB7KO2#4=0,L:3$C0A,8WP2A$Y1J$QTL];FY#RB&M-U<Q.&=,[CGU79&J\
M8U &6R:N[F,/.R$2"G4>TU(LAR:,*S(=(?Z(SNW'<OV4*UX(L0:,A4[0$-C>
M8BK," ;JC$=.02LW@VJ2P<P)EC$RF*VZX2WANO<,KIS$(H7G+ A+3P6.VR6&
MU<JX2&,$.K4]'KY'2<X@$VBLN"4 DD(E,Y+!F38.;'PDR1+HPL?ZT=:()>::
MQ\#.R!-, +H2$+CMM-,GHGI$XD1.]1QZQ8="&W2>AE#[TNL-+8,5!/5<F35M
MWQ*(S0KI/[#X_;O#1OVG(UW 5'"J#689QP*/.]J7Z!ZABCO'PY%BD'#K(,*!
M]B 1>F17V&ECY++-9_O,A(X2J7.LLUFN9.(1R)2,.,-K37;@<,:!H/=J> ^^
M3X><=)! UWF"&:Y1V-_A*XV"??*/PE;6U"-OY1.;92L!X0&RNFR]4?Q@HQ@;
M63L?APEF6 ;?NNSL/X)^[^"[0V][K5.NT9' !8[3OHU/8.DVHKG>?HGEO0&'
MKXN=/)/*7$$ ,FDBM,M/S.*IDV/+]S*S5]E!\80Z\ HJ70(0%,QA!P6R'+IH
MF0CFSGDZ'VC!!%7"&B \X3N^2JVD7%L2=N&N'6.[;,9!$@KAA.<69111$^4)
MM20$LYP22S+'"E\:5BL:O@VXG0B>P'K.MN:%UQ <@\?!L75JK<7(]DFY=:@@
MO":"V0B@6J;4L@_5B!Y;K&U84,7F$"%H!!V(1)B9Y?=-V]J =6@ZH'RL/9BZ
M4NP=R=T7!F6YRA HVM6C*)**.05<V1_R%&4F0;Q@A&<V$.T4M#0^)A"P(@//
MO*FHB'9).*%)[O+*NHS',>JNF,!8O:%^+JK)%CSA'S>75!<$6(@<U[YP#V1N
MGM9@&R:CB]G<=B7QM[LS,ICW.RZNN?<$]'$8V@W>"HX,V>U=M.YJVW@7Q="-
M;,3S!3EMZ5Q&4:ZL0U>X<X/4L=0&[^T!&;)T!$%_Y*!>B-YY8DF,R$"V/9I=
M*([6CKLS@SU.I/E"KUVOU8CJ1:&Q>>HBB3-'8,X?!;G,<#*XXTEQ@'@T/_C;
M+GI1]+R"GG'_;_2,[IC+YJ$7+#/*)O@J_,ODL@"^H/BL]08+[2CZ R.57O"]
M>P&18YP?#>?/T-= HJ+8<2:@GQ.R@R !6VC+1OAKNY1Y9/,_<@'U713G:>2.
M&KMOK37LX'QEZ[  @K;%M<UR)#C\77#UHD6;<GIGR=?704>_KH*[H_G\K/4B
M%(MNRA\P-B0A95BH^2('GT2\J/M8 MA0G@-? 33H7^=C.!U.<<84W+?Q5/KF
MV!V]6P<D'BL$> !?<I>60,/]/%' %G@.%.E$)A-NB3"EP^)7%E5D,A]GB9QQ
MC$Y'TN<N?1 4 /$?J1*5YW\W_1=\V=K*E>_?U0]JW\S:@31&CAWTFR+AX26,
M<=UJ(6" F.2J#"L2FFG>GG\Y D5F"9VU1>J4<HN.)I984>8*B=BDN!]J[E4.
M:G5[1604_K.Y^.+VJ.)NCZJ&K8^U#BNMVM/#M4I],59ULKU\Z*DSFGXH[97F
M"S+*;,_=;F3WI+[I,N>Q^MYKWR\W:A[0)@+3?3[W8_("\2T,+S"TD,-NXLZ=
M9&[!?^R5PV_=#3BG_$..>,;6A,?F5>!_A=9?6#)QK-\=">Y^6H]R>X(@E[Y=
ML;>K.U?^A :66AO?7?=*U67H:[LQ.077N[Z#G-.9Y[*#P%]L/\EIJ[?/.-RZ
MGT_;_I>7"5^[CUXF@:/ VG()'2 3<O/TDJ=NQ)Z\W"X^_3V[N_$_^0M02P,$
M%     @ S(.F4D5V52_X!P  ,"   !H   !E>&5L,C R,3 S,S%E>&AI8FET
M,S$R+FAT;=59;5,;.1+^?K]"Z]1EH<KO-F^&4.48<_$6"QPXE]U/5YH9#:-B
M//)*&AO?K]^GI?$+V"2FLI>%5,5X1E*KNY_NIUO6R4]G5[WA[]=]EMA1RJX_
M?[P8]%BI4JM]:?5JM;/A&?LT_/6"M:OU!AMJGAEII<IX6JOU+TNLE%@[[M1J
MT^FT.FU5E;ZK#6]J)*I=2Y4RHAK9J'1Z0F_P*7AT^H^3GRH5=J;"?"0RRT(M
MN!41RXW,[MB72)A[5JD4LWIJ/-/R+K&L66\VV!>E[^6$^W$K;2I.YW).:O[Y
MI.8V.0E4-#L]B>2$R>A#21Z%03V,]YK[!TW1#II[P5%XV [J]8/642.*#P_^
MVX"2-4SW:XR=I>)#:22S2B)H_\Y>>VR/IS*R2:=1K_^SY.:=GL0JL]A,8['_
MZF6L2;+BP59X*N^RCK.GY)?.AT.5*MUY5W?_CFFD$O.13&>=GWM8%6CY<]G
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MK4Q!O;MQ\R9@>\>;K:&K(<( -BALZ;ME CO6//@.+$5S6S)U!'@PH'56J'1
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M(TMPZL )W$TM\'S2 @-:X)>Q:0&]=0DWH" K&'PPB@!QD&!DQP2@737I@K8
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M?F-8_F<G+T.5 04_&)29S#2 6<8=^#)K)HLV-%K)+PSNK]0AO#SJPEO8GS
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M8GCLP6NLX+>I1YH QR_"Z9R@ ?*YO+ZX"8-_7+RZ?'^,M12UWDXPQ%F2N3>
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MPX!FF2]M,YY=XE3?Y@G7\^(4Y<U,\<OQ8T"+P<HY2#$GDT=#* WPK"ZY=5S
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M(JI][L-+G4I<HHS0ZW?+K7KQLP")MW,>&<6QVC^+<M ;)<(QJ97O6O?Z8'M
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MI!(SV(UWH8F"%M0$$H8GF!Z$-/% E)Y^ PIF[^C1?K"6HFSSZ;'2=ZJ@3XG
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M0)M,<;2SK>*T/MQ--MDG0_K>:/G@M26F9ZY*:B9>;5/U?_9<CQ/CU)GK+:-
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M0=N =GM_DH;."16;8;!OI.DJS!"+D8MX^M_ZAMI9Q:9&X.0 >C+R''" <H[
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M"=TCW$9>Y5?=O5&2UX4Q@;#C]V;MUR]=UA__#&W<T2FXF\I.8F.;Q>B_7EI
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MB1X5'$^(MTBEIV;])[8K\EJ#_$!'""OF3XK$DD[GF'NUA4)SB+WCP.Q7ETP
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M>U+GP,GV]=>E7^G>W75ZS'7J8;*YIX$[XSM?F9M4:_Z=S8;NU@@,K-V0S$;
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MBP'<%NCR9'C!DR%4P(^QY2K6\N*ZYA#RX^Z('DI"N4M@"-)1<(23):#IBEF
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M?[L7SC3SV#[$7-T/D0V@'B=ST?$2P$P3CNF8ERTDW@:V5[5@W$$**S;.BBD
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M/T-'*@0!B]&,-HRWS+D3 ) 4EXMJ'^7BG"@:O&@9O$1'S*K\MLCOW+VTLSN
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M';I8V#W3W-K* J'0\DY7FM[> GL5%!1'6 6%8-AIUMJE[*\)D7@P_-/2@T\
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M[C%Y?X9R"NQ+LUR.+\=525GF'#.(H1'FAX?[TF1@Z Z#5&DSK8F-29(4Q=7
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MK@ME9P@:A]D\3M=(T8J5+#69^XA88MV4NQ48!BN@"-R,&'%2_37E@2TV\K9
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M=L-)- A?E, PSH#@[:SI[V5)/XLL/N6"_0CC+#&/N!4DYE"UBT*+F<.TS)Y
ML3T<+<-SZ"%@Q8D+?L,#@P#XCMSA*4^"2\=\P699SMNH\HR<,*K'<=SD:QRW
M#F7#>%2_P *Z]=UC8GL&\$D(((W'U*H _P Q)HGP<?+LGH%@J2WKQS=!!P[2
MJY%GP1\C#YL01P,I9 !&3;ATD-"967*!JC3Y@*@"BKZ= F'4O8K+D@:"7*9Q
MA!<E^9Z*?%OKK0% U2 5"1\O*Z?::)6\CS1EJNP$CT++'H$]KU2C,P .)D!7
MR-L]+16?&@Z51<ZF7RH84H+RH@D8/Q&\4V"(PD:1A6=Q962&5M5RT<BNHQ_?
M+#'SE<^,/TR_'%3%P(SS4S'\!/!&,^*IV35CD4Z*,9I@-V6]0(RFWKAB2N2!
M&&C-S>X/(;!I[+=QT:RQ^TBCJD_ >O>IU77DX?OD[7$[$/258B"^-Q#>GAC/
M4_P!0><(B0R@T+=5JF^=6+=)$U\2K[AYWTRVVX.CC(8SJI1LN*<'XC(XQZ"2
M]&].+HX!GK0 X 3&6,LI R^\V]2"953+*?DU.H4NMQA!]S04(J!:+"E-F4TQ
M]N)7+VSG@;WM]WGM= )=18$J0H4H&_,1V$@=PH",A![:#AD-PI@D7/&M#].Z
MM\5/2E+\1<7$(:PX7X[-'80R&//W*&#%BT1LY8'LYWD\6VL3>^@PM2V".]"Y
M3?&,K1_!_>/OT-:!-BVE.=A0P&Z>M;AWM- VBFWM*,U!Y36A\^W 70YCE\/X
M:^0P-BL\^VE]*E+#%OLZ-X%\J+<FHEPHUM\2:<Q,[9S;&^ ;29FM!)&%*T@Q
M0$.3C<K95\G]&G<XTL=Q4):?!'0)F!P+@*=X/]*_@+U!L&ME6U0$J*I!?0]M
MF-7I$I\6VB5V"NE[)JZ96 N6H>/HX A#NL!&T$7PP8/,@+>$E!66$M#]M5!I
MO1($!C-K4"O<OQ!$T@@(3#,ODYGQW"AOD\WG6.>VK=9'3_VW%1W,02HSY@I#
M'"BAW0F$D!,=0LYLL)&[XKBE_GD3Y1"<-Z_ Q#-;6GDCL5HHEC'/I];#JJ$$
M^Y/#.,+W.%K%G7[9_,:LU6!&P1/SG*(<%4/ 25/HRU\2'(\P]Y=M>P?0:,-V
MIF/;3FH_CZJW"]CVH(T\QZJEU H+[@5X[UF3*JO7$L)N\]:-1GQ!9&P=R=R^
M*JU;0I:SZW:(70=LC4E=+WV"8#M YK%3A3(W>=:BLMC.PUM\[N71[6)IM*!1
M%*MSZL?'+27RT'4O"$\,]G:5-_=$2,8Q!\31#JM\1)7JA9"6(*USIHV@8GX+
MM7R33!B8E7P+>>E2D;A^;CYR,;[^4MQ@'U4(WJ+7,+RIRKD1Q$CAP!:_M7EJ
M'5#93KJBH^YVGL=< &9F;,_-92@I7"4#8V9Z@;;5)-8/ 8D0VI/92%?JU6RM
M4>^PC?B(;F3OYKB":'%&X'/@X?H[WD_X%,@MK#Q,?MGHJ9H66(EL!*=PWW'L
M=-IF<N^HI.LZ223_B$^0*!9G$O?AVG00H(SYXB< E 6J$KCVQ3P)+6,C-,$[
MLB1Q(\=Z86,AG5#=T)+!\@FH?U\@G(C-$01"NROC8]S K$&+0'/!M8:'\S6.
M52G90:,KH'3<6 !39,,-:[HU$5]#Q3?JJ3-C9^2.GTF-;0PQ1/?!158@[1'Z
M$6/RZG+C>#-[!^:A*5N*[N8V7NYNH.<F;\\QLF6!>P=!7+-Y"CR.YSZWE9%\
M9N"Z$4?53BAU"R4B_$(8?VY;C*-I)N$G[-!%H79%!,M!((Z*V*T(6R[ ?KAM
MXRW),,)35<2H-6+;#WX[MR2PFC/7\W6HN4<@,8EE0_5EI1="D5GIDUBJ!JX
MRW V"O(#N;KW,W?6EFS<#G*>P-9>[6Y<8R^\BHX:-*PF).)59"^4<C1S=Q#S
M4Q&:FPO62AWF:/,Y*1JJX<W<S' 2KT_?VCWN[O36FSV&_(?4$F(;T2(G4 %H
M:"RM%4E3"VM#9-LHGKM+F^W29G^%M%D_^PGU2J18RP!D2I >(U)XCW3:\K/H
MPDH?(B+IL<#:6)''Q\$(G3N-1)P]?K37^F!+=<QX.PY$-^AV=8D4FQWS>V>)
MA(SEK@0L9E#@T2+!Y!,.6.NFUG3H+E4E1 U;>S(FO3P9XE:@D4]A!JMT!A49
M^%"G'&$!4DAL56+F_)%4J/;UZ?"=#.^4V(8ZV! )F4P8 ^T(+5(NM6ZU!BC:
MK52X'4H%"&Y,]Y0+,5W29 B![*E+L#-BNBH;\.+,?X=YCEZ3I^<?,*QZ?/IN
M>GGZ5I\JL\WZZ!16?7#YPJRH'3<<_\Y7,N&'R(^/"J;.R.+6"IQ^YG@]563-
M3I_.#2 !YIM8^"#4"O87HZS)9+<$8:L)0*5AF;6'A>4=RF<\L&Z=C7.LV(!(
M:3:\YW"N0&7A1*$@J*VR9./'=N_8QF/Q1R^/Q4/Z187!,/%-4)&YXJFBT/BJ
MYS#TRB9*RX4Y4DAQ57F,E-/B$_A)CO/?'J5BMLB&C7C>@76LZ>CP$-HR(PK/
M+Z?:T?).O!"$V&97K?0JQM$+XR[G7P,[V6P^M+/KF\J'VB79EGQHI,AM%;&"
M)Z:Z\Y^I#])28:' 0B>#O&6GKVFA*VWWI1:Z1\^)3]:D\^-EA8;5MUH<RUX&
M\$R%^8(IATT9M_36=+8)>PVB!-([U::I#JE3,< [/L,VUT;.N=;$$NE22)#K
MMZ?)]>G)V_,/[S[\^CMR59Z=7Y^^>W=Z<OWQ^%UR<?GAXO3R^O?D\NS7M]=7
M\/,_SUZ?ODY^^3TY/3YYFUP<PU_?GEZ>?CQ_?7J9'%^>N@]Q;Y[CJ^3L2EK[
MP2O4-T__!]@RK][]GKP^NSIY=WSV'A@S:23'[]XIYLSDPQO\R_\^.W^=RO>2
M#Y?)V?N+=V>GYG=GYR?O/KX^._\5I^5_\_7IU=FOYVGR_O3RY*WY]?$O9^_.
MKG]/DS=GU^?PH#?F2<<XJ+.3C^^.+Y.+CY<7'ZY.T^3\P_G9^9M+\]S3]Z?G
MU_ T>/[*=<+/G%V^I@>>7J4PT./+LRL8W9O+#^_-NTX^?+R\.J7!';\S?TB3
MCU?'OY["1Z\OCU_#0AZ?F.' U\_.<3E.CJ_,?'X[NWZ;F.E?F+?#6"Y/KS\
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MM4A:2?V4K^S,Q%R6W"F@]H?FC0P&I@>EO(^,;QT%6T=F-V$75H@&8O6\9:[
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M1EWF2C?7B>B:XT,>LI'N!MN;SAO\7Y@L$8)+1#H%0UB-><@=N-G0TC0\-"K
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MY:X/=\22,O;A<ATWI+UGJR>5QG8(QH@A DPA-7?JTMI*+UIEIN!=(N$ UGC
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M' LCM:5+@]WS*XR'"FQ"UW]'WH,)O39&&.(2-YU+LV;]582HES GXH>V,H"
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M93>>I2OM6\N!C?^BRT<%<0@W ]$ZLJP8JU1-8V.VPK'&ME3J',(J+RQ>I*W
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MX]2_/#:[R?)Z_@"[R;[,>1KU<1E@QP3#$%[H78Y*<P#BNH*3@U^-LGXP"M.
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MR<D6?WA@G;^_["((\^'?A^_/_WX^Z@7G%Z=?LB\W"ZG]S5) N"FL4M#_!A_
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M6<A-4J7=O-9L]19A/&$+7EB3<.'S;%P1YS0RVQ?,>HC[%^S,X>4UO&$U(7K
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MG&%#XN(V3#(,SRWM"6S*R>V)>ZK5&=PA-4<XF<=IS.7C' (WI@3WX'!Q.@7
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M$ORO<399PG]NRWGRW_\?4$L#!!0    ( ,R#IE*L(M?_EQT  ,07 0 >
M97AH:6)I=#$P,F9I<G-T86UE;F1M96YT=&\N:'1M[3UI5]M(MM_?KZAA^LW
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MD@>4BG<B;L8K2BBHY"V\3R,1:Z,*BES%Q!TINL;P%0.9 1G#V22L2H*!@->
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M"40.%]D3HH]!Z()$_A/RBF&N@A(.Z'B+3:\]'@/[@IP#G2CZQ$!H+\) =.5
MPREW##5^R.6VXTJY EI2B:@Y&-R!L4'V8%J$%?P&HQ@/H,1Q3%^1*2I,A&-E
MCDH097#C>2,/G H(=%%QMY@$"=J_\<E@M!>3V1" (VR!"-*VA"M$-5&7WW"G
M?#X7P4(EC961;$= "[WF445I$-$P_&2E8-]>4A.^/ 1PE4F<S8(*0@EU^!*
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M:ORH:KR@JE$VOY:F?[?M_/]02P,$%     @ S(.F4O%,O>VO<P  R*H# !X
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MV)I$,1W1%+V*Y%\$&\I%<1'__6_')^^M[>9]W^85)0MJU@MF12A5' O6.75
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M,2&JM?!EC$Q21LD<"AN*->O"RK)FHQ2AUQTKV?E5:"PJN3?7BY;N,W2U0J8
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M$[G-R';E=2#W%J-:,*P[JJ)W"+H="U? )5C -X';0N^5-I=TA1IO-/SN^ A
M[@=X^019Y\[Q+A@Y]XEI_$B_'+PG1:M:EYOII^3V&-:2W6)[7XQY8!<LGXTC
M885 ^/AD#EN4K\%>DAD<U^!>VD[RD;Y9*^SMXI02J9U/')?.N+ +HR1G@=%D
MCY9CD>*='KQ*5]BY_L(GL2NC)B%Z%6#108*$N%,S;.%EYPP[GX2^!&;S)-V8
ME=>]MR5V\.JGQ$":6T;G %RV/'F)/E+F>5B.M5R<Y-'/8'$-4UH I5@WZ)YQ
MK&%WB#KDZV/KM\SQK7,$"H57G4<@[O&'DX/]O3WK0Y0%$<B^5Q_@_($@ !(
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M?G1>PYBK.\_9=&B]1^ZDZ<@-R#,'Y#'S%]:':J38\-JNRR%;*NF-C1&3QB*
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MW3:9M!,-WX&PJYV,.)(C<R07XDC$D1R1(VF-TS OON)%,KU^ U!+ P04
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M>!Q+\"59_T!J<_9(/F:A2N%](!S\(/IACR3\NE19X.N8V"("G]%LUD25/LT
M,' UL@DXK_ ;N))> "Z)O\8-3:U :DQQ;7=G<>WU\.KTW<G8]!UY&'JCV\SJ
M6AL][+8.'WF/OQ>-?$[1B,$=ML< ,1'K[B&CN8PB5*-CU*ZM6K?!7&>Q-\>J
M@*L8G)\$7(^)$8H8]?D#-T/IO#\L_[4-^6#L#LO],:#E>2K629>EQ"8>):+A
MU*7BQQ]Z3U_"6.4[$Q"C4F<6)M@30.]M),&;[Q1 $8C#@[U(P\/'EN!BX;-
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M&&T#IDGT=21BPV0CX@IZ-''*G\&86]FMR<%1<6*#3!$6LZIL+1SZ]]2EUD3
MASMSNV>#R_[ER>#!]*H];#6T0<7VO]:4 ;"_4++WFXMA-K9,$-:H5CNZ[BV0
M(% ;,O^_@90[[6=?@);7C?3MJ'S$'S<QTCLNQ7IHZX9HS/DT8PL646$C8GMH
MF*PG1G5$3Z[E1,L]:6T%AL!H&-Y93XIK.RK? LH#+].]'_![@M-I&^":S+)J
M5TH#@*E9J*(+-8.N:[#I.XQTZ.I[&2?I>O880+9YXX0:*]N/V+(1#+-(7:NO
M]Z86#GD7RTQ,U(C4F#E/80TBFW++RP1^$SS>#KP>C(KQ=3*RBI8O0PN=>]$"
M12=]E"ZDDT-M(1LK$D;',H:B42O\CMGZ6<PC</DF>9[[H0BU2<U";9?K5G:%
MAIC%\,AI 'JMWU73.P!5O"$)=*?A"GLX.]J?:P8Q&_"V\%K$I5_VG7+FVRV]
M_"S?EQ]A715Q?048 @'<.O2X0H&!B,T:(#P#39=^82T\%@/$;$8'L9I"EOL
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M+3(P,C$P-# R7V1E9BYX;6Q02P$"% ,4    " #,@Z928=$JD5D1 0#"Q@$
M%               @ '5GP( 97AE;"TR,#(Q,#0P,E]G,2YJ<&=02P$"% ,4
M    " #,@Z92SNYH6K6V  #3H0< %0              @ %@L0, 97AE;"TR
M,#(Q,#0P,E]L86(N>&UL4$L! A0#%     @ S(.F4O,H_N5L<   2D<% !4
M             ( !2&@$ &5X96PM,C R,3 T,#)?<')E+GAM;%!+ 0(4 Q0
M   ( ,R#IE)P9F\*]P<  $P@   :              "  >?8! !E>&5L,C R
M,3 S,S%E>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( ,R#IE)%=E4O^ <  # @
M   :              "  1;A! !E>&5L,C R,3 S,S%E>&AI8FET,S$R+FAT
M;5!+ 0(4 Q0    ( ,R#IE*PJ9WZ>P4  "8:   :              "  4;I
M! !E>&5L,C R,3 S,S%E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( ,R#IE+:
M]F@)H%,! %R:"0 >              "  ?GN! !E>&AI8FET,3 Q:7!S96YC
M;VQL86)O<F%T:2YH=&U02P$"% ,4    " #,@Z92K"+7_Y<=  #$%P$ '@
M            @ '50@8 97AH:6)I=#$P,F9I<G-T86UE;F1M96YT=&\N:'1M
M4$L! A0#%     @ S(.F4N>]Q%AZ#   :TD  !X              ( !J& &
M &5X:&EB:70Q,#-S96-O;F1A;65N9&UE;G1T+FAT;5!+ 0(4 Q0    ( ,R#
MIE)5><+^R0P  !).   >              "  5YM!@!E>&AI8FET,3 T=&AI
M<F1A;65N9&UE;G1T;RYH=&U02P$"% ,4    " #,@Z92\4R][:]S  #(J@,
M'@              @ %C>@8 97AH:6)I=#$P-6EP<V5N<W5P<&QY86=R964N
M:'1M4$L! A0#%     @ S(.F4NQ)>$ 8&@  3Z\  !X              ( !
M3NX& &5X:&EB:70Q,#9F:7)S=&%M96YD;65N='1O+FAT;5!+!08     $  0
+ &P$  "B" <    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
